<SEC-DOCUMENT>0001493152-24-008361.txt : 20240229
<SEC-HEADER>0001493152-24-008361.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229170930
ACCESSION NUMBER:		0001493152-24-008361
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FibroBiologics, Inc.
		CENTRAL INDEX KEY:			0001958777
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				863329066
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41934
		FILM NUMBER:		24705003

	BUSINESS ADDRESS:	
		STREET 1:		455 E. MEDICAL CENTER BLVD
		STREET 2:		SUITE 300
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77598
		BUSINESS PHONE:		281-671-5152

	MAIL ADDRESS:	
		STREET 1:		455 E. MEDICAL CENTER BLVD SUITE 300
		STREET 2:		SUITE 300
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77598

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FibroBiologics Inc.
		DATE OF NAME CHANGE:	20221216
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:FBLG="http://fibrobiologics.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_FBLG_fibrobiologics.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001958777 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AmendmentFlag" id="ixv-16887">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-16888">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityCentralIndexKey" id="ixv-16889">0001958777</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0058" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl0068" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:ParentCompanyPayable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0086" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2022-12-31" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:NetParentInvestment" contextRef="AsOf2023-12-31" id="xdx2ixbrl0112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0134" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0135" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:FairValueAdjustmentOfLiabilityInstrument" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:DeemedDividend" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0308" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0310" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0312" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0314" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0328" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0330" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0332" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0334" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_custom_NetParentInvestmentMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_custom_NetParentInvestmentMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_NetParentInvestmentMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_NetParentInvestmentMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_VotingCommonStockMember37662156" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0396" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_VotingCommonStockMember37662156" id="xdx2ixbrl0400" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_VotingCommonStockMember37662156" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0416" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_custom_VotingCommonStockMember37662156" id="xdx2ixbrl0420" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability" contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_NetParentInvestmentMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_VotingCommonStockMember37662203" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_VotingCommonStockMember37662203" id="xdx2ixbrl0506" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_NetParentInvestmentMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_VotingCommonStockMember37662203" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_VotingCommonStockMember37662203" id="xdx2ixbrl0526" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:IncreaseDecreaseInChangeInPayableToParent" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0583" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0588" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:RofnAgreementPaymentsToParent" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0592" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0597" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:AdditionToDerivativeLiabilityForDebtIssuanceDiscount" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:ObtainingOperatingLeaseRightofuseAssetAndLiability" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0633" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0637" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0643" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:DeemedDividend" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_LaboratoryEquipmentMember" id="xdx2ixbrl0736" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember" id="xdx2ixbrl0739" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" id="xdx2ixbrl0742" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="xdx2ixbrl0745" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl0748" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0754" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2022-12-31" id="xdx2ixbrl0760" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2021-12-31" id="xdx2ixbrl0762" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0766" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0767" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0768" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0769" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0771" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0772" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0776" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0777" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0781" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0782" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0786" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0787" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0788" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2022-12-31" id="xdx2ixbrl0789" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0791" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0792" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0798" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0799" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" contextRef="From2022-01-012022-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0802" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0805" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0808" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" contextRef="From2023-01-012023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0811" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0813" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0816" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0819" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MeasurementInputMaturityMember" id="xdx2ixbrl0824" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MeasurementInputMaturityMember" id="xdx2ixbrl0830" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-31" id="xdx2ixbrl0859" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-12-31" id="xdx2ixbrl0862" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0865" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0960" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0966" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsDerivativeInstruments" contextRef="AsOf2023-12-31" id="xdx2ixbrl0995" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="xdx2ixbrl1008" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:DeferredTaxLiabilitiesUnamortizedDebtDiscount" contextRef="AsOf2023-12-31" id="xdx2ixbrl1010" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1019" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1020" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="FBLG:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="AsOf2023-12-31" id="xdx2ixbrl1076" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1157" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1165" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1167" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1181" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1189" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="fblg-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_VotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_VotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NetParentInvestmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:NetParentInvestmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_VotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NetParentInvestmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:NetParentInvestmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_VotingCommonStockMember37662156">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NetParentInvestmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:NetParentInvestmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NetParentInvestmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:NetParentInvestmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_VotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_NetParentInvestmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:NetParentInvestmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_VotingCommonStockMember37662203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-18_us-gaap_NonvotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">FBLG:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">FBLG:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LaborataryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">FBLG:LaborataryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputMaturityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">FBLG:LiabilityInstrumentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">FBLG:LiabilityInstrumentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">FBLG:LiabilityInstrumentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">FBLG:LiabilityInstrumentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">FBLG:LiabilityInstrumentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-28_custom_TwoThousandTwentyTwoNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-282023-02-28_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-28</xbrli:startDate>
        <xbrli:endDate>2023-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_TwoThousandTwentyOneNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyOneNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_TwoThousandTwentyTwoNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-302023-04-30_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-30</xbrli:startDate>
        <xbrli:endDate>2023-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_TwoThousandTwentyTwoNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_NonvotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-31_us-gaap_NonvotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_SeriesBOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_SeriesB1PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesB1PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesBOnePreferredStockMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_us-gaap_NonvotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-312023-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-31</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-12_custom_SharePurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-122021-11-12_custom_SharePurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-12</xbrli:startDate>
        <xbrli:endDate>2021-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ShortTermLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:ShortTermLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-31_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OperatingLeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FBLG:OperatingLeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShorttermLeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FBLG:ShorttermLeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_FibroGenesisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">FBLG:FibroGenesisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_custom_FibroGenesisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">FBLG:FibroGenesisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FibroGenesisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">FBLG:FibroGenesisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012023-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2023-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember_custom_DirectorsAndOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">FBLG:DirectorsAndOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-24</xbrli:startDate>
        <xbrli:endDate>2024-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-24</xbrli:startDate>
        <xbrli:endDate>2024-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-012024-02-29_custom_SharePurchaseAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001958777</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-01</xbrli:startDate>
        <xbrli:endDate>2024-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_909_edei--DocumentType_c20230101__20231231_z3IVedd4FqOc"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentType" id="ixv-18197">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--DocumentAnnualReport_c20230101__20231231_zN8l3AEamvy3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport" id="ixv-18198">&#9746;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
                                            REPORT PURSUANT TO SECTION 13 OR 15(d)</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OF
    THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the fiscal year ended <span style="text-decoration: underline"><span id="xdx_90D_edei--DocumentPeriodEndDate_c20230101__20231231_zO1GQrDifbsi"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-65"><span id="xdx_90B_edei--CurrentFiscalYearEndDate_c20230101__20231231_zPhLXcekDef2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="ixv-18199">December 31</ix:nonNumeric></span>, <span id="xdx_90D_edei--DocumentFiscalYearFocus_c20230101__20231231_zH1yfuCCM0uh"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-18200">2023</ix:nonNumeric></span></ix:nonNumeric></span></span>.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>or</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--DocumentTransitionReport_c20230101__20231231_z1OphBNTGs6i"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="ixv-18201">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
                                            REPORT PURSUANT TO SECTION 13 OR 15(d)</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OF
    THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the transition period from <span style="text-decoration: underline">[&#8212;Date&#8212;] </span>to <span style="text-decoration: underline">[&#8212;Date&#8212;]</span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number: <span id="xdx_90B_edei--EntityFileNumber_c20230101__20231231_zWm9czwCcZ62"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityFileNumber" id="ixv-18202">001-41934</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_905_edei--EntityRegistrantName_c20230101__20231231_zVxygUJIE2na"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityRegistrantName" id="ixv-18203">FibroBiologics,
Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20230101__20231231_z4mAALHW3W4e"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-18204">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20230101__20231231_zSBT9bqvav8"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityTaxIdentificationNumber" id="ixv-18205">86-3329066</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20230101__20231231_zW6ob0bc8ili"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressAddressLine1" id="ixv-18206">455
                                            E. Medical Center Blvd</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20230101__20231231_zvPxt9axwJJ4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressAddressLine2" id="ixv-18207">Suite 300</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressCityOrTown_c20230101__20231231_zuxgP1JhMeR6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressCityOrTown" id="ixv-18208">Houston</ix:nonNumeric></span>,
    <span id="xdx_906_edei--EntityAddressStateOrProvince_c20230101__20231231_zgz4quE7jhW4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressStateOrProvince" id="ixv-18209">TX</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20230101__20231231_zzJPMCLnnumf"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressPostalZipCode" id="ixv-18210">77598</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20230101__20231231_zpRHwUFe0E2h"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityAddressPostalZipCode" id="ixv-18211">77598</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--CityAreaCode_c20230101__20231231_zUwQi7OoBIaf"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:CityAreaCode" id="ixv-18212">(281)</ix:nonNumeric></span>
<span id="xdx_90E_edei--LocalPhoneNumber_c20230101__20231231_zpvAGZQMpVf3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:LocalPhoneNumber" id="ixv-18213">651-5150</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section 12(g) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Common
Stock, $0.00001 par value)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate&#160;
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_901_edei--EntityWellKnownSeasonedIssuer_c20230101__20231231_zWpaYU7RPTVi"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-18214">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_90D_edei--EntityVoluntaryFilers_c20230101__20231231_z0RFGmXaudD1"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityVoluntaryFilers" id="ixv-18215">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
</b>&#8211; Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange
Act from their obligations under those Sections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90E_edei--EntityCurrentReportingStatus_c20230101__20231231_zgJVn17rdPNc"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityCurrentReportingStatus" id="ixv-18216">Yes</ix:nonNumeric></span> &#9746;  No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_900_edei--EntityInteractiveDataCurrent_c20230101__20231231_zmJoswFw563c"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:EntityInteractiveDataCurrent" id="ixv-18217">Yes</ix:nonNumeric></span> &#9746;  No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221;
in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityFilerCategory_c20230101__20231231_zuS43T62X8be"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-18218">Non-accelerated
filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_907_edei--EntitySmallBusiness_c20230101__20231231_zo6EkAAXi9C5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="ixv-18219">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20230101__20231231_z7MvZQgm1j3i"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="ixv-18220">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_905_edei--EntityExTransitionPeriod_c20230101__20231231_z11YPJLvgmWk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod" id="ixv-18221">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant has
filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting fi rm that prepared or issued its
audit report. <span id="xdx_905_edei--IcfrAuditorAttestationFlag_c20230101__20231231_zC0V0kaAG8Pg"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag" id="ixv-18222">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If securities are registered pursuant to Section 12(b)
of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of
an error to previously issued financial statements. <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_909_edei--DocumentFinStmtErrorCorrectionFlag_c20230101__20231231_zpzKIhjVS9rf"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-18223">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Segoe UI Symbol,sans-serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recover analysis of incentive-based compensation received by any of the registrant&#8217;s executive
officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744;  <span id="xdx_90D_edei--EntityShellCompany_c20230101__20231231_zwCeQxAWhrK6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="ixv-18224">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The registrant completed the direct listing of its common stock and its shares commenced trading on Nasdaq on January 31, 2024. There
was <span id="xdx_90B_edei--EntityPublicFloat_iI_do_c20230630_zb1tUKhk8B35"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-06-30" format="ixt-sec:numwordsen" decimals="0" unitRef="USD" id="ixv-18225">no</ix:nonFraction></span> public market for the registrant&#8217;s common stock as of June 30, 2023, the last business day of the registrant&#8217;s most
recently completed second fiscal quarter, therefore the registrant cannot calculate the aggregate market value of its voting and non-voting
common equity held by non-affiliates at such date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">At February 20, 2024,
<span id="xdx_90D_edei--EntityCommonStockSharesOutstanding_iI_c20240220_zzj6xrt5dTk5"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-02-20" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18226">32,634,366</ix:nonFraction></span></span> <span style="font-size: 10pt">shares
of FibroBiologics, Inc.&#8217;s Common Stock, $0.00001 par value per share, and 2,500 shares of FibroBiologics, Inc&#8217;s Series C
Preferred Stock, $0.00001 par value per share, were outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K, or Annual Report, and the documents incorporated by reference herein, if any, contain forward-looking
statements that can involve substantial risks and uncertainties. All statements other than statements of historical facts contained
in this Annual Report, including statements regarding our future results of operations and financial position, business strategy,
prospective products, product approvals, research and development costs, future revenue, timing and likelihood of success, plans and
objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of
management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221;
&#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221;
&#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221;
or &#8220;would&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain
these words. Forward-looking statements contained in this annual report include, but are not limited to, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, progress and results of preclinical studies and clinical trials for our current and future product candidates, including
    statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during
    which the results of the trials will become available and our research and development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, scope or likelihood of regulatory submissions, filings, and approvals, including final regulatory approval of our product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to develop and advance product candidates into, and successfully complete, clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding the size of the patient populations for our product candidates, if approved for commercial use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model and our strategic plans for our business, product candidates and technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    commercialization, marketing and manufacturing capabilities and strategy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    pricing and reimbursement of our product candidates, if approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate and degree of market acceptance and clinical utility of our product candidates, in particular, and cell therapy, in general;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish or maintain collaborations or strategic relationships or obtain additional funding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitive position;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of protection we and/or our licensors are able to establish and maintain for intellectual property rights covering our product
    candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    and projections relating to our competitors and our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and
    capital expenditure requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of laws and regulations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which
we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and
these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only
as of the date of this annual report and are subject to a number of risks, uncertainties and assumptions described in the section titled
&#8220;<i>Risk Factors</i>&#8221; and elsewhere in this Annual Report. Because forward-looking statements are inherently subject to risks
and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions
of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results
could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan
to publicly update or revise any forward-looking statements contained herein until after we distribute this Annual Report, whether as
a result of any new information, future events or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this annual report, and while we believe such information forms
a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain and you are cautioned not to unduly rely upon these statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#S_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#S_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">26</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">79</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#item1c_001">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">79</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">79</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">79</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">79</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">80</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">80</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">80</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">91</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">91</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">91</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">91</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">92</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">92</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><a href="#ak_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART III</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">92</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">99</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">106</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">108</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Fees and Services</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">109</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><a href="#ak_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART IV</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#ak_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">110</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unless
otherwise indicated or the context otherwise requires, all references to the &#8220;Company,&#8221; &#8220;FibroBiologics,&#8221; &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our&#8221; and the &#8220;registrant&#8221; refer to FibroBiologics, Inc. and its consolidated subsidiaries.</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S_001"></span>Item
                                            1.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering
from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and
certain cancers, and potential extension of life applications including thymic and splenic involution reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were formed in April 2021 as a Texas limited liability company under the name FibroBiologics, LLC, and converted to a Delaware corporation
in December 2021 under the name Fibrobiologics, Inc. On April 14, 2023, we changed our name to FibroBiologics, Inc. In connection with
our formation, we issued shares of our Series A Preferred Stock, or the Series A Preferred Stock, to our then parent, FibroGenesis, in
return for rights to certain intellectual property through a patent assignment agreement and an intellectual property cross-licensing
agreement. Developing the intellectual property obtained from FibroGenesis was the basis for our formation. Prior to our inception, preclinical
research and development related to the aforementioned disease pathways took place under FibroGenesis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fibroblasts
Technology Platform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fibroblasts
and stem cells are the only two cell types in the human body that can regenerate tissue and organs. Studies have indicated that mesenchymal
stem cells and fibroblasts share many surface markers in common, and can differentiate into many cells including adipocytes, chondrocytes,
osteoblasts, hepatocytes, and cardiomyocytes, and can regulate the immune system. However, transcriptomic and epigenetic studies have
indicated a clear difference between the two cell types.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fibroblasts
comprise the main cell type of connective tissue, possessing a spindle-shaped morphology, whose classical function has historically been
believed to produce an extracellular matrix responsible for maintaining the structural integrity of the tissue. Fibroblasts also play
an important role in the proliferative phase of wound healing, resulting in the deposition of the extracellular matrix.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fibroblasts
are favorable to stem cells as a cell therapy treatment platform because fibroblasts:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">can
    be non-invasively harvested from a variety of skin donors from surgical procedures such as tummy tuck flaps;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
    a faster doubling time in culture than stem cells;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">possess
    superior immune modulatory activity compared with stem cells;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exhibit
    enhanced ability to produce regenerative cytokines and growth factors compared with stem cells; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
    more economical to isolate, culture and expand compared with stem cells because fibroblasts do not require the use of expensive tissue
    culture media.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
have demonstrated that allogeneic fibroblasts, much like mesenchymal stem cells, are immune-privileged and do not provoke an immune response
<i>in vitro </i>and <i>in vivo</i>. These studies include that of Valente and colleagues (PMID 7646145) in which they looked at the aortic
valve after heart transplantation and noted that even acute cases of acute myocardial rejection did not appear to compromise the long-term
viability and durability of the valve, and the tissue viability was histologically confirmed and showed perfectly preserved fibroblasts<sup>1</sup>.
In another study by O&#8217;Brien and colleagues (PMID 3682851) the researchers illustrated, using chromosomal analysis, long-term viability
of the male donor fibroblast cells from a valve leaflet removed nine years after implantation into a female recipient. This illustrated
that donor fibroblast cells are able to survive and proliferate in the host with destruction by the immune system<sup>2</sup>. If autologous
fibroblasts were required instead, it would mean that cells would have to be harvested from each patient, processed and cultured, and
then administered to the same patient, which would be more costly and inefficient. Because allogeneic fibroblasts do not cause an immune
response, we are planning to build our own cGMP manufacturing facility to source allogeneic fibroblast cells for clinical testing of
our product candidates and for commercial sales if product candidates receive marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Strategy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are leveraging fibroblast cells as a technology platform to research and develop innovative treatments for chronic diseases with significant
unmet treatment needs. Our vision is to become a world leader in regenerative medicine through a rigorous scientific process and commitment
to serving patients&#8217; needs. To achieve our vision, we will focus our efforts on the following strategy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attract
    and retain scientists with the skill sets required to conduct preclinical studies and identify the optimal paths forward to clinical
    trials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prioritize
    our initial clinical development efforts on product candidates with the combination of significant unmet treatment needs, lower risk
    and market potential.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner
    with Clinical Research Organizations, or CROs, with the relevant expertise and experience to successfully and timely execute clinical
    trials to generate reliable pivotal data that can be used to seek approvals.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Invest
    in critical capabilities required to produce and supply fibroblasts for clinical trials and initial commercialization.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protect,
    expand and defend our intellectual property portfolio around fibroblasts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expand
    development efforts in product candidates with longer development timelines, greater risk and significant unmet treatment needs as
    funding allows. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had cash and cash equivalents of approximately $9.2 million. To advance our aforementioned strategy over the
next 12 months, in addition to ongoing expenditures for personnel and infrastructure, the following research and development initiatives
are expected to be funded with available capital:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    $0.1 million to $0.2 million in capital expenditures for laboratory equipment to enable continued research and expand capabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    $0.3 million to $0.4 million to acquire clinical skin samples;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    $0.2 million to $0.3 million for tissue and fibroblast cell characterization and optimization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    $0.2 million to $0.4 million to develop a master cell bank;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    $0.1 million to $0.3 million to develop a working cell bank;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    $0.1 million to $0.3 million to develop processes for transfer to a CDMO;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    $0.1 million to submit an IND application for CYWC628 for a phase 1/2 clinical trial in wound healing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    $0.2 million to $0.3 million to complete a preclinical animal study to determine mode of action for CYMS101 in MS prior to submitting
    an IND application for a phase 1/2 clinical trial in MS; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    $0.1 million to initiate a preclinical animal study in CYTER915 for thymic involution reversal.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our available capital will allow us to develop the master cell bank, and working cell bank for transfer to a CDMO that will ultimately
manufacture our drug products required to initiate phase 1/2 clinical trials for CybroCell, CYMS101, and CYWC628.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above estimates are preliminary and subject to change. We cannot specify with certainty all of the particular uses for our available
capital within the next 12 months. Due to uncertainties inherent in the development process, it is difficult to estimate the exact amounts
of our available capital that will be used for any particular purpose. In addition, the amount, allocation and timing of our actual expenditures
will depend upon numerous factors, including the results of our research and development efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
People</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have assembled an executive leadership team comprised of our founder, chief executive officer and chairperson of our board of directors,
our chief scientific officer, and our chief financial officer, with successful track records in startup entrepreneurial companies and
in the life sciences industry. Our executive leadership team works under the oversight of our board of directors who are recognized leaders
with hands-on industry experience. We also have a team of world-renowned scientists with relevant expertise on our scientific advisory
board to help guide our research and development efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Current Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a pipeline of product candidates at various stages of development, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_001.jpg" alt="A diagram of a process&#10;&#10;Description automatically generated with medium confidence" style="height: 329px; width: 576px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CybroCell<sup>TM
</sup>for Degenerative Disc Disease</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Degenerative
Disc Disease</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Back
pain is strongly associated with degeneration of the intervertebral disc. Disc degeneration, although in many cases asymptomatic, is
also associated with sciatica and disc herniation, pain or prolapse. It alters disc height and the mechanics of the rest of the spinal
column, adversely affecting the behavior of other spinal structures such as muscles and ligaments. In the long term, it can lead to spinal
stenosis, a major cause of pain and disability in the elderly. Its incidence is rising with current demographic changes and an increased
aged population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disc acts as a joint between two vertebra and performs the following critical functions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">absorbs
    shock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintains
    motion; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">keeps
    stability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discs
degenerate far earlier than do other musculoskeletal tissues. The first unequivocal findings of degeneration in the lumbar discs are
seen in the age group 11&#8211;16 years. About 20% of people in their teens have discs with mild signs of degeneration. The percentage
increases sharply with age, particularly in males, so that around 10% of 50-year-old discs and 60% of 70-year-old discs are severely
degenerated (<i>Current Epidemiology of Low Back Pain</i>&#8221; by Mattiuzzi et al, in 2020).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
growth and skeletal maturation, the boundary between annulus and nucleus becomes less obvious and, with increasing age, the nucleus generally
becomes more fibrotic and less gel-like. With increasing age and degeneration, the disc changes in morphology, becoming more and more
disorganized. Often, the annular lamellae becomes irregular, bifurcating and interdigitating, and the collagen and elastin networks also
appear to become more disorganized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cleft
formation with fissures frequently forms within the disc, particularly in the nucleus. Nerves and blood vessels are increasingly found
with degeneration. Cell proliferation occurs, leading to cluster formation in the nucleus. Cell death also occurs, with the presence
of cells with necrotic and apoptotic appearance. It has been reported that more than 50% of cells in adult discs are necrotic. With increasing
age comes an increased incidence of degenerative changes, including cell death, cell proliferation, mucous degeneration, granular change
and concentric tears. It is difficult to differentiate changes that occur solely due to aging from those that might be considered &#8216;pathological&#8217;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to research published in the Global Spine Journal, titled &#8220;<i>Degenerative Lumbar Spine Disease: Estimating Global Incidence and
Worldwide</i>&#8221; by Ravindra et al published in 2018, approximately 266.0 million individuals suffer from degenerative spinal disease
and lower back pain each year. In addition, 403.0 million individuals present annually with symptomatic disc degeneration, 103.0 million
with spinal stenosis and 39.0 million with spondylolisthesis. Furthermore, lower back pain is considered as one of the chief complaints
that may indicate an underlying spine-related disorder. According to the research published in the Journal of Hospital Management and
Health Policy, titled &#8220;<i>Current Epidemiology of Low Back Pain</i>&#8221; by Mattiuzzi et al, in 2020, incidence, prevalence and
disability-adjusted life years, or DALYs, of lower back pain are 245.9 million cases per year (15th worldwide cause), 577.0 million cases
(15th worldwide cause) and 64.9 million (6th worldwide cause), respectively. The paper further stated that the risk of lower back pain
is marginally higher in women compared to men. Chronic lower back pain is one of the common complaints that may indicate an underlying
serious spinal disorder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
statistics indicate the significant impact degenerative spine disorders can have on patients&#8217; lives. These indications are associated
with a diverse range of clinical symptoms such as weakness, low extremity pain and back pain, and can result in a significant reduction
in the quality of life. The treatments used presently are mainly conservative and palliative and are aimed at returning patients to work.
They range from bed rest (no longer recommended) to analgesia, the use of muscle relaxants or injection of corticosteroids, or local
anesthetic and manipulation therapies. Various interventions (e.g. intradiscal electrotherapy) are also used, but despite anecdotal statements
of success, trials thus far have found their use to be of little direct benefit. Disc degeneration-related pain may also be treated surgically
either by artificial disc replacement or by immobilization of the affected vertebrae.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Available
Treatments for Degenerative Disc Disease</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
patients suffering from degenerative disc disease, at least initially, show improvement with non-surgical interventions such as physical
therapy, core strengthening, and stretching. When those interventions no longer provide relief, patients typically use therapeutics,
which include conventional drugs such as opioids, non-steroidal anti-inflammatory drugs, and corticosteroids for pain relief. When these
non-surgical therapeutics are no longer effective, patients may undergo surgical treatment, including the use of medical devices or implants,
to provide relief.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
original surgical treatment for correcting degenerated disc is either to perform a discectomy or spinal fusion. Discectomy is an appropriate
procedure and is routinely performed to remove the degenerated nucleus through a fenestration within the annulus. It allows removal of
both the extruded nucleus (herniectomy) and the degenerated remaining inter-vertebral nucleus fragments. Although this procedure is ideal
for decompressing and relieving the nervous system (root or cauda equina), it is a poor operation for the spine, due to its resulting
disabling condition which leads to a degenerative cascade and may require an additional invasive surgical procedure, like fusion or arthroplasty.
Discectomy brings a good short-term effect in relieving radicular pain, but it causes disc height reduction with neuro-foramen stenosis,
instability of the treated level, poor result on back pain, and/or complications, such as spinal stenosis or facet pain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
who undergo these procedures are usually on painkillers for weeks and have at least three to six months of recovery time. Therefore,
there is a need for a less painful, less invasive and more effective method. The pitfalls of original treatment procedures have led to
a search for the development of non-fusion technologies, such as disc or disc nucleus prosthesis. Disc arthroplasty with an artificial
disc is an emerging treatment for patients with disc degeneration. Its advantages are to maintain motion, decrease incidence of adjacent
segment degeneration, avoid complications related to fusion and allow early return to function. Currently, two kinds of devices are marketed:
the total disc replacement and the nuclear replacement. However, both of these devices have major pitfalls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been a growing demand for spinal artificial discs in the market globally. These devices are gaining popularity as they are designed
with the intent to provide stabilization and eliminate pain while preserving motion of the functional spinal unit. In July 2021, Aesculap
Implant Systems, LLC announced the long-term reporting from its pivotal trial for the activL&#174; Artificial Disc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt="A close-up of a grey object&#10;&#10;Description automatically generated" style="height: 190px; width: 244px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Centinel
Spine&#8217;s prodiscL is a Total Disc Replacement, or TDR, technology platform that offers a surgical alternative to fusion to qualified
patients suffering from disc degeneration in the cervical and lumbar spine. ProdiscL implants are intended to relieve pain while allowing
the potential for motion at the diseased spinal segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt="A close-up of a metal object&#10;&#10;Description automatically generated" style="height: 186px; width: 263px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
activL Artificial Disc for one-level lumbar use is a weight-bearing modular implant consisting of two endplates and one polyethylene
inlay and is intended as an alternative to fusion. It&#8217;s designed to allow controlled motion at the surgery level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
disc replacement is a bulky metallic prosthesis designed to replace the entire disc: annulus, nucleus and endplates. These prostheses
use an invasive anterior (trans- or retro-peritoneal) approach that requires the presence of a vascular surgeon. Dislodgements, wear
debris, degeneration of adjacent intervertebral discs, facet joint arthrosis and subsidence of this type of prosthesis have been reported.
The artificial nucleus substitute preserves the remaining disc tissues and their functions. Its design allows its implantation through
a posterior approach, but the major limitation of such nucleus prosthesis is that it can be used only in patients in whom disc degeneration
is at an early or intermediate stage, because it requires the presence of a competent natural annulus. As a hydrogel-based device, it
is fragile, and so does not resist the outstanding biomechanical constraints of the lumbar spine (shear forces). As inert materials,
they may lose their mechanical properties over time, and tears and breakages have been reported. Replacing the nucleus only and leaving
in place a damaged annulus generates the conditions for implant extrusion or recidivism of discal herniation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to disc replacements, there are current treatment options for tissue engineering and regenerative medicine, which represent
new options for the treatment of degenerative disc disease. A variety of approaches are used to regenerate tissues. These approaches
can be categorized into the following three groups:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomaterials,
    without additional cells, that are used to send signals to attract cells and promote regeneration;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cells
    alone may be used, to form a tissue; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cells
    may be used with a biomaterial scaffold that acts as a frame for developing tissues. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
Autologous Chondrocyte Transplantation, or ACT, has been used for a few years to repair articular cartilage, tissue engineering for disc
repair remains in its infancy. Intensive research is currently underway, and animal studies have shown the feasibility of tissue-engineered
intervertebral disc. Typically, articular cartilage is a tissue that is not naturally regenerated once damaged. Recently, efforts have
been made to reconstruct damaged biological tissues by regenerating a portion of the damaged tissues in laboratories. This approach,
defined as &#8220;tissue engineering,&#8221; has received tremendous attention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tissue
engineering involves the development of biocompatible materials capable of specifically interacting with biological tissues to produce
functional tissue equivalents. Tissue engineering has a basic concept of collecting a desired tissue from a patient, isolating cells
from the tissue specimen, proliferating cells, seeding the proliferated cells onto a biodegradable polymeric scaffold, culturing the
cells for a predetermined period in vitro, and transplanting back the cell/polymer construct into the patient. More interestingly, recent
pilot clinical trials have shown that ACT is an efficient treatment of herniated disc. The main disadvantage of ACT for disc repair is
that it requires a disc biopsy. Therefore, there is a need for an improved method to restore disc anatomy and improve its functioning,
and there remains a need for an improved method of cartilage repair.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
Solution</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CybroCell&#8482;
is an allogeneic fibroblast cell-based therapy for degenerative disc disease This new technology is being designed as an alternative
method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The method is based on using Human
Dermal Fibroblasts, or HDFs, which are forced to differentiate into chondrocyte-like cells <i>in vivo</i> using the mechanical force
and intermittent hydrostatic pressure found in the spine, for chondrogenic differentiation of fibroblasts. We believe our solution will
prove superior to existing treatments because it is less invasive, regenerates the disc, restores function and reduces pain, without
debilitating long-term effects. We received IND clearance from the FDA on November 7, 2018, with an IND number of 18151. The trial is
designed to assess the safety and efficacy of CybroCell&#8482; administered through injection directly into a damaged intervertebral
disc. The trial will enroll up to 15 participants with a primary outcome of safety and a secondary outcome of efficacy. Safety will be
assessed as the occurrence/frequency of adverse events during the study procedures and for up to 12 months afterwards and will be recorded
regardless of severity or relatedness to treatment. Serious adverse events will be documented throughout the 12-month follow-up period.
The incidence and nature of adverse events will be tabulated and analyzed at baseline, pre, and post procedure including the three, six,
and 12-months evaluations. These include complete physical exam (including vital signs of blood pressure, temperature, and heart rate),
laboratory determinations (including urinalysis, hematology, and biochemistry), review of medical history, review of medication history,
Dallas pain questionnaire, and patient questionnaire (Oswestry Disability Index). Secondary efficacy outcome will assess subjective and
objective parameters at three months, six months, and 12 months post CybroCell&#8482; implantation and compare to those measured at baseline
pre-implantation. These parameters will include visual analog scale, patient questionnaire (Oswestry Disability Index), Beck Depression
Inventory, Dallas pain questionnaire, range of motion test, and radiological assessment using MRI to evaluate morphological changes to
the treated discs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently in the process of finalizing the experimental cell bank production which will be transferred to a contract development
and manufacturing organization, or CDMO, for the manufacturing of the master cell bank and working cell bank per FDA requirements and
will submit the necessary documentation to the FDA. Our quotes from the CDMO for carrying out this work have been obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed two animal studies. Sixteen animals were used in the first pilot study (PMID 27853661) with the objective of determining
the effects of intradiscal transplantation of neonatal human dermal fibroblasts, or nHDFs, on intravertebral disc, or IVD, degeneration
by measuring disc height, magnetic resonance imaging, or MRI, signal intensity, gene expression, and collagen immunostaining. The results
indicated that in the nHDF group there was a 10% increase in disk height index after eight weeks of treatment with a p value of &lt;.05,
while there was no significant difference in the saline treated group. When compared with the saline treated group, discs treated with
nHDFs showed reduced expression of inflammatory markers, a higher ratio of collagen type II over collagen type I gene expression, and
more intense immunohistochemical staining for both collagen types I and II. In the second study (PMID 30142460) 38 animals were used
with the objective of determining the impact of donor source on the therapeutic effect of dermal fibroblast treatment on disc degeneration
and inflammation when comparing rabbit dermal fibroblasts, or RDFs, to nHDFs. Eight weeks after treatment, disc height indexes of discs
treated with nHDF increased significantly by 7.8% (p&lt;.01), whereas those treated with saline or RDF increased by 1.5% and 2.0%, respectively.
Gene expression analysis showed that discs transplanted with nHDFs and RDFs displayed similar inflammatory responses (p=.2 to .8). Compared
to intact discs, expression of both collagen types I and II increased significantly in nHDF-treated discs (p&lt;.05), trending to significant
in RDF-treated discs, and not significantly in saline treated discs. The ratio of collagen type II/collagen type I was higher in the
IVDs treated with nHDFs (1.26) than those treated with RDFs (0.81) or saline (0.59) and intact discs (1.00). Last, proteoglycan contents
increased significantly in discs treated with nHDF (p&lt;.05) and were trending toward significance in the RDF- treated discs compared
to those treated with saline. The results from the studies were positive and resulted in &#8220;first in human&#8221; trial approval.
The technology allowed for differentiation of the HDFs into chondrocytes and the cells thrived in the spinal disc environment. The results
showed the cells remained in the disc and did not migrate. Further, the cells created a biologic condition which appeared to increase
the disc height.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a summary of animal study results from Howard An, M.D., Director, Spine Fellowship Program, Rush University Medical College:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
studies have shown that this biological treatment using human dermal fibroblast cells, has great potential as a cell therapy for disc
degeneration. When these cells were injected into a degenerating rabbit disc, they were retained in the disc for up to 8 weeks. Collagen
Type II gene expression, a marker for disc repair and regeneration, was higher in the discs treated with human dermal fibroblast cells
than those in the control treatment. Also higher in the cell treated discs were the disc heights and cell number. Together, this data
suggests that human dermal fibroblast cells are a promising option for cell therapy to restore the biological function and reduce symptoms
of intermediate or progressive degenerative discs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received IND clearance from the FDA, conditional upon approval of our master cell bank, to run a Phase 1/2 study for patients suffering
from degenerative disc disease and will be conducting this study within the United States. A timeline will be determined through discussions
with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Market
Opportunity</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Degenerative
disc disease therapeutics represents an approximately $26.0 billion<sup>1</sup> per year market. In addition to therapeutics, degenerative
disc disease results in approximately 1.2 million orthopedic surgeries per year, at a cost of approximately $60,000 to $100,000 each,
in the United States alone. CybroCell&#8482; could replace therapeutics or defer many of these surgeries if it proves successful in regenerating
disc cartilage and alleviating pain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1
</sup>Fortune Business Insights Report, &#8220;<i>Degenerative Disc Disease Therapeutics: Global Market Analysis. Insights and Forecast
2022-2029</i>,&#8221; p.13.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CYMS101
for Multiple Sclerosis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Multiple
Sclerosis</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
sclerosis, or MS, has been characterized into four distinct clinical subtypes, differing in the age of onset, aggressiveness and progression
of the disease, and frequency of relapses. Most MS cases (85%) follow a relapsing-remitting pattern, or RRMS, with an average relapse
every 12 to 18 months in an untreated population, and short-term episodes of neurologic deficits that resolve completely or almost completely.
MS relapse is commonly defined as new or worsening symptoms that last 24 hours in duration and occur in the absence of fever or infection.
Other patients may transition to a more aggressive disease form known as secondary progressive MS, or will experience steadily progressive
neurologic deterioration without relapses, known as primary progressive MS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no primary indicator test for MS, but common testing for suspected MS involves MRI studies, evoked potentials testing, lumbar puncture/spinal
tap, and other objective functional tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a diagnosis of MS has been determined, ongoing periodic disability measurement testing will occur as a standard clinical practice. The
first Disability Status Scale was introduced by Kurtzke in 1955 and was later enhanced in 1983 into the Expanded Disability Status Scale,
or EDSS. Over time, the EDSS has become the standard against which most MS clinical outcome measures are compared. Eight functional neurological
systems are measured by the EDSS including vision, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, mental/cerebral and ambulation
(500m walk).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
disability measurement tests include the Scripps Neurological Rating Scale, which is an overall neurological assessment; the Nine-Hole
Pin Test, which measures arm function; and the Timed 25-Foot Walk Test, which measures ambulation function. The RAND 36-Question Health
Survey may also be used, which is a general Quality of Life survey utilized by managed care organizations and by Medicare for routine
monitoring and assessment of care outcomes in adult patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Available
Treatments for MS</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no known cure for MS. Treatments available for MS include steroids for temporary flare-ups, disease-modifying drugs, and drugs that
target specific symptoms such as balance, vision, spasticity, sexual dysfunction, and bladder or bowel control. The mechanism of action
of current MS disease-modifying drugs is to block the host&#8217;s immune-mediated attacks on the nerves to inhibit or minimize the progressive
destruction of myelin. While these drugs may reduce the frequency of exacerbations and slow the disease progression from inducing further
nerve damage, there is no myelin or nerve regenerative capability in any of them to restore the cumulative damage already in place. Additionally,
as the disease progresses further, the ability for any of these drugs to effectively block immune-mediated myelin or nerve destruction
becomes more blunted. Most MS drugs come with identified risks and side effects, including &#8220;black box&#8221; warnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
companies providing existing MS treatments include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biogen,
    Inc.: Strong presence in the global market coupled with a diverse portfolio of MS drugs; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.
    Hoffmann-La Roche Ltd (commonly known as Roche): Strong focus on research and development activities to develop novel medicine for
    MS treatment; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novartis
    AG: Increased focus on investment in research and development of innovative molecules.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">New
Treatments Being Developed</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development in the neurological therapy area has always been active. Various novel molecules are being investigated for the treatment
of MS. Some of the key pharmaceutical players are emphasizing the improvement of the disabilities associated with MS. The pipeline portfolios
of various companies include agents with different mechanisms of action, which are expected to boost their demand from physicians, aiming
to change the treatment algorithm in the coming years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a decade, various companies such as Sanofi, Johnson &amp; Johnson, and Novartis AG, among others, have been investing in the treatment
for MS to bring novel therapeutics with high efficacy and potency for patients. These companies have recently launched therapeutics intended
for the most prevalent form of MS. In August 2020, the FDA approved Novartis AG&#8217;s Kesimpta, the only self-administered, targeted
B-cell therapy for patients with relapsing MS, and in March 2021, Johnson &amp; Johnson received FDA approval for the launch of Ponvory
as a daily oral drug for treatment against MS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost, outcome and quality of drugs approved is a priority of physicians as well as patients. Physicians play an important role in developing
an interdisciplinary approach for the management of MS, which is a key cause for manufacturers to focus on novel molecules with different
mechanisms of action. For instance, TG Therapeutics, Inc.&#8217;s ublituximab was recently approved by the FDA for the treatment of relapsing
forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approval and commercialization of these recently approved drugs for the treatment of symptoms associated with MS is expected to boost
the MS drug market growth globally in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
Solution</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat MS. After completing animal studies using CYMS101 (allogeneic
fibroblast cells), we received approval from Mexico for the conduct of clinical investigations using the fibroblast cell composition
for patients with MS, and have completed the Phase 1 study called &#8220;<i>Feasibility Study of Tolerogenic Fibroblasts in Patients
with Refractory Multiple Sclerosis</i>.&#8221; The study was conducted in five participants. The primary objective of the study was to
assess safety, and the secondary objective was to assess efficacy. The results of the study for safety were no adverse effects during
intravenous injection of the tolerogenic fibroblasts, no short or long-impact in complete blood count test during the 16-week monitoring
period, and no short or long impact in electrocardiogram results during the 16-week monitoring period. In addition, the results of the
study for efficacy included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paced
    Auditory Serial Addition Test (PASAT). The test was developed by Gronwell in 1977 and later adapted by Rao in 1989 for use in MS.
    The test is a measure of cognitive function that assesses auditory information processing speed as well as calculation ability. In
    the test, single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it.
    Scoring is the total number of correct responses out of 60 possible. There was a general improvement in PASAT score for all patients
    during the 16-week monitoring period.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_004.jpg" alt="A graph showing the results of a patient's recovery&#10;&#10;Description automatically generated" style="height: 270px; width: 415px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine-Hole
    Peg Test. This is a standardized quantitative test of upper extremity function. The test is the most frequently used measure of upper
    extremity function in MS. In the test, dominant and non-dominant hands are tested twice. In the test, pegs are picked up one at a
    time and placed in one of nine holes. Once all nine pegs are placed, the patient then removes the pegs one at a time and places them
    back in the container. Scoring is the time required to place pegs in holes and then remove the pegs from holes. General improvement
    of Nine-Hole Peg Test completion time for all patients during the 16-week testing period was noted. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_005.jpg" alt="A graph showing the results of a patient&#10;&#10;Description automatically generated" style="height: 242px; width: 404px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timed
    25-Foot Walk Test. The test is a quantitative mobility and leg function performance test. In the test, the patient is instructed
    to walk a 25 feet long path quickly but safely. The test is administered again by having the patient walk back the same distance.
    The score of the test is the average time of the two completed walks. No general improvement or deterioration was noted with the
    Timed 25-Foot Walk Test.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_006.jpg" alt="A graph showing the results of a patient's test&#10;&#10;Description automatically generated" style="height: 229px; width: 333px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expanded
    Disability Status Scale (EDSS). The test is used to quantify disability in MS and monitor changes in the level of disability over
    time. EDSS is widely used in clinical trials for assessment of participants with MS. The scale is based on neurological examination
    and impact on functional systems representing the network of neurons in the brain. EDSS scoring can vary widely due to complex scoring
    rules and subjective nature of the neurological testing. No general improvement or deterioration was noted with EDSS test, and no
    patient exhibited further deterioration during the study.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_007.jpg" alt="A chart of a patient's status scale&#10;&#10;Description automatically generated" style="height: 249px; width: 322px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
determining the mode of action is not necessary for filing for FDA approval (Brown and Wobst, 2020), and to date between 10-20% of approved
drugs have no known mode of action determined (Moffat et al., 2017), we are currently conducting further research to determine the mode
of action of fibroblasts in oligodendrocyte expansion. We will file an IND application for a Phase 2 clinical trial in MS in the United
States. While determining the mode of action will be optimal, having a general sense of possible mode of action will have a tangible
benefit in the development, optimization and mitigation of possible side-effects. We will likely seek a strategic partner to collaborate
with us on the development of CYMS101 either before initiating the Phase 2 study, or after its completion, if successful, and prior to
commencing with a Phase 3 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Market
Opportunity</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MS drug market&#8217;s annual revenue is presently approximately $24.0 billion<sup>2</sup> globally, with 48% of the revenues generated
in the United States. The key companies in this market include Biogen Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Novartis AG. While
there are more than 20 approved treatments, most of them have serious adverse effects and there are presently no cures. Both private
and public organizations are increasing their investments in search of better treatments for this complex disease, including treatments
that restore lost function, and government initiatives to improve access to MS drugs in developing economies are another driver of future
growth in the MS market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CYWC628
for Wound Healing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Wound
Care/Healing</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
chronic wound is one that is usually arrested in the inflammatory stage and cannot progress to the proliferative and remodeling phase
of healing. Proinflammatory cytokines produced by necrotic tissue, foreign material and bacteria allow the inflammatory stage to continue.
In addition, changes in the cellular deoxyribonucleic acid, or DNA, synthesis leads to increased formation of metalloproteases that impede
the body&#8217;s attempt to heal by overwhelming the building blocks&#8212;chemotactant factors, growth factors and mitogens&#8212;needed
for normal wound healing. Fibroblasts, an essential cell in the wound healing process, is epigenetically altered in the setting of chronic
wounds so that their ability to replicate as well as produce the necessary building blocks for the formation of granulation tissue is
altered. Further, the keratinocytes at the periphery of the wounds are phenotypically different so that while being able to proliferate,
they cannot fully differentiate into migrating keratinocytes. This explains the epithelial build up often seen around the edge of the
wound.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diabetic
foot ulcers are the most prominent type of chronic wounds. The rising prevalence of chronic diseases globally, is leading to increased
incidence of chronic wounds, including diabetic foot ulcers, pressure ulcers and venous leg ulcers. These chronic wounds, especially
late-stage &#8220;hard-to-heal ulcers,&#8221; exert a huge economic cost burden on healthcare agencies globally. Furthermore, over 50%
of diabetic foot ulcers become infected, which raises the risk of hospitalization, amputation and death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><sup>2</sup> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fortune
Business Insight Report, &#8220;Multiple Sclerosis Drugs: Global Market Analysis, Insights and Forecast, 2022-2029,&#8221; p.13.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Available
Wound Care Treatments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
treatments are presently available for treatment of chronic wounds, including Apligraf, Grafix, DermACELL and TheraSkin. Apligraf is
comprised of neonatal keratinocytes, and neonatal fibroblasts within a bovine collagen matrix, and may be used to treat venous leg ulcers
and diabetic foot ulcers. Grafix is a cryopreserved human placental membrane that may be used as a wound cover, wrap and/or barrier to
treat acute and chronic wounds, diabetic ulcers, pressure injuries, surgical wounds, burns and venous ulcers. DermACELL is a technologically
advanced dermal matrix comprised of intact cellular matrix that has at least 97% of DNA removed and may be used in the treatment of chronic
wounds such as diabetic foot ulcers. TheraSkin is a cryopreserved human skin allograft with both epidermis and dermis layers that may
be used to promote wound healing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">New
Treatments Being Developed</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing
application of bioactive therapies like skin grafting and growth factors in urgent treatment of wounds like diabetic foot ulcers is resulting
in high investment of market players in research and development of these therapies. Accordingly, the rise in adoption rate of advance
bioactive therapies for rapid wound healing is expected to propel the growth of wound care market. For example, in February 2021, Axio
Biosolutions Private Limited received CE mark from Europe for its MaxioCel advanced wound care product. The bioactive microfiber gelling
technology helps wounds heal quickly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distinct
clinical benefits offered by negative pressure wound therapy, or NPWT, coupled with introduction of new advanced features such as single
use and portability, among others, for effective wound care is boosting the demand for NPWT devices from healthcare professionals globally.
In January 2021, Smith &amp; Nephew plc published that its PICO single-use negative pressure wound therapy system significantly reduced
surgical site infections by 63.0% and dehiscence by 30.0%. In January 2019, Applied Tissue Technologies LLC received FDA approval
for its Platform Wound Dressing, NPWT device that eliminates the use of foam or gauze dressings. In April 2019, PolarityTE, Inc. launched
clinical trials for its SkinTE regenerative tissue product for chronic wounds. The trials will evaluate SkinTE&#8217;s effectiveness
in treating diabetic foot ulcers and venous leg ulcers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
new players are entering the wound care market by focusing on allograft, xenograft, nanofibre, dermal substitutes and cell-based therapies
to cater the unmet needs and growing demand for urgent and effective treatment among patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
Solution</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the early stages of developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Our studies are presently
focused on utilizing fibroblasts and fibroblast-derived cells to treat wounds in diabetic mice and rats. Based upon our results achieved
to date, we plan to pursue an IND submission with the FDA for wound healing as early as 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Market
Opportunity</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
wound care market size was valued at approximately $17.0 billion<sup>3</sup> globally in 2021, with more than half of the revenue generated
in the United States and Europe, and, according to Fortune Business Insights published in March 2022, was projected to grow to approximately
$28.0 billion by 2029. The rising prevalence of chronic diseases globally is leading to increased incidence of chronic wounds, including
diabetic foot ulcers, pressure ulcers and venous leg ulcers. The huge economic cost burden exerted by chronic and acute wounds has led
to an increase in initiatives being undertaken by governments globally, to create awareness among the general population for early diagnosis
of wounds. These initiatives, along with improving reimbursement policies for wound care in these countries, are anticipated to drive
the adoption of wound care products and lead to continued growth in this market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><sup>3</sup><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fortune
Business Insights, &#8220;Wound Care: Global Market Analysis, Insights and Forecast, 2022-2029,&#8221; p. 26.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Early-Stage Research</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CYTER915
for Extension of Life</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Extension
of Life</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fibroblasts
are no longer considered as mere structural components of organs but as dynamic participants in immune processes. Fibroblasts produce
an environment that influences regulatory T cell migration, proliferation and activity, to ensure immunotolerance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the key organs of the immune system is the thymus. It serves a vital role in T cell maturation and selection, elimination of self-reactive
cells, establishment of central tolerance and T cell migration to recognize a wide range of pathogens. A variety of cells have been identified
inside the thymus. These include epithelial cells, thymocytes, dendritic cells, or DC, macrophages, B lymphocytes, myoid cells, endothelial
cells and fibroblasts. With age, the thymus declines in functionality through a process referred to as thymus or thymic involution. Publications
have indicated that the process of involution enhances regulatory T cell generation which leads to increased susceptibility to pathogen
infections, tumors and autoimmune diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
thymus is critically important to the immune system, which serves as the body&#8217;s defense mechanism providing surveillance and protection
against diverse pathogens, tumors, antigens and mediators of tissue damage. The immune system comprises a complex network of cellular
and molecular components subdivided into thymus-independent (innate) and thymus-dependent (adaptive) arms which function synergistically
in all immune responses. Innate immunity constitutes the first line of defense and is mediated by innate immune cells such as tissue
macrophages, DC and granulocytes which elicit their effector function within minutes to hours following antigen exposure. Innate cells
become activated via germ-line encoded pattern recognition receptors, including toll like receptors and nucleotide oligomerization domain-like
receptors, which recognize invariant features of pathogens (pathogen-associate molecular patterns) and tissue damage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
activated, innate cells such as macrophages and neutrophils can effectively clear antigens via phagocytosis. Other types of innate cells,
such as DC, take up and process antigens, resulting in expression of antigenic epitopes in conjunction with their major histocompatibility
complex, or MHC, or human leukocyte antigen molecules. These DC can then serve as antigen-presenting cells for the priming of the adaptive
immune system. In this way, the early innate response is coupled to, and facilitates, adaptive immunity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
adaptive immune system consists of T and B lymphocytes which express specific antigen recognition receptors and develop highly specialized
effector functions with the ability to form long-term immunological memory. Both B cells and T cells develop from bone marrow-derived
progenitors; while mature B cells are exported to the periphery directly from the bone marrow, T cell development, maturation and export
require critical differentiation steps to occur in the thymus. Thymus-dependent T cell differentiation processes include expression of
an antigen-specific cell surface T cell receptor through recombination of germline-encoded gene segments, and thymic &#8220;education&#8221;
involving negative selection of potentially self-reactive T cells and positive selection of T cells with the capacity to recognize antigens
encountered in the periphery. These important thymic processes ensure that T cells can recognize antigens in the context of self-MHC,
but do not elicit self-reactivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
spleen is one of the key secondary lymphoid organs responsible for the rapid response of the immune system to pathogens in the blood,
and to maintain a long-term adaptive response to such pathogens. The spleen also serves as the key organ for iron metabolism and erythrocyte
homeostasis. The organ also functions as a key storage site for platelets and leukocytes. A variety of cells have been identified in
the spleen, including endothelia cells, mesothelial cells, reticular cells, erythrocytes, granulocytes, mononuclear cells, hemopoietic
cells, macrophages, dendritic cells, plasma cells, CD4+ and CD8+ T cells, and migrating B cells. With age, the structure and function
of the spleen changes, leading to decreased ability to respond positively to vaccination, increased susceptibility to viral and bacterial
pathogen infections, and increased incidence of autoimmune disease. Accordingly, there is a need for improving and extending the productive
life of the thymus and spleen through cell therapy, which could lead to an extension of human life by defeating the diseases that are
allowed to proliferate during the declining process of these vital glands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Our
Solution</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research program is in the early stages and is being designed to regenerate or reinvigorate production of the thymus and/or spleen. The
regeneration comprises organogenesis and/or T cell development, wherein the tissue is differentiated and/or expansion of epithelial cells
uses activated or inactivated fibroblasts. In addition to fibroblasts, we anticipate using other agents such as nucleic acids, cytokines,
chemokines, transcription factors, epigenetic factors, growth factors, hormones or a combination thereof. The population of cells may
be activated <i>in vitro</i> or <i>ex vivo</i>. The next step in developing fibroblasts for thymic or splenic involution reversal will
be to design and conduct preclinical studies to demonstrate whether thymic or splenic involution reversal can be achieved in animal models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Market
Opportunity</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global anti-aging therapeutics market was estimated to have exceeded $500.0 million in 2021 and is expected to experience annual double-digit
growth over the next ten years as aging populations and standards of living are increasing globally. The demand for effective regenerative
medicine solutions for the aging population is higher than ever. As a result, anti-aging therapeutics are being developed by several
companies using stem cells and regenerative medicine to identify, prevent, cure, and reverse age-related dysfunctions, illnesses, and
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>CYPS317 for the Treatment of Psoriasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Psoriasis</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Psoriasis is a complex and chronic
autoimmune inflammatory disease that afflicts approximately 2% of the world population and affects primarily the skin, nails and joints.
Psoriasis has a profound impact on the quality of life, leading to an increase in rate of anxiety and depression. The disease is also
associated with a significant number of comorbidities such arthritis, cardiometabolic disease, diabetes mellitus, obesity, non-alcoholic
fatty liver disease, inflammatory bowel disease, and depression. Psoriasis manifests as raised, red, scaly patches on the skin, which
can appear on various parts of the body. Individuals with psoriasis have an increased risk of developing psoriatic arthritis, along with
metabolic and cardiovascular comorbidities, which can have a significant impact on their overall health and quality of life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pathophysiology of psoriasis
is complex, involving immune dysregulation, keratinocyte hyperproliferation, and immune cell infiltration into psoriatic lesions. As a
result, targeted therapies have been developed to modulate the immune response and reduce inflammation in individuals with psoriasis.
While current biological therapies focusing on the selective blockade of interleukin (IL)-17 and IL-23 signaling have shown significant
efficacy in psoriasis treatment, they are accompanied by several challenges, including significant side effects, variable treatment responses,
and diminished effectiveness over time. Consequently, cell therapy has emerged as a promising approach to psoriasis management. Mesenchymal
stem cells (MSCs), derived from diverse sources, have demonstrated therapeutic potential in both psoriasis patients and animal models.
Their immunomodulatory and anti-inflammatory properties are believed to play pivotal roles. They have been shown to directly affect keratinocytes,
T lymphocytes, macrophages, and dendritic cells (DCs), thereby reducing disease severity, immune cell infiltration, and cytokine production
associated with psoriasis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Our Solution</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fibroblasts share phenotypic and functional properties
with MSCs and are increasingly recognized as key players in immune modulation. In clinical settings, fibroblasts have been applied in
wound care, effectively treating conditions such as diabetic foot ulcers and recessive dystrophic epidermolysis bullosa. Their therapeutic
potential has also been observed in preclinical models of autoimmune diseases, including type I diabetes, alopecia areata, arthritis,
and multiple sclerosis [. These findings shed light on the prospect of using fibroblasts in psoriatic patients who do not respond to currently
available therapies. As an effective immune modulator, fibroblasts have demonstrated their capacity to alleviate autoimmunity by stimulating
regulatory T cells (Tregs) while suppressing pro-inflammatory Th17 cells, autoreactive T cells, and DC maturation. Consequently, fibroblasts
may positively impact the onset and progression of autoimmune disease. Notably, fibroblasts offer a solution to scalability challenges
often associated with MSC therapy, rendering them a cost-effective alternative to MSCs, particularly for patients requiring long-term
treatment and at risk of relapse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>TCB190
for the Treatment of Certain Cancers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research on certain cancers is just beginning and further information about the opportunity will be released as it becomes available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
and Supply</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently produce our cell therapy product candidates at our laboratory facility in Houston, Texas. We are in the process of contracting
with a CDMO for the transfer of our experimental cell bank to produce our master cell bank, working cell bank and our fibroblast cell-based
product candidate to enable clinical trials. If our product candidates receive marketing approval, we will evaluate the longer-term feasibility
of building our own cGMP manufacturing facility or continuing to outsource production to a CDMO for clinical testing and commercial supply.
We presently rely on third parties for certain portions of the cell therapy manufacturing process and will likely continue to do so in
the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were formed in April 2021 as a spinout from FibroGenesis. In connection with our formation, we issued the equivalent of 8,750,000 shares
of Series A Preferred Stock to FibroGenesis in exchange for a patent assignment agreement, or the Patent Assignment Agreement, and an
intellectual property cross-license agreement, or the Intellectual Property Cross-License Agreement. The Patent Assignment Agreement
transfers all right, title and interest to certain patents/applications from FibroGenesis to us, and the Intellectual Property Cross-License
Agreement allocates between FibroGenesis and us, exclusive fields of use for both assigned and retained patents issued/pending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
the Patent Assignment Agreement and the Intellectual Property Cross-License Agreement, FibroGenesis has effectively granted to us exclusive
rights to develop fibroblasts in the following fields of use:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diagnosis,
    treatment, prevention and palliation of spinal diseases, disorders or conditions; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    cancers; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">orthopedic
    diseases, disorders or conditions; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple
    sclerosis. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FibroGenesis
has retained exclusive rights for all other fields of use for both issued patents and patent applications transferred to us or retained
by FibroGenesis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issued patents and patent applications assigned to us, along with additional patent applications filed independently by us after inception,
include, as of the date hereof, a total of 48 patents and 109 patent applications pending. Our patent protections for our issued patents
generally expire in years ranging from 2027 to 2043.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our issued patents are covered by the Patent Assignment Agreement and consist of 10 issued patents in the United States, eight issued
patents in Australia, four issued patents in Japan, four issued patents in the United Kingdom, three issued patents in France, three
issued patents in Germany, three issued patents in Italy, three issued patents in Spain, three issued patents in Hong Kong, two issued
patents in Canada, two issued patents in China, two issued patents in Switzerland, and the remaining issued patent in Europe. One of
our issued patents is also covered by the Intellectual Property Cross-License Agreement, which patent was issued in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
present patent ineligibility laws concerning products of nature, there are presently no composition of matter patents covering CybroCell&#8482;,
although there are patents related to the production of CybroCell&#8482;. We currently have patent applications pending for composition
of matter for both CYMS101 and CYWC628.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. We typically rely on trade
secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We
protect trade secrets and know-how by establishing confidentiality agreements and invention assignment agreements with our employees,
consultants, scientific advisors, contractors and partners. These agreements generally provide that all confidential information developed
or made known during the course of an individual or entity&#8217;s relationship with us must be kept confidential during and after the
relationship. These agreements also generally provide that all inventions resulting from work performed for us or relating to our business
and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition,
we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our
property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product
candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize
will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number
of products are currently under development, and may become commercially available in the future, for the treatment of conditions for
which we may attempt to develop product candidates. In addition, our products may need to compete with off-label drugs used by physicians
to treat the indications for which we seek approval. This may make it difficult for us to replace existing therapies with our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing CybroCell<sup>TM</sup> for the treatment of degenerative disc disease. Our competitors in the market for degenerative
disc disease include Aesculap Implant Systems, LLC, Novartis AG, Pfizer Inc., Eli Lilly and Company, DiscGenics, Inc., Spine BioPharma,
Inc. and Ferring B.V. In July 2021, Aesculap Implant Systems, LLC announced the long-term reporting from its pivotal trial for the activl&#174;
Artificial Disc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat MS. Key companies currently providing MS treatments include
Biogen, Inc., F. Hoffmann-La Roche Ltd and Novartis AG. Various companies, such as Sanofi and Novartis AG, have been investing in the
treatment for MS to bring novel therapeutics with high efficacy and potency for patients. These companies have recently launched therapeutics
intended for the most prevalent form of MS. In August 2020, the FDA approved Novartis AG&#8217;s Kesimpta, the only self-administered,
targeted B-cell therapy for patients with relapsing MS, and in March 2021, Johnson &amp; Johnson received FDA approval for the launch
of Ponvory as a daily oral drug for treatment against MS. TG Therapeutics, Inc.&#8217;s ublituximab for the indication of RMS was also
recently approved by the FDA for treatment of MS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the early stages of developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. We face competition from
several treatments presently available for treatment of chronic wounds, including Apligraf, Grafix, DermACELL and TheraSkin. In addition,
increasing application of bioactive therapies like skin grafting and growth factors in urgent treatment of wounds like diabetic foot
ulcers is resulting in high investment by companies in research and development of these therapies. In January 2019, Applied Tissue Technologies
LLC received FDA approval for its Platform Wound Dressing, NPWT device that eliminates the use of foam or gauze dressings. In April 2019,
PolarityTE, Inc. launched clinical trials for its SkinTE regenerative tissue product for chronic wounds. In January 2021, Smith &amp;
Nephew plc published that its PICO single-use negative pressure wound therapy system significantly reduced surgical site infections by
63.0% and the dehiscence by 30.0%, and in February 2021, Axio Biosolutions Private Limited received CE mark from Europe for its MaxioCel
advanced wound care product, a bioactive microfiber gelling technology which helps wounds heal quickly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our current and potential competitors may have significantly greater financial, manufacturing, marketing, drug development, technical
and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive
experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies
also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or
are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions.
Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds
or to in-license novel compounds that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology
and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Smaller or
early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, our competitors may succeed
in obtaining approval from the FDA, the EMA or other comparable foreign regulatory authorities or in discovering, developing and commercializing
products in our field before we do. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize
products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more
effectively, are reimbursed or are less expensive than any products that we may develop. Technological advances or products developed
by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to
compete effectively, our opportunity to generate revenue from the sale of any products we may develop, if approved, could be adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
Environment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
Regulation and Product Approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable regulatory authorities in state and local jurisdictions and in other countries and jurisdictions impose substantial
and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of products
such as those we are developing. These entities regulate, among other things, the research, development, testing, manufacture, quality
control, packaging, safety, effectiveness, labeling, storage, record keeping, approval, advertising, promotion, distribution, post-approval
monitoring and reporting, sampling, export and import of our product candidates. Any product candidates that we develop must be approved
by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may
be legally marketed in those foreign countries. Generally, our activities in other countries will be subject to regulation that is similar
in nature and scope as that imposed in the United States, although there can be important differences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Product Development Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the U.S. Federal Food, Drug, and Cosmetic Act, or the FDCA, and biologics under the
FDCA and the Public Health Service Act and their implementing regulations. The processes for obtaining regulatory approvals in the United
States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations, require
the expenditure of substantial time and financial resources. The failure to comply with applicable U.S. requirements at any time during
the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative
or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical
hold, issuance of warning letters and other types of letters, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties
brought by the FDA and the U.S. Department of Justice or other governmental entities. In addition, an applicant may need to recall a
product. Additionally, certain of our product candidates are subject to regulation in the United States as a combination product. If
marketed individually, each component would be subject to different regulatory pathways and would require approval of independent marketing
applications by the FDA. A combination product, however, is assigned to a center within the FDA that will have primary jurisdiction over
its regulation based on a determination of the combination product&#8217;s primary mode of action, which is the single mode of action
that provides the most important therapeutic action. In the case of our CybroCell&#8482; product candidate, we believe that the primary
mode of action is attributable to the biologic component of the product. We expect to seek approval of this combination product candidate
through a BLA, and we do not expect that the FDA will require a separate marketing authorization for each of the drug and biologic constituents
of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a new product may be marketed in the United States generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of nonclinical or preclinical laboratory tests, animal studies and formulation studies in accordance with the FDA&#8217;s good laboratory
    practice, or GLP, requirements and other applicable regulations; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which must become effective before human clinical trials may begin; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an IRB or ethics committee at each clinical site before each trial may be initiated; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with GCP requirements to establish the safety and efficacy of
    the proposed drug for its intended use, or with respect to biologics, the safety, purity and potency of the product candidate for
    each proposed indication; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA or BLA after completion of all pivotal trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof,
    are produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve
    the drug&#8217;s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCPs;
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA or BLA; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA&#8217;s review and approval of the NDA or BLA to permit commercial marketing of the product for particular indications for use
    in the United States.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as in vitro and animal studies to assess
potential safety and efficacy. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations
for safety/toxicology studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request
for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is
on the general investigational plan and the protocol(s) for clinical trials. Some preclinical studies may continue even after the IND
is submitted. The IND also includes results of animal and <i>in vitro</i> studies assessing the toxicology, pharmacokinetics, pharmacology,
and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data
or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin.
The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety
concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and
the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or
may not result in FDA authorization to begin a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials
involving recombinant or synthetic nucleic acid molecules are subject to oversight at the local level as set forth in the NIH Guidelines.
Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an Institutional
Biosafety Committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic
acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or
the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory
unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic
nucleic acid molecule research, many companies, and other institutions not otherwise subject to the NIH Guidelines voluntarily follow
them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCP requirements, which include the requirement that all research subjects, or their legal representative, provide their
informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other
things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness
criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during
product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the
clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins
at that site and must monitor the study until completed. An IRB is charged with protecting the welfare and rights of trial participants
and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in
relation to anticipated benefits. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various
grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet
its stated objectives. Some clinical trials also include oversight by an independent group of qualified experts organized by the clinical
trial sponsor, known as a data safety monitoring board or committee, which provides authorization for whether or not a trial may move
forward at designated check points based on access to certain data from the trial and may recommend that the clinical trial be halted
if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There
are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
    1</i></b>: The product candidate is initially introduced into healthy human subjects or, in certain cases such as certain cancers,
    patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism
    and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to
    gain early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as certain cancers,
    especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing
    is often conducted in patients. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
    2</i></b>: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate
    the preliminary efficacy, optimal dosages, dose tolerance and dosing schedule and to identify possible adverse side effects and safety
    risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase
    3 clinical trials. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
    3</i></b>: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically
    significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical
    trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to
    provide an adequate basis for physician labelling. Generally, two adequate and well-controlled Phase 3 clinical trials are required
    by the FDA for approval of an NDA or BLA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-marketing
studies, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are
used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, such
as with accelerated approval drugs, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to
submission of an IND, at the end of Phase 2 clinical trials or before an NDA or BLA is submitted. Meetings at other times may be requested.
These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide
advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the
end of a Phase 2 clinical trial to discuss the clinical trial&#8217;s results and present plans for a pivotal Phase 3 clinical trial
that they believe will support approval of their new drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry
and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate
and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product.
In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the IND is active and before product approval, progress reports summarizing the results of the clinical trials and nonclinical studies
performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted
to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant
risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans,
and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator
brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies
for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven
calendar days after the sponsor&#8217;s initial receipt of the information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Review and Approval Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
preclinical and other nonclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests
conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or
BLA requesting approval to market the product. Data may come from company-sponsored clinical trials intended to test the safety and effectiveness
of the use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing
approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational
drug product to the satisfaction of the FDA. The submission of an NDA or BLA is subject to the payment of substantial user fees; a waiver
of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs or BLAs for products
designated as orphan drugs, unless the product also includes a non-orphan indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews an NDA or BLA to determine, among other things, whether a product is safe and effective for its intended use and whether
its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription
Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221;
of a standard NDA for a new molecular entity or BLA to review and act on the submission. This review typically takes twelve months from
the date the NDA or BLA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision
after the application is submitted. The FDA conducts a preliminary review of all NDAs or BLAs within the first 60 days after submission,
before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request
additional information rather than accept an NDA or BLA for filing. In this event, the NDA or BLA must be resubmitted with the additional
information. The resubmitted application also is subject to review before the FDA accepts it for filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be
approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not
approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate
to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA
will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing
process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional
testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the
application does not satisfy the regulatory criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates an NDA or BLA, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial
marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle
of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes
the specific deficiencies in the NDA or BLA identified by the FDA and may require additional clinical data, such as an additional pivotal
Phase 3 clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing.
If a Complete Response Letter is issued, the sponsor must resubmit the NDA or BLA, addressing all of the deficiencies identified in the
letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not
satisfy the criteria for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval of a product is granted, such approval will be granted for particular indications and may contain limitations on
the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA or BLA with a REMS to ensure the
benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a
medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides,
physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other
risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development
of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing
requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more post-marketing
studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may
limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements,
including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline
for regulatory approval or otherwise impact ongoing development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
Drug Designation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease
or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the
United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States
for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting
an NDA or BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed
publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval
process. Orphan designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs,
tax advantages and user-fee waivers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to
market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for
the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for
which the orphan product has exclusivity. Orphan exclusivity also could block the approval of one of our products for seven years if
a competitor obtains approval of the same drug as defined by the FDA or if our product candidate is determined to be contained within
the competitor&#8217;s product for the same indication or disease. If an orphan designated product receives marketing approval for an
indication broader than what is designated, it may not be entitled to orphan exclusivity. In addition, exclusive marketing rights in
the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer
is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expedited
Development and Review Programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has a number of programs intended to expedite the development or review of products that meet certain criteria. For example, new
drugs are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate
the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product
and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions
with the review team during product development, and the FDA may consider for review sections of the NDA or BLA on a rolling basis before
the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA
agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and the sponsor pays any required user fee
upon submission of the first section of the NDA or BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product, including a product with a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite
development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential
to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment,
diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation
of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications
with priority review designations within six months of the filing date as compared to ten months for review of standard NDAs or BLAs
under its current PDUFA review goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a product may be eligible for accelerated approval. Products intended to treat serious or life-threatening diseases or conditions
may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably
likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality,
that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account
the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval,
the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical
trials. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which
could adversely impact the timing of the commercial launch of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy
designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence
indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance
beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including
involvement of senior managers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA may designate a product as a regenerative medicine advanced therapy, or RMAT. The RMAT designation is intended to facilitate
an efficient development program for, and expedited review of, any product candidate that meets the following criteria: (i) the product
candidate qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product,
or any combination product using such therapies or products, with limited exceptions; (ii) the product candidate is intended to treat,
modify, reverse, or cure a serious or life-threatening disease or condition; and (iii) preliminary clinical evidence indicates that the
product candidate has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential
benefits that include more frequent meetings with the FDA to discuss the development plan for the product candidate, and eligibility
for rolling review and priority review of BLAs. Cell therapy candidates granted RMAT designation may also be eligible for accelerated
approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon
data obtained from a meaningful number of sites, including through expansion to additional sites, as appropriate. RMAT-designated cell
therapy candidates that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the completion
of clinical trials, patient registries, or through submission of other sources of real world evidence, such as electronic health records,
through the collection of larger confirmatory data sets, or via post-approval monitoring of all patients treated with such therapy prior
to approval of the therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
track designation, breakthrough therapy designation, priority review, RMAT designation and accelerated approval do not change the standards
for approval, but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs,
the FDA may later decide that the product candidate no longer meets the conditions for qualification or decide that the time period for
FDA review or approval will not be shortened.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Approval
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and
distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements,
under which the FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Drug and biologic manufacturers
and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic
unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation
requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on
the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and
correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide
to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain
compliance with cGMPs and other aspects of regulatory compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition
of distribution restrictions or other restrictions under a REMS program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
potential consequences include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters, or untitled letters; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    holds on clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license
    approvals; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of products; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consent
    decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandated
    modification of promotional materials and labeling and the issuance of corrective information; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other
    safety information about the product; or </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product.
Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the
addition of new warnings and contraindications, and also may require the implementation of other risk management measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating
to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with
these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil
and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for
uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians
may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the
behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject
of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper
promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have
also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed
or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s
FDA-approved labeling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the distribution of prescription biopharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which
regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation
of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription biopharmaceutical product samples
and impose requirements to ensure accountability in distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Biosimilars
and Reference Product Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that
are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. The FDA has
issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there
be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency,
is generally shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product
is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results
as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and
the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks
of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with
an FDA-approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for
the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference
product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12
years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may
still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s
own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its
product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it
is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which
are governed by state pharmacy law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months
to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection
or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written
Request&#8221; for such a study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
Privacy and Security</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
federal legislation may affect our ability to obtain certain health information in conjunction with our research activities. We may be
subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. The Health
Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health
Act of 2009 and its implementing regulations, collectively referred to as HIPAA, imposes obligations, including mandatory contractual
terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HIPAA also
prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or
fraudulent statements or representation, or making or using any false writing or document knowing the same to contain any materially
false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services.
We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements
under HIPAA. Although we are not directly subject to HIPAA, other than with respect to providing certain employee benefits, we could
potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain or disclose individually identifiable
health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, numerous federal and state laws and regulations that address privacy and data security, including state data breach notification
laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission
Act), govern the collection, use, disclosure and protection of health-related and other personal information. Failure to comply with
data protection laws and regulations could result in government enforcement actions and create liability for us, which could include
civil and/or criminal penalties, private litigation and/or adverse publicity that could negatively affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to achieve and sustain compliance with applicable federal and state privacy, security and fraud laws could result in government enforcement
actions and create liability for us, which could include civil and/or criminal penalties, private litigation and/or adverse publicity
that could negatively affect our operating results and business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
U.S. Regulatory Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biopharmaceutical
companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states
and foreign jurisdictions in which they conduct their business that may constrain the financial arrangements and relationships through
which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws include,
without limitation, state and federal anti-kickback, fraud and abuse, false claims, and transparency laws and regulations related to
drug pricing and payments and other transfers of value made to physicians and other healthcare providers. If their operations are found
to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including,
without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations,
integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible
individuals may be subject to imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and
foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for
such product by third-party payors. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party
payors and coverage and reimbursement levels for products can differ significantly from payor to payor. The Medicare and Medicaid programs
increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies
for drugs and biologics. Factors payors consider in determining reimbursement are based on whether the product is (i) a covered benefit
under its health plan, (ii) safe, effective and medically necessary, (iii) appropriate for the specific patient, (iv) cost-effective
and (v) neither experimental nor investigational. Decisions regarding the extent of coverage and amount of reimbursement to be provided
are made on a plan-by-plan basis. These third-party payors are increasingly reducing reimbursements for medical products, drugs and services.
For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult
because of the higher prices often associated with such drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including
price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could
further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to
cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Reform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers,
and significantly affected the biopharmaceutical industry. The ACA contained a number of provisions, including those governing enrollment
in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. Additionally, the ACA:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer
    price; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">required
    collection of rebates for drugs paid by Medicaid managed care organizations; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">required
    manufacturers to participate in a coverage gap discount program, under which they must agree to offer 50% (increased to 70% pursuant
    to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable
    brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs
    to be covered under Medicare Part D; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposed
    a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified
    federal government programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to
providers of 2% per fiscal year. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers
set prices for their marketed products, which has resulted in several Congressional inquiries, proposed and enacted legislation and executive
orders issued by the former Trump administration designed to, among other things, bring more transparency to product pricing, review
the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug
products. Individual states in the United States have also become increasingly active in implementing regulations designed to control
pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>International
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements
of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing
authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will
need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing
of the product in those countries or jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulation of our product candidates outside of the United States varies by country. Certain countries regulate human tissue products
as a pharmaceutical product, which would require us to make extensive filings and obtain regulatory approvals before selling our product
candidates. Certain other countries classify our product candidates as human tissue for transplantation but may restrict its import or
sale. Other countries may have no application regulations regarding the import or sale of products similar to our product candidates,
creating uncertainty as to what standards we may be required to meet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had ten full-time employees, including six employees with medical or doctoral degrees and eight employees directly
engaged in research and development, with the rest providing administrative, business and operations support. None of our employees are
represented by labor unions or covered by collective bargaining agreements. We consider the relationship with our employees to be good.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 455 E. Medical Center Blvd., Suite 300, Houston, Texas, where we lease approximately 23,000
square feet of office space. The space serves as the location of our corporate headquarters. The lease expires in April 2027. In addition,
we have leased research labs and offices in Houston, Texas, for our research and cell manufacturing operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our facilities are adequate for our current and anticipated near-term needs and that suitable additional or substitute space
would be available if needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be party to litigation arising in the ordinary course of business. We are currently not a party to any material
legal proceedings and, to the best of our knowledge, no material legal proceedings are currently pending or threatened. Regardless of
outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other
factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S_002"></span>Item
                                            1A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
                                            Factors</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as all other information
included in this Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations,
prospects and ability to accomplish our strategic objectives could be materially harmed. As a result, the market price of our common
stock could decline and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones
we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business
operations and the market price of our common stock. This Annual Report also contains forward-looking statements that involve risks and uncertainties. See &#8220;Special
Note Regarding Forward-Looking Statements.&#8221; Our actual results could differ materially and adversely from those anticipated in these
forward-looking statements as a result of certain factors, including those described below.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    successful development of biopharmaceutical products is highly uncertain.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a limited operating history and none of our current product candidates have been approved for commercial sale, which may make
    it difficult for you to evaluate our current business and predict our future success and viability.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have incurred significant net losses since inception, expect to continue to incur significant net losses for the foreseeable future,
    and may never achieve or maintain profitability.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on
    acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or
    future commercialization efforts.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    regulatory approval processes of the FDA, the European Medicines Agency, or the EMA, and other comparable foreign regulatory authorities
    are lengthy, time consuming and inherently unpredictable.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may encounter substantial delays in completing, or ultimately be unable to complete, the development and commercialization of our
    product candidates.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    outcome of preclinical studies or early clinical trials may not be predictive of the success of later clinical trials, and the results
    of our clinical trials may not satisfy the requirements of the FDA, the EMA or other comparable foreign regulatory authorities.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim,
    topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data
    become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    current or future product candidates may cause adverse events, toxicities or other undesirable side effects when used alone or in
    combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory
    approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if approved, our product candidates may not achieve adequate market acceptance.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    refrigerated product candidates require specific storage, handling and administration at the clinical sites.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to identify and develop novel cell therapy product candidates, which makes it difficult to predict the time, cost and potential
    success of product candidate development.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    cell therapy is novel and the regulatory landscape that governs any cell therapy product candidates we may develop is rigorous, complex,
    uncertain and subject to change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for
    any product candidates we may develop.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize our product candidates.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have limited experience in designing clinical trials.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    long-term prospects depend in part upon discovering, developing and commercializing additional product candidates, which may fail
    in development or suffer delays that adversely affect their commercial viability.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have never commercialized a fibroblast cell-based therapy product candidate before and may lack the necessary expertise, personnel
    and resources to successfully commercialize any product candidates on our own or together with suitable collaborators.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face significant competition.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product
    candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience
    difficulties in managing this growth.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to risks related to our dependence on third parties (i) to conduct certain aspects of our preclinical studies and clinical
    trials and (ii) for certain portions of our manufacturing process.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are highly dependent on our Houston, Texas facility and any failure to maintain the use of this facility would have a material and
    adverse effect on our business.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to extensive government regulations.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business entails a significant risk of product liability.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    FDA, the EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of
    their jurisdiction.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements
    and oversight.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    success depends on our ability to protect our intellectual property and our proprietary technologies, and we are subject to various
    risks relating to our intellectual property.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract
    and retain executive management and qualified board members.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a &#8220;controlled company&#8221; within the meaning of the Nasdaq Stock Market Rules because our insiders beneficially own
    more than 50% of the voting power of our outstanding voting securities.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have 2,500 shares of Series C Preferred Stock with super voting rights.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have identified a material weakness in our internal controls over financial reporting due to lack of segregation of duties.</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    active trading market may not develop or continue to be liquid and the market price of our shares of common stock may be volatile.</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Condition and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
successful development of biopharmaceutical products is highly uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
development of biopharmaceutical products is highly uncertain and is dependent on numerous factors, many of which are beyond our control.
Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trial results showing the product candidates to be less effective than expected (for example, a clinical trial could fail to meet
    its primary or key secondary endpoint(s)) or have an unacceptable safety or tolerability profile;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to receive the necessary regulatory approvals or a delay in receiving such approvals, which, among other things, may be caused by
    patients who fail the trial screening process, slow enrollment in clinical trials, patients dropping out of trials, patients lost
    to follow-up, length of time to achieve trial endpoints, additional time requirements for data analysis or NDA preparation, discussions
    with the FDA, an FDA request for additional preclinical or clinical data or unexpected safety or manufacturing issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
    study results showing the product candidate to be less effective than desired or to have harmful side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-marketing
    approval requirements; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proprietary rights of others and their competing products and technologies that may prevent our product candidates from being commercialized.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
length of time necessary to complete clinical trials and submit an application for marketing approval for a final decision by a regulatory
authority varies significantly from one product candidate to the next and from one country or jurisdiction to the next and may be difficult
to predict.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are successful in obtaining marketing approval, commercial success of approved products may also depend in large part on the availability
of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs
and managed care organizations in the United States or country-specific governmental organizations in foreign countries, which may be
affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require
us to conduct additional studies, including post-marketing studies related to the cost effectiveness of an approved product, to qualify
for reimbursement, which could be costly and divert our resources. If government and other healthcare payors were to not provide coverage
and adequate reimbursement for our products once approved, market acceptance and commercial success may be reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if any of our product candidates receive marketing approval, we will be subject to significant regulatory obligations regarding
the submission of safety and other post-marketing information and reports and registration, and will need to continue to comply (or ensure
that any third-party providers comply) with cGMPs and good clinical practices, or GCPs, for any clinical trials that we conduct post-approval.
In addition, there is always the risk that we, a regulatory authority or a third party might identify previously unknown problems with
a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly,
and any failure to comply or other issues with our product candidates post-approval could adversely affect our business, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history and none of our current product candidates have been approved for commercial sale, which may make it
difficult for you to evaluate our current business and predict our future success and viability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biopharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage cell therapy
company with a limited operating history upon which you can evaluate our business and prospects. None of our current product candidates
are approved for commercial sale and we have not generated any revenue from such product candidates. To date, we have devoted substantially
all of our resources and efforts to organizing and staffing our company, business planning, executing partnerships, raising capital,
discovering, identifying and developing potential product candidates, securing related intellectual property rights and conducting and
planning preclinical studies and clinical trials of our product candidates. In relation to our current product candidates, we have not
yet demonstrated our ability to successfully complete any Phase 3 clinical trials, obtain marketing approvals, manufacture a commercial-scale
product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product
commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability than it could
be if we had a longer operating history or a history of successfully developing and commercializing biopharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently
experienced by clinical-stage biopharmaceutical companies in rapidly evolving fields. We also may need to transition from a company with
a research focus to a company capable of supporting commercial activities. If we do not adequately address these risks and difficulties
or successfully make such a transition, our business will suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred significant net losses since inception, expect to continue to incur significant net losses for the foreseeable future,
and may never achieve or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred significant net losses since our inception, have not generated any revenue from product sales to date and have financed
our operations principally through private financings. For the years ended December 31, 2023 and 2022, we incurred net losses of $16.5
million, $5.1 million, respectively. As of December 31, 2023 and 2022, we had an accumulated deficit of $24.4 million and $7.9 million,
respectively. Our losses have resulted principally from expenses incurred in research and development of our product candidates and from
management and administrative costs and other expenses that we have incurred while building our business infrastructure. We expect that
it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed
in receiving marketing approval for, and commercializing, one or more of our product candidates, we expect that we will continue to incur
substantial research and development and other expenses as we discover, develop and market additional potential product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if and
as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    the development of our lead product candidates through clinical development, and, if approved by the FDA, commercialization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    our preclinical development programs into clinical development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur
    manufacturing costs for cell production to supply our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approvals for any of our product candidates that successfully complete clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    our research and development activities to identify and develop new product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    our operational, financial and management systems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meet
    the requirements and demands of being a public company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">invest
    in further development to protect and expand our intellectual property;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain
    marketing approval and intend to commercialize; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    our manufacturing and develop our commercialization efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net losses we incur may fluctuate significantly from period to period, such that a period-to-period comparison of our results of operations
may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future
growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to
have an adverse effect on our working capital and our ability to achieve and maintain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to become and remain profitable depends on our ability to generate revenue or execute other business development arrangements.
We do not expect to generate significant revenue, if any, unless and until we are able to obtain regulatory approval for, and successfully
commercialize, one or more product candidates we are developing or may develop. Successful commercialization will require achievement
of many key milestones, including demonstrating safety and efficacy in clinical trials, obtaining regulatory approval for these product
candidates, manufacturing, marketing and selling those products for which we may obtain regulatory approval, satisfying any post-marketing
requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and
risks associated with these activities, we are unable to accurately and precisely predict the timing and amount of revenues, the extent
of any further losses or if or when we might achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never succeed in these activities and, even if we do, we may never generate revenues that are significant enough for us to achieve
profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual
basis. Our failure to become and remain profitable could impair our ability to raise capital, expand our business, diversify our product
offerings or continue our operations. If we continue to incur losses as we have since our inception, investors may not receive any return
on their investment and may lose their entire investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable
terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization
efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain
process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses
to increase in connection with our ongoing activities, particularly as we initiate and conduct clinical trials of, and seek marketing
approval for our current product candidates and any future product candidates. Even if one or more of the product candidates that we
develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product
candidate. Our expenses could increase beyond expectations if we are required by the FDA, the EMA or other comparable regulatory authorities
to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also
arise. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization
expenses related to drug sales, marketing, manufacturing and distribution. Because the design and outcome of our anticipated clinical
trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and
commercialization of any product candidate we develop. Accordingly, we will need to obtain substantial additional funding in order to
maintain our continuing operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had approximately $9.2 million in cash and cash equivalents. And subsequently raised approximately $1.9 million
in February 2024. Based on our current business plans, we believe that our existing capital will enable us to fund our operations through
at least February 28, 2025. Our estimate as to how long we expect our existing capital to be able to continue to fund our operations
is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect.
Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently
anticipate, and we may need to seek additional funds sooner than planned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future funding requirements will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, progress, timeline, cost and results of our clinical trials for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, progress, timeline, cost and results of additional research and preclinical studies related to pipeline development and
    other research programs we initiate in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost and timing of manufacturing activities, including our planned manufacturing scale-up activities associated with our product
    candidates and other programs as we advance them through preclinical and clinical development through commercialization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential expansion of our current development programs to seek new indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights, in-licensed or otherwise;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    payment of licensing fees, potential royalty payments and potential milestone payments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of general operating expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory
    approval in regions where we choose to commercialize our products on our own; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advancing
the development of our product candidates will require a significant amount of capital. In order to fund all of the activities that are
necessary to complete the development of our product candidates, we will be required to obtain further funding through equity offerings,
debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict our operating
activities. Adequate additional funding may not be available to us on acceptable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability
to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage
programs, clinical trials or future commercialization efforts, grant rights to develop and market product candidates that we would otherwise
prefer to develop and market ourselves, obtain funds through arrangement with collaborators on terms unfavorable to us or pursue merger
or acquisition strategies, all of which could adversely affect the holdings or the rights of our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raising
additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our
product candidates on unfavorable terms to us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital through a variety of means, including through equity, debt financings, or other sources, including up-front
payments and milestone payments from strategic collaborations. We may seek additional capital due to favorable market conditions or strategic
considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include
liquidation or other preferences and anti-dilution protections that adversely affect your rights as a stockholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
financing may also result in imposition of debt covenants, increased fixed payment obligations or other restrictions that may adversely
affect our ability to conduct our business. If we raise additional funds through collaborations, strategic alliances or marketing, distribution
or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams,
research programs or product candidates, or grant licenses on terms that are not favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are party to a share purchase agreement, dated November 12, 2021, with certain investors, or the Share Purchase Agreement, pursuant to
which we may elect to issue and sell to such investors, and if so elected, such investors will be obligated to purchase, for a period
commencing on the first day on which our common stock trade on a principal U.S. securities exchange and ending 60 months from such date,
up to $100,000,000 worth of shares of our common stock, or the Aggregate Limit. The Share Purchase Agreement is contingent upon our achieving
a public listing of our common stock. Pursuant to the agreement, we are required to pay the investors a commitment fee equal to 2% of
the Aggregate Limit, payable in cash or shares of our common stock. The commitment fee is payable even if we do not utilize any drawdowns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the agreement required us to issue to the investors, on our public listing date, a warrant to purchase up to the number of
shares of our common stock that is equal to 4% of our total equity interests outstanding immediately after the completion of our public
listing, at a price per share equal to the lesser of (i) the public offering price per share (in the case of an initial public offering)
or the closing bid price per share on the public listing date (in the case of a public listing other than an initial public offering)
or (ii) the quotient obtained by dividing $700,000,000 by the total number of equity interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
election to issue and sell to the investors, shares of our common stock pursuant to the Share Purchase Agreement, or the exercise of
the warrant we are issuing upon consummation of our direct listing, will result in further dilution to our existing stockholders
and investors who purchase shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Development, Regulatory Approval and Commercialization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory approval processes of the FDA, the EMA and other comparable foreign regulatory authorities are lengthy, time consuming and
inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to
generate product revenue and our business will be substantially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval
from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements. The time required to obtain approval by the
FDA, the EMA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement
of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved.
In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the
course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or
the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse
to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other
data. Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA,
the EMA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower
patient population than we originally requested. We have not submitted for, or obtained, regulatory approval for any product candidate,
and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever
obtain regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applications
for our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA, the EMA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical
    trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA, the EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective,
    only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining
    marketing approval or prevent or limit commercial use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full
    population for which we seek approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA, the EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies
    or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials of our product candidates may not be sufficient to support the submission of a Biologics License
    Application, or BLA, or other submission or to obtain regulatory approval in the United States or elsewhere;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the FDA, the EMA or other comparable foreign regulatory authorities that a product candidate&#8217;s
    risk-benefit ratio for its proposed indication is acceptable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA, the EMA or other comparable foreign regulatory authorities may fail to approve our manufacturing processes, test procedures
    and specifications or facilities or those of third-party manufacturers with which we contract for clinical and commercial supplies;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA, the EMA or other comparable foreign regulatory authorities may significantly change
    in a manner rendering our clinical data insufficient for approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
lengthy, uncertain approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to
obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations
and prospects. In addition, the FDA, the EMA or comparable foreign regulatory authorities may change their policies, adopt additional
regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates
under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay
our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we
may have obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter substantial delays in completing, or ultimately be unable to complete, the development and commercialization of our product
candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining marketing approval from the FDA, the EMA or other comparable foreign regulatory authorities for the sale of our product candidates,
we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates.
Clinical testing is expensive, difficult to design and implement, can take many years to complete and its ultimate outcome is uncertain.
A failure of one or more clinical trials can occur at any stage of the process. The outcome of preclinical studies and early-stage clinical
trials may not be predictive of the success of later clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not know whether our future clinical trials will begin on time or enroll patients on time, or whether our ongoing and/or future clinical
trials will be completed on schedule or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA, the EMA or other comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation
    and may vary significantly among different CROs and trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    approval from one or more independent institutional review boards, or IRBs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRBs
    refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects,
    or withdrawing their approval of the trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in enrollment due to travel or quarantine policies, or other factors related pandemics or other events outside our control;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    to clinical trial protocol;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites deviating from trial protocol or dropping out of a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    sufficient quantities of a product candidate or obtaining sufficient quantities of combination therapies for use in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
    failing to enroll or remain in our trial at the rate we expect, or failing to return for post- treatment follow-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
    choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing
    clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of adequate funding to continue the clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
    experiencing severe or unexpected drug-related adverse effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of serious adverse events in trials of the same class of agents conducted by other companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selection
    of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    facility manufacturing our product candidates or any of their components being ordered by the FDA, the EMA or comparable foreign
    regulatory authorities to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements,
    or infections or cross-contaminations of product candidates in the manufacturing process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    changes to our manufacturing process that may be necessary or desired;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials
    on our anticipated schedule or consistent with the clinical trial protocol, GCP or other regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    contractors not performing data collection or analysis in a timely or accurate manner; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
    contractors becoming debarred or suspended or otherwise penalized by the FDA, the EMA or other government or regulatory authorities
    for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use
    some or all of the data produced by such contractors in support of our marketing applications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of
our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result
of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory
schemes, as well as political and economic risks relevant to such foreign countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our
product candidates, we may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    delayed in obtaining marketing approval, if at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    subject to the addition of labeling statements, such as warnings or contraindications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    sued; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
    damage to our reputation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any
of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all.
Any delay in, or termination of, our clinical trials will delay the submission of a BLA to the FDA or similar applications with comparable
foreign regulatory authorities and, ultimately, our ability to commercialize our product candidates, if approved, and generate product
revenue. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our claims for differentiation
or the effectiveness or safety of our product candidate. The FDA has substantial discretion in the review and approval process and may
disagree that our data support the claims we propose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation
in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA, the
EMA or other comparable foreign regulatory authorities. The FDA, the EMA or other comparable foreign regulatory authorities may conclude
that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation
of the study. The FDA, the EMA or other comparable foreign regulatory authorities may therefore question the integrity of the data generated
at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in
approval, or rejection, of our marketing applications by the FDA, the EMA or other comparable foreign regulatory authorities, as the
case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects
of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed.
Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval
process and jeopardize our ability to commence product sales and generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of,
clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any delays to our clinical trials
that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates
and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could
be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
outcome of preclinical studies or early clinical trials may not be predictive of the success of later clinical trials, and the results
of our clinical trials may not satisfy the requirements of the FDA, the EMA or other comparable foreign regulatory authorities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Positive
results from preclinical studies and early clinical trials do not mean that future clinical trials will be successful. Failure can occur
at any time during the clinical trial process. We do not know whether any of our product candidates will perform in current or future
clinical trials as they have performed in preclinical studies and early clinical trials. Product candidates in later-stage clinical trials
may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, the EMA and other comparable foreign regulatory
authorities despite having progressed through preclinical studies and early-stage clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product
candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences
in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients
treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved
products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidate. As
a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical
trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. We do not know whether any
clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to
market our product candidates. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
some of our planned clinical trials may utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial
is one where both the patient and investigator know whether the patient is receiving either the investigational product candidate or
an existing approved pharmaceutical or placebo. Most typically, open-label clinical trials test only the investigational product candidate
and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any
therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials
may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness
of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221;
where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment
and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may
not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial
when studied in a controlled environment with a placebo or active control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product
candidates performed satisfactorily in preclinical studies or clinical trials nonetheless failed to obtain FDA, EMA or comparable foreign
regulatory authority approval. We cannot guarantee that the FDA, the EMA or comparable foreign regulatory authorities will interpret
trial results as we do, and more trials could be required before we are able to submit applications seeking approval of our product candidates.
This is particularly true for clinical trials in rare diseases, where the very small patient population makes it difficult to conduct
two traditional, adequate and well-controlled studies, and therefore the FDA, the EMA or comparable foreign regulatory authorities are
often required to exercise flexibility in approving therapies for such diseases. To the extent that the results of the trials are not
satisfactory to the FDA, the EMA or comparable foreign regulatory authorities for support of a marketing application, we may be required
to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our
product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the
scope and use of our product candidate, which may also limit its commercial potential. Furthermore, the approval policies or regulations
of the FDA, the EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient
for approval, which may lead to the FDA, the EMA or comparable foreign regulatory authorities delaying, limiting or denying approval
of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interim,
topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies or clinical trials, which is
based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following
a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate
all data. As a result, the interim, topline or preliminary results that we report may differ from future results of the same studies,
or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim,
preliminary and topline data also remain subject to audit and verification procedures that may result in the final data being materially
different from the preliminary data we previously published. As a result, interim, topline and preliminary data should be viewed with
caution until the final data are available. Adverse differences between preliminary, topline or interim data and final data could significantly
harm our business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly
disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not
agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, topline or
preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business,
operating results, prospects or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current or future product candidates may cause adverse events, toxicities or other undesirable side effects when used alone or in combination
with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval,
prevent market acceptance, limit their commercial potential or result in significant negative consequences.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with biopharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product
candidates&#8217; use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or
unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt,
delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA,
the EMA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of
enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business,
financial condition and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical
trials when used alone or in combination with other approved products or investigational new drugs we may need to interrupt, delay or
abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics
are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect
patient recruitment or the ability of enrolled subjects to complete the trial, or result in potential product liability claims. Any of
these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business,
financial condition and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
in our ongoing and planned clinical trials in the future may suffer significant adverse events or other side effects not observed in
our preclinical studies or previous clinical trials. Some of our product candidates may be used as chronic therapies or be used in pediatric
populations, for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if our product candidates
are used in combination with other therapies, our product candidates may exacerbate adverse events associated with the therapy. Patients
treated with our product candidates may also be undergoing surgical, radiation or chemotherapy treatments, which can cause side effects
or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. The inclusion
of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications
that such patients may be using or due to the gravity of such patients&#8217; illnesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty
recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development
efforts of that product candidate altogether. We, the FDA, the EMA, other comparable regulatory authorities or an IRB may suspend clinical
trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable
health risks or adverse side effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if any of our product candidates receives regulatory approval and becomes a product, and we or others later identify undesirable side
effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require
us to adopt a Risk Evaluation and Mitigation Strategy, or REMS, to ensure that the benefits of treatment with such product outweigh the
risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education,
extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what
is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient
education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects
caused by any product that we develop alone or with collaborators. Other potentially significant negative consequences include that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be forced to suspend marketing of that product, or decide to remove the product from the marketplace;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw or change their approvals of that product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label or limit access of that product to selective specialized centers with additional
    safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to create a medication guide outlining the risks of the product for patients, or to conduct post-marketing studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way the product is administered;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held liable for harm caused
    to subjects or patients; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may become less competitive, and our reputation may suffer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving
or maintaining market acceptance of the affected product candidate, if approved by applicable regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others
in the medical community necessary for commercial success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our product candidates receive regulatory approval and become a product, they may not gain adequate market acceptance among physicians,
patients, healthcare payors and others in the medical community. The degree of market acceptance of any of our approved product candidates
will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of market introduction of the product as well as competitive products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which the product is approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the use of our product, such as boxed warnings or contraindications in labeling, or a REMS, if any, which may not be required
    of alternative treatments and competitor products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential and perceived advantages of products over alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment in relation to alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement, as well as pricing, by third-party payors, including government authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience and ease of administration;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of sales and marketing efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    publicity relating to our products or similar approved products or product candidates in development by third parties; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval of other new therapies for the same indications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors
and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively
impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
refrigerated product candidates </i></b>&#160;<b><i>require specific storage, handling and administration at the clinical sites.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
refrigerated drug product candidates must be stored at low temperatures in specialized refrigerated containers until immediately prior
to use. For administration, the drug product container must be carefully removed from storage, warmed to room temperature and inverted
to place cells into suspension prior to drawing the product into syringes. The handling, warming and administration of the cell therapy
product must be performed according to specific instructions. Failure to correctly handle the product, follow the instructions for warming
and administration and/or failure to administer the product within the specified period post-warming could negatively impact the efficacy
and or safety of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
cell therapy is novel and the regulatory landscape that governs any cell therapy product candidates we may develop is rigorous, complex,
uncertain and subject to change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any
product candidates we may develop. At the moment, only a small number of cell therapy products have been approved in the United States
and the European Union.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory requirements that will govern any novel cell therapy product candidates we develop are not entirely clear and are subject
to change. Within the broader genetic medicine field, very few therapeutic products have received marketing authorization from the FDA
or the EMA. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory
landscape is still developing. Regulatory requirements governing cell therapy products have changed frequently and will likely continue
to change in the future. Moreover, there is substantial overlap in those responsible for regulation of existing cell therapy products.
For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics
Evaluation and Research to consolidate the review of cell therapy and related products. Although the FDA has approved other cell-based
therapies, there is no assurance that these previous approvals will affect the FDA&#8217;s review of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cell therapy product candidates will need to meet safety and efficacy standards applicable to any new biologic under the regulatory framework
administered by the FDA. In addition to FDA oversight and oversight by IRBs, under the National Institutes of Health Guidelines for Research
Involving Recombinant or Synthetic Nucleic Acid Molecules, or NIH Guidelines, cell therapy clinical trials are also subject to review
and oversight by an Institutional Biosafety Committee, or IBC, a local institutional committee that reviews and oversees research utilizing
recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential
risk to public health or the environment. While the NIH Guidelines are not mandatory unless the research in question is being conducted
at or sponsored by institutions receiving National Institutes of Health, or NIH, funding of recombinant or synthetic nucleic acid molecule
research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. Although the FDA
decides whether individual cell therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede
or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
same applies in the European Union. The EMA&#8217;s Committee for Advanced Therapies, or CAT, is responsible for assessing the quality,
safety, and efficacy of advanced-therapy medicinal products. Advanced-therapy medicinal products include cell therapy medicines, somatic-cell
therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing
authorization for a cell therapy medicinal candidate that is submitted to the EMA. In the European Union, the development and evaluation
of a cell therapy product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning
the development and marketing authorization for cell therapy products and require that we comply with these new guidelines. As a result,
the procedures and standards applied to cell therapy products may be applied to any cell therapy product candidate we may develop, but
that remains uncertain at this point.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
developments in preclinical studies or clinical trials conducted by others in the field of cell therapy and cell regulation products
may cause the FDA, the EMA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop
or limit the use of products utilizing cell therapy technologies, either of which could harm our business. In addition, the clinical
trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the safety
and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the
potential products. The regulatory approval process for product candidates such as ours can be more expensive and take longer than for
other, better known, or more extensively studied pharmaceutical or other product candidates. Further, as we are developing novel potential
treatments for diseases in which, in some cases, there is little clinical experience with potential new endpoints and methodologies,
there is heightened risk that the FDA, the EMA or other regulatory bodies may not consider the clinical trial endpoints to provide clinically
meaningful results, and the resulting clinical data and results may be more difficult to analyze. In addition, we may not be able to
identify or develop appropriate animal disease models to enable or support planned clinical development. Any natural history studies
that we may conduct or rely upon in our clinical development may not be accepted by the FDA, the EMA or other regulatory authorities.
Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing
cell therapy technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or
private litigation could result in expenses, delays or other impediments to our research programs or the commercialization of resulting
products. Further, approvals by one regulatory agency may not be indicative of what other regulatory agencies may require for approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory review committees and advisory groups described above and the new guidelines they promulgate may lengthen the regulatory review
process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in
regulatory positions and interpretations, delay or prevent approval and commercialization of these product candidates, or lead to significant
post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required
to consult with these regulatory and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required
to delay or discontinue development of any product candidates we identify and develop. These additional processes may result in a review
and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory
approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability
to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development,
manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing,
marketing and distribution of drugs. Rigorous preclinical studies and clinical trials and an extensive regulatory approval process must
be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these
and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. We cannot provide any assurance
that any product candidate we may develop will progress through required clinical testing and obtain the regulatory approvals necessary
for us to begin selling them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not conducted, managed or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the
FDA, the EMA or any other regulatory authority with respect to our current product candidates. The time required to obtain approvals
from the FDA and other regulatory authorities is unpredictable and requires successful completion of extensive clinical trials which
typically takes many years, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and
its foreign counterparts use when evaluating clinical trial data can and often changes during drug development, which makes it difficult
to predict with any certainty how they will be applied. We may also encounter unexpected delays or increased costs due to new government
regulations, including future legislation or administrative action, or changes in FDA policy during the period of drug development, clinical
trials and FDA regulatory review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue
from the particular product candidate for which we are developing and seeking approval. Furthermore, any regulatory approval to market
a product candidate may be subject to significant limitations on the approved uses or indications for which we may market the product
candidate or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as part of approving an NDA
or BLA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved product candidate.
These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that have undergone specialized
training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These
limitations and restrictions may significantly limit the size of the market for the product candidate and affect reimbursement by third-party
payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing
and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and
generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of
local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may develop our current and future product candidates in combination with other therapies, which exposes us to additional risks, and
certain of our product candidates are regulated as combination products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may develop our current and future product candidates in combination with one or more other approved or unapproved therapies to treat
skin and connective tissue diseases or other diseases. We may also develop certain product candidates as biologic/drug combination products.
Additional time may be required to obtain regulatory approval for our product candidates because they are combination products. Our product
candidates that are biologic/drug combination products require coordination within the FDA and similar foreign regulatory agencies for
review of their biologic and drug components. Although the FDA and similar foreign regulatory agencies have systems in place for the
review and approval of combination products such as ours, we may experience delays in the development and commercialization of our product
candidates due to regulatory timing constraints and uncertainties in the product development and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with
other existing therapies, we would continue to be subject to the risks that the FDA, the EMA or comparable foreign regulatory authorities
could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could
arise with any of those existing therapies. If the therapies we use in combination with our product candidates are replaced as the standard
of care for the indications we choose for any of our product candidates, the FDA, the EMA or comparable foreign regulatory authorities
may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own product candidates,
if approved, being removed from the market or being less successful commercially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also may choose to evaluate our current product candidates or any future product candidates in combination with one or more therapies
that have not yet been approved for marketing by the FDA, the EMA or comparable foreign regulatory authorities. We will not be able to
market and sell our product candidates we develop in combination with an unapproved therapy for a combination indication if that unapproved
therapy does not ultimately obtain marketing approval either alone or in combination with our product candidate. In addition, unapproved
therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including
the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA, the EMA or comparable foreign regulatory authorities do not approve these other products or revoke their approval of, or if
safety, efficacy, quality, manufacturing or supply issues arise with, the products we choose to evaluate in combination with our product
candidates we develop, we may be unable to obtain approval of or market such combination therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as amended, or collectively,
the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated
approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product.
Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the
reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA
until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company
may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the
sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and
potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact,
implementation and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully
adopted by the FDA, any such processes could have an adverse effect on the future commercial prospects for our biological products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of
exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our
product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner
than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of
litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a
way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of
marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing
our candidates, if approved, our products may become subject to competition from such biosimilars, with the attendant competitive pressure
and potential adverse consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or for which there is a greater likelihood of success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we focus on research programs, therapeutic platforms and product candidates that
we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or
product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success.
Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.
Our spending on current and future research and development programs, therapeutic platforms and product candidates for specific indications
may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular
product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements
in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
company has limited experience in designing clinical trials and may experience delays or unexpected difficulties in obtaining regulatory
approval for our current and future product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval.
We cannot be certain that our planned clinical trials or any future clinical trials will be successful. It is possible that the FDA may
refuse to accept any or all of our planned BLAs for substantive review or may conclude after review of our data that our application
is insufficient to obtain regulatory approval for any product candidates. If the FDA does not approve any of our planned BLAs, it may
require that we conduct additional costly clinical trials, preclinical studies or manufacturing validation studies before it will reconsider
our applications. Depending on the extent of these or any other FDA-required studies, approval of any BLA or other application that we
submit may be significantly delayed, possibly for several years, or may require us to expend more resources than we have available. Any
failure or delay in obtaining regulatory approvals would prevent us from commercializing our product candidates, generating revenues
and achieving and sustaining profitability. It is also possible that additional studies, if performed and completed, may not be considered
sufficient by the FDA to approve any BLA or other application that we submit. If any of these outcomes occur, we may be forced to abandon
the development of our product candidates, which would materially adversely affect our business and could potentially cause us to cease
operations. We face similar risks for our applications in foreign jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
intend to identify and develop novel cell therapy product candidates, which makes it difficult to predict the time, cost and potential
success of product candidate development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy is to identify, develop and commercialize cell therapy product candidates using our proprietary fibroblast technology, which
involves collecting skin biopsies from donor patients, isolating cells and expanding them in culture. Our future success depends on the
successful development of these novel therapeutic approaches. To date, no fibroblast therapy products have been approved. In addition,
there have been a few number of clinical trials involving fibroblasts as compared to other, more conventional forms of therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
sizes of the markets for our product candidates are estimates, and these markets may be smaller than estimated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimates in this annual report of the annual addressable markets for our product candidates are based on a number of third-party estimates.
While we believe the assumptions and the data underlying the estimates are reasonable, these assumptions and estimates may not be correct
and the conditions supporting the assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these
underlying factors. As a result, the estimates of the annual addressable market for our product candidates may prove to be incorrect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
long-term prospects depend in part upon discovering, developing and commercializing additional product candidates, which may fail in
development or suffer delays that adversely affect their commercial viability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize
product candidates beyond those we currently have in clinical development. A product candidate can unexpectedly fail at any stage of
preclinical or clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy,
clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical studies or early
clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the
product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of other product candidates we may develop will depend on many factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">generating
                                            sufficient data to support the initiation or continuation of clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            regulatory permission to initiate clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contracting
                                            with the necessary parties to conduct clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
                                            enrollment of patients in, and the completion of, clinical trials on a timely basis;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timely manufacture of sufficient quantities of the product candidate and other key materials
                                            needed for use in clinical trials; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
                                            events in the clinical trials.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we successfully advance any other product candidates into clinical development, their success will be subject to all of the clinical,
regulatory and commercial risks described elsewhere in this &#8220;Risk Factors&#8221; section. Accordingly, we cannot assure you that
we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have never commercialized a fibroblast cell-based therapy product candidate before and may lack the necessary expertise, personnel and
resources to successfully commercialize any product candidates, if approved, on our own or together with suitable collaborators.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never commercialized a fibroblast cell-based therapy product candidate, and we currently have no sales force, marketing or distribution
capabilities. To achieve commercial success for our current product candidates, which we may license to others, we will rely on the assistance
and guidance of those collaborators. For any approved product candidates for which we retain commercialization rights, we will have to
develop our own sales, marketing and supply organization or outsource these activities to a third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors
that may affect our ability to commercialize our product candidates on our own include recruiting and retaining adequate numbers of effective
sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our product candidates and
other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization
will be expensive and time-consuming and could delay the launch of our product candidates, if approved. We may not be able to build an
effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable
partners for the commercialization of our product candidates, we may not generate revenues from them or be able to reach or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are
more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product
candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize
will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number
of products are currently under development, and may become commercially available in the future, for the treatment of conditions for
which we may attempt to develop product candidates. See &#8220;Business&#8212;Competition&#8221; for additional details. In addition,
our products may need to compete with off-label drugs used by physicians to treat the indications for which we seek approval. This may
make it difficult for us to replace existing therapies with our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
current and potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human
resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience
in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also
have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in
late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established
pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license
novel compounds that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be
significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring
technologies complementary to, or necessary for, our programs. As a result, our competitors may succeed in obtaining approval from the
FDA, the EMA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field
before we do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less
expensive than any product candidates that we may develop. Our competitors also may obtain marketing approval from the FDA, the EMA or
other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result
in our competitors establishing a strong market position before we are able to enter the market. Even if the product candidates we develop
achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then,
resulting in reduced competitiveness. Technological advances or products developed by our competitors may render our technologies or
product candidates obsolete, less competitive or uneconomical. If we are unable to compete effectively, our opportunity to generate revenue
from the sale of any products we may develop, if approved, could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are currently a &#8220;controlled company&#8221; within the meaning of the Nasdaq Stock Market Rules because our insiders beneficially own more than 50% of the voting power of our outstanding voting securities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
founder and Chief Executive Officer, Pete O&#8217;Heeron, collectively and beneficially owns approximately 59% of the voting power of
our outstanding voting securities and we are a &#8220;controlled company&#8221; within the meaning of the listing rules of The Nasdaq
Stock Market LLC. We may rely on certain exemptions from corporate governance rules, including an exemption from the rule that a majority
of our board of directors must be independent directors. Although we currently do not intend to rely on the &#8220;controlled company&#8221;
exemption under the Nasdaq listing rules, we could elect to rely on this exemption in the future. In the event that we elected to rely
on the &#8220;controlled company&#8221; exemption, a majority of the members of our board of directors might not be independent directors,
and our nominating and corporate governance and compensation committees might not consist entirely of independent directors. Our status
as a controlled company could cause our shares of our common stock to be less attractive to certain investors or otherwise harm our trading
price. As a result, you would not have the same protection afforded to shareholders of companies that are subject to these corporate
governance requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to
new compliance initiatives. We are subject to financial reporting and other requirements for which our accounting and other management
systems and resources may not be adequately prepared.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting and
other expenses that we did not incur as a private company. In addition, the federal securities laws, including the Sarbanes-Oxley Act,
the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and rules and regulations subsequently implemented by the SEC
and Nasdaq have imposed various requirements on public companies, including requirements to file annual, quarterly, and event driven
reports with respect to their business and financial condition, and to establish and maintain effective disclosure and financial controls
and corporate governance practices. These rules and regulations will increase our legal and financial compliance costs, make certain
activities more time-consuming and costly, and require our management and other personnel to devote a substantial amount of time to compliance
initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
our best efforts, we may not be able to produce reliable financial statements or file such financial statements as part of a periodic
report in a timely manner with the SEC or comply with Nasdaq listing requirements. We also expect that these rules and regulations may
make it more difficult and more expensive for us to obtain director and officer liability insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 404 of the Sarbanes-Oxley Act, we will be required to furnish a report by our management on our internal control over financial
reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting
firm, beginning with the first full year after we become a public company. However, while we remain an emerging growth company, we will
not be required to include an attestation report on internal control over financial reporting issued by our independent registered public
accounting firm. To achieve compliance with Section 404 of the Sarbanes-Oxley Act, we will be engaged in a process to document and evaluate
our internal control over financial reporting, which is both costly and challenging. We will need to continue to dedicate internal resources,
potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial
reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented
and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there
is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe
that our internal control over financial reporting is effective as required by Section 404 of the Sarbanes-Oxley Act. This could result
in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. We could
also become subject to investigations by the SEC or other regulatory authorities, which could require additional financial and management
resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we are required to maintain disclosure controls and procedures. Disclosure controls and procedures means our controls
and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the
SEC. We do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect
all errors and all fraud. We believe a control system, no matter how well-designed and operated, can provide only reasonable, not absolute,
assurance that the control system&#8217;s objectives will be met. Due to the inherent limitations in all control systems, no evaluation
of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances
of fraud, if any, have been detected. The design of any system of controls is based in part on certain assumptions about the likelihood
of future events, and any design may not succeed in achieving its stated goals under all potential future conditions. Over time, controls
may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Accordingly,
because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have identified a material weakness in our internal control over financial reporting due to lack of segregation of duties. Failure to
maintain effective internal control over financial reporting could cause our investors to lose confidence in us and adversely affect
the market price of our common stock. If our internal controls over financial reporting are not effective, we may not be able to accurately
report our financial results or prevent fraud.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the preparation of our financial statements for the fiscal year ended December 31, 2022, our management identified a material weakness
in our internal control over financial reporting due to a lack of segregation of duties. A material weakness is defined as a deficiency,
or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
our management identified a deficiency in our internal controls within the financial reporting function that resulted from a lack of
segregation of duties for the period of time covered by our financial statements prior to our Chief Financial Officer joining us in June
2022 when all financial functions were handled by a single individual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the addition of our Chief Financial Officer and the changes made to our accounting and financial reporting processes and internal controls
during the last half of fiscal year 2022, we have strengthened our internal controls and will continue to evaluate segregation of duties
and take initiatives to improve our internal controls over financial reporting as we grow. However, the implementation of these initiatives
may not fully address the material weakness in our internal control over financial reporting and we cannot assure you that we will not
identify other material weaknesses or deficiencies, which could negatively impact our results of operations in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Dependence on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects
of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply
with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize
our product candidates and our business could be adversely harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs,
to conduct certain aspects of our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical
and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain
aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance
with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us
of our regulatory responsibilities. We, our third-party contractors and CROs are required to comply with GCP requirements, which are
regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical
development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial
sites. If we or any of these third parties or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical
trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional
clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority,
such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials
must be conducted with products manufactured under cGMP regulations. Our failure to comply with these regulations may require us to repeat
clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these
third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
there is no guarantee that any such CROs, investigators or other third parties on which we rely will devote adequate time and resources
to our development activities or perform as contractually required. These third parties may also have relationships with other commercial
entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which
could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development
of our product candidates, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines,
if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere
to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and
we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. Consequently, our results
of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate
revenues could be delayed or halted entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have
an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating
in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or
to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time
and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially
impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads
or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance
that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse
impact on our business, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we decide to establish additional collaborations but are not able to establish those collaborations on commercially reasonable terms,
we may have to alter our development and commercialization plans.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidate development programs and the potential commercialization of our product candidates will require substantial additional
cash to fund expenses. We may continue to seek to selectively form collaborations to expand our capabilities, potentially accelerate
research and development activities and provide for commercialization activities by third parties. Any of these relationships may require
us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing
stockholders, or disrupt our management and business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
would face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Whether
we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s
resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a
number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, the EMA
or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing
and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to
our ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative
product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could
be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration
or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development
for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, mergers among large biopharmaceutical companies may result in a reduced number of potential future collaborators. Even if we
are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future
agreements on certain terms with potential collaborators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms,
or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development
program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing
activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to
increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which
may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our
product candidates or bring them to market and generate product revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
the future we may enter into collaborations with third parties for the development and commercialization of product candidates. If those
collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future seek third-party collaborators for the development and commercialization of one or more of our product candidates.
Our likely collaborators for any future collaboration arrangements include large and mid-size biopharmaceutical companies, regional and
national biopharmaceutical companies and biotechnology companies. We have and will likely have limited control over the amount and timing
of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate
revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions
assigned to them in these arrangements. Collaborations involving our product candidates could pose numerous risks to us, including the
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            have significant discretion in determining the efforts and resources that they will apply
                                            to these collaborations and may not perform their obligations as expected;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may deemphasize or not pursue development and commercialization of our product candidates
                                            or may elect not to continue or renew development or commercialization programs based on
                                            clinical trial results, changes in the collaborators&#8217; strategic focus, including as
                                            a result of a sale or disposition of a business unit or development function, or available
                                            funding or external factors such as an acquisition that diverts resources or creates competing
                                            priorities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may delay clinical trials, provide insufficient funding for a clinical trial program, stop
                                            a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or
                                            require a new formulation of a product candidate for clinical testing;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            could independently develop, or develop with third parties, products that compete directly
                                            or indirectly with our product candidates if the collaborators believe that competitive products
                                            are more likely to be successfully developed or can be commercialized under terms that are
                                            more economically attractive than ours;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            collaborator with marketing and distribution rights to multiple products may not commit sufficient
                                            resources to the marketing and distribution of our product candidates relative to other products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may not properly obtain, maintain, defend or enforce our intellectual property rights or
                                            may use our proprietary information and intellectual property in such a way as to invite
                                            litigation or other intellectual property-related proceedings that could jeopardize or invalidate
                                            our proprietary information and intellectual property or expose us to potential litigation
                                            or other intellectual property-related proceedings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
                                            may arise between the collaborators and us that result in the delay or termination of the
                                            research, development or commercialization of our product candidates or that result in costly
                                            litigation or arbitration that diverts management attention and resources;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations
                                            may be terminated and, if terminated, may result in a need for additional capital to pursue
                                            further development or commercialization of the applicable product candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration
                                            agreements may not lead to development or commercialization of product candidates in the
                                            most efficient manner or at all; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            a collaborator of ours were to be involved in a business combination, the continued pursuit
                                            and emphasis on our product candidate development or commercialization program could be delayed,
                                            diminished or terminated.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage
in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse
effect on our results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators,
CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures
to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws
and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing
and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct,
kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could
also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and
serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take
to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such
actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have
a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative
penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs,
such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits
and future earnings and the curtailment or restructuring of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing
cell therapy products is complex and subject to both human and systemic risks. Our third-party manufacturers or we may encounter difficulties
in production and sourcing and may be subject to variations and supply constraints of critical components. If we or any of our third-party
manufacturers encounter such difficulties, our ability to supply our product candidates for clinical trials or our products for patients,
if approved, could be delayed or prevented.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture of biologic cell therapy product candidates, and products, if approved, is complex and requires significant expertise and
capital investment, including developing advanced manufacturing techniques and process controls. Manufacturers of biologic products often
encounter difficulties in production and sourcing, particularly in scaling up or out, validating the production process, and assuring
high reliability of the manufacturing processes (including the absence of contamination), in light of variations and supply constraints
of critical components. These problems include logistics and shipping, difficulties with production costs and yields, quality control,
including consistency, stability, purity, and efficacy of the product, product testing, operator error, and availability of qualified
personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered
in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an
extended period of time to investigate and remedy the contamination. We cannot assure you that any stability, purity, and efficacy failures,
deficiencies, or other issues relating to manufacturing our product candidates will not occur in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our product candidates are derived from cells collected from humans. Such cells may vary in type and quality as the donors may vary in
age, medical history and many other factors. We have strict specifications for donor cell material and our product candidates. The donor
cell material variability may exceed our manufacturing process capability or deviate from the specified ranges and result in failure
in the production of the cell therapy product, lower quality batches, or even require adjustments to the specifications approved by authorities.
The donor cell material may also be variable in factors that we currently may not be able to detect with the analytical methods used
or may not know how to measure. We may also discover failures with the material after production. As a result, we may not be able to
deliver the quality and consistency of our cell therapy products that we need or may need to re-collect cell material which can increase
costs and/or cause delay, adversely impact patient outcomes and otherwise harm our clinical trials, reputation, business and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may fail to manage the logistics of collecting and shipping patient material to the manufacturing site, shipping the product candidate
back to the relevant parties, and experiencing delays or shortages of certain clinical or commercial-grade supplies and components. Logistical
and shipment delays and problems caused by us, our vendors, or other factors not in our control, including business interruptions, global
supply chain issues, and weather, could prevent or delay the delivery of product candidates to patients. Additionally, we have to maintain
a complex chain of identity and chain of custody with respect to donor material as it moves to the manufacturing facility, through the
manufacturing processes, and ultimately to a patient. Failure to maintain a chain of identity and chain of custody could result in patient
death, loss of product, or regulatory action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
transfer or production of our cell banks to a contract development manufacturing organization may fail and result in delays, additional
costs, or technical failure.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently purchase our cell therapy product candidates from a contract development and manufacturing organization, or CDMO. We are in
the process of contracting with a CDMO, for the transfer of our experimental cell bank to produce our master cell bank, working cell
bank and our fibroblast cell-based product candidates to enable clinical trials. If the transfer of our experimental cell bank to the
CDMO is not successful, we may encounter delays, additional costs, or technical failure of one or more of our product candidates. Similarly,
if the CDMO is unable to produce from the experimental cell bank our master cell bank, working cell bank and our fibroblast cell-based
product candidates to enable clinical trials, we may encounter delays, additional costs, or technical failure of one or more of our product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in the methods of product candidate manufacturing or formulation may result in additional costs or delay.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
product candidates proceed through preclinical studies to late-stage clinical trials towards potential marketing approval and commercialization,
it is common that various aspects of the development program, such as manufacturing methods, formulation, materials and processes, are
altered along the way in an effort to optimize processes and product characteristics. Such alterations can also occur due to changes
in manufacturers. Such changes carry the risk that they will not achieve their intended objectives. Any such changes could cause our
product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted
with product candidates produced using the modified manufacturing methods, materials and processes. Such changes may also require additional
testing, FDA notification or FDA approval. This could delay the completion of clinical trials, require the conduct of bridging clinical
trials or the repetition of one or more clinical trials beyond those we currently anticipate, increase clinical trial costs, delay approval
of our product candidates and jeopardize our ability to commercialize our product candidates if approved. In addition, we may be required
to make significant changes to our upstream and downstream processes across our pipeline, which could delay the development of future
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law,
we may be liable for damages.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials,
by us and our third-party manufacturers. We currently outsource all manufacturing to third parties. Still, we and our manufacturers are
subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal
of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing
of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting
from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability, or local, city, state or
federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could
be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not currently have any insurance
for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive,
and current or future environmental regulations may impair our research, development and production efforts, which could harm our business,
prospects, financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third parties for our manufacturing process and may, in the future, depend on third-party manufacturers for our product candidates,
and this increases the risk related to the timely and sufficient production of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners
for compliance with cGMP regulations for manufacturing our cell therapy product candidates. Third-party manufacturers may be unable to
comply with cGMP regulations or similar regulatory requirements outside the United States. If our contract manufacturers cannot successfully
manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, the EMA or others, they will
not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over
the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA,
the EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates
or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly
impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure
of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines,
injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates,
operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates
and harm our business and results of operations. Furthermore, the raw materials for our product candidates may be sourced, in some cases,
from a single-source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future
product candidates for any reason, whether as a result of manufacturing, supply, or storage issues or otherwise, we could experience
delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely on third-party manufacturers to produce our product candidates for use in development and commercialization under the
guidance of members of our organization. In the event that we or any of our third-party manufacturers fail to comply with such requirements
or to perform with certain requirements in relation to quality, timing, or otherwise, or if our supply of components or other materials
becomes limited or interrupted for other reasons, we may be forced to enter into an agreement with another third party, which we may
not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our third-party manufacturers could
require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical
skills or technology required to manufacture our product candidates may be unique or proprietary to us or the third-party manufacturer.
We may have difficulty transferring such skills or technology to another third party, and a feasible alternative may not exist. In addition,
certain of our product candidates and our own proprietary methods have never been produced or implemented outside of our company. Therefore,
we may experience delays in our development programs if we attempt to establish new third-party manufacturing arrangements for these
product candidates or methods. These factors would increase our reliance on such manufacturers or require us to obtain a license from
such manufacturers in order to have another third party manufacture our product candidates. If we are required to or voluntarily stop
manufacturing our product candidates for any reason, we will be required to verify that the new manufacturer maintains facilities and
procedures that comply with quality standards and with all applicable regulations and guidelines and that the product produced is equivalent
to that produced in our facility. The delays associated with the verification of a new manufacturer and equivalent product could negatively
affect our ability to develop product candidates in a timely manner or within budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
or a third party&#8217;s failure to execute our manufacturing requirements, do so on commercially reasonable terms and timelines, and
comply with cGMP requirements could adversely affect our business in a number of ways, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
                                            to meet our product specifications and quality requirements consistently;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
                                            to initiate or continue clinical trials of our product candidates under development;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            in submitting regulatory applications or receiving marketing approvals for our product candidates,
                                            if at all;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
                                            to commercialize any product candidates that receive marketing approval on a timely basis;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
                                            of the cooperation of future collaborators;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjecting
                                            third-party manufacturing facilities or our manufacturing facilities to additional inspections
                                            by regulatory authorities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
                                            to cease development or to recall batches of our product candidates; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the event of approval to market and commercialize our product candidates, an inability to
                                            meet commercial demands for our product candidates or any future product candidates.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
contamination or interruption in our manufacturing processes, shortages of raw materials, or failure of our suppliers to deliver necessary
components could result in delays in our clinical development or marketing schedules.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the nature of cell therapy manufacturing, there is a risk of contamination. Any contamination could adversely affect our ability to produce
product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Additionally, although
our cell therapies are tested for contamination prior to release if a contaminated product candidate was administered to a patient, it
could result in harm to the patient. Some of the raw materials required in our manufacturing process are derived from biological sources.
Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall,
or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt
the commercial manufacturing or the production of clinical material, which could adversely affect our development timelines and our business,
financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Legal and Regulatory Compliance Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with healthcare professionals, clinical investigators, CROs and third-party payors in connection with our current and future
business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government
price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions,
civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and
diminished profits and future earnings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain
marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors
and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business
or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain marketing
approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from
                                            knowingly and willfully soliciting, offering, receiving or paying any remuneration (including
                                            any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in
                                            kind, to induce, or in return for the purchase, lease, order, arrangement, or recommendation
                                            of any good, facility, item or service for which payment may be made, in whole or in part,
                                            under a federal healthcare program, such as the Medicare and Medicaid programs. A person
                                            or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or
                                            specific intent to violate it to have committed a violation. Violations are subject to civil
                                            fines and criminal penalties for each violation, plus up to three times the remuneration
                                            involved, imprisonment, and exclusion from government healthcare programs. In addition, the
                                            government may assert that a claim including items or services resulting from a violation
                                            of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes
                                            of the federal False Claims Act or federal civil money penalties;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal civil and criminal false claims laws and civil monetary penalty laws, such as the
                                            federal False Claims Act, which impose criminal and civil penalties and authorize civil whistleblower
                                            or qui tam actions, against individuals or entities for, among other things: knowingly presenting,
                                            or causing to be presented, to the federal government, claims for payment that are false
                                            or fraudulent; knowingly making, using or causing to be made or used, a false statement of
                                            record material to a false or fraudulent claim or obligation to pay or transmit money or
                                            property to the federal government or knowingly concealing or knowingly and improperly avoiding
                                            or decreasing an obligation to pay money to the federal government. Manufacturers can be
                                            held liable under the federal False Claims Act even when they do not submit claims directly
                                            to government payors if they are deemed to &#8220;cause&#8221; the submission of false or
                                            fraudulent claims. The federal False Claims Act also permits a private individual acting
                                            as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging
                                            violations of the federal False Claims Act and to share in any monetary recovery;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among
                                            other things, a person from knowingly and willfully executing, or attempting to execute,
                                            a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent
                                            pretenses, representations or promises, any of the money or property owned by, or under the
                                            custody or control of, any healthcare benefit program, regardless of the payor (e.g., public
                                            or private) and knowingly and willfully falsifying, concealing or covering up by any trick
                                            or device a material fact or making any materially false, fictitious, or fraudulent statements
                                            or representations in connection with the delivery of, or payment for, healthcare benefits,
                                            items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute,
                                            a person or entity does not need to have actual knowledge of the statute or specific intent
                                            to violate it in order to have committed a violation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            as further amended by the Health Information Technology for Economic and Clinical Health
                                            Act of 2009, or HITECH, and their respective implementing regulations, including the Final
                                            Omnibus Rule published in January 2013, which impose certain requirements on certain covered
                                            healthcare providers, health plans and healthcare clearinghouses, as well as their respective
                                            business associates, independent contractors or agents of covered entities, that perform
                                            services for them that involve the use, creation, maintenance, receipt or disclosure of,
                                            individually identifiable health information, relating to the privacy, security and transmission
                                            of individually identifiable health information. HITECH also created new tiers of civil monetary
                                            penalties, amended HIPAA to make civil and criminal penalties directly applicable to business
                                            associates, and gave state attorneys general new authority to file civil actions for damages
                                            or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217;
                                            fees and costs associated with pursuing federal civil actions. In addition, there are additional
                                            federal, state and non-U.S. laws which govern the privacy and security of health and other
                                            personal information in certain circumstances to which we may be subject and many of which
                                            differ from each other in significant ways and may not have the same effect, thus complicating
                                            compliance efforts;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
                                            government price reporting laws, which require manufacturers to calculate and report complex
                                            pricing metrics in an accurate and timely manner to government programs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
                                            consumer protection and unfair competition laws, which broadly regulate marketplace activities
                                            and activities that potentially harm consumers;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            ACA, including the provision commonly referred to as the Physician Payments Sunshine Act
                                            and its implementing regulations, which require applicable manufacturers of drugs, devices,
                                            biologics and medical supplies for which payment is available under Medicare, Medicaid or
                                            the Children&#8217;s Health Insurance Program to report annually to the U.S. Centers for
                                            Medicare &amp; Medicaid Services, or CMS, within the U.S. Department of Health and Human
                                            Services, information related to payments or other transfers of value made to physicians,
                                            nurse practitioners, certified nurse anesthetists, physician assistants, clinical nurse specialists,
                                            and certified nurse midwives as well as teaching hospitals and to disclose ownership and
                                            investment interests held by physicians and their immediate family members; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">many
                                            state laws that govern the privacy of personal information in specified circumstances. For
                                            example, in California, the California Consumer Privacy Act, or the CCPA, which went into
                                            effect on January 1, 2020, establishes a new privacy framework for covered businesses by
                                            creating an expanded definition of personal information, establishing new data privacy rights
                                            for consumers in the State of California, imposing special rules on the sale of personal
                                            information, and creating a new and potentially severe statutory damages framework for violations
                                            of the CCPA and for businesses that fail to implement reasonable security procedures and
                                            practices to prevent data breaches. While clinical trial data and information governed by
                                            HIPAA are currently exempt from the CCPA, other personal information collection practices
                                            may be subject to the CCPA and possible changes to the CCPA may broaden its scope.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are subject to state and foreign equivalents of each of the healthcare laws and regulations described above, among others, some of
which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback
Statute and False Claims Act, and may apply to our business practices, including, but not limited to, research, distribution, sales or
marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers.
In addition, some states have passed laws that require biopharmaceutical companies to comply with the April 2003 Office of Inspector
General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s
Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require biopharmaceutical
companies to make marketing or price disclosures to the state and require the registration of biopharmaceutical sales representatives.
Privacy and data protection laws from outside of the United States, including, for example, the European Union General Data Protection
Regulation and the UK Data Protection Act 2018, or, collectively, the GDPR, also govern the privacy and security of personal information,
including health information in some circumstances, and many of these laws differ from each other in significant ways, thus complicating
compliance efforts. In addition, in the United States, there are a number of states that have enacted laws that govern the privacy and
security of personal information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts. There are ambiguities as to what is required to comply with these state requirements and if we fail
to comply with an applicable state law requirement we could be subject to penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased
their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions,
convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare and privacy
laws, as well as responding to possible investigations by government authorities, can be time and resource-consuming and can divert a
company&#8217;s attention from the business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations
will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply
with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws
and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and
regulations that may apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties,
damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment, reputational
harm and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject
to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, defending against
any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if
we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians
or other providers or entities with whom we do, or expect to do, business is found to not be in compliance with applicable laws, they
may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment.
If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be or become subject to evolving global data protection laws and regulations, which may require us to incur substantial compliance
costs, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global data protection landscape is rapidly evolving, and we may be or become subject to or affected by numerous federal, state and foreign
laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, transfer, security and processing of
personal data, such as information that we collect about participants and healthcare providers in connection with clinical trials. Implementation
standards and enforcement practices are likely to remain uncertain for the foreseeable future, which may create uncertainty in our business,
affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, result in liability
or impose additional compliance or other costs on us. Any failure or perceived failure by us to comply with federal, state, or foreign
laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against
us by governmental entities or others. For example, states, such as California, Virginia, Colorado, Utah and Connecticut have recently
enacted consumer privacy laws that grant rights to data subjects and places privacy and security obligations on entities handling personal
data of consumers or households. Some observers note that the CCPA and similar legislation could mark the beginning of a trend toward
more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our operations in the United States, which may be subject to healthcare and other laws relating to the privacy and security
of health information and other personal information, we may seek to conduct clinical trials in the United Kingdom or the European Economic
Area, or the EEA, and may become subject to additional European data privacy laws, regulations and guidelines. We will be subject to
the data protection laws of the European Union and United Kingdom in relation to personal data we collect from these territories. These
laws impose additional obligations and risk upon our business, including substantial expenses and changes to business operations that
are required to comply with these laws. The withdrawal of the United Kingdom from the European Union, or Brexit, and the subsequent separation
of the data protection regimes of these territories mean we are required to comply with separate data protection laws in the European
Union and United Kingdom, which may lead to additional compliance costs and could increase our overall risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GDPR, which deals with the processing of personal data and on the free movement of such data, imposes a broad range of strict requirements,
including requirements relating to having lawful bases for processing personal data and transferring such information outside the EEA/UK,
including to the United States, providing details to those individuals regarding the processing of their personal data, keeping personal
data secure, having data processing agreements with third parties who process personal data, responding to individuals&#8217; requests
to exercise their rights in respect of their personal data, reporting security breaches involving personal data to the competent national
data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments
and record-keeping.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GDPR imposes strict rules on the transfer of personal data out of the EEA/UK to countries not regarded by European Commission and the
United Kingdom government as providing adequate protection, or the third countries, including the United States. These transfers are
prohibited unless an appropriate safeguard specified by data protection laws is implemented, such as the Standard Contractual Clauses,
or the SCCs, approved by the European Commission, or a derogation applies. The UK has published its own transfer mechanism, the International
Data Transfer Agreement and International Data Transfer Addendum, which enables transfers from the UK and has implemented a similar Transfer
Equivalence Test. The international transfer obligations under the EU and UK data protection regimes require effort and cost and may
result in us needing to make strategic considerations around where EEA/UK personal data is located and which service providers we utilize
for the processing of EEA/UK personal data, particularly as the enforcement around GDPR international transfer compliance obligations
is currently unclear. The UK Government has also now introduced a Data Protection and Digital Information Bill, or the UK Bill, into
the UK legislative process with the intention for this bill to reform the UK&#8217;s data protection regime. If passed, the final version
of the UK Bill may have the effect of further altering the similarities between the UK and EU data protection regime. This may lead to
additional compliance costs and could increase our overall risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that any efforts to comply with any obligations under European privacy laws will be sufficient. If we are investigated
by a European data protection authority, we may face fines and other penalties. Any such investigation or charges by European data protection
authorities could have a negative effect on our reputation and materially harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability
could have an adverse effect on our business and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic
treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing product
candidates, such claims could result in an FDA, EMA or other regulatory authority investigation of the safety and effectiveness of our
product candidates, our manufacturing processes and facilities or our marketing programs. FDA, EMA or other regulatory authority investigations
could potentially lead to a recall of our product candidates or more serious enforcement action, limitations on the approved indications
for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may
also result in decreased demand for our product candidates, if approved, injury to our reputation, costs to defend the related litigation,
a diversion of management&#8217;s time and our resources and substantial monetary awards to trial participants or patients. We currently
have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior
to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against
potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we
may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that
could have an adverse effect on our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing
regulations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities,
private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to
afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in
the United States and internationally, on the extent to which the costs of our product candidates will be covered and reimbursed by third-party
payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our
product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or
maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or
the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement
is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.
For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult
because of the higher prices often associated with such drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States,
no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for
products can differ significantly from payor to payor. The Medicare and Medicaid programs increasingly are used as models for how private
payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. However, one third-party
payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage
for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This process will require
us to provide scientific and clinical support for the use of our product candidates to each third-party payor separately, with no assurance
that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Factors payors consider in determining
reimbursement are based on whether the product is: (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary;
(iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasingly,
third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the
prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and
reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and
reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known
as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmacoeconomic
studies to demonstrate the medical necessity and cost effectiveness of our product candidates. Nonetheless, our product candidates may
not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any
product candidate that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the United States, international operations are generally subject to extensive governmental price controls and other market regulations,
and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to
put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of
the European Union, medical product prices are subject to varying price control mechanisms as part of national health systems. In these
countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval.
To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness
of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in
the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional
foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates.
Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United
States and may be insufficient to generate commercially reasonable revenue and profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors,
the adoption of those product candidates and sales revenue will be adversely affected, which, in turn, could adversely affect the ability
to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any
time. Even if favorable coverage and reimbursement status is attained for one or more product candidates for which we receive regulatory
approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security
regulations promulgated under HIPAA, as amended by the HITECH. We are not currently classified as a covered entity or business associate
under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s
criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances,
we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered
healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable
health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we
receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their
healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification
of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information
than the health information protected by HIPAA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our
operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217;
health information. Patients about whom we or our collaborators obtain health information, as well as the providers who share this information
with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend
significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have
violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive
and time consuming to defend and could result in adverse publicity that could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or third-party contract manufacturing organizations, CROs or other contractors or consultants fail to comply with applicable federal,
state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217;
ability to develop and commercialize our product candidates and could harm or prevent sales of any affected product candidates that we
are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our product
candidates. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial
resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability,
breaches of data security or reputational damage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable
materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract
with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these
materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting
damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines
and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of hazardous and flammable materials, including chemicals and biological materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with
these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA, the EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their
jurisdiction.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may choose to conduct international clinical trials in the future. The acceptance of study data by the FDA, the EMA or other comparable
foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions.
In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the
FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States
population and United States medical practice; (ii) the trials are performed by clinical investigators of recognized competence and pursuant
to current GCP requirements; and (iii) the FDA is able to validate the data through an on-site inspection or other appropriate mean.
Additionally, the FDA&#8217;s clinical trial requirements, including the adequacy of the patient population studied and statistical powering,
must be met. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials
are conducted. There can be no assurance that the FDA, the EMA or any applicable foreign regulatory authority will accept data from trials
conducted outside of its applicable jurisdiction. If the FDA, the EMA or any applicable foreign regulatory authority does not accept
such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business
plan, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or
maintain regulatory approval in any other jurisdiction. For example, even if the FDA or the EMA grants marketing approval of a product
candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and
reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction
may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve
requirements and administrative review periods different from those in the United States, including additional preclinical studies or
clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions.
In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for
sale in that jurisdiction. In some cases, the price that we intend to charge for our product candidates is also subject to approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant
delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. If
we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable
marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates
will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if our product candidates receive regulatory approval and become products, they will be subject to significant post-marketing regulatory
requirements and oversight.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities
and surveillance to monitor the safety and efficacy of the products, may contain significant limitations related to use restrictions
for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management
requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for
a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution
methods, patient registries and other risk minimization tools. In addition, if the FDA, the EMA or foreign regulatory authorities approve
our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising,
promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements.
These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going
compliance with cGMPs and GCP for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and
their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for
compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such
as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory
agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product
from the market or suspension of manufacturing. In addition, failure to comply with FDA, the EMA or other comparable foreign regulatory
requirements may subject our company to administrative or judicially imposed sanctions, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            in or the rejection of product approvals;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on our ability to conduct clinical trials, including full or partial clinical holds on ongoing
                                            or planned trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the products, manufacturers or manufacturing process;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
                                            or untitled letters;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
                                            and criminal penalties;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
                                            or withdrawal of regulatory approvals;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            seizures, detentions or import bans;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
                                            or mandatory product recalls and publicity requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">total
                                            or partial suspension of production; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
                                            of restrictions on operations, including costly new manufacturing requirements.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
and could require us to expend significant time and resources in response and could generate negative publicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained, and we may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative
or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact
our business and industry. Namely, the previous U.S. administration took several executive actions, including the issuance of a number
of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine
regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of
marketing applications. It is difficult to predict whether or how these executive actions, including the Executive Orders, will be implemented,
or whether they will be rescinded or replaced under the new U.S. administration. If these executive actions impose constraints on FDA&#8217;s
ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become
subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about
prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA, the EMA or such other
regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate,
physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found
to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil
and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging
in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under
which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates,
if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may face difficulties from changes to current regulations and future legislation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval
of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained and we may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the ACA substantially changed the way healthcare is financed by both the government and private insurers, and significantly
impacts the U.S. biopharmaceutical industry. Other legislative changes have been proposed and adopted in the United States since the
ACA was enacted. These changes include aggregate reductions to Medicare payments and may result in additional reductions in Medicare
and other healthcare funding, all of which could have a material adverse effect on customers for our product candidates, if approved,
and accordingly, our financial operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have also been several changes and challenges to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers
can charge for medications sold to certain health care facilities. It is unclear how these developments could affect covered hospitals
who might purchase our future product candidate and affect the rates we may charge such facilities for our approved product candidates
in the future, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
there has been heightened governmental scrutiny in recent years over the manner in which drug manufacturers set prices for their marketed
products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed
to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient
programs, and reform government program reimbursement methodologies for pharmaceutical products. The U.S. Congress has indicated that
it will continue to seek new legislative measures to control drug costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients
to access certain investigational new product candidates that have completed a Phase 1 clinical trial and that are undergoing investigation
for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without
obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its products available
to eligible patients as a result of the Right to Try Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage
criteria and in additional downward pressure on the price that we receive for any approved product candidates. Any reduction in reimbursement
from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost
containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize
our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative
and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology
products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations
will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition,
increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as
subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends on our ability to protect our intellectual property and our proprietary technologies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product
candidates, proprietary technologies and their uses to operate without infringing the proprietary rights of others. If we or our licensors
are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our
product candidates, our competitive position could be harmed. We and our licensors generally seek to protect our proprietary position
by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses
that are important to our business. Our in-licensed patent applications cannot be enforced against third parties practicing the technology
claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover
the technology. There can be no assurance that our in-licensed patent applications will result in patents being issued or that issued
patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents
if issued will not be infringed, designed around, invalidated or rendered unenforceable by third parties. Even issued patents may later
be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices
or in courts. The degree of future protection for our and our licensors&#8217; proprietary rights is uncertain. Only limited protection
may be available and may not adequately protect our or our licensors&#8217; rights or permit us or our licensors to gain or keep any
competitive advantage. These uncertainties and/or limitations in our and our licensors&#8217; ability to properly protect the intellectual
property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we may in-license issued patents in the United States and foreign countries, we cannot be certain that the claims in our other in-licensed
U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign countries
will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the patent
offices and courts in foreign countries, nor can we be certain that the claims in our in-licensed issued patents will not be found invalid
or unenforceable if challenged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our licensors or
any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents.
These risks and uncertainties include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            USPTO and various foreign governmental patent agencies require compliance with a number of
                                            procedural, documentary, fee payment and other provisions during the patent process, the
                                            noncompliance with which can result in abandonment or lapse of a patent or patent application,
                                            and partial or complete loss of patent rights in the relevant jurisdiction;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patent
                                            applications may not result in any patents being issued;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patents
                                            may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable
                                            or otherwise may not provide any competitive advantage;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            degree and range of protection any issued patents will afford us against competitors, including
                                            whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            others will apply for or obtain patents claiming aspects similar to those covered by our
                                            patents and patent applications;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            the patent applications that we own or in-license will result in issued patents with claims
                                            that cover our product candidates or uses thereof in the United States or in other foreign
                                            countries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            competitors, many of whom have substantially greater resources than we or our licensors do
                                            and many of whom have made significant investments in competing technologies, may seek or
                                            may have already obtained patents that will limit, interfere with or block our ability to
                                            make, use and sell our product candidates;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
                                            may be significant pressure on the U.S. government and international governmental bodies
                                            to limit the scope of patent protection both inside and outside the United States for disease
                                            treatments that prove successful, as a matter of public policy regarding worldwide health
                                            concerns; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">countries
                                            other than the United States may have patent laws less favorable to patentees than those
                                            upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop
                                            and market competing products.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is also expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary
or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially
advantageous. It is also possible that we or our licensors may not identify patentable aspects of our research and development output
before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation,
filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license, including those from
our licensors and from third parties. We also may require the cooperation of our licensors in order to enforce the licensed patent rights,
and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent
with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have
been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such
patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable
intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may
be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
of matter patents for biological and pharmaceutical products such as cell therapy product candidates often provide a strong form of intellectual
property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be
certain, however, that the claims in our pending patent applications covering the composition of matter of our product candidates will
be considered patentable by the USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will
be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product
for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to
our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote
their product for our targeted indications, physicians may prescribe these products &#8220;off-label&#8221; for those uses that are covered
by our method of use patents. Although off-label prescriptions may infringe or contribute to the infringement of method of use patents,
the practice is common and such infringement is difficult to prevent or prosecute.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of
our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants,
advisors, licensors and other third parties, any of these parties may breach such agreements and disclose such output before a patent
application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the scope of any patent protection our licensors obtain is not sufficiently broad, or if our licensors lose any of the patent protection
we license, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been
the subject of much litigation in recent years. As a result, the existence, issuance, scope, validity, enforceability and commercial
value of our in-licensed patent rights are highly uncertain. Our pending and future in-licensed patent applications may not result in
patents being issued that protect our product candidates or that effectively prevent others from commercializing competitive product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the scope of claims in a patent application can be significantly reduced before any claims in a patent is issued, and claim scope can
be reinterpreted after issuance. Even if patent applications we license currently or in the future issue as patents, they may not issue
in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or
otherwise provide us with any competitive advantage. Any patents that we license may be challenged or circumvented by third parties or
may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates
will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent
our patents by developing similar or alternative technologies or products in a non-infringing manner, which could materially adversely
affect our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our licensed-in patents may not
cover our product candidates or may be challenged in the courts or patent offices in the United States and abroad. We may be subject
to a third party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination,
post-grant review, or PGR, and inter partes review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging
our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity
of our in-licensed patents, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensors and
the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our in-licensed
patents and patent applications or those of our licensors has been found. There is also no assurance that there is not prior art of which
we or licensors are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications
or those of our licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse
determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our
in-licensed patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment
to us. Such loss of licensed patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration
of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time
from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection
provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating
with us to license, develop or commercialize current or future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent,
which might adversely affect our ability to develop and market our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims
or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party
patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product
candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in
a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application
may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are
not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims
of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may
be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly
interpret relevant patents may negatively impact our ability to develop and market our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
aspect of the determination of patentability of our inventions depends on the scope and content of the &#8220;prior art,&#8221; information
that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may
be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability
of a patent claim. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates
or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own
patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly
uncertain. Because patent applications in the United States and most other countries are confidential for typically a period of 18 months
after filing, or may not be published at all, we cannot be certain that we were the first to file any patent application related to our
product candidates. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.
Furthermore, for U.S. applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding
can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered
by the patent claims of our applications. For U.S. applications containing a claim not entitled to priority before March 16, 2013, there
is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant
changes to the U.S. patent laws, including new procedures for challenging pending patent applications and issued patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example,
we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in PGR procedures, oppositions,
derivations, reexaminations or IPR proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights
of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated,
or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical
technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount
of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might
expire before or shortly after such candidates are commercialized. Any failure to obtain or maintain patent protection with respect to
our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
the future, some of our intellectual property may be discovered through government-funded programs and thus may be subject to federal
regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance
with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the intellectual property rights we may acquire or license in the future may be generated through the use of U.S. government funding
and may therefore be subject to certain federal regulations. These U.S. government rights may include retained rights in the intellectual
property, including a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose.
In addition, the U.S. government may have the right, under certain limited circumstances, to require us to grant exclusive, partially
exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been
taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government
action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;).
The U.S. government may also have the right to take title to these inventions if the grant recipient fails to disclose the invention
to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property
generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to
expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced
through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may
be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable
but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture
substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference
for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property.
To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of
the Bayh-Dole Act may similarly apply.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                            may be able to develop products that are similar to our product candidates but that are not
                                            covered by the claims of the patents that we own or license;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            or our licensors or future collaborators might not have been the first to make the inventions
                                            covered by the issued patents or pending patent applications that we own or license;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            or our licensors or future collaborators might not have been the first to file patent applications
                                            covering certain of our inventions;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                            may independently develop similar or alternative technologies or duplicate any of our technologies
                                            without infringing our intellectual property rights;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            is possible that our licensors&#8217; pending patent applications will not lead to issued
                                            patents;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
                                            patents that we own or license may be held invalid or unenforceable, as a result of legal
                                            challenges by our competitors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            competitors might conduct research and development activities in countries where we do not
                                            have patent rights and then use the information learned from such activities to develop competitive
                                            products for sale in our major commercial markets;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not develop additional proprietary technologies that are patentable;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            cannot predict the scope of protection of any patent issuing based on our patent applications,
                                            including whether the patent applications that we own or in-license will result in issued
                                            patents with claims that cover our product candidates or uses thereof in the United States
                                            or in other foreign countries;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            claims of any patent issuing based on our patent applications may not provide protection
                                            against competitors or any competitive advantages, or may be challenged by third parties;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            enforced, a court may not hold that our patents are valid, enforceable and infringed;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may need to initiate litigation or administrative proceedings to enforce and/or defend our
                                            patent rights which will be costly whether we win or lose;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may choose not to file a patent application in order to maintain certain trade secrets or
                                            know-how, and a third party may subsequently file a patent application and obtain an issued
                                            patent covering such intellectual property;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may fail to adequately protect and police our trademarks and trade secrets; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            patents of others may have an adverse effect on our business, including if others obtain
                                            patents claiming subject matter similar to or improving that covered by our patents and patent
                                            applications.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any of these events occur, they could significantly harm our business, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third
parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our
developmental and commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research,
development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual
property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit
our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair
our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and
other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations,
IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S. and foreign issued patents
and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or
patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture
of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to
claims of infringement of the patent rights of third parties. We cannot provide any assurances that third-party patents do not exist
which might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our
sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.
Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published,
we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be
certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications
can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product
candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult
because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing
the meaning of patent claims. It is also possible that patents owned by third parties of which we are aware, but which we do not believe
are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product
candidate. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.
Any claims of patent infringement asserted by third parties would be time consuming and could:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">result
                                            in costly litigation that may cause negative publicity;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">divert
                                            the time and attention of our technical personnel and management;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cause
                                            development delays;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevent
                                            us from commercializing any of our product candidates until the asserted patent expires or
                                            is held finally invalid or unenforceable or not infringed in a court of law;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            us to significant liability to third parties; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            us to enter into royalty or licensing agreements, which may not be available on commercially
                                            reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors
                                            gaining access to the same technology.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although,
to our knowledge, no third party has asserted a claim of patent infringement against us as of the date of this annual report, others may
hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming
damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for
damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop
our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be
a substantial diversion of management and employee resources from our business. We cannot predict whether we would prevail in any such
actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all.
Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result
in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product
candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding,
or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could
harm our business, financial condition and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources or more mature and developed intellectual property portfolios, or both. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that
some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation
and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a
material adverse effect on our business, our ability to compete in the marketplace, results of operations, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming
and unsuccessful. Further, our in-licensed issued patents could be found invalid or unenforceable if challenged in court.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patents or other intellectual property rights or the intellectual property rights of our licensors. To cease such infringement
or unauthorized use, we and/or our licensors may be required to file infringement claims, which can be expensive and time-consuming.
Further, our licensors may need to file infringement claims, and our licensors may elect not to file such claims. Our pending patent
applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent
issues from such applications. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is
not valid, is unenforceable and/or is not infringed. If we or any of our licensors or potential future collaborators were to initiate
legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim
that our patent is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory
requirements, including lack of novelty or written description, obviousness, written description, or non-enablement. Grounds for an unenforceability
assertion could include an allegation that someone connected with prosecution of the patent intentionally withheld material information
from the USPTO or made a misleading statement during prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all,
of the patent protection on such product candidate. There is also a risk that, even if the validity of such patents is upheld, the court
will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention
at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#8217;s use of our patented
technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). In addition, if the breadth or strength
of protection provided by our patents and patent applications or those of our licensors is threatened, it could dissuade companies from
collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would
have a material adverse impact on our business. Similarly, if we assert trademark infringement claims, a court may determine that the
marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior
rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant
expenses and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings
could substantially increase our operating losses and reduce the resources available for development activities or any future sales,
marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings
adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could compromise our ability to compete in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only
monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in
connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a
risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as
results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard
these announcements as negative, the perceived value of our existing product candidates, programs or intellectual property could be diminished.
Such announcements could also harm our reputation or the market for our future product candidates, which could have a material adverse
effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Derivation
or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease
using the related technology or to attempt to license rights from the prevailing party.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivation
or interference proceedings provoked by third parties or brought by us or our licensors, or declared by the USPTO or similar proceedings
in foreign patent offices may be necessary to determine the priority of inventions with respect to, or correct the inventorship of, our
or our licensors&#8217; patents or patent applications. An unfavorable outcome could result in a loss of our current patent rights and
require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could
be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our or our licensors&#8217; defense of
such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In
addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary
to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development
or manufacturing partnerships that would help us bring our product candidates to market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement
or defense of our issued patents.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act could increase uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith
Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are
prosecuted, redefine prior art, and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents.
In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system
in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled
to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application
in the USPTO after March 2013 but before we file an application covering the same invention, could therefore be awarded a patent covering
an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going
forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable
patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior
art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until
issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product
candidates and other proprietary technologies we may develop or (ii) invent any of the inventions claimed in our or our licensors&#8217;
patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing
the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party
benefits from a compulsory license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may
affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional
procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings.
An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent
rights, which could adversely affect our competitive position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to
invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a
claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.
Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated
if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could
increase the uncertainties and costs surrounding the prosecution of our or licensors&#8217; patent applications and the enforcement or
defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations
and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect
our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biopharmaceutical industry involves a high degree of technological and legal complexity. Therefore,
obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. Changes in either the patent laws
or in the interpretations of patent laws in the United States and other countries may diminish our ability to protect our inventions,
obtain, maintain, and enforce our intellectual property rights, and, more generally, could affect the value of our intellectual property
and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued
patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition,
Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us or narrows the scope of our
owned and licensed patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available
in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard
to our or our licensors&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect
to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities
in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our
licensors&#8217; ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future. We cannot
predict how future decisions by Congress, the federal courts or the USPTO may impact the value of our patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
or our licensors may be subject to claims challenging the inventorship or ownership of our or our in-licensed patents and other intellectual
property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our in-licensed
patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application
can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions
of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the
subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of
questions regarding co-ownership of potential joint inventions. For example, we may have inventorship disputes arise from conflicting
obligations of consultants or others who are involved in developing our product candidates. Alternatively, or additionally, we may enter
into agreements to clarify the scope of our rights in such intellectual property. Litigation may be necessary to defend against these
and other claims challenging inventorship or ownership. If we or our licensors fail in defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership or a right to use. Such an outcome could
have a material adverse effect on our business. Even if we or our licensors are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to management and other employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with
each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property
rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties,
or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims
could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years after its first effective filing date. Various extensions may be available, but the term of a patent, and the protection it
affords, is limited. Even if patents directed to our product candidates are obtained, once the patent term has expired, we may be open
to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product
candidates, patents directed to our product candidates might expire before or shortly after such candidates are commercialized. As a
result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical
to ours. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused
by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or our licensors do not obtain patent term extension for our product candidates, our business may be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of FDA marketing approval, if any, of our product candidates, one or more of our U.S. patents
may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the
Hatch-Waxman Amendments. The Hatch- Waxman Amendments permit a patent restoration term of up to five years as compensation for patent
term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA-approved
product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the
remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved
drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in
certain foreign countries upon regulatory approval of our product candidates. However, we or our licensors may not be granted an extension
because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise
failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be
less than we request. If we or our licensors are unable to obtain patent term extension or restoration or the term of any such extension
is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could
be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and clinical
trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. If we do not
have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights throughout the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we have in-licensed pending patent applications in the United States and certain other countries, filing, prosecuting and defending patents
in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside
the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries, particularly
certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United
States. Consequently, we may not be able to prevent third parties from practicing our in-licensed inventions in all countries outside
the United States or from selling or importing products made using our in-licensed inventions in and into the United States or other
jurisdictions. Competitors may use our in-licensed technologies in jurisdictions where we have not obtained patent protection to develop
their own products and, further, may export otherwise infringing products to territories where we or our licensors have patent protection,
but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our or our
licensors patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of many foreign countries do not favor the enforcement of patents, trade secrets, and other intellectual property protection,
which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our or our licensors&#8217;
patents or other intellectual property rights, or marketing of competing products in violation of our proprietary rights. Proceedings
to enforce our or our licensors&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our efforts
and attention from other aspects of our business, could put our or our licensors&#8217; patents at risk of being invalidated, held unenforceable,
or interpreted narrowly and our or our licensors&#8217; patent applications at risk of not issuing and could provoke third parties to
assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other
remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction,
competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could
have a material adverse effect on our business. Accordingly, our or our licensors&#8217; efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop
or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, certain countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to
grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we
or our licensors are compelled to grant a license to a third-party, which could materially diminish the value of those patents. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we or our licensors are forced to grant
a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business,
financial condition, results of operations and prospects may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the expense and uncertainty of litigation in certain foreign jurisdictions, we may conclude that even if a third-party is infringing
our issued patents, any patents that may be issued as a result of our pending or future patent applications or other intellectual property
rights, the risk-adjusted cost of bringing and enforcing such a claim or action, which typically last for years before they are concluded,
may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to
enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs
of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature
and developed intellectual property portfolios. In such cases, we may decide that the monetary cost of such litigation and the diversion
of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings and
that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.
In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical
trials, continue our internal research programs, in-license needed technology or other product candidates, or enter into development
partnerships that would help us bring our product candidates to market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements
imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance
with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO
and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to
remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent
offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application
process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured
by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations
in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss
of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by other types of intellectual property, we rely on the protection of our trade secrets, including
unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps
to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties (including,
but not limited to, contractors, collaborators, and outside scientific advisors), and confidential information and inventions agreements
with employees, consultants, licensors and advisors, we cannot provide any assurances that all such agreements have been duly executed,
and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may
not be able to obtain adequate remedies for such breaches. We require our employees to enter into written confidentiality agreements
that assign to us any inventions, developments, creative works and useful ideas of any description that are conceived of, reduced to
practice or developed in the course of their employment. In addition, we require our third-party contractors to enter into a written
non-disclosure agreement that requires the third party to not disclose certain of our confidential information in any manner or for any
purpose other than as necessary and/or appropriate in connection with their obligations for a defined period of time, subject to certain
exclusions. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming,
and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect
trade secrets. We may need to share our proprietary information, including trade secrets, with our current and future business partners,
collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion
by private parties or foreign actors, and those affiliated with or controlled by state actors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
third parties may still obtain this information or may come upon this or similar information independently, and we would have no right
to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection
for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we or our
licensors do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our
proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret
information may be jeopardized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used
or disclosed alleged confidential information or trade secrets of their former employers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information
of third parties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the
development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have
previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors
or potential competitors. We may become subject to claims that we, our employees, independent contractors, or consultants inadvertently
or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients.
Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful
in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other
employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current or future trademarks or trade names may be challenged, infringed, circumvented, or declared generic or descriptive or determined
to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop
using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark
registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would
be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in
comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and
to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks
may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not
be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties,
such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach
of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill
associated with our trademarks and trade names.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
any name we have proposed to use with product candidates in the United States may need FDA approval, regardless of whether we have registered
it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed
product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative
body in a foreign jurisdiction) objects to any of our proposed proprietary product names, we may be required to expend significant additional
resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing
rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration
may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors
or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and
possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners
of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names.
If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that
the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately
be forced to cease use of such trademarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Employee Matters and Managing our Growth</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product
candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have and have never had a marketing or sales team. In order to commercialize any product candidates, if approved, we
must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to
perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not
be successful in accomplishing these required tasks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishing
an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates
will be expensive and time-consuming, and will require significant attention of our executive officers to manage. Any failure or delay
in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any
of our product candidates that we obtain approval to market, if we do not have arrangements in place with third parties to provide such
services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third
parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems
or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third
parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or
at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such
commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates,
either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant
additional losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face
significant competition for experienced personnel. We are highly dependent on the principal members of our management and scientific
and medical staff. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could
adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our
executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified
personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel
necessary for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company
and may be required to expend significant financial resources in our employee recruitment and retention efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different
risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects
for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If
we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize
our product candidates will be limited and the potential for successfully growing our business will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties
in managing this growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had ten full-time employees. In order to successfully implement our development and commercialization plans
and strategies, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth
would impose significant added responsibilities on members of management, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
                                            recruiting, integrating, maintaining and motivating additional employees;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
                                            our internal development efforts effectively, including the clinical, FDA, EMA and other
                                            comparable foreign regulatory agencies&#8217; review process of our product candidates and
                                            any other product candidate we develop, while complying with any contractual obligations
                                            to contractors and other third parties we may have; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
                                            our operational, financial and management controls, reporting systems and procedures.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future financial performance and our ability to successfully develop and, if approved, commercialize any of our current product candidates
and any other product candidate we may develop will depend, in part, on our ability to effectively manage any future growth, and our
management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial
amount of time to managing these growth activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors
and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that
the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed,
or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality
or accuracy of the services provided by third party service providers is compromised for any reason, our clinical trials may be extended,
delayed or terminated, and we may not be able to obtain marketing approval of any current or future product candidates or otherwise advance
our business. We cannot assure you that we will be able to manage our existing third party service providers or find other competent
outside contractors and consultants on economically reasonable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to effectively expand our organization by hiring new employees and/or engaging additional third party service providers,
we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and any
future product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Ownership of Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>An
active trading market may not develop or continue to be liquid and the market price of shares of our common stock may be volatile.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed and traded on Nasdaq. Prior to the listing on Nasdaq, there has not been a public market for any of our securities,
and an active market for our common stock may not develop or be sustained, which could depress the market price of shares of our common
stock and could affect the ability of our stockholders to sell our common stock. In the absence of an active public trading market, investors
may not be able to liquidate their investments in our common stock. An inactive market may also impair our ability to raise capital by
selling shares of our common stock, our ability to motivate our employees through equity incentive awards and our ability to acquire
other companies, products or technologies by using shares of our common stock as consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we cannot predict the prices at which our common stock may trade on Nasdaq, and the market price of our common stock may fluctuate
significantly in response to various factors, some of which are beyond our control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of our novel listing process on Nasdaq, Nasdaq&#8217;s rules for ensuring compliance with its initial listing standards, such
as those requiring a valuation or other compelling evidence of value, are untested. In the absence of a prior active public trading market
for our common stock, if the price of our common stock or our market capitalization falls below those required by Nasdaq&#8217;s eligibility
standards, we may not be able to satisfy the ongoing listing criteria and may be required to delist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, because of our novel listing process, individual investors, retail or otherwise, may have greater influence in setting the
public prices of our common stock on Nasdaq and may participate more in our trading than is typical for a firm-commitment underwritten
initial public offering. These factors could result in a public price of our common stock that is higher than other investors (such as
institutional investors) are willing to pay, which could cause volatility in the trading price of our common stock and an unsustainable
trading price if the price of our common stock significantly rises and institutional investors believe our common stock is worth less
than retail investors, in which case the price of our common stock may decline over time. Further, if the public price of our common
stock is above the level that investors determine is reasonable for our common stock, some investors may attempt to short our common
stock, which would create additional downward pressure on the public price of our common stock. To the extent that there is a lack of
consumer awareness among retail investors, such a lack of consumer awareness could reduce the value of our common stock and cause volatility
in the trading price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public price of our common stock could be subject to wide fluctuations in response to the risk factors described in this annual report
and others beyond our control, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the industries in which we operate;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
                                            in our operating performance and the performance of our competitors in general;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                            or anticipated fluctuations in our quarterly or annual operating results;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
                                            of research reports by securities analysts about us or our competitors or our industry;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            public&#8217;s reaction to our press releases, our other public announcements and our filings
                                            with the SEC;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            failure or the failure of our competitors to meet analysts&#8217; projections or guidance
                                            that we or our competitors may give to the market;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
                                            and departures of key personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in laws and regulations affecting our business;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement
                                            of, or involvement in, litigation involving us;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in our capital structure, such as future issuances of securities or the incurrence of additional
                                            debt;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            volume of shares of our common stock available for public sale; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            economic and political conditions such as recessions, interest rates, fuel prices, foreign
                                            currency fluctuations, international tariffs, social, political and economic risks and acts
                                            of war or terrorism.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, securities exchanges have experienced price and volume fluctuations that have affected and continue to affect the market prices
of equity securities of many companies. Stock prices of many companies have fluctuated in a manner often unrelated to the operating performance
of those companies. These fluctuations may be even more pronounced in the trading market for our common stock following the listing of
our common stock on Nasdaq as a result of the supply and demand forces described above. In the past, stockholders have instituted securities
class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject
us to substantial costs, divert resources and the attention of management from our business and harm our business, results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales of common stock by our Registered Stockholders and other existing stockholders could cause our share price to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed and traded on Nasdaq. Prior to listing on Nasdaq, there has been no public market for our common stock and there
has not been a sustained history of trading in our common stock in &#8220;over-the-counter&#8221; markets. While our common stock may
be sold on Nasdaq by the registered stockholders or by our other existing stockholders in accordance with Rule 144 under the Securities
Act, there can be no assurance that any registered stockholders or other existing stockholders will sell any of their shares of common
stock and there may be a lack of supply of, or demand for, common stock on Nasdaq. There can be no assurance that the Registered Stockholders
and other existing stockholders will not sell all of their shares of common stock, resulting in an oversupply of our common stock on
Nasdaq. In the case of a lack of supply of our common stock, the trading price of our common stock may rise to an unsustainable level.
Further, institutional investors may be discouraged from purchasing our common stock if they are unable to purchase a block of our common
stock in the open market due to a potential unwillingness of our existing stockholders to sell a sufficient amount of common stock at
the price offered by such institutional investors and the greater influence individual investors have in setting the trading price. If
institutional investors are unable to purchase our common stock, the market for our common stock may be more volatile without the influence
of long-term institutional investors holding significant amounts of our common stock. In the case of a lack of market demand for our
common stock, the trading price of our common stock could decline significantly and rapidly after our listing. Therefore, an active,
liquid and orderly trading market for our common stock may not initially develop or be sustained, which could significantly depress the
public price of our common stock and/or result in significant volatility, which could affect your ability to sell your shares of common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have 2,500 shares of Series C Preferred Stock with super voting rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
capital stock as of the date hereof consists of voting common stock (which we sometimes refer to herein as &#8220;common
stock&#8221;), and Series C Preferred Stock. Our board of directors and stockholders have each approved the creation and issuance of
an aggregate of 2,500 shares of Series C Preferred Stock, all of which Series C Preferred Stock were issued in January 2024 to Pete
O&#8217;Heeron, our founder and Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock (i) have no dividend rights, (ii) convert into common stock upon any transfer from the initial holder, (iii)
have a liquidation preference of $18.00 per share (subject to appropriate adjustment in the event of any stock split, combination, or
other similar recapitalization) upon our liquidation, dissolution or winding up and (iv) are entitled to 13,000 votes for each share
of Series C Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock are subject to an irrevocable proxy issued by Pete O&#8217;Heeron, the holder of all of the Series C Preferred
Stock, in favor and for the benefit of, our board of directors, granting our board of directors the irrevocable proxy, for as long as
the Series C Preferred Stock remain outstanding, to vote all of the Series C Preferred Stock on all matters on which the Series C Preferred
Stock are entitled to vote, in any manner that our board of directors may determine in its sole and absolute discretion; provided, however,
that such irrevocable proxy shall not, without the written consent of Pete O&#8217;Heeron, permit our board of directors to vote the
Series Preferred Stock with respect to any proposal to amend, delete or waive any rights of Pete O&#8217;Heeron with respect to the Series
C Preferred Stock as set forth in our amended and restated certificate of incorporation. In light of the superior voting rights associated
with the Series C Preferred Stock, the irrevocable proxy is intended to ensure that such superior voting rights are utilized in our best
interest and to avoid or mitigate conflicts that may arise in the future for Pete O&#8217;Heeron as an individual stockholder employee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the dilutive effect on the voting power and value of our common stock, the foregoing structure of our capital stock may render
our common stock ineligible for inclusion in certain securities market indices, and thus adversely affect the price and liquidity of,
and public sentiment regarding, our common stock or other securities. The existence of, and voting rights associated with, our Series
C Preferred Stock, either alone or in conjunction with certain of the other provisions of our amended and restated certificate of incorporation,
such as the requirement to have a staggered board, could also have the effect of delaying, deterring or preventing a change in our control
or make the removal of our management more difficult.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;controlled company&#8221; within the meaning of the Nasdaq Stock Market Rules because our insiders beneficially own more
than 50% of the voting power of our outstanding voting securities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
founder and Chief Executive Officer, Pete O&#8217;Heeron, collectively beneficially owns approximately 59% of the voting power of our
outstanding voting securities and we are a &#8220;controlled company&#8221; within the meaning of the listing rules of The Nasdaq Stock
Market LLC. We may rely on certain exemptions from corporate governance rules, including an exemption from the rule that a majority of
our board of directors must be independent directors. Although we currently do not intend to rely on the &#8220;controlled company&#8221;
exemption under the Nasdaq listing rules, we could elect to rely on this exemption in the future. In the event that we elected to rely
on the &#8220;controlled company&#8221; exemption, a majority of the members of our board of directors might not be independent directors,
and our nominating and corporate governance and compensation committees might not consist entirely of independent directors. Our status
as a controlled company could cause our shares of common stock to be less attractive to certain investors or otherwise harm our trading
price. As a result, you do not have the same protection afforded to shareholders of companies that are subject to these corporate governance
requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>You
may be diluted by future issuances of preferred stock or additional common stock in connection with our incentive plans, acquisitions
or otherwise; future sales of such shares in the public market, or the expectations that such sales may occur, could lower our stock
price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted an amended and restated certificate of incorporation which authorizes us to issue shares of common stock and
options, rights, warrants and appreciation rights relating to our common stock for the consideration and on the terms and conditions
established by our board of directors in its sole discretion. We could issue a significant number of shares of common stock in the
future in connection with investments or acquisitions. Any of these issuances could dilute our existing stockholders, and such
dilution could be significant. Moreover, such dilution could have a material adverse effect on the market price for the shares of
our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future issuance of shares of preferred stock with voting rights may adversely affect the voting power of the holders of shares of our
common stock, either by diluting the voting power of our common stock if the preferred stock votes together with the common stock as
a single class, or by giving the holders of any such preferred stock the right to block an action on which they have a separate class
vote, even if the action were approved by the holders of our shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future issuance of shares of preferred stock with dividend or conversion rights, liquidation preferences or other economic terms favorable
to the holders of preferred stock could adversely affect the market price for our common stock by making an investment in the common
stock less attractive. For example, investors in the common stock may not wish to purchase common stock at a price above the conversion
price of a series of convertible preferred stock because the holders of the preferred stock would effectively be entitled to purchase
common stock at the lower conversion price, causing economic dilution to the holders of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we have no current plans to pay cash dividends on our common stock, you may not receive any return on investment unless you sell your
common stock for a price greater than that which you paid for it.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to retain all available funds and any future earnings to fund the development, commercialization and growth of our business,
and therefore we do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future. Any future determination
to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results,
capital requirements, general business conditions and other factors that our board of directors may deem relevant. Our future ability
to pay cash dividends on our common stock may also be limited by the terms of any future debt securities or credit facility. As a result,
capital appreciation, if any, of the common stock you purchase or own will be your sole source of gain for the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth
companies and smaller reporting companies may make our common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company,
we may take advantage of certain exemptions and relief from various reporting requirements that are applicable to other public companies
that are not emerging growth companies, including (i) not being required to comply with the auditor attestation requirements of Section
404 of the Sarbanes-Oxley Act, (ii) having the option of delaying the adoption of certain new or revised financial accounting standards,
(iii) reduced disclosure obligations regarding executive compensation in this annual report and our periodic reports and proxy statements
and (iv) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of
any golden parachute payments not previously approved. We may take advantage of these exemptions until such time that we are no longer
an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other
public companies in which you hold stock. Further, pursuant to Section 107 of the JOBS Act, we have elected to take advantage of the
extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private
companies. As a result, our operating results and financial statements may not be comparable to the operating results and financial statements
of other companies who have adopted the new or revised accounting standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company until the earliest of (i) December 31, 2028, (ii) the last day of the fiscal year in which we
have total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which we are deemed to be a &#8220;large
accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held
by non-affiliates was $700.0 million or more as of the last business day of the second fiscal quarter of such year or (iv) the date on
which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company
even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller
reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates
is $250 million or more measured on the last business day of our second fiscal quarter, or our annual revenues are less than $100 million
during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is $700 million or more
measured on the last business day of our second fiscal quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that some investors will find our common stock less attractive as a result of the foregoing, which may result in a less active
trading market for our common stock and higher volatility in our stock price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management and principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters
subject to stockholder approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, our executive officers, directors and five percent or greater stockholders and their respective affiliates, beneficially
own, in the aggregate, approximately 19% of our outstanding common stock on an as converted basis. To the extent that the same group
continue to own a significant percentage of our common stock, these stockholders, if they act together, will
be able to control the management and affairs of our company and most matters requiring stockholder approval, including the election
of directors, amendments of our organizational documents and approval of any merger, sale of substantially all our assets or other significant
corporate transactions. This concentration of ownership may prevent or discourage unsolicited acquisition proposals or offers for our
common stock that you or other stockholders may feel are in your or their best interest as one of our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
of our amended and restated certificate of incorporation and bylaws, in each case, may delay or prevent a take-over that may not be in
the best interests of our stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our amended and restated certificate of incorporation and bylaws, in each case, may be deemed to have anti-takeover effects, which
include, among others, (i) the existence of our Series C Preferred Stock entitled to 13,000 votes per share of Series C Preferred Stock,
as more particularly described elsewhere in this annual report, (ii) a classified board of directors serving staggered three-year terms,
(iii) who can fill vacancies of our board of directors, (iv) supermajority voting thresholds for the removal of members of our board,
and (v) when and by whom special meetings of our stockholders may be called, and may delay, defer or prevent a takeover attempt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our amended and restated certificate of incorporation will authorize the issuance of shares of preferred stock which will have
such rights and preferences determined from time to time by our board of directors. Following the adoption of the amended and restated
certificate of incorporation, our board of directors may, without stockholder approval (except as may be required under Nasdaq rules),
issue additional preferred shares with dividends, liquidation, conversion, voting or other rights that could adversely affect the voting
power or other rights of the holders of our common stock. Further, our amended and restated certificate of incorporation will authorize
the issuance of &#8220;blank check&#8221; preferred stock that our board of directors could use to implement a stockholder rights plan
(also known as a &#8220;poison pill&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
amended and restated certificate of incorporation, in each case, will provide for an exclusive forum in the Court of Chancery of the
State of Delaware for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a
favorable judicial forum for disputes with us or our directors, officers or employees.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation, in each case, will provide that, unless we consent in writing to the selection of
an alternative forum, (i) the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the
federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for
(a) any derivative action or proceeding brought on our behalf, (b) any action asserting a claim of breach of a fiduciary duty owed by
any of our directors, officers or other employees to us or our stockholders, (c) any action arising pursuant to any provision of the
General Corporation Law of the State of Delaware, or the DGCL, our certificate of incorporation or our bylaws or (d) any action asserting
a claim governed by the internal affairs doctrine and (ii) to the fullest extent permitted by law, the federal district courts of the
United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising
under the Securities Act, including all causes of action asserted against any defendant to such complaint. Pursuant to our planned amended
and restated certificate of incorporation, any person or entity purchasing or otherwise acquiring or holding any interest in shares of
our common stock will be deemed to have had notice of and consented to the forum selection clause in our planned amended and restated
certificate of incorporation described in this paragraph.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing provision would not preclude stockholders that assert claims under the Exchange Act from bringing such claims in federal court,
to the extent that the Exchange Act confers exclusive federal jurisdiction over such claims, subject to applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our choice of forum provision may benefit us by providing increased consistency in the application of Delaware law by chancellors
and judges particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative
to other forums and protection against the burdens of multi-forum litigation. However, our choice of forum provision may impose additional
litigation costs on stockholders in pursuing claims and may limit a stockholder&#8217;s ability to bring a claim in a judicial forum
that it believes to be favorable for disputes with us or any of our directors, officers or other employees, which may discourage lawsuits
with respect to such claims. In addition, while the Delaware courts have determined that such choice of forum provisions are facially
valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the choice of forum provision,
and there can be no assurance that such provision will be enforced by a court in those other jurisdictions. If a court were to find the
choice of forum provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional
costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risks</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reports
published by analysts, including projections in those reports that differ from our actual results, could adversely affect the price and
trading volume of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
research analysts may establish and publish their own periodic projections for our Company. These projections may vary widely and may
not accurately predict the results we actually achieve. The price of our common stock may decline if our actual results do not match
the projections of these securities research analysts. Similarly, if one or more of the analysts who write reports on us downgrades our
stock or publishes inaccurate or unfavorable research about our business, our stock price could decline. If one or more of these analysts
ceases coverage of us or fails to publish reports on us regularly, our stock price or trading volume could decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those of any of our CROs, manufacturers, other contractors, consultants, collaborators or potential future
collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction
of our proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant
liabilities, harm to our brand and material disruption of our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors,
consultants, collaborators and third-party service providers, are vulnerable to damage from computer viruses, cybersecurity threats,
unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. Because the techniques used to obtain
unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may
be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may
remain undetected for an extended period. If such an event were to occur and cause interruptions in our operations or result in the unauthorized
acquisition of or access to personally identifiable information or individually identifiable health information (violating certain privacy
laws such as HIPAA and GDPR), it could result in a material disruption of our drug discovery and development programs and our business
operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government
requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable
information, which could result from breaches experienced by us or by our vendors, contractors or organizations with which we have formed
strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur
significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future
clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce
the lost data. We also rely on third parties for certain portions of our manufacturing process, and similar events relating to their
computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were
to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed
to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed,
and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy
and security laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security
breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our
insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of
its merit, could be costly and divert management attention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operations are vulnerable to interruption by fire, severe weather conditions, power loss, telecommunications failure, terrorist activity
and other events beyond our control, which could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
facility is located in a region which experiences severe weather from time to time. We have not undertaken a systematic analysis of the
potential consequences to our business and financial results from a major tornado, flood, fire, earthquake, power loss, terrorist activity
or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate
us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business.
The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs
and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>Item 1B.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unresolved Staff Comments</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><b><span id="item1c_001"></span>Item 1C.</b></td>
  <td style="text-align: justify"><b>Cybersecurity</b></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk
Management and Strategy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have processes for assessing, identifying and managing cybersecurity risks, which are an integral part of decision-making at every level.
Such processes include physical, procedural and technical safeguards, response plans, and routine review of our policies and procedures
to identify risks and refine our practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have engaged an external Information Technology
Managed Service Provider, or IT MSP, to help our management team design, implement and maintain our information technology systems and
infrastructure. Members of our executive leadership team provide oversight of the activities of the IT MSP to ensure appropriate controls.
Furthermore, the Audit Committee has oversight with respect to our internal controls and managing the risks of cybersecurity threats.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Governance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee of the Board of Directors is responsible for overseeing cybersecurity risk and periodically updates our Board of Directors
on such matters. The Audit Committee receives periodic updates from management regarding cybersecurity matters and is notified between
such updates regarding any significant new cybersecurity threats or incidents. We do not believe that there are currently any known risks
from cybersecurity threats that are reasonably likely to materially affect us or our business strategy, results of operations or financial
condition, and have not had previous cybersecurity incidents that have materially affected us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>Item 2.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Properties</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease approximately 23,000 square feet of office space for our headquarters in Houston, Texas. This lease ends in November 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease approximately 1,600 square feet of office and lab space in Houston, Texas. This lease ends in July 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our leased facilities are adequate to meet our current needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>Item 3.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal Proceedings</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time we may be involved in legal proceedings relating to intellectual property, commercial, employment and other matters arising
in the ordinary course of business. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings
will not have a material adverse effect on our business, results of operations, financial position or cash flows. There are no legal
proceedings at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>Item 4.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mine Safety Disclosures</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Item
                                            5.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
                                            for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of
                                            Equity Securities</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information for Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;FBLG&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 20, 2024, we have 32,634.366 shares of common stock outstanding held by 1,170 stockholders of record, and 2,500 shares
of Series C Preferred Stock held by one holder of record. The actual number of stockholders is greater than this number of record
holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.
The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our capital
stock in the foreseeable future. We currently intend to retain all available funds and any future earnings, if any, to fund the development
and expansion of our business. Any future determination related to dividend policy will be made at the discretion of our board of directors,
subject to applicable laws, and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions
and capital requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no sales of unregistered securities by us during the year ended December 31, 2023, that were not previously reported in our
Registration on Form S-1 filed with the SEC on February 12, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases
of Equity Securities by the Issuer and Affiliated Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>Item 6.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reserved</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>Item 7.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should read the following discussion and analysis of our financial condition and results of operations together with our financial statements
and related notes and other financial information appearing elsewhere in this annual report. Some of the information contained in this discussion
and analysis or set forth elsewhere in this annual report, including information with respect to our plans and strategy for our business,
includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth
in the &#8220;Risk Factors&#8221; section of this annual report, our actual results could differ materially from the results described in
or implied by the forward-looking statements contained in the following discussion and analysis.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering
from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and
certain cancers, and potential extension of life applications including thymic and splenic involution reversal. At present, our novel
manufacturing process entails collecting excess tissue from surgical procedures and using the allogeneic fibroblasts to grow a cell bank
for use in our procedures. Our most advanced product candidates are CybroCell&#8482; and CYMS101.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CybroCell&#8482;
is an allogeneic fibroblast cell-based therapy for degenerative disc disease and is being designed as an alternative method for repairing
the cartilage of the intervertebral disc (or any other articular cartilage). We have completed two animal studies. The results from the
studies were positive and resulted in &#8220;first in human&#8221; trial approval. We have received IND clearance from the FDA, conditional
upon approval of our master cell bank, to run a Phase 1/2 study for patients suffering from degenerative disc disease and will be conducting
this study within the United States. A timeline will be determined through discussions with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat MS. After completing animal studies using CYMS101 (allogeneic
fibroblast cells), we received approval to conduct clinical investigations in Mexico using the fibroblast cell composition for patients
with MS and have completed a Phase 1 study. The study was conducted in five participants. The primary objective of the study was to assess
safety, and the secondary objective was to assess efficacy. We are currently conducting further research to determine the mode of action
of fibroblasts in oligodendrocyte expansion and expect to file an IND application for a Phase 2 clinical trial in MS. We will likely
seek a strategic partner to collaborate with us on the development of CYMS101 either before initiating the Phase 2 study, or after its
completion, if successful, and prior to commencing with a Phase 3 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the early stages of developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Our studies are presently
focused on utilizing fibroblasts and fibroblast-derived cells to treat wounds in diabetic mice and rats. Based upon our results achieved
to date, we plan to pursue an IND submission with the FDA for wound healing as early as 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have cancer and extension of life programs in the early stages of development, and we plan to accelerate such programs as funding
allows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently purchase our cell therapy product candidates from a contract development and manufacturing organization, or CDMO. We are
in the process of contracting with a CDMO for the transfer of our experimental cell bank to produce our master cell bank, working
cell bank and our fibroblast cell-based product candidates to enable clinical trials. If our product candidates receive marketing
approval, we will evaluate the longer-term feasibility of building our own cGMP manufacturing facility or continuing to outsource
production to a CDMO for clinical testing and commercial sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our spinoff from FibroGenesis in April 2021, our operations have included business planning, hiring personnel, raising capital, building
our intellectual property portfolio and performing research and development on our product candidates and our fibroblast technology,
leveraging the clinical benefits of fibroblasts as the basis of our cell therapy platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred net losses since inception and expect to incur losses in the future as we continue our research and development activities.
To date, we have funded our operations primarily through investment from FibroGenesis, the sale of $5.6 million of our convertible promissory
notes, which were all subsequently converted to equity, the sale of $18.6 million of preferred stock, and $1.9 million in proceeds
from the sale of common stock through the GEM Capital Stock Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had cash and cash equivalents of approximately $9.2 million. Since our inception, we have incurred significant
operating losses. We incurred net losses of approximately $16.5 million and $5.1 million for the years ended December 31, 2023 and 2022,
respectively. As of December 31, 2023, we had an accumulated deficit of approximately $24.4 million. We expect to continue to incur significant
expenses and operating losses for the next several years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if and
as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    the development of our lead product candidates through clinical development, and, if approved by the FDA, commercialization;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    our preclinical development programs into clinical development;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur
    manufacturing costs for cell production to supply our product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approvals for any of our product candidates that successfully complete clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    our research and development activities to identify and develop new product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional personnel;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    our operational, financial and management systems;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meet
    the requirements and demands of being a public company;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">invest
    in further development to protect and expand our intellectual property;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain
    marketing approval and intend to commercialize; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    our manufacturing and develop our commercialization efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the numerous risks and uncertainties associated with biopharmaceutical product development and the economic and developmental uncertainty,
we may be unable to accurately predict the timing or magnitude of all expenses. Our ability to ultimately generate revenue to achieve
profitability will depend heavily on the development, approval, and subsequent commercialization of our product candidates. If we fail
to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at
planned levels and be forced to reduce or terminate our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we will need substantial additional funding to support our long-term continuing operations and pursue our growth strategy.
Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale
of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions.
We may not be able to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at
all. If we fail to raise capital or enter into such agreements as and when needed, we will have to significantly delay, reduce or eliminate
the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the
foreseeable future. If our development efforts for any of our product candidates are successful and result in regulatory approval, we
may generate revenue in the future from product sales. We cannot predict if, when or to what extent we will generate revenue from the
commercialization and sale of any of our product candidates. We may never succeed in obtaining regulatory approval for any of our product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses consist of expenses incurred in connection with the development of our product candidates and include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses, which include salaries, benefits, travel and stock-based compensation for our research and development personnel;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">laboratory
    equipment and supplies;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">direct
    third-party costs such as expenses incurred under agreements with CROs and CMOs;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consultants
    that conduct research and development activities on our behalf;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    associated with conducting preclinical studies and clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    associated with technology; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facilities
    and other allocated expenses, which include expenses for rent and other facility related costs and other supplies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expense research and development costs as incurred. Nonrefundable advance payments that we make for goods or services to be received
in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the
related goods are delivered or the services are performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research
and development activities related to developing our product candidates as they advance into later stages of clinical development and
our other product candidates in preclinical development as they advance into clinical development. The process of conducting the necessary
clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates
is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects
or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. This is due
to the numerous risks and uncertainties associated with developing product candidates, including uncertainty related to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    duration, costs and timing of clinical trials of our current development programs and any further clinical trials related to new
    product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    acceptance of IND applications for future clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful and timely enrollment and completion of clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful completion of preclinical studies and clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended populations;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if any of our
    product candidates are approved;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    entry into collaborations to further the development of our product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    launching our product candidates and achieving commercial sales, if and when approved.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these variables with respect to the development of any of our programs or any product candidate we develop
would significantly change the costs, timing and viability associated with the development and/or regulatory approval of such programs
or product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General,
Administrative and Other Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general, administrative, and other expenses consist primarily of personnel costs, allocated facilities costs, and other expenses for
outside professional services, including legal, marketing, investor relations, human resources services, and accounting services. Personnel
costs consist of salaries, benefits, and stock-based compensation for our general and administrative personnel. We expect to incur additional
expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the
SEC, Nasdaq, additional insurance expenses, investor relations activities and other administrative and professional services. We also
expect to increase the size of our administrative function to support the growth of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
interest expense consists primarily of accrued interest expense and amortization of discount on our convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of Fiscal Years December 31, 2023 and 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our results of operations for the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year Ended<br/> December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change Amount</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">(in thousands)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center"/><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses<b>:</b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,147</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,221</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">General, administrative and other</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,521</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,201</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total operating expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,889</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,467</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,422</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,889</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,467</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,422</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in fair value of liability instrument</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,236</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,236</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Other (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(213</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(213</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Interest expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(147</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(654</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">507</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(16,485</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,121</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,364</td><td style="text-align: left">)</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were $2.4 million and $1.1 million for the years ended December 31, 2023 and 2022, respectively. The increase
of $1.3 million was primarily due to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    personnel related expenses of $0.8 million due to hiring a net four additional research scientists during 2023 and increased stock
    compensation expense in 2023 resulting from stock option grants.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    research supplies of $0.2 million due to increased laboratory personnel and preclinical studies; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    research facility and equipment depreciation costs of $0.1 million due to increased personnel and costs associated with moving to
    a new rented lab facility.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are not tracked by product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General,
Administrative and Other Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General,
administrative and other expenses were $6.5 million and $3.3 million for the years ended December 31, 2023 and 2022, respectively. The
increase of $3.2 million was primarily due to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    personnel-related expenses of $1.7 million due to stock compensation expense in 2023 resulting from stock option grants, bonus paid
    to the chief executive officer in 2023, the timing of hiring our chief financial officer in June 2022, and the timing of benefits
    made available in July 2022;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    accounting, legal, marketing, consulting and travel expenses of $0.9 million for costs associated with preparing to become a public
    company;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    facilities expense of $0.3 million for the cost of our leased office space, and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    board of directors expenses of $0.3 million due to stock compensation expense in 2023 resulting from stock option grants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Loss</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
loss was $7.4 million for the year ended December 31, 2023, and was comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    loss of $7.2 million due to an increase in the liability instrument prior to our Direct Listing; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    loss of $0.2 million due to an increase in the derivative liability related to the 2022 Notes prior to conversion.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense was $0.1 million and $0.7 million for the years ended December 31, 2023 and 2022, respectively. The decrease of $0.6 million
was due to the conversion in 2023 of convertible notes issued in December 2021, January 2022, and April 2022. Interest expense was recorded
in 2022 and 2023, up to the point of the conversion, which occurred from February 2023 to June 2023, for the nominal interest rate of
6.0% plus the amortization of the discount on the 2022 convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effective income tax rate was 0.0% for all periods. Currently, we have recorded a full valuation allowance against our net deferred tax
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
February 20, 2024, we have financed our operations primarily with investment from FibroGenesis, proceeds from borrowings under our convertible
loan agreements, proceeds from the issuance of preferred stock, and proceeds from the sale of common stock through the GEM Capital Stock
Purchase Agreement. From inception through December 31, 2023, we have received aggregate proceeds of approximately $5.6 million from
sales of our convertible notes and $18.6 million from the sales of preferred stock. As of December 31, 2023, we had cash and cash equivalents
of approximately $9.2 million and an accumulated deficit of approximately $17.1 million. As of December 31, 2023, we had no outstanding
debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of our cash flows for the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(6,401</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(4,066</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(495</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,793</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,925</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,897</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,859</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $6.4 million and $4.1 million for the years ended December 31, 2023 and 2022, respectively, and
consisted primarily of net losses of $16.5 million and $5.1 million, respectively. Net losses for the year ended December 31, 2023 were
partially offset by $7.2 million in other loss due to increase in liability instrument, $1.8 million in noncash stock-based compensation
expense, an increase of $0.7 million in accounts payable and accrued expenses, $0.1 million increase in payable to Parent, $0.1 million
net change in operating lease right-of-use asset and liability, and other noncash expenses of $0.1 million in noncash amortization of
convertible notes debt discount and $0.1 million in other loss on derivative liability. An increase of $0.5 million in accounts payable
and accrued expenses, plus noncash expenses of $0.3 million in stock-based compensation expense and $0.4 million in amortization of convertible
notes debt discount, partially offset the net losses for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was approximately $0.5 million and none for the years ended December 31, 2023 and 2022, respectively.
In 2023, we purchased approximately $0.5 million of equipment for cash and $0.3 million of equipment in accounts payable and accrued
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was approximately $13.8 million and $5.9 million for the years ended December 31, 2023 and 2022,
respectively. In 2023, we received $14.9 million from the sale of Series B Preferred Stock, $1.2 million from the sale of Series B-1
Preferred Stock, and $0.3 million in repayment of a note receivable from FibroGenesis, and we paid $2.6 million to FibroGenesis pursuant
to the ROFN Agreement. In 2022, we received $4.3 million from the issuance of convertible notes in January and April 2022, and received
$2.2 million from the issuance of preferred stock in December 2022. We repaid $0.2 million and loaned $0.4 million to FibroGenesis in
2022, and FibroGenesis repaid $0.1 million to us in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Funding
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any products approved for sale, and we have never generated any revenue from contracts with customers. We do not expect to
generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our current or future product
candidates and we do not know when, or if, that will occur. We expect to continue to incur significant losses for the foreseeable future,
and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our current and future product
candidates, and begin to commercialize any approved products. We are subject to all the risks typically related to the development of
new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that
may adversely affect our business. Moreover, following the completion of our direct listing, we expect to incur additional costs associated
with operating as a public company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been prepared as though we will continue as a going concern, which contemplates the realization of assets and
satisfaction of liabilities in the normal course of business. We have incurred operating losses and negative cash flows from operations
since inception. As of December 31, 2023, we had an accumulated deficit of approximately $17.1 million. Management expects to continue
to incur operating losses and negative cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to raise additional capital to continue to fund our operations. We believe we will be able to obtain additional capital through
equity financings or other arrangements to fund operations; however, there can be no assurance that such additional financing, if available,
can be obtained on acceptable terms. If we are unable to obtain such additional financing, future operations would need to be scaled
back or discontinued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing capital will enable us to fund our operations through at least February 28, 2025. We may need to raise additional
capital in connection with our cash needs for capital expenditures and working capital beyond December 31, 2024. We have based the foregoing
estimate on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we expect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future funding requirements will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, progress, timeline, cost and results of our clinical trials for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, progress, timeline, cost and results of additional research and preclinical studies related to pipeline development and
    other research programs we initiate in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost and timing of manufacturing activities, including our planned manufacturing scale-up activities associated with our product
    candidates and other programs as we advance them through preclinical and clinical development through commercialization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential expansion of our current development programs to seek new indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights, in-licensed or otherwise;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    payment of licensing fees, potential royalty payments and potential milestone payments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of general operating expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory
    approval in regions where we choose to commercialize our products on our own; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials
and other research and development expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we need to raise additional capital to fund our operations, funding may not be available to us on acceptable terms, or at all. If we
are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our preclinical
studies, clinical trials, research and development programs or commercialization efforts. We may seek to raise any necessary additional
capital through a combination of public or private equity offerings, debt financings, collaborations and other licensing arrangements.
If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through
marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we
may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or
grant licenses on terms that may not be favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations and Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see &#8220;Part II., Item 1A. Risk Factors&#8212;Risks Related to Our Financial Condition and Need for Additional Capital.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have material cash requirements and other contractual obligations related to our office and lab rent (as described in Note 10, &#8220;Leases&#8221;
to the financial statements in this Annual Report on Form 10-K).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements or holdings in any variable interest
entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements,
which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates, judgments
and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the
dates of the balance sheets and the reported amounts of expenses during the reporting periods. In accordance with GAAP, we evaluate our
estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe
are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and
liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions
or conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
define our critical accounting estimates as those under GAAP that require us to make subjective estimates and judgments about matters
that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific
manner in which we apply those principles. While our significant accounting policies are more fully described in Note 2 to our financial
statements included elsewhere in this annual report, we believe the following are the critical accounting estimates used in the preparation
of our financial statements that require significant estimates and judgments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research
and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory
supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain
research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern
of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure all stock option grants to employees, directors and non-employees based on their fair value on the date of the grant and recognize
the corresponding compensation expense of those awards using the straight-line method over the requisite service period, which is generally
the vesting period of the respective award. Forfeitures are accounted for as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
classify stock-based compensation expense in our statements of operations in the same way the award recipient&#8217;s payroll costs are
classified or in which the award recipient&#8217;s service payments are classified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate the fair value of each stock option grant using the Black-Scholes option-pricing model, which uses as inputs the fair value
of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free
interest rate for a period that approximates the expected term of our stock options and our expected dividend yield.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of our common stock underlying our stock-based awards has been determined by our board of directors as of each option
grant date with input from management, considering our most recently available third-party valuations of common stock and our board of
directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed
from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company
Equity Securities Issued as Compensation (the Practice Aid).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Now
that a public trading market for our common stock has been established in connection with the completion of the Direct Listing, it
will no longer be necessary for our board of directors to estimate the fair value of our common stock in connection with our
accounting for granted stock options and other such awards we may grant, as the fair value of our common stock will be determined
based on the quoted market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 11 to our audited financial statements included elsewhere in this annual report for further information concerning the assumptions
we used in in determining stock-based compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ROFN
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, we entered into an Agreement Regarding Right of First Negotiation with FibroGenesis, or the ROFN Agreement. In exchange
for FibroGenesis&#8217; consent to amend our certificate of incorporation to (i) eliminate upon our underwritten initial public offering
or the direct listing of our common stock on a securities exchange (which we collectively refer to as an IPO) or sale of our company,
the liquidation preference for the Series A Preferred Stock, (ii) make the Series B Preferred Stock liquidation preference equal to Series
A Preferred Stock, and (iii) to provide that upon an IPO or sale of our company, the Series A Preferred Stock will be canceled for no
consideration, we agreed to pay to FibroGenesis 15% of the gross proceeds from any equity investments in us prior to an IPO or sale of
our company. In addition, we received a five-year right of first negotiation if FibroGenesis decides to license externally any of its
technology. Based upon our management&#8217;s estimates at execution of the ROFN Agreement of capital to be raised in advance of a public
listing, we recorded a derivative liability of $2.6 million for the expected future payments to FibroGenesis. As a deemed dividend, the
derivative liability was recorded first against the net Parent Investment and then to Additional paid-in capital after the net Parent
Investment was eliminated. Amounts paid to FibroGenesis in excess of the derivative liability are recorded as other losses in the statement
of operations. The deemed dividend is included as a reduction to net loss in the calculation of amount available to common stockholders
in determining earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><i>Liability Instrument</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2021, the Company entered into a Share Purchase Agreement with certain investors for the sale of up to $100,000
thousand of common stock at the option of the Company (the &#8220;Aggregate Limit&#8221;) at 90% of the average applicable Daily
Closing Price during the Draw Down Pricing Period. This agreement is contingent upon the Company achieving a public listing of its
common stock. Major terms of the agreement include five-year warrants issued to the investors at the time of public listing to
purchase common stock shares equal to 4% of the total equity interests of the Company at the lesser of a) the price per share at the
time of the public listing or b) the quotient of $700,000 thousand divided by the total number of equity interests (fully diluted
common shares). The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this
agreement following the public listing unless terminated earlier.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Upon issuance, the warrants will be freestanding
derivative financial instruments and must be liability classified until such time as they qualify for equity classification. A
change to equity classification may not occur until the Adjustment Date when the strike price adjustment period is concluded. For
accounting purposes, the warrants are considered issued regardless of the contingent event (public listing) for future issuance. The
Company valued the contingent warrant at inception at $0 based upon the low likelihood of a future public listing. As of December
31, 2023, the fair value of the contingent warrant was included with the contingent put option and recognized as Liability
instrument, and the increase in fair value since inception was recognized as other loss (Change in fair value of liability
instrument) in the Statement of Operations. Any future changes in the fair value of the Liability instrument, up to the point of
reclassification to equity classification, will be recognized in other gains and losses in the Statement of Operations each
reporting period. The Company will reassess the liability classification criteria each reporting period to determine if
reclassification to equity classification is required, and any prior gains and losses recognized in earnings up to the point of
reclassification will not be reversed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the liability instrument includes the contingent warrant and the contingent put option as a single unit of
account. As of December 31, 2023, the  liability instrument value was determined using a Black-Scholes valuation model and
management&#8217;s assumption of a 50% likelihood as of December 31, 2023, of becoming a public company prior to the expiration of
the Stock Purchase Agreement. Inputs used in the Black-Scholes valuation model included an estimated number of warrants, an assumed
common stock share price of $15.00 per share, the five-year time to maturity, a 0% dividend yield, an annual risk-free interest rate
of 3.84% for the five-year time to maturity, and an assumed annualized volatility of 96% based on comparable companies with a
five-year history of stock prices. As of December 31, 2023, the Company evaluated the put option component of the liability instrument and determined
that any value as it relates to the liability instrument would be de minimus given the Company&#8217;s financial condition, intention
to seek other sources of financing as needed, and ability do so given access to public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
JOBS Act</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting
new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have elected to use this extended transition period for complying with new or revised accounting standards that have different effective
dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively
and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be
comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. If we were to
subsequently elect instead to comply with these public company effective dates, such election would be irrevocable pursuant to the JOBS
Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company until the earliest of (i) December 31, 2028, (ii) the last day of the fiscal year in which we
have total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which we are deemed to be a &#8220;large
accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held
by non-affiliates was $700.0 million or more as of the last business day of the second fiscal quarter of such year or (iv) the date on
which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_001"></span>Item
    7A. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quantitative
    and Qualitative Disclosures About Market Risk</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and
are not required to provide the information specified under this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_002"></span>Item
    8.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Supplementary Data</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements required by this item are attached to this Form 10-K beginning with page F-1, and is incorporated here by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_003"></span>Item
    9.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_004"></span>Item
    9A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Controls
    and Procedures</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures (as defined in Exchange Act Rule 13a&#8211;15(e) and 15d-15(e)) that are designed to ensure
that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act,
and the rules and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s
rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and
Chief Financial Officer, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls
and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit
relationship of possible controls and procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have carried out an evaluation, under the supervision, and with the participation, of management including our chief executive officer
and chief financial officer, of our disclosure controls and procedures (as defined in Rule 13a-15(e)) of the Securities Exchange Act
of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Annual Report on Form 10&#8211;K. During the preparation
of our financial statements for the fiscal year ended December 31, 2023, our management identified a material weakness in our internal
control over financial reporting due to a lack of segregation of duties. A material weakness is defined as a deficiency, or a combination
of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of our annual or interim financial statements will not be prevented or detected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Specifically, our management
identified a material weakness in our internal controls within the financial reporting function that resulted from an ineffective design and implementation of controls over proper segregation of duties
for the period of time covered by our financial statements prior to our Chief Financial Officer joining us in June 2022 when all financial
functions were handled by a single individual, and afterward, through December 31, 2023, due to a limited number of
individuals. Based upon such evaluation, and due to the material weakness identified, our principal executive officer and principal
financial and accounting officer have concluded that our disclosure controls and procedures were not effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Remediation Plan for Material
Weakness</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">With the addition of our Chief Financial
Officer and the changes made to our accounting and financial reporting processes and internal controls during the last half of
fiscal year 2022 and through December 31, 2023, we have strengthened our internal controls and will continue to add staff, evaluate
segregation of duties, and implement initiatives to improve our internal controls over financial reporting as we grow.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been no change in the Company&#8217;s internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) that
occurred during the year ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
on the Effectiveness of Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of
the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures and our
internal control over financial reporting are designed to provide reasonable, not absolute, assurance that the objectives of the control
system are met. We continue to implement, improve and refine our disclosure controls and procedures and our internal control over financial
reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span id="ak_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
    Information</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_006"></span>Item
    9C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
    Regarding Foreign Jurisdictions that Prevent Inspections</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_007"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_008"></span>Item
    10.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors,
    Executive Officers and Corporate Governance</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information, as of the date of this annual report, concerning our executive officers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pete
    O&#8217;Heeron, MSHA </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founder,
    Chairperson and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Andersen, CPA CFA </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hamid
    Khoja, Ph.D. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a biographical summary of the experience of our executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pete
O&#8217;Heeron</i>, <i>MSHA.</i></b> Pete O&#8217;Heeron founded our company and has served as our Chief Executive Officer, and the Chairperson
and member of our board of directors since our inception in April 2021. Mr. O&#8217;Heeron is also the founder of FibroGenesis, our affiliate,
and has served as the Chief Executive Officer of FibroGenesis since January 2006. Mr. O&#8217;Heeron is a preeminent biopharma inventor,
with over 300 patents issued and pending in the areas of biologics, cell therapy and medical devices. Mr. O&#8217;Heeron is a seasoned
leader in his field, with over 25 years of experience in medical technology and biotech development. As Chief Executive Officer, he aims
to position us to become a global leader in fibroblast-based cell therapies with the development and commercialization of therapies that
can cure and treat patients suffering from chronic diseases. Mr. O&#8217;Heeron brings together multi-disciplinary teams and resources
necessary to commercialize unique technologies. Prior to founding our company and FibroGenesis, he founded an operational investment
group, Advanced Medical Technologies, LLC, that identified early-stage opportunities in the medical field with strong intellectual property
potential in 2006. He also founded in 1998 NeoSurg Technologies, which developed the T2000 Minimally Invasive Access System. NeoSurg
Technologies was sold to Cooper Surgical in 2006. Mr. O&#8217;Heeron also previously served in a variety of executive-level positions
at Christus Health Care Corporation from 1988 until 1995 and has provided strategic advisory services to healthcare companies in the
areas of biologics, advanced surgical instrumentation and telemedicine. Mr. O&#8217;Heeron received his Bachelor&#8217;s Degree in Healthcare
Administration from Texas State University, his Masters in Healthcare Administration from the University of Houston Clear Lake, and his
Executive Management Certification in Mergers and Acquisition from the University of Chicago. We believe Mr. O&#8217;Heeron is qualified
to serve as a member of our board of directors based on our review of his experience, qualifications, attributes and skills, including
co-founding our company and his executive leadership experience in the biotechnology industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mark
Andersen, CPA CFA</i></b>. Mark Andersen has served as our Chief Financial Officer since June 2022. Prior to joining us, Mr. Andersen
most recently served as Chief Financial Officer and Vice President of Administration for the Indiana Biosciences Research Institute in
Indianapolis, Indiana, from May 2016 until May 2022. In that role, he was responsible for finance, human resources, legal, and information
technology for the institute. Mr. Andersen helped create the operating infrastructure for the institute, assisted with fundraising and
provided oversight for the endowment investment portfolio, which grew to nearly $150.0 million. Prior to that, from August 2015 until
February 2016, Mr. Andersen served as Vice President Finance and Corporate Controller for MiMedx with responsibility for SEC reporting
and finance functions. Previously, from January 2004 to August 2015, Mr. Andersen held multiple financial leadership roles at Eli Lilly
and Company, including Investments Director for the company&#8217;s pension plan, Finance Director for Mergers and Acquisitions, and
Controller for Lilly USA. Mr. Andersen received his Bachelor of Science degree in accounting and Master of Science in accountancy from
Southern Utah University, and his MBA from the University of Michigan Ross School of Business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Hamid
Khoja, Ph.D. </i></b>Hamid Khoja has served as our Chief Scientific Officer since August 2021. Dr. Khoja has more than 25 years of experience
as a leader of scientific teams, development of cell-based genomic, proteomic, epigenetics assays, and tools, protocols and technologies
for use in drug discovery and development and clinical diagnostics. Prior to joining us, Dr. Khoja most recently served from March 2009
to August 2021 as the Principal Scientist as Covaris, LLC, a privately-held scientific tools company with emphasis in genomics, epigenetics,
and proteomics, where he provided long-term strategic applications proposals to the Chief Executive Officer, managed external collaborations
for product and applications development, assessed new technologies for acquisition and OEM opportunities, and presented posters and
presentations at numerous scientific conferences. Dr. Khoja led the effort in successfully incorporating Covaris technology into the
Illumina Next Generation Sequencing technology protocols leading to over 15,000 citations. Dr. Khoja also developed the Covaris chromatin
immunoprecipitation methodology with over 3,000 citations in peer-reviewed publications, as well as leading the effort in using Covaris
technology for simplifying epigenetics assay workflows for use in drug development and discovery, and clinical use. Dr. Khoja also led
collaborations with the U.S. National Cancer Institute for successful development of microbiome DNA extraction using acoustics, and completion
of FDA EUA SARA-CoC-2 bridge study design for approval of new sample collection and viral ribonucleic acid (RNA) extraction using Covaris
technology. Dr. Khoja also developed a patented workflow for the manufacturing of synthetic cell-free DNA for use as reference standard
in sequencing based liquid biopsy clinical oncology-based assays. Prior to Covaris, Dr. Khoja was a Senior Applications Scientist at
Genomic Solutions, a startup scientific tools company later acquired by Harvard Apparatus, from March 2022 to March 2009, where he led
the development of a high throughput protein crystallization platform used in pharmaceutical industry for drug development, managed the
scientific applications group, presented company resources at scientific meetings and assessed new technologies for acquisition and OEM
opportunities. During the startup phase of Sequenom, Inc., from January 2000 to March 2003, Dr. Khoja established the methodology for
highly multiplexed polymerase chain reaction, or PCR, used in the development of Sequenom&#8217;s massEXTEND technology for MALDI-TOF
MS-based analysis of single nucleotide polymorphisms and genetic disease. Dr. Khoja led the effort in developing diagnostic MS-based
assays for hemochromatosis, cystic fibrosis and ten predominantly Jewish genetic diseases using Sequenom&#8217;s massEXTEND technology
which were then transferred to a large clinical diagnostic company. Dr. Khoja also previously worked at Eli Lilly and Company from November
1998 to September 1999 and Chiron Corporation from October 1995 to October 1998. During his career at Eli Lilly, Dr. Khoja established
a high throughput PCR and sequencing strategy using a variety of sequencing strategies and bioinformatic tools available in 1999 for
obtaining high coverage genome sequencing which led to the finalizing of the first ever complete sequence of the S. pneumoniae genome.
At Chiron Corporation, which was subsequently acquired by Novartis, Dr. Khoja helped in the design, development and optimization of HTP
binding assays for FGFR, VEGF, PDGF, and EPO receptors, identification of novel g-protein coupled seven transmembrane receptors, and
identification of novel proteins involved in the TNF signaling pathway, and development of branched-DNA based HTP screening for ligand-induced
oncogene quantification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Khoja received his Bachelor of Science in Molecular Biology from the University of Southern California and his Ph.D. in Molecular Biology
from Boston University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee
Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information, as of the date of this annual report, concerning our non-employees who serve on our board
of directors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Hoffman, CPA (inactive)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Victoria
    Niklas, M.D. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    Cilento, Jr., MBA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stacy
    Coen, MBA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    Link</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a biographical summary of the experience of our non-employee directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Robert
Hoffman, CPA (inactive).</i></b> Robert Hoffman has served on our board of directors since April 2021. Mr. Hoffman currently serves as
President, Chief Executive Officer and Chairperson of the board of directors of Kintara Therapeutics, Inc. (Nasdaq: KTRA), a clinical
stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies, a member of the board of directors
of ASLAN Pharmaceuticals Limited (Nasdaq: ASLN), an oncology-focused biotechnology company developing a portfolio of immuno-oncology
agents and targeted therapies, and Chairperson, and a member, of the board of directors of Antibe Therapeutics Inc., a Toronto, Canada-based
pharmaceutical company listed on the Toronto Stock Exchange. Mr. Hoffman previously served as Senior Vice President and Chief Financial
Officer of Heron Therapeutics, Inc., (Nasdaq: HRTX), a commercial-stage biotechnology company, from April 2017 to October 2020, and as
Chief Financial Officer of AnaptysBio, Inc. (Nasdaq: ANAB), a specialty pharmaceutical company, from July 2015 to September 2016. From
June 2012 to July 2015, Mr. Hoffman served as the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals,
Inc., or Arena, a biopharmaceutical company, prior to its acquisition by Pfizer Inc. in March 2022. From August 2011 to June 2012 and
previously from December 2005 to March 2011, Mr. Hoffman served as Arena&#8217;s Vice President, Finance and Chief Financial Officer
and in a number of various roles of increasing responsibility from 1997 to December 2005. Mr. Hoffman formerly served as a member of
the board of directors of Saniona AB, a biopharmaceutical company, from September 2021 to May 2022, and as a member of the board of directors
of Kura Oncology, Inc. (Nasdaq: KURA), a cancer research company, from March 2015 to August 2021. He also previously served as a member
of the board of directors of CombiMatrix Corporation, a molecular diagnostics company, MabVax Therapeutics Holdings, Inc., a biopharmaceutical
company, and Aravive, Inc. (Nasdaq: ARAV), a clinical stage biotechnology company. Mr. Hoffman serves as a member of the steering committee
of the Association of Bioscience Financial Officers. Mr. Hoffman formerly served as a director and President of the San Diego Chapter
of Financial Executives International and was an advisor to the Financial Accounting Standard Board, or FASB, from 2010 to 2020, advising
the U.S. accounting rulemaking organization on emerging issues and new financial guidance. Mr. Hoffman holds a B.B.A. from St. Bonaventure
University. We believe Mr. Hoffman&#8217;s financial and executive business experience qualifies him to serve on our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Victoria
Niklas, M.D</i></b>. Victoria Niklas has served on our board of directors since April 2021. Dr. Niklas has a distinguished career spanning
more than two decades in translational research, clinical care and teaching at academic health centers, and is currently the Chief Medical
Officer of Oak Hill Bio, a clinical-stage neonatology and rare disease therapeutics company, a position she has held since 2022. Prior
to joining Oak Hill Bio, Dr. Niklas served in Global Medical Affairs and as Global Program Leader of the OHB-607 program in Rare Disease
and Hematology at Takeda Pharmaceuticals. Before Takeda, she was Chief Medical and Scientific Officer at Prolacta Bioscience, a neonatal
nutritional product development company based on human donor milk. Dr. Niklas has over 20 years of experience as an academic neonatologist
with expertise in developmental and acquired inflammatory disorders of the gut, the lung and the mucosal immune system with relevance
to diseases across the lifespan. She has held positions as Chief, Division of Newborn Medicine at Nemours Children&#8217;s Hospital,
Chief of Neonatology at UCLA Olive View Medical Center, and Visiting Professor of Clinical Pediatrics at the David Geffen School of Medicine
at UCLA. Dr. Niklas is board certified in Perinatal and Neonatal Medicine and holds a California medical license. In addition to being
a co-author on numerous scientific and clinical publications, she has helped lead the development of patented products and has served
as a board member for multiple biotech and early-stage companies in functional foods. Dr. Niklas received her MD from Harvard Medical
School, her MA in Biochemistry and Molecular Biology from Harvard University, and her bachelor&#8217;s in Biological Sciences from Goucher
College. We believe Dr. Niklas&#8217; extensive experience and knowledge in the biotechnology sector qualifies her to serve on our board
of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Richard
Cilento, Jr., MBA.</i></b> Richard Cilento has served on our board of directors since April 2021. Mr. Cilento is the founder, Chairperson
of the board of directors and Chief Executive Officer of GlycosBio Inc., a life sciences research and development company. Mr. Cilento
was the founder, President and Chief Executive Officer of FuelQuest, Inc., a provider of information technology, supply chain management
and tax automation technologies, which was acquired by Saracen Energy Advisors LP in May 2007. Mr. Cilento has held senior-management
positions with several technology firms, including Xerox Corporation, where he served as Vice President of Strategic Services of Xerox
Connect. Prior to that, he was the Vice President of Corporate Services for XLConnect Solutions, where he served as the lead technologist
for advanced systems and supported the organization through its initial public offering and its eventual merger with Xerox. An aeronautical
and astronomical engineer, Mr. Cilento began his career at the U.S. National Aeronautics and Space Administration (NASA), where he and
his team built space shuttle flight plans for the U.S. Department of Defense Star Wars program and a diverse set of government-funded
technology and life science experimentation. Mr. Cilento was a lead engineer who designed and planned the space station assembly sequences
for the construction of the International Space Station. Mr. Cilento holds a BS degree in Aeronautical and Astronomical Engineering from
the University of Illinois and an MBA at the University of Houston. We believe Mr. Cilento&#8217;s business experience across a broad
set of technical industries and executive-level knowledge of capital markets, including venture capital, private equity and public markets,
qualifies him to serve on our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stacy
Coen, MBA</i></b>. Stacy Coen has served as a member of our board of directors since July 2021. Ms. Coen has over 25 years of business
and corporate development experience from leading oncology and rare disease companies. She is currently the Chief Business Officer for
ImmunoGen, Inc., a company that is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients.
Prior to ImmunoGen, Ms. Coen worked at Editas Medicine, Inc., a biotechnology company developing therapies for rare diseases, where she
served as Vice President, Business Development and was responsible for business development, strategy, transactions and alliance management.
Prior to joining Editas, Ms. Coen served in multiple roles of increasing responsibility at Genzyme Corporation (now known as Sanofi Genzyme),
including as Vice President, Head of Rare Disease Business Development and Licensing, and as Vice President, Global Head of Strategy
and Business Development, Multiple Sclerosis, among others. Ms. Coen currently serves on the Huntington&#8217;s Disease Society of America&#8217;s
Center Programs &amp; Education Advisory Committee and is a member of MassBio and the Alliance for Regenerative Medicine. Ms. Coen received
a BS in Finance and Economics from the University of Massachusetts and an MBA from the Darden Graduate School of Business at the University
of Virginia. We believe Ms. Coen&#8217;s extensive executive-level experience in the biotechnology industry qualifies her to serve on
our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Matthew
Link</i></b>. Matthew Link has served on our board of directors since April 2021. Mr. Link has more than 20 years of experience in the
healthcare and medical technology industries and currently serves as Chief Commercial Officer for Sight Sciences (SGHT). From 2021 to
2023 he served as managing partner at Orion Healthcare Advisors, LLC, a consulting services provider. From 2006 to 2021 Mr. Link served
in regional and executive leadership positions at NuVasive Inc., a global leader in surgical implants and enabling technology for spine
surgery and orthopedics. As President of NuVasive, Inc., his responsibilities included oversight of global business units in spine, neurophysiology,
and orthopedics. Prior to NuVasive, Inc., Mr. Link held commercial leadership roles at Depuy Orthopedics and Depuy Spine. He also currently
serves as chairman of the board of directors at Galen Robotics and as a member of the board of directors of Springbok Analytics and DinamicOR,
and the Coulter Translational Research Endowment at the University of Virginia. Mr. Link received a BSEd in Physical Education and Sports
Medicine from the University of Virginia. We believe Mr. Link&#8217;s extensive medical technology industry and executive experience
qualifies him to serve on our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisory Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a scientific advisory board, comprised of the following world-renowned scientists with relevant expertise, which helps guide our
research and development efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claudia
    Lucchinetti, M.D., Ph.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S.
    Thomas Carmichael, M.D., Ph.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kate
    Rubins, Ph.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elizabeth
    Shpall, M.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Bhowmick, Ph.D.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors currently consists of six directors. Our certificate of incorporation provides that, subject to the rights of holders
of any series of our preferred stock to elect directors, the number of directors on our board of directors shall be fixed from time to
time solely by resolution of the majority of the total number of authorized directors, whether or not there exist any vacancies in previously
authorized directorships. Each of our directors serves a term ending on the next annual meeting of our stockholders following such director&#8217;s
election or appointment, subject to such director&#8217;s earlier death, disqualification, resignation or removal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our certificate of incorporation, subject to the preferential rights of holders of any series of our preferred stock, any newly created
directorship that results from an increase in the number of directors or any vacancy on our board of directors can only be filled by
the affirmative vote of a majority of the total number of directors then in office, even if less than a quorum, or by a sole remaining
director and cannot be filled by the stockholders. Further, any member of our board of directors or our entire board of directors may
only be removed for cause, and then only by the affirmative vote of the holders of at least 66<sup>2/3</sup>% in voting power of our
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our amended and restated certificate of incorporation, our board of directors is divided into three classes, with directors serving staggered three-year terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
considering whether directors have the experience, qualifications, attributes or skills, taken as a whole, to enable our board of directors
to satisfy its oversight responsibilities effectively in light of our business and structure, the board of directors focuses primarily
on each person&#8217;s background and experience as reflected in the information discussed in each of the directors&#8217; individual
biographies set forth above. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and
nature of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has determined that all members of our board of directors, except Pete O&#8217;Heeron, are independent directors for
purposes of the rules of Nasdaq and the SEC. In making this determination, our board of directors considered the relationships that each
non-employee director has with us and all other facts and circumstances that our board of directors deemed relevant, including the beneficial
ownership of our common stock by each non-employee director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe that the composition and functioning of our board
of directors and each of our committees complies with all applicable requirements of Nasdaq and the rules and regulations of the SEC,
subject to applicable phase-in periods for committees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Staggered
Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the terms of our amended and restated certificate of incorporation, our board of directors is divided into three
staggered classes of directors and each is assigned to one of the three classes. At each annual meeting of our stockholders, a class
of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms
of the directors will expire upon the election and qualification of successor directors at the annual meeting of shareholders to be held
during the years 2024 for Class I directors, 2025 for Class II directors and 2026 for Class III directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Class I directors will be Robert Hoffman and Richard Cilento, Jr.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Class II directors will be Mathew Link and Victoria Niklas; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Class III directors will be Stacy Coen and Pete O&#8217;Heeron.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect
a change of our management or a change in our control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Leadership Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is currently chaired by our founder, Pete O&#8217;Heeron. Our corporate governance guidelines further provide the
flexibility for our board of directors to modify our leadership structure in the future as it deems appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee,
each of which operates pursuant to a charter adopted by our board of directors. Our board of directors may also establish other committees
from time to time to assist the board of directors. The composition and functioning of all of our committees complies with all applicable
requirements of the Sarbanes-Oxley Act, Nasdaq and SEC rules and regulations. Each committee&#8217;s charter
is available on our website at www.fibrobiologics.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our audit committee are Mr. Hoffman, Dr. Niklas, and Mr. Cilento. Mr. Hoffman serves as the chairperson of the committee.
Our board of directors has determined that each member of the audit committee is &#8220;independent&#8221; as that term is defined in
Nasdaq rules and has sufficient knowledge in financial and auditing matters to serve on the audit committee. In addition, our board of
directors has determined that each member of the audit committee meets the heightened independence requirements for audit committees
required under Section 10A of the Exchange Act and related SEC and Nasdaq rules. Our board of directors has determined that Mr. Hoffman
is an &#8220;audit committee financial expert,&#8221; as defined under the applicable rules of the SEC. The audit committee&#8217;s responsibilities
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing,
    approving the compensation of and assessing the independence of our independent registered public accounting firm;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving
    auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public
    accounting firm;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the overall audit plan with our independent registered public accounting firm and members of management responsible for preparing
    our financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements
    and related disclosures as well as critical accounting policies and practices used by us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">coordinating
    the oversight and reviewing the adequacy of our internal control over financial reporting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    policies and procedures for the receipt and retention of accounting-related complaints and concerns;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    based upon the audit committee&#8217;s review and discussions with management and our independent registered public accounting firm
    whether our audited financial statements shall be included in our annual report on Form 10-K;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring
    the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial
    statements and accounting matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the audit committee report required by SEC rules to be included in our annual proxy statement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    all related person transactions for potential conflict of interest situations and approving all such transactions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    quarterly earnings releases.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our compensation committee are Mr. Hoffman, Ms. Coen and Mr. Link. Mr. Hoffman serves as the chairperson of the committee.
Our board of directors has determined that each member of the compensation committee is &#8220;independent&#8221; as that term is defined
in Nasdaq rules and is a &#8220;non-employee director&#8221; under Rule 16b-3 under the Exchange Act. In addition, our board of directors
has determined that each member of the compensation committee meets the heightened independence requirements for compensation committee
purposes under Section 10C of the Exchange Act and related SEC and Nasdaq rules. The compensation committee&#8217;s responsibilities
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving our philosophy, policies and plans with respect to the compensation of our chief executive officer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    recommendations to our board of directors with respect to the compensation of our chief executive officer and our other executive
    officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and assessing the independence of compensation advisors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    and administering our equity incentive plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and making recommendations to our board of directors with respect to director compensation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing
    the compensation committee reports required by the SEC, including our &#8220;compensation discussion and analysis&#8221; disclosure.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating
and Corporate Governance Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our nominating and corporate governance committee are Ms. Coen, Dr. Niklas and Mr. Link. Ms. Coen serves as the chairperson
of the committee. Our board of directors has determined that each member of the nominating and corporate governance committee is &#8220;independent&#8221;
as defined in Nasdaq rules. The nominating and corporate governance committee&#8217;s responsibilities include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and recommending to the board of directors criteria for board and committee membership;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for identifying and evaluating board of director candidates, including nominees recommended by shareholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the composition of the board of directors to ensure that it is composed of members containing the appropriate skills and expertise
    to advise us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
    and screening individuals qualified to become members of the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    to the board of directors the persons to be nominated for election as directors and to each of the board&#8217;s committees;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and recommending to the board of directors a code of business conduct and ethics and a set of corporate governance guidelines; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the evaluation of our board of directors and management.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Conduct</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a written code of business conduct and ethics, that applies to our directors, officers and employees, including our
principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar
functions. A current copy of the code can be found on our website at www.fibrobiologics.com. If we make any substantive amendments
to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of
such amendment or waiver on our website or in a current report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_009"></span>Item
    11.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
    Compensation</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section discusses the material components of the executive compensation program for our executive officers who are named in the &#8220;&#8212;<i>2023
Summary Compensation Table</i>&#8221; below. For the fiscal year ended December 31, 2023, our &#8220;named executive officers&#8221;
and their positions were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pete
    O&#8217;Heeron, Chairperson and Chief Executive Officer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hamid
    Khoja, Ph.D., Chief Scientific Officer; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Andersen, Chief Financial Officer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations
regarding future compensation programs. Actual compensation programs that we adopt following the filing of this annual report may differ
materially from the currently planned programs summarized in this discussion. As an &#8220;emerging growth company&#8221; and a &#8220;smaller
reporting company,&#8221; each as defined under SEC rules, we are not required to include a compensation discussion and analysis section
and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies and/or smaller reporting companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents information regarding the total compensation awarded to, earned by or paid to our named executive officers
during the fiscal year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Salary</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">($)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(2)</sup></b></span></p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(3)</sup></b></span></p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other Compensation</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(4)</sup></b></span></p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total <br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 41%; text-align: justify">Pete O&#8217;Heeron</td><td style="width: 2%">&#160;</td>
    <td style="width: 6%; text-align: center">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">600,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">22,485</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">622,485</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify">Chairperson and Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,335,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,452,273</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Hamid Khoja, Ph.D.</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">446,113</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: justify">Chief Scientific Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">325,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">818,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,241,219</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Andersen<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">189,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,401</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">313,084</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">325,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">820,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,282,227</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Andersen joined us in June 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus
    amounts reflect actual bonus payments made during the calendar year.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    accordance with SEC rules, amounts in this column reflect the aggregate grant date fair value of stock options granted computed in
    accordance with ASC 718, rather than the amounts paid or realized by the named individual. We provide information regarding the assumptions
    used to calculate the value of the stock options granted in Note 11 to our audited financial statements included elsewhere in this
    annual report.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    in the &#8220;All Other Compensation&#8221; column consist of the amounts set forth in the table below:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Named Executive Officer (2022)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">401(k) Plan<br/> Matching<br/> Contributions ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Healthcare Benefits</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">($)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Relocation</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">($)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">Pete O&#8217;Heeron</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">22,485</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Hamid Khoja, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mark Andersen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,512</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,389</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Named Executive Officer (2023)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">401(k) Plan<br/> Matching<br/> Contributions ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Healthcare Benefits</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">($)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Relocation</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">($)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">Pete O&#8217;Heeron</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">50,723</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Hamid Khoja, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mark Andersen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2022
Salaries</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, our named executive officers received an annual base salary to compensate them for services rendered to us. The base salary payable
to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set,
experience, role, and responsibilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal year 2022, Mr. O&#8217;Heeron&#8217;s annual base salary was $600,000 and Mr. Andersen&#8217;s annual base salary was $325,000.
Dr. Khoja&#8217;s annual base salary was increased from $290,000 to $325,000 during fiscal year 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023
Salaries</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, our named executive officers received an annual base salary to compensate them for services rendered to us. The base salary payable
to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set,
experience, role, and responsibilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal year 2023, Mr. O&#8217;Heeron&#8217;s annual base salary was $600,000, Mr. Andersen&#8217;s annual base salary was $325,000, and
Dr. Khoja&#8217;s annual base salary was $325,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2022
Bonuses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fiscal year 2022, each named executive officer was eligible to earn his bonus based on the attainment of pre-established annual company
and individual performance objectives, as determined by our board of directors in their discretion. Mr. O&#8217;Heeron was eligible to
receive an annual cash bonus targeted at 50% of his base salary, and was paid a $300,000 bonus in 2023 based on 2022 performance. Dr.
Khoja was eligible to earn an annual cash bonus targeted at 35% of base salary and was paid a bonus of $101,500 in 2022 after his first
anniversary in 2022, and was paid a $47,396 bonus in 2023 based upon 2022 performance pro rata from the date of his first anniversary
with us. Future bonuses will be based upon calendar years. Mr. Andersen was eligible to earn an annual cash bonus targeted at 35% of
base salary, and was paid a $66,354 bonus in 2023 based on 2022 performance and prorated for 2022 based upon the beginning of his employment
with us in June 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023
Bonuses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal year 2023, each named executive officer is eligible to earn his bonus based on the attainment of pre-established annual company
and individual performance objectives, as determined by our board of directors in their discretion. Mr. O&#8217;Heeron is eligible to
receive an annual cash bonus targeted at 50% of his base salary, or $300,000, Dr. Khoja is eligible to earn an annual cash bonus targeted
at 35% of base salary, or $113,750, and Mr. Andersen is eligible to earn an annual cash bonus targeted at 35% of base salary, or $113,750.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
bonuses are determined based upon both company performance and individual contributions for the fiscal year and are generally determined
and awarded in January of the subsequent year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Khoja and Mr. Andersen each received commitments in their employment agreements for the equivalent of 7,500 stock options. These options
were granted in 2022 after the 2022 Stock Plan (as defined herein) was approved and authorized. Dr. Khoja was also awarded the equivalent
of 1,250 shares of non-voting common stock in 2022 prior to establishment of the 2022 Stock Plan. The stock options granted to named
executives in 2022 vest 1/3 on the first anniversary date of employment and 1/36<sup>th</sup> each month thereafter until fully vested,
subject to continued service, and will accelerate in full upon the occurrence of a &#8220;change in control&#8221; of the Company (as
defined in the 2022 Stock Plan).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, Mr. O&#8217;Heeron, Dr. Khoja, and Mr. Andersen each received a grant of stock options under the 2022 Stock Plan. Mr. O&#8217;Heeron
was awarded the equivalent of 1,853,000 shares, Dr. Khoja was awarded the equivalent of 454,500 shares, and Mr. Andersen was awarded
the equivalent of 455,750 shares. The stock options granted in 2023 vest 1/4th on the first anniversary of the vesting start date, which
was January 1, 2023, with the remainder to vest monthly over 36 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information about the 2022 Stock Plan, please see the section titled &#8220;&#8212;Equity Compensation Plans&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Elements of Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Retirement
Plans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
participate in Insperity&#8217;s 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy
certain eligibility requirements. Our named executive officers are eligible to participate in the Insperity 401(k) plan on the same terms
as other full-time employees. In 2022 and 2023, contributions made by participants in the 401(k) plan were matched up to a specified
percentage of the employee contributions on behalf of the named executive officers. These matching contributions are fully vested as
of the date on which the contribution is made. We anticipate that, following the consummation of the Direct Listing, our named executive
officers will continue to participate in this Insperity 401(k) plan on the same terms as other full-time employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Benefits and Perquisites</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Health/Welfare
Plans.</i> All of our full-time employees, including our named executive officers, are eligible to participate in Insperity&#8217;s health
and welfare plans, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medical,
    dental and vision benefits;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medical
    and dependent care flexible spending accounts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">short-term
    and long-term disability insurance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">life
    insurance.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the employee benefits described above are necessary and appropriate to provide a competitive compensation package to our
named executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements with our Named Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pete
O&#8217;Heeron Employment Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2023, we entered into an employment agreement with Mr. Peter O&#8217;Heeron, pursuant to which Mr. O&#8217;Heeron agreed
to serve as our President and Chief Executive Officer. Mr. O&#8217;Heeron&#8217;s employment pursuant to the agreement is &#8220;at-will&#8221;
and is terminable by either party for any reason and with or without notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Mr. O&#8217;Heeron is entitled to receive an initial base salary of $600,000, which is to be reviewed annually
by the Board of Directors or Compensation Committee but may not be reduced without Mr. O&#8217;Heeron&#8217;s consent. In addition, the
agreement provides that Mr. O&#8217;Heeron is eligible to receive an annual performance bonus, as reasonably determined by the Board
of Directors or, to the extent delegated by the board, the Compensation Committee, based one or more performance targets annually determined
by the board or the committee, provided that to the extent all performance targets are met, the bonus is required to equal not less than
50% of his base salary. The percentage bonus target is to be reviewed periodically by the board or Compensation Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement also provides that Mr. O&#8217;Heeron is eligible to participate in the health and welfare benefit plans and programs maintained
by us for the benefit of our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the agreement, if Mr. O&#8217;Heeron&#8217;s employment is terminated by the Company without cause (as defined in the agreement) or
by Mr. O&#8217;Heeron for good reason (as defined in the agreement), then he will be eligible to receive severance in an amount equal
to twelve months&#8217; base salary, paid as if he was still employed during such 12 month period, and the amount of the target bonus
that would have been due during such 12 month period (payable 60 days after notice of termination). Additionally, Mr. O&#8217;Heeron
shall continue to vest options during such 12 month period. If the agreement is terminated for any reason, Mr. O&#8217;Heeron is due
all compensation earned through the date of termination, including unused and accrued vacation, any unpaid bonus which he is due, and
a prorated portion of the bonus which would have accrued for the year of termination (with such bonus amounts being paid at the same
time as bonuses are paid to other Company executives).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event an involuntary termination of Mr. O&#8217;Heeron&#8217;s employment occurs during the 12 months following a change in control
(as defined in the agreement), or within two months prior to a change in control, or in the event Mr. O&#8217;Heeron terminates his employment
for any reason not sooner than six months after the occurrence of a change in control, and subject to Mr. O&#8217;Heeron entering into
a release with the Company, all stock options and stock-based awards held by Mr. O&#8217;Heeron, as of the date of notice of such termination
are to vest and become exercisable or nonforfeitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement contains customary assignment of inventions and confidentiality obligations of Mr. O&#8217;Heeron, and a 12 months non-compete/non-solicitation
prohibition, following the termination of his employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation under the employment agreement (including bonus target) may be increased from time to time, by the Compensation Committee,
or the Board of Directors (with the recommendation of the Compensation Committee), which increases do not require the entry into an amended
employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee, or the board, with the recommendation of the Compensation Committee, may also pay or grant discretionary cash
bonuses or equity bonuses from time to time in their discretion, at any time, in its/their discretion. The equity bonus may be in the
form of common stock, stock options or other equity consideration, in such amounts and with such terms as may be determined by the Compensation
Committee or the board, with the recommendation of the Compensation Committee, from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Hamid
Khoja, Ph.D. Employment Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an employment agreement with Dr. Khoja, dated July 20, 2021, pursuant to which Dr. Khoja serves as our Chief Scientific
Officer. Dr. Khoja&#8217;s employment pursuant to the agreement is &#8220;at-will&#8221; and is terminable by either party for any reason
and with or without notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to his agreement, Dr. Khoja is entitled to receive an initial base salary of $290,000, which was increased to $325,000 in 2022. In addition,
the agreement provides that Dr. Khoja is eligible to receive an annual performance bonus of up to 35% of his base salary, to be paid
based on the achievement of company and individual performance goals. In connection with his entry into the offer letter, Dr. Khoja was
granted a stock option award for the equivalent of 7,500 shares of common stock, which vests as to 1/3 of the shares underlying the stock
option on the first anniversary of employment date and 1/36<sup>th</sup> per month thereafter until fully vested, subject to continued
employment through the applicable vesting date. Pursuant to the agreement, Dr. Khoja was also paid a one-time cash bonus equal to $15,000
in connection with his commencement of employment and was entitled to payment of up to $45,000 of relocation expenses. The agreement
also provides that Dr. Khoja is eligible to participate in the health and welfare benefit plans and programs maintained by us for the
benefit of our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 105 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the agreement, if Dr. Khoja&#8217;s employment is terminated by the Company without cause, then he will be eligible to receive severance
in an amount equal to nine months&#8217; base salary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mark
Andersen Employment Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an employment agreement with Mr. Andersen, dated May 20, 2022, pursuant to which Mr. Andersen serves as our Chief Financial
Officer. Mr. Andersen&#8217;s employment pursuant to the agreement is &#8220;at-will&#8221; and is terminable by either party for any
reason with or without notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to his agreement, Mr. Andersen is entitled to receive an initial base salary of $325,000. In addition, the agreement provides that Mr.
Andersen is eligible to receive an annual performance bonus of up to 35% of his base salary, to be paid based on the achievement of company
and individual performance goals. In connection with his entry into the agreement, Mr. Andersen was granted a stock option award for
the equivalent of 7,500 shares of common stock, which vests as to 1/3 of the shares underlying the stock option on the first anniversary
of employment date and 1/36<sup>th</sup> per month thereafter, subject to continued employment through the applicable vesting date. Pursuant
to the agreement, Mr. Andersen was also paid a one-time cash bonus equal to $15,000 in connection with his commencement of employment
and was entitled to payment of up to $45,000 of relocation expenses. The agreement also provides that Mr. Andersen is eligible to participate
in the health and welfare benefit plans and programs maintained by us for the benefit of our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the agreement, if Mr. Andersen&#8217;s employment is terminated by the Company without cause, then he will be eligible to receive
severance in an amount equal to nine months&#8217; base salary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the material terms of the FibroBiologics, Inc. 2022 Stock Plan, or the 2022 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2022
Stock Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors adopted on August 10, 2022, and our stockholders approved on August 18, 2022, our 2022 Stock Plan. The 2022 Stock
Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards,
restricted stock unit awards, and other stock awards. The 2022 Stock Plan, through the grant of stock awards, is intended to help us
secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for our success
and provide a means by which the eligible recipients may benefit from increases in value of our common stock. Through December 31, 2023,
we have issued the equivalent of 101,250 options with a strike price of the equivalent of $3.28 per share to employees, directors, and
scientific advisory board members, and the equivalent of 3,689,750 options with a strike price of the equivalent of $2.28 per share to
employees and directors under the 2022 Stock Plan. In August 2023, a total of 2,500 options with a strike price of $3.28 per share were
forfeited. Generally, awards granted by us vest over four years and have an exercise price equal to the estimated fair value of our common
stock as determined by our board of directors with consideration given to contemporaneous valuations of our common stock prepared by
an independent third-party valuation firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, there were the equivalent of 8,711,500 shares available for future issuance under the 2022 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information regarding outstanding equity awards held by our named executive officers as of December 31, 2023.
Other than the equivalent of 1,250 shares of non-voting common stock awarded to Dr. Khoja in 2022 prior to establishment of the 2022
Stock Plan, all awards were granted under our 2022 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of securities underlying unexercised options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(#) exercisable</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unexercised</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(#) unexercisable</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>expiration date</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: justify">Pete O&#8217;Heeron</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,853,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">2.28</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%; text-align: right">February 16, 2033</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Hamid Khoja, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,861</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,639</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">September 25, 2032</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Hamid Khoja, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">454,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">February 16, 2033</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mark Andersen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,472</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,028</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">September 25, 2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mark Andersen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">455,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">February 16, 2033</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-employee
Director Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the total compensation for each person who served as a non-employee member of our board of directors during
the fiscal year ended December 31, 2022. Other than as set forth in the table and described more fully below, we did not pay any compensation,
make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our board of directors
in 2022 for their services as members of our board of directors. Pete O&#8217;Heeron, our Chairperson and Chief Executive Officer, received
no additional compensation for his service as a director. See the section titled &#8220;Executive Compensation&#8221; for more information
on the compensation paid to or earned by O&#8217;Heeron as an employee for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fees Earned or Paid in Cash <br/>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards<br/>
 ($) <sup>(1)(3)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;Option Awards</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(2)(3)</sup></b></span></p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/>
 ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Robert Hoffman</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">24,600</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">12,800</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">87,400</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Victoria Niklas</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Richard Cilento, Jr.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stacy Coen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Matthew Link</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,400</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    January 2022, each of our non-employee directors was awarded the equivalent of 7,500 shares of stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    September 2022, each of our non-employee directors was granted the equivalent of 5,000 stock options with an exercise price of the
    equivalent of $3.28 per share. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts reported represent the aggregate grant date fair value of the stock and stock options awarded to the non-employee directors
    during fiscal year 2022, calculated in accordance with ASC Topic 718. Such grant date fair value does not take into account any estimated
    forfeitures. The assumptions used in calculating the grant date fair value of the awards reported in this column are set forth in
    the notes to our financial statements included elsewhere in this annual report. The amounts reported in this column reflect the accounting
    cost for the stock and stock options and do not correspond to the actual economic value that may be received upon exercise of the
    stock options or any sale of any of the underlying shares of common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the total compensation for each person who served as a non-employee member of our board of directors during
the fiscal year ended December 31, 2023. Other than as set forth in the table and described more fully below, we did not pay any compensation,
make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our board of directors
in 2023 for their services as members of our board of directors. Pete O&#8217;Heeron, our Chairperson and Chief Executive Officer, received
no additional compensation for his service as a director. See the section titled &#8220;Executive Compensation&#8221; for more information
on the compensation paid to or earned by O&#8217;Heeron as an employee for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fees Earned or Paid in Cash<br/>
 ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Awards<br/>
 ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards<br/>
 ($)<sup>(1)(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Total</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">($)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Robert Hoffman</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">55,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">333,540</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">388,540</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Victoria Niklas</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,540</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381,540</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Richard Cilento, Jr.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,540</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">376,540</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stacy Coen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,540</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">384,540</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Matthew Link</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333,540</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">379,540</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    February 2023, each of our non-employee directors was granted the equivalent of 185,300 stock options with an exercise price of the
    equivalent of $2.28 per share. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts reported represent the aggregate grant date fair value of the stock options awarded to the non-employee directors during
    fiscal year 2023, calculated in accordance with ASC Topic 718. Such grant date fair value does not take into account any estimated
    forfeitures. The assumptions used in calculating the grant date fair value of the awards reported in this column are set forth in
    the notes to our financial statements included elsewhere in this annual report. The amounts reported in this column reflect the accounting
    cost for the stock options and do not correspond to the actual economic value that may be received upon exercise of the stock options
    or any sale of any of the underlying shares of common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the non-employee members of our board of directors held the following aggregate number of unexercised options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">Name</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Securities<br/> Underlying Unexercised Options</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Robert Hoffman</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">5,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Victoria Niklas</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Richard Cilento</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stacy Coen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Matthew Link</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth above, no non-employee member of our board of directors held unexercised options or unvested shares of our common stock
as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the non-employee members of our board of directors held the following aggregate number of unexercised options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">Name</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Securities<br/> Underlying Unexercised Options</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Robert Hoffman</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">190,300</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Victoria Niklas</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Richard Cilento</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stacy Coen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Matthew Link</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,300</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth above, no non-employee member of our board of directors held unexercised options or unvested shares of our common stock
as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Employee
Director Compensation Policy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors adopted a non-employee director compensation policy. The policy is designed to enable us to attract and retain, on a long-term basis, highly
qualified non-employee directors. Under the policy, each director who is not an employee shall be paid cash compensation from and after
the completion of our direct listing:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
    Retainer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
    of Directors:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 79%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
    (other than chair)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    Committee:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
    (other than chair)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retainer
    for chair</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    Committee:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
    (other than chair)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retainer
    for chair</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating
    and Corporate Governance Committee:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
    (other than chair)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retainer
    for chair</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the non-employee director compensation policy provides that, upon initial election to our board of directors, each non-employee
director will be granted an equity award the equivalent of 7,500 shares of common stock, or the Initial Grant. Furthermore, on the date
of each of our annual meeting of stockholders, each non-employee director who continues as a non-employee director following such meeting
will be granted an annual equity award of stock options, to purchase the equivalent of 5,000 shares, or the Annual Grant. The Annual
Grant will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting;
provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a
director, unless the board of directors determines that the circumstances warrant continuation of vesting. In addition, all vested options
remain exercisable for 12 months if the director resigns from the board of directors or otherwise ceases to serve as a director. Notwithstanding
the foregoing, if an outside director was initially elected to the board of directors within 12 months preceding the annual meeting,
then such outside director shall receive an Annual Grant that is pro-rated on a monthly basis for time serving as an outside director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_010"></span>Item
    12.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Security
    Ownership of Beneficial Owners and Management and Related Stockholder Matters</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth information with regard to securities authorized for issuance under our equity compensation plans as of December
31, 2023. As of December 31, 2023, we had one active equity compensation plan, which was approved by our stockholders:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Plan Category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of securities to be issued upon exercise of outstanding options (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-average exercise price of outstanding options (2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(a)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(b)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(c)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,788,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2.31</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">8,711,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity compensation plans not approved by stockholders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,788,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2.31</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,711,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Beneficial Ownership</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the beneficial ownership of our common stock as of February 15, 2024 by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our executive officers and directors as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment
power with respect to our securities. Unless otherwise indicated, to our knowledge, the persons or entities identified in the table have
sole voting power and sole investment power with respect to all shares shown as beneficially owned by them, subject to community property
laws where applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based our calculation of the percentage of beneficial ownership on 32,634,366 shares of our common stock outstanding as of February
20, 2024. We have deemed shares of our common stock subject to stock options that are currently exercisable or exercisable within 60
days of February 20, 2024, to be outstanding and to be beneficially owned by the person holding the stock option for the purpose of computing
the percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the percentage
ownership of any other person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, the address for each person or entity listed in the table is c/o FibroBiologics, Inc, 455 E, Medical Center Blvd,
Suite 300, Houston TX 77598.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td colspan="20" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; padding-bottom: 1.5pt">Beneficial Ownership</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series C Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Percentage
                                            of Total</b></span></p>
                                                                      <p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Voting</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    and address of Beneficial Owner</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Power<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5% Stockholders:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 50%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Golden Knight
    Incorporated, L.P.<sup>(2)</sup></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,125,001</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan and Pam Linscomb<sup>(3)
    </sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,627,219</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Executive Officers and Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pete O&#8217;Heeron, MSHA<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,048,147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60.0</td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mark Andersen, CPA CFA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">*</p></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hamid Khoja, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Hoffman, CPA (inactive)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Victoria Niklas, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Richard Cilento, Jr., MBA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stacy Coen, MBA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Matthew Link</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Directors
    and Executive Officers as a Group (8 persons)</i></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,172,622</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">18.9</p></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61.0</td><td style="text-align: left">%</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than 1%.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
    giving effect to the rights of the Series C Preferred Stock to 13,000 votes per share.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    F. Newlin and Cindy L. Newlin, as General Partners of Golden Knight Incorporated, L.P., share discretionary authority to vote and
    dispose of the shares directly held by Golden Knight Incorporated, L.P. and may be deemed to be the beneficial owners of such shares.
    The address for Golden Knight Incorporated, L.P. is 3773 Howard Hughes Pkwy, Suite 500S, Las Vegas, NV 89189-6014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    address for Dan and Pam Linscomb is 5110 San Felipe St, #374, Houston, TX 77056.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2,500 shares of Series C Preferred Stock held constitute the maximum number of Series C Preferred Stock we are authorized to issue.
    Each share of Series C Preferred Stock is entitled to 13,000 votes. For as long as they remain outstanding, the Series C Preferred
    Stock is subject to an irrevocable proxy issued by Pete O&#8217;Heeron in favor and for the benefit of our board of directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_011"></span>Item
    13.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
    Relationships and Related Transactions, and Director Independence</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Relationships and Related Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of transactions or series of transactions since inception, or currently proposed transactions or series of transactions,
to which we were, or will be, a party, in which the amount involved exceeded, or will exceed, $120,000, and in which any of our directors,
executive officers, or to our knowledge, beneficial owners of 5% or more of our capital stock, or 5%+ Security Holders, or any member
of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material
interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, as part our formation, we issued the equivalent of 8,750,000 shares of our Series A Preferred Stock to FibroGenesis in exchange
for a Patent Assignment Agreement, which assigns certain patents/applications to us, and an Intellectual Property Cross-License Agreement,
which provides to us an exclusive license within defined fields of use for patents/applications retained by FibroGenesis and provides
to FibroGenesis an exclusive license to the patents/applications assigned to FibroBiologics for all other fields of use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Direct Listing, all of our then outstanding Series A Preferred Stock was automatically canceled, without the payment
of additional consideration by or to the holder thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Series C Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2024, in conjunction with our Direct Listing,
we issued 2,500 shares of Series C Preferred Stock with super voting rights to our CEO for no consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FibroGenesis
Loans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, we loaned $300,000 to FibroGenesis at 0% interest and one year maturity date. In October 2022, we loaned an additional $60,000
to FibroGenesis at 0% interest and one year maturity. The $60,000 was fully repaid in December 2022 and the $300,000 was fully repaid
in April 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ROFN
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, we entered into an Agreement Regarding Right of First Negotiation with FibroGenesis, or the ROFN Agreement. In exchange
for FibroGenesis&#8217; consent to amend our certificate of incorporation to (i) eliminate upon our underwritten initial public offering
or the direct listing of our common stock on a securities exchange (which we collectively refer to as an IPO) or sale of our company,
the liquidation preference for the Series A Preferred Stock, (ii) make the Series B Preferred Stock liquidation preference equal to Series
A Preferred Stock and (iii) to provide that upon an IPO or sale of our company, the Series A Preferred Stock will be canceled for no
consideration, we agreed to pay to FibroGenesis 15% of the gross proceeds from any equity investments in us prior to an IPO or sale of
our company. In addition, we received a five-year right of first negotiation if FibroGenesis decides to license externally any of its
technology. Through December 31, 2023, we have paid a total of $2.6 million to FibroGenesis under the ROFN Agreement based upon gross
proceeds from equity investments received through December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2021
and 2022 Convertible Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, we issued and sold to investors, some of whom hold more than 5% shares, in a private placement $1.3 million of our convertible
promissory notes, or the 2021 Notes. The 2021 Notes bore interest at an initial interest rate of 6.0% per annum and would have automatically
converted into shares of our common stock in the event of a qualified financing. The conversion price of the 2021 Notes was equal to
$200.0 million divided by the total number of equity interests prior to the dilution from the offering. The 2021 Notes were unsecured
and subordinated in right of payment to the prior payment in full to all of our commercial finance lenders, insurance companies, lease
financing institutions or other lending institutions approved by our board of directors and regularly engaged in the business of lending
money. In April 2023, $1.3 million of these notes were converted into shares of our Series B Preferred Stock and none of the 2021 Notes
are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022 and April 2022, we issued and sold to investors, some of whom hold more than 5% of shares, in a private placement $0.35
million and $3.95 million, respectively, of our convertible promissory notes, or the 2022 Notes. The 2022 Notes bore interest at an initial
interest rate of 6.0% per annum, had a one-year maturity, and could have been converted at the holder&#8217;s request into shares of
our common stock in the event of a qualified financing. The conversion price of the 2022 Notes was the lesser of (i) a 15% discount to
the offering price of our common stock in the event of an IPO or (i) the quotient of $200.0 million divided by total equity interests
prior to the dilution from the offering. The 2022 Notes were unsecured and subordinated in right of payment to the prior payment in full
to all of our commercial finance lenders, insurance companies, lease financing institutions or other lending institutions approved by
our board of directors and regularly engaged in the business of lending money. In February 2023 through June 2023, $4.3 million of these
notes were converted into shares of our Series B Preferred Stock and none of the 2022 Notes are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
and Compensation Arrangements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
adopted on August 10, 2022, and our stockholders approved on August 18, 2022, our 2022 Stock Plan, or the 2022 Plan. The 2022 Plan provides
for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted
stock unit awards, and other stock awards. We issued in 2022 a total of the equivalent of 101,250 options with an exercise price the
equivalent of $3.28 per share to employees, directors, and scientific advisory board members under the 2022 Plan. In February 2023, we
issued an additional equivalent of 3,689,750 options with an exercise price the equivalent of $2.28 per share to employees and directors.
Generally, awards granted by the Company vest over three years and have an exercise price equal to the estimated fair value of the common
stock as determined by our board of directors with consideration given to contemporaneous valuations of our common stock prepared by
an independent third-party valuation firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq. As a company listed on Nasdaq, we are required under Nasdaq listing rules to maintain a board comprised
of a majority of independent directors as determined affirmatively by our board. Under Nasdaq listing rules, a director will only qualify
as an independent director if, in the opinion of that listed company&#8217;s board of directors, the director does not have a relationship
that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In addition, the Nasdaq
listing rules require that, subject to specified exceptions, each member of our audit, compensation and nominating and corporate governance
committees be independent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
committee members must also satisfy the additional independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of
1934, as amended, or the Exchange Act, and Nasdaq listing rules applicable to audit committee members. Compensation committee members
must also satisfy the additional independence criteria set forth in Nasdaq listing rules applicable to compensation committee members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has undertaken a review of the independence of each of our directors. Based on information provided by each director
concerning his or her background, employment and affiliations, our board of directors has determined that all members of our board of
directors, except Pete O&#8217;Heeron, do not have a relationship that would interfere with the exercise of independent judgment in carrying
out the responsibilities of a director and that each of these directors is an &#8220;independent director&#8221; as defined under the
listing standards of Nasdaq. Pete O&#8217;Heeron is not considered an independent director because of his position as our Chief Executive
Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
making these determinations, our board of directors considered the current and prior relationships that each non-employee director has
with our company and all other facts and circumstances that our board of directors deemed relevant in determining their independence,
including the beneficial ownership of our capital stock by each non-employee director, and the transactions involving them described
in the section titled &#8220;Related Person Transactions.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors, director nominees or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_012"></span>Item
    14.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Accountant Fees and Services</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Appointment
of the Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee has appointed WithumSmith+Brown, PC, as our independent registered public accounting firm to audit our consolidated financial
statements for our fiscal year ending December 31, 2023. WithumSmith+Brown, PC served as our independent registered public accounting
firm for the fiscal year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees
Paid to the Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents fees for professional audit services and other services rendered to us by WithumSmith+Brown, PC for our fiscal
years ended 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">268,482</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">117,450</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees<sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total fees</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268,482</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117,450</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)
</sup>Audit fees consist of fees for professional services for the audit of our annual consolidated financial statements, including the
review of interim financial statements, audits, and related services that are normally provided in connection with registration statements,
including consents. The audit fees for the fiscal year ended December 31, 2023 include fees associated with our Direct Listing completed
in January 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)
</sup>Audit-related fees include fees for assurance and related services that are reasonably related to the performance of the audit
or review of our consolidated financial statements. There were no audit-related fees incurred in 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)
</sup>Tax fees include fees billed for professional services rendered by the principal accountant for tax compliance, tax advice, and
tax planning. There were no tax fees incurred in 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Auditor
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023 and 2022, there were no other professional services provided by WithumSmith+Brown, PC, other than those listed above, that would
have required our audit committee to consider their compatibility with maintaining the independence of WithumSmith+Brown, PC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee has established a policy governing our use of the services of our independent registered public accounting firm. Under
the policy, our audit committee is required to pre-approve all audit and permissible non-audit services performed by our independent
registered public accounting firm in order to ensure that the provision of such services does not impair such accounting firm&#8217;s
independence. All fees paid to WithumSmith+Brown, PC for our fiscal years ended December 31, 2023 and 2022 were pre-approved by our audit
committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_014"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_015"></span>Item
    15.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits,
    Financial Statement Schedules</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Financial Statements and Financial Statement Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements filed as part of this Annual Report on Form 10-K are listed in the Index to Financial Statements (see page F-1). Certain
schedules are omitted because they are not applicable, or not required, or because the required information is included in the
financial statements or notes thereto. The Exhibits are listed in the Exhibit Index below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>EXHIBIT INDEX</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="text-align: justify; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation of the registrant, as currently in effect (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1 filed on November 7, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex3-2.htm" style="-sec-extract: exhibit">Bylaws of the registrant, as currently in effect (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form S-1 filed on November 7, 2023 (File No. 333-275361)).</a> </span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
    is made to exhibits <a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex3-1.htm" style="-sec-extract: exhibit">3.1</a> through <a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex3-2.htm" style="-sec-extract: exhibit">3.2</a>.</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of registrant&#8217;s securities.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex10-1.htm" style="-sec-extract: exhibit">Intellectual Property Cross-License Agreement dated as of May 17, 2021, between SpinalCyte LLC and FibroBiologics, LLC (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 filed on November 7, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex10-2.htm" style="-sec-extract: exhibit">Patent Assignment Agreement dated May 17, 2021, between SpinalCyte LLC and FibroBiologics, LLC (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 filed on November 7, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex10-3.htm" style="-sec-extract: exhibit">Share Purchase Agreement dated as of November 12, 2021, by and among FibroBiologics, LLC GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 filed on November 7, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex10-4.htm" style="-sec-extract: exhibit">Registration Rights Agreement dated November 12, 2021, by and among FibroBiologics, LLC GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 filed on November 7, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-5.htm" style="-sec-extract: exhibit">Bridge Note dated April 1, 2021, between SpinalCyte LLC and FibroBiologics, Inc (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-6.htm" style="-sec-extract: exhibit">Sublease Agreement between United Fire &amp; Casualty Company and FibroBiologics, Inc., effective October 5, 2022 (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-7.htm" style="-sec-extract: exhibit">License Agreement, dated November 30, 2021, between K2 Biolabs, LLC and FibroBiologics, LLC (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-8.htm" style="-sec-extract: exhibit">Amendment No. 1, effective July 1, 2022, to the License Agreement between K2 Biolabs, LLC and FibroBiologics, Inc. (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-9.htm" style="-sec-extract: exhibit">Amendment No. 2, effective August 1, 2022, to the License Agreement between K2 Biolabs, LLC and FibroBiologics, Inc. (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-10.htm" style="-sec-extract: exhibit">Amendment No. 3, effective October 1, 2022, to the License Agreement between K2 Biolabs, LLC and FibroBiologics, Inc. (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-11.htm" style="-sec-extract: exhibit">Amendment No. 4, effective January 1, 2023, to the License Agreement between K2 Biolabs, LLC and FibroBiologics, Inc. (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex10-12.htm" style="-sec-extract: exhibit">2022 Stock Plan (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1 filed on November 7, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-13.htm" style="-sec-extract: exhibit">Employment Agreement effective from July 20, 2021, between FibroBiologics, LLC and Hamid Khoja (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-14.htm" style="-sec-extract: exhibit">Employment Agreement effective from May 31, 2022, between FibroBiologics, Inc. and Mark Andersen (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-15.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement between the Registrant and each of its Directors and Executive Officers (incorporated by reference to Exhibit 10.15 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-16.htm" style="-sec-extract: exhibit">Energy Research Park Industrial Lease between University of Houston System, as Landlord, and FibroBiologics, Inc., as Tenant, effective August 1, 2023 (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex10-17.htm" style="-sec-extract: exhibit">IP Transfer Agreement between SpinalCyte, LLC and FibroBiologics, LLC, dated as of May 17, 2021 (incorporated by reference to Exhibit 10.17 to the Registration Statement on Form S-1 filed on November 7, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex10-18.htm" style="-sec-extract: exhibit">Amendment 1 to the Patent Assignment Agreement, effective August 2, 2022 (incorporated by reference to Exhibit 10.18 to the Registration Statement on Form S-1 filed on November 7, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223039680/ex10-19.htm" style="-sec-extract: exhibit">Agreement Regarding Right of First Negotiation dated January 20, 2023 (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form S-1 filed on November 7, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-20.htm" style="-sec-extract: exhibit">Form of Stock Option Notice and Grant Agreement (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223042818/ex10-21.htm" style="-sec-extract: exhibit">Amendment 1 to Energy Research Park Industrial Lease between University of Houston System, as Landlord, and FibroBiologics, Inc., as Tenant, effective October 1, 2023 (incorporated by reference to Exhibit 10.21 to the Registration Statement on Form S-1/A filed on November 28, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315223043517/ex10-22.htm" style="-sec-extract: exhibit">Employment Agreement effective from December 1, 2023, between FibroBiologics, Inc. and Pete O&#8217;Heeron (incorporated by reference to Exhibit 10.22 to the Registration Statement on Form S-1/A filed on December 4, 2023 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1958777/000149315224003183/ex10-23.htm" style="-sec-extract: exhibit">Engagement Letter between FibroBiologics, Inc. and Maxim Group LLC dated April 24, 2023 (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form S-1/A filed on January 22, 2024 (File No. 333-275361)).</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex14.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-2.htm">Consent of Howard An, M.D.</a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#poa_001">Power of Attorney (included in the signature page).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">97</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex97.htm">Policy relating to recovery of erroneously awarded compensation.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">101</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Interactive Data File.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">104</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Cover Page Interactive Data File.</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FibroBiologics, Inc.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
February 29, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    <i></i></span></td>
    <td style="border-bottom: Black 1.5pt solid"><i>/s/ Pete O&#8217;Heeron</i></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pete O&#8217;Heeron</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></p>

</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="poa_001"></span>Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Pete O&#8217;Heeron</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairperson
    and Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    29, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pete
    O&#8217;Heeron</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Mark Andersen</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    29, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Andersen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and Principal Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert Hoffman</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    29, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Hoffman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Victoria Niklas</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    29, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Victoria
    Niklas, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Richard Cilento</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    29, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    Cilento</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Matthew Link</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    29, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    Link</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 115 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIBROBIOLOGICS,
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audited Financial Statements
    for the Years Ended December 31, 2023 and 2022</span></td>
    <td style="width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_002">Balance Sheets as of December 31, 2023 and 2022</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_003">Statements of Operations for the Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_004">Statements of Changes in Stockholders&#8217; Equity/(Deficit) for the Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_005">Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_006">Notes to the Financial Statements</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 116 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_001"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FibroBiologics,
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of FibroBiologics, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022,
and the related statements of operations, changes in stockholders&#8217; equity (deficit), and cash flows for each of the two years in the
period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and
2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity
with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_90E_edei--AuditorName_c20230101__20231231_za1h31F3YTw2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorName" id="ixv-18227">WithumSmith+Brown, PC.</ix:nonNumeric></span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>We
have served as the Company&#8217;s auditor since 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--AuditorLocation_c20230101__20231231_zHDaMlRafRPb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorLocation" id="ixv-18228">East
Brunswick, New Jersey</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
29, 2024</span></p>


<p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCAOB
ID Number <span id="xdx_902_edei--AuditorFirmId_c20230101__20231231_zevVZNlTzNe"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="dei:AuditorFirmId" id="ixv-18229">100</ix:nonNumeric></span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 117; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FibroBiologics,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_002"></span>Balance
Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except shares and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_111_pn3n3_zM9CztzDQ1z6" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zcrNGKVuOwob" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231_zITlkAA2b3Nd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pn3n3_maACzmNK_zIBdsmpCQmg1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18230">9,163</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18231">2,266</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidExpenseCurrent_i02I_pn3n3_maACzmNK_z1xQA8k0dRH1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18232">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18233">29</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_i02I_pn3n3_maACzmNK_zYAlSZeY5KPb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Parent company receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0058">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18234">300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsCurrent_i02I_pn3n3_maACzmNK_zMOqzdeKtqLg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18235">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18236">30</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzmNK_maAzsHe_zld5h9BRKSvb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18237">9,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18238">2,625</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pn3n3_maAzsHe_zTJW39TN72T6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18239">797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0068">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_maAzsHe_zdlfyRfnvcL" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use asset, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18240">1,809</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18241">2,199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Assets_i01TI_pn3n3_mtAzsHe_zco65TBZo4Wa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18242">11,821</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18243">4,824</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Liabilities and stockholders&#8217; equity/(deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pn3n3_maLCz5lB_zKGjnBulfSY" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18244">1,444</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18245">758</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ParentCompanyPayable_i02I_pn3n3_maLCz5lB_zbKufDUDZVng" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Parent company payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FBLG:ParentCompanyPayable" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18246">141</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0086">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pn3n3_maLCz5lB_zeLiUiWNqV7h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Operating lease liability, short-term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18247">362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18248">326</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--LiabilityInstrument_i02I_pn3n3_maLCz5lB_zllvXkgEKg6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Liability instrument</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18249">7,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DerivativeLiabilitiesCurrent_i02I_pn3n3_maLCz5lB_zK1KsYHi3Ub9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0094">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18250">538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayableCurrent_i02I_pn3n3_maLCz5lB_zcOR9WaGA4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Convertible notes payable, net of debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0097">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18251">5,451</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCz5lB_maLzBCl_zF4MXOe0JHxe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18252">9,183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18253">7,073</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pn3n3_maLzBCl_zRkNSxHMflG4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability, long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18254">1,385</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18255">1,747</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Liabilities_i01TI_pn3n3_mtLzBCl_maLASEzksY_zq9FGJn1dWy5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18256">10,568</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18257">8,820</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; equity/(deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--NetParentInvestment_i02I_pn3n3_maSEzO54_z21cNQA6wRS7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net Parent investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0112">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FBLG:NetParentInvestment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18258">1,461</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zf9WccNoKzKg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred Stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMOq47Ifyldf" title="Preferred stock, par value"><span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7Byqd0AO2F8" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18259"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18260">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAblgzizfkLk" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjj6K3f6goEk" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxKprS6Y5PP4" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrIewCs1hpd6" title="Preferred stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zaPyjH2q0bK4" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsiI81eJSIkd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18261"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18262"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18263"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18264"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18265"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18266">8,750,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></span></span> Series A Preferred shares authorized, issued and outstanding as of December 31, 2023 and 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0115">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0116">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwVzJgovqQta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred Stock, $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z4OciQux4uf5" title="Preferred stock, par value"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z4SLnPDVcrT6" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18267"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18268">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8SwGXVDZ3l8" title="Preferred stock, shares authorized"><span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCtxETcuHiK3" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18269"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18270">5,000,000</ix:nonFraction></ix:nonFraction></span></span> Series B Preferred shares authorized; <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zggJ6U2EYyZa" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zf8Ok67o0C2j" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18271"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18272">4,171,445</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2023; <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zAigqcTkOYI2" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzGfKl70IRMf" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18273"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18274">381,658</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0134">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0135">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zuqsZl2jobil" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred Stock, $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_znShUTGf5Dme" title="Preferred stock, par value"><span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zqvIkxo1rR1g" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18275"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18276">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zvQ26rye0do3" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_ziMKzL0U7wi4" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18277"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18278">5,000,000</ix:nonFraction></ix:nonFraction></span></span> Series B-1 Preferred shares authorized; <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zAud20Lnlb6h" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zYpKI6Tz9pVh" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18279"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18280">89,781</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2023; <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zZg8q3U0IMK5" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zipD8MHyKCFl" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares" id="ixv-18281"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares" id="ixv-18282">no</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0154">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zQ4SsiDistPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred Stock, $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zolZzc1T3K7h" title="Preferred stock, par value"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zpWnNsq40myf" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18283"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18284">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdUULcaWZDrg" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zAZlbtIfdDWk" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18285"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18286">2,500</ix:nonFraction></ix:nonFraction></span></span> Series C Preferred shares authorized; <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_pid_do_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z4rOrmGXjNp9" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_do_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zT3iVRIQN99a" title="Common stock, shares outstanding"><span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_do_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zh8Vcc3V8EF" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pid_do_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zkyRBqhVK7Ig" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares" id="ixv-18287"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares" id="ixv-18288"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares" id="ixv-18289"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares" id="ixv-18290">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of December 31, 2023 and 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0172">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0173">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i02I_maSEzO54_z7VKnBDeMKmd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred Stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommonStockValue_i02I_hus-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zv0CqgqFzLSa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-voting Common Stock, $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zpLT9gaP3282" title="Common stock, par value"><span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zGFR0XqvZNY7" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18291"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18292">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_z4Wy9MAeU5O" title="Common stock, shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zMYxyWTwmPr1" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18293"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18294">30,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zAfvE8BkMxCe" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zf0DHtcpY3Ib" title="Common stock, shares outstanding"><span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_z0QZHH4lMIDl" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zEbYUmODUe63" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18295"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18296"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18297"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18298">28,230,842</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of December 31, 2023, and 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18299">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18300">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommonStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_zi1YFuK1AbXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Voting Common Stock, $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_zteca3QUKh8e" title="Common stock, par value"><span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_zEshfo94GSZf" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_VotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18301"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_VotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18302">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_zSZyIJxg4Fh9" title="Common stock, shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_zl2nVjrRhN29" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_VotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18303"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_VotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18304">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_do_c20231231__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_z4nP1sxZI7O5" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pid_do_c20231231__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_zf0ZODtYKYRd" title="Common stock, shares outstanding"><span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_zE61HiwslK99" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pid_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_zSEJZBjJbutl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_custom_VotingCommonStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares" id="ixv-18305"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_VotingCommonStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares" id="ixv-18306"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31_custom_VotingCommonStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares" id="ixv-18307"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_VotingCommonStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares" id="ixv-18308">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of December 31, 2023 and 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0213">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0214">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockValue_i02I_maSEzO54_zkvGJ7TKQZ68" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common Stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_maSEzO54_zqEeYgCU8kWc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18309">25,609</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18310">2,414</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEzO54_zJUwg6tZhVc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18311">24,357</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18312">7,872</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquity_i02TI_pn3n3_mtSEzO54_maLASEzksY_zxfoyQYO9Nlc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; equity/(deficit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18313">1,253</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18314">3,996</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEzksY_zEOpoeGcmcG8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity/(deficit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18315">11,821</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18316">4,824</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FibroBiologics,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_003"></span>Statements
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except shares and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_113_pn3n3_zsevLda8Sad4" summary="xdx: Statement - Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zQz9ENgiFz1k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zZrp6htjUT8g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingExpensesAbstract_iB_zC7uJdYP5bBb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEz4QM_zsAcJ4kGHHBe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18317">2,368</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18318">1,147</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEz4QM_zirkpMoKS00f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General, administrative and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18319">6,521</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18320">3,320</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_mtOEz4QM_msOILzLdP_zjIigRCAWCrb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18321">8,889</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18322">4,467</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_iT_maNILz10U_mtOILzLdP_zXz7g44l5rof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18323">8,889</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18324">4,467</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--FairValueAdjustmentOfLiabilityInstrument_iN_pn3n3_di_msNILz10U_zYhZuSmQ8RSd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of  liability instrument</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FBLG:FairValueAdjustmentOfLiabilityInstrument" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18325">7,236</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NonoperatingIncomeExpense_pn3n3_maNILzcFH_maNILz10U_zcjbK7wTNDy7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18326">213</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpense_iN_di_msNILz10U_z6P1tEIWR3a9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Interest expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18327">147</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18328">654</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_mtNILz10U_maNILATzDad_zaVVcqEci4B4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18329">16,485</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18330">5,121</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--DeemedDividend_pn3n3_maNILATzDad_zFeoXhJqoVih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="FBLG:DeemedDividend" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18331">2,573</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_pn3n3_mtNILATzDad_zgOW4ToPti5f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18332">19,058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18333">5,121</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zBNXtXbsI6v5" title="Net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zeXRdDIh4kLa" title="Net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-18334"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-18335">0.68</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zPc30IiucHF8" title="Net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_zlmQvE4Y96N7" title="Net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-18336"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-18337">0.18</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zHLARcc7ih7" title="Weighted-average shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_z6Zy2LlzmJig" title="Weighted-average shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18338"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18339">28,230,842</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231_zELexNp4maDj" title="Weighted-average shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20221231_zG974FOL9Qi2" title="Weighted-average shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18340"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18341">28,230,842</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FibroBiologics,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_004"></span>Statements
of Changes in Stockholders&#8217; Equity/(Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Years Ended December 31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" summary="xdx: Statement - Statements of Changes in Stockholders' Equity/(Deficit)" id="xdx_305_114_pn3n3_zOT7PESTfcWf" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_custom--NetParentInvestmentMember_zUhKFrBQuZK5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Investment</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_zh6In864Pj1e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_zQf7imEYOq0h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesBOnePreferredStockMember_zb48hpBFkjZ3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zkEEeTkl5Zah" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_custom--VotingCommonStockMember_zek8Y82QL5X">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zhSdSCLaUM16" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Capital</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zpjl0EK0AQZi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deficit</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_zgglRacggzbi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(Deficit)</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Net
    Parent</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series
    &#8220;A&#8221; Preferred Stock</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series
    &#8220;B&#8221; Preferred Stock</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series
    &#8220;B-1&#8221; Preferred Stock</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Non-voting
    Common &#160;Stock</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Voting
    Common Stock</b></span></td>
    <td><b>&#160;</b></td>
    <td><b>&#160;</b></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;Additional
    Paid-in</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Accumulated</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Total<br/>
    Stockholders&#8217;<br/>
    Equity/</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Investment</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Capital</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deficit</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(Deficit)</span></td>
    <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_43D_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zApGFkYJ8iU1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance &#8211; December 31, 2021</span></td>
    <td style="font-weight: bold; width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; width: 2%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_NetParentInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18342">1,461</ix:nonFraction></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td style="font-weight: bold; width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z6rSHKbRhEul" style="font-weight: bold; text-align: right; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18343">8,750,000</ix:nonFraction></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td style="font-weight: bold; width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; width: 2%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td style="font-weight: bold; width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7r8yhlWqL2b" style="font-weight: bold; text-align: right; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td style="font-weight: bold; width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; width: 2%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td style="font-weight: bold; width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_z6CouJfuzFrh" style="font-weight: bold; text-align: right; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td style="font-weight: bold; width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; width: 2%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td style="font-weight: bold; width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHbTBey4J1Md" style="font-weight: bold; text-align: right; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td style="font-weight: bold; width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; width: 2%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--VotingCommonStockMember_z4wRJDUWTbIi" title="Balance, shares" style="text-align: right; width: 2%">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><b>$</b></td>
    <td style="text-align: right; width: 2%"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; width: 2%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left">&#160;</td>
    <td style="font-weight: bold; width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; width: 2%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18344">2,751</ix:nonFraction></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font-weight: bold; width: 1%">&#160;</td>
    <td style="font-weight: bold; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; width: 2%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18345">1,290</ix:nonFraction></span></td>
    <td style="font-weight: bold; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_432_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zj8ptlQmbq3c" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance</span></td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_NetParentInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18346">1,461</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zCK5fEBaKpN" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18347">8,750,000</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zo1LuH8VtXdk" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zQxjZ69Ltgc2" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXQy7G1ieZib" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--VotingCommonStockMember_zyaRezLvV6Dh" title="Balance, shares" style="text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><b>$</b></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18348">2,751</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18349">1,290</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
<tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zUC4n1cfdun9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of Non-Voting Common Stock to Parent company members</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwpP4tCSulA3" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18350">28,179,592</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18351">1</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18352">1</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zhL157qGXOqe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Sale of Series B Preferred Stock</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0349">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zTNkSlfaFLJ8" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18353">381,658</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18354">2,150</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18355">2,150</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zbE0aHDwAXY6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based compensation expense</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbLEL967whA6" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18356">51,250</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18357">265</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18358">265</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zz3hy6JmtXvk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net loss</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18359">5,121</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18360">5,121</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_433_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zzVkhyFAm96j" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance &#8211; December 31, 2022</span></td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_NetParentInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18361">1,461</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zPKoHjJs4Phh" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18362">8,750,000</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLQ3DgVHwzxb" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18363">381,658</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_z9rF7luyzi7f" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp0IDSQKgAH6" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18364">28,230,842</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18365">1</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--VotingCommonStockMember_z26Qekkjyo2j" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18366">2,414</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18367">7,872</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18368">3,996</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_431_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zke4KSXPq7Fk" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance</span></td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_NetParentInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18369">1,461</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zC7qGGo2roN6" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18370">8,750,000</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1gCTfbEatag" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18371">381,658</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_z0m6AF3uZOFe" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7IhFCQGUp6i" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18372">28,230,842</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18373">1</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--VotingCommonStockMember_zBmZYBh8o24e" title="Balance, shares" style="text-align: right; vertical-align: bottom"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; vertical-align: bottom"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18374">2,414</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18375">7,872</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18376">3,996</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_40F_ecustom--SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_z9ZGZr5vp2cf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Sale of Series B Preferred Stock, net of direct costs</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_98E_ecustom--SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zb5CJXXmYxGe" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="FBLG:SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18377">2,570,394</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0426">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18378">14,945</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18379">14,945</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zDpSqcn0l9j7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Sale of Series B-1 Preferred Stock</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0434">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Sale of Series &quot;B-1&quot; Preferred Stock shares, net of direct costs, shares" id="xdx_987_ecustom--SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_z3EIuv8mK801" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="FBLG:SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18380">89,781</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18381">1,193</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18382">1,193</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest_zzPKFHSKZha4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of Series B Preferred Stock for conversion of Notes and accrued interest</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Issuance of Series B Preferred Stock shares for conversion of Notes and accrued interest, shares" id="xdx_980_ecustom--IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zuf82Ram1PX5" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="FBLG:IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18383">1,219,393</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0449">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18384">6,404</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18385">6,404</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DeemedDividendRelatedToRofnAgreementDerivativeLiability_z5KIowBISkv5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deemed dividend related to ROFN Agreement derivative liability</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability" contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18386">1,461</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18387">1,112</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18388">2,573</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zSkKEWCSTUBe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based compensation expense</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18389">1,765</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0475">&#8212;</span></span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18390">1,765</ix:nonFraction></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zgyusxA5cnvb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net loss</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td title="Balance, shares" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0482">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18391">16,485</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18392">16,485</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_430_c20230101__20231231_eus-gaap--StockholdersEquity_iE_z8QyAPD1fb16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance &#8211; December 31, 2023</span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#8212;</span></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhLi3uGtnZyl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18393">8,750,000</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0489">&#8212;</span></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zb4UdlXt4Oqa" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18394">4,171,445</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0490">&#8212;</span></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zmTSZXPlpuka" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18395">89,781</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjABKdzBfiHd" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18396">28,230,842</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18397">1</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--VotingCommonStockMember_zBGCFpBGgC98" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double"><b>$</b></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18398">25,609</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18399">24,357</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18400">1,253</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zjUqxyqNYp4a" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance </span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0508">&#8212;</span></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zq9nnt1XnsXj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18401">8,750,000</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8212;</span></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBWcN56vPY4h" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18402">4,171,445</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8212;</span></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zmLg3QY3uxHe" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18403">89,781</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td title="Balance, shares" id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zByxw9apGnIh" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18404">28,230,842</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18405">1</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--VotingCommonStockMember_z676OgDo6Bfg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; vertical-align: bottom"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18406">25,609</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18407">24,357</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18408">1,253</ix:nonFraction></span></td>
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FibroBiologics,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_005"></span>Statements
of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_112_pn3n3_zuFwZ6shK3ya" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zasmqH9h6mAe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zuhgDmi3G5xj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zN5jyxPrHUd7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_i01_maNCPBUzaOB_zlcURnq1c3F7" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18409">16,485</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18410">5,121</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zfvZjVrliO1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FairValueAdjustmentOfLiabilityInstrument_i02_maNCPBUzaOB_zHckTO1GO8H7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of  liability instrument</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FBLG:FairValueAdjustmentOfLiabilityInstrument" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18411">7,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i02_maNCPBUzaOB_zKqnGWXNTnI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18412">1,765</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18413">265</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DerivativeLossOnDerivative_i02_maNCPBUzaOB_zcnEsVl0CZka" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18414">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maNCPBUzaOB_zjddRjQB57f7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization of convertible notes debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18415">81</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18416">389</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUzaOB_z41JQcmR3gub" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18417">390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18418">94</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Depreciation_i02_maNCPBUzaOB_zHEi7TAIxzM9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18419">47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zYbhh31omBE3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_di_msNCPBUzaOB_zwA1wcOTsIk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18420">7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18421">8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maNCPBUzaOB_zJ5yNH9I1SW9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18422">671</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18423">525</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i03N_di_msNCPBUzaOB_zprf6dgMvEU8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18424">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18425">6</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--IncreaseDecreaseInChangeInPayableToParent_i03_maNCPBUzaOB_zmtRBlLRuKBi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in payable to Parent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FBLG:IncreaseDecreaseInChangeInPayableToParent" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18426">141</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzaOB_z6DDiNNyzFv2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Change in operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18427">326</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18428">220</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCzElZ_mtNCPBUzaOB_zSCBiEumTLK4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18429">6,401</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18430">4,066</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zbjFQjzYucV6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzujp_z1eRVUMNNNhk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchases of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18431">495</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzujp_maCCERCzElZ_zwjhVb5r8Mhf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18432">495</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0583">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zxcPPuiMwzGk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RepaymentsOfRelatedPartyDebt_i01N_di_msNCPBUzaG1_zVWYGe3qUKnk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Payment of loan to Parent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0588">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18433">225</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--RofnAgreementPaymentsToParent_i01N_di_msNCPBUzaG1_zruwWatxm9x1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">ROFN Agreement payments to Parent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FBLG:RofnAgreementPaymentsToParent" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18434">2,645</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0592">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_i01_maNCPBUzaG1_zzCZES4Pun96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Repayment and proceeds of note receivable from Parent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18435">300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18436">300</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzaG1_zONBvUz8opIj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0597">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18437">4,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_i01_maNCPBUzaG1_zAQKwnfqHWD8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of Series B Preferred Stock, net of direct costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18438">14,945</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18439">2,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1_i01_maNCPBUzaG1_z77u386jONvj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from issuance of Series B-1 Preferred Stock, net of direct costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="FBLG:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18440">1,193</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0604">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCCERCzElZ_mtNCPBUzaG1_z5D2BYLF9Eti" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18441">13,793</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18442">5,925</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzElZ_zdl7NOoVLyHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18443">6,897</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18444">1,859</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zF6eUEbBgDkc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18445">2,266</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18446">407</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_z148YqDCJvFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18447">9,163</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18448">2,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zXPCbk1pQa8e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxesPaidNet_i01_zCrtjVF4hxPj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0622">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InterestPaidNet_i01_zQznccJnVri2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cash paid for interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18449">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_ziUK2VpcllCg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AdditionToDerivativeLiabilityForDebtIssuanceDiscount_i01_zKBZuMOlTGli" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Addition to derivative liability for debt issuance discount</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="FBLG:AdditionToDerivativeLiabilityForDebtIssuanceDiscount" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18450">538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ObtainingOperatingLeaseRightofuseAssetAndLiability_i01_zFBX1ls574f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Obtaining operating lease right-of-use asset and liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="FBLG:ObtainingOperatingLeaseRightofuseAssetAndLiability" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18451">2,293</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest_i01_zB98d7Ho0lch" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of Series B Preferred Stock for conversion of Notes and accrued interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="FBLG:IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18452">5,866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0637">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_i01_z1RtRY20plj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="FBLG:ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18453">538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment_i01_zPADEpgjFXLg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additions to accounts payable and accrued expenses for purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="FBLG:AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18454">349</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FibroBiologics,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_006"></span>Notes
to the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-14706"><p id="xdx_805_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z8yDXCzy2FT4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_z4uUjpBA0Hre">Organization, Description of Business, and Liquidity</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization
and Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FibroBiologics,
Inc. (the &#8220;Company&#8221; or &#8220;FibroBiologics&#8221;) was originally formed as a limited liability company (&#8220;LLC&#8221;)
under the laws of the State of Texas on April 8, 2021 (&#8220;Inception&#8221;) and then converted to a Delaware corporation on December
14, 2021. FibroBiologics is an early stage, cell therapy company headquartered in Houston, Texas, developing innovative treatments for
chronic diseases using fibroblast cells. The Company&#8217;s primary focus is the initiation and progression of preclinical studies and
clinical-stage U.S. Food and Drug Administration trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis,
Cancer, Wound Healing and other diseases. Prior to Inception, preclinical research and development related to these disease pathways
took place under the parent company, SpinalCyte, LLC (the &#8220;Parent&#8221; or &#8220;FibroGenesis&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Direct
Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2024, the Company completed a direct listing of its common stock on Nasdaq (the &#8220;Direct Listing&#8221;). Upon completion
of the Direct Listing, all outstanding shares of the Company&#8217;s Non-voting Common Stock, Series B Preferred Stock, and Series B-1
Preferred Stock automatically converted into shares of Voting Common Stock on a one-for-one basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern and Management&#8217;s Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred operating losses since Inception and expects such losses to continue in the future as it builds infrastructure,
develops intellectual property and conducts research and development activities. The Company has primarily relied on a combination of
angel investors and private debt placements to funds its operations. As of December 31, 2023, the Company had an accumulated deficit
of $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20231231_z98ot1puN5v5"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18455">24,357</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand
and cash and cash equivalents of $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20231231_zbYmnjiej6kf"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18456">9,163</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand. A transition to profitability will
depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues
to support the Company&#8217;s cost structure. The Company currently does not generate revenues and may never achieve profitability.
Unless and until such time that revenue and net income are generated, the Company will need to continue to raise additional capital.
As further described in Note 8, management has entered into a share purchase agreement as of November 12, 2021. With the completion of
the Company&#8217;s Direct Listing, this agreement provides the Company with access to additional liquidity. In February 2024, the Company
utilized this facility to raise a total of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20230101__20231231_zXVMtP5hN2T7"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18457">1,924</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand. As a result, the Company believes it
has adequate capital to fund its current operating plan for at least the next 12 months from the date of issuance of these Financial
Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief executive
officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources
and evaluating financial performance. The Company operates and manages its business as a single operating segment and therefore has one
reportable segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-14772"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zYB9wikvYkDl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_z4wlpIcxE08c">Summary of Significant Accounting Policies</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-14781"><p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zLg19Zjf7Xtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z8O3Z4jtpqqg">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding
annual financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from January 1, 2021, to its formation on April 8, 2021, the Company operated as a line of business of FibroGenesis rather
than as a separate stand-alone entity. Consequently, prior to the Company&#8217;s formation on April 8, 2021, the financial statements
were derived from the historical accounting records of the Parent. All general and administrative expenses and research and development
expenses directly associated with the business activity of the Company that were originally incurred by the Parent from January 1, 2021,
through the Company&#8217;s formation on April 8, 2021, were allocated and included in the Company&#8217;s financial statements. The
resulting net Parent investment was presented within stockholders&#8217; equity/(deficit) and represented the Parent&#8217;s interest
in the recorded net assets of the Company and has been eliminated through the ROFN Agreement as further described in Notes 7 and 11.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, the Company amended and restated its certificate of incorporation with the State of Delaware to immediately effect a 1-for-4
shares reverse stock split. All share and per share amounts have been adjusted on a retroactive basis to reflect the effect of the
reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:UseOfEstimates" id="ixv-14800"><p id="xdx_847_eus-gaap--UseOfEstimates_zwt2zNhO5J4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zw1DrwJNNSH8">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements
and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date
of the Financial Statements; therefore, actual results could differ from those estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-14811"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zbzlq04VIvr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zIVIo5Wbo1Te">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The
Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit
of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20231231_z1s2CkMyVJma" title="Federally insured limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-18458">250,000</ix:nonFraction></span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial
condition, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="FBLG:RisksAndUncertaintiesPolicyTextBlock" id="ixv-14824"><p id="xdx_84A_ecustom--RisksAndUncertaintiesPolicyTextBlock_zCM0wh8e2bCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zKNfC1n28vKk">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the
Company believes could have a material adverse effect on the future financial position or results of operations: the timing of, and the
Company&#8217;s ability to advance its current and future product candidates into and through clinical development; costs and timelines
associated with the manufacture of clinical supplies of the Company&#8217;s product candidates; regulatory approval and market acceptance
of its product candidates; performance of third-party contract research organizations (&#8220;CROs&#8221;) and contract manufacturing
organizations (&#8220;CMOs&#8221;); competition from pharmaceutical companies with greater financial resources or expertise; protection
of the intellectual property, litigation or claims against the Company based on intellectual property, or other factors; the need to
obtain additional funding; and its ability to attract and retain employees necessary to support its growth. Disruption from CROs&#8217;,
CMOs&#8217; or suppliers&#8217; operations would likely have a negative impact on the Company&#8217;s business, financial position and
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-14836"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zOqnLLqHGWq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zKIHFte91RX1">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three
months or less at the time of purchase. There were <span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_zdGKDMCreLA3" title="Cash equivalents"><span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zTcjr9BCeQn" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD" id="ixv-18459"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD" id="ixv-18460">no</ix:nonFraction></ix:nonFraction></span></span> cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-14861"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zMVkNCl4TJTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zoHu2zwW1ubi">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is computed using the straight-line
method over the estimated useful lives of the respective assets, generally three to five years, and includes laboratory equipment that is
recorded at cost and depreciated using the straight-line method over the estimated useful lives of five years. Depreciation expense is
classified in either research and development expense or in general and administrative expense, depending upon the nature of the asset,
in the accompanying Statements of Operations. When property and equipment assets are retired or otherwise disposed of, the cost and related
accumulated depreciation are removed from the balance sheets and the resulting gain or loss is recorded in other income (loss) in the
period realized. Maintenance and repairs are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets
might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable
market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that
would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used,
the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and
measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for
the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-14877"><p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_znec43ArZIxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_865_zYvw03D16fRi">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company determines if an arrangement is a lease at inception. An arrangement is or contains a lease if it conveys the right to control
the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification is determined
at lease commencement. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement
date. The Company&#8217;s leases do not provide an implicit interest rate and therefore the Company estimates its incremental borrowing
rate to discount lease payments. The incremental borrowing rate reflects the interest rate that the Company would have to pay to borrow
on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term. Operating lease
right-of-use (&#8220;ROU&#8221;) assets are based on the corresponding lease liability adjusted for any lease payments made at or before
commencement, initial direct costs, and lease incentives. Renewals or early terminations are not accounted for unless the Company is
reasonably certain to exercise these options. Operating lease expense is recognized and the ROU asset is amortized on a straight-line
basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Operating
leases are included in operating lease right-of-use asset, operating lease liability, short-term, and operating lease liability, long-term
on the Company&#8217;s Balance Sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company has elected in accordance with ASC 842-20-25-2 an accounting policy to not record short-term leases, defined as those with terms
of 12 months or less, on the Balance Sheets. Rent expense recorded under leases, for financial statement purposes, is recognized on a
straight-line basis over the lease term based on the most recent contractual terms available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-14896"><p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgvxc4Dp8Fl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86E_z69gfL6mD6u2">Fair
Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Accounting
Standards Codification (&#8220;ASC&#8221;) 820, <i>Fair Value Measurement</i>, establishes a fair value hierarchy for instruments measured
at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions
(unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market
data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about
the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available
in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions
in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Level
1 - Quoted market prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Level
2 - Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates
and yield curves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Level
3 - Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#8217;s
own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about
risk).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Categorization
within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:DerivativesPolicyTextBlock" id="ixv-14937"><p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zey6YkvhidG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><b><span id="xdx_863_zuS18C0BfOIb">Derivatives</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Derivative financial instruments,
including the Liability instrument, are recorded at fair value on the Balance Sheet. Liability classified derivatives are remeasured at their
fair value at each reporting date, with decreases or increases in the fair value recognized as other gain or loss, respectively, within
the Statement of Operations. Equity classified derivatives are not remeasured at each reporting date. If a liability classified derivative
becomes eligible for reclassification to an equity classified derivative, any gains or losses recognized up to the point of reclassification
are not reversed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-14945"><p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZ1BEmZTWuR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zAmDAIw1ZIO5">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research
and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory
supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain
research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern
of costs incurred, and are reflected in the Financial Statements as prepaid or accrued research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="ixv-14957"><p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zbOxJbLR5wDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zbLAotx4dYh8">Patent
Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company continues to incur costs to obtain market approval of patented technology, patent costs are expensed as incurred in general,
administrative and other expense in the Statements of Operations. Costs include fees to renew or extend the term of recognized intangible
assets, patent defense costs, and patent application costs. Management will continue to expense such costs until market approval is obtained
through regulatory approval by the appropriate governing body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-14969"><p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zHewRXz5l1E1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zFTimCOV9u3k">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is a C corporation, and accounts for income taxes under the asset and liability
method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement
and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.
Valuation allowances are established when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the provisions of ASC 740-10, <i>Income Taxes</i>, the Company evaluates uncertain tax positions by reviewing against applicable tax
law all positions taken by the Company with respect to tax years for which the statute of limitations is still open. ASC 740-10 provides
that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained
upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The Company recognizes
interest and penalties related to the liability for unrecognized tax benefits, if any, as a component of the income tax expense line
in the accompanying Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="ixv-14984"><p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z2DJvtjEuD1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zbrppPtA8Sm9">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs related to stock options granted to employees and nonemployees based on the estimated fair value
of the awards on the date of grant and recognizes expense on a straight-line basis over the requisite service period, which is generally
the vesting period of the award. Forfeitures are recognized as they occur. The fair value of stock options is estimated on the date of
grant using a Black-Scholes option pricing model which requires management to apply judgment and make estimates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
    Value of Common Stock</i>&#8212;The estimated fair value of our common stock underlying our stock-based awards has been determined
    by our board of directors as of each option grant date with input from management, considering our most recently available
    third-party valuations of common stock and our board of directors&#8217; assessment of additional objective and subjective factors
    that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant.
    These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public
    Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the
    Practice Aid). Now that a public trading market for our common stock has been established in connection with the completion of the
    Direct Listing, the fair value of common stock in future grants will be based on the closing price as reported on The Nasdaq Global Select Market on the
    date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Term</i>&#8212;The expected term represents the period that a stock-based award is expected to be outstanding. The Company uses the
    simplified method to determine the expected term, which is based on the average of the time-to-vesting and the contractual life of
    the option.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Volatility</i>&#8212; Due to the Company&#8217;s limited operating history and lack of company-specific historical and implied volatility
    data, the expected volatility is estimated based on the average historical volatilities of common stock of comparable publicly traded
    entities over a period of time commensurate with the expected term of the stock option grants. The comparable companies are chosen
    based on their size, stage in the product development cycle, or area of specialty. The Company will continue to apply this process
    until sufficient historical information regarding the volatility of its own stock price becomes available.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
    Interest Rate</i>&#8212;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon
    U.S. Treasury notes with maturities approximately equal to the expected term of the awards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Dividend</i>&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock.
    Therefore, the Company used an expected dividend yield of zero.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="FBLG:EmergingGrowthCompanyPolicyTextBlock" id="ixv-15052"><p id="xdx_847_ecustom--EmergingGrowthCompanyPolicyTextBlock_z4MVFVraF6ue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zvsvRe7B3p5k">Emerging
Growth Company</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the completion of the Direct Listing, the Company is an emerging growth company (EGC), as defined in the Jumpstart Our Business Startups
Act of 2012 (JOBS Act). Under the JOBS Act, an EGC can delay adopting new or revised accounting standards issued subsequent to the enactment
of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition
period for complying with new or revised accounting standards that have different effective dates for public and private companies; however,
the Company may adopt new or revised accounting standards early if the standard allows for early adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company will utilize other exemptions and reduced reporting requirements provided to EGCs by the JOBS Act. Subject to certain
conditions set forth in the JOBS Act, an EGC is not required to, among other things, (i) provide an auditor&#8217;s attestation report
on the company&#8217;s system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002,
(ii) provide all of the compensation disclosure that may be required of non-EGC public companies under the Dodd-Frank Wall Street Reform
and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding
mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the
financial statements (auditor discussion and analysis), or (iv) disclose certain executive compensation-related items, such as the correlation
between executive compensation and performance and comparisons of the chief executive officer&#8217;s compensation to median employee
compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-15067"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zF9lBFxyj566" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zy4HvretUkF8">Recently
Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There have been no accounting pronouncements issued but not yet adopted by the Company that are expected to have a material impact on
the Company&#8217;s Financial Statements.</p>

</ix:nonNumeric><p id="xdx_85A_zFDTBd9KMsG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-15077"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_z2u7DmYYXDTd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zBXZptKVMQFk">Net Loss per Share Attributable to Common Stockholders</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-15086"><p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z0dYk4poM839" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zVKpKEtpCaTa" style="display: none">Schedule
of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zu8kbZ2g6hlf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20221231_zQsA2Qcw3FAd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">(in thousands, except share and per share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zi9yPG10Rbrh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18461">16,485</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18462">5,121</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Adjustment to numerator for earnings per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeemedDividend_pn3n3_zejgX65pHSMk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="FBLG:DeemedDividend" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18463">2,573</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zMGm5Vglj8Q8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net loss attributable to common stockholders:</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18464">19,058</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18465">5,121</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted-average number of common shares outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zdJApRGVbmnf" title="Weighted average number of shares outstanding, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zlhNGNuwHShi" title="Weighted average number of shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18466"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18467">28,230,842</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231_zpuyPZbdiYSf" title="Weighted average number of shares outstanding, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20221231_zqNTkQR0nUtg" title="Weighted average number of shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18468"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18469">28,230,842</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net loss per common share attributable to common stockholders, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zXJeHCOo15C7" title="Net loss per share, basic"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zT0ZKNo8sKmf" title="Net loss per share, diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-18470"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-18471">0.68</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zWoD99bcKbqf" title="Net loss per share, basic"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_zdCCF9wil7Mh" title="Net loss per share, diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-18472"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares" id="ixv-18473">0.18</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zLZZJHROg5lk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
further described in Note 7, the Company issued <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zyI04K1twSRf" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-08-18_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18474">28,230,842</ix:nonFraction></span> shares of non-voting common stock on August 18, 2022. The weighted average
number of shares outstanding for the years ended December 31, 2023 and 2022, is based upon the non-voting common stock shares issued
on August 18, 2022. Because the issuance of nonvoting common stock shares was treated as a stock split for accounting purposes, these
shares are treated as having been issued on January 1, 2022, and outstanding for the entire years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
further described in Note 11, the Company agreed to pay to FibroGenesis 15% of the gross proceeds from any equity investments in FibroBiologics
prior to an Initial Public Offering (&#8220;IPO&#8221;), Direct Listing or Sale of the Company to eliminate upon the occurrence of such
event the Series A Preferred Stock and its $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn6n6_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5p5yDhUxLU" title="Preferred stock liquidation value"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD" id="ixv-18475">35</ix:nonFraction></span> million liquidation preference. This redemption of preferred stock created a derivative
liability that exceeded the net Parent Investment of $<span id="xdx_908_eus-gaap--PreferredStockRedemptionAmount_iI_pn3n3_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_znyXxZJdeAgj" title="Preferred stock, redemption amount"><ix:nonFraction name="us-gaap:PreferredStockRedemptionAmount" contextRef="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18476">1,461</ix:nonFraction></span> thousand by $<span id="xdx_903_eus-gaap--PreferredStockRedemptionAmount_iI_pn3n3_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zhorCztprQo8" title="Preferred stock, redemption amount"><ix:nonFraction name="us-gaap:PreferredStockRedemptionAmount" contextRef="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18477">1,112</ix:nonFraction></span> thousand, and is reflected here as a reduction of the
amount available to common stockholders in the calculation of earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had $<span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231_zVOm3YkF9PAl" title="Convertible notes outstanding"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18478">5,600</ix:nonFraction></span> thousand of convertible notes outstanding as of December 31, 2022, which could have been converted into common stock
in the event that the Company sold and issued shares of capital stock in excess of $<span id="xdx_900_ecustom--CapitalStockInExcess_iI_pn3n3_c20221231_z6mkqfnyFqk" title="Capital stock in excess"><ix:nonFraction name="FBLG:CapitalStockInExcess" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18479">10,000</ix:nonFraction></span> thousand, and were all converted by December
31, 2023, into shares of Series B Preferred Stock as further described in Note 6. As of December 31, 2022, the estimated number of shares
of common stock that would have been issued upon conversion was <span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220101__20221231_zo42ctilWFl6" title="Issued upon conversion of common stock"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18480">801,145</ix:nonFraction></span> shares. For the years ended December 31, 2023 and 2022, the Company
reported net losses and, accordingly, potential common shares were not included since such inclusion would have been anti-dilutive. As
a result, the Company&#8217;s basic and diluted net losses per share are the same because it generated a net loss in all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-15237"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_ziBYyVzNIDYi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zn1Stxouvjgl">Property and Equipment</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-15246"><p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwkvNwMSVfij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zrZpqfg7xer2" style="display: none">Schedule
of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zJHTNJbuNowg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zfBe724ZDyel" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zVFYgHl8sNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Laboratory equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18481">816</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0736">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zhVeI3z0qLvg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Computer equipment, software, and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18482">28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzT4x_zdxjoNYWrnJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total property and equipment at cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18483">844</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzT4x_zVMRjGrd2pWh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18484">47</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzT4x_z9sJOuSJjzkg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18485">797</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z2nWgZqRmgei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The useful life of Laboratory
equipment is <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaborataryEquipmentMember_zSvB5AL4Iaj2"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_LaborataryEquipmentMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18486">five
years</ix:nonNumeric></span>, and the useful life of Computer equipment, software, and other is <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zi2KZge2USk3"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-18487">three
years</ix:nonNumeric></span>, for deprecation. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was $<span id="xdx_904_eus-gaap--Depreciation_pn3n3_c20230101__20231231_z2rUirPXyKCh" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18488">47</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand and $<span id="xdx_906_eus-gaap--Depreciation_dxL_c20220101__20221231_zu74kcDkYkyf" title="Depreciation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0754">0</span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2023 and 2022,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-15342"><p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zg0tRzLLlj1g" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zBdkAFbTAe48">Fair Value of Financial Instruments</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company measured its derivative liability related to the conversion option feature in the 2022 Notes, as described
in Note 6, at fair value. As of December 31, 2023, the 2022 Notes had been converted, which eliminated the derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company measured its liability instrument to investors under the Share Purchase Agreement, as further
described in Note 8, at $<span id="xdx_901_ecustom--LiabilityInstrument_iI_pn3n3_c20231231_z06TqnkKKje6" title="Liability instrument"><ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18489">7,236</ix:nonFraction></span>
thousand. This liability instrument is classified within Level 3 of the value hierarchy because the liability was based upon a
valuation model that used inputs and assumptions including potential outcomes, interest rates, probabilities, and timing. As of
December 31, 2022 and 2021, this liability instrument was assigned <span id="xdx_908_ecustom--LiabilityInstrument_iI_pn3n3_dxL_c20221231_z5fMYDm37JCl" title="Liability instrument::XDX::-"><span id="xdx_906_ecustom--LiabilityInstrument_iI_pn3n3_dxL_c20211231_zUHhhLd97fU2" title="Liability instrument::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0760"><span style="-sec-ix-hidden: xdx2ixbrl0762">no</span></span></span></span>
value by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="ixv-15364"><p id="xdx_893_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zxcyuXtjdMae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the Company&#8217;s financial liabilities measured at fair value on a recurring basis based on the three-tier
fair value hierarchy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zNKASbrI9hL4" style="display: none">Schedule
of Financial Liabilities Measured at Fair Value</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLLuS0PczDq9" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4QwOa4vrGDf" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqK5YCQi6hRc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_zHDTFayCne1h" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurement as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3n3_maFLFVDzjkJ_zd28TiS69tu" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0769">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LiabilityInstrument_iI_pn3n3_maFLFVDzjkJ_zSVJOIJHeuMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1.5pt">Liability instrument</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0771">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18490">7,236</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="FBLG:LiabilityInstrument" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18491">7,236</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iTI_pn3n3_mtFLFVDzjkJ_zUTrzedZQ5v4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18492">7,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18493">7,236</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zv9FVDrwyWrh" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbm3b64kBb53" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAs0SJ0b4x91" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zVaRRvyjdPe3" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurement as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3n3_maFLFVDzjkJ_zE4RX3P8S3nb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: justify">Derivative liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0781">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18494">538</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18495">538</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LiabilityInstrument_iI_pn3n3_maFLFVDzjkJ_zEUrEX1sjtxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Liability instrument</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0786">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0788">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0789">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iTI_pn3n3_mtFLFVDzjkJ_zrwptT3BQmp4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0791">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18496">538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18497">538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zip3wzSjs8xb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="ixv-15615"><p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z6c68rgTTnp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the transfers in and out of Level 3 financial liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zTHKXPMPqPb5" style="display: none">Schedule
of Financial Liability Transfers</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zDan4JiNQ9Ji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--FinancialInstrumentAxis_custom--LiabilityInstrumentMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zaoNWEPM5a0c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Liability Instrument</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43B_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z92TrGkB33X8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0799">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_i01_zOqdkfh6hZhf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify; padding-bottom: 1.5pt">Addition to derivative liability for debt issuance discount</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="FBLG:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" contextRef="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18498">538</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z3GoE9sf6z76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value at December 31, 20222</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18499">538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zTb4d5OK5Ltl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value, beginning balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18500">538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_i01_zGJdBDaCkNN2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FBLG:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" contextRef="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD" id="ixv-18501">538</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_i02_zT8ZthOEVd78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Increase in the fair value of the liability instrument</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18502">7,236</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zApiiV7yRhxd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Fair value at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18503">7,236</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zVTS1vt1qSaa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Fair value, ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18504">7,236</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A2_zcA3Gu1mOI3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the liability instrument includes the contingent warrant and the contingent put option as a single unit of
account. The liability instrument value was determined using a Black-Scholes valuation model and management&#8217;s assumption of a
50% likelihood as of December 31, 2023, of becoming a public company prior to the expiration of the Stock Purchase Agreement. Inputs
used in the Black-Scholes valuation model included an estimated number of warrants, an assumed common stock share price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20231231_zGZgzBBrQirl" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18505">15.00</ix:nonFraction></span>
per share, the <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputMaturityMember_zl0YAK8Sb2n" title="Maturity period::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0824">five-year</span></span>
time to maturity, a <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJdWIEpXDIy" title="Dividend yield"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18506">0</ix:nonFraction></span>%
dividend yield, an annual risk-free interest rate of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ziQDhX260m44" title="Dividend yield"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18507">3.84</ix:nonFraction></span>%
for the <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputMaturityMember_zoBmK2rRcmp3" title="Maturity period::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0830">five-year</span></span>
time to maturity, and an assumed annualized volatility of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zHWZLdXUg6fe" title="Dividend yield"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18508">96</ix:nonFraction></span>%
based on comparable companies with a five-year history of stock prices. As of December 31, 2023, the Company evaluated the put option component of the liability instrument and determined
that any value as it relates to the liability instrument would be de minimus given the Company&#8217;s financial condition, intention
to seek other sources of financing as needed, and ability to do so given access to public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liability was determined based upon a valuation model that used inputs and assumptions including potential outcomes, interest
rates, probabilities, and timing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, prepaid expenses, other current assets, accounts payable, accrued expenses, convertible
notes payable, and Parent company payable and receivable approximate their fair values due to their short-term maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than those transfers noted in the table above, there were no transfers in or out of Level 1, Level 2 or Level 3 assets and liabilities
for the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-15745"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zQzF13VFyLuj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zFvXv0qrDcHj">Convertible Notes Payable</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company entered into multiple convertible promissory note agreements in December 2021 (collectively, the &#8220;2021 Notes&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
the inception of the 2021 Notes, and at December 31, 2021 and 2022, the Company determined that an embedded derivative for the conversion
feature did not meet the criteria because it met the &#8220;indexed to the entity&#8217;s own stock&#8221; exception per the guidance
in ASC 815-10-15-74(a) and therefore was not required to be bifurcated from the host instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company issued additional convertible promissory notes between January and April 2022 with a total principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20221231_zMPzXaM98Ebe" title="Long-term debt, gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18509">4,300</ix:nonFraction></span> thousand
and a one-year maturity (collectively, the &#8220;2022 Notes&#8221;). The 2022 Notes may be converted at the lesser of <span id="xdx_902_eus-gaap--ConversionOfStockDescription_c20220101__20221231_z1EosKjra0Na"><ix:nonNumeric contextRef="From2022-01-012022-12-31" name="us-gaap:ConversionOfStockDescription" id="ixv-18510">a) a 15% discount
to the offering price of the Company&#8217;s common stock in the event of an initial public offering of the Company or b) the quotient
of $200,000 thousand divided by total equity interests prior to the dilution from the offering. The conversion option feature in the
2022 Notes was evaluated in accordance with ASC 815, and a derivative liability for the $538 thousand estimated fair value of the conversion
option was recorded at the time the notes were issued and as of December 31, 2022.</ix:nonNumeric></span> An offsetting discount on the issuance of the notes
was recorded and is being amortized to interest expense over the expected life of the 2022 Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
interest expense, excluding amortization of the discount recorded on the 2022 Notes, on the 2021 and 2022 Notes for the years ended December
31, 2023 and 2022, was $<span id="xdx_905_eus-gaap--InterestExpenseDebt_pn3n3_c20230101__20231231_zheOCS5KAJu5" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18511">65</ix:nonFraction></span> thousand and $<span id="xdx_900_eus-gaap--InterestExpenseDebt_pn3n3_c20220101__20221231_z1pC6uGJWesb" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18512">265</ix:nonFraction></span> thousand, respectively. Accrued interest was outstanding and included within accounts payable
and accrued expenses at December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, the Company converted the principal and interest on $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230228__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_z3ytIkqOtnih" title="Face value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-02-28_custom_TwoThousandTwentyTwoNotesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18513">3,700</ix:nonFraction></span> thousand of principal value of the 2022 Notes into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230228__20230228__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zWMOTQ4RQKHg" title="Converted principal shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-02-282023-02-28_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18514">799,603</ix:nonFraction></span>
shares of Series &#8220;B&#8221; Preferred Stock. In April 2023, the Company also converted the principal and interest on $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230430__us-gaap--AwardDateAxis__custom--TwoThousandTwentyOneNotesMember_zIoGHQedMyZg" title="Face value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-04-30_custom_TwoThousandTwentyOneNotesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18515">1,300</ix:nonFraction></span> thousand
of principal value of the 2021 Notes and $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230430__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zFzUss0XgUS9" title="Face value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-04-30_custom_TwoThousandTwentyTwoNotesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18516">300</ix:nonFraction></span> thousand of principal value on the 2022 Notes into <span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230430__20230430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zTJC820zOXkc" title="Converted principal shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-04-302023-04-30_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18517">353,713</ix:nonFraction></span> shares of Series &#8220;B&#8221;
Preferred Stock. In September 2023, the Company converted the principal and interest on $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230930__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zlv5MlBJA2D1" title="Face value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-09-30_custom_TwoThousandTwentyTwoNotesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18518">300</ix:nonFraction></span> thousand of principal value of the 2022
Notes into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zIlIicarrrhk" title="Converted principal shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-09-30_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18519">66,077</ix:nonFraction></span> shares of Series &#8220;B&#8221; Preferred Stock. No interest was outstanding and included within accounts payable
and accrued expenses at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock" id="ixv-15796"><p id="xdx_89A_eus-gaap--ConvertibleDebtTableTextBlock_zVO08cHnhuP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible debt balances consisted of the following at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zX3mntGP8fJj" style="display: none">Schedule
of Convertible Debt</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_z25Oeg9YnNC2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_z1IL1owBFkX9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_zCuYZINdJ0Rl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Convertible notes principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18520">5,600</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_ziuOa8C2CBp6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Convertible notes discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18521">149</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_ztByUfwJGlS8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Convertible notes payable, net of discount</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18522">5,451</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zGjAiLLeI8dl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-15861"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z5LOF9CdNifl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zJQs3LQTfNEd">Stockholders&#8217; Equity/(Deficit) and Net Parent Investment</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Authorized
Capital - </b>As of December 31, 2023 and 2022, the Company authorized <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zNxjJLRwUema" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18523">20,000,000</ix:nonFraction></span> and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_zitD7LmHlsP5" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18524">12,500,000</ix:nonFraction></span> preferred stock shares, respectively.
As of December 31, 2022, the Company had issued <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zvexj6QAIVN6" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18525">8,750,000</ix:nonFraction></span> Series &#8220;A&#8221; Preferred Stock shares to FibroGenesis, which were tendered
pursuant to the formation of the Company in exchange for the contribution of certain in-process research and development and patent assets
through Patent Assignment and Intellectual Property Cross-License Agreements. The Series &#8220;A&#8221; Preferred Stock shares had the
right to vote and ranked prior to non-voting common stock and common stock with respect to payment of dividends and distributions and
upon liquidation, dissolution, winding-up or otherwise. In addition, the Series &#8220;A&#8221; Preferred Stock had a liquidation preference
equal to $<span id="xdx_90A_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGmZYyyCqEac" title="Preferred stock liquidation value"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18526">35,000</ix:nonFraction></span> thousand to be allocated among the holders of the Series &#8220;A&#8221; Preferred Stock shares in the event of a liquidation,
dissolution, or winding-up of the Company, which was subsequently eliminated as part of the ROFN Agreement as further described below,
and each share of Series &#8220;A&#8221; Preferred Stock could have been converted into one share of common stock at any time at the
election of the holder of such shares of Series &#8220;A&#8221; Preferred Stock. Unless otherwise elected by the holder(s), a merger
or consolidation in which the Company is not the majority surviving entity or the sale of all or substantially all of the assets of the
corporation would have been a deemed liquidation event. The Company had also authorized <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_z6bMcFqJxuO5" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18527">62,500,000</ix:nonFraction></span> shares of non-voting common stock,
and issued during the year ended December 31, 2022, a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_z7sIcyE2Pqf6" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18528">28,230,842</ix:nonFraction></span> shares. In August 2022, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zHvRzkOXrY98" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-08-012022-08-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18529">28,179,592</ix:nonFraction></span> shares
of non-voting common stock to its Parent, which in turn distributed the shares to its members. This issuance of non-voting common stock
was accounted for as stock split and no proceeds were received by the Company. The Company also issued to its board of directors, a consultant,
and an employee an additional <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_pid_c20220101__20221231_zESTNHBcIcVa" title="Employee benefit plan"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18530">51,250</ix:nonFraction></span> total shares in 2022 and recorded $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_pn3n3_c20220101__20221231_z3U0aVm2nR68" title="Share based compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18531">168</ix:nonFraction></span> thousand of expense for the issuance of these shares, which
was based upon a third-party valuation of the shares at the time of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, the Company amended its Certificate of Incorporation to authorize <span id="xdx_90C_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zMiPAcOdm0a2" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:CapitalUnitsAuthorized" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18532">2,500,000</ix:nonFraction></span>
shares of Series &#8220;B&#8221; Preferred Stock and issued <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfRvAiLvbaJf" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18533">381,658</ix:nonFraction></span>
shares in exchange for $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7IVPaNKa1Xe" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18534">2,150</ix:nonFraction></span>
thousand. The Series &#8220;B&#8221; Preferred Stock has a liquidation preference after Series &#8220;A&#8221; Preferred Stock and
prior to Common Stock and Non-Voting Common Stock. The Series &#8220;B&#8221; Preferred Stock has a liquidation preference of $<span id="xdx_905_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0ZgEiQz3yY2" title="Preferred stock, liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18535">6.76</ix:nonFraction></span>
per share, subject to adjustment, has voting rights, and will automatically convert into Common Stock upon closing of an IPO
transaction, as defined in the Company&#8217;s Amended and Restated Certificate of Incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, to reflect the ROFN Agreement with its Parent, as further discussed in Note 11, the Company amended its Certificate of
Incorporation to a) eliminate upon IPO, Direct Listing, or Sale of the Company the Series &#8220;A&#8221; Preferred Stock $<span id="xdx_905_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20230131_z3OWPL4A6bh9" title="Liquidation preference"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2023-01-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18536">35,000</ix:nonFraction></span> thousand
liquidation preference, b) make the Series &#8220;B&#8221; Preferred Stock liquidation preference equal to Series &#8220;A&#8221; Preferred
Stock, and c) to provide that upon IPO, Direct Listing, or Sale of the Company Series &#8220;A&#8221; Preferred Stock will be canceled
for no consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company amended its Certificate of Incorporation to authorize <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230430_zH4UoocHHqaa" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-04-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18537">10,000,000</ix:nonFraction></span>
shares of Common Stock, increase the number of authorized Series &#8220;B&#8221; Preferred Stock shares up to <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zTixlp10BV51" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-04-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18538">5,000,000</ix:nonFraction></span>
shares, and to authorize <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230430__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_znXCQLUyK8o5" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-04-30_custom_SeriesBOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18539">5,000,000</ix:nonFraction></span>
shares of Series &#8220;B-1&#8221; Preferred Stock with liquidation preference equal to the Series &#8220;A&#8221; and
&#8220;B&#8221; Preferred Stock. The Series &#8220;B-1&#8221; Preferred Stock has a liquidation preference of $<span id="xdx_906_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20230430__us-gaap--StatementClassOfStockAxis__custom--SeriesB1PreferredStockMember_z0Bycmxl5uG" title="Preferred stock, liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2023-04-30_custom_SeriesB1PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18540">20.00</ix:nonFraction></span> per share,
subject to adjustment, has voting rights, and will automatically convert into Common Stock upon closing of an IPO transaction, as
defined in the Company&#8217;s Amended and Restated Certificate of Incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company raised $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9TcR8k4MWh5" title="Stock issued during period, value, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18541">4,620</ix:nonFraction></span> thousand, net of fees, through a Regulation CF offering with <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zq9dCVQGC9Wh" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18542">890,310</ix:nonFraction></span> shares
of Series &#8220;B&#8221; Preferred Stock issued, raised $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zQzmMRrT05ac" title="Stock issued during period, value, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18543">10,325</ix:nonFraction></span> thousand in a private placement with <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsO7B3kYHwuf" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18544">1,680,084</ix:nonFraction></span> shares of Series &#8220;B&#8221;
Preferred Stock issued, and raised $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwgWnsGoe8D5" title="Stock issued during period, value, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_SeriesBOnePreferredStockMember_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18545">1,193</ix:nonFraction></span> thousand in a private placement with <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNbS7M5wBBBh" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_custom_SeriesBOnePreferredStockMember_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18546">89,781</ix:nonFraction></span> shares of &#8220;B-1&#8221; Preferred Stock and
<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1RpZw0vSZAh" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18547">10,321</ix:nonFraction></span> warrants issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In October 2023, the Company
amended and restated its certificate of incorporation with the State of Delaware to increase to <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231031_zpSY6lLf1KM8" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-10-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18548">100,000,000</ix:nonFraction></span> shares its authorized shares
of voting common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231031_z9E8NiAEnDg6" title="Common stock, par or stated value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-10-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18549">0.00001</ix:nonFraction></span> per share, reduce to <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zNKOLyacYD2k" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-10-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18550">30,000,000</ix:nonFraction></span> shares its authorized shares of non-voting common stock, par
value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zrqhY3xKB5bk" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-10-31_us-gaap_NonvotingCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18551">0.00001</ix:nonFraction></span> per share, and authorize <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z8HzskKL2ZN4" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-10-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18552">2,500</ix:nonFraction></span> shares of Series C Preferred Stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zx3OZYbNhPDg" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-10-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18553">0.00001</ix:nonFraction></span> per share. The Series C Preferred
Stock ranks senior to common stock and non-voting common stock and junior to the Series A Preferred Stock, Series B Preferred Stock and
Series B-1 Preferred Stock upon liquidation, dissolution, winding-up or otherwise. The Series C Preferred Stock shall have no voting
rights prior to an IPO, and <span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zwV0eJaB6pGj" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-10-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18554">13,000</ix:nonFraction></span> votes per share upon closing of an IPO. <span id="xdx_909_eus-gaap--DebtInstrumentConvertibleTypeOfEquitySecurity_c20231001__20231031_zqik6QoV0D0i" title="Debt instrument convertible descreption"><ix:nonNumeric contextRef="From2023-10-012023-10-31" name="us-gaap:DebtInstrumentConvertibleTypeOfEquitySecurity" id="ixv-15936">The Series C Preferred Stock is not entitled to dividends,
has a liquidation preference of $<span id="xdx_90B_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ztAzwKsxJ93k" title="Preferred stock, liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2023-10-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18555">18.00</ix:nonFraction></span> per share, subject to adjustment, may be converted 1:1 at any time at the option of the holder
into common stock, and upon closing of an IPO will if transferred automatically convert 1:1 into common stock.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
in October 2023, the Company filed an amended and restated certificate of incorporation with the State of Delaware to immediately effect
a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_pid_c20231031__20231031_zAzQtfGjPTx2" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-10-312023-10-31" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-18556">1-for-4 reverse stock split</ix:nonNumeric></span>. All share and per share amounts in these Financial Statements have been adjusted on a retroactive basis
to reflect the effect of the reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="FBLG:ShareSubscriptionAgreementTextBlock" id="ixv-15945"><p id="xdx_80C_ecustom--ShareSubscriptionAgreementTextBlock_zUaGaCJNG1g" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zxWgJ1ZWCn1j">Share Subscription Agreement</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2021, the Company entered into a Share Purchase Agreement with certain investors for the sale of up to $<span id="xdx_909_eus-gaap--CapitalUnitsTotalCostToInvestors_iI_pn3n3_c20211112__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z65PP2rkf3z3" title="Investors sales"><ix:nonFraction name="us-gaap:CapitalUnitsTotalCostToInvestors" contextRef="AsOf2021-11-12_custom_SharePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18557">100,000</ix:nonFraction></span> thousand
of common stock (the &#8220;Aggregate Limit&#8221;). This agreement is contingent upon the Company achieving a public listing of its
common stock. Major terms of the agreement include a commitment fee of <span id="xdx_90D_ecustom--CommitmentFeePercentage_iI_pid_dp_uPure_c20211112__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zBr2fg71fX44" title="Commitment fee percentage"><ix:nonFraction name="FBLG:CommitmentFeePercentage" contextRef="AsOf2021-11-12_custom_SharePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18558">2</ix:nonFraction></span>% of the Aggregate Limit, which is due no later than one year
after public listing even if no drawdowns are taken, and five-year warrants issued to the investors at the time of public listing to
purchase common stock shares equal to 4% of the total equity interests of the Company at the lesser of a) the price per share at the
time of the public listing or b) the quotient of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20211112__20211112__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zac7KAK5cftj" title="Shares issues  initial public offering"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-11-122021-11-12_custom_SharePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18559">700,000</ix:nonFraction></span> thousand divided by the total number of equity interests (fully diluted common
shares). <span id="xdx_90D_ecustom--DescriptionOfShareSubscriptionAgreement_c20230101__20231231_zVis86ayY9Hg" title="Description of share subscription agreement"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" name="FBLG:DescriptionOfShareSubscriptionAgreement" id="ixv-18560">The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement
following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the
Company&#8217;s common stock shares over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average
price per share over that same period. A 1% fee must be paid to the investors if the Company is sold in a private sale transaction rather
than completing a public listing of its shares.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-15975"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zAFP1B4hpDd4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zOCIb512Ivea">Income Taxes</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> </p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-15984"><p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMyajH8Q5Dw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income
tax rate is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B9_zGyMnfEQJVhe">Schedule
of Effective Income Tax Rate</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49A_20230101__20231231_zQjyP5rCczO" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49F_20220101__20221231_zlEW1BEVXLT4" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maIT1_zhpFB2bOyrZa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18561">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18562">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maIT1_z1MMpSlI4bla" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Permanent items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FBLG:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18563">9.2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FBLG:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18564">0.8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets_iN_pid_dpi_maIT1_zu54jBvn6Dx6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">True-up prior-year net operating loss deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0960">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FBLG:EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18565">6.1</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_maIT1_ziVacqX65X78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Non-deductible stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18566">1.6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18567">0.0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maIT1_z9OXNpePOoX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other changes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18568">1.9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maIT1_zh5Ip47Jbugl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18569">10.2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18570">24.4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtIT1_zGACPGAZr545" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18571">0.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18572">0.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zdBQlNy50d7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-16089"><p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zZVySOlNpsJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the Company&#8217;s net deferred tax assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zgVOZU6KCUYa">Schedule
of Net Deferred Tax Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49D_20231231_zoKa37FeocX" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49F_20221231_zFmEtHCPGy01" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands of dollars)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zof6IgjI7NRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzVPk_zzEu0bznNSig" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: justify">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18573">2,005</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18574">896</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzVPk_zzj6ANgkgWDc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18575">675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18576">299</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability_iI_pn3n3_maDTAGzVPk_zWUnvKIYM492" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FBLG:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18577">367</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="FBLG:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18578">435</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzVPk_zw5gAXVTkeij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18579">156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18580">81</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzVPk_zOff63TXUi01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18581">123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18582">17</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsDerivativeInstruments_iI_pn3n3_maDTAGzVPk_zJEuhrbFNNH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDerivativeInstruments" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18583">31</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzVPk_maDTANzrSY_zGxD84s8cJi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18584">3,326</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18585">1,759</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_pn3n3_zTyyXVBVfxv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_iNI_pn3n3_di_maDITLzuqP_zVFjhlXtF8P7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FBLG:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18586">380</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="FBLG:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18587">462</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_maDITLzuqP_zGQ8CV25vpLl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18588">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesUnamortizedDebtDiscount_iNI_pn3n3_di_maDITLzuqP_zioBQTZ1W2Bj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Unamortized debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1010">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="FBLG:DeferredTaxLiabilitiesUnamortizedDebtDiscount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18589">31</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzuqP_msDTANzrSY_zTgYuoWn5gI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18590">391</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18591">493</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzrSY_zjv9ACfJB2l3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18592">2,935</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18593">1,266</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzrSY_zaO9ru3yPtf4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1020">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zFmecsOB2FJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was initially formed as an LLC and was converted to a Delaware corporation in December 2021. As a result of generating net operating
losses during the years ended December 31, 2023 and 2022, the Company had <span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_do_c20230101__20231231_zqpqr8sTM2Ih" title="Income tax expenses"><span id="xdx_90D_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_do_c20220101__20221231_zpvOMOSR3Lf" title="Income tax expenses"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD" id="ixv-18594"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD" id="ixv-18595">no</ix:nonFraction></ix:nonFraction></span></span> income tax expense for years ended December 31, 2023 and
2022. As of December 31, 2023, the Company had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20231231_zzg8Ahi5mNS6" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18596">9,547</ix:nonFraction></span> thousand.
The federal NOL carries forward indefinitely and may become subject to an annual limitation in the event of certain cumulative changes
in the ownership interest. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income
or tax liabilities. Subsequent ownership changes may further affect the limitation in future years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental
to research and experimentation (&#8220;R&amp;E&#8221;) activities under IRC Section 174. While taxpayers historically had the option
of deducting these expenses under Internal Revenue Code (&#8220;IRC&#8221;) Section 174, the December 2017 Tax Cuts and Jobs Act mandates
capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection
with R&amp;E activities in the United States must be amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside
the United States must be amortized over a 15-year period. R&amp;E activities are broader in scope than qualified research activities
considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an
analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization
and amortization of its R&amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect
R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company has included the impact
of this provision, which results in a deferred tax asset of approximately $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_c20231231_z52aJ2Mc9QVf" title="Deferred tax assets"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18597">680</ix:nonFraction></span> thousand as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated the positive and negative evidence bearing upon the realizability of the Company&#8217;s net deferred tax assets and has
determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result,
the Company has recorded a full valuation allowance at December 31, 2023 and 2022. The Company will continue to assess the realizability
of its deferred tax assets going forward and will adjust the valuation allowance as needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, the Company had <span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20231231_z59Ay7r2cY06" title="Uncertain tax positions"><span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20221231_zLijGq7bmyH9" title="Uncertain tax positions"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD" id="ixv-18598"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD" id="ixv-18599">no</ix:nonFraction></ix:nonFraction></span></span> uncertain tax positions. The Company recognizes both interest and penalties associated
with unrecognized tax benefits as a component of income tax expense. The Company has not recorded any interest or penalties for unrecognized
tax benefits since its inception, and no taxes are due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-16306"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zCLqrIYI2o52" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zPKT8WWMx8l8">Leases, Commitments and Contingencies</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company had entered into two short-term lease agreements for lab and office space. The Company opted on March
30, 2022, to extend the lease term for one of its leases for lab and office space, with a commencement date for the lease extension on
May 1, 2022. The extended lease term was <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20211231_zNWSb3bjMqCe" title="Extended lease term"><ix:nonNumeric contextRef="AsOf2021-12-31" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-18600">126 months</ix:nonNumeric></span> and was accounted for as an operating lease under the ASC 842 guidance for lease
accounting. A right-of-use lease asset and tenant improvement allowance receivable with a combined total of $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--ShortTermLeaseAgreementMember_zFyVFAjEw8el" title="Operating lease right-of-use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31_custom_ShortTermLeaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18601">2,799</ix:nonFraction></span> thousand and a lease
liability of $<span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--ShortTermLeaseAgreementMember_zbD1czDHoJbk" title="Lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31_custom_ShortTermLeaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18602">2,799</ix:nonFraction></span> thousand were recorded at the time of the extension. This lease was terminated as of July 31, 2022, and the remaining
balances of the right-of-use asset, tenant improvement allowance receivable, and lease liability were written off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expanded the scope and extended for six months the term for the remaining lease for temporary lab and office space on July 1,
2022, then further expanded the scope on August 1, 2022, and October 7, 2022, which increased the monthly license fee to $<span id="xdx_905_ecustom--LicenseFee_iI_pn3n3_c20231231_zfIdHlCa3wXf" title="License fee"><ix:nonFraction name="FBLG:LicenseFee" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18603">15</ix:nonFraction></span> thousand
per month. In January 2023, the Company extended this lease for an additional six months and it expired at the end of June 2023. This
lease for temporary lab and office space was accounted for as a short-term lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2022, the Company entered into a lease agreement for office space with a term of <span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20221031_zfUEngX8MJ6a" title="Extended lease term"><ix:nonNumeric contextRef="AsOf2022-10-31" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-18604">62 months</ix:nonNumeric></span>, which expires on November 30, 2027.
This lease will be accounted for as an operating lease under the ASC 842 guidance for lease accounting. A right-of-use lease asset and
lease liability of $<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221031__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zBbz7GvV0kX8" title="Operating lease right-of-use asset"><span id="xdx_90C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20221031__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zLyqbpYaBJP7" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-10-31_custom_LeaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18605"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-10-31_custom_LeaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18606">2,293</ix:nonFraction></ix:nonFraction></span></span> thousand each were recorded at inception of the lease term using a discount rate of <span id="xdx_900_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_c20221031__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zZ6utFKyho7b" title="Operating lease discount rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2022-10-31_custom_LeaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18607">7.5</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company entered into a new lease for temporary lab and office space for its research operations. This lease has a term
of <span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20230630_zocVOGhQTBr3" title="Extended lease term"><ix:nonNumeric contextRef="AsOf2023-06-30" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-18608">12 months</ix:nonNumeric></span> and monthly rent of $<span id="xdx_90B_eus-gaap--PaymentsForRent_pn3n3_c20230601__20230630_zirCUd32eMfc" title="Monthly rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-06-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18609">6</ix:nonFraction></span> thousand and will be accounted for as a short-term lease. This lease commenced in August 2023. In
September 2023, the Company entered into an amendment of this lease to additional space, and the monthly rent increased to $<span id="xdx_909_eus-gaap--PaymentsForRent_pn3n3_c20230901__20230930_zocx9o0Xrx54" title="Monthly rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-09-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18610">7</ix:nonFraction></span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense for the years ended December 31, 2023 and 2022, was $<span id="xdx_90A_eus-gaap--PaymentsForRent_pn3n3_c20230101__20231231_z2tbG4unDuSg" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18611">685</ix:nonFraction></span> thousand and $<span id="xdx_900_eus-gaap--PaymentsForRent_pn3n3_c20220101__20221231_z8IdFn2081Yd" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18612">392</ix:nonFraction></span> thousand, respectively. As of December 31, 2023, noncancelable
lease payments under operating leases were $<span id="xdx_905_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--OperatingLeasesMember_zxwa3Iw5OoB2" title="Noncancelable lease payments"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="AsOf2023-12-31_custom_OperatingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18613">2,017</ix:nonFraction></span> thousand and noncancelable lease payments under short-term leases were $<span id="xdx_902_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ShorttermLeasesMember_zXEYXhLgz22i" title="Noncancelable lease payments"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="AsOf2023-12-31_custom_ShorttermLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18614">45</ix:nonFraction></span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-16350"><p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zCRnIEfM2V4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of operating lease liabilities as of December 31, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zf9BJJ1cuxO5">Schedule
of Operating Lease Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_494_20231231_zf2juYoMbqC8" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">(in thousands of dollars)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzBez_zhOzemaUykAg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18615">477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzBez_z9nlfMXuyQzk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18616">487</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzBez_zqXVngmSJso3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18617">544</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzBez_zD9NssKUpFKf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18618">509</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzBez_ze69Bh99KOJi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1076">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzBez_zovClIaNjQ5f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18619">2,017</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zcY2uAGnGOwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18620">270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z4Z5KHIIc0wg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18621">1,747</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zMB0sVExmf1l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Current lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18622">362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zqnsXs4umSc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18623">1,385</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zw00hGigI3wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-16446"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5nBpXuPHj97" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zD6hWj5F1Wz">Related Party Transactions</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">The
Company repaid in April 2022 the remaining Parent company payable of $<span id="xdx_90A_eus-gaap--RepaymentsOfRelatedPartyDebt_pn3n3_c20220401__20220430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_z0CHr6Zmlb8f"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-04-012022-04-30_custom_FibroGenesisMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18624">225</ix:nonFraction>
</span></span><span style="background-color: white">thousand<span style="background-color: white">, which was outstanding at December
31, <span style="background-color: white">2021</span></span>. In July 2022, the Company loaned $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20220731_zNIArsqJy5U8"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18625">300</ix:nonFraction>
</span></span><span style="background-color: white">thousand to the Parent on a one-year note bearing no interest. In October 2022, the
Company loaned $<span id="xdx_904_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20221031_znXza2ik8YKf"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2022-10-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18626">60</ix:nonFraction></span></span> <span style="background-color: white">thousand
to the Parent on a one-year note bearing no interest and this note was repaid before December 31, 2022. In April 2023, FibroGenesis repaid
in full the $<span id="xdx_90A_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20230430_zifVC6LjHs1l"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-04-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18627">300</ix:nonFraction></span></span> <span style="background-color: white">thousand
Parent company receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 7, the Company acquired from FibroGenesis certain in-process research and development and patent assets through Patent
Assignment and Intellectual Property Cross-License Agreements. The Patent Assignment Agreement transferred the right, title and interest
in and to certain patents from FibroGenesis to the Company for further development. The Intellectual Property Cross-License Agreement
grants to the Company exclusive rights to patents owned by FibroGenesis in a limited field of use, which includes the diagnosis, treatment,
prevention and palliation of a) spinal diseases, disorders, or conditions, b) cancer, c) orthopedics diseases, disorders or conditions,
and d) multiple sclerosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company entered into an Agreement Regarding Right of First Negotiation (&#8220;ROFN Agreement&#8221;) with its Parent,
FibroGenesis. In exchange for FibroGenesis&#8217; consent to amend the Certificate of Incorporation to a) eliminate upon IPO, Direct
Listing, or Sale of the Company the Series A Preferred Stock $<span id="xdx_907_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zeVVni01342l" title="Liquidation preference"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="AsOf2023-01-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18628">35,000</ix:nonFraction></span> thousand liquidation preference, b) make the Series B Preferred
Stock liquidation preference equal to Series &#8220;A&#8221; Preferred Stock, and c) to provide that upon IPO, Direct Listing, or Sale
of the Company Series A Preferred Stock will be canceled for no consideration, FibroBiologics agreed to pay to FibroGenesis <span id="xdx_900_ecustom--PercentageOfGrossProceedsFromEquityInvestments_pid_dp_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_zR3a02I16Y08" title="Percentage of gross proceeds from equity investments"><ix:nonFraction name="FBLG:PercentageOfGrossProceedsFromEquityInvestments" contextRef="From2023-01-012023-01-31_custom_FibroGenesisMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18629">15</ix:nonFraction></span>% of the
gross proceeds from any equity investments in FibroBiologics prior to an IPO, Direct Listing or Sale of the Company. In addition, FibroBiologics
will receive a five-year right of first negotiation if FibroGenesis decides to license externally any of its technology. In January 2023,
the Company amended its Certificate of Incorporation to reflect these changes, recorded a derivative liability of $<span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_c20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zaVBJu9Tipnd" title="Related party transaction, expenses"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-01-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" id="ixv-18630">2,573</ix:nonFraction></span> thousand for
the expected future payments to FibroGenesis, and paid $<span id="xdx_90F_ecustom--PaymentsForEquityInvestments_pn3n3_c20230101__20230131_zZzryng7GmD7" title="Payments for equity investments"><ix:nonFraction name="FBLG:PaymentsForEquityInvestments" contextRef="From2023-01-012023-01-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18631">323</ix:nonFraction></span> thousand to FibroGenesis for <span id="xdx_902_ecustom--PercentageOfGrossProceedsFromEquityInvestments_dp_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_ziQNRmxG1tfh" title="Percentage of gross proceeds from equity investments"><ix:nonFraction name="FBLG:PercentageOfGrossProceedsFromEquityInvestments" contextRef="From2023-01-012023-01-31_custom_FibroGenesisMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18632">15</ix:nonFraction></span>% of the gross proceeds from equity issued
by the Company in December 2022. Based on its relationship to Series A Preferred Stock as described above, the derivative liability was
recorded first against the net Parent Investment and then to Additional paid-in capital after the net Parent Investment was eliminated.
During the year ended December 31, 2023, the Company raised gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_pn3n3_c20230101__20231231_zUFfRpabf6k7" title="Proceeds from (repayments of) related party debt"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18633">16,418</ix:nonFraction></span> thousand from equity issuances and paid $<span id="xdx_909_ecustom--PaymentsForEquityInvestments_pn3n3_c20230101__20231231_zdKijQ4HKGq" title="Payments for equity investments"><ix:nonFraction name="FBLG:PaymentsForEquityInvestments" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18634">2,322</ix:nonFraction></span>
thousand of these proceeds to FibroGenesis. Amounts paid in excess of the derivative liability are recorded as other loss in the Statements
of Operations. There was <span id="xdx_907_eus-gaap--DerivativeLiabilities_iI_pn3n3_do_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_zDGjWxvMnXt2" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-12-31_custom_FibroGenesisMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD" id="ixv-18635">no</ix:nonFraction></span> derivative liability and a payable of $<span id="xdx_902_ecustom--DerivativeLiabilitiesPayableToRelatedParties_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_zRiEp6s6poW9" title="Derivative liabilities payable to related parties"><ix:nonFraction name="FBLG:DerivativeLiabilitiesPayableToRelatedParties" contextRef="AsOf2023-12-31_custom_FibroGenesisMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18636">141</ix:nonFraction></span> thousand to FibroGenesis as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-16486"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zb9c2CAOUUj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_zk9OGRxvCbyg">Share-Based Compensation</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company adopted on August 10, 2022, and the stockholders approved on August 18, 2022, the 2022 Stock Plan (the &#8220;Plan&#8221;). The
Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards,
restricted stock unit awards, and other stock awards. The Plan, through the grant of stock awards, is intended to help the Company secure
and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of
the Company and provide a means by which the eligible recipients may benefit from increases in value of the common stock. In September
2022, the Company issued a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220901__20220930_zka9horPxiG9" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-09-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18637">101,250</ix:nonFraction></span> options with a strike price of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20220930_zc3qfwciguw7" title="Strike price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18638">3.28</ix:nonFraction></span> per share to employees, directors, and scientific advisory
board members under this Plan. In February 2023, the Company issued an additional total of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230201__20230228_zSLJPrlLJs1h" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-02-012023-02-28" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18639">3,689,750</ix:nonFraction></span> options with a strike price of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230228_znbPofZfhsg3" title="Strike price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-02-28" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18640">2.28</ix:nonFraction></span>
per share to employees and directors under this Plan. In August 2023, a total of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831_zfSBCI55HU08" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-08-012023-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18641">2,500</ix:nonFraction></span> options with a strike price of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230831_z9VpmBUofC6f" title="Strike price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18642">3.28</ix:nonFraction></span> per share
were forfeited. Generally, awards granted by the Company vest over four years and have an exercise price equal to the estimated fair
value of the common stock as determined by the board of directors with consideration given to contemporaneous valuations of the Company&#8217;s
common stock prepared by an independent third-party valuation firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of December 31, 2023 and 2022, respectively, there were <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231_zOFJaGZrd4W1" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18643">8,711,500</ix:nonFraction></span> shares and <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231_zVS6Et3ol1f9" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18644">12,398,750</ix:nonFraction></span> shares available for future issuance under the
Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="ixv-16522"><p id="xdx_89B_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zh0yQPadnZPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
compensation expense is recognized in the Statements of Operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B3_zUX2A2LrRE1b">Schedule
of Stock Based Compensation Expense</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49B_20230101__20231231_z9eSO3sapg91" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49E_20220101__20221231_z702WuTnT3z4" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands of dollars)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zhcrZZFUICT" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18645">262</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18646">115</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTRmoKvIK3Ik" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18647">1,503</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18648">150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zXxazF0T9EQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18649">1,765</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18650">265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zb2tNHog1mEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
compensation expense for the year ended December 31, 2022, includes $<span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20220101__20221231_zM0EQhjuM81" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18651">168</ix:nonFraction></span> thousand of expense for non-voting common stock issued to the
Board of Directors and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="ixv-16591"><p id="xdx_89A_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zHxjvMNJjb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Unrecognized
stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized
as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zWdVvGnHmbtl">Schedule
of Unvested Awards and Weighted Average Period</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Unrecognized stock-based compensation expense (in thousands)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20231231_zYSDmsjuEUQ" title="Unrecognized stock-based compensation expense" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18652">5,039</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected weighted-average period compensation costs to be recognized (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231_zcpL9ld1uW9b" title="Expected weighted average period compensation cost"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-18653">3.0</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zjJfVT3RGgU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-16619"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwqf5TqVMjnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
summary of the Company&#8217;s stock option activity is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B2_zqqTOyjFUZgg">Schedule
of Stock Option Activity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Remaining Contractual Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value (in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Outstanding as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbP6kgzJ6Gcb" title="Stock options, outstanding, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18654">101,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBz6REdlYfF4" title="Weighted-average exercise price, outstanding, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18655">3.28</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z72N8IwOlim2" title="Weighted average remaining contractual life (years), outstanding" style="width: 11%; text-align: right"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-18656">9.4</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOpPuF3DMiGe" title="Stock options, outstanding, beginning balance" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1157">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Ci2rNYjzti" title="Number of options, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18657">3,689,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXvfUXGGWWLl" title="Weighted-average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18658">2.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqdx6fStLRpb" title="Weighted average remaining contractual life (years), granted" style="text-align: right"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="FBLG:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="ixv-18659">10.0</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7Xzq41y6Pl8" title="Exercise of stock options, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1165">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4xd9My6xiWb" title="Weighted-average exercise price, exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z70lZiLhfzve" title="Number of options,  forfeited/cancelled" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18660">2,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRldCJLlibJk" title="Weighted-average exercise price, forfeited/ cancelled" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18661">3.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTgq4surmE2j" title="Weighted average remaining contractual life (years), forfeited/canceled" style="text-align: right"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="FBLG:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" id="ixv-18662">8.7</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Outstanding as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSnTPuaaFv1d" title="Stock options, outstanding, ending balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18663">3,788,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHeGMDESVcwa" title="Weighted-average exercise price, outstanding, ending balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18664">2.31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmicfoetnQE4" title="Weighted average remaining contractual life (years), outstanding" style="text-align: right"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-18665">9.1</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlri9qo5oMm5" title="Stock options, outstanding, beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1181">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Exercisable as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNP45NBCRnB7" title="Number of options, exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18666">68,519</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKqLUqZV62Z8" title="Weighted-average exercise price, exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18667">3.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPzPEQo5P3Kg" title="Weighted average remaining contractual term, exercisable" style="text-align: right"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-18668">8.7</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3Z6Wgu1Fs5g" title="Stock options, outstanding, exercisable" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1189">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z6JLObo2IKgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-16757"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zW2ZWmdL32ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes
option pricing model using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B3_zs1LT43eQ5wi">Schedule
of Fair Value of Option Granted Black Scholes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_497_20230101__20231231_z0Jq0AAdL8Z7" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_492_20220101__20221231_zv9X23ehdzDk" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Assumptions:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_zLGdqDw2rX28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18669">3.9</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18670">4.1</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_zOB81iNekj4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18671">90</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18672">100</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zcOM7z7aJ6E3" title="Expected term"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-18673">7.0</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zPTTjRTBR7w5" title="Expected term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-18674">5.4</ix:nonNumeric></span> to <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zJUCTi2LkEL5" title="Expected term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-18675">6.4</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_zX4zcYzKkln9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected dividend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18676">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure" id="ixv-18677">0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_ztuJbgiEKRe8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
weighted-average grant date fair value of the options granted during the years ended December 31, 2023 and 2022 was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zPaivk3O5Cyd" title="Weighted-average grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-01to2023-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18678">1.80</ix:nonFraction></span> per share and
$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zE92Vuyjax82" title="Weighted-average grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18679">2.64</ix:nonFraction></span> per share, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-16848"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zUFhYfNdmdWj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zZiyznBGbnRh">Subsequent Events</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s registration statement filed with the Securities and Exchange Commission (SEC) was declared effective on January 24,
2024, and trading of the Company&#8217;s stock commenced on Nasdaq on January 31, 2024 (Direct Listing). <span style="background-color: white">In
January 2024, in conjunction with <span style="background-color: white">its</span> Direct Listing, <span style="background-color: white">the Company</span> issued <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhNiqXno1mM2" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-012024-01-31_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18680">2,500</ix:nonFraction></span> shares of Series C Preferred Stock with super voting rights to
our CEO. </span> Upon the effectiveness of <span style="background-color: white">its</span> registration with the SEC, the Company obtained a public company directors and
officers insurance policy at a cost of $<span id="xdx_901_ecustom--InsurancePolicyCost_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zK7qwlwueBT9" title="Insurance policy cost"><ix:nonFraction name="FBLG:InsurancePolicyCost" contextRef="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember_custom_DirectorsAndOfficersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18681">756</ix:nonFraction></span>
thousand, which will be expensed over the one-year life of the policy. Upon approval from Nasdaq and prior to <span style="background-color: white">the Direct Listing</span>, the
$<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z4oTAv7qYPv2" title="Application fee"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18682">270</ix:nonFraction></span>
thousand remainder of the listing application fee was due and paid to Nasdaq. Also upon completion of the Direct Listing, the
Company <span style="background-color: white">paid </span> $<span id="xdx_90D_eus-gaap--RepaymentsOfRelatedPartyDebt_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z4WjQU7PiGL9" title="Payable to its services as advisor"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18683">200</ix:nonFraction></span>
thousand to Maxim for its services as advisor on the Direct Listing, and recorded a $<span id="xdx_902_ecustom--CommitmentFee_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zL6dCV1oSyn8" title="Commitment fee"><ix:nonFraction name="FBLG:CommitmentFee" contextRef="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD" id="ixv-18684">2,000</ix:nonFraction></span>
thousand payable for the commitment fee and issued <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zTm9og39D99d" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18685">1,299,783</ix:nonFraction></span>
warrants to purchase common stock shares at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zUjCo1ho6M95" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" id="ixv-18686">21.54</ix:nonFraction></span>
and an expiration of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zJFS7VRaQbNk" title="Warrant term"><ix:nonNumeric contextRef="AsOf2024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-18687">five
years</ix:nonNumeric></span> from the Direct Listing, which were both due to the investors in the Share Purchase Agreement as described in Note
8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2024, the
Company sold a total of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240201__20240229__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAhBPDRKvNQ7" title="Shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-012024-02-29_custom_SharePurchaseAgreementMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-18688">142,298</ix:nonFraction></span>
shares for $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pdn3_c20240201__20240229__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBkHJsZtjcU6" title="Shares sold, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-02-012024-02-29_custom_SharePurchaseAgreementMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD" id="ixv-18689">1,921</ix:nonFraction></span>
thousand through the Share Purchase Agreement described in Note 8.</p>

</ix:nonNumeric><p id="xdx_818_zP2fz7qEQ4S9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 134; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>














































































</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ex4-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE REGISTRANT&rsquo;S SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
PURSUANT TO SECTION 12 OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 12, 2024 FibroBiologics, Inc. (&ldquo;FibroBiologics&rdquo;, the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;,
and &ldquo;our&rdquo;) has 32,492,068 shares of common stock, $0.00001 par value per share, and 2,500 shares of our Series C Preferred
Stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description summarizes certain important terms of our capital stock. We adopted an amended and restated certificate of incorporation
that became effective in connection with the Direct Listing, and this description summarizes the provisions included in such document.
It is only a summary and does not purport to be complete. For a complete description of the matters set forth herein, refer to our amended
and restated certificate of incorporation and our bylaws, which are incorporated by reference as an exhibit to the Annual Report on Form
10-K of which this Exhibit 4.2 forms a part, and to the applicable provisions of the General Corporation Law of the State of Delaware
(the &ldquo;DGCL&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Direct Listing, (i) all of our outstanding Series A Preferred Stock, all of which were held by FibroGenesis, were
automatically canceled without the payment of additional consideration by or to the holder thereof, (ii) all of our outstanding non-voting
common stock automatically converted, without the payment of additional consideration by or to the holder thereof, into voting common
stock, on a one-for-one basis, (iii) all of our outstanding Series B Preferred Stock and all of our outstanding Series B-1 Preferred
Stock automatically converted, without the payment of additional consideration by or to the holder thereof, into common stock, on a one-for-one
basis and (iv) all of our outstanding Series C Preferred Stock remained Series C Preferred Stock. Immediately after the Direct Listing,
our issued and outstanding capital stock consisted of voting common stock and Series C Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the Reverse Stock Split and the automatic conversion, in connection with the Direct Listing, of all of our outstanding
non-voting common stock and convertible preferred stock (being our Series B Preferred Stock and Series B-1 Preferred Stock), as of January
31, 2024, there were 32,492,068 shares of our common stock outstanding, held by 1,169 stockholders of record, and 2,500 shares of our
Series C Preferred Stock, being all of the authorized Series C Preferred Stock, outstanding, held by one stockholder of record. Pursuant
to our amended and restated certificate of incorporation, our board of directors will have the authority, without stockholder approval
except as required by Nasdaq rules, to issue additional shares of our capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized
Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation and our bylaws, authorize us to issue 110,000,000 shares of capital stock, which may
consist of: (i) 100,000,000 shares of common stock, par value $0.00001 per share and (ii) 10,000,000 shares of preferred stock, par value
$0.00001 per share, of which 2,500 shares are designated as Series C Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation provides that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders
    of common stock have voting rights for the election of our directors and all other matters requiring stockholder action, except with
    respect to amendments to our certificate of incorporation that alter or change the powers, preferences, rights or other terms of
    any outstanding preferred stock if the holders of such affected series of preferred stock are entitled to vote on such an amendment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders
    of common stock are entitled to one vote per share on matters to be voted on by stockholders and are also entitled to receive such
    dividends, if any, as may be declared from time to time by our board of directors in its discretion out of funds legally available
    therefor;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    payment of dividends, if any, on the common stock will be subject to the prior payment of dividends on any outstanding preferred
    stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    our liquidation or dissolution, the holders of common stock will be entitled to receive pro rata all assets remaining available for
    distribution to stockholders after payment of all liabilities and provision for the liquidation of any shares of preferred stock
    outstanding at that time; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    stockholders have no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable
    to the common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation provides that shares of preferred stock may be issued from time to time in one or more
series. Our board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating,
optional or other special rights, if any, and any qualifications, limitations and restrictions thereof, applicable to the shares of each
series. Our board of directors is able to, without stockholder approval, issue preferred stock with voting and other rights that could
adversely affect the voting power and other rights of the holders of the common stock and could have anti-takeover effects. The ability
of our board of directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing
a change of our control or the removal of our existing management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
C Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is currently one series of designated preferred stock, being the Series C Preferred Stock, 2,500 total shares of which are authorized
and all of which 2,500 authorized shares of Series C Preferred Stock are issued, outstanding and held by Pete O&rsquo;Heeron, our founder,
Chief Executive Officer and Chairperson of our board of directors. The outstanding shares of Series C Preferred Stock are fully paid
and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock rank senior to our common stock upon our liquidation, dissolution, winding up or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock is entitled to vote on any matter to be voted on by our stockholders, in each case voting together with the
holders of our common stock as a single class, and each share of Series C Preferred Stock is entitled to 13,000 votes. The Series C Preferred
Stock is entitled to receive the same prior notice of any meeting of stockholders as provided to our common stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock is not entitled to any dividend, whether payable in cash, stock or property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the superior rights of other, then outstanding, classes or series of preferred stock, in the event of any liquidation, dissolution
or winding up of our company, the Series C Preferred Stock shall be entitled to receive, prior and in preference to any distribution
in such liquidation, dissolution or winding up of any of our assets to the holders of our common stock, a liquidation preference of $18.00
per share (subject to appropriate adjustment in the event of any stock split, combination or other similar recapitalization).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock may be converted at any time as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    the option of the holder, a share of Series C Preferred Stock may be converted into one share of our common stock; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    the election of the holders of a majority of the then outstanding shares of Series C Preferred Stock, all outstanding shares of Series
    C Preferred Stock may be converted into an equal number of shares of our common stock, on a one-for-one basis.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Series C Preferred Stock is subject to a mandatory conversion upon any transfer of the Series C Preferred Stock. Each share
of Series C Preferred Stock shall automatically convert, without the payment of additional consideration by or to the holder thereof,
into one fully paid and non-assessable share of our common stock, upon any transfer of any share of Series C Preferred Stock, whether
or not for value. Any shares of Series C Preferred Stock converted as described above must be retired and cancelled and may not be reissued
as shares of such series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
as long as the Series C Preferred Stock remain outstanding, the aggregate number of shares of Series C Preferred Stock then outstanding,
shall be proportionately adjusted for any increase or decrease in the number of issued shares of our common stock resulting from a subdivision
or combination of our common stock or other similar recapitalization, in each case effected without our receipt of consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series C Preferred Stock is subject to an irrevocable proxy issued by Pete O&rsquo;Heeron, the holder of all of the Series C Preferred
Stock, in favor and for the benefit of, our board of directors, granting our board of directors the irrevocable proxy, for as long as
the Series C Preferred Stock remains outstanding, to vote all of the Series C Preferred Stock on all matters on which the Series C Preferred
Stock are entitled to vote, in any manner that our board of directors may determine in its sole and absolute discretion; provided, however,
that such irrevocable proxy shall not, without the written consent of Pete O&rsquo;Heeron, permit our board of directors to vote the
Series Preferred Stock with respect to any proposal to amend, delete or waive any rights of Pete O&rsquo;Heeron with respect to the Series
C Preferred Stock as set forth in our amended and restated certificate of incorporation. In light of the superior voting rights associated
with the Series C Preferred Stock, the irrevocable proxy is intended to ensure that such superior voting rights are utilized in our best
interest and to avoid or mitigate conflicts that may arise in the future for Pete O&rsquo;Heeron as an individual stockholder employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of our Certificate of Incorporation, Bylaws and Delaware Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring
or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral
takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include
the items described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Classified
Board</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation requires our board of directors to be divided into three classes serving staggered
three-year terms, with one class elected each year. The classification of directors has the effect of making it more difficult for stockholders
to change the composition of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stockholder
Actions by Written Consent</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation requires that, any action required or permitted to be taken by our stockholders must
be effected at a duly-called annual or special meeting of our stockholders and may not be effected by written consent in lieu of a meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
Notice Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election
as directors or new business to be brought before meetings of our stockholders. These procedures specify that notice of stockholder proposals
must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken, and define what is
considered timely. Our bylaws specify the requirements as to form and content of all stockholder notices. These requirements may preclude
stockholders from bringing matters before the stockholders at an annual or special meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Director
Removal and Vacancies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation requires that, a member of our board of directors or our entire board may only be removed
for cause, and then only by the affirmative vote of the holders of at least 662/3% in voting power of our stock entitled to vote on such
removal. In addition, our amended and restated certificate of incorporation requires that, any newly created directorship that results
from an increase in the number of directors or any vacancy on our board of directors, must be filled solely by the affirmative vote of
a majority of the total number of directors then in office, even if less than a quorum, or by a sole remaining director and may not be
filled by the stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Supermajority
Voting Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation requires the affirmative vote of the holders of at least 662/3% in voting power of
our stock entitled to vote thereon to (i) amend, alter or repeal our bylaws and adopt new bylaws or (ii) to amend, alter, change or repeal,
or adopt any provision inconsistent with, certain provisions of our certificate of incorporation, including the provisions relating to
the requirement to have a classified board, the provisions relating to the removal of directors, the provision precluding stockholder
action by written consent and the choice of forum provision in our amended and restated certificate of incorporation (as explained below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Undesignated
Preferred Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation provides for authorized shares of preferred stock. The existence of authorized but
unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger,
tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were
to determine that a takeover proposal is not in the best interests of our shareholders, our board of directors could cause shares of
preferred stock to be issued without shareholder approval in one or more private offerings or other transactions that might dilute the
voting or other rights of the proposed acquirer or insurgent shareholder or shareholder group. In this regard, our amended and restated
certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued
shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution
to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these
holders and may have the effect of delaying, deterring or preventing a change in our control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive
Forum</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum,
the (i) Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court
for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a) any derivative action
or proceeding brought on our behalf, (b) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers
or other employees to us or our stockholders, (c) any action arising pursuant to any provision of the DGCL, our certificate of incorporation
or our bylaws or (d) any action asserting a claim governed by the internal affairs doctrine and (ii) to the fullest extent permitted
by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint
asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant
to such complaint. The foregoing provision would not preclude stockholders that assert claims under the Exchange Act from bringing such
claims in federal court, to the extent that the Exchange Act confers exclusive federal jurisdiction over such claims, subject to applicable
law. Our choice of forum provision may impose additional litigation costs on stockholders in pursuing claims and may limit a stockholder&rsquo;s
ability to bring a claim in a judicial forum that it believes to be favorable for disputes with us or any of our directors, officers
or other employees, which may discourage lawsuits with respect to such claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitation
of Liability and Indemnification of Directors and Officers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws provide that our directors and officers will be indemnified by us to the fullest extent authorized by Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions
also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action,
if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder&rsquo;s investment may be adversely affected
to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
We believe that these provisions and insurance are necessary to attract and retain talented and experienced directors and officers. In
addition, in connection with the Direct Listing, we entered into separate indemnification agreements with each of our directors and executive
officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Section
203 of the DGCL</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a Delaware corporation, we are subject to the provisions of Section 203 of the DGCL. This statute prevents certain Delaware corporations,
under certain circumstances, from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder.&rdquo; In general,
Section 203 defines an &ldquo;interested stockholder&rdquo; as an entity or person who, together with the person&rsquo;s affiliates and
associates, beneficially owns 15% or more of the outstanding voting stock of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;business combination&rdquo; includes a merger or sale of more than 10% of our assets. However, the above provisions of Section
203 of the DGCL do not apply if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    business combination takes place more than three years after the interested stockholder became an &ldquo;interested stockholder;&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    board of directors approves the transaction that made the stockholder an &ldquo;interested stockholder&rdquo; prior to the date of
    the transaction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">after
    the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at
    least 85% of our voting stock outstanding, other than statutorily excluded shares of common stock; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    or subsequent to the date of the transaction, the business combination is approved by our board of directors and authorized at a
    meeting of our stockholders, and not by written consent, by an affirmative vote of at least two-thirds of the outstanding voting
    stock not owned by the interested stockholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on the Nasdaq Global Market under the symbol &ldquo;FBLG&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is VStock Transfer LLC. The transfer agent and registrar&rsquo;s address is 18 Lafayette
Place, Woodmere, NY 11598. The transfer agent and registrar can be contacted by phone at: (212) 828-8436.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14
<SEQUENCE>3
<FILENAME>ex14.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
14</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FibroBiologics,
Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code
of Ethics and Business Conduct</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">1.
<FONT STYLE="background-color: white"><U>Introduction </U></FONT><U>and Purpose</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
The Board of Directors of FibroBiologics, Inc. (together with its subsidiaries, the &ldquo;<B>Company</B>&rdquo;) has adopted this Code
of Ethics and Business Conduct (the &ldquo;<B>Code</B>&rdquo;) in order to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
promote full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to,
the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) and in other public communications made by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
promote compliance with applicable governmental laws, rules and regulations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
promote the protection of Company assets, including corporate opportunities and confidential information;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
promote fair dealing practices;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
deter wrongdoing; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
ensure accountability for adherence to the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
All directors, officers and employees are required to be familiar with the Code, comply with its provisions and report any suspected
violations as described below in Section 10, Reporting and Enforcement. The Company expects its directors, officers and employees to
exercise reasonable judgment when conducting the Company&rsquo;s business. The Company encourages its directors, officers and employees
to refer to the Code frequently to ensure that they are acting within both the letter and spirit of the Code. The Company also understands
that the Code will not provide an answer to every problem you may encounter or address every concern you may have about conducting the
Company&rsquo;s business ethically and legally. In these situations, or if you otherwise have questions or concerns about the Code, the
Company encourages you to speak with your supervisor (if applicable) or, if you are uncomfortable doing that, with the Chief Compliance
Officer. Unless and until another Chief Compliance Officer is named, the Chief Financial Officer shall serve in this capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">2.&nbsp;<FONT STYLE="background-color: white"><U>Honest
and Ethical Conduct</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
The Company&rsquo;s policy is to promote high standards of integrity by conducting its affairs honestly and ethically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
Each director, officer and employee must act with integrity and observe the highest ethical standards of business conduct in his or her
dealings with the Company&rsquo;s customers, suppliers, partners, service providers, competitors, employees and anyone else with whom
he or she has contact in the course of performing his or her job.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">3.&nbsp;<FONT STYLE="background-color: white"><U>Conflicts
of Interest</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
A conflict of interest occurs when an individual&rsquo;s private interest (or the interest of a member of his or her family) interferes,
or even appears to interfere, with the interests of the Company as a whole. A conflict of interest can arise when an employee, officer
or director (or a member of his or her family) takes actions or has interests that may make it difficult to perform his or her work for
the Company objectively and effectively. Conflicts of interest also arise when an employee, officer or director (or a member of his or
her family) receives improper personal benefits as a result of his or her position in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
Loans by the Company to, or guarantees by the Company of obligations of, employees or their family members are of special concern and
could constitute improper personal benefits to the recipients of such loans or guarantees, depending on the facts and circumstances.
Loans by the Company to, or guarantees by the Company of obligations of, any director, officer, or their family members are expressly
prohibited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
Whether or not a conflict of interest exists or will exist can be unclear. Conflicts of interest should be avoided unless specifically
authorized as described in Section 3.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
Persons other than directors and executive officers who have questions about a potential conflict of interest or who become aware of
an actual or potential conflict should discuss the matter with, and seek a determination and prior authorization or approval from, their
supervisor or the Chief Compliance Officer. A supervisor may not authorize or approve conflict of interest matters or make determinations
as to whether a problematic conflict of interest exists without first providing the Chief Compliance Officer with a written description
of the activity and seeking the Chief Compliance Officer&rsquo;s written approval. If the supervisor is themself involved in the potential
or actual conflict, the matter should instead be discussed directly with the Chief Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5
Directors and executive officers must seek determinations and prior authorizations or approvals of potential conflicts of interest exclusively
from the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">4.&nbsp;<FONT STYLE="background-color: white"><U>Compliance
</U></FONT><U>with Laws, Rules and Regulations</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
Employees, officers and directors should comply, both in letter and spirit, with all applicable laws, rules and regulations in the cities,
states and countries in which the Company operates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
Although not all employees, officers and directors are expected to know the details of all applicable laws, rules and regulations, it
is important to know enough to determine when to seek advice from appropriate personnel. Questions about compliance should be addressed
to the Legal Department. Until the Company hires General Counsel and establishes a Legal Department, the Chief Executive Officer and
the Chief Financial Officer together shall serve as the Legal Department.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
No director, officer or employee may purchase or sell any Company securities while in possession of material nonpublic information regarding
the Company, nor may any director, officer or employee purchase or sell another company&rsquo;s securities while in possession of material
nonpublic information regarding that company. It is against Company policies and illegal for any director, officer or employee to use
material nonpublic information regarding the Company or any other company to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
obtain profit for himself or herself; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
directly or indirectly &ldquo;tip&rdquo; others who might make an investment decision on the basis of that information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
The Company does not permit or condone bribes, kickbacks or other improper payments, transfers or receipts. No director, officer or employee
should offer, give, solicit or receive any money or other item of value for the purpose of obtaining, retaining or directing business
or bestowing or receiving any kind of favored treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
Many countries regulate international trade transactions, such as imports, exports and international financial transactions and prohibit
boycotts against countries or firms that may be &ldquo;blacklisted&rdquo; by certain groups or countries. The Company&rsquo;s policy
is to comply with these regulations and prohibitions even if compliance may result in the loss of some business opportunities. Employees
should learn and understand the extent to which international trade controls apply to transactions conducted by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">5.&nbsp;<FONT STYLE="background-color: white"><U>Disclosure</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
The Company&rsquo;s periodic reports and other documents filed with the SEC, including all financial statements and other financial information,
must comply with applicable federal securities laws and SEC rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
Each director, officer and employee who contributes in any way to the preparation or verification of the Company&rsquo;s financial statements
and other financial information must ensure that the Company&rsquo;s books, records and accounts are accurately maintained. Each director,
officer and employee must cooperate fully with the Company&rsquo;s accounting and internal audit departments, as well as the Company&rsquo;s
independent public accountants and counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
Each director, officer and employee who is involved in the Company&rsquo;s disclosure process must:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
be familiar with and comply with the Company&rsquo;s disclosure controls and procedures and its internal control over financial reporting;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
take all necessary steps to ensure that all filings with the SEC and all other public communications about the financial and business
condition of the Company provide full, fair, accurate, timely and understandable disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">6.&nbsp;<FONT STYLE="background-color: white"><U>Protection
and Proper Use of Company Assets</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
All directors, officers and employees should protect the Company&rsquo;s assets and ensure their efficient use. Theft, carelessness and
waste have a direct impact on the Company&rsquo;s profitability and are prohibited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
All Company assets should be used only for legitimate business purposes. Any suspected incident of fraud or theft should be reported
for investigation immediately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
The obligation to protect Company assets includes the Company&rsquo;s proprietary information. Proprietary information includes intellectual
property such as trade secrets, patents, trademarks, and copyrights, as well as business and marketing plans, engineering and manufacturing
ideas, designs, databases, records and any nonpublic financial data or reports. Unauthorized use or distribution of this information
is prohibited and could also be illegal and result in civil or criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
Business contributions to political campaigns are strictly regulated by federal, state, provincial and local law in the U.S. and many
other jurisdictions. Accordingly, all political contributions proposed to be made with the Company&rsquo;s funds must be coordinated
through and approved by the Chief Compliance Officer. Directors, officers and employees may not, without the approval of the Chief Compliance
Officer, use any Company funds for political contributions of any kind to any political candidate or holder of any national, state or
local government office. Directors, officers and employees may make personal contributions, but should not represent that they are making
contributions on the Company&rsquo;s behalf. Specific questions should be directed to the Chief Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<FONT STYLE="font-weight: normal; vertical-align: baseline; background-color: white"><U>Corporate Opportunities</U></FONT>. All directors,
officers and employees owe a duty to the Company to advance its interests when the opportunity arises. Directors, officers and employees
are prohibited from taking for themselves personally (or for the benefit of friends or family members) opportunities that are discovered
through the use of Company assets, property, information or position. Directors, officers and employees may not use Company assets, property,
information or position for personal gain (including gain of friends or family members). In addition, no director, officer or employee
may compete with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<FONT STYLE="font-weight: normal; vertical-align: baseline; background-color: white"><U>Confidentiality</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1
Directors, officers and employees should maintain the confidentiality of information entrusted to them by the Company or by its customers,
suppliers or partners, except when disclosure is expressly authorized or is required or permitted by law. Confidential information includes
all nonpublic information (regardless of its source) that might be of use to the Company&rsquo;s competitors or harmful to the Company
or its customers, suppliers or partners if disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2
Employees should take appropriate precautions to ensure that confidential or sensitive business information, whether it is proprietary
to the Company or another company, is not communicated within the Company except to employees who have a need to know such information
to perform their responsibilities for the Company. Subject to the exceptions in this Code, employees, officers and directors (other than
the Company&rsquo;s authorized spokespersons) must not discuss internal Company matters with, or disseminate internal Company information
to, anyone outside the Company, except as required in the performance of their Company duties and, if appropriate, after a confidentiality
agreement is in place.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3
The prohibition in the preceding paragraph applies particularly to inquiries concerning the Company from the media, market professionals
(such as securities analysts, institutional investors, investment advisers, brokers and dealers) and security holders. All responses
to inquiries on behalf of the Company must be made only by the Company&rsquo;s authorized spokespersons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4
All employees must abide by any lawful obligations that owed to former employers. These obligations may include restrictions on the use
and disclosure of confidential information, restrictions on the solicitation of former colleagues to work at the Company and non-competition
obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<FONT STYLE="font-weight: normal; vertical-align: baseline; background-color: white"><U>Fair Dealing</U></FONT>. Each director, officer
and employee must deal fairly with the Company&rsquo;s customers, suppliers, partners, service providers, competitors, employees and
anyone else with whom he or she has contact in the course of performing his or her job. No director, officer or employee may take unfair
advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of facts or any other unfair
dealing practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">10.&nbsp;<FONT STYLE="background-color: white"><U>Reporting
and Enforcement</U></FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 21.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1
Reporting and Investigation of Violations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Actions prohibited by this Code involving directors or executive officers must be reported to the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Actions prohibited by this Code involving anyone other than a director or executive officer must be reported to the reporting person&rsquo;s
supervisor or the Chief Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
After receiving a report of an alleged prohibited action, the Board of Directors, the relevant supervisor, or the Chief Compliance Officer
must promptly take all appropriate actions necessary to investigate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
All directors, officers and employees are expected to cooperate in any internal investigation of misconduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2
Enforcement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company must ensure prompt and consistent action against violations of this Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If, after investigating a report of an alleged prohibited action by a director or executive officer, the Board of Directors determines
that a violation of this Code has occurred, the Board of Directors will report such determination to the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If, after investigating a report of an alleged prohibited action by any other person, the relevant supervisor or the Chief Compliance
Officer determines that a violation of this Code has occurred, the relevant supervisor or Chief Compliance Officer will report such determination
to the General Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Upon receipt of a determination that there has been a violation of this Code, the Board of Directors or the General Counsel will take
such preventative or disciplinary action as it deems appropriate, including, but not limited to, reassignment, demotion, dismissal and,
in the event of criminal conduct or other serious violations of the law, notification of appropriate governmental authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3
Waivers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Each of the Board of Directors (in the case of a violation by a director or executive officer) and the General Counsel (in the case of
a violation by any other person) may, in its discretion, waive any violation of this Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any waiver for a director or an executive officer shall be disclosed as required by SEC and Nasdaq rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4
Prohibition on Retaliation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.3in; text-align: justify; text-indent: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not tolerate acts of retaliation against any director, officer or employee who makes a good faith report of known or suspected
acts of misconduct or other violations of this Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adopted
by the Board: June 20, 2023.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex23-2_001.jpg" ALT="" STYLE="height: 166px; width: 670px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
16, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Summary
of animal study results from Howard An, M.D., Director, Spine Fellowship Program, Rush University Medical College:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
studies have shown that this biological treatment using human dermal fibroblast cells, has great potential as a cell therapy for disc
degeneration. When these cells were injected into a degenerating rabbit disc, they were retained in the disc for up to 8 weeks. Collagen
Type II gene expression, a marker for disc repair and regeneration, was higher in the discs treated with human dermal fibroblast cells
than those in the control treatment. Also higher in the cell treated discs were the disc heights and cell number. Together, this data
suggests that human dermal fibroblast cells are a promising option for cell therapy to restore the biological function and reduce symptoms
of intermediate or progressive degenerative discs.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
approve for Fibrobiologics, Inc. to use this statement for its SEC filings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><IMG SRC="ex23-2_002.jpg" ALT="" STYLE="height: 69px; width: 250px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Howard
S. An, M.D</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Pete O&rsquo;Heeron, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of FibroBiologics, Inc;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or
    persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    February 29, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Pete O&rsquo;Heeron</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pete
    O&rsquo;Heeron</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Mark Andersen, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of FibroBiologics, Inc;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or
    persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    February 29, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mark Andersen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Andersen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENT
PURSUANT TO 18 U.S.C. SECTION 1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
reference to the Annual Report of FibroBiologics, Inc. (the &ldquo;Company&rdquo;), on Form 10-K for the year ended December 31, 2023,
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Pete O&rsquo;Heeron, Chief Executive
Officer of the Company, and Mark Andersen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted
pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Pete O&rsquo;Heeron</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pete
    O&rsquo;Heeron</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mark Andersen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Andersen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    February 29, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.CLAWBACK
<SEQUENCE>8
<FILENAME>ex97.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
97</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FibroBiologics,
Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clawback
Policy</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of FibroBiologics, Inc. (the &ldquo;<B>Company</B>&rdquo;) believes that it is in
the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability
and that reinforces the Company&rsquo;s pay-for-performance compensation philosophy. The Board has therefore adopted this policy which
provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance
with financial reporting requirements under the federal securities laws (the &ldquo;<B>Policy</B>&rdquo;). This Policy is designed to
comply with Section 10D of the Securities Exchange Act of 1934 (the &ldquo;<B>Exchange Act</B>&rdquo;) and the requirements of the Nasdaq
Stock Market (the &ldquo;<B>Nasdaq</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Administration</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be administered by the Board or, if so designated by the Board, the Compensation Committee, in which case references herein
to the Board shall be deemed references to the Compensation Committee. Any determinations made by the Board shall be final and binding
on all affected individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Covered
Executives</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to the Company&rsquo;s current and former executive officers, as determined by the Board in accordance with Section 10D
of the Exchange Act and the listing standards of the Nasdaq (&ldquo;<B>Covered Executives</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Recoupment;
Accounting Restatement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event the Company is required to prepare an accounting restatement of its financial statements due to the Company&rsquo;s material
noncompliance with any financial reporting requirement under the securities laws, the Board will require reimbursement or forfeiture
reasonably promptly of any erroneously awarded Incentive Compensation received by any Covered Executive during the three (3) completed
fiscal years immediately preceding the date on which the Company is required to prepare an accounting restatement and during any transition
period that results from a change in the Company&rsquo;s fiscal year within or immediately following those three (3) completed fiscal
years; however, a transition period between the last day of the Company&rsquo;s previous fiscal year end and the first day of its new
fiscal year that comprises a period of nine (9) to 12 months would be deemed a completed fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting restatement includes any required accounting restatement to correct an error in previously issued financial statements that
is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected
in the current period or left uncorrected in the current period. The Company&rsquo;s obligation to recover erroneously awarded compensation
is not dependent on if or when the restated financial statements are filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Incentive
Compensation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, Incentive Compensation means any of the following erroneously awarded (provided that, such compensation is granted,
earned, or vested based wholly or in part on the attainment of a financial reporting measure), and any earnings accrued to date on such
amount:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
    bonuses and other short- and long-term cash incentives.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    options.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    appreciation rights.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock units.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    units.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
reporting measures include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    stock price.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    shareholder return.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    income.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
    before interest, taxes, depreciation, and amortization (EBITDA).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funds
    from operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
    measures such as working capital or operating cash flow.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
    measures such as return on invested capital or return on assets.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
    measures such as earnings per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Erroneously
Awarded Incentive Compensation: Amount Subject to Recovery</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount to be recovered will be the excess of the Incentive Compensation paid to the Covered Executive based on the erroneous data over
the Incentive Compensation that would have been paid to the Covered Executive had it been based on the restated amounts, computed on
a gross (not after-tax) basis, as determined by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Board cannot determine the amount of excess Incentive Compensation received by the Covered Executive directly from the information
in the accounting restatement, then it will make its determination based on a reasonable estimate of the effect of the accounting restatement.
For Incentive Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is
not subject to mathematical recalculation directly from the information in an accounting restatement, the amount will be based on a reasonable
estimate of the effect of the accounting restatement on the stock price or total shareholder return upon which the Incentive Compensation
was received; and the Company will maintain documentation of the determination of that reasonable estimate and, if required, provide
such documentation to the Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Method
of Recoupment</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board will determine, in its sole discretion, the method for recouping Incentive Compensation hereunder which may include, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
requiring reimbursement of cash Incentive Compensation previously paid;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based
awards;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Executive;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d))
cancelling outstanding vested or unvested equity awards; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
taking any other remedial and recovery action permitted by law, as determined by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>No
Indemnification</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded Incentive Compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Interpretation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the
administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of
Section 10D of the Exchange Act and any applicable rules or standards adopted by the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;)
or the Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Effective
Date</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be effective as of the date it is adopted by the Board (the &ldquo;<B>Effective Date</B>&rdquo;) and shall apply to Incentive
Compensation that is approved, awarded or granted to Covered Executives on or after that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Amendment;
Termination</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to reflect final regulations
adopted by the SEC under Section 10D of the Exchange Act and to comply with any rules or standards adopted by the Nasdaq. The Board may
terminate this Policy at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Other
Recoupment Rights</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board intends that this Policy will be applied to the fullest extent of the law. The Board may require that any employment agreement,
equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit
thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in
addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms
of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Impracticability</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board shall recover any excess Incentive Compensation in accordance with this Policy unless such recovery would be impracticable, as
determined by the committee of independent directors responsible for executive compensation decisions, or a majority of the independent
directors of the Board, in accordance with Rule 10D-1 of the Exchange Act and the listing standards of the Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Successors</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other
legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adopted
by the Board: June 20, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" %) D # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *8!BGTV@!"1]/>@8/.1]17$:_>2WVK7,$
MDLD=I:@?NXVP7)]:30;R:PU>V@CED>UNMP\N0YV$>AK3ECS>SYO>M>WD<WMI
M\OM.7W+VOYG<9S2UGZSJ#Z9IDURD9=UP%&,C)]:S6\03PR1K(BO^]6.0)&VX
M93/3UI1IRDKHJ=>$)<K.B'UH[5DCQ'8LR -)\T?F9V'"KSU/;I4D&LPW8Q"L
MF]6 9'0AL$<''I2E&45=HN%6$WRQ9I"EJH+U.H!Y'W<<YZ8H-ZH8'!"X.01S
MGCC]:RYX]S;DD6Z*K?;4Z;7W9QMV\TU;Z,\C)!QM ')XS1SQ[AR,MTM5EO49
MPH#$D9/'3ZU8JDT]A--;BT444Q!129J.6XBA&99%0>K'% 7L2T4Q)4D4-&P9
M3W4Y%.R*-@%HI,BHY+B*+'F2(F>FY@,T!<EHIBR*Z[E8,#W!S3MPH 6BDW"H
MC=P"Y6W,B^<R[@F><>M 7)J*3<*,B@!:*:&!ILD\<(!E=4!XRQQ0*Y)14#WE
MO'"9FF01#J^X8'XU*KJRAE.01D$=Z NAU%)FHYKB*WA:69PD:C+,>@H&]"6B
MH$O('E6-94+LN\*#SM]:FW"AZ"33V%HI,T9H&+1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %1,0JL^"<#H.]2TW;S2>H'-26$NLPRWEK&EI/(P'[U,E@.Y]*KI'
M#H]S').B3WL:;=L9VJ,_7UYQ76!3UK#U;P_+>79N;=X@S@!TE4E3CH1CZTXI
M\N^O=_UL9U%'FND^7LNGFK]2T&@\0Z0Z O&DAVL.C*P/3]*BG\/)-,TRW$T<
MIE$JL,':P7;5O2=-.FV@B:3S)&8N[XQECUP*O5?-RMJ.Q"I*:3J+4QH/#=M#
M')'OD99(/)8'N,DY^N2:DLM&%HSR?:)9)FVC>^.B]!CTYK5HQ2E.4E9E0HP@
MTXK8J"Q  (=MXYS[YSFC[#G[SL7.3N'KQ_A5NBL^2)OSLHR6LBGS$):0GD\#
MC%+%8E$0[R)% &<>@J]12]FKW#G=BH;,LZ,9&.W'..3^-6L<4M%4DD)NX4E+
M13$--<TEM%JOBJ\2^7S$@0>7&W09[XKIL5EWV@07MT+D2RP3@8+Q-@L/>K@T
MMS*K%R2L84<SZ1-K<=BVV*&,.@/(5O2M7^TKG^T-+AW+LN8B\@V]3C]*M6^@
MVEO8S6H#,L^?,=CEF_&H;/PU;V=U#<+-/))""%+MGCTK64X2O?\ K0QC3J1M
M;;_@D&AW6I:A-)--+']FC=X]@7YF]#FJWB41#6-.\^!IX]K9C49+?A6[I^FQ
MZ;"\<+,5=RYW>II+C38[B_M[MF8209"@'@Y]:E32G=;%2I2=/EZG-1/?Z-I+
MR11F'SKH"&*3G:IK0N+O4XIK/3A<1?:Y]S/-LX51V K5U#3(]1A2.5F4)()!
MM]13-1TB'4O*9W>.6(Y22,X84_:1;NT)T9Q347_74QFUZ\M;&^2;RY+FWE6)
M7 P#GOBF0"\B\31&\ECEE%JS*ZKCCWK63P[:+I\MHV]Q,=SNQRS'US19>'H+
M*Z6X$T\LH383(^<BFIP2=A>RJ-J[,U-:O#HME<;T\Z6X$;G;P1GTJ<7FHW^K
M7<5G-%#%:L%(=<[SW^E2+X3LU=2);C8C[T3?\JG.:FN?#UO<7K7*S3Q,^/,6
M-L!_K0Y4^@*%7K^90TA;P^([_=<@JC#S%V_>XX ],4_Q:%\NP\Q#(@N!E ,E
MN.F*T5T6)-5-_'+*CMC>@;Y6P,<BIK[38K]K=I&8&"02+M..:7M%SJ17LI>S
M<3E6MY;73]4N5M#!:/M\J"9<C.>NVM*:\U"34XK&RFBB5K99,LF<?2MG4+"/
M4;-[:9F"/U*GFL>[T22ZUQ&)DC@2W""5&PVX4U.,OB(E2E#X2L?$-V=(@;Y1
M<O.8&<)N QU.*;<7]U=:#JD=R&=8U'ERF(IO!]JV#X>LSIT=FOF*L3;U<-\P
M;US3O[#1K*>VFNKB43@!F=LD?2CGAVZC]G5ZOH9=O.8]40*D8*Z>&#[1NSCU
M]*BMM7U01V%W-)$T%Q+Y9C"<_7-;BZ+ ESYRL^[R/(QGC;Z_6HQX?MQ:6MN'
MDVVSB1#GDGWHYX/</95%L_ZT,B]UV^-[>"V; MWVI$(2_F>N3VKI[>0RV\<C
M*59E!*GM6=/X?BENI9XKFXMS*<R")\!JU$38BJ"2%&,GK6=246ERFM*,XM\S
M'4445F;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1124 +15>[O8;& SW+A(P0"2.YX%
M1V^J6MVJM!*KJRE@W8 '!SZ&@"Y14?FH.KJ.,]>WK2K(&Z$'Z&@!]%1^<F-V
M]-N<9R*9<7<-I;R3W$@2*,;F;T% $U)CFJ=MK%E>2(D$ZNSJ6 Z=#@CZ\]*L
M^<GS'>N%."=PXHV%<DI:C\P%BH(+#J,\T\&@8M%)FC- "T4F:IS:O9V]ZEI+
M<(L[XPA]^G/O0!=HJ/S5R!N7).,9[^E03ZE;6TB))(-S[L <].O3ZT 6Z*AD
MN8XE+.PX(! Y().!2^<G]],@X^]W]* ):*@M[J.Z5FA;<%=D/&.0<&IJ %HI
M*6@ HHHH ***J3:I:6]TMO-<Q),PW!&/)% %NBHH9UGB26-@T;J&5AW!Z4_=
MSVH =15>YO(+2,27$J1(2%!<XR3T%3YH 6BDI: "BBB@ HHHH ***IWFJVFG
M&,7<RQ&3.W(/;J: +E%5X+Z"Y5VBE4A&*MST(ZU)YJY W+R,CGJ* N245!/=
MPVUL]Q(X\I!DL!G^5%K=17MND]NZO$XRK#O0!/1110 4444 %%%0W%S%:Q&6
MXD2*,=6<X% $U%00W<-P2(94D( 8[3G@]#4N3G% #J*87V@EL #G)J.VO(;M
M-]O*DJ9QE#GF@">BBB@ HHHH **** "BBB@ HHHH **** "BD/2N-U3Q;>:7
MJNIO,H-K8*K"U6([YH\ M('Z<$XV^U '9T5P4'C;6%U*>U?2Q,[NGE*-R^4K
M;,;CC&/F//L:5O&NHW;1H+<:=#Y^R6Z>)I0G!PA7 ^8D=>@S0!WE%>>W/C76
M;N)&M+![7%RT1W1EV8=B1CY3W^AKJ-*C\01ZA)_:MQ92V>SY#"A5]WOVQUH
MVJ0T#D5R_BW7[C3F2UM"$ED&YI,9*CVJZ=.527+$QKUHT(.<C8UFTFO;#R[;
M8)5D21=Y(!VL#V^E8T_AN\G%Q([PF2XW.\:L54.2,?7&.<]:Y,ZUJ6<_;Y_^
M^Z3^V=1_Y_KC_ONNY8"HNJ/+>;TW]EG62>'KZ3S=YM7D?8WF'<I; &8\=E./
MUH7PS=YC"W"11N&,L:%CM(),84^@W?I7)_VSJ/\ S_W'_?=']LZC_P _]Q_W
MW3^HU/YD+^UZ7\K.NL/"[(UO]M5'6/=O7S"P)*A0P'&.A_.ELM$NY?#]Y!/(
MRW%PVQ&;JL:'"?C@9_&N0_MG4?\ G^N/^^Z/[9U'_G^N/^^Z7U&?=#_M>G_*
MSLKOPNLDFZ$J2(FP\A)?S2P);/X56D\-ZA+)>2.UN6E*[ K%06#$AB,8]..<
MURW]LZC_ ,_UQ_WW1_;.H_\ /]<?]]T?4:G\PO[7I?RL[;2]#N+/5Y+NXD$F
M[<0ZN1G.."N.@[<UO UY7_;6H_\ /_<?]]TC:UJ0'_'_ ''_ 'W2> F^J*6<
M4_Y6>K9S1FO*O[9U'_G_ +C_ +[H_MG4?^?^X_[[H_L^?</[9I_RL]5S6/<:
M&+O69+R9RT11 L08@%E)(+#OC-<%_;.H_P#/]<?]]T?VUJ/_ #_7'_?="R^:
MZA_;%-_89U0\*S(UF$<"..,+(%D*E7SDN/4TY/#EW]GCCS;QO'N!="V9,X^8
M^_%<G_;.H_\ /]<?]]T?VUJ/_/\ 7'_?=5]1J?S$_P!KTOY6=A_PC-PDC212
MHDDCL9&!;+9D##\@*@F\-Z@^GK;1?9$(<EI 3N<]GSV/M7+?VUJ7_/\ W'_?
M=']LZC_S_P!Q_P!]T?4:G\R'_:]+^5GI&E6;V-LT<C*S&1WR!ZG-7<UY5_;.
MH_\ /]<?]]T?VUJ7_/\ W'_?=3_9\^X_[9I_RL]5S2BO*AK6I \7]Q_WU70Z
M!KUU?NMO<2L9$!.X?Q#'>LZF"G37-<WP^9TZT^2S3.TI:R?.E_YZ-1Y\G_/1
MJY+'HW-:L&\T%KW6)KF1L0F--B \,ZY(+>PS5CSY/^>C4>=)_P ]&II-"=F8
MLWAN^BTXVUHL>UXXPX:0\.%(9ESTY(I\^A:F_P!H"NN)!$7W2DF0KC<H..%(
M['O6OYTG_/1J/.D/_+1J=V*R*MUIET?#45E%$)YU*G,\@RN&W=<>V*W(]Q12
MX"MCD9SBLSSI/^>C?G2^=)_ST:E89JTM9/G2?\]&H\^3_GHU*P[FM25E>?+_
M ,]&J+[1-]IQYK8\O/ZT<H7-JEK)\^3_ )Z-1Y\G_/1J+!<UJR=3T?\ M._M
MWDD9;>.-TD16(,@;'!]N.:/.D_YZ-1YTG_/1J+-";3,U_#-Q&\TMJ;=99#+N
MW@X<,P*@_0"H$\+WZP1HMQ'&_DO&TNXL0&)( ';&>HK9\Z3_ )Z-1YTG_/1J
MJ[%9$%GIE]I^ASPV9B2\D8E2\A9%)P,CCCUQZU?TBU-CIT-NR*A0'(5BV3G)
M.?4]:K^=)_ST:CSI/^>C4G=C6AK45D^?)_ST:CSY/^>C4K#N:M+609I?^>C4
MR.XF,LH,K8!&/RHL%S:K+UZQFU"Q2&W(603(^X@' !Y.#P:;Y\O_ #T:CSI/
M^>C46"YEKX<GL;PRV);]WY00F3 8?-OW ?6H+?2M91%+1L&%RLBQ&;Y ,#=G
MG.,]*VO.D_YZ-2^=)_ST:JNR;(J:+I]_:SW<E\TLK.K  L"DAR2"/3CCFIO#
MMA<V1O7N(S&)Y@ZAB"WW0#G'&..*D\Z3_GHU+YTG_/1J6H]#6HK)\^3_ )Z-
M1Y\G_/1J5AW-:BLGSY/^>C4>?)_ST:BP7-6EK*6XE4Y#D_6KEG,9A*Q/ ? '
MIP*+!<LT444AA1110 4444 )UIDT$5Q&T<T:2(PP59<@BI** $"@= !1M'(P
M.?:EHH 3:/0<T4M% !7*>,-"GOY([NS3S)$7:Z#J1VQ75TW(S5TZCIR4D8UZ
M$:]-TY;'D_\ 9E\./L=Q_P!^S2?V;??\^=Q_W[->LTN*[?[0E_*>7_8T/YF>
M2_V;??\ /G<?]^S1_9M]_P ^=Q_W[->M8HQ1_:,OY0_L:'\S/)?[-OO^?.X_
M[]FC^S;[_GSN/^_9KUK%&*/[1E_*']C0_F9Y+_9M]_SYW'_?LT?V;??\^=Q_
MW[->M8HQ1_:,OY0_L:'\S/)?[-OO^?.X_P"_9I'TV]"Y-G< >OEFO6\57O?^
M/8X_O#^=/^T)?RA_8T/YF>7'3;[_ )\KC_OV:3^S;[_GSN/^_9KUG%+BE_:$
MOY0_L:'\S/)?[-OO^?.X_P"_9H_LV^_Y\[C_ +]FO6L48H_M&7\H?V-#^9GD
MO]FWW_/G<?\ ?LT?V;??\^=Q_P!^S7K6*,4?VC+^4/[&A_,SR7^S;[_GSN/^
M_9H_LV^_Y\[C_OV:]:Q1BC^T9?RA_8T/YF>2_P!FWW_/G<?]^S1_9M]_SYW'
M_?LUZUBC%']H2_E#^QH?S,\E_LV^/'V*XY_Z9FNB\/Z+<V4R7%S$RR2954QT
M&.]=QBH)O^/F#ZG^514QLJD>6UC>AEE.C452]VC/\M_[C?E1Y4G]QORK7HKC
M3/1L9'E2?W&_*CRI/[C?E6O11<+&1Y4G]QORH\J3^XWY5KT47"QD>5)_<;\J
M/*D_N-^5:]%%PL9'E2?W&_*CRI/[C?E6O11<+&1Y4G]QORJ+RW^V8V-_JO3W
MK<JM_P O_P#VR_K33!HH^7)_<;\J/*D_N-^5:XZ4M*X[&/Y4G]QORH\J3^XW
MY5L447"QC^5)_<;\J/*D_N-^5;%%%PL8_E2?W&_*CRI/[C?E6Q11<+&/Y4G]
MQORH\J3^XWY5L4E%PL9'E2?W&_*HXXW\^?Y&^\O;V%;9J&'_ (^+C_>'\A3N
M)HSO*D_N-^5'E2?W&_*M>EI7"QC^5)_<;\J/*D_N-^5;%%%QV,?RI/[C?E1Y
M4G]QORK8HHN%C'\J3^XWY4>5)_<;\JV**+A8Q_*D_N-^5'E2?W&_*MBBBX6,
MA89&. A_&KEB@C$RYZ2'^0JT:@M?O3_]=#1?0+%BBDI:0PHHHH **** $/2N
M0U/Q5>VE_JJVT5HR::H9K>1R)YUVAF9.V,''U!KKS43V\;.7:*-G*[=Q49QZ
M?2@#@[OX@:I8336T^FPM<;8FAV,Q7D!I Q[;588]:M)XXN5G:.=+-674$MG7
M?G$; D$-G#'CD=LUV?DQGDQH3_NBF?9(,<V\1^;=]P=?7ZT <;8>.KJY:T\Z
M.R1)[V.W8B0\*ZD[1GJZD8/UKN1WJ$VD!QFWBP&W#Y!P?7ZU,.E "UROB[7I
MM.=+6S;9+(-SOCD#VKJJY+QCHEQ>NEY:(9'C4JZ+U(]16^&Y?:+GV./'.HJ#
M]GN<H=7U$\F^N,_[])_:VH?\_P!<?]]U&;*[''V6<?\ ;,T?8KK_ )]9_P#O
MV:]E*GY'S#E7[O\ $D_M;4/^?ZX_[[H_M;4/^?ZX_P"^ZC^QW7_/K/\ ]^S1
M]CNO^?6?_OV:=J?9"O7[O\23^UM0_P"?ZX_[[H_M;4/^?ZX_[[J/['=?\^L_
M_?LT?8[K_GUG_P"_9HM3[(+U^[_$D_M;4/\ G^N/^^Z/[6U#_G^N/^^ZC^QW
M7_/K/_W[-'V.Z_Y]9_\ OV:+4^R"]?N_Q)/[6U#_ )_KC_OND;5;\J0U[<$?
M[],^QW7_ #ZS_P#?LTUK.Z"Y-M./^V9HM3[(?-6[O\2;^UM0_P"?ZX_[[H_M
M;4/^?ZX_[[J/[%=?\^L__?LT?8[K_GUG_P"_9HM3[(.:OW?XDG]K:A_S_7'_
M 'W1_:VH?\_UQ_WW4?V.Z_Y]9_\ OV:/L=U_SZS_ /?LT6I]D*]?N_Q)/[6U
M#_G^N/\ ONC^UM0_Y_KC_ONH_L=U_P ^L_\ W[-'V.Z_Y]9_^_9HM3[(+U^[
M_$D_M;4/^?ZX_P"^Z/[6U#_G^N/^^ZC^QW7_ #ZS_P#?LT?8[K_GUG_[]FBU
M/L@O7[O\23^UM0_Y_KC_ +[H_M;4/^?ZX_[[J/['=?\ /K/_ -^S1]CNO^?6
M?_OV:+4^R"]?N_Q)/[6U#_G^N/\ OND.JZAN4_;;C/;YZ9]CNO\ GUG_ ._9
MI#9W6Y1]FGY_Z9FBU/LAJ5;N_P 27^UM0_Y_KC_ONC^UM0_Y_KC_ +[J/[%=
M_P#/K/\ ]^S1]CNO^?6?_OV:+4^R_ 7-7[O\23^UM0_Y_KC_ +[H_M;4/^?Z
MX_[[J/['=?\ /K/_ -^S1]CNO^?6?_OV:+4^R"]?N_Q)/[6U#_G^N/\ ONC^
MUM0_Y_KC_ONH_L=U_P ^L_\ W[-'V.Z_Y]9_^_9HM3[(+U^[_$D_M;4/^?ZX
M_P"^Z/[6U#_G^N/^^ZC^QW7_ #ZS_P#?LT?8[K_GUG_[]FBU/L@O7[O\23^U
MM0_Y_KC_ +[H_M;4/^?ZX_[[J/['=?\ /K/_ -^S1]CNO^?6?_OV:+4^R"]?
MN_Q)5UC448,+Z?(]6S75:%J\VIAGE8B:-0KX[\]:Y%;"[=@%M9R3V\LUU>@:
M5-IRD3*1-*@9E'\//2N7%*ER:;GI98Z_M=;V\S:\V3_GHWYT>;)_ST;\Z38_
M]UORHV/_ '&_*O+/?LQ?-D_YZ-^='FR?\]&_.DV/_<;\J-C_ -QORHT#47S9
M/^>C?G1YLG_/1OSI-C_W&_*C8_\ <;\J- U%\V3_ )Z-^='FR?\ /1OSI-C_
M -QORHV/_<;\J- U%\V3_GHWYT>;)_ST;\Z38_\ <;\J-C_W&_*C0-1?.D_Y
MZ-^=1132>?/\[?>'?V%/,;_W6_*HXD?SY_E;[R]O84*P/<F\Z3_GHWYT>;)_
MST;\Z3RW_N-^5&Q_[C?E1H&HOFR?\]&_.CS9/^>C?G2;'_N-^5&Q_P"XWY4:
M!J+YLG_/1OSH\V3_ )Z-^=)L?^XWY4;'_N-^5&@:B^;)_P ]&_.CS9/^>C?G
M2;'_ +C?E1L?^XWY4:!J+YLG_/1OSH\V3_GHWYTFQ_[C?E1Y;_W&_*C0-1RW
M$B'(<GV-7+%_,21QWD-4EAD8@!#^57;!/+B=>N)&_G28T6:6BBI*"BBB@ HH
MHH *3(%!Z5R6I>+KJSO=56WMK:2+30&DB>7$TJ[0S,B], ''US0!UN11FN!N
M_B'<Z?<K;7FFHLI =MKDA5=08N?=CM/TI]S\0+BUB:66VM5'VDV_E^83)%MS
MO9QZ<'&* .[W#UHK@+_XB7%FD\D5M9SQI=B!)8Y3@KMRV1UR.,_6N]B;=&K#
M'S 'B@!],8X-/KFO&UY-:Z6B0L4$TFUF'ICI5TX>TDH]S*M55&FZCZ&LVKZ?
M&Q5KV ,.HWBC^VM-_P"?ZW_[^"O*MH]*-H]!^5>E_9\?YCP_[9G_ "H]5_MK
M3?\ G^M_^_@H_MK3?^?ZW_[^"O*L#T'Y48'H/RH_LZ/=A_;,_P"5?B>J_P!M
M:;_S_6__ '\%']M:;_S_ %O_ -_!7E6!Z#\J,#T'Y4?V='NP_MF?\J_$]5_M
MK3?^?ZW_ ._@H_MK3?\ G^M_^_@KRK ]!^5&!Z#\J/[.CW8?VS/^5?B>J_VU
MIO\ S_6__?P5#=ZQIYMSMOK?.1_RT'K7F&T>@_*D8#'04?V?'NP_MB;^ROQ/
M5O[9T[_G^M_^^Q1_;6F_\_UO_P!_!7E6T>@HP/0?E1_9T>[#^V9_RK\3U7^V
MM-_Y_K?_ +^"C^VM-_Y_K?\ [^"O*L#T'Y48'H/RH_LZ/=A_;,_Y5^)ZK_;6
MF_\ /];_ /?P4?VSIO\ S_6__?P5Y5@>@_*C ]!2_LZ/=A_;,_Y5^)ZW#?6M
MPI:&XCD4=2K U)YT?_/1?SKRS2KF2SU&!XB1E@K#^\#ZBN^(Y-<F(P_L7:YZ
M>#Q?UF+;5FC5\Z/_ )Z+^='G1_\ /1?SK*P*,"L.5'9<U?.C_P">B_G4,LT?
MVF#]XN,MW]JH8%12#_2(/JW\J%%!<VO.C_OK^='G1_\ /1?SK*P*,"E8+FKY
MT?\ ST7\Z/.C_P">B_G65@48%/E07-7SH_\ GHOYT>='_P ]%_.LK HP*.5!
M<U?.C_YZ+^='G1_\]%_.LK HP*.5!<U?.C_YZ+^='G1_\]%_.LK HP*.5!<U
M?-C_ +Z_G4'FI]O^^N/*]?>J.!47_+U_VS_K0D)LV_.C_P">B_G1Y\?_ #T7
M\ZR<#THP*+#N:WGQ_P#/1?SH\^/_ )Z+^=9.!1@46"YK>?'_ ,]%_.CSX_\
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M;^=*UD-.Y:HHHI#"BBB@ HHHH 0C(Q4#V-O),99((6D*["Y0%BOIGT]JL44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M #_7'_?=']KZC_S_ %Q_WW5.BCV<>P>UG_,RY_:^H_\ /]<?]]T?VOJ/_/\
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M:*N":U&/D.TCD8XJJV"Q(Z9X^E:TJSJ-IQ:]3&K1C32:DGZ#:***W, HHHH
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M@,]<GGWJ1M4TEH]K:>2%/R>PSDU/M)?RLU]C'^=&)FBME-2TI8T#6'S'_68
MYYS@?AQ4<-]I:7-RTNGEHG8-"H."GUH527\K_ '2A_.C*HS6Q]OT@D%K!A\O
M0=SZ=?UILFHZ?]DG2&S,4LBA0P' &1^5+VDOY6'LH_SHR:*VWU32IF=Y=//F
M,1EAWYY_&E;5],\ORQ8,8E8E$(&!1[27\K&J$']M&'16AJKV#BV_L]0H"'S!
M@YS[GO6?5PE=7M8QG'E=KW"BBBJ)"BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "^ /0# 2(  A$! Q$!_\0
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M24F: '9HS3-PI-U #Z*9OHWT /HIF^C?0 ^BF;Z-] #Z*9OHWT /HIF^C?0
M^BF;Z-] #Z*9OHWT /HIF^C?0 ^BF;Z-] #\TN:CWTNX4 /S13<TM "T444
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MF!F*_*HSR/S/KQT_I3$:*W&P/Y18 X)$??!^OY4])2Q(8D$G&"#@_-S@^O\
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M06.>,UKU3TU0FGPJ.@&*N4BT%<;K-QLUVX3/3;_Z"*[*O/O$$F/$UV,_W/\
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M2D(G2-$Z FG/(D2;I"%4=R?\YK/DOF/$851W9QD_I59$EN)0 &DE/&2<G_\
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M_C9E_P"8;G_MO_\ 8U#<6F<\50DL<GI0!HGQVP_YA?\ Y,?_ &-)_P )Z_\
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MX3U_^@5_Y,?_ &-'_">-_P! O_R8_P#L:Q_L'M2_8/:@#:7QRS?\PS_R/_\
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?8IU% #<48IU% #<48IU% "44M% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Z 0<# 2(  A$! Q$!_\0
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M24F: '9HS3-PI-U #Z*9OHWT /HIF^C?0 ^BF;Z-] #Z*9OHWT /HIF^C?0
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MN;K25>QC,SVTOFPC/+*W#1_7H1]*]4A_UY_W:FDCWH5(4J>"I'!%.+LP/"?
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M <M&WN,T :X1">@_E4JJ1PKLOT>L^.\MW_U=S$3Z;P*LJ^>CJ?HP- RP;42
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M"V9PK7^T^ULW]<5TMCX<L)HEDDN;J53_  @! :GN;>.0IE.A[&M6V 2%0HP
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M6W_Z^5_]!:NG&<]L5S/CK_D"V_\ U\K_ .@M4C.7L.U=/8]!7,6':NGL>@H
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M+6/ %106V.U:,46.U $\2X%3BHT&*E% "BBBB@ I*6B@!A%1-'FIZ0B@"FT
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*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $. 9\# 2(  A$! Q$!_\0
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M6[7-M<ZC) D4B#;GE9&VGYA][% $W_"%6O\ S_ZW_P"#N]_^/4?\(5:_\_\
MK?\ X.[W_P"/5JR>(M#BM+:[DUG3TMKIMMO,UT@28^B-G#'Z5+'K>DS3W4,6
MIV3RV@S<QK<*6A'JXS\OXT 8O_"%6O\ S_ZW_P"#N]_^/4?\(5:_\_\ K?\
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M6O\ S_ZW_P"#N]_^/5U%% '+_P#"%6O_ #_ZW_X.[W_X]1_PA5K_ ,_^M_\
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MKT"O/_C;_P DAUW_ +=__2B.O0* "BBB@ HHHH **** "BBB@ HHHH ****
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M2.>_N$8HR6D>Y58=5:0XC5AU*LP/3CD99_PC]O/_ ,A*XNM2[;;IQY9'8&)
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M% !1110 4444 <S:_P#)2]6_[!5C_P"C;JNFKF;7_DI>K?\ 8*L?_1MU734
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M'^UC!(!#\;?^20Z[_P!N_P#Z41UZ!7C_ ,;?&WAW_A$-=\*?VA_Q._\ 1_\
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M9/\ 56&S'7[1,%S]-N[]<?C1]EN9/]??.!T*P($4C\=S ^X(]L=:N44>RO\
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M% !1110 4444 %5[&PL],LX[.PM(+2UCSLA@C$:+DDG"C@9))_&J7B7^V?\
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MH,D 9_$BDVDKL:3;LB6BBBF(**** "BBB@ HHHH **** (Y[B"V0//-'$A.
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MYN4>"2.12"ISLC,>#E>A4G..?0B@!^F:]%JFKZC900L(K,(!<$_+*26#;1Z
MH1GN<^G.O63IWAK2-)U2[U#3["VM9[I%67R(40-@L<\ $DEN2>N!6M0 4444
M <S:_P#)2]6_[!5C_P"C;JNFKF;7_DI>K?\ 8*L?_1MU734 9/BC_D4=:_Z\
M)_\ T6U<W72>*/\ D4=:_P"O"?\ ]%M7-UV4/A9A5W-421VJK'/>7I;8I"PM
MA5!'3DU2NKEI7*I/</#U E;)_P *T7,\4<*Q:>D\?EJ0\D1<].?ISVK,NB[7
M#&2%86XRBKM _"JCJR7L:_@__D75_P"OJZ_]*)*W:PO!_P#R+J_]?5U_Z425
MNUR5/C9O#X4<QX<_Y&;Q;_V$X_\ TCMJZ>N8\.?\C-XM_P"PG'_Z1VU=/4%!
M3##$TZSF)#*BE5D*C< <9 /H<#\A3Z* "BBB@#S_ .-O_)(==_[=_P#THCKT
M"O/_ (V_\DAUW_MW_P#2B.O0* "BBB@ HHHH **I7&K65K>K:7$Z12-&9,R,
M%7&<=3W//'L:/MTLW%K9S/\ [<P,* ^AW#=^(4C]<9>VA=I.[7S-?93LG;0N
MU#<7=O:[1/,B,^=BD_,_LHZD].!ZU!]CN)O^/J]<KT*6Z^4I_');/T8?3KF>
MWM+>UW&"%$9\;V ^9_=CU)Z\GUHYIO96]?\ )?YA:"W=_3_-_P"1!]LN)O\
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M:_\ )2]6_P"P58_^C;JNFKF;7_DI>K?]@JQ_]&W5=-0!D^*/^11UK_KPG_\
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M_P#83C_]([:NGKF/#G_(S>+?^PG'_P"D=M73U(PHHHH **** "BBB@ HHHH
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MG_T+>C?^"^+_ .)H Z>BN8_X5YX3_P"A;T;_ ,%\7_Q-'_"O/"?_ $+>C?\
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MG_T+>C?^"^+_ .)H Z>BN8_X5YX3_P"A;T;_ ,%\7_Q-'_"O/"?_ $+>C?\
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=[- D6_&<9V@9QD_G6M0 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #R 90# 2(  A$! Q$!_\0
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M* "BBB@ HHHH *YWQO\ \B]#_P!A/3O_ $LAKHJYWQO_ ,B]#_V$]._]+(:
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M:FFHW=JSW";,XGD5'V$LF] P5]I)(W X[5KT44 %%%% !1110 4444 %%%%
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M-BB@ HHHH **** "N=\;_P#(O0_]A/3O_2R&NBKG?&__ "+T/_83T[_TLAH
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M)SR?7/-:5 &&G@WPZ+:6VETBVN;>683M%=K]H4. 0-HDR% !( &  3@#-5_
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M"<8YX!!Y_B2PYN+2RU6(<LUD3;2^FU8I&96QU+&5>"<#(&[/V4)?PY?)Z/\
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M ".!CD]:WJQ_"]K+9^'K:"=KAI%W9-R@63[Q/(#-_,UL4 %<_P"#?^0'<_\
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M%%9#"BBB@ HHHH **** "BBB@ KG?&__ "+T/_83T[_TLAKHJYWQO_R+T/\
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M Z"BN?\ ^$RTO_GUUS_P17O_ ,9H_P"$RTO_ )]=<_\ !%>__&: .@HKG_\
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MT?5M2ET\11:?*,CSR=\)/,O*C@ ,>-RG'#'G'.#XEZ9)XDTZ\O-)U)+E()8
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M$8..E2T %%%% !1110 4444 %%%% !BC ]*** # ]*,#THHH ,#THP/2BB@
MP/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2
MBB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#T
MHP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
? ,#THP/2BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #E 4T# 2(  A$! Q$!_\0
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M .#R]_\ CM'_  A5I_S_ .M_^#R]_P#CM=/10!S'_"%6G_/_ *W_ .#R]_\
MCM'_  A5I_S_ .M_^#R]_P#CM=/10!S'_"%6G_/_ *W_ .#R]_\ CM'_  A5
MI_S_ .M_^#R]_P#CM=/10!S'_"%6G_/_ *W_ .#R]_\ CM'_  A5I_S_ .M_
M^#R]_P#CM=/10!RY\%V@!/V_6_\ P>7O_P =JYX-U"ZU7P9HM_>R>;=7%C#+
M+)M W,R DX' Y/:MMONGZ5S?P]_Y)YX=_P"P;;_^BUH 3PY_R,GBW_L)Q_\
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MC%L<\%CT],5ZI10!QVJ>'KG5_AG)I.H6*7FIK:LJK<LLI:< @.&8D D\@Y&
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MU9?-*_3:YS-QXGO=-BC@O[: 7SJ[!"QCR/FV?*"XR=O(#Y[^PCM/&IGF-O\
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MM>MWNEG3KR%K158SR&(QN&)QC:Y8$X)PP!Q]15/P]_R'/%G_ &%8_P#TBM:
M.@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L:?PU9&>2YL9;G3
M+J1B[26,NQ6<GYG:(YB=CT+,C'ISD C9HJX5)P^%V$U<P_-\0Z;\LEM#K%LO
M22%Q!<D= #&V(W;H2V^,')P@P ;6GZ]IVISM;P3.ETJ[S;7,+P3;,@;_ "Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW'/7I0!U%%%% !7-^.?&=CX%\-2:Q?1R3$N(;>!.#-*02%SC"C"DDGH < G
M/25EZ_X<TCQ3I;:;K5C'=VA</L8E2K#H592"IZC((X)'0F@#G] ^*W@WQ!I:
MWRZU::>=Y1K?49XX)5(]BV"",$$$CG'4$#4_X3OP?_T->A_^#&'_ .*K0T31
M-.\.:/!I.DV_V>Q@W>7%O9]NYBQY8DGDD\FM"@#G_P#A._!__0UZ'_X,8?\
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M** $;[I^E<W\/?\ DGGAW_L&V_\ Z+6ND;[I^E<W\/?^2>>'?^P;;_\ HM:
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M%\_VK2[K'_+'[-)!N_X'O?'K]TYQCC.0?:/$/_0+TO\ \&,G_P 8JUY>I?\
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M_67_ ,D4?\)#JG_0F:Y_W^LO_DB@#H**Y_\ X2'5/^A,US_O]9?_ "15>_\
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M\\._]@VW_P#1:UTC?=/TKF_A[_R3SP[_ -@VW_\ 1:T )X<_Y&3Q;_V$X_\
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M-(WPO5]#M-/;6)#+#?&\DG9';>2 ,#=(6'"CJS#U!& .A_X3OP?_ -#7H?\
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MRKA^1@YQU&2*V?\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ
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M#7H?_@QA_P#BJ -]ONGZ5S?P]_Y)YX=_[!MO_P"BUJ1O'?A#:?\ BJ]#Z?\
M01B_^*J+X>_\D\\._P#8-M__ $6M &^]K'(Y<YW'T-)]CC_VOS-%% !]CC_V
MOS-'V./_ &OS-%% !]CC_P!K\S1]CC_VOS-%% !]CC_VOS-'V./_ &OS-%%
M!]CC_P!K\S1]CC_VOS-%% !]CC_VOS-'V./_ &OS-%% !]CC_P!K\S1]CC_V
MOS-%% !]CC_VOS-'V./_ &OS-%% !]CC_P!K\S1]CC_VOS-%% !]CC_VOS-'
MV./_ &OS-%% !]CC_P!K\S1]CC_VOS-%% !]CC_VOS-'V./_ &OS-%% !]CC
M_P!K\S1]CC_VOS-%% !]CC_VOS-'V./_ &OS-%% !]CC_P!K\S1]CC_VOS-%
M% !]CC_VOS-'V./_ &OS-%% !]CC_P!K\S1]CC_VOS-%% !]CC_VOS-'V./_
M &OS-%% !]CC_P!K\S1]CC_VOS-%% !]CC_VOS-'V./_ &OS-%% !]BB_P!K
..\S4L42PH$08 HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Y 4(# 2(  A$! Q$!_\0
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M70;8H+C6]-B,CLB>9=QKN93M(&3R0>"/7BN7L?A[/IT6IQV]UHBM?"X4W?\
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MF;@ &S]\DG/([02_#_59[*PM)?%=Q)#;2"5HWCE96(E$B@9F+$ #;AV?CW%
M&Y9>-=%U"PO;FWN8VELO-,]JT\2S((V*DD%P%!*\%B!@CI5.;XC:!:VUM<WD
MQM(;B>2W1IY8E^=)!&>-^2,\[@" !DD<9SO^%<3R6MS:SZS$T+17D=OY=EM:
M,W+[F+G>=X'   7W[8;)\,W*6!CU=5FLII9XV>U+*6>X289 <<#9MZ\YSQ0!
MV]MJ5C>[/LM[;S[X_-3RI5;<F<;A@\C((S6#=^.M+L+C55NH;R.VTQ3Y]X8P
M8=P"DH"#D-AUP& SGC.#3/!_A^72KK6+R>!X/M5RPMX7928X02P'RD@ N\A
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MXENA%Y%Y*Y=KRTBBM[C<3EB)HT5P3DY(;D$@Y!-=111[&']-_P"8>QA_3?\
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MF^%GPT\:^&_B2NK:S;^3:*DPFN//CE^T%A@?Q;AEL-G&>,'K7T!16;IIN_\
M6]_Z_P S-TTY<W];W_K_ #"BBBM#0**** "BBB@ KE]7_P"2@:%_V#;[_P!&
MVE=17+ZO_P E T+_ +!M]_Z-M* .HHHHH YCP]_R-7BS_L(Q_P#I';5T]<QX
M>_Y&KQ9_V$8__2.VKIZ "BBB@#D]*L?$,7B/6YII9DAE5_L\MS+YT!8M^[*1
M!P5"KPP^3<>YZT1Z#XJBUFYU1=?T;S[BWAMW4Z/+M"QM(RD?Z3G.96SSV'3O
MUE% '/\ V/QA_P!!W0__  33?_)5'V/QA_T'=#_\$TW_ ,E5T%% '/\ V/QA
M_P!!W0__  33?_)5'V/QA_T'=#_\$TW_ ,E5/XKU:?0_"^H:G;"+SK>/>OG#
M*=0.?F7CG^\/J*X[2_B=<33:5:SV=M=S7LDJ-+;3*F%4D*50-(KY/!V2-COZ
M4 ;6HW'C"POM)MO[7T.3^T+MK;=_9$P\O$,LN['VGG_58QQ][/;!T/L?C#_H
M.Z'_ .":;_Y*KD?^%FF^&C.GAZ&:6=9IEE%RKBUD577Y0RJTA +!RF-H8C)S
M5N+XBWL>SS])CN$W?O&@E*NH. H5"#N)8_WAUH Z/['XP_Z#NA_^":;_ .2J
M/L?C#_H.Z'_X)IO_ )*I?!WB.7Q3X?CU2;3_ +"[2,GE"X6=2 ?O*Z\,/Z@C
MM6_0!S_V/QA_T'=#_P#!--_\E4?8_&'_ $'=#_\ !--_\E5T%% '/_8_&'_0
M=T/_ ,$TW_R51]C\8?\ 0=T/_P $TW_R57044 <_]C\8?]!W0_\ P33?_)5'
MV/QA_P!!W0__  33?_)5=!7'6/BC4K_Q%XCTN%;,M81$VJ[3NWC@>9AB<$XZ
MJG'W=PY  NNW'C#1/#VIZM_:^AS?8;26Y\K^R)EW[$+;<_:3C.,9P:T/L?C#
M_H.Z'_X)IO\ Y*KBQ\1[Z_L+Q[C0[>ZL);22Z2!UVB6VSY160N=JYDSDD8"9
MX.,U/)\5+YUV1>&I8W_L];S+7*2$,2/E" @LA!P),@$X% '6_8_&'_0=T/\
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M1=21M*D>#DJ" 3Z#K^//H:P-/^(GA/4[N_M[;6[7_0<">25_+0$L5P&; ;G
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M!R_E>-O^@KHG_@HE_P#DFCRO&W_05T3_ ,%$O_R37444 <OY7C;_ *"NB?\
M@HE_^2:/*\;?]!71/_!1+_\ )-=110!R_E>-O^@KHG_@HE_^2:/*\;?]!71/
M_!1+_P#)-=110!R_E>-O^@KHG_@HE_\ DFCRO&W_ $%=$_\ !1+_ /)-=110
M!R_E>-O^@KHG_@HE_P#DFCRO&W_05T3_ ,%$O_R37444 <OY7C;_ *"NB?\
M@HE_^2:/*\;?]!71/_!1+_\ )-=110!R_E>-O^@KHG_@HE_^2:/*\;?]!71/
M_!1+_P#)-=110!R_E>-O^@KHG_@HE_\ DFCRO&W_ $%=$_\ !1+_ /)-=110
M!R_E>-O^@KHG_@HE_P#DFCRO&W_05T3_ ,%$O_R37444 <OY7C;_ *"NB?\
M@HE_^2:/*\;?]!71/_!1+_\ )-=110!R_E>-O^@KHG_@HE_^2:/*\;?]!71/
M_!1+_P#)-=110!R_E>-O^@KHG_@HE_\ DFCRO&W_ $%=$_\ !1+_ /)-=110
M!R_E>-O^@KHG_@HE_P#DFCRO&W_05T3_ ,%$O_R37444 <OY7C;_ *"NB?\
M@HE_^2:/*\;?]!71/_!1+_\ )-=110!R_E>-O^@KHG_@HE_^2:/*\;?]!71/
M_!1+_P#)-=110!R_E>-O^@KHG_@HE_\ DFCRO&W_ $%=$_\ !1+_ /)-=110
M!R_E>-O^@KHG_@HE_P#DFCRO&W_05T3_ ,%$O_R37444 <OY7C;_ *"NB?\
M@HE_^2:/*\;?]!71/_!1+_\ )-=110!R_E>-O^@KHG_@HE_^2:9:Z-KT_B*U
EU35K^QG%M;301QVMD\'^L:)B26E?./*'&!U-=710 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex23-2_001.jpg
<TEXT>
begin 644 ex23-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "F IX# 2(  A$! Q$!_\0
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MF6]\/6'BKPY>:M!:6VN:9)=>SG]I_P#9L7XF_#[X*M^T%\$5^,7Q:\)1^/\
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M(WQI_;!\<_'[1]&^/NEWGPS\/?$#5/@#\>/A)_PKSQ#\*_&_C._\2^$OA/\
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M?&'AX^%]0NY?VKOAM\*/B5X'%]>I;>$?$FG>)_%W[,^FV'A_5_B?XFUWX/\
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MHJ&O.[)_&PC/%.5X2IMWV<JJTA.-G[S7LY*4(2FU.,*D(MS]K"7LUZS^UO\
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MY7,_P[^)7C'X(^$-/_95^,?CW]KS]FKX;WOA7]H3Q+_PSY\1?%_['_C+XO\
MP7^*7CNW^&&K_&?4/VC--\7^,M"^*%YX?^%_A/4O@7H'ACXF^!7?_!3O]HSP
MS\(_B'\1OAC\>;C]I3XZ>%?^"77[/?Q9\?\ [*6N>'?V>YO&WPB_:+^)'@#X
M<^(M=_:%M/A/\&=&T7XUVWP;^%7@O5_^%Q_'RRU[4/B+\+OB%KGQV^"O@WX#
M>/O GAQ=8BTC^I!K2W971D)612DB^9+AU*",AAOP<Q@(>^WY>A(-#4?#V@ZO
M9ZII^K:-IFJ6&NV-QI>MV.HV5O?6FM:7=P3VMUIFKVUU'+#J6FW-M<W%M<6%
MZD]I-;SS0R0M'(REVIZ:-M?$]+R6ETG=..MY)I/WG)\J4HJG,Y5^51I^R3<]
M>>[IPIV=HJFH.I5<9>XE/$45[+V?[UUJ#>*^(OAQ^T[\;/$/B']A?PW%^S+\
M4/%O@+]I3]GK4OBE\8?VB+Z\\+>#-'_9]\6:9\.O!?BKP[X1^(GPWEGN=='B
M+XD:QXAU+1!I>ESV:>%]8M8+?3[?Q+IMOXJN_!OP]^W?^V)\=O@)XZ_;@U/X
M4?'K1QX0^%O_  3F\5_M#^#K+4=/^#/Q"\&_!SX[_"'XE6WAW6?#7CFWTO0?
M"WQ!^'%_\5]&U&TTSP'HWQ5\7?%#3_BSK.F_%:Z^'FG_  UN/V?O$&@?$?\
M<VTL[2PM+:PL;:"SL;."*UM+.UB2"UM+6W18K>VMH(@L4%O!$B1001*D4,2+
M'&BHH48VH^$/">L6FK6&K^&=!U6PU^2&77K'4M(L+ZRUR6V6V6VEUFUNH);?
M5)+9;.T6V>^CG:W6UMA"4$$6U145\2E+7757WM=722:AHE=IR5^:STM.2E"7
MNJTE*244TTKMW4_:1DW)W3<(05HJ5-Q4E+\\]"_:5TRS_;Y^/?PCU#]LGX87
M/A'PE\+OAAIM[\ ?&VN_!31O$WPY^.7CWQ+X?L/">G?#^#35\,_%C4;/4_"_
MC#X>W7CZT^).K^-K'7_&'QQ^"FC?"S4?"5U)XB\+W_P7\+/^"F7Q8L/B=^Q+
M\.;3QW??M1_!/]H7]J_X\:%XA_:TT+X=6FO6%M\!(/A3\>/&/P%\&>)_$OP(
M\!V/P"\/?$&^?P=X<^//C?6-9N?A'XE^'W[)S^ M9USX>>-M4USXI?$3P7^_
MEIX*\'6&H:EJUAX4\-V.J:S!9VNKZE9:'IEKJ&JVNG0FWT^VU*\M[:.XO[>Q
M@8PV<-U)+%;1'9"J+@5BV_PF^%MG:^&K&S^''@6SLO!>O7WBKP;9V?A/0K2T
M\(^*-3T3Q#X:U/Q+X7MK>QCA\/\ B#4?#?BWQ7X>O]:TE+/4KW0O$_B+1[FY
MET[6]3MKHULU=:ZZ0Y6G;77VDFXMI)QLDUJN1MBYJB?NQBX^SC%QJ5.92E%Z
M-<F&IRARIR4)*JY*+Y:D<1I*/X9_$;_@H]\?_@)_P3P_;"^))>^^.W[57P8^
M)'[7W@[X8);^&-/\=64'@+X;>,?&=K\/OCIXZB_9J\%7MIXS^$OPZT#3],T?
MXD>//#GPF^'WA30OB]IVH? 3XHZAX&U3PYXV^+D6!^U5_P %1?BS^S[X"_;V
M^+WPC\7G]H&\^&W[.OPPUCX9? K4OA/KD'C;]G+X\7G@/QW\2_BGK_QG^&GP
MY\'7WQY\(_ OX2_"7Q-^S;XE^+NL?%W0;S1]*^,OC#4OAOJ_Q,^!FFR^(]/^
M'O[\7OPY^'^I>%-1\!ZCX(\)W_@?5_"UWX&U7P9>^'M*NO">I>";_3YM)O\
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M +/_ ,2O^$WU_P 6:]J_PI\'7?C'QMX?\#Z+H^N:!JGA+P!X[\=_#;1=;M?
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M,T&_U7PK\/?#]GX6U$2>(8+KQ#?W.LW=A_9FKV?A[1/H:^^%?PZU.SBT[4O
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MR:?J&EI,VBZUIFMZ77V!$_F)NR"-S $$$$*Q&01@$<<' R,$@'(KS/5?@O\
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MZMW>KU'KHKMVM:[E*W+:UN:<DGHKM)-V7,W:+7Y<?#O_ ()?Z!\*K+]F_2O
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M.PN89C6K8W'4,"JD<-#$XFO*558><E4AAUADO:_V4/'_ (7_ ."LW_!5Z?\
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M?@;7OB)^TE\&O@O^R!\&/'G[?W[$7B7Q3\*?BQ\:?#>I?$[XQ?M3^&OC7??
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M[%7_  UY\(O@!^UA\>M2T"V_X)8?'?\ ;8LH/&7Q!OOB7\6/V</CA\"_C/\
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MM=))W2=_>:NDEJ9=;:IIR33BXM.+2::?75.VMMFU)-'44444 %%%% !1110
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M>/V?QAXM=O&&N/>^("_BCQ&QU MK>IFZ]$^&_P"R=^R[\'/$VB^-/A)^S=\
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M 4444 %%%% !1110 4ASC@@$\ D9&>W&1GGMD?6EI",X]B#^5 'X/:1^TY\
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MQ6'Q$U3Q#\!/B%\4+/XU^(OBOX/\>ZGX?_8M_:+^-,7C;QKXJ^%&E^!_V@_
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MKNXH?%'_ ()P>!OCGXBCUSXT?%_XE?$J#1]9U"7PC8^)?"'[/FI3Z/X%U?\
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MY\:Z/):-=RVGQ$U/Q)^PE\5_B]XKMK:0:I<_'?P5X"U349KOQ)KO@[6)^/\
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M">>!G@9/X <D^U,CD66-)4(9)%5T8$$,K#*L""0000002""""0:?10 4444
M%%%% !1110 4444 %%%% !1110 4444 (<X..N#C/3/:@9P,]<#..F>]+10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -5P
MV_ (V.4.>Y !R/;D4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex23-2_002.jpg
<TEXT>
begin 644 ex23-2_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "I F0# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOTC^V/#U]JVC:M_97B/1[ZU&K:->2Z/+&1+;RNF&H ^T:*** "BBB@ HHHH
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MS_@X^_:XU3]K;_@KG^U#=07OB'_A#?V=-=7]DKX?:+XB\.>&M,U7P]IO[/\
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M:?W10 ^BBB@ HHHH **** "BBB@ HHHH **** "BJ\4CR>@_S]*/-_VOT_\
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MH?$7P?JL D^"L'Q%^+O@3Y&^*7_!ZI^PII/@S6+_ ."W[+'[6GCWXB1#2O\
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MPQX7_;R_;P\2_$+Q3_PKWX4^"/"'PQ^/7QKTS5?%6K:9I.@?#?P-X>T7P?\
M#;Q#8'Q%X^\3"TTA=7O$T9_&'Q)\<2R>+_&+^)/'GB/6-8U8 _VDO,D\SRO^
M66,>=CVS],Y_&KU?XXOQ7\ _\%T/VX/A!\)M/^(GP/\ ^"J?[1_P=_X1S1_'
MW@_6?$'A+]O#X\?#KXKW>NW'C'Q'X.^.UHGQ&U+XC^ 6\1-\.OB,O@3PCXE^
M%FC^$?";?#==&?8_B36?&/B[QC\O?\.H_P#@J)_TC:_;]_\ $.?V@_\ Y@*
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M^TT_5[.T\1>#O&/QAT3QCX0\1*MX/[6\.>+_  WX<\6>&RK:/K>EIJZ-I">
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M'W]HC]B,^$_ )\+GX7BU_P"$<_X1 _M!_P#"O_\ A=7_  GAL_\ BKS\1AK
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MV(!_#'_P>,_\%%/'%Q\2_AE_P3;^%OQ BTSX;:)X"T?XW?M0Z-X1\<:+=_\
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M>+_$U_I'AS1TUCQ#K.D:+I;W^HJ-5UG5HM'B7S9(P #U.BOQW_:<_P""\?\
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MT_&H9'DZF:V\H9\W)[?7/?/-?XUG[2/_  78_P""L'[2GQ5UGXL:[^W'\?\
MX3B\-];Z%\/?V</B?XS_ &?OAAX3\,MXC\0:SH_AS2?"7PXU[PY_PDB:0WB/
M^Q[+QQ\1F\8?$G5]#CT>/Q;XQ\0C148?-FK>)O\ @H#^UEX_\*:9?0?M+_M
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MP]-X_P#^"C?ACPWXRF\.Z1+XLT#PE^RC?^-?"6A>*;NQ1_$>D>$_%VM?M >
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M+T_Q%J%CHEKJ^LQ7>KRZ3H_B.6/2=[QZ,[(%H _N _X-,_\ @DM^SO\ &/\
M9]^-?[:W[77[.W@CXY?\+#\?W/P0^ WA7X__  ;L_&G@S2O!OP\MM.U?XD?%
M+P<GCHZOX#\=CQUX]OE^&Y\8+X-&J^ -8^!GCKPAX=\8X\7^,O#2?V5_#/\
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MS/C9_P ';O\ P1\^$X\.R^!?&7Q\_::;6_[575V^"/P0UK03X+&E_P!G$?\
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M^&_PL\/^#_ /@71?#/PX\'>&?#/AO1O#/AS1D&C^&QA?,:0G_7!_;B_X)O\
M[#G@+]B#]N+6_@'^Q=^Q7\$OC!<?L1_M<^%/ GQ-\,_!W]G+X%:GX5NO&G[.
M?Q-\'WC-\8+S3/!&D_#GP[=Z?XDET;Q+XG\2>+?"?A#2-#U2YD\2:Y!X=6X=
M/\=EQ'%+#WCA/^NN/]*M3;?]N??- 'Z<?\$SO^"2/[87_!5[QQXR\)_LNZ3X
M LM"^%R>'A\4_B=\3?&EAX1\!?#_ /X3/2?'VK>!!K=EI%CXA^(_B%O%UUX"
MUOP[HS_#GX;^,FTB01GQ>/#?AMQ.O]%7P/\ ^#)[]I_7CXF3]I7]M3X%_"R2
MS726\%#X(_#[QY^T /$*7+Z@/$C>+#X\/[-Z>$I+3;I']D)I#>,O[56;5/-6
M Z7&^L?R ?#SX!?'CXP>&/BAXT^$'P5^+'Q-\!_!+1!XJ^,OBKP#X \6^./#
M/PH\+_V3K^KCQ%\4/$7AW0+S2/"6DC1O#?C"^_X2#Q7_ &5I*QZ-XFDQY<<C
M)]&_\.I_^"HG7_AV_P#M^>=T_P"3.?VD/Y_\*_S^'7\* /[BOV:/^#+[]DKX
M?>)GUS]JO]JGXL?M':79:YX2UCPYX$^''@O1_P!FWPUKMIH.K:A>^,?#/Q)O
MSXM^-'CKQ'HOCRR.C:.Q^'/B[X/^)?#>CQZL\?B35/$4^D^(/#?Z6>#_ /@U
ML_X(E:#X<T'0]:_9.U[Q]J6D:)H.C:MXU\4_M&?M-6OB[QCJFEV-A:WWB[Q'
M9^!/BYX0\'6/B+Q%?JVM:S_PB?AKPWX9661U\.>'-&T@QQI_!9_P3"_X+*?M
MT?\ !)+X\^"?A#XQ\?\ Q:A_9>^'WQ:L_#'[1W['WQ&T'^WI/"/AC2O&/B^U
M^+_AGX<^ OB/?>&M8^!'Q3T;6/%_COQ(VD>$/$WPVT76_C5I6BCXV+XD\.I-
M"/\ 6H^$?Q5\%_''X6_#CXU?#35QXE^''Q:\">%OB;\._$2Z5J^BMXA\"^/O
M#^G^*O"7B/\ L?Q!8Z5X@TA=8\/ZI:WHTG5](@U>+>$N((I8Y 0#X.^%_P#P
M1>_X).?"#P1H7PX\)?\ !.O]D+5- T ZF--U#XF_!3P=\</'5R-4UK4=7O\
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M+XO\&_\ "A_^$<\2PMX0^+J.W\V?_!NO_P $C?#'_!5?]K+Q.?C4FNK^RO\
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M1]6U;1U82>'?AM\"](^%OYLU^[7_  1%_P"")'Q>_P""M'QE_M/47\1_#/\
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MHV;PSXA@\<GPP'_S8?\ @C7\4/V5?@C_ ,%+_P!DWXS?MJZ^_AO]G/X4>/\
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ME-_Q8@H?M?A[XO\ Q?T:[!/_  O8$6FK?#GP#K(*_ ECI?B3Q.K_ !_&CP_
MW^HW]D3_ ()M_L)_L+:=967[)W[+/PD^#>K6.BZSX9/C_2?#L>N?&'6/"VO^
M)F\5ZIX=\2_&OQ<VO_%[Q;H[:R+.1=*\6>-]7ATV/1O#^E0Q1Z1X?T2*'[K\
MM/[HH -@]3^G^%/HHH **** "BBB@ HHHH **^3?VS?VO_A%^PG^S5\6?VL/
MCS=^(K?X5_!C1;75_$<?A;0CK_B?5=3UW7-.\(^#_"7AK1C)8VU[XC\7^,?$
M'AWPOHDFJZSX?\-VUQK*:KXL\2>'?#4<^L1_P_\ [2/_  >Q?%+4QJ^F?L>_
ML5> O""6/C^[.B_$']I'X@>(?B.?%/PQM?[?M-).L?"/X6_\*K_X0+QWKF?"
M6KWRI\<_B-X<\,@:SX90^+U>/QA  ?Z$<<S?NO,E'/48 S]3W_\ UY[U\ _M
M/_\ !4[_ ()V_L:_\)Q;_M(?MF_ +X<>+OAL_AV#QG\+&\;Z/XR^-^C3^,$T
M*Z\/2'X!^ V\1?&[5EOM/\2^'O$:+I'@61U\(3+XQE5/#22:O'_DI_M:_P#!
M6K_@I%^W/8WN@?M-?M=_&/XB^#]0T30?#NN?#+2+_2?A=\(_$%GX:\2/XPTF
M[\7?!WX0:;X!^%WB3Q%9>)C%?1>+O$?A+5_$2"+PXC^('C\.:(D7@7[,?[&'
M[6?[9_B0>$?V5OV>?B]\>=7LM=\%Z#K]Q\.O!6L:WX7\$:E\0KJ^TKPE=_$C
MQVUA'X-^%ND:S=Z1K3+XO^(FM^&O":+HFN:W-JZ0>&]7E0 _T'_CQ_P>8_L
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M[X?\(;'\5/BBS?'7Q%XN^'7ANQU[5;/?XD^%GC[X.>'/%WB2\LO#.L>(-6\
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MK313K/B+XB>/?#?AOQC\.?V?/!I UKQW\2U\'>!/#'A'PVKS>&O D8!\D?\
M!VI^W=XY_93_ &#?AW\&/@[\5G\ ?$G]LCQ]\0?A=XP\--X*T?Q>GQ(_953X
M+>,_"'[06CC5/$GA'Q+H?@[_ (J/XI_!>S^WZ1>^&_B2YU?S/ TS0P^+/*_5
M#_@B+^TWXM_;"_X)2_L1?'/QI#KL_C'5OA*?ASXWUGQCXTO/B+XH\<>*/@7X
MG\5? KQ#\1_$GC'5+2PU?6/$GQ2U3X8/\1]9;5EN#%)XN.D2ZYXBFA;Q#/\
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M3O%?P>^+'PHU+Q/J6F>!/ GPY\$ZI\3M)UWPCH_Q<^$/PBN_#OQ%O/#WQ?\
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M.G7/^?QYKQ+X+_L[? +]FWPS?^"/V>/@C\)/@)X+U7Q#/XMU/P9\&?AGX/\
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M ^'?#>C7=EK'AO6?$?COX/>#O#@\71^6GB/5H_$/AD^(_P#7_J-(UC''XDT
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M#<ZEI^JVE]H][XN^&VD:/XLC*+--X><QZ5K$<DD4R '^O-\(_A;X$^!_PO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "HHHHXQB.,1CT  Z_0FI:* &>6G]T4^BB@
M HHHH ***9)]QOI0!^ 7_!SX8Y?^"&?[<D6?^C9?3/\ R>!^S_Z'OQ7\;?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>fblg-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWauCmbP9z5Z8KekhvWB9bdnK3yItVFWwjS0bcBq2gSsG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:FBLG="http://fibrobiologics.com/20231231" elementFormDefault="qualified" targetNamespace="http://fibrobiologics.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://fibrobiologics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit" id="StatementsOfChangesInStockholdersEquitydeficit">
          <link:definition>00000005 - Statement - Statements of Changes in Stockholders' Equity/(Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidity" id="OrganizationDescriptionOfBusinessAndLiquidity">
          <link:definition>00000007 - Disclosure - Organization, Description of Business, and Liquidity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholders" id="NetLossPerShareAttributableToCommonStockholders">
          <link:definition>00000009 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>00000010 - Disclosure - Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
          <link:definition>00000011 - Disclosure - Fair Value of Financial Instruments</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayable" id="ConvertibleNotesPayable">
          <link:definition>00000012 - Disclosure - Convertible Notes Payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestment" id="StockholdersEquitydeficitAndNetParentInvestment">
          <link:definition>00000013 - Disclosure - Stockholders&#8217; Equity/(Deficit) and Net Parent Investment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ShareSubscriptionAgreement" id="ShareSubscriptionAgreement">
          <link:definition>00000014 - Disclosure - Share Subscription Agreement</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000015 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingencies" id="LeasesCommitmentsAndContingencies">
          <link:definition>00000016 - Disclosure - Leases, Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000017 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/Share-basedCompensation" id="Share-basedCompensation">
          <link:definition>00000018 - Disclosure - Share-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000019 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" id="NetLossPerShareAttributableToCommonStockholdersTables">
          <link:definition>00000021 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>00000022 - Disclosure - Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
          <link:definition>00000023 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayableTables" id="ConvertibleNotesPayableTables">
          <link:definition>00000024 - Disclosure - Convertible Notes Payable (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000025 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesTables" id="LeasesCommitmentsAndContingenciesTables">
          <link:definition>00000026 - Disclosure - Leases, Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/Share-basedCompensationTables" id="Share-basedCompensationTables">
          <link:definition>00000027 - Disclosure - Share-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" id="OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative">
          <link:definition>00000028 - Disclosure - Organization, Description of Business, and Liquidity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
          <link:definition>00000030 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative" id="NetLossPerShareAttributableToCommonStockholdersDetailsNarrative">
          <link:definition>00000031 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>00000032 - Disclosure - Schedule of Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>00000033 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails" id="ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails">
          <link:definition>00000034 - Disclosure - Schedule of Financial Liabilities Measured at Fair Value (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails" id="ScheduleOfFinancialLiabilityTransfersDetails">
          <link:definition>00000035 - Disclosure - Schedule of Financial Liability Transfers (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" id="FairValueOfFinancialInstrumentsDetailsNarrative">
          <link:definition>00000036 - Disclosure - Fair Value of Financial Instruments (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails" id="ScheduleOfConvertibleDebtDetails">
          <link:definition>00000037 - Disclosure - Schedule of Convertible Debt (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative" id="ConvertibleNotesPayableDetailsNarrative">
          <link:definition>00000038 - Disclosure - Convertible Notes Payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative" id="StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative">
          <link:definition>00000039 - Disclosure - Stockholders&#8217; Equity/(Deficit) and Net Parent Investment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative" id="ShareSubscriptionAgreementDetailsNarrative">
          <link:definition>00000040 - Disclosure - Share Subscription Agreement (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" id="ScheduleOfEffectiveIncomeTaxRateDetails">
          <link:definition>00000041 - Disclosure - Schedule of Effective Income Tax Rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails" id="ScheduleOfNetDeferredTaxAssetsDetails">
          <link:definition>00000042 - Disclosure - Schedule of Net Deferred Tax Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000043 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" id="ScheduleOfOperatingLeaseLiabilitiesDetails">
          <link:definition>00000044 - Disclosure - Schedule of Operating Lease Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative" id="LeasesCommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000045 - Disclosure - Leases, Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000046 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails" id="ScheduleOfStockBasedCompensationExpenseDetails">
          <link:definition>00000047 - Disclosure - Schedule of Stock Based Compensation Expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails" id="ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails">
          <link:definition>00000048 - Disclosure - Schedule of Unvested Awards and Weighted Average Period (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>00000049 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails" id="ScheduleOfFairValueOfOptionGrantedBlackScholesDetails">
          <link:definition>00000050 - Disclosure - Schedule of Fair Value of Option Granted Black Scholes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative" id="Share-basedCompensationDetailsNarrative">
          <link:definition>00000051 - Disclosure - Share-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000052 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="fblg-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="fblg-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="fblg-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="fblg-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="FBLG_SeriesBOnePreferredStockMember" name="SeriesBOnePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_VotingCommonStockMember" name="VotingCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_NetParentInvestmentMember" name="NetParentInvestmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_LaborataryEquipmentMember" name="LaborataryEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_LiabilityInstrumentMember" name="LiabilityInstrumentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_TwoThousandTwentyTwoNotesMember" name="TwoThousandTwentyTwoNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_TwoThousandTwentyOneNotesMember" name="TwoThousandTwentyOneNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_SeriesB1PreferredStockMember" name="SeriesB1PreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_SharePurchaseAgreementMember" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_ShortTermLeaseAgreementMember" name="ShortTermLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_LeaseAgreementMember" name="LeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_OperatingLeasesMember" name="OperatingLeasesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_ShorttermLeasesMember" name="ShorttermLeasesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_FibroGenesisMember" name="FibroGenesisMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_DirectorsAndOfficersMember" name="DirectorsAndOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_ParentCompanyPayable" name="ParentCompanyPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_LiabilityInstrument" name="LiabilityInstrument" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_NetParentInvestment" name="NetParentInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_FairValueAdjustmentOfLiabilityInstrument" name="FairValueAdjustmentOfLiabilityInstrument" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_DeemedDividend" name="DeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" name="SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" name="SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" name="SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares" name="SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" name="IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares" name="IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability" name="DeemedDividendRelatedToRofnAgreementDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_IncreaseDecreaseInChangeInPayableToParent" name="IncreaseDecreaseInChangeInPayableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_RofnAgreementPaymentsToParent" name="RofnAgreementPaymentsToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" name="ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount" name="AdditionToDerivativeLiabilityForDebtIssuanceDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability" name="ObtainingOperatingLeaseRightofuseAssetAndLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" name="IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" name="ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment" name="AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_DisclosureShareSubscriptionAgreementAbstract" name="DisclosureShareSubscriptionAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_ShareSubscriptionAgreementTextBlock" name="ShareSubscriptionAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_EmergingGrowthCompanyPolicyTextBlock" name="EmergingGrowthCompanyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_CapitalStockInExcess" name="CapitalStockInExcess" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" name="FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" name="FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_CommitmentFeePercentage" name="CommitmentFeePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_DescriptionOfShareSubscriptionAgreement" name="DescriptionOfShareSubscriptionAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" name="EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount" name="DeferredTaxLiabilitiesUnamortizedDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_LicenseFee" name="LicenseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_PercentageOfGrossProceedsFromEquityInvestments" name="PercentageOfGrossProceedsFromEquityInvestments" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_PaymentsForEquityInvestments" name="PaymentsForEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_DerivativeLiabilitiesPayableToRelatedParties" name="DerivativeLiabilitiesPayableToRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_InsurancePolicyCost" name="InsurancePolicyCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_CommitmentFee" name="CommitmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="FBLG_WarrantLiability" name="WarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>fblg-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://fibrobiologics.com/role/Cover" xlink:href="fblg-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/BalanceSheets" xlink:href="fblg-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/BalanceSheetsParenthetical" xlink:href="fblg-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StatementsOfOperations" xlink:href="fblg-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:href="fblg-20231231.xsd#StatementsOfChangesInStockholdersEquitydeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StatementsOfCashFlows" xlink:href="fblg-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:href="fblg-20231231.xsd#OrganizationDescriptionOfBusinessAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="fblg-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:href="fblg-20231231.xsd#NetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/PropertyAndEquipment" xlink:href="fblg-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstruments" xlink:href="fblg-20231231.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayable" xlink:href="fblg-20231231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestment" xlink:href="fblg-20231231.xsd#StockholdersEquitydeficitAndNetParentInvestment" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ShareSubscriptionAgreement" xlink:href="fblg-20231231.xsd#ShareSubscriptionAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/IncomeTaxes" xlink:href="fblg-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingencies" xlink:href="fblg-20231231.xsd#LeasesCommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/RelatedPartyTransactions" xlink:href="fblg-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/Share-basedCompensation" xlink:href="fblg-20231231.xsd#Share-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SubsequentEvents" xlink:href="fblg-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fblg-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:href="fblg-20231231.xsd#NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/PropertyAndEquipmentTables" xlink:href="fblg-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="fblg-20231231.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayableTables" xlink:href="fblg-20231231.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/IncomeTaxesTables" xlink:href="fblg-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesTables" xlink:href="fblg-20231231.xsd#LeasesCommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/Share-basedCompensationTables" xlink:href="fblg-20231231.xsd#Share-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:href="fblg-20231231.xsd#OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="fblg-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="fblg-20231231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative" xlink:href="fblg-20231231.xsd#NetLossPerShareAttributableToCommonStockholdersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="fblg-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="fblg-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails" xlink:href="fblg-20231231.xsd#ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails" xlink:href="fblg-20231231.xsd#ScheduleOfFinancialLiabilityTransfersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:href="fblg-20231231.xsd#FairValueOfFinancialInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails" xlink:href="fblg-20231231.xsd#ScheduleOfConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="fblg-20231231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative" xlink:href="fblg-20231231.xsd#StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative" xlink:href="fblg-20231231.xsd#ShareSubscriptionAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="fblg-20231231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:href="fblg-20231231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative" xlink:href="fblg-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="fblg-20231231.xsd#ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative" xlink:href="fblg-20231231.xsd#LeasesCommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="fblg-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:href="fblg-20231231.xsd#ScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails" xlink:href="fblg-20231231.xsd#ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="fblg-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails" xlink:href="fblg-20231231.xsd#ScheduleOfFairValueOfOptionGrantedBlackScholesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative" xlink:href="fblg-20231231.xsd#Share-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative" xlink:href="fblg-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ParentCompanyPayable" xlink:label="loc_FBLGParentCompanyPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_FBLGParentCompanyPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrument" xlink:label="loc_FBLGLiabilityInstrument" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_FBLGLiabilityInstrument" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_NetParentInvestment" xlink:label="loc_FBLGNetParentInvestment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_FBLGNetParentInvestment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FairValueAdjustmentOfLiabilityInstrument" xlink:label="loc_FBLGFairValueAdjustmentOfLiabilityInstrument" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_FBLGFairValueAdjustmentOfLiabilityInstrument" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeemedDividend" xlink:label="loc_FBLGDeemedDividend" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_FBLGDeemedDividend" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity/(Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FairValueAdjustmentOfLiabilityInstrument" xlink:label="loc_FBLGFairValueAdjustmentOfLiabilityInstrument" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_FBLGFairValueAdjustmentOfLiabilityInstrument" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaapDerivativeLossOnDerivative" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeLossOnDerivative" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_IncreaseDecreaseInChangeInPayableToParent" xlink:label="loc_FBLGIncreaseDecreaseInChangeInPayableToParent" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_FBLGIncreaseDecreaseInChangeInPayableToParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_RofnAgreementPaymentsToParent" xlink:label="loc_FBLGRofnAgreementPaymentsToParent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_FBLGRofnAgreementPaymentsToParent" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" xlink:label="loc_FBLGProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_FBLGProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:title="00000007 - Disclosure - Organization, Description of Business, and Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:title="00000009 - Disclosure - Net Loss per Share Attributable to Common Stockholders" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/FairValueOfFinancialInstruments" xlink:title="00000011 - Disclosure - Fair Value of Financial Instruments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ConvertibleNotesPayable" xlink:title="00000012 - Disclosure - Convertible Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestment" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity/(Deficit) and Net Parent Investment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ShareSubscriptionAgreement" xlink:title="00000014 - Disclosure - Share Subscription Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/LeasesCommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Leases, Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Share-basedCompensation" xlink:title="00000018 - Disclosure - Share-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:title="00000021 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/PropertyAndEquipmentTables" xlink:title="00000022 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000023 - Disclosure - Fair Value of Financial Instruments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ConvertibleNotesPayableTables" xlink:title="00000024 - Disclosure - Convertible Notes Payable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Leases, Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Share-basedCompensationTables" xlink:title="00000027 - Disclosure - Share-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:title="00000028 - Disclosure - Organization, Description of Business, and Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="00000030 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative" xlink:title="00000031 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000033 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails" xlink:title="00000034 - Disclosure - Schedule of Financial Liabilities Measured at Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrument" xlink:label="loc_FBLGLiabilityInstrument" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:to="loc_FBLGLiabilityInstrument" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails" xlink:title="00000035 - Disclosure - Schedule of Financial Liability Transfers (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:title="00000036 - Disclosure - Fair Value of Financial Instruments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails" xlink:title="00000037 - Disclosure - Schedule of Convertible Debt (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000038 - Disclosure - Convertible Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative" xlink:title="00000039 - Disclosure - Stockholders&#8217; Equity/(Deficit) and Net Parent Investment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative" xlink:title="00000040 - Disclosure - Share Subscription Agreement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000041 - Disclosure - Schedule of Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="loc_FBLGEffectiveIncomeTaxRateReconciliationPermanentItems" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_FBLGEffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" xlink:label="loc_FBLGEffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_FBLGEffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="00000042 - Disclosure - Schedule of Net Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" xlink:label="loc_FBLGDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_FBLGDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="loc_us-gaapDeferredTaxAssetsDerivativeInstruments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsDerivativeInstruments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="loc_FBLGDeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_FBLGDeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount" xlink:label="loc_FBLGDeferredTaxLiabilitiesUnamortizedDebtDiscount" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_FBLGDeferredTaxLiabilitiesUnamortizedDebtDiscount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000043 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:title="00000044 - Disclosure - Schedule of Operating Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_FBLGLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_FBLGLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative" xlink:title="00000045 - Disclosure - Leases, Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000046 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="00000047 - Disclosure - Schedule of Stock Based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails" xlink:title="00000048 - Disclosure - Schedule of Unvested Awards and Weighted Average Period (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000049 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails" xlink:title="00000050 - Disclosure - Schedule of Fair Value of Option Granted Black Scholes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative" xlink:title="00000051 - Disclosure - Share-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000052 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>fblg-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://fibrobiologics.com/role/Cover" xlink:href="fblg-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/BalanceSheets" xlink:href="fblg-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/BalanceSheetsParenthetical" xlink:href="fblg-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StatementsOfOperations" xlink:href="fblg-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:href="fblg-20231231.xsd#StatementsOfChangesInStockholdersEquitydeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StatementsOfCashFlows" xlink:href="fblg-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:href="fblg-20231231.xsd#OrganizationDescriptionOfBusinessAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="fblg-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:href="fblg-20231231.xsd#NetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/PropertyAndEquipment" xlink:href="fblg-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstruments" xlink:href="fblg-20231231.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayable" xlink:href="fblg-20231231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestment" xlink:href="fblg-20231231.xsd#StockholdersEquitydeficitAndNetParentInvestment" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ShareSubscriptionAgreement" xlink:href="fblg-20231231.xsd#ShareSubscriptionAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/IncomeTaxes" xlink:href="fblg-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingencies" xlink:href="fblg-20231231.xsd#LeasesCommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/RelatedPartyTransactions" xlink:href="fblg-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/Share-basedCompensation" xlink:href="fblg-20231231.xsd#Share-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SubsequentEvents" xlink:href="fblg-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fblg-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:href="fblg-20231231.xsd#NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/PropertyAndEquipmentTables" xlink:href="fblg-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="fblg-20231231.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayableTables" xlink:href="fblg-20231231.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/IncomeTaxesTables" xlink:href="fblg-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesTables" xlink:href="fblg-20231231.xsd#LeasesCommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/Share-basedCompensationTables" xlink:href="fblg-20231231.xsd#Share-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:href="fblg-20231231.xsd#OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="fblg-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="fblg-20231231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative" xlink:href="fblg-20231231.xsd#NetLossPerShareAttributableToCommonStockholdersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="fblg-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="fblg-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails" xlink:href="fblg-20231231.xsd#ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails" xlink:href="fblg-20231231.xsd#ScheduleOfFinancialLiabilityTransfersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:href="fblg-20231231.xsd#FairValueOfFinancialInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails" xlink:href="fblg-20231231.xsd#ScheduleOfConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="fblg-20231231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative" xlink:href="fblg-20231231.xsd#StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative" xlink:href="fblg-20231231.xsd#ShareSubscriptionAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="fblg-20231231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:href="fblg-20231231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative" xlink:href="fblg-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="fblg-20231231.xsd#ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative" xlink:href="fblg-20231231.xsd#LeasesCommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="fblg-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:href="fblg-20231231.xsd#ScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails" xlink:href="fblg-20231231.xsd#ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="fblg-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails" xlink:href="fblg-20231231.xsd#ScheduleOfFairValueOfOptionGrantedBlackScholesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative" xlink:href="fblg-20231231.xsd#Share-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative" xlink:href="fblg-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesBOnePreferredStockMember" xlink:label="loc_FBLGSeriesBOnePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGSeriesBOnePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaapNonvotingCommonStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapNonvotingCommonStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_VotingCommonStockMember" xlink:label="loc_FBLGVotingCommonStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGVotingCommonStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_150" xlink:to="loc_us-gaapAssetsCurrentAbstract_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_150" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_150" xlink:to="loc_us-gaapPrepaidExpenseCurrent_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_150" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_150" xlink:to="loc_us-gaapOtherAssetsCurrent_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_150" xlink:to="loc_us-gaapAssetsCurrent_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_150" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_150" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_150" xlink:to="loc_us-gaapAssets_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_150" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_150" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ParentCompanyPayable" xlink:label="loc_FBLGParentCompanyPayable_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_150" xlink:to="loc_FBLGParentCompanyPayable_150" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_150" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_150" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrument" xlink:label="loc_FBLGLiabilityInstrument_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_150" xlink:to="loc_FBLGLiabilityInstrument_150" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_150" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_150" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_150" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_150" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_150" xlink:to="loc_us-gaapLiabilitiesCurrent_150" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_150" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_150" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_150" xlink:to="loc_us-gaapLiabilities_150" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_150" xlink:to="loc_us-gaapStockholdersEquityAbstract_150" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_NetParentInvestment" xlink:label="loc_FBLGNetParentInvestment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_150" xlink:to="loc_FBLGNetParentInvestment_150" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_150" xlink:to="loc_us-gaapPreferredStockValue_150" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_150" xlink:to="loc_us-gaapCommonStockValue_150" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_150" xlink:to="loc_us-gaapAdditionalPaidInCapital_150" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_150" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_150" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_150" xlink:to="loc_us-gaapStockholdersEquity_150" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_150" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_150" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesBOnePreferredStockMember" xlink:label="loc_FBLGSeriesBOnePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGSeriesBOnePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaapNonvotingCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapNonvotingCommonStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_VotingCommonStockMember" xlink:label="loc_FBLGVotingCommonStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGVotingCommonStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_130" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity/(Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_NetParentInvestmentMember" xlink:label="loc_FBLGNetParentInvestmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_FBLGNetParentInvestmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_VotingCommonStockMember" xlink:label="loc_FBLGVotingCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_FBLGVotingCommonStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesBOnePreferredStockMember" xlink:label="loc_FBLGSeriesBOnePreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGSeriesBOnePreferredStockMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_FBLGSaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGSaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" xlink:label="loc_FBLGSaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGSaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_FBLGSaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGSaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares" xlink:label="loc_FBLGSaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGSaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" xlink:label="loc_FBLGIssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGIssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares" xlink:label="loc_FBLGIssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGIssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability" xlink:label="loc_FBLGDeemedDividendRelatedToRofnAgreementDerivativeLiability_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGDeemedDividendRelatedToRofnAgreementDerivativeLiability_100" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:title="00000007 - Disclosure - Organization, Description of Business, and Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:title="00000009 - Disclosure - Net Loss per Share Attributable to Common Stockholders" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/FairValueOfFinancialInstruments" xlink:title="00000011 - Disclosure - Fair Value of Financial Instruments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ConvertibleNotesPayable" xlink:title="00000012 - Disclosure - Convertible Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestment" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity/(Deficit) and Net Parent Investment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ShareSubscriptionAgreement" xlink:title="00000014 - Disclosure - Share Subscription Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/LeasesCommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Leases, Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Share-basedCompensation" xlink:title="00000018 - Disclosure - Share-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:title="00000021 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/PropertyAndEquipmentTables" xlink:title="00000022 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000023 - Disclosure - Fair Value of Financial Instruments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ConvertibleNotesPayableTables" xlink:title="00000024 - Disclosure - Convertible Notes Payable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Leases, Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Share-basedCompensationTables" xlink:title="00000027 - Disclosure - Share-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:title="00000028 - Disclosure - Organization, Description of Business, and Liquidity (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="00000030 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative" xlink:title="00000031 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaapNonvotingCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapNonvotingCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionAmount" xlink:label="loc_us-gaapPreferredStockRedemptionAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionAmount_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_CapitalStockInExcess" xlink:label="loc_FBLGCapitalStockInExcess_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_FBLGCapitalStockInExcess_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LaboratoryEquipmentMember" xlink:label="loc_FBLGLaboratoryEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_FBLGLaboratoryEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000033 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LaborataryEquipmentMember" xlink:label="loc_FBLGLaborataryEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_FBLGLaborataryEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails" xlink:title="00000034 - Disclosure - Schedule of Financial Liabilities Measured at Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrument" xlink:label="loc_FBLGLiabilityInstrument_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_FBLGLiabilityInstrument_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails" xlink:title="00000035 - Disclosure - Schedule of Financial Liability Transfers (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrumentMember" xlink:label="loc_FBLGLiabilityInstrumentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_FBLGLiabilityInstrumentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:label="loc_FBLGFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_FBLGFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:label="loc_FBLGFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_FBLGFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:title="00000036 - Disclosure - Fair Value of Financial Instruments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="loc_us-gaapMeasurementInputMaturityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputMaturityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrument" xlink:label="loc_FBLGLiabilityInstrument_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_FBLGLiabilityInstrument_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails" xlink:title="00000037 - Disclosure - Schedule of Convertible Debt (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000038 - Disclosure - Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_TwoThousandTwentyTwoNotesMember" xlink:label="loc_FBLGTwoThousandTwentyTwoNotesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_FBLGTwoThousandTwentyTwoNotesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_TwoThousandTwentyOneNotesMember" xlink:label="loc_FBLGTwoThousandTwentyOneNotesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_FBLGTwoThousandTwentyOneNotesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapConversionOfStockDescription_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_110" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative" xlink:title="00000039 - Disclosure - Stockholders&#8217; Equity/(Deficit) and Net Parent Investment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaapNonvotingCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapNonvotingCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesBOnePreferredStockMember" xlink:label="loc_FBLGSeriesBOnePreferredStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGSeriesBOnePreferredStockMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesB1PreferredStockMember" xlink:label="loc_FBLGSeriesB1PreferredStockMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGSeriesB1PreferredStockMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_250" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_250" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_250" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash_250" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaapCapitalUnitsAuthorized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCapitalUnitsAuthorized_250" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_250" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_250" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_250" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_250" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_250" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_250" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity" xlink:label="loc_us-gaapDebtInstrumentConvertibleTypeOfEquitySecurity_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleTypeOfEquitySecurity_250" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_250" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative" xlink:title="00000040 - Disclosure - Share Subscription Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SharePurchaseAgreementMember" xlink:label="loc_FBLGSharePurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_FBLGSharePurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsTotalCostToInvestors" xlink:label="loc_us-gaapCapitalUnitsTotalCostToInvestors_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCapitalUnitsTotalCostToInvestors_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_CommitmentFeePercentage" xlink:label="loc_FBLGCommitmentFeePercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_FBLGCommitmentFeePercentage_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DescriptionOfShareSubscriptionAgreement" xlink:label="loc_FBLGDescriptionOfShareSubscriptionAgreement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_FBLGDescriptionOfShareSubscriptionAgreement_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000041 - Disclosure - Schedule of Effective Income Tax Rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="00000042 - Disclosure - Schedule of Net Deferred Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000043 - Disclosure - Income Taxes (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:title="00000044 - Disclosure - Schedule of Operating Lease Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative" xlink:title="00000045 - Disclosure - Leases, Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ShortTermLeaseAgreementMember" xlink:label="loc_FBLGShortTermLeaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_FBLGShortTermLeaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LeaseAgreementMember" xlink:label="loc_FBLGLeaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_FBLGLeaseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_OperatingLeasesMember" xlink:label="loc_FBLGOperatingLeasesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_FBLGOperatingLeasesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ShorttermLeasesMember" xlink:label="loc_FBLGShorttermLeasesMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_FBLGShorttermLeasesMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LicenseFee" xlink:label="loc_FBLGLicenseFee_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_FBLGLicenseFee_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000046 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FibroGenesisMember" xlink:label="loc_FBLGFibroGenesisMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_FBLGFibroGenesisMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShortTermBorrowings_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_PercentageOfGrossProceedsFromEquityInvestments" xlink:label="loc_FBLGPercentageOfGrossProceedsFromEquityInvestments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_FBLGPercentageOfGrossProceedsFromEquityInvestments_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_PaymentsForEquityInvestments" xlink:label="loc_FBLGPaymentsForEquityInvestments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_FBLGPaymentsForEquityInvestments_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DerivativeLiabilitiesPayableToRelatedParties" xlink:label="loc_FBLGDerivativeLiabilitiesPayableToRelatedParties_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_FBLGDerivativeLiabilitiesPayableToRelatedParties_110" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="00000047 - Disclosure - Schedule of Stock Based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails" xlink:title="00000048 - Disclosure - Schedule of Unvested Awards and Weighted Average Period (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000049 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_FBLGSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_FBLGSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="loc_FBLGSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_FBLGSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails" xlink:title="00000050 - Disclosure - Schedule of Fair Value of Option Granted Black Scholes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative" xlink:title="00000051 - Disclosure - Share-Based Compensation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000052 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SharePurchaseAgreementMember" xlink:label="loc_FBLGSharePurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_FBLGSharePurchaseAgreementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DirectorsAndOfficersMember" xlink:label="loc_FBLGDirectorsAndOfficersMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_FBLGDirectorsAndOfficersMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_InsurancePolicyCost" xlink:label="loc_FBLGInsurancePolicyCost_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_FBLGInsurancePolicyCost_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_CommitmentFee" xlink:label="loc_FBLGCommitmentFee_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_FBLGCommitmentFee_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="9" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>fblg-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesBOnePreferredStockMember" xlink:label="FBLG_SeriesBOnePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SeriesBOnePreferredStockMember" xlink:to="FBLG_SeriesBOnePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_SeriesBOnePreferredStockMember_lbl" xml:lang="en-US">Series B-1 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvotingCommonStockMember" xlink:to="us-gaap_NonvotingCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xml:lang="en-US">Nonvoting Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_VotingCommonStockMember" xlink:label="FBLG_VotingCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_VotingCommonStockMember" xlink:to="FBLG_VotingCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_VotingCommonStockMember_lbl" xml:lang="en-US">Voting Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_NetParentInvestmentMember" xlink:label="FBLG_NetParentInvestmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_NetParentInvestmentMember" xlink:to="FBLG_NetParentInvestmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_NetParentInvestmentMember_lbl" xml:lang="en-US">Parent Investment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LaboratoryEquipmentMember" xlink:label="FBLG_LaboratoryEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LaboratoryEquipmentMember" xlink:to="FBLG_LaboratoryEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LaborataryEquipmentMember" xlink:label="FBLG_LaborataryEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LaborataryEquipmentMember" xlink:to="FBLG_LaborataryEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_LaborataryEquipmentMember_lbl" xml:lang="en-US">Laboratary Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="us-gaap_MeasurementInputMaturityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputMaturityMember" xlink:to="us-gaap_MeasurementInputMaturityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputMaturityMember_lbl" xml:lang="en-US">Measurement Input, Maturity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeMember" xlink:label="us-gaap_DerivativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeMember" xlink:to="us-gaap_DerivativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeMember_lbl" xml:lang="en-US">Derivative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrumentMember" xlink:label="FBLG_LiabilityInstrumentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LiabilityInstrumentMember" xlink:to="FBLG_LiabilityInstrumentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_LiabilityInstrumentMember_lbl" xml:lang="en-US">Liability Instrument [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_TwoThousandTwentyTwoNotesMember" xlink:label="FBLG_TwoThousandTwentyTwoNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_TwoThousandTwentyTwoNotesMember" xlink:to="FBLG_TwoThousandTwentyTwoNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_TwoThousandTwentyTwoNotesMember_lbl" xml:lang="en-US">2022 Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_TwoThousandTwentyOneNotesMember" xlink:label="FBLG_TwoThousandTwentyOneNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_TwoThousandTwentyOneNotesMember" xlink:to="FBLG_TwoThousandTwentyOneNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_TwoThousandTwentyOneNotesMember_lbl" xml:lang="en-US">2021 Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesB1PreferredStockMember" xlink:label="FBLG_SeriesB1PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SeriesB1PreferredStockMember" xlink:to="FBLG_SeriesB1PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_SeriesB1PreferredStockMember_lbl" xml:lang="en-US">Series B1 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SharePurchaseAgreementMember" xlink:label="FBLG_SharePurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SharePurchaseAgreementMember" xlink:to="FBLG_SharePurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_SharePurchaseAgreementMember_lbl" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ShortTermLeaseAgreementMember" xlink:label="FBLG_ShortTermLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ShortTermLeaseAgreementMember" xlink:to="FBLG_ShortTermLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_ShortTermLeaseAgreementMember_lbl" xml:lang="en-US">Short Term Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LeaseAgreementMember" xlink:label="FBLG_LeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LeaseAgreementMember" xlink:to="FBLG_LeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_LeaseAgreementMember_lbl" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_OperatingLeasesMember" xlink:label="FBLG_OperatingLeasesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_OperatingLeasesMember" xlink:to="FBLG_OperatingLeasesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_OperatingLeasesMember_lbl" xml:lang="en-US">Operating Leases [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ShorttermLeasesMember" xlink:label="FBLG_ShorttermLeasesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ShorttermLeasesMember" xlink:to="FBLG_ShorttermLeasesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_ShorttermLeasesMember_lbl" xml:lang="en-US">Short-term Leases [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FibroGenesisMember" xlink:label="FBLG_FibroGenesisMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_FibroGenesisMember" xlink:to="FBLG_FibroGenesisMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_FibroGenesisMember_lbl" xml:lang="en-US">Fibro Genesis [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DirectorsAndOfficersMember" xlink:label="FBLG_DirectorsAndOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DirectorsAndOfficersMember" xlink:to="FBLG_DirectorsAndOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_DirectorsAndOfficersMember_lbl" xml:lang="en-US">Directors and Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Parent company receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; equity/(deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ParentCompanyPayable" xlink:label="FBLG_ParentCompanyPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ParentCompanyPayable" xlink:to="FBLG_ParentCompanyPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_ParentCompanyPayable_lbl" xml:lang="en-US">Parent company payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, short-term</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrument" xlink:label="FBLG_LiabilityInstrument" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LiabilityInstrument" xlink:to="FBLG_LiabilityInstrument_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_LiabilityInstrument_lbl" xml:lang="en-US">Liability instrument</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable, net of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity/(deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_NetParentInvestment" xlink:label="FBLG_NetParentInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_NetParentInvestment" xlink:to="FBLG_NetParentInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_NetParentInvestment_lbl" xml:lang="en-US">Net Parent investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity/(deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity/(deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General, administrative and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FairValueAdjustmentOfLiabilityInstrument" xlink:label="FBLG_FairValueAdjustmentOfLiabilityInstrument" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_FairValueAdjustmentOfLiabilityInstrument" xlink:to="FBLG_FairValueAdjustmentOfLiabilityInstrument_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="FBLG_FairValueAdjustmentOfLiabilityInstrument_lbl" xml:lang="en-US">Change in fair value of liability instrument</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeemedDividend" xlink:label="FBLG_DeemedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeemedDividend" xlink:to="FBLG_DeemedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average shares outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Non-Voting Common Stock to Parent company members</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Sale of Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Sale of Series B Preferred Stock, net of direct costs</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" xlink:label="FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" xlink:to="FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Sale of Series B-1 Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares" xlink:label="FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares" xlink:to="FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares_lbl" xml:lang="en-US">Sale of Series "B-1" Preferred Stock shares, net of direct costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" xlink:label="FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" xlink:to="FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest_lbl" xml:lang="en-US">Issuance of Series B Preferred Stock for conversion of Notes and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares" xlink:label="FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares" xlink:to="FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares_lbl" xml:lang="en-US">Issuance of Series B Preferred Stock shares for conversion of Notes and accrued interest, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability" xlink:label="FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability" xlink:to="FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability_lbl" xml:lang="en-US">Deemed dividend related to ROFN Agreement derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_FairValueAdjustmentOfLiabilityInstrument" xlink:to="FBLG_FairValueAdjustmentOfLiabilityInstrument_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_FairValueAdjustmentOfLiabilityInstrument_2_lbl" xml:lang="en-US">Change in fair value of liability instrument</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLossOnDerivative_lbl" xml:lang="en-US">Loss on derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of convertible notes debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Change in prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Change in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Change in other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_IncreaseDecreaseInChangeInPayableToParent" xlink:label="FBLG_IncreaseDecreaseInChangeInPayableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_IncreaseDecreaseInChangeInPayableToParent" xlink:to="FBLG_IncreaseDecreaseInChangeInPayableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_IncreaseDecreaseInChangeInPayableToParent_lbl" xml:lang="en-US">Change in payable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Change in operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Payment of loan to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_RofnAgreementPaymentsToParent" xlink:label="FBLG_RofnAgreementPaymentsToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_RofnAgreementPaymentsToParent" xlink:to="FBLG_RofnAgreementPaymentsToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="FBLG_RofnAgreementPaymentsToParent_lbl" xml:lang="en-US">ROFN Agreement payments to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment and proceeds of note receivable from Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of Series B Preferred Stock, net of direct costs</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" xlink:label="FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" xlink:to="FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1_lbl" xml:lang="en-US">Proceeds from issuance of Series B-1 Preferred Stock, net of direct costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:label="FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:to="FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount_lbl" xml:lang="en-US">Addition to derivative liability for debt issuance discount</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability" xlink:label="FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability" xlink:to="FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability_lbl" xml:lang="en-US">Obtaining operating lease right-of-use asset and liability</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" xlink:label="FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" xlink:to="FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest_lbl" xml:lang="en-US">Issuance of Series B Preferred Stock for conversion of Notes and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:label="FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:to="FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_lbl" xml:lang="en-US">Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment" xlink:label="FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment" xlink:to="FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment_lbl" xml:lang="en-US">Additions to accounts payable and accrued expenses for purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Organization, Description of Business, and Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share Attributable to Common Stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity/(Deficit) and Net Parent Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DisclosureShareSubscriptionAgreementAbstract" xlink:label="FBLG_DisclosureShareSubscriptionAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DisclosureShareSubscriptionAgreementAbstract" xlink:to="FBLG_DisclosureShareSubscriptionAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_DisclosureShareSubscriptionAgreementAbstract_lbl" xml:lang="en-US">Share Subscription Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ShareSubscriptionAgreementTextBlock" xlink:label="FBLG_ShareSubscriptionAgreementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ShareSubscriptionAgreementTextBlock" xlink:to="FBLG_ShareSubscriptionAgreementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FBLG_ShareSubscriptionAgreementTextBlock_lbl" xml:lang="en-US">Share Subscription Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Leases, Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_RisksAndUncertaintiesPolicyTextBlock" xlink:label="FBLG_RisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_RisksAndUncertaintiesPolicyTextBlock" xlink:to="FBLG_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivatives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patent Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_EmergingGrowthCompanyPolicyTextBlock" xlink:label="FBLG_EmergingGrowthCompanyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_EmergingGrowthCompanyPolicyTextBlock" xlink:to="FBLG_EmergingGrowthCompanyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US">Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Financial Liabilities Measured at Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Financial Liability Transfers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xml:lang="en-US">Schedule of Unvested Awards and Weighted Average Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Option Granted Black Scholes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federally insured limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss attributable to common stockholders:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average number of shares outstanding, basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average number of shares outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Preferred stock liquidation value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionAmount" xlink:label="us-gaap_PreferredStockRedemptionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionAmount" xlink:to="us-gaap_PreferredStockRedemptionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionAmount_lbl" xml:lang="en-US">Preferred stock, redemption amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_CapitalStockInExcess" xlink:label="FBLG_CapitalStockInExcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_CapitalStockInExcess" xlink:to="FBLG_CapitalStockInExcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_CapitalStockInExcess_lbl" xml:lang="en-US">Capital stock in excess</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Issued upon conversion of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment at cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US">Schedule of Fair Value, off-Balance-Sheet Risks [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair value, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:label="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:to="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_lbl" xml:lang="en-US">Addition to derivative liability for debt issuance discount</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:label="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:to="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_lbl" xml:lang="en-US">Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase in the fair value of the liability instrument</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Fair value, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Maturity period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Convertible notes principal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Convertible notes discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xml:lang="en-US">Convertible notes payable, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term debt, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockDescription" xlink:label="us-gaap_ConversionOfStockDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockDescription_lbl" xml:lang="en-US">Conversion of Stock, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Face value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Converted principal shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_2_lbl" xml:lang="en-US">Liquidation preference</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock issued during period, shares, new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Employee benefit plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock, liquidation preference per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock issued during period, value, new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity" xlink:label="us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity" xlink:to="us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity_lbl" xml:lang="en-US">Debt instrument convertible descreption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsTotalCostToInvestors" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsTotalCostToInvestors" xlink:to="us-gaap_CapitalUnitsTotalCostToInvestors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors_lbl" xml:lang="en-US">Investors sales</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_CommitmentFeePercentage" xlink:label="FBLG_CommitmentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_CommitmentFeePercentage" xlink:to="FBLG_CommitmentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_CommitmentFeePercentage_lbl" xml:lang="en-US">Commitment fee percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Shares issues initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DescriptionOfShareSubscriptionAgreement" xlink:label="FBLG_DescriptionOfShareSubscriptionAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DescriptionOfShareSubscriptionAgreement" xlink:to="FBLG_DescriptionOfShareSubscriptionAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_DescriptionOfShareSubscriptionAgreement_lbl" xml:lang="en-US">Description of share subscription agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xml:lang="en-US">Permanent items</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" xlink:label="FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" xlink:to="FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets_lbl" xml:lang="en-US">True-up prior-year net operating loss deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Non-deductible stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other changes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" xlink:label="FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" xlink:to="FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount" xlink:label="FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount" xlink:to="FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount_lbl" xml:lang="en-US">Unamortized debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Uncertain tax positions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: Current lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Total non-current lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Extended lease term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LicenseFee" xlink:label="FBLG_LicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LicenseFee" xlink:to="FBLG_LicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_LicenseFee_lbl" xml:lang="en-US">License fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Operating lease discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Noncancelable lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Repayments of Related Party Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_2_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_PercentageOfGrossProceedsFromEquityInvestments" xlink:label="FBLG_PercentageOfGrossProceedsFromEquityInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_PercentageOfGrossProceedsFromEquityInvestments" xlink:to="FBLG_PercentageOfGrossProceedsFromEquityInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_PercentageOfGrossProceedsFromEquityInvestments_lbl" xml:lang="en-US">Percentage of gross proceeds from equity investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_PaymentsForEquityInvestments" xlink:label="FBLG_PaymentsForEquityInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_PaymentsForEquityInvestments" xlink:to="FBLG_PaymentsForEquityInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_PaymentsForEquityInvestments_lbl" xml:lang="en-US">Payments for equity investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from (repayments of) related party debt</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DerivativeLiabilitiesPayableToRelatedParties" xlink:label="FBLG_DerivativeLiabilitiesPayableToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DerivativeLiabilitiesPayableToRelatedParties" xlink:to="FBLG_DerivativeLiabilitiesPayableToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_DerivativeLiabilitiesPayableToRelatedParties_lbl" xml:lang="en-US">Derivative liabilities payable to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Expected weighted average period compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Stock options, outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Stock options, outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, forfeited/ cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), forfeited/canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Stock options, outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted-average exercise price, outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Stock options, outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Stock options, outstanding, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Strike price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares available for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_InsurancePolicyCost" xlink:label="FBLG_InsurancePolicyCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_InsurancePolicyCost" xlink:to="FBLG_InsurancePolicyCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_InsurancePolicyCost_lbl" xml:lang="en-US">Insurance policy cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Application fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_3_lbl" xml:lang="en-US">Payable to its services as advisor</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_CommitmentFee" xlink:label="FBLG_CommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_CommitmentFee" xlink:to="FBLG_CommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_CommitmentFee_lbl" xml:lang="en-US">Commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Shares sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ParentCompanyPayable" xlink:to="FBLG_ParentCompanyPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_ParentCompanyPayable_doc" xml:lang="en-US">Parent company payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_NetParentInvestment" xlink:to="FBLG_NetParentInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_NetParentInvestment_doc" xml:lang="en-US">Net parent investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SeriesBOnePreferredStockMember" xlink:to="FBLG_SeriesBOnePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_SeriesBOnePreferredStockMember_doc" xml:lang="en-US">Series B-1 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_WarrantLiability" xlink:label="FBLG_WarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_WarrantLiability" xlink:to="FBLG_WarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_WarrantLiability_doc" xml:lang="en-US">Warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeemedDividend" xlink:to="FBLG_DeemedDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_DeemedDividend_doc" xml:lang="en-US">Deemed dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_NetParentInvestmentMember" xlink:to="FBLG_NetParentInvestmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_NetParentInvestmentMember_doc" xml:lang="en-US">Parent Investment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_doc" xml:lang="en-US">Sale of series B adjustments to additional paid in capital stock issued issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" xlink:to="FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares_doc" xml:lang="en-US">Sale of series b preferred stock shares net of direct costs shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_doc" xml:lang="en-US">Sale of series B one adjustments to additional paid in capital stock issued issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares" xlink:to="FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares_doc" xml:lang="en-US">Sale of series B1 preferred stock shares net of direct costs shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" xlink:to="FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest_doc" xml:lang="en-US">Issuance of series B adjustments to additional paid in capital conversion of notes and accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares" xlink:to="FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares_doc" xml:lang="en-US">Issuance of series B preferred stock shares for conversion of notes and accrued interest shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability" xlink:to="FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability_doc" xml:lang="en-US">Deemed dividend related to rofn agreement derivative liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_IncreaseDecreaseInChangeInPayableToParent" xlink:to="FBLG_IncreaseDecreaseInChangeInPayableToParent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_IncreaseDecreaseInChangeInPayableToParent_doc" xml:lang="en-US">Increase decrease in change in payable to parent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_RofnAgreementPaymentsToParent" xlink:to="FBLG_RofnAgreementPaymentsToParent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_RofnAgreementPaymentsToParent_doc" xml:lang="en-US">Rofn agreement payments to parent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" xlink:to="FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1_doc" xml:lang="en-US">Proceeds from issuance of Series B-1 Preferred Stock, net of direct costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:to="FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount_doc" xml:lang="en-US">Addition to derivative liability for debt issuance discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability" xlink:to="FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability_doc" xml:lang="en-US">Obtaining operating lease right of use asset and liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" xlink:to="FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest_doc" xml:lang="en-US">Issuance of series b preferred stock for conversion of notes and accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:to="FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_doc" xml:lang="en-US">Reclassification of derivative liability for conversion of notes to series b preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment" xlink:to="FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment_doc" xml:lang="en-US">Additions to accounts payable and accrued expenses for purchases of property and equipment&#9;.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_RisksAndUncertaintiesPolicyTextBlock" xlink:to="FBLG_RisksAndUncertaintiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_RisksAndUncertaintiesPolicyTextBlock_doc" xml:lang="en-US">Risks and Uncertainties [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_EmergingGrowthCompanyPolicyTextBlock" xlink:to="FBLG_EmergingGrowthCompanyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_EmergingGrowthCompanyPolicyTextBlock_doc" xml:lang="en-US">Emerging Growth Company [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_CapitalStockInExcess" xlink:to="FBLG_CapitalStockInExcess_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_CapitalStockInExcess_doc" xml:lang="en-US">Capital stock in excess.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LaboratoryEquipmentMember" xlink:to="FBLG_LaboratoryEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_LaboratoryEquipmentMember_doc" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_TwoThousandTwentyOneNotesMember" xlink:to="FBLG_TwoThousandTwentyOneNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_TwoThousandTwentyOneNotesMember_doc" xml:lang="en-US">2021 Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_TwoThousandTwentyTwoNotesMember" xlink:to="FBLG_TwoThousandTwentyTwoNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_TwoThousandTwentyTwoNotesMember_doc" xml:lang="en-US">2022 Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ShareSubscriptionAgreementTextBlock" xlink:to="FBLG_ShareSubscriptionAgreementTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_ShareSubscriptionAgreementTextBlock_doc" xml:lang="en-US">Share Subscription Agreement [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SharePurchaseAgreementMember" xlink:to="FBLG_SharePurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_SharePurchaseAgreementMember_doc" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_CommitmentFeePercentage" xlink:to="FBLG_CommitmentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_CommitmentFeePercentage_doc" xml:lang="en-US">Commitment fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DescriptionOfShareSubscriptionAgreement" xlink:to="FBLG_DescriptionOfShareSubscriptionAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_DescriptionOfShareSubscriptionAgreement_doc" xml:lang="en-US">Description of share subscription agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems_doc" xml:lang="en-US">Effective income tax rate reconciliation permanent items.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" xlink:to="FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets_doc" xml:lang="en-US">Effective income tax rate reconciliation prior year net operating loss deferred tax assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" xlink:to="FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability_doc" xml:lang="en-US">Deferred tax assets tax deferred expense compensation and benefits lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_doc" xml:lang="en-US">Deferred tax liabilities operating lease right of use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount" xlink:to="FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount_doc" xml:lang="en-US">Deferred tax liabilities unamortized debt discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ShortTermLeaseAgreementMember" xlink:to="FBLG_ShortTermLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_ShortTermLeaseAgreementMember_doc" xml:lang="en-US">Short Term Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LicenseFee" xlink:to="FBLG_LicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_LicenseFee_doc" xml:lang="en-US">License fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LeaseAgreementMember" xlink:to="FBLG_LeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_LeaseAgreementMember_doc" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_OperatingLeasesMember" xlink:to="FBLG_OperatingLeasesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_OperatingLeasesMember_doc" xml:lang="en-US">Operating Leases [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ShorttermLeasesMember" xlink:to="FBLG_ShorttermLeasesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_ShorttermLeasesMember_doc" xml:lang="en-US">Short-term Leases [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xml:lang="en-US">Lessee operating lease liability payments due after year four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_FibroGenesisMember" xlink:to="FBLG_FibroGenesisMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_FibroGenesisMember_doc" xml:lang="en-US">Fibro Genesis [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_PercentageOfGrossProceedsFromEquityInvestments" xlink:to="FBLG_PercentageOfGrossProceedsFromEquityInvestments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_PercentageOfGrossProceedsFromEquityInvestments_doc" xml:lang="en-US">Percentage of gross proceeds from equity investments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_PaymentsForEquityInvestments" xlink:to="FBLG_PaymentsForEquityInvestments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_PaymentsForEquityInvestments_doc" xml:lang="en-US">Payments for equity investments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DerivativeLiabilitiesPayableToRelatedParties" xlink:to="FBLG_DerivativeLiabilitiesPayableToRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_DerivativeLiabilitiesPayableToRelatedParties_doc" xml:lang="en-US">Derivative liabilities payable to related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeited weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DirectorsAndOfficersMember" xlink:to="FBLG_DirectorsAndOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_DirectorsAndOfficersMember_doc" xml:lang="en-US">Directors and Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_InsurancePolicyCost" xlink:to="FBLG_InsurancePolicyCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_InsurancePolicyCost_doc" xml:lang="en-US">Insurance policy cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:to="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_doc" xml:lang="en-US">Addition to derivative liability for debt issuance discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:to="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_doc" xml:lang="en-US">Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_CommitmentFee" xlink:to="FBLG_CommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_CommitmentFee_doc" xml:lang="en-US">Commitmentt fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_VotingCommonStockMember" xlink:to="FBLG_VotingCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_VotingCommonStockMember_doc" xml:lang="en-US">Voting Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LaborataryEquipmentMember" xlink:to="FBLG_LaborataryEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_LaborataryEquipmentMember_doc" xml:lang="en-US">Laboratary Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SeriesB1PreferredStockMember" xlink:to="FBLG_SeriesB1PreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_SeriesB1PreferredStockMember_doc" xml:lang="en-US">Series B1 Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LiabilityInstrument" xlink:to="FBLG_LiabilityInstrument_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_LiabilityInstrument_doc" xml:lang="en-US">Liability instrument.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_LiabilityInstrumentMember" xlink:to="FBLG_LiabilityInstrumentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_LiabilityInstrumentMember_doc" xml:lang="en-US">Liability Instrument [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_FairValueAdjustmentOfLiabilityInstrument" xlink:to="FBLG_FairValueAdjustmentOfLiabilityInstrument_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="FBLG_FairValueAdjustmentOfLiabilityInstrument_doc" xml:lang="en-US">Change in fair value of liability instrument.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2_lbl" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" xlink:to="FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares_3_lbl" xml:lang="en-US">SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_RofnAgreementPaymentsToParent" xlink:to="FBLG_RofnAgreementPaymentsToParent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_RofnAgreementPaymentsToParent_3_lbl" xml:lang="en-US">RofnAgreementPaymentsToParent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" xlink:to="FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest_3_lbl" xml:lang="en-US">IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_ShareSubscriptionAgreementTextBlock" xlink:to="FBLG_ShareSubscriptionAgreementTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_ShareSubscriptionAgreementTextBlock_3_lbl" xml:lang="en-US">ShareSubscriptionAgreementTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_2_lbl" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:to="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_3_lbl" xml:lang="en-US">FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:to="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_3_lbl" xml:lang="en-US">FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitsAuthorized_2_lbl" xml:lang="en-US">Capital Units, Authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" xlink:to="FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets_3_lbl" xml:lang="en-US">Effective income tax rate reconciliation prior year net operating loss deferred tax assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_2_lbl" xml:lang="en-US">Deferred Tax Assets, Derivative Instruments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount" xlink:to="FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesUnamortizedDebtDiscount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_2_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xml:lang="en-US">Employee Benefits and Share-Based Compensation</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>fblg-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://fibrobiologics.com/role/Cover" xlink:href="fblg-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/BalanceSheets" xlink:href="fblg-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/BalanceSheetsParenthetical" xlink:href="fblg-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StatementsOfOperations" xlink:href="fblg-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:href="fblg-20231231.xsd#StatementsOfChangesInStockholdersEquitydeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StatementsOfCashFlows" xlink:href="fblg-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:href="fblg-20231231.xsd#OrganizationDescriptionOfBusinessAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="fblg-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:href="fblg-20231231.xsd#NetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/PropertyAndEquipment" xlink:href="fblg-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstruments" xlink:href="fblg-20231231.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayable" xlink:href="fblg-20231231.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestment" xlink:href="fblg-20231231.xsd#StockholdersEquitydeficitAndNetParentInvestment" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ShareSubscriptionAgreement" xlink:href="fblg-20231231.xsd#ShareSubscriptionAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/IncomeTaxes" xlink:href="fblg-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingencies" xlink:href="fblg-20231231.xsd#LeasesCommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/RelatedPartyTransactions" xlink:href="fblg-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/Share-basedCompensation" xlink:href="fblg-20231231.xsd#Share-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SubsequentEvents" xlink:href="fblg-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fblg-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:href="fblg-20231231.xsd#NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/PropertyAndEquipmentTables" xlink:href="fblg-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="fblg-20231231.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayableTables" xlink:href="fblg-20231231.xsd#ConvertibleNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/IncomeTaxesTables" xlink:href="fblg-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesTables" xlink:href="fblg-20231231.xsd#LeasesCommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/Share-basedCompensationTables" xlink:href="fblg-20231231.xsd#Share-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:href="fblg-20231231.xsd#OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="fblg-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="fblg-20231231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative" xlink:href="fblg-20231231.xsd#NetLossPerShareAttributableToCommonStockholdersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="fblg-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="fblg-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails" xlink:href="fblg-20231231.xsd#ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails" xlink:href="fblg-20231231.xsd#ScheduleOfFinancialLiabilityTransfersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:href="fblg-20231231.xsd#FairValueOfFinancialInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails" xlink:href="fblg-20231231.xsd#ScheduleOfConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="fblg-20231231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative" xlink:href="fblg-20231231.xsd#StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative" xlink:href="fblg-20231231.xsd#ShareSubscriptionAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="fblg-20231231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:href="fblg-20231231.xsd#ScheduleOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative" xlink:href="fblg-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="fblg-20231231.xsd#ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative" xlink:href="fblg-20231231.xsd#LeasesCommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="fblg-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:href="fblg-20231231.xsd#ScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails" xlink:href="fblg-20231231.xsd#ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="fblg-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails" xlink:href="fblg-20231231.xsd#ScheduleOfFairValueOfOptionGrantedBlackScholesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative" xlink:href="fblg-20231231.xsd#Share-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative" xlink:href="fblg-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesBOnePreferredStockMember" xlink:label="loc_FBLGSeriesBOnePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGSeriesBOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaapNonvotingCommonStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapNonvotingCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_VotingCommonStockMember" xlink:label="loc_FBLGVotingCommonStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGVotingCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ParentCompanyPayable" xlink:label="loc_FBLGParentCompanyPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_FBLGParentCompanyPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrument" xlink:label="loc_FBLGLiabilityInstrument" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_FBLGLiabilityInstrument" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_NetParentInvestment" xlink:label="loc_FBLGNetParentInvestment" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_FBLGNetParentInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesBOnePreferredStockMember" xlink:label="loc_FBLGSeriesBOnePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGSeriesBOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaapNonvotingCommonStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapNonvotingCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_VotingCommonStockMember" xlink:label="loc_FBLGVotingCommonStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGVotingCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FairValueAdjustmentOfLiabilityInstrument" xlink:label="loc_FBLGFairValueAdjustmentOfLiabilityInstrument" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_FBLGFairValueAdjustmentOfLiabilityInstrument" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeemedDividend" xlink:label="loc_FBLGDeemedDividend" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_FBLGDeemedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity/(Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_NetParentInvestmentMember" xlink:label="loc_FBLGNetParentInvestmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_FBLGNetParentInvestmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_VotingCommonStockMember" xlink:label="loc_FBLGVotingCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_FBLGVotingCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesBOnePreferredStockMember" xlink:label="loc_FBLGSeriesBOnePreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_FBLGSeriesBOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_FBLGSaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGSaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" xlink:label="loc_FBLGSaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGSaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_FBLGSaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGSaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares" xlink:label="loc_FBLGSaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGSaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" xlink:label="loc_FBLGIssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGIssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares" xlink:label="loc_FBLGIssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGIssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability" xlink:label="loc_FBLGDeemedDividendRelatedToRofnAgreementDerivativeLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_FBLGDeemedDividendRelatedToRofnAgreementDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FairValueAdjustmentOfLiabilityInstrument" xlink:label="loc_FBLGFairValueAdjustmentOfLiabilityInstrument" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_FBLGFairValueAdjustmentOfLiabilityInstrument" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaapDerivativeLossOnDerivative" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeLossOnDerivative" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_IncreaseDecreaseInChangeInPayableToParent" xlink:label="loc_FBLGIncreaseDecreaseInChangeInPayableToParent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_FBLGIncreaseDecreaseInChangeInPayableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_RofnAgreementPaymentsToParent" xlink:label="loc_FBLGRofnAgreementPaymentsToParent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_FBLGRofnAgreementPaymentsToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" xlink:label="loc_FBLGProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_FBLGProceedsFromIssuanceOfPreferredStockAndPreferenceStock1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:label="loc_FBLGAdditionToDerivativeLiabilityForDebtIssuanceDiscount" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_FBLGAdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability" xlink:label="loc_FBLGObtainingOperatingLeaseRightofuseAssetAndLiability" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_FBLGObtainingOperatingLeaseRightofuseAssetAndLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" xlink:label="loc_FBLGIssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_FBLGIssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:label="loc_FBLGReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_FBLGReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment" xlink:label="loc_FBLGAdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_FBLGAdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:title="00000007 - Disclosure - Organization, Description of Business, and Liquidity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:title="00000009 - Disclosure - Net Loss per Share Attributable to Common Stockholders">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/FairValueOfFinancialInstruments" xlink:title="00000011 - Disclosure - Fair Value of Financial Instruments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ConvertibleNotesPayable" xlink:title="00000012 - Disclosure - Convertible Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestment" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity/(Deficit) and Net Parent Investment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ShareSubscriptionAgreement" xlink:title="00000014 - Disclosure - Share Subscription Agreement">
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DisclosureShareSubscriptionAgreementAbstract" xlink:label="loc_FBLGDisclosureShareSubscriptionAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ShareSubscriptionAgreementTextBlock" xlink:label="loc_FBLGShareSubscriptionAgreementTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FBLGDisclosureShareSubscriptionAgreementAbstract" xlink:to="loc_FBLGShareSubscriptionAgreementTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/LeasesCommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Leases, Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Share-basedCompensation" xlink:title="00000018 - Disclosure - Share-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_FBLGRisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_FBLGRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_FBLGEmergingGrowthCompanyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_FBLGEmergingGrowthCompanyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:title="00000021 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/PropertyAndEquipmentTables" xlink:title="00000022 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000023 - Disclosure - Fair Value of Financial Instruments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ConvertibleNotesPayableTables" xlink:title="00000024 - Disclosure - Convertible Notes Payable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Leases, Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Share-basedCompensationTables" xlink:title="00000027 - Disclosure - Share-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:title="00000028 - Disclosure - Organization, Description of Business, and Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="00000030 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeemedDividend" xlink:label="loc_FBLGDeemedDividend" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_FBLGDeemedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative" xlink:title="00000031 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapEarningsPerShareBasicLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaapNonvotingCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapNonvotingCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionAmount" xlink:label="loc_us-gaapPreferredStockRedemptionAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapPreferredStockRedemptionAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_CapitalStockInExcess" xlink:label="loc_FBLGCapitalStockInExcess" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_FBLGCapitalStockInExcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000032 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LaboratoryEquipmentMember" xlink:label="loc_FBLGLaboratoryEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_FBLGLaboratoryEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000033 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LaborataryEquipmentMember" xlink:label="loc_FBLGLaborataryEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_FBLGLaborataryEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails" xlink:title="00000034 - Disclosure - Schedule of Financial Liabilities Measured at Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrument" xlink:label="loc_FBLGLiabilityInstrument" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_FBLGLiabilityInstrument" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails" xlink:title="00000035 - Disclosure - Schedule of Financial Liability Transfers (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrumentMember" xlink:label="loc_FBLGLiabilityInstrumentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_FBLGLiabilityInstrumentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:label="loc_FBLGFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_FBLGFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:label="loc_FBLGFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_FBLGFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:title="00000036 - Disclosure - Fair Value of Financial Instruments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="loc_us-gaapMeasurementInputMaturityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputMaturityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LiabilityInstrument" xlink:label="loc_FBLGLiabilityInstrument" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_FBLGLiabilityInstrument" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails" xlink:title="00000037 - Disclosure - Schedule of Convertible Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000038 - Disclosure - Convertible Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_TwoThousandTwentyTwoNotesMember" xlink:label="loc_FBLGTwoThousandTwentyTwoNotesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_FBLGTwoThousandTwentyTwoNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_TwoThousandTwentyOneNotesMember" xlink:label="loc_FBLGTwoThousandTwentyOneNotesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_FBLGTwoThousandTwentyOneNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapConversionOfStockDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative" xlink:title="00000039 - Disclosure - Stockholders&#8217; Equity/(Deficit) and Net Parent Investment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaapNonvotingCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapNonvotingCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesBOnePreferredStockMember" xlink:label="loc_FBLGSeriesBOnePreferredStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGSeriesBOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SeriesB1PreferredStockMember" xlink:label="loc_FBLGSeriesB1PreferredStockMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_FBLGSeriesB1PreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationNoncash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaapCapitalUnitsAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCapitalUnitsAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity" xlink:label="loc_us-gaapDebtInstrumentConvertibleTypeOfEquitySecurity" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleTypeOfEquitySecurity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative" xlink:title="00000040 - Disclosure - Share Subscription Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DisclosureShareSubscriptionAgreementAbstract" xlink:label="loc_FBLGDisclosureShareSubscriptionAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FBLGDisclosureShareSubscriptionAgreementAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SharePurchaseAgreementMember" xlink:label="loc_FBLGSharePurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_FBLGSharePurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsTotalCostToInvestors" xlink:label="loc_us-gaapCapitalUnitsTotalCostToInvestors" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCapitalUnitsTotalCostToInvestors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_CommitmentFeePercentage" xlink:label="loc_FBLGCommitmentFeePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_FBLGCommitmentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DescriptionOfShareSubscriptionAgreement" xlink:label="loc_FBLGDescriptionOfShareSubscriptionAgreement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_FBLGDescriptionOfShareSubscriptionAgreement" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000041 - Disclosure - Schedule of Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="loc_FBLGEffectiveIncomeTaxRateReconciliationPermanentItems" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_FBLGEffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" xlink:label="loc_FBLGEffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_FBLGEffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails" xlink:title="00000042 - Disclosure - Schedule of Net Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsGrossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" xlink:label="loc_FBLGDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_FBLGDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="loc_us-gaapDeferredTaxAssetsDerivativeInstruments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsDerivativeInstruments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="loc_FBLGDeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_FBLGDeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount" xlink:label="loc_FBLGDeferredTaxLiabilitiesUnamortizedDebtDiscount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_FBLGDeferredTaxLiabilitiesUnamortizedDebtDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000043 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" xlink:title="00000044 - Disclosure - Schedule of Operating Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_FBLGLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_FBLGLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative" xlink:title="00000045 - Disclosure - Leases, Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ShortTermLeaseAgreementMember" xlink:label="loc_FBLGShortTermLeaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_FBLGShortTermLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LeaseAgreementMember" xlink:label="loc_FBLGLeaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_FBLGLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_OperatingLeasesMember" xlink:label="loc_FBLGOperatingLeasesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_FBLGOperatingLeasesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_ShorttermLeasesMember" xlink:label="loc_FBLGShorttermLeasesMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_FBLGShorttermLeasesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_LicenseFee" xlink:label="loc_FBLGLicenseFee" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_FBLGLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000046 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_FibroGenesisMember" xlink:label="loc_FBLGFibroGenesisMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_FBLGFibroGenesisMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaapPreferredStockLiquidationPreferenceValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreferenceValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_PercentageOfGrossProceedsFromEquityInvestments" xlink:label="loc_FBLGPercentageOfGrossProceedsFromEquityInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_FBLGPercentageOfGrossProceedsFromEquityInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_PaymentsForEquityInvestments" xlink:label="loc_FBLGPaymentsForEquityInvestments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_FBLGPaymentsForEquityInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DerivativeLiabilitiesPayableToRelatedParties" xlink:label="loc_FBLGDerivativeLiabilitiesPayableToRelatedParties" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_FBLGDerivativeLiabilitiesPayableToRelatedParties" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails" xlink:title="00000047 - Disclosure - Schedule of Stock Based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails" xlink:title="00000048 - Disclosure - Schedule of Unvested Awards and Weighted Average Period (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000049 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_FBLGSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_FBLGSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:label="loc_FBLGSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_FBLGSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails" xlink:title="00000050 - Disclosure - Schedule of Fair Value of Option Granted Black Scholes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative" xlink:title="00000051 - Disclosure - Share-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000052 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_SharePurchaseAgreementMember" xlink:label="loc_FBLGSharePurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_FBLGSharePurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_DirectorsAndOfficersMember" xlink:label="loc_FBLGDirectorsAndOfficersMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_FBLGDirectorsAndOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_InsurancePolicyCost" xlink:label="loc_FBLGInsurancePolicyCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_FBLGInsurancePolicyCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="fblg-20231231.xsd#FBLG_CommitmentFee" xlink:label="loc_FBLGCommitmentFee" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_FBLGCommitmentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687026623696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 20, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FibroBiologics,
Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001958777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">86-3329066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455
                                            E. Medical Center Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-5150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,634,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WithumSmith+Brown, PC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">East
Brunswick, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687026315840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,163<span></span>
</td>
<td class="nump">$ 2,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Parent company receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,215<span></span>
</td>
<td class="nump">2,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">797<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">2,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">11,821<span></span>
</td>
<td class="nump">4,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_ParentCompanyPayable', window );">Parent company payable</a></td>
<td class="nump">141<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, short-term</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_LiabilityInstrument', window );">Liability instrument</a></td>
<td class="nump">7,236<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, net of debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,451<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,183<span></span>
</td>
<td class="nump">7,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, long-term</a></td>
<td class="nump">1,385<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,568<span></span>
</td>
<td class="nump">8,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity/(deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_NetParentInvestment', window );">Net Parent investment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">25,609<span></span>
</td>
<td class="nump">2,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(24,357)<span></span>
</td>
<td class="num">(7,872)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity/(deficit)</a></td>
<td class="nump">1,253<span></span>
</td>
<td class="num">(3,996)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity/(deficit)</a></td>
<td class="nump">11,821<span></span>
</td>
<td class="nump">4,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity/(deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity/(deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FBLG_SeriesBOnePreferredStockMember', window );">Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity/(deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity/(deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Nonvoting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity/(deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FBLG_VotingCommonStockMember', window );">Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity/(deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_LiabilityInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_LiabilityInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_NetParentInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net parent investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_NetParentInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_ParentCompanyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Parent company payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_ParentCompanyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FBLG_SeriesBOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FBLG_SeriesBOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FBLG_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FBLG_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687026378752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">8,750,000<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">8,750,000<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">8,750,000<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">4,171,445<span></span>
</td>
<td class="nump">381,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">4,171,445<span></span>
</td>
<td class="nump">381,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FBLG_SeriesBOnePreferredStockMember', window );">Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">89,781<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">89,781<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Nonvoting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">28,230,842<span></span>
</td>
<td class="nump">28,230,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">28,230,842<span></span>
</td>
<td class="nump">28,230,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">62,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FBLG_VotingCommonStockMember', window );">Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FBLG_SeriesBOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FBLG_SeriesBOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FBLG_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FBLG_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687024350720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,368<span></span>
</td>
<td class="nump">$ 1,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General, administrative and other</a></td>
<td class="nump">6,521<span></span>
</td>
<td class="nump">3,320<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,889<span></span>
</td>
<td class="nump">4,467<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,889)<span></span>
</td>
<td class="num">(4,467)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_FairValueAdjustmentOfLiabilityInstrument', window );">Change in fair value of liability instrument</a></td>
<td class="num">(7,236)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other loss</a></td>
<td class="num">(213)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(654)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,485)<span></span>
</td>
<td class="num">(5,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_DeemedDividend', window );">Deemed dividend</a></td>
<td class="num">(2,573)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (19,058)<span></span>
</td>
<td class="num">$ (5,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">28,230,842<span></span>
</td>
<td class="nump">28,230,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">28,230,842<span></span>
</td>
<td class="nump">28,230,842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_FairValueAdjustmentOfLiabilityInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of liability instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_FairValueAdjustmentOfLiabilityInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687024293520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity/(Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Parent Investment [Member]</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B-1 Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Voting Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Series B Preferred Stock [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,461<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,290)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Non-Voting Common Stock to Parent company members</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Balance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,179,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Sale of Series B Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Balance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Balance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,121)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">1,461<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,414<span></span>
</td>
<td class="num">(7,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,996)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
<td class="nump">381,658<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,230,842<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Non-Voting Common Stock to Parent company members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Balance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,765<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Sale of Series B Preferred Stock, net of direct costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,945<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares', window );">Balance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,570,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Sale of Series B-1 Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,193<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares', window );">Sale of Series "B-1" Preferred Stock shares, net of direct costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest', window );">Issuance of Series B Preferred Stock for conversion of Notes and accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,404<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares', window );">Issuance of Series B Preferred Stock shares for conversion of Notes and accrued interest, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,219,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability', window );">Deemed dividend related to ROFN Agreement derivative liability</a></td>
<td class="num">(1,461)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,112)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,573)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 25,609<span></span>
</td>
<td class="num">$ (24,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,253<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
<td class="nump">4,171,445<span></span>
</td>
<td class="nump">89,781<span></span>
</td>
<td class="nump">28,230,842<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend related to rofn agreement derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of series B adjustments to additional paid in capital conversion of notes and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of series B preferred stock shares for conversion of notes and accrued interest shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of series B1 preferred stock shares net of direct costs shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of series B adjustments to additional paid in capital stock issued issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of series B one adjustments to additional paid in capital stock issued issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of series b preferred stock shares net of direct costs shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687122924752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,485)<span></span>
</td>
<td class="num">$ (5,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_FairValueAdjustmentOfLiabilityInstrument', window );">Change in fair value of liability instrument</a></td>
<td class="nump">7,236<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,765<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Loss on derivative liability</a></td>
<td class="nump">72<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of convertible notes debt discount</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use asset</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">47<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Change in prepaid expenses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Change in accounts payable and accrued expenses</a></td>
<td class="nump">671<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Change in other current assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_IncreaseDecreaseInChangeInPayableToParent', window );">Change in payable to Parent</a></td>
<td class="nump">141<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in operating lease liability</a></td>
<td class="num">(326)<span></span>
</td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(6,401)<span></span>
</td>
<td class="num">(4,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(495)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(495)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payment of loan to Parent</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_RofnAgreementPaymentsToParent', window );">ROFN Agreement payments to Parent</a></td>
<td class="num">(2,645)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Repayment and proceeds of note receivable from Parent</a></td>
<td class="nump">300<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Series B Preferred Stock, net of direct costs</a></td>
<td class="nump">14,945<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1', window );">Proceeds from issuance of Series B-1 Preferred Stock, net of direct costs</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">13,793<span></span>
</td>
<td class="nump">5,925<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">6,897<span></span>
</td>
<td class="nump">1,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">2,266<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">9,163<span></span>
</td>
<td class="nump">2,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount', window );">Addition to derivative liability for debt issuance discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability', window );">Obtaining operating lease right-of-use asset and liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest', window );">Issuance of Series B Preferred Stock for conversion of Notes and accrued interest</a></td>
<td class="nump">5,866<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock', window );">Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock</a></td>
<td class="nump">538<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment', window );">Additions to accounts payable and accrued expenses for purchases of property and equipment</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition to derivative liability for debt issuance discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions to accounts payable and accrued expenses for purchases of property and equipment	.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_FairValueAdjustmentOfLiabilityInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of liability instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_FairValueAdjustmentOfLiabilityInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_IncreaseDecreaseInChangeInPayableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in change in payable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_IncreaseDecreaseInChangeInPayableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of series b preferred stock for conversion of notes and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obtaining operating lease right of use asset and liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of Series B-1 Preferred Stock, net of direct costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability for conversion of notes to series b preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_RofnAgreementPaymentsToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rofn agreement payments to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_RofnAgreementPaymentsToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687029380048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of Business, and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization, Description of Business, and Liquidity</a></td>
<td class="text"><p id="xdx_805_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z8yDXCzy2FT4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_z4uUjpBA0Hre">Organization, Description of Business, and Liquidity</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization
and Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FibroBiologics,
Inc. (the &#8220;Company&#8221; or &#8220;FibroBiologics&#8221;) was originally formed as a limited liability company (&#8220;LLC&#8221;)
under the laws of the State of Texas on April 8, 2021 (&#8220;Inception&#8221;) and then converted to a Delaware corporation on December
14, 2021. FibroBiologics is an early stage, cell therapy company headquartered in Houston, Texas, developing innovative treatments for
chronic diseases using fibroblast cells. The Company&#8217;s primary focus is the initiation and progression of preclinical studies and
clinical-stage U.S. Food and Drug Administration trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis,
Cancer, Wound Healing and other diseases. Prior to Inception, preclinical research and development related to these disease pathways
took place under the parent company, SpinalCyte, LLC (the &#8220;Parent&#8221; or &#8220;FibroGenesis&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Direct
Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2024, the Company completed a direct listing of its common stock on Nasdaq (the &#8220;Direct Listing&#8221;). Upon completion
of the Direct Listing, all outstanding shares of the Company&#8217;s Non-voting Common Stock, Series B Preferred Stock, and Series B-1
Preferred Stock automatically converted into shares of Voting Common Stock on a one-for-one basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern and Management&#8217;s Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred operating losses since Inception and expects such losses to continue in the future as it builds infrastructure,
develops intellectual property and conducts research and development activities. The Company has primarily relied on a combination of
angel investors and private debt placements to funds its operations. As of December 31, 2023, the Company had an accumulated deficit
of $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20231231_z98ot1puN5v5">24,357</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand
and cash and cash equivalents of $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20231231_zbYmnjiej6kf">9,163
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand. A transition to profitability will
depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues
to support the Company&#8217;s cost structure. The Company currently does not generate revenues and may never achieve profitability.
Unless and until such time that revenue and net income are generated, the Company will need to continue to raise additional capital.
As further described in Note 8, management has entered into a share purchase agreement as of November 12, 2021. With the completion of
the Company&#8217;s Direct Listing, this agreement provides the Company with access to additional liquidity. In February 2024, the Company
utilized this facility to raise a total of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20230101__20231231_zXVMtP5hN2T7">1,924</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand. As a result, the Company believes it
has adequate capital to fund its current operating plan for at least the next 12 months from the date of issuance of these Financial
Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief executive
officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources
and evaluating financial performance. The Company operates and manages its business as a single operating segment and therefore has one
reportable segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687026620480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zYB9wikvYkDl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_z4wlpIcxE08c">Summary of Significant Accounting Policies</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zLg19Zjf7Xtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z8O3Z4jtpqqg">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding
annual financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from January 1, 2021, to its formation on April 8, 2021, the Company operated as a line of business of FibroGenesis rather
than as a separate stand-alone entity. Consequently, prior to the Company&#8217;s formation on April 8, 2021, the financial statements
were derived from the historical accounting records of the Parent. All general and administrative expenses and research and development
expenses directly associated with the business activity of the Company that were originally incurred by the Parent from January 1, 2021,
through the Company&#8217;s formation on April 8, 2021, were allocated and included in the Company&#8217;s financial statements. The
resulting net Parent investment was presented within stockholders&#8217; equity/(deficit) and represented the Parent&#8217;s interest
in the recorded net assets of the Company and has been eliminated through the ROFN Agreement as further described in Notes 7 and 11.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, the Company amended and restated its certificate of incorporation with the State of Delaware to immediately effect a 1-for-4
shares reverse stock split. All share and per share amounts have been adjusted on a retroactive basis to reflect the effect of the
reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--UseOfEstimates_zwt2zNhO5J4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zw1DrwJNNSH8">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements
and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date
of the Financial Statements; therefore, actual results could differ from those estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zbzlq04VIvr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zIVIo5Wbo1Te">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The
Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit
of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20231231_z1s2CkMyVJma" title="Federally insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial
condition, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84A_ecustom--RisksAndUncertaintiesPolicyTextBlock_zCM0wh8e2bCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zKNfC1n28vKk">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the
Company believes could have a material adverse effect on the future financial position or results of operations: the timing of, and the
Company&#8217;s ability to advance its current and future product candidates into and through clinical development; costs and timelines
associated with the manufacture of clinical supplies of the Company&#8217;s product candidates; regulatory approval and market acceptance
of its product candidates; performance of third-party contract research organizations (&#8220;CROs&#8221;) and contract manufacturing
organizations (&#8220;CMOs&#8221;); competition from pharmaceutical companies with greater financial resources or expertise; protection
of the intellectual property, litigation or claims against the Company based on intellectual property, or other factors; the need to
obtain additional funding; and its ability to attract and retain employees necessary to support its growth. Disruption from CROs&#8217;,
CMOs&#8217; or suppliers&#8217; operations would likely have a negative impact on the Company&#8217;s business, financial position and
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zOqnLLqHGWq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zKIHFte91RX1">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three
months or less at the time of purchase. There were <span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_zdGKDMCreLA3" title="Cash equivalents"><span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zTcjr9BCeQn" title="Cash equivalents">no</span></span> cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zMVkNCl4TJTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zoHu2zwW1ubi">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is computed using the straight-line
method over the estimated useful lives of the respective assets, generally three to five years, and includes laboratory equipment that is
recorded at cost and depreciated using the straight-line method over the estimated useful lives of five years. Depreciation expense is
classified in either research and development expense or in general and administrative expense, depending upon the nature of the asset,
in the accompanying Statements of Operations. When property and equipment assets are retired or otherwise disposed of, the cost and related
accumulated depreciation are removed from the balance sheets and the resulting gain or loss is recorded in other income (loss) in the
period realized. Maintenance and repairs are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets
might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable
market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that
would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used,
the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and
measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for
the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_znec43ArZIxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_865_zYvw03D16fRi">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company determines if an arrangement is a lease at inception. An arrangement is or contains a lease if it conveys the right to control
the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification is determined
at lease commencement. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement
date. The Company&#8217;s leases do not provide an implicit interest rate and therefore the Company estimates its incremental borrowing
rate to discount lease payments. The incremental borrowing rate reflects the interest rate that the Company would have to pay to borrow
on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term. Operating lease
right-of-use (&#8220;ROU&#8221;) assets are based on the corresponding lease liability adjusted for any lease payments made at or before
commencement, initial direct costs, and lease incentives. Renewals or early terminations are not accounted for unless the Company is
reasonably certain to exercise these options. Operating lease expense is recognized and the ROU asset is amortized on a straight-line
basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Operating
leases are included in operating lease right-of-use asset, operating lease liability, short-term, and operating lease liability, long-term
on the Company&#8217;s Balance Sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company has elected in accordance with ASC 842-20-25-2 an accounting policy to not record short-term leases, defined as those with terms
of 12 months or less, on the Balance Sheets. Rent expense recorded under leases, for financial statement purposes, is recognized on a
straight-line basis over the lease term based on the most recent contractual terms available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgvxc4Dp8Fl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86E_z69gfL6mD6u2">Fair
Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Accounting
Standards Codification (&#8220;ASC&#8221;) 820, <i>Fair Value Measurement</i>, establishes a fair value hierarchy for instruments measured
at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions
(unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market
data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about
the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available
in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions
in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Level
1 - Quoted market prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Level
2 - Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates
and yield curves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Level
3 - Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#8217;s
own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about
risk).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Categorization
within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zey6YkvhidG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><b><span id="xdx_863_zuS18C0BfOIb">Derivatives</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Derivative financial instruments,
including the Liability instrument, are recorded at fair value on the Balance Sheet. Liability classified derivatives are remeasured at their
fair value at each reporting date, with decreases or increases in the fair value recognized as other gain or loss, respectively, within
the Statement of Operations. Equity classified derivatives are not remeasured at each reporting date. If a liability classified derivative
becomes eligible for reclassification to an equity classified derivative, any gains or losses recognized up to the point of reclassification
are not reversed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZ1BEmZTWuR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zAmDAIw1ZIO5">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research
and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory
supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain
research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern
of costs incurred, and are reflected in the Financial Statements as prepaid or accrued research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zbOxJbLR5wDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zbLAotx4dYh8">Patent
Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company continues to incur costs to obtain market approval of patented technology, patent costs are expensed as incurred in general,
administrative and other expense in the Statements of Operations. Costs include fees to renew or extend the term of recognized intangible
assets, patent defense costs, and patent application costs. Management will continue to expense such costs until market approval is obtained
through regulatory approval by the appropriate governing body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zHewRXz5l1E1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zFTimCOV9u3k">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is a C corporation, and accounts for income taxes under the asset and liability
method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement
and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.
Valuation allowances are established when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the provisions of ASC 740-10, <i>Income Taxes</i>, the Company evaluates uncertain tax positions by reviewing against applicable tax
law all positions taken by the Company with respect to tax years for which the statute of limitations is still open. ASC 740-10 provides
that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained
upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The Company recognizes
interest and penalties related to the liability for unrecognized tax benefits, if any, as a component of the income tax expense line
in the accompanying Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z2DJvtjEuD1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zbrppPtA8Sm9">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs related to stock options granted to employees and nonemployees based on the estimated fair value
of the awards on the date of grant and recognizes expense on a straight-line basis over the requisite service period, which is generally
the vesting period of the award. Forfeitures are recognized as they occur. The fair value of stock options is estimated on the date of
grant using a Black-Scholes option pricing model which requires management to apply judgment and make estimates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
    Value of Common Stock</i>&#8212;The estimated fair value of our common stock underlying our stock-based awards has been determined
    by our board of directors as of each option grant date with input from management, considering our most recently available
    third-party valuations of common stock and our board of directors&#8217; assessment of additional objective and subjective factors
    that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant.
    These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public
    Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the
    Practice Aid). Now that a public trading market for our common stock has been established in connection with the completion of the
    Direct Listing, the fair value of common stock in future grants will be based on the closing price as reported on The Nasdaq Global Select Market on the
    date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Term</i>&#8212;The expected term represents the period that a stock-based award is expected to be outstanding. The Company uses the
    simplified method to determine the expected term, which is based on the average of the time-to-vesting and the contractual life of
    the option.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Volatility</i>&#8212; Due to the Company&#8217;s limited operating history and lack of company-specific historical and implied volatility
    data, the expected volatility is estimated based on the average historical volatilities of common stock of comparable publicly traded
    entities over a period of time commensurate with the expected term of the stock option grants. The comparable companies are chosen
    based on their size, stage in the product development cycle, or area of specialty. The Company will continue to apply this process
    until sufficient historical information regarding the volatility of its own stock price becomes available.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
    Interest Rate</i>&#8212;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon
    U.S. Treasury notes with maturities approximately equal to the expected term of the awards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Dividend</i>&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock.
    Therefore, the Company used an expected dividend yield of zero.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_ecustom--EmergingGrowthCompanyPolicyTextBlock_z4MVFVraF6ue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zvsvRe7B3p5k">Emerging
Growth Company</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the completion of the Direct Listing, the Company is an emerging growth company (EGC), as defined in the Jumpstart Our Business Startups
Act of 2012 (JOBS Act). Under the JOBS Act, an EGC can delay adopting new or revised accounting standards issued subsequent to the enactment
of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition
period for complying with new or revised accounting standards that have different effective dates for public and private companies; however,
the Company may adopt new or revised accounting standards early if the standard allows for early adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company will utilize other exemptions and reduced reporting requirements provided to EGCs by the JOBS Act. Subject to certain
conditions set forth in the JOBS Act, an EGC is not required to, among other things, (i) provide an auditor&#8217;s attestation report
on the company&#8217;s system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002,
(ii) provide all of the compensation disclosure that may be required of non-EGC public companies under the Dodd-Frank Wall Street Reform
and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding
mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the
financial statements (auditor discussion and analysis), or (iv) disclose certain executive compensation-related items, such as the correlation
between executive compensation and performance and comparisons of the chief executive officer&#8217;s compensation to median employee
compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zF9lBFxyj566" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zy4HvretUkF8">Recently
Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There have been no accounting pronouncements issued but not yet adopted by the Company that are expected to have a material impact on
the Company&#8217;s Financial Statements.</p>

<p id="xdx_85A_zFDTBd9KMsG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687029319280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_z2u7DmYYXDTd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zBXZptKVMQFk">Net Loss per Share Attributable to Common Stockholders</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z0dYk4poM839" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zVKpKEtpCaTa" style="display: none">Schedule
of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zu8kbZ2g6hlf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20221231_zQsA2Qcw3FAd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">(in thousands, except share and per share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zi9yPG10Rbrh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(16,485</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(5,121</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Adjustment to numerator for earnings per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeemedDividend_pn3n3_zejgX65pHSMk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,573</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zMGm5Vglj8Q8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net loss attributable to common stockholders:</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(19,058</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,121</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted-average number of common shares outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zdJApRGVbmnf" title="Weighted average number of shares outstanding, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zlhNGNuwHShi" title="Weighted average number of shares outstanding, diluted">28,230,842</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231_zpuyPZbdiYSf" title="Weighted average number of shares outstanding, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20221231_zqNTkQR0nUtg" title="Weighted average number of shares outstanding, diluted">28,230,842</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net loss per common share attributable to common stockholders, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zXJeHCOo15C7" title="Net loss per share, basic"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zT0ZKNo8sKmf" title="Net loss per share, diluted">(0.68</span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zWoD99bcKbqf" title="Net loss per share, basic"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_zdCCF9wil7Mh" title="Net loss per share, diluted">(0.18</span></span></td><td style="text-align: left">)</td></tr>
  </table>

<p id="xdx_8AC_zLZZJHROg5lk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
further described in Note 7, the Company issued <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zyI04K1twSRf" title="Common stock, shares issued">28,230,842</span> shares of non-voting common stock on August 18, 2022. The weighted average
number of shares outstanding for the years ended December 31, 2023 and 2022, is based upon the non-voting common stock shares issued
on August 18, 2022. Because the issuance of nonvoting common stock shares was treated as a stock split for accounting purposes, these
shares are treated as having been issued on January 1, 2022, and outstanding for the entire years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
further described in Note 11, the Company agreed to pay to FibroGenesis 15% of the gross proceeds from any equity investments in FibroBiologics
prior to an Initial Public Offering (&#8220;IPO&#8221;), Direct Listing or Sale of the Company to eliminate upon the occurrence of such
event the Series A Preferred Stock and its $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn6n6_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5p5yDhUxLU" title="Preferred stock liquidation value">35</span> million liquidation preference. This redemption of preferred stock created a derivative
liability that exceeded the net Parent Investment of $<span id="xdx_908_eus-gaap--PreferredStockRedemptionAmount_iI_pn3n3_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_znyXxZJdeAgj" title="Preferred stock, redemption amount">1,461</span> thousand by $<span id="xdx_903_eus-gaap--PreferredStockRedemptionAmount_iI_pn3n3_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zhorCztprQo8" title="Preferred stock, redemption amount">1,112</span> thousand, and is reflected here as a reduction of the
amount available to common stockholders in the calculation of earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had $<span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231_zVOm3YkF9PAl" title="Convertible notes outstanding">5,600</span> thousand of convertible notes outstanding as of December 31, 2022, which could have been converted into common stock
in the event that the Company sold and issued shares of capital stock in excess of $<span id="xdx_900_ecustom--CapitalStockInExcess_iI_pn3n3_c20221231_z6mkqfnyFqk" title="Capital stock in excess">10,000</span> thousand, and were all converted by December
31, 2023, into shares of Series B Preferred Stock as further described in Note 6. As of December 31, 2022, the estimated number of shares
of common stock that would have been issued upon conversion was <span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220101__20221231_zo42ctilWFl6" title="Issued upon conversion of common stock">801,145</span> shares. For the years ended December 31, 2023 and 2022, the Company
reported net losses and, accordingly, potential common shares were not included since such inclusion would have been anti-dilutive. As
a result, the Company&#8217;s basic and diluted net losses per share are the same because it generated a net loss in all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687031775296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_ziBYyVzNIDYi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zn1Stxouvjgl">Property and Equipment</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwkvNwMSVfij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zrZpqfg7xer2" style="display: none">Schedule
of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zJHTNJbuNowg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zfBe724ZDyel" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zVFYgHl8sNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Laboratory equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">816</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0736">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zhVeI3z0qLvg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Computer equipment, software, and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzT4x_zdxjoNYWrnJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total property and equipment at cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzT4x_zVMRjGrd2pWh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzT4x_z9sJOuSJjzkg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">797</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z2nWgZqRmgei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The useful life of Laboratory
equipment is <span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaborataryEquipmentMember_zSvB5AL4Iaj2">five
years</span>, and the useful life of Computer equipment, software, and other is <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zi2KZge2USk3">three
years</span>, for deprecation. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was $<span id="xdx_904_eus-gaap--Depreciation_pn3n3_c20230101__20231231_z2rUirPXyKCh" title="Depreciation expense">47
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand and $<span id="xdx_906_eus-gaap--Depreciation_dxL_c20220101__20221231_zu74kcDkYkyf" title="Depreciation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0754">0</span></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2023 and 2022,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687027539888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zg0tRzLLlj1g" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zBdkAFbTAe48">Fair Value of Financial Instruments</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company measured its derivative liability related to the conversion option feature in the 2022 Notes, as described
in Note 6, at fair value. As of December 31, 2023, the 2022 Notes had been converted, which eliminated the derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company measured its liability instrument to investors under the Share Purchase Agreement, as further
described in Note 8, at $<span id="xdx_901_ecustom--LiabilityInstrument_iI_pn3n3_c20231231_z06TqnkKKje6" title="Liability instrument">7,236</span>
thousand. This liability instrument is classified within Level 3 of the value hierarchy because the liability was based upon a
valuation model that used inputs and assumptions including potential outcomes, interest rates, probabilities, and timing. As of
December 31, 2022 and 2021, this liability instrument was assigned <span id="xdx_908_ecustom--LiabilityInstrument_iI_pn3n3_dxL_c20221231_z5fMYDm37JCl" title="Liability instrument::XDX::-"><span id="xdx_906_ecustom--LiabilityInstrument_iI_pn3n3_dxL_c20211231_zUHhhLd97fU2" title="Liability instrument::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0760"><span style="-sec-ix-hidden: xdx2ixbrl0762">no</span></span></span></span>
value by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zxcyuXtjdMae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the Company&#8217;s financial liabilities measured at fair value on a recurring basis based on the three-tier
fair value hierarchy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zNKASbrI9hL4" style="display: none">Schedule
of Financial Liabilities Measured at Fair Value</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLLuS0PczDq9" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4QwOa4vrGDf" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqK5YCQi6hRc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_zHDTFayCne1h" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurement as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3n3_maFLFVDzjkJ_zd28TiS69tu" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0769">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LiabilityInstrument_iI_pn3n3_maFLFVDzjkJ_zSVJOIJHeuMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1.5pt">Liability instrument</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0771">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">7,236</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">7,236</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iTI_pn3n3_mtFLFVDzjkJ_zUTrzedZQ5v4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,236</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zv9FVDrwyWrh" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbm3b64kBb53" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAs0SJ0b4x91" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zVaRRvyjdPe3" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurement as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3n3_maFLFVDzjkJ_zE4RX3P8S3nb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: justify">Derivative liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0781">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LiabilityInstrument_iI_pn3n3_maFLFVDzjkJ_zEUrEX1sjtxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Liability instrument</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0786">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0788">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0789">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iTI_pn3n3_mtFLFVDzjkJ_zrwptT3BQmp4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0791">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">538</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zip3wzSjs8xb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z6c68rgTTnp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the transfers in and out of Level 3 financial liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zTHKXPMPqPb5" style="display: none">Schedule
of Financial Liability Transfers</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zDan4JiNQ9Ji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--FinancialInstrumentAxis_custom--LiabilityInstrumentMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zaoNWEPM5a0c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Liability Instrument</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43B_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z92TrGkB33X8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0799">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_i01_zOqdkfh6hZhf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify; padding-bottom: 1.5pt">Addition to derivative liability for debt issuance discount</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">538</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z3GoE9sf6z76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value at December 31, 20222</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zTb4d5OK5Ltl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value, beginning balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_i01_zGJdBDaCkNN2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(538</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_i02_zT8ZthOEVd78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Increase in the fair value of the liability instrument</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,236</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zApiiV7yRhxd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Fair value at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,236</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zVTS1vt1qSaa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Fair value, ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,236</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A2_zcA3Gu1mOI3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the liability instrument includes the contingent warrant and the contingent put option as a single unit of
account. The liability instrument value was determined using a Black-Scholes valuation model and management&#8217;s assumption of a
50% likelihood as of December 31, 2023, of becoming a public company prior to the expiration of the Stock Purchase Agreement. Inputs
used in the Black-Scholes valuation model included an estimated number of warrants, an assumed common stock share price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20231231_zGZgzBBrQirl" title="Share price">15.00</span>
per share, the <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputMaturityMember_zl0YAK8Sb2n" title="Maturity period::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0824">five-year</span></span>
time to maturity, a <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJdWIEpXDIy" title="Dividend yield">0</span>%
dividend yield, an annual risk-free interest rate of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ziQDhX260m44" title="Dividend yield">3.84</span>%
for the <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputMaturityMember_zoBmK2rRcmp3" title="Maturity period::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0830">five-year</span></span>
time to maturity, and an assumed annualized volatility of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zHWZLdXUg6fe" title="Dividend yield">96</span>%
based on comparable companies with a five-year history of stock prices. As of December 31, 2023, the Company evaluated the put option component of the liability instrument and determined
that any value as it relates to the liability instrument would be de minimus given the Company&#8217;s financial condition, intention
to seek other sources of financing as needed, and ability to do so given access to public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liability was determined based upon a valuation model that used inputs and assumptions including potential outcomes, interest
rates, probabilities, and timing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, prepaid expenses, other current assets, accounts payable, accrued expenses, convertible
notes payable, and Parent company payable and receivable approximate their fair values due to their short-term maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than those transfers noted in the table above, there were no transfers in or out of Level 1, Level 2 or Level 3 assets and liabilities
for the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687120331424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zQzF13VFyLuj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zFvXv0qrDcHj">Convertible Notes Payable</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company entered into multiple convertible promissory note agreements in December 2021 (collectively, the &#8220;2021 Notes&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
the inception of the 2021 Notes, and at December 31, 2021 and 2022, the Company determined that an embedded derivative for the conversion
feature did not meet the criteria because it met the &#8220;indexed to the entity&#8217;s own stock&#8221; exception per the guidance
in ASC 815-10-15-74(a) and therefore was not required to be bifurcated from the host instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company issued additional convertible promissory notes between January and April 2022 with a total principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20221231_zMPzXaM98Ebe" title="Long-term debt, gross">4,300</span> thousand
and a one-year maturity (collectively, the &#8220;2022 Notes&#8221;). The 2022 Notes may be converted at the lesser of <span id="xdx_902_eus-gaap--ConversionOfStockDescription_c20220101__20221231_z1EosKjra0Na">a) a 15% discount
to the offering price of the Company&#8217;s common stock in the event of an initial public offering of the Company or b) the quotient
of $200,000 thousand divided by total equity interests prior to the dilution from the offering. The conversion option feature in the
2022 Notes was evaluated in accordance with ASC 815, and a derivative liability for the $538 thousand estimated fair value of the conversion
option was recorded at the time the notes were issued and as of December 31, 2022.</span> An offsetting discount on the issuance of the notes
was recorded and is being amortized to interest expense over the expected life of the 2022 Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
interest expense, excluding amortization of the discount recorded on the 2022 Notes, on the 2021 and 2022 Notes for the years ended December
31, 2023 and 2022, was $<span id="xdx_905_eus-gaap--InterestExpenseDebt_pn3n3_c20230101__20231231_zheOCS5KAJu5" title="Interest expense">65</span> thousand and $<span id="xdx_900_eus-gaap--InterestExpenseDebt_pn3n3_c20220101__20221231_z1pC6uGJWesb" title="Interest expense">265</span> thousand, respectively. Accrued interest was outstanding and included within accounts payable
and accrued expenses at December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, the Company converted the principal and interest on $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230228__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_z3ytIkqOtnih" title="Face value">3,700</span> thousand of principal value of the 2022 Notes into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230228__20230228__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zWMOTQ4RQKHg" title="Converted principal shares">799,603</span>
shares of Series &#8220;B&#8221; Preferred Stock. In April 2023, the Company also converted the principal and interest on $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230430__us-gaap--AwardDateAxis__custom--TwoThousandTwentyOneNotesMember_zIoGHQedMyZg" title="Face value">1,300</span> thousand
of principal value of the 2021 Notes and $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230430__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zFzUss0XgUS9" title="Face value">300</span> thousand of principal value on the 2022 Notes into <span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230430__20230430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zTJC820zOXkc" title="Converted principal shares">353,713</span> shares of Series &#8220;B&#8221;
Preferred Stock. In September 2023, the Company converted the principal and interest on $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230930__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zlv5MlBJA2D1" title="Face value">300</span> thousand of principal value of the 2022
Notes into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zIlIicarrrhk" title="Converted principal shares">66,077</span> shares of Series &#8220;B&#8221; Preferred Stock. No interest was outstanding and included within accounts payable
and accrued expenses at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ConvertibleDebtTableTextBlock_zVO08cHnhuP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible debt balances consisted of the following at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zX3mntGP8fJj" style="display: none">Schedule
of Convertible Debt</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_z25Oeg9YnNC2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_z1IL1owBFkX9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_zCuYZINdJ0Rl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Convertible notes principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,600</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_ziuOa8C2CBp6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Convertible notes discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(149</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_ztByUfwJGlS8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Convertible notes payable, net of discount</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,451</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zGjAiLLeI8dl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687031784848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity/(Deficit) and Net Parent Investment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity/(Deficit) and Net Parent Investment</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z5LOF9CdNifl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zJQs3LQTfNEd">Stockholders&#8217; Equity/(Deficit) and Net Parent Investment</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Authorized
Capital - </b>As of December 31, 2023 and 2022, the Company authorized <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zNxjJLRwUema" title="Preferred stock, shares authorized">20,000,000</span> and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_zitD7LmHlsP5" title="Preferred stock, shares authorized">12,500,000</span> preferred stock shares, respectively.
As of December 31, 2022, the Company had issued <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zvexj6QAIVN6" title="Preferred stock, shares issued">8,750,000</span> Series &#8220;A&#8221; Preferred Stock shares to FibroGenesis, which were tendered
pursuant to the formation of the Company in exchange for the contribution of certain in-process research and development and patent assets
through Patent Assignment and Intellectual Property Cross-License Agreements. The Series &#8220;A&#8221; Preferred Stock shares had the
right to vote and ranked prior to non-voting common stock and common stock with respect to payment of dividends and distributions and
upon liquidation, dissolution, winding-up or otherwise. In addition, the Series &#8220;A&#8221; Preferred Stock had a liquidation preference
equal to $<span id="xdx_90A_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGmZYyyCqEac" title="Preferred stock liquidation value">35,000</span> thousand to be allocated among the holders of the Series &#8220;A&#8221; Preferred Stock shares in the event of a liquidation,
dissolution, or winding-up of the Company, which was subsequently eliminated as part of the ROFN Agreement as further described below,
and each share of Series &#8220;A&#8221; Preferred Stock could have been converted into one share of common stock at any time at the
election of the holder of such shares of Series &#8220;A&#8221; Preferred Stock. Unless otherwise elected by the holder(s), a merger
or consolidation in which the Company is not the majority surviving entity or the sale of all or substantially all of the assets of the
corporation would have been a deemed liquidation event. The Company had also authorized <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_z6bMcFqJxuO5" title="Common stock, shares authorized">62,500,000</span> shares of non-voting common stock,
and issued during the year ended December 31, 2022, a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_z7sIcyE2Pqf6" title="Common stock, shares issued">28,230,842</span> shares. In August 2022, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zHvRzkOXrY98" title="Number of shares issued">28,179,592</span> shares
of non-voting common stock to its Parent, which in turn distributed the shares to its members. This issuance of non-voting common stock
was accounted for as stock split and no proceeds were received by the Company. The Company also issued to its board of directors, a consultant,
and an employee an additional <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_pid_c20220101__20221231_zESTNHBcIcVa" title="Employee benefit plan">51,250</span> total shares in 2022 and recorded $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_pn3n3_c20220101__20221231_z3U0aVm2nR68" title="Share based compensation">168</span> thousand of expense for the issuance of these shares, which
was based upon a third-party valuation of the shares at the time of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, the Company amended its Certificate of Incorporation to authorize <span id="xdx_90C_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zMiPAcOdm0a2" title="Preferred stock, shares authorized">2,500,000</span>
shares of Series &#8220;B&#8221; Preferred Stock and issued <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfRvAiLvbaJf" title="Preferred stock, shares issued">381,658</span>
shares in exchange for $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7IVPaNKa1Xe" title="Preferred stock, shares issued">2,150</span>
thousand. The Series &#8220;B&#8221; Preferred Stock has a liquidation preference after Series &#8220;A&#8221; Preferred Stock and
prior to Common Stock and Non-Voting Common Stock. The Series &#8220;B&#8221; Preferred Stock has a liquidation preference of $<span id="xdx_905_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0ZgEiQz3yY2" title="Preferred stock, liquidation preference per share">6.76</span>
per share, subject to adjustment, has voting rights, and will automatically convert into Common Stock upon closing of an IPO
transaction, as defined in the Company&#8217;s Amended and Restated Certificate of Incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, to reflect the ROFN Agreement with its Parent, as further discussed in Note 11, the Company amended its Certificate of
Incorporation to a) eliminate upon IPO, Direct Listing, or Sale of the Company the Series &#8220;A&#8221; Preferred Stock $<span id="xdx_905_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20230131_z3OWPL4A6bh9" title="Liquidation preference">35,000</span> thousand
liquidation preference, b) make the Series &#8220;B&#8221; Preferred Stock liquidation preference equal to Series &#8220;A&#8221; Preferred
Stock, and c) to provide that upon IPO, Direct Listing, or Sale of the Company Series &#8220;A&#8221; Preferred Stock will be canceled
for no consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company amended its Certificate of Incorporation to authorize <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230430_zH4UoocHHqaa" title="Common stock, shares authorized">10,000,000</span>
shares of Common Stock, increase the number of authorized Series &#8220;B&#8221; Preferred Stock shares up to <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zTixlp10BV51" title="Common stock, shares authorized">5,000,000</span>
shares, and to authorize <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230430__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_znXCQLUyK8o5" title="Common stock shares authorized">5,000,000</span>
shares of Series &#8220;B-1&#8221; Preferred Stock with liquidation preference equal to the Series &#8220;A&#8221; and
&#8220;B&#8221; Preferred Stock. The Series &#8220;B-1&#8221; Preferred Stock has a liquidation preference of $<span id="xdx_906_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20230430__us-gaap--StatementClassOfStockAxis__custom--SeriesB1PreferredStockMember_z0Bycmxl5uG" title="Preferred stock, liquidation preference per share">20.00</span> per share,
subject to adjustment, has voting rights, and will automatically convert into Common Stock upon closing of an IPO transaction, as
defined in the Company&#8217;s Amended and Restated Certificate of Incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company raised $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9TcR8k4MWh5" title="Stock issued during period, value, new issues">4,620</span> thousand, net of fees, through a Regulation CF offering with <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zq9dCVQGC9Wh" title="Stock issued during period, shares, new issues">890,310</span> shares
of Series &#8220;B&#8221; Preferred Stock issued, raised $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zQzmMRrT05ac" title="Stock issued during period, value, new issues">10,325</span> thousand in a private placement with <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsO7B3kYHwuf" title="Stock issued during period, shares, new issues">1,680,084</span> shares of Series &#8220;B&#8221;
Preferred Stock issued, and raised $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwgWnsGoe8D5" title="Stock issued during period, value, new issues">1,193</span> thousand in a private placement with <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNbS7M5wBBBh" title="Stock issued during period, shares, new issues">89,781</span> shares of &#8220;B-1&#8221; Preferred Stock and
<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1RpZw0vSZAh" title="Stock issued during period, shares, new issues">10,321</span> warrants issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In October 2023, the Company
amended and restated its certificate of incorporation with the State of Delaware to increase to <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231031_zpSY6lLf1KM8" title="Preferred stock, shares authorized">100,000,000</span> shares its authorized shares
of voting common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231031_z9E8NiAEnDg6" title="Common stock, par or stated value per share">0.00001</span> per share, reduce to <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zNKOLyacYD2k" title="Common stock, shares authorized">30,000,000</span> shares its authorized shares of non-voting common stock, par
value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zrqhY3xKB5bk" title="Common stock, par value">0.00001</span> per share, and authorize <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z8HzskKL2ZN4" title="Preferred stock, shares authorized">2,500</span> shares of Series C Preferred Stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zx3OZYbNhPDg" title="Preferred stock, par value">0.00001</span> per share. The Series C Preferred
Stock ranks senior to common stock and non-voting common stock and junior to the Series A Preferred Stock, Series B Preferred Stock and
Series B-1 Preferred Stock upon liquidation, dissolution, winding-up or otherwise. The Series C Preferred Stock shall have no voting
rights prior to an IPO, and <span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zwV0eJaB6pGj" title="Sale of stock, price per share">13,000</span> votes per share upon closing of an IPO. <span id="xdx_909_eus-gaap--DebtInstrumentConvertibleTypeOfEquitySecurity_c20231001__20231031_zqik6QoV0D0i" title="Debt instrument convertible descreption">The Series C Preferred Stock is not entitled to dividends,
has a liquidation preference of $<span id="xdx_90B_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ztAzwKsxJ93k" title="Preferred stock, liquidation preference per share">18.00</span> per share, subject to adjustment, may be converted 1:1 at any time at the option of the holder
into common stock, and upon closing of an IPO will if transferred automatically convert 1:1 into common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
in October 2023, the Company filed an amended and restated certificate of incorporation with the State of Delaware to immediately effect
a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_pid_c20231031__20231031_zAzQtfGjPTx2" title="Reverse stock split">1-for-4 reverse stock split</span>. All share and per share amounts in these Financial Statements have been adjusted on a retroactive basis
to reflect the effect of the reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687027499312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Subscription Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_DisclosureShareSubscriptionAgreementAbstract', window );"><strong>Share Subscription Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_ShareSubscriptionAgreementTextBlock', window );">Share Subscription Agreement</a></td>
<td class="text"><p id="xdx_80C_ecustom--ShareSubscriptionAgreementTextBlock_zUaGaCJNG1g" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zxWgJ1ZWCn1j">Share Subscription Agreement</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2021, the Company entered into a Share Purchase Agreement with certain investors for the sale of up to $<span id="xdx_909_eus-gaap--CapitalUnitsTotalCostToInvestors_iI_pn3n3_c20211112__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z65PP2rkf3z3" title="Investors sales">100,000</span> thousand
of common stock (the &#8220;Aggregate Limit&#8221;). This agreement is contingent upon the Company achieving a public listing of its
common stock. Major terms of the agreement include a commitment fee of <span id="xdx_90D_ecustom--CommitmentFeePercentage_iI_pid_dp_uPure_c20211112__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zBr2fg71fX44" title="Commitment fee percentage">2</span>% of the Aggregate Limit, which is due no later than one year
after public listing even if no drawdowns are taken, and five-year warrants issued to the investors at the time of public listing to
purchase common stock shares equal to 4% of the total equity interests of the Company at the lesser of a) the price per share at the
time of the public listing or b) the quotient of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20211112__20211112__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zac7KAK5cftj" title="Shares issues  initial public offering">700,000</span> thousand divided by the total number of equity interests (fully diluted common
shares). <span id="xdx_90D_ecustom--DescriptionOfShareSubscriptionAgreement_c20230101__20231231_zVis86ayY9Hg" title="Description of share subscription agreement">The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement
following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the
Company&#8217;s common stock shares over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average
price per share over that same period. A 1% fee must be paid to the investors if the Company is sold in a private sale transaction rather
than completing a public listing of its shares.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_DisclosureShareSubscriptionAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_DisclosureShareSubscriptionAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_ShareSubscriptionAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Subscription Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_ShareSubscriptionAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687028417424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zAFP1B4hpDd4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zOCIb512Ivea">Income Taxes</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> </p>

<p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMyajH8Q5Dw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income
tax rate is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B9_zGyMnfEQJVhe">Schedule
of Effective Income Tax Rate</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49A_20230101__20231231_zQjyP5rCczO" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49F_20220101__20221231_zlEW1BEVXLT4" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maIT1_zhpFB2bOyrZa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maIT1_z1MMpSlI4bla" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Permanent items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets_iN_pid_dpi_maIT1_zu54jBvn6Dx6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">True-up prior-year net operating loss deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0960">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.1</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_maIT1_ziVacqX65X78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Non-deductible stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maIT1_z9OXNpePOoX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other changes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.9</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maIT1_zh5Ip47Jbugl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10.2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtIT1_zGACPGAZr545" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A3_zdBQlNy50d7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zZVySOlNpsJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the Company&#8217;s net deferred tax assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zgVOZU6KCUYa">Schedule
of Net Deferred Tax Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49D_20231231_zoKa37FeocX" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49F_20221231_zFmEtHCPGy01" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands of dollars)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zof6IgjI7NRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzVPk_zzEu0bznNSig" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: justify">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,005</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">896</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzVPk_zzj6ANgkgWDc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">299</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability_iI_pn3n3_maDTAGzVPk_zWUnvKIYM492" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">435</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzVPk_zw5gAXVTkeij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzVPk_zOff63TXUi01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsDerivativeInstruments_iI_pn3n3_maDTAGzVPk_zJEuhrbFNNH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzVPk_maDTANzrSY_zGxD84s8cJi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,326</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,759</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_pn3n3_zTyyXVBVfxv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_iNI_pn3n3_di_maDITLzuqP_zVFjhlXtF8P7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(380</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(462</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_maDITLzuqP_zGQ8CV25vpLl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesUnamortizedDebtDiscount_iNI_pn3n3_di_maDITLzuqP_zioBQTZ1W2Bj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Unamortized debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1010">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzuqP_msDTANzrSY_zTgYuoWn5gI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(391</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(493</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzrSY_zjv9ACfJB2l3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,935</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,266</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzrSY_zaO9ru3yPtf4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1020">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zFmecsOB2FJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was initially formed as an LLC and was converted to a Delaware corporation in December 2021. As a result of generating net operating
losses during the years ended December 31, 2023 and 2022, the Company had <span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_do_c20230101__20231231_zqpqr8sTM2Ih" title="Income tax expenses"><span id="xdx_90D_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_do_c20220101__20221231_zpvOMOSR3Lf" title="Income tax expenses">no</span></span> income tax expense for years ended December 31, 2023 and
2022. As of December 31, 2023, the Company had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20231231_zzg8Ahi5mNS6" title="Operating loss carryforwards">9,547</span> thousand.
The federal NOL carries forward indefinitely and may become subject to an annual limitation in the event of certain cumulative changes
in the ownership interest. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income
or tax liabilities. Subsequent ownership changes may further affect the limitation in future years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental
to research and experimentation (&#8220;R&amp;E&#8221;) activities under IRC Section 174. While taxpayers historically had the option
of deducting these expenses under Internal Revenue Code (&#8220;IRC&#8221;) Section 174, the December 2017 Tax Cuts and Jobs Act mandates
capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection
with R&amp;E activities in the United States must be amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside
the United States must be amortized over a 15-year period. R&amp;E activities are broader in scope than qualified research activities
considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an
analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization
and amortization of its R&amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect
R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company has included the impact
of this provision, which results in a deferred tax asset of approximately $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_c20231231_z52aJ2Mc9QVf" title="Deferred tax assets">680</span> thousand as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated the positive and negative evidence bearing upon the realizability of the Company&#8217;s net deferred tax assets and has
determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result,
the Company has recorded a full valuation allowance at December 31, 2023 and 2022. The Company will continue to assess the realizability
of its deferred tax assets going forward and will adjust the valuation allowance as needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, the Company had <span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20231231_z59Ay7r2cY06" title="Uncertain tax positions"><span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20221231_zLijGq7bmyH9" title="Uncertain tax positions">no</span></span> uncertain tax positions. The Company recognizes both interest and penalties associated
with unrecognized tax benefits as a component of income tax expense. The Company has not recorded any interest or penalties for unrecognized
tax benefits since its inception, and no taxes are due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687027504304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Leases, Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zCLqrIYI2o52" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zPKT8WWMx8l8">Leases, Commitments and Contingencies</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company had entered into two short-term lease agreements for lab and office space. The Company opted on March
30, 2022, to extend the lease term for one of its leases for lab and office space, with a commencement date for the lease extension on
May 1, 2022. The extended lease term was <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20211231_zNWSb3bjMqCe" title="Extended lease term">126 months</span> and was accounted for as an operating lease under the ASC 842 guidance for lease
accounting. A right-of-use lease asset and tenant improvement allowance receivable with a combined total of $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--ShortTermLeaseAgreementMember_zFyVFAjEw8el" title="Operating lease right-of-use asset">2,799</span> thousand and a lease
liability of $<span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--ShortTermLeaseAgreementMember_zbD1czDHoJbk" title="Lease liability">2,799</span> thousand were recorded at the time of the extension. This lease was terminated as of July 31, 2022, and the remaining
balances of the right-of-use asset, tenant improvement allowance receivable, and lease liability were written off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expanded the scope and extended for six months the term for the remaining lease for temporary lab and office space on July 1,
2022, then further expanded the scope on August 1, 2022, and October 7, 2022, which increased the monthly license fee to $<span id="xdx_905_ecustom--LicenseFee_iI_pn3n3_c20231231_zfIdHlCa3wXf" title="License fee">15</span> thousand
per month. In January 2023, the Company extended this lease for an additional six months and it expired at the end of June 2023. This
lease for temporary lab and office space was accounted for as a short-term lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2022, the Company entered into a lease agreement for office space with a term of <span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20221031_zfUEngX8MJ6a" title="Extended lease term">62 months</span>, which expires on November 30, 2027.
This lease will be accounted for as an operating lease under the ASC 842 guidance for lease accounting. A right-of-use lease asset and
lease liability of $<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221031__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zBbz7GvV0kX8" title="Operating lease right-of-use asset"><span id="xdx_90C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20221031__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zLyqbpYaBJP7" title="Operating lease liability">2,293</span></span> thousand each were recorded at inception of the lease term using a discount rate of <span id="xdx_900_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_c20221031__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zZ6utFKyho7b" title="Operating lease discount rate">7.5</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company entered into a new lease for temporary lab and office space for its research operations. This lease has a term
of <span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20230630_zocVOGhQTBr3" title="Extended lease term">12 months</span> and monthly rent of $<span id="xdx_90B_eus-gaap--PaymentsForRent_pn3n3_c20230601__20230630_zirCUd32eMfc" title="Monthly rent">6</span> thousand and will be accounted for as a short-term lease. This lease commenced in August 2023. In
September 2023, the Company entered into an amendment of this lease to additional space, and the monthly rent increased to $<span id="xdx_909_eus-gaap--PaymentsForRent_pn3n3_c20230901__20230930_zocx9o0Xrx54" title="Monthly rent">7</span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense for the years ended December 31, 2023 and 2022, was $<span id="xdx_90A_eus-gaap--PaymentsForRent_pn3n3_c20230101__20231231_z2tbG4unDuSg" title="Rent expense">685</span> thousand and $<span id="xdx_900_eus-gaap--PaymentsForRent_pn3n3_c20220101__20221231_z8IdFn2081Yd" title="Rent expense">392</span> thousand, respectively. As of December 31, 2023, noncancelable
lease payments under operating leases were $<span id="xdx_905_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--OperatingLeasesMember_zxwa3Iw5OoB2" title="Noncancelable lease payments">2,017</span> thousand and noncancelable lease payments under short-term leases were $<span id="xdx_902_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ShorttermLeasesMember_zXEYXhLgz22i" title="Noncancelable lease payments">45</span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zCRnIEfM2V4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of operating lease liabilities as of December 31, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zf9BJJ1cuxO5">Schedule
of Operating Lease Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_494_20231231_zf2juYoMbqC8" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">(in thousands of dollars)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzBez_zhOzemaUykAg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">477</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzBez_z9nlfMXuyQzk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">487</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzBez_zqXVngmSJso3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">544</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzBez_zD9NssKUpFKf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">509</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzBez_ze69Bh99KOJi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1076">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzBez_zovClIaNjQ5f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,017</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zcY2uAGnGOwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(270</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z4Z5KHIIc0wg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,747</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zMB0sVExmf1l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Current lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(362</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zqnsXs4umSc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,385</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zw00hGigI3wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687027465216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5nBpXuPHj97" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zD6hWj5F1Wz">Related Party Transactions</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">The
Company repaid in April 2022 the remaining Parent company payable of $<span id="xdx_90A_eus-gaap--RepaymentsOfRelatedPartyDebt_pn3n3_c20220401__20220430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_z0CHr6Zmlb8f">225
</span></span><span style="background-color: white">thousand<span style="background-color: white">, which was outstanding at December
31, <span style="background-color: white">2021</span></span>. In July 2022, the Company loaned $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20220731_zNIArsqJy5U8">300
</span></span><span style="background-color: white">thousand to the Parent on a one-year note bearing no interest. In October 2022, the
Company loaned $<span id="xdx_904_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20221031_znXza2ik8YKf">60</span></span> <span style="background-color: white">thousand
to the Parent on a one-year note bearing no interest and this note was repaid before December 31, 2022. In April 2023, FibroGenesis repaid
in full the $<span id="xdx_90A_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20230430_zifVC6LjHs1l">300</span></span> <span style="background-color: white">thousand
Parent company receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 7, the Company acquired from FibroGenesis certain in-process research and development and patent assets through Patent
Assignment and Intellectual Property Cross-License Agreements. The Patent Assignment Agreement transferred the right, title and interest
in and to certain patents from FibroGenesis to the Company for further development. The Intellectual Property Cross-License Agreement
grants to the Company exclusive rights to patents owned by FibroGenesis in a limited field of use, which includes the diagnosis, treatment,
prevention and palliation of a) spinal diseases, disorders, or conditions, b) cancer, c) orthopedics diseases, disorders or conditions,
and d) multiple sclerosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company entered into an Agreement Regarding Right of First Negotiation (&#8220;ROFN Agreement&#8221;) with its Parent,
FibroGenesis. In exchange for FibroGenesis&#8217; consent to amend the Certificate of Incorporation to a) eliminate upon IPO, Direct
Listing, or Sale of the Company the Series A Preferred Stock $<span id="xdx_907_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zeVVni01342l" title="Liquidation preference">35,000</span> thousand liquidation preference, b) make the Series B Preferred
Stock liquidation preference equal to Series &#8220;A&#8221; Preferred Stock, and c) to provide that upon IPO, Direct Listing, or Sale
of the Company Series A Preferred Stock will be canceled for no consideration, FibroBiologics agreed to pay to FibroGenesis <span id="xdx_900_ecustom--PercentageOfGrossProceedsFromEquityInvestments_pid_dp_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_zR3a02I16Y08" title="Percentage of gross proceeds from equity investments">15</span>% of the
gross proceeds from any equity investments in FibroBiologics prior to an IPO, Direct Listing or Sale of the Company. In addition, FibroBiologics
will receive a five-year right of first negotiation if FibroGenesis decides to license externally any of its technology. In January 2023,
the Company amended its Certificate of Incorporation to reflect these changes, recorded a derivative liability of $<span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_c20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zaVBJu9Tipnd" title="Related party transaction, expenses">2,573</span> thousand for
the expected future payments to FibroGenesis, and paid $<span id="xdx_90F_ecustom--PaymentsForEquityInvestments_pn3n3_c20230101__20230131_zZzryng7GmD7" title="Payments for equity investments">323</span> thousand to FibroGenesis for <span id="xdx_902_ecustom--PercentageOfGrossProceedsFromEquityInvestments_dp_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_ziQNRmxG1tfh" title="Percentage of gross proceeds from equity investments">15</span>% of the gross proceeds from equity issued
by the Company in December 2022. Based on its relationship to Series A Preferred Stock as described above, the derivative liability was
recorded first against the net Parent Investment and then to Additional paid-in capital after the net Parent Investment was eliminated.
During the year ended December 31, 2023, the Company raised gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_pn3n3_c20230101__20231231_zUFfRpabf6k7" title="Proceeds from (repayments of) related party debt">16,418</span> thousand from equity issuances and paid $<span id="xdx_909_ecustom--PaymentsForEquityInvestments_pn3n3_c20230101__20231231_zdKijQ4HKGq" title="Payments for equity investments">2,322</span>
thousand of these proceeds to FibroGenesis. Amounts paid in excess of the derivative liability are recorded as other loss in the Statements
of Operations. There was <span id="xdx_907_eus-gaap--DerivativeLiabilities_iI_pn3n3_do_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_zDGjWxvMnXt2" title="Derivative liability">no</span> derivative liability and a payable of $<span id="xdx_902_ecustom--DerivativeLiabilitiesPayableToRelatedParties_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_zRiEp6s6poW9" title="Derivative liabilities payable to related parties">141</span> thousand to FibroGenesis as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687027504304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zb9c2CAOUUj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_zk9OGRxvCbyg">Share-Based Compensation</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company adopted on August 10, 2022, and the stockholders approved on August 18, 2022, the 2022 Stock Plan (the &#8220;Plan&#8221;). The
Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards,
restricted stock unit awards, and other stock awards. The Plan, through the grant of stock awards, is intended to help the Company secure
and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of
the Company and provide a means by which the eligible recipients may benefit from increases in value of the common stock. In September
2022, the Company issued a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220901__20220930_zka9horPxiG9" title="Number of options granted">101,250</span> options with a strike price of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20220930_zc3qfwciguw7" title="Strike price per share">3.28</span> per share to employees, directors, and scientific advisory
board members under this Plan. In February 2023, the Company issued an additional total of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230201__20230228_zSLJPrlLJs1h" title="Number of options granted">3,689,750</span> options with a strike price of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230228_znbPofZfhsg3" title="Strike price per share">2.28</span>
per share to employees and directors under this Plan. In August 2023, a total of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831_zfSBCI55HU08" title="Number of options granted">2,500</span> options with a strike price of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230831_z9VpmBUofC6f" title="Strike price per share">3.28</span> per share
were forfeited. Generally, awards granted by the Company vest over four years and have an exercise price equal to the estimated fair
value of the common stock as determined by the board of directors with consideration given to contemporaneous valuations of the Company&#8217;s
common stock prepared by an independent third-party valuation firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of December 31, 2023 and 2022, respectively, there were <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231_zOFJaGZrd4W1" title="Shares available for future issuance">8,711,500</span> shares and <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231_zVS6Et3ol1f9" title="Shares available for future issuance">12,398,750</span> shares available for future issuance under the
Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zh0yQPadnZPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
compensation expense is recognized in the Statements of Operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B3_zUX2A2LrRE1b">Schedule
of Stock Based Compensation Expense</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49B_20230101__20231231_z9eSO3sapg91" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49E_20220101__20221231_z702WuTnT3z4" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands of dollars)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zhcrZZFUICT" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">262</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">115</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTRmoKvIK3Ik" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,503</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zXxazF0T9EQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,765</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">265</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zb2tNHog1mEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
compensation expense for the year ended December 31, 2022, includes $<span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20220101__20221231_zM0EQhjuM81" title="Stock-based compensation expense">168</span> thousand of expense for non-voting common stock issued to the
Board of Directors and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zHxjvMNJjb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Unrecognized
stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized
as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zWdVvGnHmbtl">Schedule
of Unvested Awards and Weighted Average Period</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Unrecognized stock-based compensation expense (in thousands)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20231231_zYSDmsjuEUQ" style="width: 16%; text-align: right" title="Unrecognized stock-based compensation expense">5,039</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected weighted-average period compensation costs to be recognized (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231_zcpL9ld1uW9b" title="Expected weighted average period compensation cost">3.0</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zjJfVT3RGgU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwqf5TqVMjnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
summary of the Company&#8217;s stock option activity is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B2_zqqTOyjFUZgg">Schedule
of Stock Option Activity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Remaining Contractual Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value (in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Outstanding as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbP6kgzJ6Gcb" style="width: 11%; text-align: right" title="Stock options, outstanding, beginning balance">101,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBz6REdlYfF4" style="width: 11%; text-align: right" title="Weighted-average exercise price, outstanding, beginning balance">3.28</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z72N8IwOlim2" style="width: 11%; text-align: right" title="Weighted average remaining contractual life (years), outstanding">9.4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOpPuF3DMiGe" style="width: 11%; text-align: right" title="Stock options, outstanding, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1157">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Ci2rNYjzti" style="text-align: right" title="Number of options, granted">3,689,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXvfUXGGWWLl" style="text-align: right" title="Weighted-average exercise price, granted">2.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqdx6fStLRpb" style="text-align: right" title="Weighted average remaining contractual life (years), granted">10.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7Xzq41y6Pl8" style="text-align: right" title="Exercise of stock options, shares"><span style="-sec-ix-hidden: xdx2ixbrl1165">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4xd9My6xiWb" style="text-align: right" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1167">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z70lZiLhfzve" style="text-align: right" title="Number of options,  forfeited/cancelled">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRldCJLlibJk" style="text-align: right" title="Weighted-average exercise price, forfeited/ cancelled">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTgq4surmE2j" style="text-align: right" title="Weighted average remaining contractual life (years), forfeited/canceled">8.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Outstanding as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSnTPuaaFv1d" style="text-align: right" title="Stock options, outstanding, ending balance">3,788,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHeGMDESVcwa" style="text-align: right" title="Weighted-average exercise price, outstanding, ending balance">2.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmicfoetnQE4" style="text-align: right" title="Weighted average remaining contractual life (years), outstanding">9.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlri9qo5oMm5" style="text-align: right" title="Stock options, outstanding, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1181">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Exercisable as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNP45NBCRnB7" style="text-align: right" title="Number of options, exercisable">68,519</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKqLUqZV62Z8" style="text-align: right" title="Weighted-average exercise price, exercisable">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPzPEQo5P3Kg" style="text-align: right" title="Weighted average remaining contractual term, exercisable">8.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3Z6Wgu1Fs5g" style="text-align: right" title="Stock options, outstanding, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1189">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z6JLObo2IKgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zW2ZWmdL32ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes
option pricing model using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B3_zs1LT43eQ5wi">Schedule
of Fair Value of Option Granted Black Scholes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_497_20230101__20231231_z0Jq0AAdL8Z7" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_492_20220101__20221231_zv9X23ehdzDk" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Assumptions:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_zLGdqDw2rX28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.1</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_zOB81iNekj4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zcOM7z7aJ6E3" title="Expected term">7.0</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zPTTjRTBR7w5" title="Expected term">5.4</span> to <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zJUCTi2LkEL5" title="Expected term">6.4</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_zX4zcYzKkln9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected dividend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A6_ztuJbgiEKRe8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
weighted-average grant date fair value of the options granted during the years ended December 31, 2023 and 2022 was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zPaivk3O5Cyd" title="Weighted-average grant date fair value">1.80</span> per share and
$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zE92Vuyjax82" title="Weighted-average grant date fair value">2.64</span> per share, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687027717184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zUFhYfNdmdWj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zZiyznBGbnRh">Subsequent Events</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company&#8217;s registration statement filed with the Securities and Exchange Commission (SEC) was declared effective on January 24,
2024, and trading of the Company&#8217;s stock commenced on Nasdaq on January 31, 2024 (Direct Listing). <span style="background-color: white">In
January 2024, in conjunction with <span style="background-color: white">its</span> Direct Listing, <span style="background-color: white">the Company</span> issued <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhNiqXno1mM2" title="Sale of stock number of shares issued in transaction">2,500</span> shares of Series C Preferred Stock with super voting rights to
our CEO. </span> Upon the effectiveness of <span style="background-color: white">its</span> registration with the SEC, the Company obtained a public company directors and
officers insurance policy at a cost of $<span id="xdx_901_ecustom--InsurancePolicyCost_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zK7qwlwueBT9" title="Insurance policy cost">756</span>
thousand, which will be expensed over the one-year life of the policy. Upon approval from Nasdaq and prior to <span style="background-color: white">the Direct Listing</span>, the
$<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z4oTAv7qYPv2" title="Application fee">270</span>
thousand remainder of the listing application fee was due and paid to Nasdaq. Also upon completion of the Direct Listing, the
Company <span style="background-color: white">paid </span> $<span id="xdx_90D_eus-gaap--RepaymentsOfRelatedPartyDebt_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z4WjQU7PiGL9" title="Payable to its services as advisor">200</span>
thousand to Maxim for its services as advisor on the Direct Listing, and recorded a $<span id="xdx_902_ecustom--CommitmentFee_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zL6dCV1oSyn8" title="Commitment fee">2,000</span>
thousand payable for the commitment fee and issued <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zTm9og39D99d" title="Number of warrants">1,299,783</span>
warrants to purchase common stock shares at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zUjCo1ho6M95" title="Exercise price">21.54</span>
and an expiration of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zJFS7VRaQbNk" title="Warrant term">five
years</span> from the Direct Listing, which were both due to the investors in the Share Purchase Agreement as described in Note
8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2024, the
Company sold a total of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240201__20240229__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAhBPDRKvNQ7" title="Shares sold">142,298</span>
shares for $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pdn3_c20240201__20240229__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBkHJsZtjcU6" title="Shares sold, value">1,921</span>
thousand through the Share Purchase Agreement described in Note 8.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687026369840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zLg19Zjf7Xtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z8O3Z4jtpqqg">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding
annual financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from January 1, 2021, to its formation on April 8, 2021, the Company operated as a line of business of FibroGenesis rather
than as a separate stand-alone entity. Consequently, prior to the Company&#8217;s formation on April 8, 2021, the financial statements
were derived from the historical accounting records of the Parent. All general and administrative expenses and research and development
expenses directly associated with the business activity of the Company that were originally incurred by the Parent from January 1, 2021,
through the Company&#8217;s formation on April 8, 2021, were allocated and included in the Company&#8217;s financial statements. The
resulting net Parent investment was presented within stockholders&#8217; equity/(deficit) and represented the Parent&#8217;s interest
in the recorded net assets of the Company and has been eliminated through the ROFN Agreement as further described in Notes 7 and 11.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, the Company amended and restated its certificate of incorporation with the State of Delaware to immediately effect a 1-for-4
shares reverse stock split. All share and per share amounts have been adjusted on a retroactive basis to reflect the effect of the
reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_847_eus-gaap--UseOfEstimates_zwt2zNhO5J4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zw1DrwJNNSH8">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements
and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date
of the Financial Statements; therefore, actual results could differ from those estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zbzlq04VIvr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zIVIo5Wbo1Te">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The
Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit
of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20231231_z1s2CkMyVJma" title="Federally insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#8217;s financial
condition, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_84A_ecustom--RisksAndUncertaintiesPolicyTextBlock_zCM0wh8e2bCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zKNfC1n28vKk">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the
Company believes could have a material adverse effect on the future financial position or results of operations: the timing of, and the
Company&#8217;s ability to advance its current and future product candidates into and through clinical development; costs and timelines
associated with the manufacture of clinical supplies of the Company&#8217;s product candidates; regulatory approval and market acceptance
of its product candidates; performance of third-party contract research organizations (&#8220;CROs&#8221;) and contract manufacturing
organizations (&#8220;CMOs&#8221;); competition from pharmaceutical companies with greater financial resources or expertise; protection
of the intellectual property, litigation or claims against the Company based on intellectual property, or other factors; the need to
obtain additional funding; and its ability to attract and retain employees necessary to support its growth. Disruption from CROs&#8217;,
CMOs&#8217; or suppliers&#8217; operations would likely have a negative impact on the Company&#8217;s business, financial position and
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zOqnLLqHGWq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zKIHFte91RX1">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three
months or less at the time of purchase. There were <span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_zdGKDMCreLA3" title="Cash equivalents"><span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zTcjr9BCeQn" title="Cash equivalents">no</span></span> cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zMVkNCl4TJTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zoHu2zwW1ubi">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is computed using the straight-line
method over the estimated useful lives of the respective assets, generally three to five years, and includes laboratory equipment that is
recorded at cost and depreciated using the straight-line method over the estimated useful lives of five years. Depreciation expense is
classified in either research and development expense or in general and administrative expense, depending upon the nature of the asset,
in the accompanying Statements of Operations. When property and equipment assets are retired or otherwise disposed of, the cost and related
accumulated depreciation are removed from the balance sheets and the resulting gain or loss is recorded in other income (loss) in the
period realized. Maintenance and repairs are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets
might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable
market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that
would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used,
the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and
measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for
the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_znec43ArZIxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_865_zYvw03D16fRi">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company determines if an arrangement is a lease at inception. An arrangement is or contains a lease if it conveys the right to control
the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification is determined
at lease commencement. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement
date. The Company&#8217;s leases do not provide an implicit interest rate and therefore the Company estimates its incremental borrowing
rate to discount lease payments. The incremental borrowing rate reflects the interest rate that the Company would have to pay to borrow
on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term. Operating lease
right-of-use (&#8220;ROU&#8221;) assets are based on the corresponding lease liability adjusted for any lease payments made at or before
commencement, initial direct costs, and lease incentives. Renewals or early terminations are not accounted for unless the Company is
reasonably certain to exercise these options. Operating lease expense is recognized and the ROU asset is amortized on a straight-line
basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Operating
leases are included in operating lease right-of-use asset, operating lease liability, short-term, and operating lease liability, long-term
on the Company&#8217;s Balance Sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company has elected in accordance with ASC 842-20-25-2 an accounting policy to not record short-term leases, defined as those with terms
of 12 months or less, on the Balance Sheets. Rent expense recorded under leases, for financial statement purposes, is recognized on a
straight-line basis over the lease term based on the most recent contractual terms available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgvxc4Dp8Fl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86E_z69gfL6mD6u2">Fair
Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Accounting
Standards Codification (&#8220;ASC&#8221;) 820, <i>Fair Value Measurement</i>, establishes a fair value hierarchy for instruments measured
at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions
(unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market
data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about
the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available
in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions
in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Level
1 - Quoted market prices in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Level
2 - Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates
and yield curves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Level
3 - Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#8217;s
own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about
risk).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Categorization
within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zey6YkvhidG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><b><span id="xdx_863_zuS18C0BfOIb">Derivatives</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Derivative financial instruments,
including the Liability instrument, are recorded at fair value on the Balance Sheet. Liability classified derivatives are remeasured at their
fair value at each reporting date, with decreases or increases in the fair value recognized as other gain or loss, respectively, within
the Statement of Operations. Equity classified derivatives are not remeasured at each reporting date. If a liability classified derivative
becomes eligible for reclassification to an equity classified derivative, any gains or losses recognized up to the point of reclassification
are not reversed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZ1BEmZTWuR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zAmDAIw1ZIO5">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research
and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory
supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain
research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern
of costs incurred, and are reflected in the Financial Statements as prepaid or accrued research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent Costs</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zbOxJbLR5wDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zbLAotx4dYh8">Patent
Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company continues to incur costs to obtain market approval of patented technology, patent costs are expensed as incurred in general,
administrative and other expense in the Statements of Operations. Costs include fees to renew or extend the term of recognized intangible
assets, patent defense costs, and patent application costs. Management will continue to expense such costs until market approval is obtained
through regulatory approval by the appropriate governing body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zHewRXz5l1E1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zFTimCOV9u3k">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is a C corporation, and accounts for income taxes under the asset and liability
method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement
and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.
Valuation allowances are established when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the provisions of ASC 740-10, <i>Income Taxes</i>, the Company evaluates uncertain tax positions by reviewing against applicable tax
law all positions taken by the Company with respect to tax years for which the statute of limitations is still open. ASC 740-10 provides
that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained
upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The Company recognizes
interest and penalties related to the liability for unrecognized tax benefits, if any, as a component of the income tax expense line
in the accompanying Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z2DJvtjEuD1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zbrppPtA8Sm9">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs related to stock options granted to employees and nonemployees based on the estimated fair value
of the awards on the date of grant and recognizes expense on a straight-line basis over the requisite service period, which is generally
the vesting period of the award. Forfeitures are recognized as they occur. The fair value of stock options is estimated on the date of
grant using a Black-Scholes option pricing model which requires management to apply judgment and make estimates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
    Value of Common Stock</i>&#8212;The estimated fair value of our common stock underlying our stock-based awards has been determined
    by our board of directors as of each option grant date with input from management, considering our most recently available
    third-party valuations of common stock and our board of directors&#8217; assessment of additional objective and subjective factors
    that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant.
    These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public
    Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the
    Practice Aid). Now that a public trading market for our common stock has been established in connection with the completion of the
    Direct Listing, the fair value of common stock in future grants will be based on the closing price as reported on The Nasdaq Global Select Market on the
    date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Term</i>&#8212;The expected term represents the period that a stock-based award is expected to be outstanding. The Company uses the
    simplified method to determine the expected term, which is based on the average of the time-to-vesting and the contractual life of
    the option.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Volatility</i>&#8212; Due to the Company&#8217;s limited operating history and lack of company-specific historical and implied volatility
    data, the expected volatility is estimated based on the average historical volatilities of common stock of comparable publicly traded
    entities over a period of time commensurate with the expected term of the stock option grants. The comparable companies are chosen
    based on their size, stage in the product development cycle, or area of specialty. The Company will continue to apply this process
    until sufficient historical information regarding the volatility of its own stock price becomes available.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
    Interest Rate</i>&#8212;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon
    U.S. Treasury notes with maturities approximately equal to the expected term of the awards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Dividend</i>&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock.
    Therefore, the Company used an expected dividend yield of zero.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"><p id="xdx_847_ecustom--EmergingGrowthCompanyPolicyTextBlock_z4MVFVraF6ue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zvsvRe7B3p5k">Emerging
Growth Company</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the completion of the Direct Listing, the Company is an emerging growth company (EGC), as defined in the Jumpstart Our Business Startups
Act of 2012 (JOBS Act). Under the JOBS Act, an EGC can delay adopting new or revised accounting standards issued subsequent to the enactment
of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition
period for complying with new or revised accounting standards that have different effective dates for public and private companies; however,
the Company may adopt new or revised accounting standards early if the standard allows for early adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company will utilize other exemptions and reduced reporting requirements provided to EGCs by the JOBS Act. Subject to certain
conditions set forth in the JOBS Act, an EGC is not required to, among other things, (i) provide an auditor&#8217;s attestation report
on the company&#8217;s system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002,
(ii) provide all of the compensation disclosure that may be required of non-EGC public companies under the Dodd-Frank Wall Street Reform
and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding
mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the
financial statements (auditor discussion and analysis), or (iv) disclose certain executive compensation-related items, such as the correlation
between executive compensation and performance and comparisons of the chief executive officer&#8217;s compensation to median employee
compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zF9lBFxyj566" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zy4HvretUkF8">Recently
Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There have been no accounting pronouncements issued but not yet adopted by the Company that are expected to have a material impact on
the Company&#8217;s Financial Statements.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687028426880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z0dYk4poM839" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zVKpKEtpCaTa" style="display: none">Schedule
of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zu8kbZ2g6hlf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20221231_zQsA2Qcw3FAd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">(in thousands, except share and per share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zi9yPG10Rbrh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(16,485</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(5,121</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Adjustment to numerator for earnings per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeemedDividend_pn3n3_zejgX65pHSMk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,573</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zMGm5Vglj8Q8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net loss attributable to common stockholders:</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(19,058</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,121</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted-average number of common shares outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zdJApRGVbmnf" title="Weighted average number of shares outstanding, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zlhNGNuwHShi" title="Weighted average number of shares outstanding, diluted">28,230,842</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231_zpuyPZbdiYSf" title="Weighted average number of shares outstanding, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20221231_zqNTkQR0nUtg" title="Weighted average number of shares outstanding, diluted">28,230,842</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net loss per common share attributable to common stockholders, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zXJeHCOo15C7" title="Net loss per share, basic"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zT0ZKNo8sKmf" title="Net loss per share, diluted">(0.68</span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zWoD99bcKbqf" title="Net loss per share, basic"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_zdCCF9wil7Mh" title="Net loss per share, diluted">(0.18</span></span></td><td style="text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687027711488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwkvNwMSVfij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zrZpqfg7xer2" style="display: none">Schedule
of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zJHTNJbuNowg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zfBe724ZDyel" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zVFYgHl8sNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Laboratory equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">816</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0736">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zhVeI3z0qLvg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Computer equipment, software, and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzT4x_zdxjoNYWrnJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total property and equipment at cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzT4x_zVMRjGrd2pWh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzT4x_z9sJOuSJjzkg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">797</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687027549520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Liabilities Measured at Fair Value</a></td>
<td class="text"><p id="xdx_893_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zxcyuXtjdMae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the Company&#8217;s financial liabilities measured at fair value on a recurring basis based on the three-tier
fair value hierarchy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zNKASbrI9hL4" style="display: none">Schedule
of Financial Liabilities Measured at Fair Value</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLLuS0PczDq9" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4QwOa4vrGDf" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqK5YCQi6hRc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_zHDTFayCne1h" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurement as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3n3_maFLFVDzjkJ_zd28TiS69tu" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0769">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LiabilityInstrument_iI_pn3n3_maFLFVDzjkJ_zSVJOIJHeuMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1.5pt">Liability instrument</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0771">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">7,236</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">7,236</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iTI_pn3n3_mtFLFVDzjkJ_zUTrzedZQ5v4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,236</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zv9FVDrwyWrh" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbm3b64kBb53" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAs0SJ0b4x91" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zVaRRvyjdPe3" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurement as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3n3_maFLFVDzjkJ_zE4RX3P8S3nb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: justify">Derivative liability</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0781">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--LiabilityInstrument_iI_pn3n3_maFLFVDzjkJ_zEUrEX1sjtxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Liability instrument</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0786">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0788">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0789">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iTI_pn3n3_mtFLFVDzjkJ_zrwptT3BQmp4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0791">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">538</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Financial Liability Transfers</a></td>
<td class="text"><p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z6c68rgTTnp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the transfers in and out of Level 3 financial liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zTHKXPMPqPb5" style="display: none">Schedule
of Financial Liability Transfers</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zDan4JiNQ9Ji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--FinancialInstrumentAxis_custom--LiabilityInstrumentMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zaoNWEPM5a0c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Liability Instrument</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43B_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z92TrGkB33X8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value at December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0799">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_i01_zOqdkfh6hZhf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: justify; padding-bottom: 1.5pt">Addition to derivative liability for debt issuance discount</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">538</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z3GoE9sf6z76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value at December 31, 20222</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zTb4d5OK5Ltl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value, beginning balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_i01_zGJdBDaCkNN2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(538</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_i02_zT8ZthOEVd78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Increase in the fair value of the liability instrument</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,236</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zApiiV7yRhxd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Fair value at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,236</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zVTS1vt1qSaa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Fair value, ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,236</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687027651936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ConvertibleDebtTableTextBlock_zVO08cHnhuP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible debt balances consisted of the following at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zX3mntGP8fJj" style="display: none">Schedule
of Convertible Debt</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_z25Oeg9YnNC2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_z1IL1owBFkX9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_zCuYZINdJ0Rl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Convertible notes principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,600</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_ziuOa8C2CBp6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Convertible notes discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(149</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_ztByUfwJGlS8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Convertible notes payable, net of discount</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,451</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687027670688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMyajH8Q5Dw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&#8217;s effective income
tax rate is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B9_zGyMnfEQJVhe">Schedule
of Effective Income Tax Rate</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49A_20230101__20231231_zQjyP5rCczO" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49F_20220101__20221231_zlEW1BEVXLT4" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maIT1_zhpFB2bOyrZa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maIT1_z1MMpSlI4bla" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Permanent items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets_iN_pid_dpi_maIT1_zu54jBvn6Dx6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">True-up prior-year net operating loss deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0960">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.1</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_maIT1_ziVacqX65X78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Non-deductible stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maIT1_z9OXNpePOoX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other changes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.9</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maIT1_zh5Ip47Jbugl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10.2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtIT1_zGACPGAZr545" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Assets</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zZVySOlNpsJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the Company&#8217;s net deferred tax assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zgVOZU6KCUYa">Schedule
of Net Deferred Tax Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49D_20231231_zoKa37FeocX" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49F_20221231_zFmEtHCPGy01" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands of dollars)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zof6IgjI7NRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzVPk_zzEu0bznNSig" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: justify">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,005</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">896</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzVPk_zzj6ANgkgWDc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">299</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability_iI_pn3n3_maDTAGzVPk_zWUnvKIYM492" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">435</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzVPk_zw5gAXVTkeij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzVPk_zOff63TXUi01" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsDerivativeInstruments_iI_pn3n3_maDTAGzVPk_zJEuhrbFNNH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzVPk_maDTANzrSY_zGxD84s8cJi6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,326</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,759</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_pn3n3_zTyyXVBVfxv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_iNI_pn3n3_di_maDITLzuqP_zVFjhlXtF8P7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(380</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(462</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_maDITLzuqP_zGQ8CV25vpLl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesUnamortizedDebtDiscount_iNI_pn3n3_di_maDITLzuqP_zioBQTZ1W2Bj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Unamortized debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1010">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzuqP_msDTANzrSY_zTgYuoWn5gI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(391</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(493</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzrSY_zjv9ACfJB2l3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,935</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,266</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzrSY_zaO9ru3yPtf4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1020">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687027799008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liabilities</a></td>
<td class="text"><p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zCRnIEfM2V4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of operating lease liabilities as of December 31, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zf9BJJ1cuxO5">Schedule
of Operating Lease Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_494_20231231_zf2juYoMbqC8" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">(in thousands of dollars)</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzBez_zhOzemaUykAg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">477</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzBez_z9nlfMXuyQzk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">487</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzBez_zqXVngmSJso3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">544</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzBez_zD9NssKUpFKf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">509</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzBez_ze69Bh99KOJi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1076">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzBez_zovClIaNjQ5f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,017</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zcY2uAGnGOwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(270</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z4Z5KHIIc0wg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,747</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zMB0sVExmf1l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Current lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(362</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zqnsXs4umSc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,385</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687022133856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock Based Compensation Expense</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zh0yQPadnZPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
compensation expense is recognized in the Statements of Operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B3_zUX2A2LrRE1b">Schedule
of Stock Based Compensation Expense</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49B_20230101__20231231_z9eSO3sapg91" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49E_20220101__20221231_z702WuTnT3z4" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">(in thousands of dollars)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zhcrZZFUICT" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">262</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">115</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTRmoKvIK3Ik" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,503</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zXxazF0T9EQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,765</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">265</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Unvested Awards and Weighted Average Period</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zHxjvMNJjb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Unrecognized
stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized
as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zWdVvGnHmbtl">Schedule
of Unvested Awards and Weighted Average Period</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Unrecognized stock-based compensation expense (in thousands)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20231231_zYSDmsjuEUQ" style="width: 16%; text-align: right" title="Unrecognized stock-based compensation expense">5,039</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected weighted-average period compensation costs to be recognized (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231_zcpL9ld1uW9b" title="Expected weighted average period compensation cost">3.0</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwqf5TqVMjnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
summary of the Company&#8217;s stock option activity is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B2_zqqTOyjFUZgg">Schedule
of Stock Option Activity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Remaining Contractual Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value (in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Outstanding as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbP6kgzJ6Gcb" style="width: 11%; text-align: right" title="Stock options, outstanding, beginning balance">101,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBz6REdlYfF4" style="width: 11%; text-align: right" title="Weighted-average exercise price, outstanding, beginning balance">3.28</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z72N8IwOlim2" style="width: 11%; text-align: right" title="Weighted average remaining contractual life (years), outstanding">9.4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOpPuF3DMiGe" style="width: 11%; text-align: right" title="Stock options, outstanding, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1157">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Ci2rNYjzti" style="text-align: right" title="Number of options, granted">3,689,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXvfUXGGWWLl" style="text-align: right" title="Weighted-average exercise price, granted">2.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqdx6fStLRpb" style="text-align: right" title="Weighted average remaining contractual life (years), granted">10.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7Xzq41y6Pl8" style="text-align: right" title="Exercise of stock options, shares"><span style="-sec-ix-hidden: xdx2ixbrl1165">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4xd9My6xiWb" style="text-align: right" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1167">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Forfeited/canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z70lZiLhfzve" style="text-align: right" title="Number of options,  forfeited/cancelled">2,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRldCJLlibJk" style="text-align: right" title="Weighted-average exercise price, forfeited/ cancelled">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTgq4surmE2j" style="text-align: right" title="Weighted average remaining contractual life (years), forfeited/canceled">8.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Outstanding as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSnTPuaaFv1d" style="text-align: right" title="Stock options, outstanding, ending balance">3,788,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHeGMDESVcwa" style="text-align: right" title="Weighted-average exercise price, outstanding, ending balance">2.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmicfoetnQE4" style="text-align: right" title="Weighted average remaining contractual life (years), outstanding">9.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlri9qo5oMm5" style="text-align: right" title="Stock options, outstanding, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1181">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Exercisable as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNP45NBCRnB7" style="text-align: right" title="Number of options, exercisable">68,519</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKqLUqZV62Z8" style="text-align: right" title="Weighted-average exercise price, exercisable">3.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPzPEQo5P3Kg" style="text-align: right" title="Weighted average remaining contractual term, exercisable">8.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3Z6Wgu1Fs5g" style="text-align: right" title="Stock options, outstanding, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1189">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Option Granted Black Scholes</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zW2ZWmdL32ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes
option pricing model using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B3_zs1LT43eQ5wi">Schedule
of Fair Value of Option Granted Black Scholes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_497_20230101__20231231_z0Jq0AAdL8Z7" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_492_20220101__20221231_zv9X23ehdzDk" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Assumptions:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_zLGdqDw2rX28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.1</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_zOB81iNekj4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zcOM7z7aJ6E3" title="Expected term">7.0</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zPTTjRTBR7w5" title="Expected term">5.4</span> to <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zJUCTi2LkEL5" title="Expected term">6.4</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_zX4zcYzKkln9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected dividend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687030114336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of Business, and Liquidity (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="nump">$ 24,357<span></span>
</td>
<td class="nump">$ 7,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">9,163<span></span>
</td>
<td class="nump">$ 2,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="nump">$ 1,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687026498640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federally insured limit</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687029554464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,485)<span></span>
</td>
<td class="num">$ (5,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_DeemedDividend', window );">Deemed dividend</a></td>
<td class="num">(2,573)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders:</a></td>
<td class="num">$ (19,058)<span></span>
</td>
<td class="num">$ (5,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, basic</a></td>
<td class="nump">28,230,842<span></span>
</td>
<td class="nump">28,230,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, diluted</a></td>
<td class="nump">28,230,842<span></span>
</td>
<td class="nump">28,230,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687020787072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Aug. 18, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock liquidation value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes outstanding</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_CapitalStockInExcess', window );">Capital stock in excess</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Issued upon conversion of common stock</a></td>
<td class="nump">801,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Nonvoting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">28,230,842<span></span>
</td>
<td class="nump">28,230,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,230,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock liquidation value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionAmount', window );">Preferred stock, redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionAmount', window );">Preferred stock, redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_CapitalStockInExcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital stock in excess.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_CapitalStockInExcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687022119056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment at cost</a></td>
<td class="nump">$ 844<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(47)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">797<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=FBLG_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment at cost</a></td>
<td class="nump">816<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment at cost</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=FBLG_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=FBLG_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687026547872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=FBLG_LaborataryEquipmentMember', window );">Laboratary Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=FBLG_LaborataryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=FBLG_LaborataryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687025835904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Financial Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_LiabilityInstrument', window );">Liability instrument</a></td>
<td class="nump">7,236<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total fair value</a></td>
<td class="nump">7,236<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_LiabilityInstrument', window );">Liability instrument</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_LiabilityInstrument', window );">Liability instrument</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_LiabilityInstrument', window );">Liability instrument</a></td>
<td class="nump">7,236<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total fair value</a></td>
<td class="nump">$ 7,236<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_LiabilityInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_LiabilityInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687025769312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Financial Liability Transfers (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning balance</a></td>
<td class="nump">$ 538<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount', window );">Addition to derivative liability for debt issuance discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock', window );">Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock</a></td>
<td class="num">(538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Increase in the fair value of the liability instrument</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=FBLG_LiabilityInstrumentMember', window );">Liability Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount', window );">Addition to derivative liability for debt issuance discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock', window );">Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Increase in the fair value of the liability instrument</a></td>
<td class="nump">7,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, ending balance</a></td>
<td class="nump">$ 7,236<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition to derivative liability for debt issuance discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=FBLG_LiabilityInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=FBLG_LiabilityInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687020781008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details Narrative)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_LiabilityInstrument', window );">Liability instrument | $</a></td>
<td class="nump">$ 7,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputMaturityMember', window );">Measurement Input, Maturity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Maturity period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Dividend yield</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Dividend yield</a></td>
<td class="nump">0.0384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Dividend yield</a></td>
<td class="nump">0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_LiabilityInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_LiabilityInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputMaturityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputMaturityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687026570048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Convertible Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes principal</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Convertible notes discount</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, net of discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687024268000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversion of Stock, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a) a 15% discount
to the offering price of the Company&#8217;s common stock in the event of an initial public offering of the Company or b) the quotient
of $200,000 thousand divided by total equity interests prior to the dilution from the offering. The conversion option feature in the
2022 Notes was evaluated in accordance with ASC 815, and a derivative liability for the $538 thousand estimated fair value of the conversion
option was recorded at the time the notes were issued and as of December 31, 2022.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=FBLG_TwoThousandTwentyTwoNotesMember', window );">2022 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=FBLG_TwoThousandTwentyTwoNotesMember', window );">2022 Notes [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted principal shares</a></td>
<td class="nump">353,713<span></span>
</td>
<td class="nump">799,603<span></span>
</td>
<td class="nump">66,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=FBLG_TwoThousandTwentyOneNotesMember', window );">2021 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=FBLG_TwoThousandTwentyTwoNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=FBLG_TwoThousandTwentyTwoNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=FBLG_TwoThousandTwentyOneNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=FBLG_TwoThousandTwentyOneNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687021645360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity/(Deficit) and Net Parent Investment (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Aug. 18, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Employee benefit plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity', window );">Debt instrument convertible descreption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Series C Preferred Stock is not entitled to dividends,
has a liquidation preference of $18.00 per share, subject to adjustment, may be converted 1:1 at any time at the option of the holder
into common stock, and upon closing of an IPO will if transferred automatically convert 1:1 into common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-4 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Nonvoting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,179,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,230,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,171,445<span></span>
</td>
<td class="nump">381,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,680,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FBLG_SeriesBOnePreferredStockMember', window );">Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,781<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FBLG_SeriesBOnePreferredStockMember', window );">Series B-1 Preferred Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=FBLG_SeriesB1PreferredStockMember', window );">Series B1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference per share</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">0.00001<span></span>
</td>
<td class="nump">0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the type of equity security or securities into which conversion will be made (for example, common stock or preferred shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FBLG_SeriesBOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FBLG_SeriesBOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=FBLG_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=FBLG_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687030070256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Subscription Agreement (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issues initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_DescriptionOfShareSubscriptionAgreement', window );">Description of share subscription agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement
following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the
Company&#8217;s common stock shares over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average
price per share over that same period. A 1% fee must be paid to the investors if the Company is sold in a private sale transaction rather
than completing a public listing of its shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=FBLG_SharePurchaseAgreementMember', window );">Share Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsTotalCostToInvestors', window );">Investors sales</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_CommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issues initial public offering</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_CommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_CommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_DescriptionOfShareSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of share subscription agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_DescriptionOfShareSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsTotalCostToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost to investors of each class of capital shares or other capital units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsTotalCostToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=FBLG_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=FBLG_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687026246496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">9.20%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets', window );">True-up prior-year net operating loss deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(6.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible stock compensation</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other changes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">10.20%<span></span>
</td>
<td class="nump">24.40%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation prior year net operating loss deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687022124752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 2,005<span></span>
</td>
<td class="nump">$ 896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">3,326<span></span>
</td>
<td class="nump">1,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Lease right-of-use asset</a></td>
<td class="num">(380)<span></span>
</td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount', window );">Unamortized debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(391)<span></span>
</td>
<td class="num">(493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(2,935)<span></span>
</td>
<td class="num">(1,266)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense compensation and benefits lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities unamortized debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687024360944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">9,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred tax assets</a></td>
<td class="nump">680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687021504512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(270)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">1,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current lease liability</a></td>
<td class="num">(362)<span></span>
</td>
<td class="num">$ (326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Total non-current lease liability</a></td>
<td class="nump">$ 1,385<span></span>
</td>
<td class="nump">$ 1,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687025704048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Commitments and Contingencies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">62 months<span></span>
</td>
<td class="text">126 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,809<span></span>
</td>
<td class="nump">$ 2,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">685<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FBLG_OperatingLeasesMember', window );">Operating Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Noncancelable lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FBLG_ShorttermLeasesMember', window );">Short-term Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Noncancelable lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=FBLG_ShortTermLeaseAgreementMember', window );">Short Term Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=FBLG_LeaseAgreementMember', window );">Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FBLG_OperatingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FBLG_OperatingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FBLG_ShorttermLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=FBLG_ShorttermLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=FBLG_ShortTermLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=FBLG_ShortTermLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=FBLG_LeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=FBLG_LeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687021576320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Aug. 18, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable, after Allowance for Credit Loss, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_PaymentsForEquityInvestments', window );">Payments for equity investments</a></td>
<td class="nump">323,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,322,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Proceeds from (repayments of) related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=FBLG_FibroGenesisMember', window );">Fibro Genesis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_PercentageOfGrossProceedsFromEquityInvestments', window );">Percentage of gross proceeds from equity investments</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_DerivativeLiabilitiesPayableToRelatedParties', window );">Derivative liabilities payable to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 2,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_DerivativeLiabilitiesPayableToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liabilities payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_DerivativeLiabilitiesPayableToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_PaymentsForEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_PaymentsForEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_PercentageOfGrossProceedsFromEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds from equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_PercentageOfGrossProceedsFromEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=FBLG_FibroGenesisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=FBLG_FibroGenesisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687028584288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,765<span></span>
</td>
<td class="nump">$ 265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,503<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687029475440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Unvested Awards and Weighted Average Period (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 5,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period compensation cost</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687020738864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">3,689,750<span></span>
</td>
<td class="nump">101,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options, outstanding, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years), outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options, outstanding, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,689,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life (years), granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited/cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, forfeited/ cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life (years), forfeited/canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options, outstanding, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,788,500<span></span>
</td>
<td class="nump">101,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options, outstanding, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Stock options, outstanding, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeited weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687024406528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Option Granted Black Scholes (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687028058848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">3,689,750<span></span>
</td>
<td class="nump">101,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Strike price per share</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,711,500<span></span>
</td>
<td class="nump">12,398,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="nump">$ 2.64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140687025729232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th"><div>Nov. 12, 2021</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payable to its services as advisor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Non-Voting Common Stock to Parent company members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=FBLG_SharePurchaseAgreementMember', window );">Share Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Non-Voting Common Stock to Parent company members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Application fee</a></td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payable to its services as advisor</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_CommitmentFee', window );">Commitment fee</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="nump">1,299,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 21.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Non-Voting Common Stock to Parent company members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,921,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share Purchase Agreement [Member] | Directors and Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_FBLG_InsurancePolicyCost', window );">Insurance policy cost</a></td>
<td class="nump">$ 756,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_CommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitmentt fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_CommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_FBLG_InsurancePolicyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance policy cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">FBLG_InsurancePolicyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>FBLG_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=FBLG_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=FBLG_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=FBLG_DirectorsAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=FBLG_DirectorsAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=N$UMC%/)/16_P2+TI'E@&*WV[Z\T'(S:C],J16YY?;#QIU#UBK[@M%R3+C
M6_O"TBU;N'A<94RGL!UV;CMLW"U\XMF<R9S'F$L[(-)I6_6VU=9V_7AH95JG
ML!EV;C/LHVS&=Q:&]:<8^GLR830!=CX9)4E: @_7O-.-MBX>5!G;*7R&G?L,
M^RB?\8V'D!)3L9X4$-H)IP-*);",V@I3:D58N:VPC[(5VUFG]6QY$,^R 5,_
M2W= \0?31;EX5&5JI_ 2=NXE[*.\Q$CE\.LE?S4_1[<8M=1PQ3)J1GV *;4B
MM=P'V$?Y@*PY$A?RL1D7VCF3 SIW/*Y3SV,@ R+^6E!+SZ@1,*56I)<; ?LH
M(S"):!B2FS2!KQ-]^\1URE8!\;#*L$Z1_CMY^N\<E?[?1DS,5&_V%RC(.21G
MT8+&VCIW0+",&AY6>9_"*;)_)\_^G0/9O]K&! WJCDOPE^1KPHB<,W+[+)G:
M%+._K+I>]]*"Q)]1NJZ*QU4F>0H_X.1^P#EJ.6(RA]P-K76X3#DLHZ[ E%H1
MUM[6HJ,6(\;I- P\,@PYU8Z@N$KE_45F-QBMU=J9FMJDN.R!/UGJL.3IOW/<
M*@./(FAP$\F]IS.H411>AWQ))1CSV(>^38O*9#[O;M0Z>X5S[([3<M2T^[*
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M6%I^7%,B%U\9R-]7C(GG"_4F5?WFW.Q_4$L#!!0    ( "R)75C1V!2<600
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M'!I-)M'(D$X[R*D5\@\N)5D+7AY!\9PP 4X'?5\;" U6XXAQAQA;$>\S5FU
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M0493.C:GU9UI(W,Z2)B+A'E(F(^$!4C8 @2KJ&5Z4,M4WQ_R)M#/C8Q5<=[
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MW+-$A-%G7JJU1#^5.<T/!8Q WT9I_*ST%0Y*_$"S]RB.WB$\QK%'H>OCI^.
M.G%CP]C(BWOD&:NMC-56@F\0[#%!%"OOJR!EBE&OV2JIB5^JWK]G<DLR>C&
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M&2&&"VPUQ'@ A@SA+JCJ &A ].I7Y%$QI"1BH2=0:O:36=[#?<XN$F1U0 R
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M(;_;(7Q!ZELC*%*@TFQ4P;/0R%97])[28IB-:Y2@@%<('U-D&[CD/&-#D4N
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M3:9>1,Q3/Z->@J_[3GU 'KU*=S]OZ%&_#<6E7(I;G)TOU).?/US=H&COCH<
M"@KQ(05FA67H&@96J34UWTBG?,/R3NZ[P*]--6ZAA%SW6]1N!(?Z9;R,FP O
MQS^.FU$,:<68ESA1<?LZ]U<&JF(BU/1DJ&V&FQ:3'O"D#X31/3?9R)(Y'=-#
M6*Z<ZZ>#.&F00T=\UL"5S]?LDX,BMV)3B.YB-"= (;=SB/2V1P N)9'O\WZA
M-BA($0BF)S9-DOE7,2(MRGA\DQY+(A .9( HD=O_*#'BO8ZI[3&&Z,DC_C89
M#IE<B'. HXQ1C8JLZ-("D6*OG44/$PH),R1-TUW^_>M?13F<$<8##6@@F?6^
M4>;C*%Y5[H$A2]$5J]C+ 5.(%T_L\;CSKQ$[@&:&.U? PR%^'2![*7(;>MIT
M#+N ;"^] L+0NDXG,S&$'[@^3SVZT,<NPDW\]N?9V;,GR^-\>5_[I8:+GGSX
M4B,D9_<\6\R*)W;,?%VG.9/$-[K[&;LO.\G#43"8@QQW0C*+%CC<31JPU1M7
M50AWNOVL_J"5;CI/7V%=4PN]D8LM5/8@&M&9<[RA) H!EV!3'"==1=F-S6'"
M%UO?Z%JYL)0,;_0IQP>"-'P&=N7(CH?/%1JR;(&DI$T('K :3.7+4%IN!^6T
MPEEQ3_&BHRA=SE[##:?)M=2AS\6+I<M[A^ZAJR=Q%59*+Y]>,+H%U1UR_3&?
M'3^QM\=);28?!\#!RIY#QEB])PG1 !8T8>@MYH,2^1:D2 CU,)5TN3K?H),Z
M%C+W-HR^)"DWUJQ&--QJ!1@R"&U"DVXUTZ7OX8I7,7Y/#862/\$HWDLF&'^G
MXUWK^G@H$^*Q[7#7NW73SVLF@V->21=!=U033(UJ\F'#/E;>O^:9[X.-(V_>
M\:'B=ZX.?3]U.OKNC9(V?]W'=TO;3CZ!RT_S!X27\MW<,%R^/OQ54\ZG\\L5
MII[-?_CN2(Y;TH_.;?DKNJ7K.M?PGQNCX<LT .]7#BX:?] "^;/*5_\+4$L#
M!!0    ( "R)75B-9\W#,P0  *H)   8    >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&ULK591;]LV$'[7KSBH6Y$ FBW)EN,YM@&[:;L ;6K4VXIAV ,MG2TN
M$JF2E)WLU^](V8HS.$8W[$6BQ+OO^^YX1W*\D^I>YX@&'LI"Z(F?&U.-NEV=
MYE@RW9$5"II92U4R0Y]JT]650I8YI[+HQF$XZ):,"W\Z=O\6:CJ6M2FXP(4"
M79<E4X]S+.1NXD?^X<=GOLF-_=&=CBNVP26:7ZJ%HJ]NBY+Q$H7F4H#"]<2?
M1:-YW]H[@U\Y[O31&&PD*RGO[<=M-O%#*P@+3(U%8/3:XALL"@M$,K[N,?V6
MTCH>CP_H[USL%,N*:7PCBR\\,_G$'_J0X9K5A?DL=S_A/I[$XJ6RT.X)N\8V
M27Q(:VUDN7<F!247S9L][/-PY# ,7W"(]PZQT]T0.94WS+#I6,D=*&M-:';@
M0G7>)(X+NRA+HVB6DY^9WM&Z?Y!:0X4*ECE3"#-C%%_5AJT*!"/AC2Q+RM_2
MR/0^ET6&2H^[AK@M0C?=\\P;GO@%GBB&CU*87,-;D6'V'*!+HEOE\4'Y/#Z+
M>(-I!WI1 '$8]\[@]=I,]!Q>[P6\MTP)+C8:%FTF?I^MM%%4.'^<"KB!ZY^&
ML\TTTA5+<>)3MVA46_2GKU]%@_#ZC-A^*[9_#OU_7+:S/*>CZ'7@O_'#SSEZ
M:UG03D"9AL:TV0[X7ZC!Y BI+"L"<2TKU[;C> I,9)#QHC:8@2#JXD"M'37[
M!W7:4.MC:L*R\*2J8N)Q!$O:WK*Z0(\FYBW)S9ZDC6_Q;^+S?D.F]A4.5)]8
MKLB=:M2[X(+H9:V)1 > #RE6YJ">>(]B*64MC+YT96T?L7=7EZB8D6KDW1V"
M_PXNHD'0'R9P:<=)$,417'JS[$_:,VC3-%:B.#@"[=Z AP)OR4;>#6*)-K=;
MGB'IN(B#Y*I'F*]?#>,HOGXB_(8<CYRJ'X,P&3Y7=8-"TM[5A/#%;928_<"V
M)&Z#5J5-$ZW# =-JHQ6KC3:4'-(<G*B#>!C$O3 8]N.CX9->&^0QWK<$<(J&
MP@@[@WU 82>RHYGVUK6B<E)T .B48,F05OA.&H2KX+C0@&M=/U=[UCN*GKNS
MC4*:)KT5>[2O=WREY'L4J+F&*/G^4-@;Y:)6,B5[#6LE2[  ^+7FAF2(+3:%
MH2V70YES6<@-3[57*4X%0NA,P*W@AK,"%O6JH%Q\6J]1V6Z]L"41A]>WBT]N
M%%U?!M0OBHY7^,"UL38$LF24WN?-9H&QX*X"$.I*"C<KT[16"D7J['6=YAYN
M7>72Y))(J09FL*!3&LDL:SK-K0TWM@%Z"41!?Q#1,Z+CQ>XM!\*<V85+@D$8
M0A0&(;V&(9GU$SBU^7:/SD_JF(V[)6BJ$.K$YBAM_[87D5ES_CZ9-[>8CTQM
MN-!0X)I<P\X5G?NJN1DT'T96[C1>24-GNQOF=)E"90UH?BVI#/8?EJ"]GDW_
M!E!+ P04    "  LB5U8*[EF6@ #  #B!@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6R55=]OVC 0?L]?<4JKJI40@9 61@&IOZ9-:B74=MO#M >3
M7,"J8Z>V4\I_O[,#@4J4:2^)?;[[[KN[^,MHJ?2+62!:>"^$-.-P86TYC"*3
M+K!@IJU*E'22*UTP2UL]CTRID64^J!!1W.E<1 7C,IR,O&VJ)R-56<$E3C68
MJBB87EVC4,MQV TWAD<^7UAGB":CDLWQ">V/<JII%S4H&2]0&JXD:,S'X55W
M>)TX?^_PD^/2[*S!53)3ZL5MOF?CL.,(H<#4.@1&KS>\02$<$-%X76.&34H7
MN+O>H'_UM5,M,V;P1HE?/+.+<3@((<.<5<(^JN4W7-=S[O!2)8Q_PK+V32AC
M6AFKBG4P[0LNZS=[7_=A)V#0^20@7@?$GG>=R+.\999-1EHM03MO0G,+7ZJ/
M)G)<NJ$\64VGG.+L9*IIOMJN@,D,[EXK7E+'[2BRA.T\HG2-<UWCQ)_@=&-X
M4-(N#-S)#+./ !&1:IC%&V;7\4'$6TS;T.NV(.[$O0-XO:;2GL?K_:/2%DP%
MD_9CP?#[:F:LIF_DS[[::^1D/[*[-T-3LA3'(5T,@_H-P\G)4?>B<WF =]+P
M3@ZA_\>$#N+L9YFT83]^8PZ<&3?F%D@2BE31I3065 YV@9 K07>;R_D0GD@T
MLDI@0$?[@0.:*Q8SU&ZVP2F7!*$J0S[FS(_:/>+@GLV49E;IU38Y',.@>T'/
MDZ-!W(TO@QM5E)4EJ!U^1N5VR32V?%I%_#3$@R;D65DFH-REML5GKC2J:Y D
M3< ]&C.$JS2MBDHPBQG=>>I?RIE7E=.D#V>-\W0O;MVT8^A_Z6_)PS-UKC*8
M5P($S]$U<UMTL"7%#>0D7,$*F3;4+(V;]>TN$7PGG38(2V8H2=(/-FWU7(ZA
M0V/2?EQU,+IK"KO#J+OOO-T$6@%])"5ZT12K-NS[DJ,=W2E0S[VZ&NIA)6TM
M08VU$?"K6K>V[K7Z/S ]Y]* P)Q".^W^>0BZ5M1Z8U7I56RF+&FB7R[H)X3:
M.=!YKI3=;%R"YK<V^0M02P,$%     @ +(E=6-,Y<B$_!@  #Q$  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&ULM5A;;]LV%'[7KSAPNZ(%'%^3-$N3
M $FS8@7:+6BZ[F'8 RW1$1&)5$G*CO?K]QU*EF57<;H!?8@ED8?G\ITK<[8T
M]MZE4GIZR#/MSGNI]\7I<.CB5.;"#4PA-7;FQN;"X]/>#5UAI4C"H3P;3D:C
MXV$NE.Y=G(6U&WMQ9DJ?*2UO++DRSX5=7<G,+,][X]YZX9.Z2STO#"_."G$G
M;Z7_H[BQ^!HV7!*52^V4T63E_+QW.3Z].F3Z0/!%R:5KO1-;,C/FGC_>)^>]
M$2LD,QE[YB#P6,BW,LN8$=3X6O/L-2+Y8/M]S?U=L!VVS(23;TWVITI\>MX[
MZ5$BYZ+,_">S_%76]APQO]AD+OS2LJ*='O<H+ITW>7T8&N1*5T_Q4./0.G R
M>N3 I#XP"7I7@H*6U\*+BS-KEF29&MSX)9@:3D,YI=DIM]YB5^&<OW@GE*4O
M(BLEF3F]4UKH6(F,WFOG;0GTO3L;>@AB\F%<,[VJF$X>83J>T$>C?>KH%YW(
M9)O!$!HV:D[6:EY-]G*\EO& IN,^34:3Z1Y^T\;L:> W?=KL:^7BS+C22D=_
M7<Y@-B+E[RZC*Y:'W2PY>TY=(6)YWD-Z.&D7LG?QXMGX>/1FC\*'C<*'^[C_
M7S_M9=JM\M& OD,87;H(>_"+S&?2KGTSZ9-/);TU>2'TBG(I&-B$%$XDTJJ%
MX"2D3(F9RI1?(:\SX4'@33@8&[V0-F2\*4+:SJ7P8$%*!P*60;\9+UV?!/-T
ML54SF438YV4ZQKJG.5NP8 L&T)0Z-)WV=_A1*A*:2:EK):!5GY:IBE.2F4+J
M57KB3)<A@T< F>X!9(.":H!E(!3$(_&MHQ+I8P.#VU0 A)O2QBEJ$%W>62F9
M/J P+RUH;-2@06LT3@(:S^EU?S(])FWH<RJCN<E0BY6^(R]F&2RO*K+Z1[9U
M??'L9#)^_0;<&_^O%58XTUBRA39QH853X]):%H""J5PHFPEO,7N?0O4#\+!1
MZUR*;P'C5J=TB\:3E)F,MF+O0TOVQY;L3:Q&+T.,F-()G;A7]$$N9$;C^CFI
MGU/Z;+S(HE:,U^P"_*([6/X;[Y:NI]%U5]@'<"=O'GLV'+9"8Y>X<FKXC8+@
MMB/V$?\XH"8_&JBCZ0G_?1] NZ@^"5+-O2M+-DGBJC"V0KLY:A7G&FPE3#R,
MR-K SJQY*KA7]'G-=A?(%CH;ZLW;IC17#JOL0W[L>FB,:K VMWF++I-$A7*+
M\M-9IS'^86/F23E70FM40?1-4P)U!FS-9[]LE-INXCX*[YW2NBH96>#?IOPD
MXTPXI^8J%D%-H/>HFNT>,J]K.\RZ!3W>KN@&<Y^T7#YNO8GOZ25+>M7(>J]C
M3+>NZ3CMXC8/*YUU>RO/GL!ANN6#W1-]DCII(_$-\?Y>TZF>TG%6)G7L B$/
M ;R^%!81YT,$[VP5'-!5$T:R"W)81QZ46G&@1R(.[A]PLG3+K.Q?AC;MI44+
M!>8ELP&WJTS$]P=(!\,=B$DKS^8F0?ZP.KG0N!8PIZ85(0;*O%A'@(B.1C]!
M]#WZ<VI,\ECQ[O/J3,8FKT07Y2Q3,4RM>G)A%:*F'D#D0Z%L$V.A\X8@^;;S
M#I!S@,A%I:L:+A/OMZIV A35A ZO\C!2Z#)H"W&U,WBTT96MV(::.3BXH(8+
M8P TCD,T/J?QT6 T0K%9R(.5%)9&-!V<'+86?CX.U:PS6W9<4[7IL@@]?%=W
MGR*0:U/9[."BC3]<;1PC7"#E$$6H:ZB)4)]G-:4A!C9' )>_"VMF35GL5^''
M0]9=B*<H!A*KX*V<@RSX-18N#83A17XM85 F UR87@NA$O8>[HO,T/! 1#R&
M5,W*R0!K%;.."K'BHAY6;"G;)^OI3V$[TJ%X;(@A_$8$CDWP5'MA"V./A$[A
MLX"!#\'!'!=([4T9 >9(BRK>L.928_T!.P$1CU$W(#*@W\-$!]1#%W#MAL-:
M-1%7-2<Q,PL9TA_AL>0?S'I;+0HAOM6AD!OKGHRM==>J@ K6M-I6Q&65A7%$
M.2Y/D/]M4>-37.4'U'7A&;8NJ;FT=^$J[B@XI+JO-JO-;?^RNN1NR*M_%7P4
M%MT" [2<X^AH\/JH1[:Z?E<?WA3ARCLS'A?H\)I*@1Q@ NS/#2"L/UA \S^0
MBW\!4$L#!!0    ( "R)75@6Z ;;&04  +<+   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;)566V_K-@Q^SZ\@<KJ#%LAI;.?6:X!>=K SX S%Z2X/
MPQYDFTF$8TNN)"?-?OU(R7;<K2VPAZ:R1%(?R8\4KW;:?+<;1 ?/9:'L]7#C
M7'4Q'MML@Z6PI[I"12<K;4KAZ-.LQ[8R*'*O5!;C)(KFXU)(-5Q>^;T'L[S2
MM2NDP@<#MBY+8?:W6.C=]3 >MAO?Y'KC>&.\O*K$&A_1_58]&/H:=U9R6:*R
M4BLPN+H>WL07MU.6]P*_2]S9WAK8DU3K[_SQ);\>1@P("\P<6Q#T;XMW6!1L
MB& \-3:'W96LV%^WUC][W\F75%B\T\4?,G>;Z^'9$')<B;IPW_3N)VS\F;&]
M3!?6_\(NR":+(62U=;ILE E!*57X+YZ;./04SJ(W%))&(?&XPT4>Y;UP8GEE
M] X,2Y,U7GA7O3:!DXJ3\N@,G4K2<\L[K;9HG$P+A%^T0PL/8B_HZVKLR#P+
MC;/&U&TPE;QA*D[@JU9N8^%'E6/^TL"8<'7@DA;<;?*NQ7O,3F$2CR")DLD[
M]B:=LQ-O;_*FO=3!O;19H6UM$/Z\2:TS1(R_7O,VV)J^;HN+Y<)6(L/K(56#
M1;/%X?+CAW@>7;Z#=-HAG;YG_?^EY5U3KP.=G\*;5\"O&QS<Z;(2:@^H'!K,
M02JGH22JRXHDLIYN970IK=5F#XK,@%@;1"I;9TD)*(58IF@XA3$<$UU]/6ZQ
MV(_ ;1 ^?CA+DNC2'WL8?B.^/#F%&S=@":DRK'P)ZY57.<B.0*@<A#M<T[ E
M]@>T2,(MK3LYDCM41N21VY">4,!Z.?&5SHS<"L8&U.R\6O"3&]!@A<(Q9W*9
MLY]0<L?T,D:232D@Q4S4EO#RH>L[)ZD>GOE*[7<I-M+M^2Q>7%K0.P54Y]GW
MQG/ Y];A"@..=2US06$84$1O'N_@+)Y]BJ-/]+N8'HL3[RS)44/3!'$GK(=H
M\*F6)MR;(J1R59M,.-I84<Z\X8VVC@),55!SRDY?Y)ZR6I.PR'/):$3Q7MXM
M7>%VB I^%JJF_NY!W51&%CX/U-?<!@1A<62(ME4F*UJ)4M?*<6J/8#J:1!&P
M/Q#/?J!0VXP/!TW<]&I%@59KULZP94.#M@MGILM2-Q%E!OJ(;S'<0?F6BKQA
M"'5:R.Q@]*4Y( :D)W[GJ=9.DOZ ,=)C-XH(I-OHVK*'N=Q*9D^Z;USCH+L]
M%PSEPU(5$%JF4_ AET7M4]NEH 7@8]]C'.C @99XP96!CV6H5\XS;D51^YQ*
M?N(R;3Q10K0;JC15TB=X(44J"\;94OUH-CD[>$7 91FH(J0!OJ0+>*\H&H@,
MQ"#?C;X:68KTT2\".7;(+C2$8C26S?V[;)- P#9V5 DT?%@<<4D4=<YI(KX0
M ?\6_8;0$N4 0JNV4R1MISAL'9I#$\@V!GL4AD+*KU<';="^/[V.POX>P7P&
M"?U]48//F!I/>99[V7":BO']!ONT5WE'$89V!)/1@GBU.#\?S:,)Q+X4_-^,
M3N*)7\_GHVBQ\#'JEV+.[UHJ"LX\%P"-3):O;,*SHJ:K=SYX_^V4![\NX)%&
MOKPND)G>?Q[XW1P<>P(&?MB3H,IJ@[[%MZ7Z]@(E#L$X\HTR3BYI-2/WHU>D
MNQRWHL?Q]!Q.7K,;GK$1*/0UWVF^O&8ZB^&UEWK<&Z9*-&L_,G)4R428J[K=
M;BJ]"</803R,M%^%65-SA0)7I!J=+F9#,&%,#!].5WXT2[6C0<\O-S19HV$!
M.E]I\JCYX NZ67WY#U!+ P04    "  LB5U8*/O7UAH$  #&"0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6RU5FUOXS8,_IY?0?B*PPYP8\N.$[=-
M J3)'=9AUP;M;OLP[(-J,[%0V_))2G/=KQ\EYZ5%T^" 8A\24R\DGX>D* W7
M4CWH M' CZJL]<@KC&G.@T!G!59<=V6#-:TLI*JXH:%:!KI1R'.G5)5!%(;]
MH.*B]L9#-S=7XZ%<F5+4.%>@5U7%U=,EEG(]\IBWG;@5R\+8B6 \;/@2[]!\
M:^:*1L'.2BXJK+60-2A<C+P).[_LV?UNPY\"U_J9#);)O90/=G"5C[S0 L(2
M,V,M</H\XA3+TAHB&-\W-KV=2ZOX7-Y:_^*X$Y=[KG$JR[]$;HJ1EWJ0XX*O
M2G,KU[_BAD]B[66RU.X?UNW>9.!!MM)&5AME0E")NOWR'YLX/%-(PS<4HHU"
MY'"WCAS*&3=\/%1R#<KN)FM6<%2=-H$3M4W*G5&T*DC/C.^,S!X*6>:H],</
M:<0&%_#Y^TJ8I^"7&2Y$)LPGX'4.UU0@<ZZP-G!5/Z(VE!DS# QAL):";./O
MLO47O>&/1?!5UJ;0\+G.,7]I("#P.P;1EL%E=-3B#+,NQ,R'*(SB(_;B741B
M9R]^PU[+'OZ>W&NCJ&C^.42R-=$[;,(>I'/=\ Q''IT4C>H1O?''#ZP?7AP!
MV-L![!VS_C^D[*B_PVP&77@?#IBL3"&5^!?SSI0WPO 23BF'?ABZ'[#(3S9B
MZ@^25HH3]^GOUZ+4C^+03WN1%=G@S$_.(DB8'R5DHY^2RPZ5"%;WJ&R)1#Z8
M F$JJX;73\ )"]4A"*-ABLH(PLT-@ER08B95(Q5W[<-(X%O$L'<?I\SO)RG-
M,/+7[P[ZUN%OO%Y1BW,EZ5M5:C6V#SG7MS=?KF&R5(@N#FMA"N>^#9$/7,-B
MI6BG@EQHZ@':XJOA6A(NQGX6?^<U_D^ I: F8C>L&IJ\FM_X,!/*0OM=:"/J
MI0]2P1TO70B>>[+R'2J!&FRVH_!BXK[L N9$#Y4B&*XFX&2;)PK%I%&BW ;B
MW8%G^_I(#DA1V*7_V4H1D8[U]H1<0>MH5P3;7O$2C^+"QOD$>GX_HI(["_V8
MA=9A'"5 24[)1=HCB9W%M.P/4M:N,@(,-YF1FPI[:;BS)6I/ AT?0R1;UME+
MUN(%:U<5+N1FLS[#DJ^I1&Q :"_=P-K)+-S'Q-(/0P;QZRE7LKL1B]WB'_N<
M3E]E46BHI:'H&6%*FB5?N7@4.='1?J>@,N50"CKP>0NY<?I89P[N";#4)F-2
M:MD11P($"U&Z\,#!2+TG2E6%N:"%\@EPL: B[W!@I_22.>V1@T?J6PC:<=5-
M*0P<:L[!L[NU0K5T+PA*GES5IKUF=[.[1\JDO9OWV]L7SE>NEJ+64.*"5,/N
M(/% M:^&=F!DXV[J>VGHWG=B00\M5'8#K2\DM8#-P#K8/=W&_P%02P,$%
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MI0UX/M?:;6[(0/L1Z.K_4$L#!!0    ( "R)75AP:[:J3 0  #8*   9
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M7<0;V[M%2]QNBK)R=0Q)F)+U))J%\/&58&LU)_]LW$I>5<9P3KT]<Q)3%K4
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MD2W\A+.P0X(MI&$'!$[9-3I6$A.2VS$I58&2CP_L \2N[)*HU]?R]B]XH,N
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M#4P$L$ L1($2HQFP$)IGDV?/N+"GO0M[.NO"/GDFQ5O?FIKL^I3WFH4P[;T
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M30PT[8;MT"%HNNTP["#;="Q4ECQ);MI_/TIV/!=P<K%$B7ST4C*YW$OUK L
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M9B\GH9R*%'\'W-%,&\BL E, R27'2F9B1RC>(:10)J"ZQR%49'82+<A!^FA
M^NB"":3)6J._OFQ";=BH3SSNU><)]]M6BHF45923#^3\;!Z%T0W.9E?703#@
MG>';RUJ8SO4BG'XBET/<IARNB, .B9ETD>^/F<Y",O3<?J\T2U [UX#LK2*B
MJ=)NM>MQMTUI_W=O&N0#53LF-.&08V@P_H@M135-IS&,K%RA)])@VW#3 OLT
M*.N ^[G$C%K#'M!U_O@?4$L#!!0    ( "R)75C*LMK54P0  /@)   9
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M!+$@+$8<%B/CVAZ,[<P@F_&+P$94VDBCS!E[UIW;<&18>D5 (9!: JO'&L9
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M09HU5^J; ;B>H-XO&)/;CJY*RZ\0_Q]02P,$%     @ +(E=6)AEQG;R @
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M1#"C1:)N^/([K 2U-5_($VE^R;)<V\'%82$53U=@K"!E6?E/'U=&; #<S@Z
MMP)X+P&M'0!_!?"-T+(R(VM,%0WZ@B^)T*N133\8;PP:U;!,'^.M$OB6(4X%
M$X$=(=03H5E$+AX*EN,9*7(X!D59(LD/*@353A^1+^3N=DP.#X[( 6$9^1GS
M0B)*]FV%A6@Z.UQM.BPW]79LZGKDFF<JEN0BBR#:)K!1027#6\L8>HV,8PA/
MB.\>$\_Q_)J"1F^'>PWE^)6KON'S7W'UF$P2BG9NF_OG"I>32P6I_%MG7LG=
MJN?6W_69S&D( PL_7 EB 5;P^9/;<;[6"=\3V98-K<J&5A,[VHJD(:/F@X5'
MO'HDU DN6=J&1=\[BZ#5[=N+31F-&]7+( T*VI6"=J."*SKEV/]XP6V>WS6D
M4Q"U9]=(]]ZSVQ/9EO).I;SS@2W<V:<->R+;LJ%;V=!M;(!&&X[)G819D9 K
M-JMM[&;N-GD"*NKNSU$C\#\EGU:23QO+&O$T+Q2(-W9\(]E[CWI/9%NZ>Y7N
MW@=V?&^?-NR);,L&UWF.!,X']OPKY/[NIF]&OE>VO1&*4A!SDQ4E"7F1J3)8
M5+-5'CTW*>S%_%#G5!.VGFG*D'M-Q9QEDB0P0TKGI(L7MBAS8SE0/#?1:\H5
M!CGS&&/6!J$7X/L9YVH]T!M4Z3WX!U!+ P04    "  LB5U8,+JB'?@#  !Q
M&P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6S-F=MNVS@0AE^%T!:+
M%D@C4?*I6=M $R)H@&01)#U<%'M!V^.8J"1Z2<INWGY)69$L1*$MA0OD)M:!
M\W'XCS7*;XZW7/R2*P"%?B=Q*B?>2JGUF>_+^0H2*D_Y&E)]9\E%0I4^%0^^
M7 N@BSPHB?TP" 9^0EGJ3<?YM5LQ'?-,Q2R%6X%DEB14/)Y#S+<3#WM/%^[8
MPTJ9"_YTO*8/< _JV_I6Z#._I"Q8 JED/$4"EA/O,SXC86 "\A'?&6SEWC$R
M2YEQ_LN<7"TF7F R@ACFRB"H_MC !<2Q(>D\_BV@7CFG"=P_?J)?YHO7BYE1
M"1<\_L$6:C7Q1AY:P))FL;KCVR]0+*AO>',>R_POVA9C P_-,ZEX4@3K#!*6
M[C[I[T*(O0#<>R$@+ +"8P.B(B Z-J!7!/1R979+R74@5-'I6/ M$F:TIIF#
M7,P\6B^?I:;N]TKHNTS'J>F]_B(MLA@07Z)+EM)TSFB,KAF=L9@I!A+= )69
M@ 6B"EU2)M!W&F> WA-0E,7R _J(OMT3]/[=!_0.L11]7?%,TG0AQ[[2"9II
M_'F1S/DNF?"%9 C,3U&$3U 8A%%#^,7QX6%#.#D^'-?#?:UJ*6U82AOFO.@%
M7B76"?HL)2B)M"S-VNHGX [FF1 L?<A'_<U345XXIY))]/-:3X"N%"3RGR9M
M=]GTFK,Q_>-,KND<)IYN$!+$!KSIGW_@0?!7D](N8<01K%:%J*Q"9*/KJ@JV
MH::YH+A0_K%)/2NE.4?4)-R.T\\YINENIOUH-/8W^WITF.N@'KU2CYY5CZ>O
MWZ-^5J42F>[AJDF/'66PMXYA& WJ"[FP3G6\:.3UG)H6_5*+OE6+KUSI9K<T
MS^G&/*=-.O2/T>'YH.=%MZ;2L>B#<J$#ZT+W6]%5NLZ4/$'7L($88?3S!I(9
MB,:68J6V;2DN8<01K*;FL%1S^*8:^]!E%5S"B"-8K0JCL@HC)XW=2FG1V!UQ
M2 ?.0<T^E9I]<M+\K906FCGBD Z<@YKAH/H7.7CU:\*.:"&9*Q#I CHLVIZO
MP!U?.:'UE6/'MNUV3FG$%:TN:>4G\-LR%-BIHW!*(ZYH]5)4I@*[<15V3)NV
MX A$NH ."U>Y#^S&?M@Q;81SY5&Z@ X+5UD5_'JO8D>T$<T1B'0!'1:MLCVX
MJ^^)["\AI\;'*8VXHM4EK;P/?EOF!SMU/TYIQ!6M7HK* &$W#LB.:=,61D?\
MSM%EML.B5 X'N[$X!>; #SOVR=HTPO_#PH25A0E?;V$*1-^N2,.HY]\!>S9M
M5^OO;6^8S:@;*AYT<5$,2XT/3H<Z&;';W]F=*+[.=SQF7"F>Y(<KH L09H"^
MO^1</9V8391REVWZ'U!+ P04    "  LB5U85IT-108$   E$@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S-2YX;6S%6&UOVRH4_BO(=[K:I+:.[;RT71*I
M:6ZU2.U4-7OY,-T/Q#Y.4#'D DZV?S_ KI-T#FTB[^Y+ ICS<)Z' QSHK[EX
ME L A;YGE,F!MU!J>>G[,EY AN497P+37U(N,JQT5<Q]N12 $VN443]LM;I^
MA@GSAGW;=B^&?9XK2AC<"R3S+,/BQP@H7P^\P'MJ>"#SA3(-_K"_Q'.8@OJ\
MO!>ZYE<H"<F 2<(9$I .O*O@\CKH&@/;XPN!M=PJ(T-EQOFCJ4R2@=<R'@&%
M6!D(K/]6< V4&B3MQW\EJ%>-:0RWRT_H-Y:\)C/#$JXY_4H2M1AXYQY*(,4Y
M50]\_0%*0AV#%W,J[2]:EWU;'HISJ7A6&FL/,L**?_R]%&++0!.M-PA+@_"Y
M07N/050:1)9HX9FE-<8*#_N"KY$PO36:*5AMK+5F0YB9QJD2^BO1=FHXU7&1
MY!003]$-89C%!%-T2_",4*)^H$\",YF"D.CM&!0F5+Y#I^@&$X&^8)K#"9JP
M9:[D";J%%5 4H6]WD,U _*N[?9Z.T=LW[] ;1!CZM."YQ"R1?5]IQ\WP?EPZ
M.2J<#/<X&83HCC.UD.@?ED"R"^!KQA7M\(GV*'0BCB$^0U%P@L)6&-4X=/UZ
M\]#A3E3-0F3QVGOQ!%EA$]"5?'4J.4',@K^42QS#P-,K6H)8@3?\^Z^@VWI?
MQ[ AL!V^[8IOVZ)'>_ANQP]/T],1ICKRX'1J=ZX'(A]U0(V)C"F7N0 =8\6&
M91;^MUL-AB8*,EDK4KM)D1H"VQ&I4XG4<0:%%6E5B#2#.6&,L+G>LZQ4=<P+
MN(Z%,]OW:MB)SOO^:IN0<\AZ0LC!I5MQZ3JY7"4)L;.GN-YDJV"GU3ZCYU=_
MF"E$I,P-093HZ><Y4W5,G8,=.L<%6'>/;#MT>Q7=GI/N \042TE2$A=!JW?7
MO;1CSE9Z@RV[?>0*I)%IJOOKT@C=ZX,-A( $316/'^OTZ/U"X?37J7>Z?&0L
MGU>"G#L%F;!8)QD2S$&@%H#2*K8-9].RT80PJ42N4X7:J7>.\ZH +M0X N=%
M-2XJ-2Y>O;*!)2\L:R?6 8PO7A_G06N3/K2<5#:9PJ2:-N<9YL8[=.TVA;;+
M?BMY"O[8.58.W910#:'M"A5NA J;/<O<> =$?0- NYPW.5W@3NH:/O/<HQT<
M#T>@.679I'Z!,VGZW\]&MSN'1-+O2 :#3388N-/!YH[0<J#MDZ 71MUGZ8+;
MG6/I;A+&P)TQ'G9&EF"=%R@=D3?6!KV_=>'.0,SM.X1$=NT6E]"JM7KKN+(W
M_&?M(_,&8B_R&YCB >4."[U-2D0AU9"MLY[F)HHWB:*B^-)>ZV=<*9[9X@*P
M7DFF@_Z><KU:RHH9H'H9&OX$4$L#!!0    ( "R)75B9SJ /OP0  -$E   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;,6:6T_K1A#'O\K*1=6IA.);
M;M DT@%?BG2H$!SHPU$?-LF&K/#M[*X)2/WPW;4=QPYF2=J1>"&^[/QFG/EG
M)AEVLDG9$U\3(M!+'"5\:JR%R,Y-DR_6),:\EV8DD7=6*8NQD*?LT>09(WA9
M&,61Z5C6T(PQ38S9I+AVPV:3-!<13<@-0SR/8\Q>+TB4;J:&;6POW-+'M5 7
MS-DDPX_DCHC[[(;),[.F+&E,$D[3!#&RFAI?[?/0'BJ#8L4#)1O>.$;J4>9I
M^J1.KI93PU(1D8@LA$)@^?),+DD4*9*,XV<%-6J?RK!YO*4'Q</+AYEC3B[3
MZ"^Z%.NI,3;0DJQP'HG;=/,'J1YHH'B+-.+%7[2IUEH&6N1<I'%E+".(:5*^
MXI?JC6@8N.X[!DYEX.P9.(-W#-S*P#W4H%\9]/<-G'<,!I7!X% /P\I@>*B'
M464P*I)5OKM%:CPL\&S"T@UB:K6DJ8,BOX6US A-E!3O!)-WJ;03LP!3AAYP
ME!.4KE! $YPL*([05<(%RZ7F!$=?/"(PC3CZ$S.&E71^0R?(1'R-&>&()N@^
MH8*?RHOR^/LZS3E.EGQB"AF@<F,NJF NRF"<=X+QR**'7/L4.9;CHOL[#WTY
M:;KJ(%[JB5_SQP912_+TI(#,>\@9'T+R#W]*9_N4'9A C[DCF<18%48;4'AX
M0'9W0*:45:TMI]:64W#=C[5U33#/&5%ZDM+*<JDJ*9'B)BY*TG>R6"?T9R[U
M]..;Y* K06+^=Y>&2J?];J>J=)_S#"_(U)"UF1/V3(S9K[_80^OW+OE PCQ(
MF \)"R!A(1"LI2FWUI2KH\^^43RG$16OLM1L*Q3Z!YUT":4D#0J2:LG/LY'C
M#B?F<U, 6G?'"@ 2YO\'&.K*/610X?\/JI7V?IWVOC;M=ZJTH8S1!5'9UA6[
MB_Z;M-N#O:272\:-)6[/&;<7>6\7.6\6^=JPC_V4'A)6".2QE89!G8:!-@UO
MRO@INL8B9^KS^..:Q'/".DNVEGILR8:$>9 P'Q(60,)"(%A+-,-:-,//^!HP
MA-04),R#A/F0L  2%@+!6IH:U9H:Z0O1MNIDA-%TV:4//6" 7@EFG;\HM(;'
M:@$2YD/" DA8" 1K:6%<:V%\;%/R7S*R$&2)//I,ET26F%LLB+9%:7T<6TX@
M81XDS(>$!9"P$ C6DM!9+:&SSVA19Y":@H1YD# ?$A9 PD(@6$M3MK4;K5G:
MPE07GU=*HLX>50&&C6_\UMY/%;V/8_,.2O-!:0$H+82BM7/?&*O:QS:E6\J?
M4,"(K!B)(-*I^+@KZ;T<6T) :1XHS0>E!:"T$(K6UM)NC&I_RAS5!AVD@M(\
M4)H/2@M :2$4K:VMW3C5UL]3#^A1)>"LV:-ZECON[S<JT$DJ*,T'I06@M!"*
MUA; ;K!JZR>K'8WJIABS/J21+"G11Z,]/?[H*@))\T!I/B@M *6%4+2VB'9C
M87OP*1T*=&X,2O- :3XH+0"EA5"TMK9VTV-;.T@\I$.5 /6-O]&BSO;_TZ?W
M<W3^0:>\H+0 E!9"T<K\FXV]*FJSTS5FCS3A*"(KB;=Z(ZDV5NX?*D]$FA7;
M5^:I$&E<'*X)7A*F%LC[JS05VQ.U(Z;>Q37[%U!+ P04    "  LB5U8.SIH
MG64"  #2!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6RME5UOTS 4
MAO^*%2:T25OSU108::2M%8(+I&IE<(&X<)/3QIIC!]MIMW_/L9-%':35*G&3
M^-A^7Y\GCH_3G50/N@0PY+'B0D^]TICZVO=U7D)%]4C6('!D+55%#89JX^M:
M 2V<J.)^% 03OZ),>%GJ^A8J2V5C.!.P4$0W5475TRUPN9MZH??<<<<VI;$=
M?I;6= -+,/?U0F'D]RX%JT!H)@51L)YZ-^'U++'SW83O#'9ZKTTLR4K*!QM\
M*:9>8!,"#KFQ#A1?6Y@!Y]8(T_C=>7K]DE:XWWYV_^38D65%-<PD_\$*4TZ]
M]QXI8$T;;N[D[C-T/"[!7'+MGF37SIV,/9(WVLBJ$V,&%1/MFSYVWV%/$!X2
M1)T@>JT@[@2Q VTS<UAS:FB6*KDCRLY&-]MPW\:ID88)NXM+HW"4H<YD2_PM
MBH8#D6LRDV(+RK 5AG-8&7(^!T,9UQ?DBMPOY^3\[(*<$2;(MU(VFHI"I[[!
M)*R5GW<+WK8+1@<6G$,^(G%X2:(@B@?DL]?+HY=R']%[_JCGCYQ??- /.>=,
MYUSJ1@'Y>;/21N'/]6L(K?4:#WO9 W>M:YK#U,,3I4%MP<O>O@DGP<<AT/]D
M]@([[K'C8^[9_E8+:4"36C&1LYKR(>ZC9L.IDB'DUB=Q/K:^;+-D$@2IOQU
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MVG7@>H*ZOV!,O@QT0UC_ 0C_ E!+ P04    "  LB5U8'S]A_<8%  "D,@
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M./F6O">?'USRYM>W5UVELQ>,;EQGNJTR.2]DLLE'GJNE)%X^8[.6>/>5>,<
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MLYV$OT,& BGKS'4C_ ,QJ035_]Y7U?A.\+<F;D]@-1W.*QW./[C&S_<IU9[
M:E*YSG-3X;Q3E9? M9N\Y336ZGRSU5JAVRM=40IB:II%B4PP&44W4:U6#6G7
MM&%KZSW=J)INZQFFZ'*OJ9BR3)($)@CIG)PB(U$TCL5$\=ST7F.NL),SPQB;
M;1#: +]/.%?+B=Z@:M^#_U!+ P04    "  LB5U8AJ7["84"  "?!0  &0
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MSOHW;6H@6*6I^T53]YU-;1U4Y;B[VD_H?W\2B2;6X>7,T'1X0<(H)(Q!PF9
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M9%+ _+Z,8[V_2!(4_X\P^0]02P,$%     @ +(E=6&N[+$Y> P   @X  !D
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M<9[563F]C,OB,")C^R-Q+&?<X=!=/WP#NQ%QO%?A03]\"SG.;FFXTR5'/SR
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MR]F*R^0$\_Y:"/V\DR0HEEA-_P-02P,$%     @ +(E=6$,[H1M( P  O!0
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MY[(08UTTM5!N%T<CJ@"H[%*N;(<I7HM!9Z37PH3W\0^X*G?OYCP4B)0YD_Z
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M)_X1UN\O>%7<&A;^[+X3Y?VPE#MOJFKD]]VH:\W+_<\U]C\U^?H+4$L#!!0
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M2P$"% ,4    "  LB5U8U]8X ^X    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  LB5U8F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( "R)75B7]8E]< <  /HP   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  LB5U8X Z! X(&  !%)P
M&               @(&S#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ +(E=6-'8%)Q9!   G1H  !@              ("!:Q8  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "R)75@YA-U1( 0
M ,D.   8              " @?H:  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    "  LB5U8\YH/2F (   ^40  &               @(%0
M'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ +(E=6.\"
MKT6&!P  6B4  !@              ("!YB<  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( "R)75A Z/>>*0@  ( 2   8
M  " @:(O  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  L
MB5U8Q>U.&4L5  !B.0  &               @($!.   >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ +(E=6(UGS<,S!   J@D  !@
M         ("!@DT  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( "R)75@KN69:  ,  .(&   9              " @>M1  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ +(E=6-,Y<B$_!@  #Q$
M !D              ("!(E4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    "  LB5U8%N@&VQD%  "W"P  &0              @(&86P
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "R)75@H^]?6
M&@0  ,8)   9              " @>A@  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ +(E=6*N_$612 P  K0<  !D
M ("!.64  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  L
MB5U8A>KZM&D'   0$@  &0              @('":   >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "R)75AP:[:J3 0  #8*   9
M          " @6)P  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#
M%     @ +(E=6*6"L8+0!   W H  !D              ("!Y70  'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  LB5U8) T.87T&  #6
M#P  &0              @('L>0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM
M;%!+ 0(4 Q0    ( "R)75@N*W\.[0(  %0&   9              " @:"
M  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ +(E=6'Q$
MR(5Z%@  WD$  !D              ("!Q(,  'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6Q02P$"% ,4    "  LB5U8> %DGDL#  #%!P  &0
M    @(%UF@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M "R)75CA<1(0MP(  "X&   9              " @?>=  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ +(E=6,(H&T#4 P  8@L  !D
M             ("!Y:   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    "  LB5U8;+'7\YH"   %!@  &0              @('PI   >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "R)75C*LMK54P0
M /@)   9              " @<&G  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ +(E=6);R]R'; @  7P8  !D              ("!
M2ZP  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  LB5U8
M<T_83B8%  #,#0  &0              @(%=KP  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( "R)75ALH[[M[P(  &<'   9
M      " @;JT  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ +(E=6,3^='A& @  U04  !D              ("!X+<  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  LB5U84B[+1UH#  !8"@
M&0              @(%=N@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( "R)75BGK=3CU00  )8?   9              " @>Z]  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ +(E=6'U$;XT!
M P  D0P  !D              ("!^L(  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    "  LB5U8F&7&=O("  #)"P  &0
M@($RQ@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "R)
M75@PNJ(=^ ,  '$;   9              " @5O)  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ +(E=6%:=#44&!   )1(  !D
M         ("!BLT  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    "  LB5U8F<Z@#[\$  #1)0  &0              @(''T0  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "R)75@[.FB=90(  -(&
M   9              " @;W6  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ +(E=6)F&LIZR!0  R2   !D              ("!6=D
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  LB5U8]""W
M8^ ,  #)H@  &0              @(%"WP  >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( "R)75AN&+^)B 0  /,0   9
M  " @5GL  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M+(E=6/AX0*=" P  %0H  !D              ("!&/$  'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    "  LB5U8;$8-,,\#  !F#@  &0
M            @(&1]   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( "R)75@F2GH.N0(  -@'   9              " @9?X  !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ +(E=6-XU8S\W P
M# P  !D              ("!A_L  'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    "  LB5U8'S]A_<8%  "D,@  &0              @('U
M_@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( "R)75CI
MUJ8^.08  !<Z   9              " @?($ 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ +(E=6')T"O@K P  R@L  !D
M     ("!8@L! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "R)75AEPMG')@8  &XU   9              "
M@44? 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ +(E=
M6$,[H1M( P  O!0   T              ( !HB4! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  LB5U8EXJ[',     3 @  "P              @ $5*0$
M7W)E;',O+G)E;'-02P$"% ,4    "  LB5U8BM=3=:X$  #N(@  #P
M        @ '^*0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ +(E=6(HQ
M=E_/ 0  ,Q\  !H              ( !V2X! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ +(E=6#+A@>'' 0  $A\  !,
M     ( !X# ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #P / !;$
&V#(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>149</ContextCount>
  <ElementCount>275</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Changes in Stockholders' Equity/(Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit</Role>
      <ShortName>Statements of Changes in Stockholders' Equity/(Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Organization, Description of Business, and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidity</Role>
      <ShortName>Organization, Description of Business, and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://fibrobiologics.com/role/ConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Stockholders??? Equity/(Deficit) and Net Parent Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestment</Role>
      <ShortName>Stockholders??? Equity/(Deficit) and Net Parent Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Share Subscription Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ShareSubscriptionAgreement</Role>
      <ShortName>Share Subscription Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Leases, Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/LeasesCommitmentsAndContingencies</Role>
      <ShortName>Leases, Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/Share-basedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/PropertyAndEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Convertible Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://fibrobiologics.com/role/ConvertibleNotesPayableTables</Role>
      <ShortName>Convertible Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/ConvertibleNotesPayable</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Leases, Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesTables</Role>
      <ShortName>Leases, Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/LeasesCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/Share-basedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/Share-basedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Organization, Description of Business, and Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative</Role>
      <ShortName>Organization, Description of Business, and Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Schedule of Financial Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Schedule of Financial Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Financial Liability Transfers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails</Role>
      <ShortName>Schedule of Financial Liability Transfers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Fair Value of Financial Instruments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative</Role>
      <ShortName>Fair Value of Financial Instruments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails</Role>
      <ShortName>Schedule of Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Convertible Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative</Role>
      <ShortName>Convertible Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/ConvertibleNotesPayableTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Stockholders??? Equity/(Deficit) and Net Parent Investment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity/(Deficit) and Net Parent Investment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestment</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Share Subscription Agreement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative</Role>
      <ShortName>Share Subscription Agreement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/ShareSubscriptionAgreement</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Schedule of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/IncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Schedule of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Schedule of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Leases, Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Leases, Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Schedule of Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Schedule of Unvested Awards and Weighted Average Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails</Role>
      <ShortName>Schedule of Unvested Awards and Weighted Average Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Schedule of Fair Value of Option Granted Black Scholes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails</Role>
      <ShortName>Schedule of Fair Value of Option Granted Black Scholes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Share-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative</Role>
      <ShortName>Share-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/Share-basedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://fibrobiologics.com/role/SubsequentEvents</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>fblg-20231231.xsd</File>
    <File>fblg-20231231_cal.xml</File>
    <File>fblg-20231231_def.xml</File>
    <File>fblg-20231231_lab.xml</File>
    <File>fblg-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="593">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "FBLG",
   "nsuri": "http://fibrobiologics.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "fblg-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "fblg-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fblg-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "fblg-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fblg-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 233,
   "keyCustom": 42,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 16,
   "hidden": {
    "total": 205,
    "http://fasb.org/us-gaap/2023": 148,
    "http://fibrobiologics.com/20231231": 54,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 149,
   "entityCount": 1,
   "segmentCount": 43,
   "elementCount": 432,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 593,
    "http://xbrl.sec.gov/dei/2023": 37
   },
   "report": {
    "R1": {
     "role": "http://fibrobiologics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://fibrobiologics.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://fibrobiologics.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit",
     "longName": "00000005 - Statement - Statements of Changes in Stockholders' Equity/(Deficit)",
     "shortName": "Statements of Changes in Stockholders' Equity/(Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_custom_NetParentInvestmentMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_custom_NetParentInvestmentMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://fibrobiologics.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidity",
     "longName": "00000007 - Disclosure - Organization, Description of Business, and Liquidity",
     "shortName": "Organization, Description of Business, and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholders",
     "longName": "00000009 - Disclosure - Net Loss per Share Attributable to Common Stockholders",
     "shortName": "Net Loss per Share Attributable to Common Stockholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://fibrobiologics.com/role/PropertyAndEquipment",
     "longName": "00000010 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://fibrobiologics.com/role/FairValueOfFinancialInstruments",
     "longName": "00000011 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://fibrobiologics.com/role/ConvertibleNotesPayable",
     "longName": "00000012 - Disclosure - Convertible Notes Payable",
     "shortName": "Convertible Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestment",
     "longName": "00000013 - Disclosure - Stockholders\u2019 Equity/(Deficit) and Net Parent Investment",
     "shortName": "Stockholders\u2019 Equity/(Deficit) and Net Parent Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://fibrobiologics.com/role/ShareSubscriptionAgreement",
     "longName": "00000014 - Disclosure - Share Subscription Agreement",
     "shortName": "Share Subscription Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "FBLG:ShareSubscriptionAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "FBLG:ShareSubscriptionAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://fibrobiologics.com/role/IncomeTaxes",
     "longName": "00000015 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://fibrobiologics.com/role/LeasesCommitmentsAndContingencies",
     "longName": "00000016 - Disclosure - Leases, Commitments and Contingencies",
     "shortName": "Leases, Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://fibrobiologics.com/role/RelatedPartyTransactions",
     "longName": "00000017 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://fibrobiologics.com/role/Share-basedCompensation",
     "longName": "00000018 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://fibrobiologics.com/role/SubsequentEvents",
     "longName": "00000019 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersTables",
     "longName": "00000021 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)",
     "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://fibrobiologics.com/role/PropertyAndEquipmentTables",
     "longName": "00000022 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables",
     "longName": "00000023 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://fibrobiologics.com/role/ConvertibleNotesPayableTables",
     "longName": "00000024 - Disclosure - Convertible Notes Payable (Tables)",
     "shortName": "Convertible Notes Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://fibrobiologics.com/role/IncomeTaxesTables",
     "longName": "00000025 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesTables",
     "longName": "00000026 - Disclosure - Leases, Commitments and Contingencies (Tables)",
     "shortName": "Leases, Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://fibrobiologics.com/role/Share-basedCompensationTables",
     "longName": "00000027 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
     "longName": "00000028 - Disclosure - Organization, Description of Business, and Liquidity (Details Narrative)",
     "shortName": "Organization, Description of Business, and Liquidity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "longName": "00000030 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "shortName": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative",
     "longName": "00000031 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details Narrative)",
     "shortName": "Net Loss per Share Attributable to Common Stockholders (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:PreferredStockLiquidationPreferenceValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "00000032 - Disclosure - Schedule of Property and Equipment (Details)",
     "shortName": "Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "00000033 - Disclosure - Property and Equipment (Details Narrative)",
     "shortName": "Property and Equipment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_LaborataryEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails",
     "longName": "00000034 - Disclosure - Schedule of Financial Liabilities Measured at Fair Value (Details)",
     "shortName": "Schedule of Financial Liabilities Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails",
     "longName": "00000035 - Disclosure - Schedule of Financial Liability Transfers (Details)",
     "shortName": "Schedule of Financial Liability Transfers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member",
      "name": "FBLG:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative",
     "longName": "00000036 - Disclosure - Fair Value of Financial Instruments (Details Narrative)",
     "shortName": "Fair Value of Financial Instruments (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "FBLG:LiabilityInstrument",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails",
     "longName": "00000037 - Disclosure - Schedule of Convertible Debt (Details)",
     "shortName": "Schedule of Convertible Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative",
     "longName": "00000038 - Disclosure - Convertible Notes Payable (Details Narrative)",
     "shortName": "Convertible Notes Payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative",
     "longName": "00000039 - Disclosure - Stockholders\u2019 Equity/(Deficit) and Net Parent Investment (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity/(Deficit) and Net Parent Investment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2023-10-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-04-30",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative",
     "longName": "00000040 - Disclosure - Share Subscription Agreement (Details Narrative)",
     "shortName": "Share Subscription Agreement (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "FBLG:DescriptionOfShareSubscriptionAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "FBLG:ShareSubscriptionAgreementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "FBLG:DescriptionOfShareSubscriptionAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "FBLG:ShareSubscriptionAgreementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails",
     "longName": "00000041 - Disclosure - Schedule of Effective Income Tax Rate (Details)",
     "shortName": "Schedule of Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails",
     "longName": "00000042 - Disclosure - Schedule of Net Deferred Tax Assets (Details)",
     "shortName": "Schedule of Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000043 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails",
     "longName": "00000044 - Disclosure - Schedule of Operating Lease Liabilities (Details)",
     "shortName": "Schedule of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000045 - Disclosure - Leases, Commitments and Contingencies (Details Narrative)",
     "shortName": "Leases, Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000046 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:RepaymentsOfRelatedPartyDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-10-31",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails",
     "longName": "00000047 - Disclosure - Schedule of Stock Based Compensation Expense (Details)",
     "shortName": "Schedule of Stock Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://fibrobiologics.com/role/ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails",
     "longName": "00000048 - Disclosure - Schedule of Unvested Awards and Weighted Average Period (Details)",
     "shortName": "Schedule of Unvested Awards and Weighted Average Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "00000049 - Disclosure - Schedule of Stock Option Activity (Details)",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2023-08-012023-08-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails",
     "longName": "00000050 - Disclosure - Schedule of Fair Value of Option Granted Black Scholes (Details)",
     "shortName": "Schedule of Fair Value of Option Granted Black Scholes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative",
     "longName": "00000051 - Disclosure - Share-Based Compensation (Details Narrative)",
     "shortName": "Share-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2023-08-012023-08-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000052 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:RepaymentsOfRelatedPartyDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent company receivable",
        "verboseLabel": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r136",
      "r491"
     ]
    },
    "FBLG_AdditionToDerivativeLiabilityForDebtIssuanceDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "AdditionToDerivativeLiabilityForDebtIssuanceDiscount",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Addition to derivative liability for debt issuance discount",
        "documentation": "Addition to derivative liability for debt issuance discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r635",
      "r756"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r514",
      "r685",
      "r686",
      "r687",
      "r734",
      "r758"
     ]
    },
    "FBLG_AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions to accounts payable and accrued expenses for purchases of property and equipment",
        "documentation": "Additions to accounts payable and accrued expenses for purchases of property and equipment\t."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r357"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of convertible notes debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r63",
      "r86",
      "r285"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative",
      "http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative",
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r137",
      "r164",
      "r200",
      "r204",
      "r206",
      "r240",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r385",
      "r387",
      "r408",
      "r485",
      "r554",
      "r635",
      "r647",
      "r698",
      "r699",
      "r742"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r143",
      "r164",
      "r240",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r385",
      "r387",
      "r408",
      "r635",
      "r698",
      "r699",
      "r742"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r661",
      "r662"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r661",
      "r662"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r661",
      "r662"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Description of Business, and Liquidity",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r91",
      "r92"
     ]
    },
    "FBLG_CapitalStockInExcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "CapitalStockInExcess",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock in excess",
        "documentation": "Capital stock in excess."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalUnitsAuthorized",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares authorized",
        "label": "Capital Units, Authorized",
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalUnitsTotalCostToInvestors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalUnitsTotalCostToInvestors",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investors sales",
        "documentation": "Cost to investors of each class of capital shares or other capital units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r134",
      "r615"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r88",
      "r159"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r88"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r753"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federally insured limit",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative",
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative",
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r138",
      "r139",
      "r140",
      "r164",
      "r186",
      "r187",
      "r190",
      "r192",
      "r198",
      "r199",
      "r240",
      "r265",
      "r267",
      "r268",
      "r269",
      "r272",
      "r273",
      "r293",
      "r294",
      "r297",
      "r300",
      "r307",
      "r408",
      "r505",
      "r506",
      "r507",
      "r508",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r542",
      "r563",
      "r586",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r669",
      "r683",
      "r688"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r198",
      "r293",
      "r294",
      "r295",
      "r297",
      "r300",
      "r305",
      "r307",
      "r505",
      "r506",
      "r507",
      "r508",
      "r628",
      "r669",
      "r683"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative",
      "http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "FBLG_CommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "CommitmentFee",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment fee",
        "documentation": "Commitmentt fee."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_CommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "CommitmentFeePercentage",
     "presentation": [
      "http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment fee percentage",
        "documentation": "Commitment fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r259",
      "r260",
      "r612",
      "r697"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r638",
      "r639",
      "r641",
      "r642",
      "r643",
      "r644",
      "r685",
      "r686",
      "r734",
      "r754",
      "r758"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r542"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r76",
      "r542",
      "r560",
      "r758",
      "r759"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r487",
      "r635"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r122"
     ]
    },
    "us-gaap_ConversionOfStockDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockDescription",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Description",
        "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converted principal shares",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued upon conversion of common stock",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Convertible Debt",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes outstanding",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r113",
      "r752"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable, net of debt discount",
        "verboseLabel": "Convertible notes payable, net of discount",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r161",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r286",
      "r287",
      "r289"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt, gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r113",
      "r290"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleTypeOfEquitySecurity",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument convertible descreption",
        "documentation": "Description of the type of equity security or securities into which conversion will be made (for example, common stock or preferred shares)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r44",
      "r47",
      "r100"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes principal",
        "verboseLabel": "Face value",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r66",
      "r275",
      "r417",
      "r624",
      "r625"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Convertible notes discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r66",
      "r701"
     ]
    },
    "FBLG_DeemedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "DeemedDividend",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend",
        "documentation": "Deemed dividend."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_DeemedDividendRelatedToRofnAgreementDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "DeemedDividendRelatedToRofnAgreementDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend related to ROFN Agreement derivative liability",
        "documentation": "Deemed dividend related to rofn agreement derivative liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r112",
      "r370"
     ]
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative liability",
        "label": "Deferred Tax Assets, Derivative Instruments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r732"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r732"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r732"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r732"
     ]
    },
    "FBLG_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Deferred tax assets tax deferred expense compensation and benefits lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r732"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r732"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Lease right-of-use asset",
        "documentation": "Deferred tax liabilities operating lease right of use assets.",
        "label": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r732"
     ]
    },
    "FBLG_DeferredTaxLiabilitiesUnamortizedDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "DeferredTaxLiabilitiesUnamortizedDebtDiscount",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unamortized debt discount",
        "documentation": "Deferred tax liabilities unamortized debt discount.",
        "label": "DeferredTaxLiabilitiesUnamortizedDebtDiscount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r38"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative liability",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r407",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r555",
      "r557",
      "r558",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r617",
      "r755"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "FBLG_DerivativeLiabilitiesPayableToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "DerivativeLiabilitiesPayableToRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities payable to related parties",
        "documentation": "Derivative liabilities payable to related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLossOnDerivative",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on derivative liability",
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_DerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeMember",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative [Member]",
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r56",
      "r57",
      "r58",
      "r59",
      "r168"
     ]
    },
    "FBLG_DescriptionOfShareSubscriptionAgreement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "DescriptionOfShareSubscriptionAgreement",
     "presentation": [
      "http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of share subscription agreement",
        "documentation": "Description of share subscription agreement."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_DirectorsAndOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "DirectorsAndOfficersMember",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors and Officers [Member]",
        "documentation": "Directors and Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/Share-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r322",
      "r350",
      "r351",
      "r353",
      "r633"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_DisclosureShareSubscriptionAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "DisclosureShareSubscriptionAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Subscription Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r661",
      "r662"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r661",
      "r662",
      "r664"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r183",
      "r186",
      "r190",
      "r191",
      "r192",
      "r196",
      "r399",
      "r400",
      "r483",
      "r495",
      "r619"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r190"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r186",
      "r190",
      "r191",
      "r192",
      "r196",
      "r399",
      "r400",
      "r483",
      "r495",
      "r619"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share Attributable to Common Stockholders",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r193",
      "r194",
      "r195"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r365",
      "r380"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r733"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible stock compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r733"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other changes",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r733"
     ]
    },
    "FBLG_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent items",
        "documentation": "Effective income tax rate reconciliation permanent items."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "True-up prior-year net operating loss deferred tax asset",
        "documentation": "Effective income tax rate reconciliation prior year net operating loss deferred tax assets.",
        "label": "Effective income tax rate reconciliation prior year net operating loss deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_EmergingGrowthCompanyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Emerging Growth Company [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation",
        "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized stock-based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfUnvestedAwardsAndWeightedAveragePeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected weighted average period compensation cost",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r130",
      "r149",
      "r150",
      "r151",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r197",
      "r241",
      "r242",
      "r309",
      "r354",
      "r355",
      "r356",
      "r376",
      "r377",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r398",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r422",
      "r498",
      "r499",
      "r500",
      "r514",
      "r586"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_FairValueAdjustmentOfLiabilityInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "FairValueAdjustmentOfLiabilityInstrument",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows",
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of liability instrument",
        "label": "Change in fair value of liability instrument",
        "documentation": "Change in fair value of liability instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r406"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r406"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails",
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r403",
      "r437",
      "r438",
      "r439",
      "r624",
      "r625",
      "r629",
      "r630",
      "r631"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r311",
      "r316",
      "r403",
      "r437",
      "r629",
      "r630",
      "r631"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r311",
      "r316",
      "r403",
      "r438",
      "r624",
      "r625",
      "r629",
      "r630",
      "r631"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails",
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r403",
      "r439",
      "r624",
      "r625",
      "r629",
      "r630",
      "r631"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Liabilities Measured at Fair Value",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r108"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Liability Transfers",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in the fair value of the liability instrument",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value, beginning balance",
        "periodEndLabel": "Fair value, ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails",
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r437",
      "r438",
      "r439",
      "r624",
      "r625",
      "r629",
      "r630",
      "r631"
     ]
    },
    "FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Addition to derivative liability for debt issuance discount",
        "documentation": "Addition to derivative liability for debt issuance discount.",
        "label": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock",
        "documentation": "Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock.",
        "label": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_FibroGenesisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "FibroGenesisMember",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fibro Genesis [Member]",
        "documentation": "Fibro Genesis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r288",
      "r305",
      "r396",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r494",
      "r623",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r691",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total fair value",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r469",
      "r470"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General, administrative and other",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r565"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r661",
      "r662"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r570"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r570"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r360",
      "r366",
      "r368",
      "r374",
      "r378",
      "r381",
      "r382",
      "r383",
      "r510"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expenses",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r128",
      "r180",
      "r181",
      "r202",
      "r364",
      "r379",
      "r496"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r362",
      "r363",
      "r368",
      "r369",
      "r373",
      "r375",
      "r504"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "FBLG_IncreaseDecreaseInChangeInPayableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "IncreaseDecreaseInChangeInPayableToParent",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in payable to Parent",
        "documentation": "Increase decrease in change in payable to parent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r681"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "FBLG_InsurancePolicyCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "InsurancePolicyCost",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance policy cost",
        "documentation": "Insurance policy cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Costs",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r465",
      "r466",
      "r467",
      "r469",
      "r618"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r116",
      "r152",
      "r201",
      "r416",
      "r571",
      "r645",
      "r757"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r284",
      "r291",
      "r626",
      "r627"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r157",
      "r158"
     ]
    },
    "FBLG_IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B Preferred Stock for conversion of Notes and accrued interest",
        "documentation": "Issuance of series B adjustments to additional paid in capital conversion of notes and accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Series B Preferred Stock for conversion of Notes and accrued interest",
        "documentation": "Issuance of series b preferred stock for conversion of notes and accrued interest.",
        "label": "IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B Preferred Stock shares for conversion of Notes and accrued interest, shares",
        "documentation": "Issuance of series B preferred stock shares for conversion of notes and accrued interest shares."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_LaborataryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "LaborataryEquipmentMember",
     "presentation": [
      "http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratary Equipment [Member]",
        "documentation": "Laboratary Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_LeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "LeaseAgreementMember",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreement [Member]",
        "documentation": "Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "FBLG_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Lessee operating lease liability payments due after year four."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extended lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r164",
      "r240",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r386",
      "r387",
      "r388",
      "r408",
      "r541",
      "r620",
      "r647",
      "r698",
      "r742",
      "r743"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity/(deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r114",
      "r489",
      "r635",
      "r684",
      "r695",
      "r737"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders\u2019 equity/(deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r133",
      "r164",
      "r240",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r386",
      "r387",
      "r388",
      "r408",
      "r635",
      "r698",
      "r742",
      "r743"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_LiabilityInstrument": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "LiabilityInstrument",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability instrument",
        "documentation": "Liability instrument."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_LiabilityInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "LiabilityInstrumentMember",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Instrument [Member]",
        "documentation": "Liability Instrument [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_LicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "LicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License fee",
        "documentation": "License fee."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r318",
      "r464",
      "r497",
      "r533",
      "r534",
      "r594",
      "r595",
      "r596",
      "r597",
      "r605",
      "r613",
      "r614",
      "r622",
      "r628",
      "r632",
      "r636",
      "r700",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_MeasurementInputMaturityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputMaturityMember",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Maturity [Member]",
        "documentation": "Measurement input using due date of last payment of principal and interest for financial instrument. Excludes expected term."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r318",
      "r464",
      "r497",
      "r533",
      "r534",
      "r594",
      "r595",
      "r596",
      "r597",
      "r605",
      "r613",
      "r614",
      "r622",
      "r628",
      "r632",
      "r636",
      "r700",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://fibrobiologics.com/role/StatementsOfCashFlows",
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit",
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r90",
      "r115",
      "r131",
      "r146",
      "r147",
      "r151",
      "r164",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r188",
      "r200",
      "r203",
      "r205",
      "r207",
      "r240",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r400",
      "r408",
      "r493",
      "r562",
      "r584",
      "r585",
      "r621",
      "r645",
      "r698"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common stockholders",
        "label": "Net loss attributable to common stockholders:",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r174",
      "r175",
      "r176",
      "r177",
      "r183",
      "r184",
      "r189",
      "r192",
      "r200",
      "r203",
      "r205",
      "r207",
      "r621"
     ]
    },
    "FBLG_NetParentInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "NetParentInvestment",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Parent investment",
        "documentation": "Net parent investment."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_NetParentInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "NetParentInvestmentMember",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Investment [Member]",
        "documentation": "Parent Investment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other loss",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NonvotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvotingCommonStockMember",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvoting Common Stock [Member]",
        "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_ObtainingOperatingLeaseRightofuseAssetAndLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "ObtainingOperatingLeaseRightofuseAssetAndLiability",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obtaining operating lease right-of-use asset and liability",
        "documentation": "Obtaining operating lease right of use asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r203",
      "r205",
      "r207",
      "r621"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease liability",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, short-term",
        "negatedLabel": "Less: Current lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, long-term",
        "verboseLabel": "Total non-current lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset, net",
        "verboseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of operating lease right-of-use asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncancelable lease payments",
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118"
     ]
    },
    "FBLG_OperatingLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "OperatingLeasesMember",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases [Member]",
        "documentation": "Operating Leases [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r635"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "FBLG_ParentCompanyPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "ParentCompanyPayable",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent company payable",
        "documentation": "Parent company payable."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_PaymentsForEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "PaymentsForEquityInvestments",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for equity investments",
        "documentation": "Payments for equity investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expense",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative",
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares issued",
        "label": "Application fee",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "FBLG_PercentageOfGrossProceedsFromEquityInvestments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "PercentageOfGrossProceedsFromEquityInvestments",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of gross proceeds from equity investments",
        "documentation": "Percentage of gross proceeds from equity investments."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, liquidation preference per share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r75",
      "r683",
      "r702"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative",
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock liquidation value",
        "verboseLabel": "Liquidation preference",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r297"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r638",
      "r641",
      "r642",
      "r643",
      "r644",
      "r754",
      "r758"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r293"
     ]
    },
    "us-gaap_PreferredStockRedemptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockRedemptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, redemption amount",
        "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r43"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r542"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r293"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r542",
      "r560",
      "r758",
      "r759"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r486",
      "r635"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r251",
      "r252",
      "r616"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of convertible notes",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series B Preferred Stock, net of direct costs",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "FBLG_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series B-1 Preferred Stock, net of direct costs",
        "documentation": "Proceeds from issuance of Series B-1 Preferred Stock, net of direct costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment and proceeds of note receivable from Parent",
        "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (repayments of) related party debt",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r123",
      "r126",
      "r127"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total property and equipment at cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r135",
      "r492"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r484",
      "r492",
      "r635"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r123",
      "r126",
      "r490"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r310",
      "r318",
      "r345",
      "r346",
      "r347",
      "r440",
      "r464",
      "r497",
      "r533",
      "r534",
      "r594",
      "r595",
      "r596",
      "r597",
      "r605",
      "r613",
      "r614",
      "r622",
      "r628",
      "r632",
      "r636",
      "r639",
      "r696",
      "r700",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails"
     ],
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r310",
      "r318",
      "r345",
      "r346",
      "r347",
      "r440",
      "r464",
      "r497",
      "r533",
      "r534",
      "r594",
      "r595",
      "r596",
      "r597",
      "r605",
      "r613",
      "r614",
      "r622",
      "r628",
      "r632",
      "r636",
      "r639",
      "r696",
      "r700",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749"
     ]
    },
    "FBLG_ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock",
        "documentation": "Reclassification of derivative liability for conversion of notes to series b preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r426",
      "r427",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r559",
      "r561",
      "r593"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r426",
      "r427",
      "r428",
      "r429",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r559",
      "r561",
      "r593"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r567",
      "r570"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r426",
      "r427",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r559",
      "r561",
      "r593",
      "r741"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r427",
      "r430",
      "r511",
      "r512",
      "r513",
      "r568",
      "r569",
      "r570",
      "r590",
      "r592"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://fibrobiologics.com/role/StatementsOfCashFlows",
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of loan to Parent",
        "label": "Repayments of Related Party Debt",
        "verboseLabel": "Payable to its services as advisor",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r359",
      "r750"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r101",
      "r488",
      "r501",
      "r502",
      "r509",
      "r543",
      "r635"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r241",
      "r242",
      "r354",
      "r355",
      "r356",
      "r376",
      "r377",
      "r390",
      "r392",
      "r393",
      "r395",
      "r398",
      "r498",
      "r500",
      "r514",
      "r758"
     ]
    },
    "FBLG_RisksAndUncertaintiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties",
        "documentation": "Risks and Uncertainties [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_RofnAgreementPaymentsToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "RofnAgreementPaymentsToParent",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "ROFN Agreement payments to Parent",
        "documentation": "Rofn agreement payments to parent.",
        "label": "RofnAgreementPaymentsToParent"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Series \"B-1\" Preferred Stock shares, net of direct costs, shares",
        "documentation": "Sale of series B1 preferred stock shares net of direct costs shares."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Series B Preferred Stock, net of direct costs",
        "documentation": "Sale of series B adjustments to additional paid in capital stock issued issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Series B-1 Preferred Stock",
        "documentation": "Sale of series B one adjustments to additional paid in capital stock issued issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Balance, shares",
        "documentation": "Sale of series b preferred stock shares net of direct costs shares.",
        "label": "SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock number of shares issued in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative",
      "http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/Share-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Based Compensation Expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r186",
      "r187",
      "r190"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table]",
        "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r109"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://fibrobiologics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r566",
      "r567",
      "r570"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails",
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/Share-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r51"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/Share-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Option Granted Black Scholes",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r44",
      "r45",
      "r46",
      "r48",
      "r99",
      "r100",
      "r101",
      "r138",
      "r139",
      "r140",
      "r198",
      "r293",
      "r294",
      "r295",
      "r297",
      "r300",
      "r305",
      "r307",
      "r505",
      "r506",
      "r507",
      "r508",
      "r628",
      "r669",
      "r683"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/Share-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unvested Awards and Weighted Average Period",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative",
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r680",
      "r703"
     ]
    },
    "FBLG_SeriesB1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "SeriesB1PreferredStockMember",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B1 Preferred Stock [Member]",
        "documentation": "Series B1 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_SeriesBOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "SeriesBOnePreferredStockMember",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B-1 Preferred Stock [Member]",
        "documentation": "Series B-1 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r680",
      "r703"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative",
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r680",
      "r703"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://fibrobiologics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails",
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted-average exercise price, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, forfeited/cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails",
      "http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, granted",
        "verboseLabel": "Number of options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Stock options, outstanding, beginning balance",
        "periodEndLabel": "Stock options, outstanding, beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Stock options, outstanding, beginning balance",
        "periodEndLabel": "Stock options, outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average exercise price, outstanding, beginning balance",
        "periodEndLabel": "Weighted-average exercise price, outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average exercise price, forfeited/ cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative",
      "http://fibrobiologics.com/role/Share-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "verboseLabel": "Strike price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_SharePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "SharePurchaseAgreementMember",
     "presentation": [
      "http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative",
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Purchase Agreement [Member]",
        "documentation": "Share Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_ShareSubscriptionAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "ShareSubscriptionAgreementTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/ShareSubscriptionAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share Subscription Agreement",
        "documentation": "Share Subscription Agreement [Text Block]",
        "label": "ShareSubscriptionAgreementTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFairValueOfOptionGrantedBlackScholesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Stock options, outstanding, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (years), forfeited/canceled",
        "documentation": "Share based compensation arrangement by share based payment award options forfeited weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (years), granted",
        "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (years), outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r111",
      "r635",
      "r751"
     ]
    },
    "FBLG_ShortTermLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "ShortTermLeaseAgreementMember",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Lease Agreement [Member]",
        "documentation": "Short Term Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_ShorttermLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "ShorttermLeasesMember",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Leases [Member]",
        "documentation": "Short-term Leases [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r160"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative",
      "http://fibrobiologics.com/role/NetLossPerShareAttributableToCommonStockholdersDetailsNarrative",
      "http://fibrobiologics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative",
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r138",
      "r139",
      "r140",
      "r164",
      "r186",
      "r187",
      "r190",
      "r192",
      "r198",
      "r199",
      "r240",
      "r265",
      "r267",
      "r268",
      "r269",
      "r272",
      "r273",
      "r293",
      "r294",
      "r297",
      "r300",
      "r307",
      "r408",
      "r505",
      "r506",
      "r507",
      "r508",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r542",
      "r563",
      "r586",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r669",
      "r683",
      "r688"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r20",
      "r130",
      "r149",
      "r150",
      "r151",
      "r169",
      "r170",
      "r171",
      "r173",
      "r179",
      "r181",
      "r197",
      "r241",
      "r242",
      "r309",
      "r354",
      "r355",
      "r356",
      "r376",
      "r377",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r398",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r422",
      "r498",
      "r499",
      "r500",
      "r514",
      "r586"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r197",
      "r468",
      "r503",
      "r525",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r542",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r561",
      "r564",
      "r565",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r640"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r197",
      "r468",
      "r503",
      "r525",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r542",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r561",
      "r564",
      "r565",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r640"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee benefit plan",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Balance, shares",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative",
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance, shares",
        "verboseLabel": "Stock issued during period, shares, new issues",
        "terseLabel": "Shares sold",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r75",
      "r76",
      "r101",
      "r505",
      "r586",
      "r607"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Balance, shares",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r75",
      "r76",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r75",
      "r76",
      "r101",
      "r331"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Series B Preferred Stock",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative",
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit",
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative",
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Non-Voting Common Stock to Parent company members",
        "verboseLabel": "Stock issued during period, value, new issues",
        "terseLabel": "Shares issues initial public offering",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r75",
      "r76",
      "r101",
      "r514",
      "r586",
      "r607",
      "r646"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r75",
      "r76",
      "r101"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://fibrobiologics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity/(deficit)",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r79",
      "r80",
      "r93",
      "r544",
      "r560",
      "r587",
      "r588",
      "r635",
      "r647",
      "r684",
      "r695",
      "r737",
      "r758"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity/(deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity/(Deficit) and Net Parent Investment",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r163",
      "r292",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r309",
      "r397",
      "r589",
      "r591",
      "r611"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r432"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r432"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r432"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r432"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r432"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r433"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://fibrobiologics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r690",
      "r740"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfFinancialLiabilityTransfersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r288",
      "r305",
      "r396",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r494",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r691",
      "r692",
      "r693",
      "r694"
     ]
    },
    "FBLG_TwoThousandTwentyOneNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "TwoThousandTwentyOneNotesMember",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Notes [Member]",
        "documentation": "2021 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "FBLG_TwoThousandTwentyTwoNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "TwoThousandTwentyTwoNotesMember",
     "presentation": [
      "http://fibrobiologics.com/role/ConvertibleNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Notes [Member]",
        "documentation": "2022 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://fibrobiologics.com/role/LeasesCommitmentsAndContingenciesDetailsNarrative",
      "http://fibrobiologics.com/role/ShareSubscriptionAgreementDetailsNarrative",
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://fibrobiologics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Uncertain tax positions",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r367"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://fibrobiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r120",
      "r121",
      "r124",
      "r125"
     ]
    },
    "FBLG_VotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fibrobiologics.com/20231231",
     "localname": "VotingCommonStockMember",
     "presentation": [
      "http://fibrobiologics.com/role/BalanceSheets",
      "http://fibrobiologics.com/role/BalanceSheetsParenthetical",
      "http://fibrobiologics.com/role/StatementsOfChangesInStockholdersEquitydeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voting Common Stock [Member]",
        "documentation": "Voting Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://fibrobiologics.com/role/StockholdersEquitydeficitAndNetParentInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r638",
      "r641",
      "r642",
      "r643",
      "r644"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://fibrobiologics.com/role/FairValueOfFinancialInstrumentsDetailsNarrative",
      "http://fibrobiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity period",
        "verboseLabel": "Warrant term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average shares outstanding, diluted",
        "verboseLabel": "Weighted average number of shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r192"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://fibrobiologics.com/role/ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://fibrobiologics.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average shares outstanding, basic",
        "verboseLabel": "Weighted average number of shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r192"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://fibrobiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001493152-24-008361-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-008361-xbrl.zip
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M"O*[\>;U]KMWWW5''I#D7%^_U[;2Z6R>#K??Z?P^S\[K[=?#P=E$B4,CRT0
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M\37/<"'8B*]T!I_8/IY_1[A7A+8BEU.5C(*F?](Y/(.:LG_*3F IA84Y$ 9
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M@,<F^57>W=6O<M14/NHCC7MW2;!E[Y9FN<$+)@&3-2R3Q4I%6RP+:V,E;1#
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M]?+PX]%O!_CAY[-?3@_^'U!+ P04    "  MB5U85'JKRBT$  !3$P  "@
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M7Z6:ZG0J: VK^##_@8G)):\83U(]%[@[&^D@<OE:8 "1_\DJO[ '=F3^HTI
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M>>7$MWK%EV]6@][X%EX!1V^*^Q]02P,$%     @ +8E=6 H[8G%D!   %"
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M5L+86)<+S^&@:VQ$>LBM%05KL_?7@M#K/]EZAKJ5A-Z9TZ,IX] 92W*N<FS
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M#N$[Y9:M@Y^MT#:QI)-FI"0YKO)IJE2)U<I4>L8U!\'^5Z2GTP,;"R5ML;_
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MU"9J155\-:;SXH/AP%8:H:A:A<SZKLA<FX4'>A?BID  X]OE3$WUG#4G!EJ
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MI^&'<197:5EI88<163'EB+FA[B=:EK8_'L>J@D=&,H5+40^OT1-:R!R454R
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M<L%>/N_#S\M7&XO<GSC&_KIUC/V" ].'8^M__=CZJS][;'VC#FQON"98(2R
MPM[)^]-?\47@O9^&[RZ._@]02P,$%     @ +8E=6'4Z[?/U#@  EZ0  !$
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MXR+P"?R1EO$=2DE1V$9ROD.8N2@6U0-=:X3!:H7]I^G\ABX8+"D<S.2)X_"
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M"%X3J"YQ87R03[<^9@([J4AU9:X57H6P2L@.:7XHS; 'Z=GA:*BVT%UUVH%
MLZDZI,:BDDPKB(KA$<WM5'%#:78]0/71K9D@7P-0^-U]LNHJI%I!4@AG)&R0
MX=-CL7FDL4W$L5'D<:\0W;"//*)7T:]^:V>;0<A;E=$N%!D6M4*^$"AI%Y!$
MKXS0O@\TCDRF@:[)MT*S$$HICU+V:&TC7)D&SH[4"L-"\,0B=-D#NDD,,PUD
M/8D5@(6 264\LX>M:=@D#54QV0J>VA!*C\AV8BEIG&R)K=!K%U?I8=UD[9X&
MLY[$"L)"J*5J'=^CMOUS2>=$8NJ)C]A7AR_O28MS2@465J@7HC=MSBVA5Z%P
M%$OO.\<6(@SEO:)E6:ON4!(YLH\X])V@82=PEL0-/%B<@).E#ACS.?4"2=R&
M@86PW</>L66F-MUFOQBH"FNAG8:JAW8884V28,95LV!&6*>^6VTSHE7N9#9E
M8M5MMA;EZCU/6\]3%MJJ\"=UI%9P%\)@:2]1%1+K;;YM!+/<L*THK> L1,2>
M@;"WSL;6&4<5+RF>40^J0L0'6%E#>[LG,HYN5AALP])6H!>/':5L. F"IB2B
M2"3",ATT[2U[T\Y@SE/,JV> %B6L0"_$YNI!#\]ES/LYV[;V-,I=>=-"5E@7
M(GE6^QR]BV]KU:E=B',RJYI[55!9(5H,[*6L-[T)HCCW!KO1GE6YH=H26\%9
MB-C5[&/U9OFB9_4KXG,;,K'J!<5 W49G^?NNLKWS_16]PI[>I@-\7PRYU9S_
M[^%M/T"_F\^)HUHLWMB^QK)JR55/; 5L(2B6'JYC_JGM<:1$].-V4US!#X)?
M)#ZL3*$13X0@LFH=54=JA6EMY$LYY(B]QM,(Z!%M? REW//6$5BA5PAT98^F
M]*ZUK0F&=PVQA3XMDHH95=CAL_16<-:&L&(1Y@1+)I#5&^1V3B&5FVGS8E9H
M%V)7EB>3>JO>SE=@Y6!;4UMA7(A957\EU@/;WEWK)>9I_HS9NT?ULVI";%7&
M"N3:,)86@TK.JH62>M_=%.P['1L@[LD#]EWEBS\3NEBJA'L8(1?DBOB4NQ6H
M-RML!7_Q,\,4_)$\9 1J?QZ)1*%,9(3V/:&5V4]-S$*M/9.SAJ7&7DYIA7$Q
MJ%4P\6D8V0C9]V@VWD5,-HU,6[Z'T1',Y-3#SA<@ ^K*[<0&16WP?EU[;"R[
M[Q3B'DI$6B0*9?:=8*-SY#7Q2@MB*Z"+,:W*L^7]]&RS[\:KS@P_0V4%8S&,
ME?^N_/\>/_6/,IIK,D?Z@8-#=:O^\4!0]<3$($Q;^F1^/)C/O,4PNNG^5U![
MYW'E121*0LT#!QK[?$N%@B,6V'<*7 H/,  3?6H+%KVCJ/(1 TFE*GZ5$H.4
M'!@91EO4W,.SIII#$>*]H,J7BO]+Z H=M*FNN3[]0AJ?)5)>0F^PKJ9Z9PWR
MA=0^CX44M3X:95^8@+_SKU <@>+<EX@5'K6H>Y/$O*9RR1W-JJ:(^FL8E1NJ
MI.%X;[@_WGD4;E+3)I5(FJ%9):)R+2I1\3)*F7Q11:Y^Z,YD*[3BA95:H:5E
M1L23(DII787T>RP;U$&S:52)YQ]YJ:K.<R7UWZ)5)]#?#OE/33I"NDCT1SLT
MDI=T[("(Z T(ZG&=MF);](*B\,HN$#Z^8TX&GEZ^__6&^.#X3J>,P !NMA?U
M&OH#6<W4<S>JLC S?(Z*>IXZ3'0\D'Z@O*=Z>>EPK6,IM]KYNX%Y,&* S& 0
MOS1TZ/(5IFPBR4I1@LXP702_&YBU(P_6QP/#C@))G2J?N K-ISX[R>I0G=V%
MRI><^<E6OXZ@"PK 9(CKA].>XD/]607J"#JD 'Y.@5*"3B@0G:Q.#MWF%*@A
MZ(("MP_\=LD#@9E[^P Y3Y"@SRIFU7B>K)/*@/.T4:9 U@5E0O\_MA@CJF@Z
MH88**%T%OK.$26I\[BVG1CU--]2 :<0M\5=ZE[I2CWJB+BA25_\.5SM[PB1G
MT%697:BX[A,RZA.BI,.49':AXA<JKJF>9A4T5^O2G"Y4^9SZQ('9CMK8G,[G
MU"%^KNJU%%U0P<PW5>0=LZ?XS0!3^8J\9ZMMXA0RRIJ9I_^.!PX,&.H%-*.,
MR82).E'3K9>9&]7,BCJL2.EC )4KA XK$N\3GKB_!::VTWD-3 WH&]A.3F>7
MS%Y0Y7,UEKGG])ZZA+FQ&\BGMJ_^"T-V@_7^O9GG)3"(6W[BNCH\BKTK3-T)
M.\-K*K&G9X 3(0+BJG]5)<^X4-<6AT/.%AEV%?2,CMFYL9YJ"C#;Z=R,!5H7
MDUK:1(V*-QY!#(70Y;>M.*QJMMYA-N?YI^@SXPT[3;/RW[K71! U<@OFXT9!
MU:UG>O$,,ZH3Q_$5Y RFM# :1DWS@OR[VIL**I=UB ON6VB9[68OP?A;][_L
M:!P>$;[EUWR>_A;/I_?ZV$(\_R@?S)L4[^RH/V$@ *MSN.;_8!7ZO> )B^[7
MY6;:&7>+!@6Z:C,9P*#:H7_(*OH<46<AO?*Y0X@K+GR^2HPX:[U@HR:!J*?>
M5<HX7ONU+MY5N"._?\M+C!,\F+KT(-)4G6U26XM1:[0LV]G.,9U)3!EEBVPD
MZUH=E.;S0!#]Y:&^5#3G_%J5[&P[/#.ZV8UKED.E-;/.MM8U<3PLA+[Z4VHE
MRJVAH.8M+VV1V,=NGV]GVS#R)&HB:JY.C2X!2?I"^*F*FE9%FQ2B_-:]O'_:
M&M?.ME]RZK3Z'H43X.UC)VZ=9F5P^"O2O?5T5?K@';>UHU5:Z5OR*$^]E"79
MD6X0=Y81FVVX$RJ^* ]X!_W&5Z.*C-Y%>BHH9DG;$<W>K8B_ /"AT(-<1@'T
M<LTL:3NB62;>PMX].D3$2\6*O,X'I_6E#M%XHZ<O\: 3W5@X93!&!;XR:'6)
ML;AC?":(?Z\4F[!U("&;,P?*: PVF6IVKUJ='0M>L*E>:JKSYZIR9Y%//MF_
M(.H;4D=]E;"(-RZKL^V=4=Z+K@V;K82?4@\XU+T.'86;;,F_]42E_,ZC;"\%
M-%:8A0T9#QVM2FXP)&X/3*N:0Y7\_Q#LJXA\O&SF0A3N$FK4'DVX=J*M"A6#
M'U%:N#I)?P((T[U3PLB<2I&YYB45B-T:O]:3E)?>38XU3-T_4Q)ZF<[OPM"+
M*&F=)F6[.ETK5^<.=.6^I+\35U^'FIM,-2W45>4O82I-2/FM1T]15/H\("=S
M2;1/N.!!ZI1=N\*=;0SJ*-.&H3TYWI-*Z:@I)].0Z1P*"I&.L)O[.9,S/;$1
M-R[5"4<?=2J8;59K5D_3U5V$XIR:)H]0\M1M1I2D/'&C,EVU.SWW+-P#<.+[
M:N-/D9X^)20AO/H:%G-E@PBO;,C= '--5F9#05V[I>)N ?;4D>9,2.N/E-IR
M%AVE=J"AP:3FA/[Q3=U"[K=O[ F#Q;:R'Q-S4R=EDDWNLJRN>J;,HK=T)=SA
MRG]6ET0P69CBEZ1_>_=X-#+?;,+/_P%02P,$%     @ +8E=6+RQ3%,)$@
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MF7*ZI-R0B70&F9"*L4E=S0_7(1N?3$3V":-:(E#K-$1EW88DU;H+Z0ODF[2
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MIX/.-S;T+TO[>S+F8 "VR$L<>0TMA16I#9@U/3TI"@<":H,S0^G[&C)(-3'
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M$W!!\KWX4B$A=@KJ;B](3N)[-PK^8KZ'4Y1X<?"0LJ_I.$L(>@G]H"Z"/[/
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M3XQ>;:9U=Z/X%5UN6\*MF0VZZ>>&E02"O0]MER"FAEJZ--3$ '#;&GLEJ04
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MZ$ A[&KR@/^=N0>1/WYR8Y_>AOD=T5NZY!>/9(;?HUPIPI/^1]%)?]F_DP_
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M#6&K9?;*8//A(]^B_.'FXN['5M.''%M QXK#!W0<5*?0L2 /#AU['570.?\
MW3U=.KLG!8=_]Z15771/4O+@&+/748&Q2[@(NR_R]Z).\]?+8KTN<C/ = P^
M\656? @O-348=!E5G(*K8T"<P\_,][,56O2DWN8Z@[+=)*>@"XX-"^6FJ/CY
MB) X7'#@^A_;M-[1L'Z1D_^L; ($<IX@00*=^M) @8PA.+I<M)S"C).BGO9
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M7AE+%)PLC <4(#"B5$NU+!Z^%1"F=MYVF:7Q359$ZBC+B,9SQ3Q1O4FQO)X
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M%L;SU)_V=!<ZC9K0:<[DT/UKQ22AHA=UAI94&*P.;ZYE"'8[=+E*Q,ETNM&
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M0',)9/_K24'VAC3C =J$BX$*V*&1<_%*99PD7 >*2]#ZST<ZJ+75<+&J<:D
MXCZ"O!W<[F5H=X [2TIP..ZMNG"QG&SO<40)3\:)[CE"83K-?9PEK',11ZVE
ME0Y0QI*S-@TU;&A^SMOL!WH!@5X+7:PER3![R@(#6I.YU@A6"8)V9KR/$?)3
MY-OU9DOH44JXB-+ALV84QAD/&P)<X+5467Y^ ^N2K9U^.@=I=0G$?R=<;LM2
MD;:IY_#U[*C]X+?45S[.&RK8G46?M''NKYX)WDNQ]BK+AU9>Y.>Q>\\%6XB\
MX')-7PS+=?=E;!A#+S'DAIC6$V,N,$[=6M4I"*^_UI@61&VP1U8(:Q .8W*M
MPNPL)@S0'85*74WFQ(P;)+!71,"[2%34U#D'\]RJH%L:TU2L&^$00OC57WA,
M4*F/>74_!7>3<GV$910GH*].@9QZVVL2FM=@S&RAIUV9$:9)=\@3'$N.BII\
M1KNA/\@++'O#KHV8W13ED_JVGT#E$U0*%8<8FI" @8Q<+_%5:H*&)NLV."#&
M^*YNMO6VQ#^E>;K>KLU1<FON<+$<HTGJE8R2%0S@W/25O'(0TSLG&7U[&5J0
MO'^]^HDH6./D,2KKW?!9W(O=Z!>KI]"=9(5Y[7R&N?('S1T$@0'T/MH+]98:
M6?3QP(8',28TE'>&EKO)SU >(U<TP9WA@7$SFT]@VQHQQ+")!PQ<+1455P *
M-%J_PWW4#FOG@/$@I!>YY9VEIO<< M!WE86:8D>U3*(3H8S!7<3S6U'6-!!X
M491E\86L!%1>04KI=893JSJ:OT0R,!A2ZR:^DTPHSRFI$2=';/)%S+:>U1..
M<?I.)[5[7&N.TW3T\*)Y5MI*JIXR)M1SG2&6L82Z.]MH593HLL1)6B-Z ^ZL
M/7H[4MBO?S']8<7*K;%ZX#BI;DAOTJ(M]>XV?\?R5[QF2? 6/IQG6A=B=&,/
M[B?FZRQY++410B>>5RH&;1HYB+8OPDP22GM1P2>COIZD39D4*:W?:Y8:=<>W
M+"6$T+RA3DD?A3]5OJT/B=EY,BV]/[]EH7;OI33$0'R264/! [4+7SH9 G0V
M0Z]JLV69AFJMV;W&OAV-&@7%+7F#(W*FP@) 1]/A'\OA5NU/J&SV:ANV5TL.
ML%=35K23^%TR>.C*\J48V"+.A3/X/=:S<S=K4,[.GCDX'.=J;#&I$F(:4&?A
M];H881)"S;$^V'J]WF3%#N-G7+ZGL>*]9+H_BMF_Z!AM+^:3E6I:)+3L?647
M@C_HM\*$Z(_07/(0_@$_%'R<^;!.#,,0D>=,)FH6-&A1EO2M5OKO,]042TK8
MRUF#)[7.$$^\!W,6<)BVNC,<'1S\*UX?@SU.$XU>C#WL)\",R>/8=831>&=W
M/.)E2#;M@1-Y<S7&J(*7ELP^!Y";0:/ L14G&+@[J2M/ZZ_H8S[G2X;EX9,^
M8!)[K(;T?<%V]#A9L%)MS+3I:T;W1?VON.X'_#XN9-[WP$TB^S2;\W0RYV-@
M1MJQ+12+@/4EP_X#CU$^*;,T1/8G2O?!=Q<IE/@F1K.V@;T,<:D&W_ZXUYDM
MWGW:X)@&7+Y@>JN&KBO?<4G/U#9,RM@IQ 6 J].*E7>_2+[8]23-&IJUWL.&
M9;,];.NJ)JOG-'^]WZZ7RC*G1_B.WUR2(S73.!/EP!_Q.CHYQ)_KJ*QUQX;'
M,E+^^&6Q:7(NBY[M#"WQ:YKG],K$,LI %,$_8*O\TOB>!7<]UU]Q&:<5?BQ3
MY8L.WKY^HD/6IDF/-)!UG_[&A[>%Z=-!W[*<M_,N;IC0AG*=AAM8FEMOZ=QZ
M3W@=I=36]OKV-LIHMN!'73_ZUL2[>PC3U(*K\*L&F#5[.-M5?J-;KY>M +)*
M[R2@+%UA],<=CLKJ3R-? L-Q',;MWA)[T[Q*8_I8D(<5P_1[)[I&D#?;D58%
MXX]]X^L J;'_L9?[/Q+"NKK->7!"]V#Y4;YT2D-4TU2'')R2S\":9X]BFW#!
ME^W(:09Y-Q)?*3-.X ^YRJD5CK'+/J0&H(;HX9O6:>@>[O.G,Z0/;K/S5OM
M U^1!;OOWN%'KIWEOD&6P>E; V^9N&&:MLOE]?OYX",ZG,T'V02#F=[I^O^V
MJK8XN=J2[<(K=VRLU2KV8]-4K6]3I97,$>1ULIUMZ&C.=)82?*#LK;IX6MM,
M6&2Y6HVWCQ43%A[4^\[RK8E!EZV.2IS4RG56 Q]T\>JD 9Q!',)LYR5L^]\
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M#,1#NZ6K]#U-<)[XGD+'WSWY"536C$>?/H<?A35(/5BJ'*M)0WNB^04!2SZ
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M G1&?Y+:EFL6D*"S[Y(!F3[R0/3J+=2+.(T+<L4D+C(Q#] 5_4UI:]Z!\?"
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MO5=\-^CGV\=[Q4U,+6*>]U[!>9:S@M.8!D[A1/'4\>()LTEF>9X%P'3"+WS
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M)CPS\\9C'LB>"!YXYX/[,?K2"8^U/V>7__ V HGR^T^I#Q]G.J./[\3=>UB
M!*KG(7Q#7W0Y\Y"P/KX#P#Y5*I6/?2>,ACYPL#9@YWNG4>]'SC40=NA\X[?.
MI>RQH*J_J#KH!FA_<'I,=43PWH%+/SB(T9O,%QWXP@5"1";Z,>RS(/O<S3;K
M"7_X_J$GT[6A^)MK0#8^_?=_-7;K'SZ^PP=^^OBN_VE>$.M'_Y_-3>=4<-][
M[US&/M^\8!WN;&Y^^@B[9=^JG[49R;YYGOFB)2,0/N:[6^%%782M_L^-W-TM
MJ>  ]-V??>;>.-L ?BA]X>67CT\Q%]LGZ^L;M1U[1[H_>)KFWYDUO,LMHCSL
M(B'>1X@_MC[]]NWL^N2X<G5]>'UR]?%=Z].:P7]U<O3;Y=GUV<E5Y?#;L7/R
MGZ-?#K_]?.(<G7_]>G9U=7;^;8T6U32+^L["K@@ZD0RJE>/:4<UIUG>V#]9H
M(76S$$L2HX#/SJ@(4H?%D4RX4G/G0::483*C;&DUF,XZG-]:\K/3\\NO%?U$
MU$CNO+L?!_6#']SC8G/S6+IQS^CU/UR,VM8;]<:/'_BI ?_\^'OK['?N>=NG
M?YV[\#C0. (9D$XF7,?HOY>\/9JN$<DT KSA! PM*GCA^^S[-@@><3?8;.PW
M#O8V/C7JF_\BI29]14HE):67E+YVE$Y B@ =! !VK;DC@CSD/F^G"N=]&FB1
MBWOSE:F;RGG W^86^/05YHYAX<N9=%81:_D< /)]^-8%S>&GC?H&_=UGGF?_
M?O1J,U9 HLR[TO=9/P1P["<R^#Y&ZO'/'W 5"9?Y=D=A"XWU^#'RG@[N*-;-
MA=^-BIC]$1%S& 0Q\R]Y7ZIHLJCYMN]O'9ZPWF"X]611TY:JQR(4*]'[EI0^
M9T&D8CY)!F4!RLNB?42J@[WMW0^SB*/(>_(1P3)7FP_"N1Y^^_;;X9>,<^7A
M_UV>7)Q?7CL7OUU>_7;X[=JY/G? *KD&T\-I;#GGETYCYXWW=E0TTAZN_':<
MGQ*@U[^<.*FEE5I9AT?7SOFITSC8VE[/]9U*19!&7>ZT10C,R!ERIAP.4LQS
M<J\B6#SN2D5%$.^=&*Y1O@CXQA@W.![A!A?D3CW1OM;)[."\\?._U;%HMT)1
M"#OP,"L&[NMZ;(A+XL$DKI #+&4+NSOC:_ILUG04*WA8=$J[]0<\^=YE772_
M_,?E-\>\W2Q\6?DE38,KS^P.-CX=<U<' #"-92+#JSH/'6CZEE/X)IR\]E\:
MPW9\=/2U'G<+-"9&7IU=7K->WZ!DU*F,?,K7])_:" D_B]=GQ?$<U1^ $/ZE
M5D4%F<2O+,3/VLRY,T*IBI/RF17;PZFLZNG,52D\&?4[8.,>@=+C/L6P<=[O
M?OYV_7.X6XPD,(IAF_GA1,UP%*H\1VD8[7"[U Y;GZXO#[]=G:%J5VJ(KU!#
MC!)*<72 W&D##<ZN)OY___U?^\U&\P.J)>;C_^^8+8GD\YXSV77X7(I<A-Q^
M1^Z+3\]PDCT0S5R:\W-M%X0#^T2(N3&54^%S!U@^*,SOQ]1B:Q.<4 8+7JJO
MG"S8OO<.W+]OC]S_W7VZ+9"*K]%WYL56$W.7&IO;FO',V\N^[/-Z<0CX2@,)
MR][V%X-'^U,T\IT<P[KD'6I7$43?@*U,9EJ_WPT[O_UZ=M(,6&%,*__>/./:
MVOA$K3L_"^G+CG##:N4L<&LOG(>].;EC;E3!C7)DVU')!CDL=,(^=S'CU',$
MG&44.FZ7*0#@[4M8>:%1]N7RCY)?+QUSUC(2^!R?S@0740+N]L$_EQ@)U*P>
M6RBIOC'BJ%3U2,9!I(9'TILB<;9[AX=??OF^]7V;%^'_V0RYBZGA$>\K.4 .
MF_>;SP!G7D)MHPO=9[<,4WGGZA(:/UY-7BF?^.=\;=27A)?U'%Y>L[LS4\FA
MFWK=9[A=?;X^:/TU8(/]PE2@*>_/8]K.QJ?]W<VMK>9!?7=W1EQ[1CB@8#ZT
M\@[--T3GC_)D2N7(J,N5\V>L1.@):D(/&MN:^?5$EMM5[,)4AP7B;_KN;7%Q
ML,DL;/Z&6_'L:^*9]//*G-&(QO6A0A'WK'99NZHYI@F0&L6^(O^WE 7F6:/S
M3=;&$'(I?&XUI>UKA*H4<\_1A8YSNM"AYRD>AN8_7T3 &U,<V+NR56^Y^\)_
M>F1V5!&:\/*\$K2[\6E[9^=1?.VDYGSE'IZ3<T3;"3;SP)LYV>7S [O3G+P[
M@XN[Z(#=W?[ZZ_8<=Z>9WYV]C4]7L8BXLU6OS^@CRW/U=4'9^J1#.8*/Y^I:
MW@:3CR2^ZUPT?NU^Y9>[11])^NK\@8")\(O$0O9@&K[I QA9WNZDY9%^>JXN
MP&X%C6V*N=SY>_NO^&3OS^[WPM%NY/WYA1YL?+K^SY0USK:\"PEFN?^_HC_=
M%_#WKQ=?C[X$0=QK%[VXW-MS2VN +K.WMW.P/QM!K;Q^/$^[WCHD%LX/MIZ(
M4?W+7VY_.^7UDV8128FS8E3C$1BU4MK-W&UPLW?:"&T[?06<1O1!<O,[[L;8
M2!V^QJY5X=MY8O"ZT-LBC@0PF !&-'X[$2V7DK)BMW6=0T3C?.S(II4C'U&<
M3>=<O]W^6^R=R\]GK A9F'U?GE<U 06:^XVW4WC56'6IS?+$\0C^15<&]R;!
M] >'/__OO[_V?V\_O>PG7<7H._,K@3?L[C0V=QH[L^K&:XQ8+R9WP2[H"OB_
M$I'@847'P[GBGM./51AC8#R2<+/VOS::;UIO47I@DN*A&[U_007$\X]HKEH!
MXTY][N$AZI=I50[.W*[C8O/<8D3VXI:!V3.Y5? [MXO]PQP@BMNN@&]2REFG
MFI'5U,46#6F!ZM:RN=C* _XH8=-YJ<)FM0%_@VG9,JA0^_*J\X]ZK8[]&9T^
M4\Z ^3$O*B%N_1+?R@2WLG':5(C_C,-(M(>%!F@##*]@]0V"7FD-';?+X=
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M16X0BKT3?TGQZV,YKV5A9+"^"T)=IG+V4A:T](DZ1<S%<NKS[PX#QRT^_1:
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M]^&<>Z K=8E'@E;2E?!8UT<)C[I^.PZT"M,%*=L58205?@^$V@(\J+2X+_A
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MF?Y0^W%]W-Q0FNGNNGUQ0T.V4]]$@#>E[]E5PH^[^L>]\1\5=T+,D,?\Z/1
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M6:?D0!.M]CL /[#D/L+;K!3J=X<AS5<V/*V*S)1C[B\/.O!=D+CC\*L(]/0
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M#_*%T2<KV+K#ZI.DG::R0*NC<:B]_>2^$L&-\'UT:Z'\NN7\1OOO=0,!:SJ
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M*^FCZ9?G-\A%T4JE996FP+SQ"Z5>9<RB(Q1JQ?[-4#,0,#4SAG3N.,UM.G
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M7FA>G?N>.(#$YV!8 9AA4P,-E?Z--4O13<P(!W=-_LTL.MP[\'K3@S'Q)'^
M;]L]!_?C;VQY('/4V0,>;%!Z-Z<'9SU^KJI=G! 4;DR^!_06:D:+B+]AP_"C
MX#2"/M+SPS.?QT%/[E:,6RTNN0'W"D,8N@-CKH!1)8@?H&I"W+'UW\TEN!MG
M<3[A+'X[SN*;"6<QX2R.T/?^XE_PO7^CP_WY>>APGWW^P1WNR;>>?.O)M^:2
M,'TL:;(#*IC30<XJ\JNWM=9(.!>6K[T+3,X2IZEPN'5\F<B=#3U-N.^5-,?K
M(,@?!'41W>W\BW25YYTDZND'&[H_.<#HNN\[KD*4^\$( VB2H'R0EMMDUV:I
M[+9\!_96N;1!YS0S-V+$/E<G22.K6 3Q@9$BLA=IG]_4094)UR?_E([]L;04
M$[]'O'SF5CJ521E$,4K0,V6C/OJ)^.6_EHW"(OJ-!^/Y-\'!^/CQX^E@G [&
MZ6#\7<9J-(0\P-M8#S\!N]^G\3'$^2(ZQ^2X7.U#'D9.#_&1J54&[>EH+6]2
MHNZD,K'V(Z2P7:;G5 D%@7-8YI:>0H'<$!0L4BDXK9CU+$04Q)TO+3\,E.08
M(@+T8MCXD[_/D+!BJ 7&P>A=5>NM0E)$XT%TTC!F$:N\8]%TH_VMW ,S#Z(^
M5*N9(@B.7@.JH(^X[%$BT@/VO7V-A]+TEBYJ>X=KH*'V_NR.>Y@DH_,O'\X\
M3G%D))O'HS#'(G_/)$WH:Q)2H<'%@A03 P+^VYWE=Z>1'D]II-^>1GIT-N61
MICS2$7K-7T5>,RCTNZ&'W,K9RL?1;TTA19[R^?E_CYKM Q_R10F&^?4F,5YJ
M.^VV]3+W?0Y"!=C1R0P("Y- TKF[(F]'6<VC9I]/GC;,>$+'[8_U'"<OVI@^
M56AC#0U4]&QU-VC;HK5V?O8GI^=V3?Z;P-89".K(*P?C"60B/WE5KU89'>7H
MK#W%O1Y])9A6)H06ND=:>H$XI9WUCJ* V57TBN[Q$W\[: C$(%(ZY];T'1,$
M!V >X@&LLJMJEBN0.-)[@GXG/5L)DGB3;C7US?.!%ZC^9B19EYA<IM!"_LR;
M,B%-Z,1NP5"MZ12/N %--?_"@#FCE^#IS]*.G%U\)YG3KU>%ZS,/6L]G<B_K
M1V!?N3! <'0?$"&>*.[4SU-9O,NY62U_QX5AV =H(<#[K?)&'$DZFN9PRG)!
M[?:.<'/ +&&(Y[S@-RPG)@VZZ%1=SP.*5?>4=1HRAE,#5N6KCC,(^GD9OYE*
M? @P*N%&C&HAO.Q,/297?3QXH\?5 C&05#JND4]BI<<P9+0TQ8U$KD$NJRH0
M_3:TI:N>PUN-2JVI*9 K_7P@5WJN<J76C:2:.)]__2<+*_6RK7="1J5!)<#F
MIL& /T($C;7QR9KMA+*0F_QFZ7>GXTQ@,]?A/&AE5H.>"-DN*Q$(6RY-]/F9
M[^+R#*0S@;H8Q:Y(R^?26#V$]2L@0Z_LYY%.5!!!TV,^K6E^R)Y=PZJR;4.#
MXF)(V<[FD[E^U'P63<#TPW.CIRB-BTYU&-(N)O[FN;-D0-!%:$2X_NN)Z0DQ
M<7#)P)Z(\WF-W$JE:%$QZL:W+$D!.L1@L/$7Q\\;M92F0,C6VT(I3NC=2-S?
M%->"9976M42[VW2)T+54__:H-ML1V@?3Q?OQ\LOSK[E1Z,>:;#>+%=#KFR3Q
MCD,2CU]:<DE;[#/WYJ8S]K["NF2Q:6IT:]WPWBD$#<C&E1/>/4?C6=,(BE&-
M7%&MRFR[S;AW@4)[%:=>T)%6=ZX5W'H&Z+_+8F5,\/@BL'_+G(-"$#QQ!+61
MEW^:7C5U='T*F^IW4!O&A9P&$4683=W1P.F,;'LZ)>"_TS2E./@Y0F+F?]'R
MR[AY\N:VL7/@@)1VGY\F4;_7((>/#%E?9DC^UN_W33&OJWY1HB,S6Q1+#A">
M_7 Q0R,]6JUI!LL\6RK+OZ?!LTX/,/GG'89&3];A4U6OHR,J7_*!G\[KY=[[
M/1W4%;@9 ].%>< Q=[/)RZW%+/.^*/FP9 K[EG][_H1\C&W=T6P G+KB/D9:
M%GITZ7];1 9?Q7Y7Y;EQD508=ZD+Q;VM[\(N/UJ5:&QA,3+IY=2)BWYD'2XS
M;B#?%7"S+.^3E5+DU]^UN7 /H'-$%FK"EVK3MI:I$C_#"BHL)B 1=![Q2LC*
MT:J!Y28&4^6Z5Z,WM&ZRREIN9*W1L!,=)SU_J#'P3I3;.=+'VU)T:U/L-NBZ
M4?]2GX#=K4U..V:_TZ?W5&/V>#<<R@N]&B=M :MU^RF?88WL;>-1\!E>!"TZ
M(KZU+=8B*1^/4''6^?M=">(4'AR]#_J_$B^0IX=!R13TPGD#&5S#;Y*_N5Q;
M)49>RN3Q_,Y#?E9D<^P4VH[TMOMR83QY 4T0 .@,]=[O\F#;Z*+3#N"BE6TH
MG$*+Z(OJ=K=!@*1VC"U,8,DH*EI QV(Q<J/0:U_JL--@V#..-!AX;\]!RTK;
MB@$ZDK\Z"J7!Q7-6B,'H$G3KG8@=UU;O3=8L3[KZA$VDWLYZL_/W>0.H^Z:G
M[ZN#OTC!9$/+O:&'0;IHPW)7+"4%(L!%$<R&V_&(P69L?M,OSOZ4<&'W\#E-
ML$X$1;U65I,5K6+PH?^!"=S4+>T]Q]<! JM=W_E<V9)BG\VTQW[OJ"(:;%!4
M>MV7^8D5EL*2FU8BSK] V>^P^LEEMY'29WCG<*Y0T=+_#4M:T>V/;1I_I\$&
MV9P/2D?7]56>/ 5!!;S8%U7+$I&O<V0!9V9E#DD@TF=((OPY?2ZZ$Y(\3"^J
MK-RSUK1>2$P=W29?9%KS.#^A__G&&:G=Z:/'1[_1[P8,?#X!!CX 8.#1!!CX
MHP$&_AB%%R\-*3D]I(<"*<(I0W1O0WZ3LU9M$F3JXSI!K H9<<?='A)<4(Q.
M(>EJECZG_RW>S])GY%%?7'[[\B6?CDR.^.8=\(/V543=* V0NPP@(^"&=96!
M72**:16]9Y^%U7C4><!(F,[K:]3OV2RA+D/!?H,Q</XCVYNNK2?2.HA+A%5]
MQ-\_U0>2OHI%LZ]YIAK49S8]3;@TQ4+G.=WFVWF36;HMO#$37TC.A&D.*&IH
MLAW&]QDT++.F*;C>+6\ES19]IQFXP8R[(1Y$747U4]^PBCS]IR H[4<4"%51
M/&:/YM\1/UV7+S:5X2\I$LN6UR+\3=MXR\);F-8T>FE%A2243Z3I=W@&F'B^
M0ZA)T=@W7W$][MD/%]HIO#QX/4/ZWK$LD7('C[\JM\IN?ULM/F52-'JMG90*
MYZB'Y;L"CUFT&IOQ/Y6ZWMYG$BPD1.9U-\B$';V3]]"'/$E7'.%+>^&JR$D(
MAT+5N*B5>%:X#I&8 2I(MBEO49,%'Z2VZ6,R<YP8"\V%F@F^QFCZIFBUYT>H
M[X3Y.]"O00I?XCS3K?@911NA8'7#I_-M0:L1AR(R;9H/RH4YMQ9D)!*]C+H2
M^YJ,S0(+I-,_EX-4^X"BE:S03AC-;8)L$D0Y74O7S%:,WH!=*2R^W^7SID?*
M7!B]+]X7=?*TJ%ME"6W3*X$'I"^++4,D'$WDY;=\4:%W^+;'_7FP@%"]RN@Z
MES0>=W($0Y&4O;8J^D?>%HNFIE.=SK\U'2*LGV'GT)X>N]RU]E8Y_Z>MA9.E
M_=USTVB_6'2)0[4I$!#-<BNNZ7#5;BU50.>'W%@] =2E7$'[X>K'M[-8KA.<
MD[P:U Z ELRMF57.32'^L!?ZLP0L;4+-WW1:'QJ* BAKHY%F^L6'AAFP&5M1
MS11<='C8U 484H2TQ*>+:=&N1#X;C3HN9XRBXE^R*MA!;[9X+F'$_R'?;>B!
M=N5"D#6M: *@#DBS=_7B\F_Z2"=XI)^90NW4H5^L*TBH9^RDBR3X,G&^7EMT
MEI3F_4OOYLO'IV=_4I.U*=H%IQ+H[X_/Z._<ZNL?X=$W9 1@FVFD;Z4H]M9Y
M@S0O+U]>CA/\)[;WK\JL8RD#"?">-4)Y-POG5R8A+PON4=)T>2^8U%6=;;%:
MUEG_3VAXR\];T40@?[/445[5Y&;2JW_[K9"L.]6%9*RM"B.#0_CVVUB^7 M_
M:I/XJV.%%;T2HU516^EA$N5ZKH;KUAN2BPPLPX%T6YWDEK+(49F&([1FK^HF
MY\ KJ7AG!I)4R-V963@X.;%?6"> B]9!Y#!+W]-+U']6C/.;HWZDH5+;S^D9
MNK[3EK<#5F?:5*P3Q=24O VJ;0Z<?:X<CCC.>1%Y2Z4.#_[3&[E +6.K_?>B
MN'!4[^<(E]3$P/[@AZP,[)I7(!>^5(00-_Q'Q.P,.ORUQ.S8E /X#+WIU*C8
MH[Q:PF9$6G9I'90B@A>FLWB;N_^FI=3P:<M)>9^Z4E\8R%8[7K8X6AF&E:&]
MXBF/L=_!M>H;1W&0+39%CBX;;<3A3AFRA!7'$7V#\U";5LAZ;0OV>AS/A9,F
MB<,1FC"95OH'.4*?3U;G 5F=J=OA(P[YK:&H(G<"W^!&=3B32(%VP_Z&1U\-
M^AL>#_H;L/4EYN"]Z5L'-EFY&K0\_$S' QL-B>$Y63X#AEZ2%S *6CE/AY7S
M-@AK0FFP\QD_&CW.3RY! 3>&E0O"ITS^Q_G7_BGA8Z%<_J]@F6Z#,J6_#,J4
M_%8HTQVX(T8F291L]Q>AI;YSD$%DR$LQR:QW):/'I(8]#H(6Y(W=9>]RGC#?
M#A$"N^!1XI0@2WY#JXY?FKB%G"'2/L!=O3, ) ?,;,!I)M854 ^)2Z,96"L8
M"ZT09GF2*)X;+S"V)B^V]-BM,#/LZK)86!(K#,(KS9:Q)(04*Z030\@N=,EP
M0P9C95W&+$YJ:=36*J%5M@P!ORY3&+?N3 ?3^)#_F+"HWQO%I#;[]P<QM0Z^
MY.OJ'P2PE)Y_>?1;YF[$TA<38ND#();.)\32'PZQ-'</=V3=>#1R9&*^A<-S
M\H8AYJ^UM'>,SW*\;X'[/-]^^_J;1U]P >';]UW.)!KP]%X6JWQJ]CR.9D_W
MXA+WXJ8,PST-.>C4XS1G53,#+ZM#5F!<:01YM@47@%#W]@C_6(ZQXLB17AHW
M_;?,U M<U;[*MDK!X@@($8YNM\@$:*,?8 ZAMJ)VXT&S.:^N"PIVMZ).@9)G
MM2K9)P#P8HVX$WV:;Z6;4/O8T!P3-)5J?PP#!+C(2^$=K3)&N6$<-:L2,@?P
M4;VP(UQC?ZNXE[=38@Q=+/H7711:H#;1D,U^VZ-LVZ4,O ,0[QIM4$[DV]X]
MJOS^;;>LZ\A+P0K$>AZPF#WYB%SO2MCC0\,8W*FBW3B@8 X=RS)U:T-PIX-U
M)@VEK./V3[ <@;8R;= 3++2;W8:;94_3"]!:%KEHFTL*GEDWYFB:1&:)9KK@
MM!IV6O3DEC01JI"@_U*'CN\9MI6)I HDH/1#=!Q?SFAR%DV]VZ!4,4N?IN5^
MN]O8;[;[NEC:]^GWM5Y?IF901@#=$K,4K?-9,$JZ,<KET@GM:4&YY7;3@!B,
MY=UYM].$T;Y4"1CHD,H5N+=V#V-15-=:VSI-KYA*A.>Z37C&Z)SB]MVEZ^]U
M%V;\J/V6'F63W6(GK'*/@@2WVXVT8;=]N\AW7>$[A^UU)AX707/0;ZTU&@QU
MNH8ML3@9E'M(B^L" C4,KWU)Y&X9UU,Y9<+(NEB;I9D4L351+_V25BGXS;8Y
MFOR+=IMR=I)3PW1V7.<%A8!F%[@_GY=$PO3S$*<MA$?'&0%;*S-.4.(O@EAF
MK42L(9A!P9$LLRUM,,D(QU;1P-*,1U8BG(!BUW#3B1 -DPED%'5P1+?]G$9&
M-F8IK=\R>>S][7)V =-/B@IPFD^5^H<_#SYEX4MZ./J\V;8ZD4X#H-W3UEH#
M["6@;X%'VU,X64?@<"KN/\<'V&!P,@SBP$WV14.S"*,BQ55Y&YF04*C )&?#
MB^!"2C#NH%XRGTED_IY=*B "??O:BB\/D2//;)0! HD .Z$]FO8'T%DB@ZS3
M3=TW2$N#/$* I?QB :FLX5^XI^11)=KKRR</C_ZZ )M>LSWAQR2OIL9[V8'&
MH:GL8!&,9PYCQ*LGH#NJE?7.?RS=#2"=J#L<)$PO2!Z;D>HM:5<5U0E^E 37
MU*9C=Y*1&:7CBKD@##T7GF?I)_;/DZQMZP4S"?CEI@_0Z@J*UO1169<C-(A0
M>TO<"IO9[HBW1; ?M!VF[_"'HFR9@MO!@4!W26=CXTT6EBQ^B8V#\LYI^C>F
MO0*?@)[ _H:SQ.X()P3%)M!%J,'D(]NN._,P:A;E?L\U,_78]$OD&L#[J7?B
M9I#!^"G<FKIOM]E/M&DW9(%JYEVS$SQ1<\D^T:OO+_G_I8FCS/MWPKYI&UC7
M<N[<+S(:F!A6IN-#0[ =_.V3@/)<YMF(0J#;KO0D4G\2RYE$-EU54L#KGBG$
M6TIH.I-F,_F 4]1K5TLWTBI;X.$R:6S2RSN;.FVV>_ ^XED/#FKRY%N)B=_R
MNXK<;CMQ9)VG3%>QXI*N+,!1VQ_V"W"G ?!'0G0!^<ODX,AJ/=XF8,!A6"U"
M^Q,0P&H,;#3YVYQ\E+V2^CU-?0SP5O]M]V=H\QQL4#3C37UC *,$]$XY2QRT
M3Y2?9BNT_.YR#?/<UHU6:&,6G&4!!6AZ-+Z#^&7N+C-SX2/>V$'L)]=.5&K2
M>841\PW[*EV^XW.\7BSZQO6+N;AKX/G8G0=7<4D,'Z.%U@M9##,4[C7SA<A#
M6$$ 4Z]KK]E%3%@#VWD0N<)5@*=P8IX"XA@R1VLE=31_C6Z@53S NOGG6HE+
M.#[B&KO#B;M(62AV.Z%G8B+=(%!V[U\@\VUQ^%O[AEMSBPRE%*-=<E&RFOP$
M3]%7$9^36P4N[/5NO#R8GVU-X7 4:+>&C3Z\4RA-2@;!)0%P"B3(5"UK9J56
M_R]\[LF*WH\5;>E8RROCEPM21*)#CZX"L9[%TK)&>BX6KK48:!]N<7(GYFAB
M*8CDO19)6=?+6:*\XG"1H6%+,98WD\[.NZO3-]F]"=(\+*DBCY*5;3V(+UW*
M2WH)&MHVX'>;DY-.X25;KF:/W8\C(MF0WUZW7<9.%BXL/^7K>@//K< \460Z
M4('BS@U<?P?FHS)WN!;U<7YY,HHFAV$S\D!AX.&S1)8WHA=L>2/[4P,@E(2?
MFEOR#]?.HO@+?+25<.7YKX.1;E<73&AE=PGCN(-<%SUPNW4CNGSV^?_D)[]\
M]O7_- .A/=R.[DQ/I&%2R[+;$F_:9%OF4E^P<O_-0L#8,K?T4<0XAP7CK6;)
M?[W.%@NU[;,[TT[713-@*RP36W)IF(KBV'@<L7:8FCIL+)2VIHQ[!F2!.CR6
M'*IT,BR=H)[V6Y$SBS2[4\.35 PG8&66[##C(\ZU<8GW0^:_](@KQ!UAW4Y]
M<UR=HGPD #+?;V7 /;;^Y$\D3.#HFAB-_R[4W9$49< OZ-LM):&\+B'*/9G[
M!P0YGAH=/DX2@:;=-2DS76NV%<G.P\X'S<@)J'29HZ]0MJ%KD,/)!4AG=5VL
M67K!60_9Z+'A (.%V X^]1+?9U=70?J3#T-NJV@+][NQV. &ELU<>^/GC$DP
ME_9[)[Z!80TK+6@8;8/D'2QDY?\SJI$$)+$<<84DJ#<A0C755C#.H8!LI/-9
MFI [EG[G>&YG";.URK_3CLY1KY+CJ%L];^IM=*YTPE(@6%<\F9).=L$&'P?U
M2OR. -_K_ 5EK_"/3[N:)ID,:5-CA^*2]*?\/?WIFO\BUZK@?R/N&G"IAXTK
M*U\*TK50154A1J,W+1A)BK+$,/CDQ<J3YC@1: 'LVO5P6@\-?W.+5#,O1%H<
MDKWZ1;=#=,$/+9TOW(1?%4QE KKBXS\Z[D8X?CDA'#\ PO'QA'#\PR$<_Q"<
M;%-[V$?.H4C?#CL7)]E:PQZ*MW(ZQA9.<P8M59!"W5I_#(?^^?L%,[FG_^.+
ML[/3,PJ1I9=*F\/,RPNY8O#OILBE!,YZ.\NZIPU[LBS616>R)TR W-G)#Y[P
M/;F/DK?@,7KO0N/&+D.^9\GA65E(_!EKQWBNY;<Q]X9O8P_9&1)4BQ>HL'H^
M&DL8#<> AT1FG0>-B)2&3Z$RXF(I4,UNG5\,TKQ@)85"X-HJ09X7 1*73ZH$
M+J4:T4FX 0.1(OF8/;>17;-+"]V=F?Y*0 9D"D^:O.17NMRW+CTT2^D]5IPO
MY1\D$S#EOBSG!QQL>G;;<!7Z?/7F\:.OW)I^&S)87;5U4R"'Z"'0O_^(PM/N
M=[_CKSBB@LD(3J;?<W0V$[_G/=Q3*4VAPH("OL<DR/]%^B9J#C2-MEJ5!?=!
M1BW$YT[X[*9NRF5H+!GUICIAJ'5G38'DYD8(UT!D4JAY^ZDN0"*2^+$RFR,3
M(HFRC%,5Q\__T0MXD(^ 51[E6 >=K8[]K'K/*6VID5H!3H\(?4S,3]G6B0.M
M+$US,:!#HKA[.Q<%+YK*NID7".0=?U33;9!U1D!.IU116P9_X07)I LX!TR)
M3M&N!PYS3O$IL,=57=$+7-0;_"1991T-N63%L$#/+'A#\_HF+_UGPZ?S\TF+
MAV:*B1]:D0]8(@=/_P-1W3VJ%(M-[N0NY05Q'C9!7$OO'+GWFO7760@.F&V'
MS04T#FD-QH[UF57Y=L'K9.V>( %MN@5!E"]?1TXBF$;? 9SXN12Y(,SO==8Z
M$)M_&2Z%S(WJK# :OL)H-14->R& H0D5%U]]L,1.C]\.<*X&A8'=9D^K@PGO
M4-*U=Y1X\;Q9Z@O!5A?8MPJ4Y8I$2)J;;BBD;2)$O58;/.8.J[8H.\W3,;30
MO^TRQVIMQ9%*S)'JZ)GR+J0P"LI0WH="0:Y>8F!Y6,US93CQ@UB^Q^T<=5V+
M6]?K:2(BN"KK"P)!0T"$I(F>J4G4ADIU+UD0*!.QVP*9 937Z(:?O'CYZ0D=
MQ1C3BY<GYX]Y50JWB:@L;B!"'"Q5@#;H'POF8?#;R=$P<6EF+WWM"_,A0\<2
M=:BRS*44Y4MTX6Y@2+GJ.<YX?XM4D/,3'"QSIL3%D 5F/H:(C4R=>5J8I^DE
MOH_<18?R45C=8<N>;W-ZN<I4S*HS/)%\LF0BE+P+31<YL!C):?H*4*K%9K\E
MESEPD3]Y]>:R_93YL)C%AK$A!K%MZ[Y9X/%YBH/\WC+TT#VV 5/-)+U^"$9S
M)4=:E-1+WHI4)<-D="7",LLW*1:([#4S:#:=\?7,\U)RA7C@,J//B^O:NA>D
MKKL/5KTL#R0I#00CQ^N PSIY.X#PAW51.2*BVFCZR3.>/4[KSI7N3RCEY&#D
MM<3GTVU;6JYK.>@@@W]PF/H]=OPF]5?6JM+16M6Q3T+8FM5N8EFRJ$ .+A"W
M_$5?&]M6=DH4PC/EI,)TV$@ P1 PY.HJU-W&GLZ+R@MBJ^P;/498-_#;*%/J
MR:(*.'-F$:S5L2JB6E!(4N N-G ]9E WQ@% IZ4@9A?&]%TS*4(Z[\NR;C/>
MV443VI_$VQ_V?8'CX-'6<Z44QPD0U"S$_HR7[V,<.+2\7CBWDUTJA@5BUK,N
MFP7NEG0&F#9-Z[1I_H\AKE8%5_GQJFE()4O;Z/E'+Q<(-HXKY6 <B-G[$]_9
MTYM-;? JPT%TM1V[((5W\@ AYS'SIOEL3KP<ZF;DO0^M/LU]"#_#$7G-,'4W
ME_@$QRB=9[S(JG5RT"E$EI.BZ77[J0(9VWZW4RI1S$9L^M]NZ.0WF$D/X>$8
M.B<F]-EE %<<GJ/!8R6@L@\@(^K2XCW@)YW!J-<A4'H$YO%#C31Z?&VAW(7/
M;#4N8)EHS1EJQ?L4B8C[#8T\[6N/YF@ D#2<Q99#T+8[\:^/Q1 K26VQG/(E
MT#K<$@K/OA3F.[=D!+>)RSGT51+04E9,<V71!;)>N_:(W/=[ZH=_>_GTT3=G
MR6A.Z!+$3[1=+]&_U+13<_Q'0%4 S*"O82&O =D)W)4.!1I29;BKE<@)PAES
MLJ,4)/=J"GRU16B%YXB,2L6@T34[51ALO1#+E/O]_7?@JZSJ@;-@^!F?N6_H
MZ"CWTSZ[%YI6YU\X95]0ET91JG%UT^Y;%LM,!7GQ-=HD\.]QI&M_#0?GW]<T
M5 1";_/W&2"C>1JPP0:80L#,&QS]].8UO7CY[-7?7'Z>$3LKR3#B?E)(VXKH
M#X]QGE7O%,GH!K^E@SMO_.<SI&/?6<^1_ 3K#-\=I9E-#IY8B! $)A"3G9.[
M+6,;F27E;==ZHHOJK[.2L4TQN3F>5U@D!$6]@O^O#5D0[#"%9=P+H>_B^:LK
MY /\YO'OH&Z,E4\SP60$)?0/ 65P]OQ\^^?*6Z?]0?9PFS=HFV&'#@3\/X:2
M50W\+?9YBV8ICHJR#YK)AM'ED$'3H]'*BH?O.]V6,C?HO2SWCF"0H_T:@LX*
MMU[U0!Y/1OKW-](OJH[>&SFI?58F5Q*Y3A;Z?BST#?#F\&@D[C5)!D -D#)L
M=T4%'X?S?)R >"Y03TD$U%65!YV?;//,.V(KQ$!/U2&G:(*Y7]GW_7KVU1=G
ML[.S,TEE,#TIADGCOTBO'#7%FZY>L D.[RV=J8+[9W.0(6CAH*1%OE7B$PK(
M<LG<JKV_DN]<^.]<^.](%C$I@J5H212R$11PMR=EL9#>]X,KAPLXM06<7O*O
M7NJOW+VD%';'8!([F%INV6\0^L_2KNA*[;OG7JV6&16<(>3+M9\%0DSMX4O#
M+WK7H/:+QIVX83%_^H*/GGG>W2!C$ET;%\7%Z<V4/2=G5D"(M9*ED!?%V5YY
M22H4U^08OW3;<]0I*^:SG30Y3.;W=P<L<5](\C,;Y-<LF7!;12N$"Q)![@^M
M1PIBZEN_;I)&V$P9(ZQ-KG%^BX]GQ_80+;,_']7LCRT8CQ<-\:%#_.BO?JP(
MXYFD:0 8_>47&8&6_IM"0CV:]%>/Z>ST_ -SW0WFM5M^J$'>PXKXYLNOOOE
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MW,1JD0ECC\<@;^:H;,+QFK$Q"968)%,SM+_6NK$3R&17(+ED? %YV2PP&$9
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MSB<M7Y"$G::O1XES-0,A;6H\:9I=$"HXL)LM#R._D'Z.[GDM8I+)NCD08LO
M=;:42=5 S5E)/(4XSR!I;1584H$(G;;$3DYW#0LX6. AZE4T!(6MA82:*$IL
M\[QC\BKF EX&-D$S@0=3&^3S@I!2PK1P>^#1=K$%%TT49%76Y'?_TQ.$+**3
MQ69TEKZKZIO*5!B[S Q.8(+F==8L%89CD:!8?4>#=<C79(M,R>6SH'5P2X^$
MK.X-+IO!<( DC*=FL<G)B]W5!4 ZGN"+;1%O> WC>:0N#>QWKL1@7#.KEOZU
M'.S5=$/O#RH,*U9[5HBR%=PYE<1)Z,%KU[GAU\Y5"ELTGH/.%IL1(U<0P=Z"
MGLH?VU%MI1')0W[G$49)Z.QLYWL97@9<K6L.[X8+IQKF]EPVV(>T#5DJ40$Y
M^KCIH0_Y>SA@R9CE[/8[S1+[\Y0-;9-#G9R/2S;JFZS- \UXK E(.-."FQO%
M7;Z<Z'GN9IF9Z'E^TR G4,<!__05]B6/\9%13?_9F(.'M=!64W]"K]497I7^
M6:LCL1^&:CB8(3:FQ]V"C8 =*?ZOJ*"T H6-M9OY5!1M+1.GY_.[DHR[T?('
M!DD.8?%VP"04M=PNZQ9!?U=#&*L"^T\V)^=A)X #"F&R>5T6[59 N2-Z 7<%
MJI:5MS9?Q'PJWX-T;KU@C@%YKD )E\:D645N&2!7K2W(A@ 9P<. 9K0J".=P
M4IAJMXH#J -BSE8*LRI-PT>\Z EQG7&5G\! TW#X6-:9#0[[T3?##<WR]LDI
MJB+DCA;8NAK^WB97>76NPG*7-1@:^)=!B3M8-9(/S9D76*:8UYFN)I5,$.P/
M @4:=WS<>$7S"2XXP04GN.##.EG.?\')XNV"D2R7*I:L>YL,X\ZXWQ2NTTJ-
M,5^.G@UL=S21%# XJ)8;H&D:O<S2F@X X$OD>&CYG A."3D))%G30@X;]2%.
M9-56?]L[NVT*7P/[CQJ;@!LP%,Y6G*:O(#^^H]_P7*7GMT S EN'TBR3^(?0
M$E I"VV\ASJQ;F CL22SWCAE-_]>'A\">B;S.9G/R7P^+//Y^%\QGQ5V?,:T
M-",&%.!6R58[$ZG&;R8=85*Q0)Z/ 7!PW7@LH;BI]T97WI XVARUCW8;=L4]
M('86,/4B(V"&<)U#@'1GWB+9]5W>A$@OL>2^L\0)"X_D)APQSP'/#[(/7,PA
M._R9)G%3SFO]G),OCZ44HC)+ $Q:.]V<?'KQMW>;?0N-CDJ$NDH6$0M$H;J;
M^FY:(SD3#FRT9J>%--FXT Q9Q+6  (T?,0],$/G[1B!#3LWK3RA2=<;!6<?7
M:O)5WMB6;?65?SY\Y;-#/T" EQ8F!7H#^O+OV!9)K[4 #BPS)PZ2!OK@04::
MHD2GB&*AN592_/X*E")\TP8'I19) BK#VK 29":9!OA>I3KH(V&1):^^Q+EV
MQ@QIV<L3A&%8M\R:"9.8.UBO_.P<U3+ZU3B;1Q/.Y@/@;+Z><#83SN;!#_F9
MER<+<0L,S+2&D9D52<5Y6"-I&(A=:Q,5JKL1?SH<,S/?4LFT4T7KFH:JU^@S
M&<,]SPQ G L_P&V1+M>!1/4A8DN*&T5>Y7S,,796=<5XOG0DVFE#WTQDH%O[
M/D#W@;\6*GVO!J5Y]%YLQ'WT$;;O/>"*+;F%&W.U1>'(KJ*=/'JO!/0PG&96
M'$EX(X/"Z$\:QH9DZR97"3(Y9"M:/U(]P_0%[_@T?6-OU1?AT"G"-!7!1 %4
MHK.?W3+_(KC5+GH%X\:?!CV?4H/ECAG!.#$&13S>S)'7C;NNB=6D]TX,B@64
MK--ET$9:-&X!'_UY_="'?%E7B[Y!UCX1HI&A ^HEF/NVUW*O0'Y"#W)$LH%A
M0XP),'G?X/OC.\SU5FEG%N(HX+7&6[*<AA84($MZ)NGC8Z#%BI$V(6%+6+,H
MJK IF0(QTW:.J&.3<>850>K'%[?;&A)MD>WX:$=\# A3VTE91 : 7QB1RCSK
MZ*F';6:!-!E7AVY3FO:CH _XYDY*6?E?V/1(%44\]U]$ZF+#X9EUG69)K$,8
MB"D[S6HW XX-AFT=FV;M-R"709AS7,>@35J8Z_2(DT@XC@>2^ 3(LLX%?\_P
MQW4=@UT8%5/4!ENYSH6VM]WDY8J+89-Y^9V'S!TAB778(5TE;80L?2>GOLNO
M.-E1^G\Z"UDA"L<#_( M#5IZ;;1CQ/I#1W%]=/%0<$876J+1(RVPMH!#S]U-
M6=L-;^@7L?D?.$S+'%_-JDJLH._J4KW !M_4OEL%6>GP#RZ7!"UAHK(;8I:E
M9LO(/_ZTKT2!$./N6_V7U1K080LDLJ(!6PG@Q5+8!FO[]5I-0!;F\1+K%)+B
M=8@6E-+YENLJ*CYNL7E\)S7\(,2V3GTS-[?=-HUO*VVX(8X5( .G1:GU<J[V
M+GS:,7-3=#@G\*=XQ_/9U=@3X1W"$CL!,8?EY='[5P 5U\6&;*J8>H?</&S\
MCEZT=;H^^H+,=TE^%^;,]\J&#N (7"\Z$@T,*4P"#C@7CX?/5AX4&4 4HFQ)
ML0N^#]?-*E-]W0,$P!VSIX\#^$"5_,P3>=(P34P%)*B#AYML[OW)R[_VZ/$+
M\[$G>?E['?)%2Z<7)X&E'V'5.]!\0/[MM!#->(Z(&.![AYIDP)W'[2R#$W*D
MN6&6#-B[], 8.31' +EM)/>^S-M%4^SNH$KT0NGD3.X[N1"4WA+O\6G(ZP*
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MDM/#,O\K#O'OT"3^ML&!$)[G<F;O#\@)+<UC!9X[2+KC"(:):3U' OLB/@/
MBM)<XR6W8)MW6J@I]8B_*S8ZE4?H#AZ!PQ2I?J@/"$G%$0Q48J"!$;1"''DY
MD4=)F"_C_F:N**[\8$*?^S#JY]34JE&9)LQQ(]UA;>*]&&W R+.M2C^-=D=&
M_#Q:(V)\<+KR"Z?-%U'/8U NQ&2EX')DZ1GFA92#RSG/0I]R2U?%S#P\FX@
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M7:Q9A5B_[1J3MS&0W'A:#&'7<LD?G6P+:P4_7-B\?&A2Z+'KGA-PRH#%;VG
M '/+E5><^SAD^VI=EFN+CGZO>X<#&8UMI8K +WH\BJ ?HMW!A5O5:D%C!6TA
MVB#2O19-YFEZ&2_(<1$I?GXF/^"B&^]>54^:I<+?R=M-&A!\!C^H6VJC=UA9
M]$O4'<':J2@0O +A-!Z("3)X)9O=:..._HB>G3<N683&A[I(XY&;4^AOA2 ?
M,RVMBC+-WFS<.I>XSJUS*?[&31X0QR#H[=%?<L'""71M4*S%O^)V3:/!L R_
M4OC :%2Y(Q$ ,$41./1&L@ I:OZAL5QKB57P-L*HD(PNM8!5->/UJ\D&SPWF
M?C5Y0O=(O>M(-NXBUKA%;\-$S20$^)>9-9)#9HW3]*6X[47+O<E[68*TL^J^
MA>)C)4PQ[M(*S!L#[T5J4;@.C"D%PL6.HQN#0R +KVG=Q=Y1/=W&J2AR%%E1
M,AM.+3.VOW.VS":!W")EGL1K(=$=GM&).W(E0\G ,F7Y".BDGH@]<>B* .(0
M4FH-U3BD20K&-K@LT_0\X??EKIE(W[CGGS%>FM@_B/XJA[?2!>D1/6WGWWG(
M?\-[2'QM!)!M35NU5K888_7Y\U$]Y=B+\2FT,&4V3*G]ZL>*TEY)F@8YM%]^
MD9%LV[]IELPGV'[UF,Y.S[\HJM]Q7KOEAQKD/:R(;[[\ZIL/-/3?>:RAE>1!
M:B$M(%T:<LK&8=[,-T_8D>WK&ZX#V90^]!CPA6+$KAEMDR=I.%V<QWT0"SQ*
M+W_@MW@O5WY(4_DPC<-D#=Q8 2AI9SR\FZQA%(50C(I?V5N?OOYQVK33IITV
M[<<>JP-X8H";NEPRN'007DU;==JJTU;]V&.%9E&K.]4+9*8.&80BK622(P(J
M!@WN=B%'KY-C"KXWDR^VNUQP9-(=5UM9V,O.TB_H*SD/PQ6O)@LQ68C)0GSL
ML5KJ&>-K\^*?2./6PE-520V6=S6;D4 ND3G9MBP6S*08\B_/HS%M[FES3YO[
M8X^5$^"5;.YEO@#?!])G#>U6:]A;,P2.N4"T.+/,YUECV#0EOT/O)E)JJWR9
MHQHNF&=H(CJPV;3CIQT_[?B//=8M:M!H5,$ N8^IB-SQL1[M*E"PL!YW-&89
MFL20'==Y7'6=]ONTWZ?]_G''BC9!C"W<KZ:#4HI.\[,\:]+O_8%])0U^C<^T
M[[A]L,E+X2[Q *5(O:<U'F#8"<W6>_B#!! 'V(PTF]=]A#1G<,5D.B;3,9F.
MCSO6HOJIK\)"?..B>H^E6A37!8O^+!IN70;+#/TO&!=/1S>Q]D(=(XKF[J;"
M+Z:FP@_05'@^-15.384/?LB&"W8"@0Y '[-GJ?+T3.4:';',Y_Z3,5V[4,3.
M\>BLHO8,ZVE):-#@_E?XK_8&2?\@,+OB<"%1$RG><5=Y./"@"\:!@YUN@[NK
MA8$Q74#NB%,P2H!EG?=G;49-%K3,:-O.<.[T<)&BDHM)%3O+4HU,A;,5-@FF
MEYM8<>YKI;,X5-!JTL:@O%FP-.[LQPK%N5CNE)DT*V:(@(07M"!!>\'ZAM)(
MY3K+T+L1:SC2B@($?==+DI(%+3O TI4CKPGZN08=0&AWXA80#][7(,3 YE[V
M.EC\I\G;X"+:IN$:DWB#T?!S!#@+6=)E=M,J%93OE:%+;HIY811<\1S5J]4)
MWXP%:\&U/8:>3Z27-VHS$,(RQ<V/ZY,:RE]DOD2.:(BL"A(Z!R_3@Z?A^7'K
MUXCK1W9.%5Y%[\3TRIGP2KN_R")PGY(R&JURIMI ZDD9:G[JEVOAVB[S=08F
M,J_F%@D L:ZO>^-HK3#%<!.F/C!I@X06_51T?0P9BN77J5;;WC4;':ZE\$F5
MQK,L\FMM=>;6P?AU\A"9&29G,C/C2UL)K'7OZ3MHY-=94PQEF#S?K5-@LTW)
MMGB>;[+K0G@A=_XMN&E?;.I"N\ "#LKPFH$2DZ%QHPXI-XF#\%^1NMJ6EPQ7
MLFZHH@GV/VYK-8- ]A0T1B6:))?"B:)A1K38&!I(>P\*1YV:$>OAH\62K_.E
M\-[M@/F_=7_Q15FAJ?JIYEZ<X%)8"WFU%J5C2-JY7[H+!FK!SB"$NJAF&Z"M
MG(0M<KKL_-W8AQ864JW+6$V&X<EY0^] &)]=7):&/:#*I)\OHSPN.O.5TUK.
M^&4B;%4=;26T\7UO[]J/!.NXW?!";?IN [X@/!SW+!5MF6=+F0^?Q3'.5B_]
MRG3X+8S%H.7(5@^.E9,#SV(ZT.^;YB[J7)+F,=C.G32#%_6.%L(V6S!WFU>5
M:U6-P!IP<:6K\)?<,_S*><(L=4H+[^K9JPMC<XU]B>$X5#L#;;6X%#>!8\-+
MLM",1@E75YQH<%&PFG>_#7KMC$%,.9XRUYCIC^/$_!(W!/0NJXWG#F&R5$]K
M]1#P!-;/U^GQ+OK0__ILVM,E4?-K2&KE!.65H-CHA<DHA;><ML^]<&,\+>J6
M7CF=3?+*7N<L";C(C1<\_=;+Q4UT&?<7JCPU/EQZ$?!R3%_2-OV+JJJOQ09<
M+!B0='YV]@U;IJ=7ER_(-"V4- W!]GS><(MZ1**==9L;.A]7HV*;XH8F.#HW
MQ7K#Y+F\3O@6./K.SY[,W>J9\5\>/1&=02$%E%.:G5PY.*LT.BD;M]8.;^^=
M$?)H$B;/U+Y=^%=*>>MH"NBX[KM2ZC666P Y1*">$#!48++\R&$1W7\$HJ:.
M_]NH?AIXI. ,"@B% QY"4]-$!^8\[VYR50L>T3&UTK.? ,=B0;\A]ZCUQ2V+
M"6=A4#B# J)0MC*M\08Y&:. RLA9VHM1UIY@_+;8QO^]#(GO1208YXOC1@_>
MG]CG>#Z<$X21^,FT _3PR>R9G4 !J E"EF=QO!SMO@AF"]F&_$;IIZ"TZ08N
M(2*9KO;V"44HLD:ZR+$D,K7$*J!4#8+L)0Y>,'O0K;=T[6)7"LF39)2J0 )\
M%KU?IH:(!Q&0C+ J@M'F2VZKI4T!42'MC@>_%;SW.19.T/<>C0C["%7&HL+N
M%J+8H)V;$8SXAS1R\P]Q!TLP: +B6KD@3.W3AS0C@P]IQ'6A,7%H\-)OV?#)
MK]GPFD 38FTP8%@01E<(9%=E6@:R$4$E.-2IX?R@R>H>+HV8ODPV/1:?2PQP
MDL@M/!9KSY0\(^*"&<KN.B&:B:?_'H?\=P20_*KU_!L5[ E6;;CPC)G-1,G,
MCN$ 0FL>E'C[1L6)/=,T^\G.>$7+S%$:0]M6)+ZT-R!.NARH4(2GU,^-=YLM
M\T"7*4@,RJ ?G2<Z9.L2YM&"CM^1+1UNC,,1GZ;/I$&YVY"Y?W1^@JL:ZQV-
M,]($SRH'J>!\*(TWH;==EK8KG+(S79#%3CS!U8@!][T<:D? R4T';LER;184
M^2LZFC\/X1#K+FNA\F&[L(GD[C#A4@*':?B', W?)3 R0K,1'VCYX R/\KHU
MI+?:)/)W>.6J@K9Z;T;0%$ILR\2WYKF9(Q.TKK0'!CG(5'?R&CGW0H$8)*-%
M47E1XK7>;')^?^YP7 (PNS2?;W!A\_N"M0>N0\Z.(LTVPSIMD&B!HP*!A:+K
M-1FI(21[)!)(XPB6[)E\0R)3_1Z('6^.WH[>77O_<JJ]?X#:^^.I]C[5WA_\
MD"^2$3<8'B@? .I5[IA9O^$@@D_/\"#0DM#?*U:">*,)OBOWD^A<II-4%0%0
M.Z/CPVL#)AP.J)#.V$G#!U?&.7".3W%<%7R%$[Y"?"<-H/LJ<#Q .^>*X-$M
M&CH0%Y*];,*;S"QL,AV#>0;G2<."Z[I$\M!8Y'(O#.EG#.'N?JP^JH&)IA7T
M8/NQ@>M7,4%LWG9VL 6Z$GR]HS^ 'OJ0)3'YC'RPY*HIKG'N8_F]R1?L1$U)
MR/ND&//5B771*J\NRX>H9"'(_31!Y"-A\UE5+R(LK[$JF"O[J2I8SY1RY'MB
MER&4*:3T_F.N)B )ZC/LG.^"A='JPAA0_\ZMS#%2E76BS6PQ,2@Q63>YJS)B
M4'-(\3!-.9QS 98G+U"]8%-R!4E&?7A<\2(N:&A:]M$WWWPI(B!;4=]13UDN
M1_&?GYRW^6)3X420I.RW-)9Z*YFE]-*"#1U&D/05% @*688YBHF0&0<AZAS7
M@GRA($MS%S2N[U]<78 AF8LUD#DKE>RT#<%1TFXCK)U"B]M#2Q&'P<PX$)GD
M,U5LR[K/FJ5'A?#[FOF7Q:^ YK$-A$E\:@UI("7T90_K<"6=RKCYK$P,A-(R
M/(VI4"5BHT@$H2+-)WV/-@C#>N@!%G0]9>!BM!F3$^\@+*/-0AR["$'7.\DJ
M[]UG>CE(N8#>JU.9I&359#TDPJM.%I9FIK&X43PS+-@LN"R8?UJ[/E\TO6D*
M(P>S]+8]E4^ 2F5=TD[1R)*QD:5C(V,H';W)O>[)*@^VI'#WEX7Q<(JPN8-W
M!$V1IIB$*)()/QLH1UT7P'<DNH'5+(R8 W4/BF;).3^.!(VEVID$P"(0-,J2
M=*G:F)!ZS!SXLJ-23/.2H0BX1!9US?O=X6Q8#UIB5+NL[@R#'675P4(7"2FF
MRK8XG?9@O<_#B6&KTI?+),PLSJ,'. 0>P5V[@2 7TZ="M#ECL2+ 87I!:D7+
M7>=8^-09XW;[=DI&WD1 X4H&*I-G/S$H)GXK_B:V"*V5Q@$E,'E93Q/:T.&Q
M-("'9-'H2C+E1W7R'>%A'6$A*C(:#7:^G7R#&O\0PB<[2J75PJVDBDT++4#Y
MPT NQA_/F<D7J\ U8":XRTR_-++4[!;R-=SH<*  W> Q@O! !O])?KH^Q43(
MW[YP9"]ZB;<-<J*7T+7D<P4'Y:<S/?P'2E4S5#YFMF$8DR HS\[3>\OX3[AP
MPL54@T;1*F\9EQ0=2K<@'-5IB1]E^!Y$$]BS!0<.B\(PQ7E1Q)1@R')^K84Y
M'2L^45PY@Z^H?+")@YY]-MKE,I,7PY<+^<[Q[0.LI4&^</TJ7V?J6@1NH7.>
MCFHC'>'>UR7'(FB+#4,V!8K?BC,^(/;6/#A+_AULNW$_C=T'6;._;(TF_^H:
M33_D&DU^=HT"49FIM\R%9-&&F%;N?4;Z$FC^_?3-:?K:PTTGF9[['_+3(:HO
M\4C:@<<=J&@&P4 0@7,E/CBU-.J])1B'RRD^I/B^51">,RX-:7AZ;'KJIFB7
MQCU?!(7,O0O=!9IMNUA.*H0A"RG-Z<579%FJ!4*]K&E0S?+Z!H*2H&]OBIV3
MX4Q<BL "DTBIN\U1]+(*)YPG)VL4ZA=+T<Y=2KUVWV=EGK2Z$V\0"['A-5+W
MQ" @C-34@%+%7R)/JBM.WA6+=_-L\6ZF%IQ1/W/V>236=/H^%HQ3$,;%R5'_
MQ'R@KDZT^04ZT=I-(=%AV%+/%UQ!AH3<J.NL[+5>C;#)H_G]]V.F'6[<!Q+)
MH/9JJ_E4@1QOW0-OPU 4]!<4=>G ()AO8$+<Y*G:LMS'+ST&$ W]8#H>1>9Y
M;_GG2)W''42!HM38*S'8CHAJS\9P_\'%EMF6(KIV)KT [)*NZT;6I, "%.=N
MD3NW,_0!;[B?GEGBV8YJKJ^O-R;A[L2KPB3/@/F( W&6RM"$W:&;,$**I#=H
M=T#+(\;TT6<[,I'H9RC(?\;S3.?LO9RSEU@,M,H4YUMLYSVY2W@!T_EZ/T-^
MDP$9KP;*"G[2.C8SV-O,"EPTE%R$\+0II@_4SEA.<IZGEI^9Q]I19(WK)DBE
MZ0[6@X+M?6(G:MBL=+BMN9F&XG ^* N7^L82DB;69?@K,EGD+?S3#(NEV:6U
M@;6?@E7'T+SHJ4:?@B%2!U7.&8"X?54@]$YW-3G\>R%PDC6NUFAP-W\(<[&S
MU;;"X)Z)W%.[?6^]%C]0&U\2A5OMO/,B94@HJE'=UXR.Y7](0>$5=P=JUD'^
MHUBZF4\\QA-!2\,P38;V;.NEW7U3W[B(*!CZR$&GGVI#M770W?Z(/*=T-K'*
MJ^]@L8HU-W.*-)Y>F=NDEMSWY>"9$EF%E^64L=5Q#6D4XH*+-OVD^)0Q8KJT
M)8^J&5SD^#6EM"NQY3XIZ-NH-\P"(!PO3^F]I+FK<@@X9<V>OXV+>SEV!R#3
MGK.%@83QW>M/&?5YXB[,IO,3^G.5%UK(1H5<I[AB'&R@%@<QQ&=TV5;=IW50
M$='M/5RSM")[^7,\;^+HJ%^T9)P4.U/PM'DF3N;[$_P_9K>0BA4:/P^V$[^!
M:&DQQO7@3<GZL@966^6S8"GX-/]WX3Z(\,KRTJ27$I*=A95Z,N\#SM0+YBQZ
M-!<&OHNG0IT)<5/(>6N8-0 (9XK@DWF^R (\,WH7.(M8B-8]33JTL.I%,1"4
MY^<Z>D_D;G#95Q.X[ . RSZ?P&43N.S!#_F@.Y83;-XEL*2! 3O 09*&F1;_
M56GY=CJBRQAGP">D%J.WRH"@KJ,+D1.VOZ8<VOIN?.NVO\,1D;\$':0"R)J[
MFC!,/?="X?#V*.=EO?.MJ^'=A>EA.&KC83$E9O]K5IQW X:0@+I&\'3B?!0?
M)PY(9S=4=\2N+[7@%<7SK+7,#;<M(H,TC@S8=VB$J)!S5OXH/_1LPXB"&QV6
MZG=(-?? #^"R;5<G//&^F\OE][GMQ1W1Y'K:R[$>JF6^U=42N6^.#X>73("G
M<)J<FGVOY)F/_L1]Z$.6V-^38B:O<>ILIY#_WLSP*P:QG)\].A-#?'%YP2TV
M>94M&(QK\?T<O?X*#U&&"_X!FG2#(+MH-7<M<3_CW*)03XK8$A1RR XJ'+9Z
M<6 JA3"]R6%'?U$M:3Z:O02K&+7:2T2A !G,\T:YEI5H*";3 @1%QL6HX@I=
M,UP<#%**HQF'@?U?XK7XY'+ [S7(:G.N%Y;?2A.:R,78)^'36^X]"9].PJ<?
MG&Y5W!:A9F=V-24S<8E E^UJ\CE#<,DIX?4]'PK?HU>_8<X>X!XE^\ 9M4=?
MG#[Z$ZS ^6/\PSC.U(\,+\+#8!]P8G*?Z)@G.N://5;KG><!>C2>)#W%'/BD
M\PY6@JR"LQA6=C@L.$R[>]K=T^[^V&.-=G=\EG/YR\ %N:#)7>9GG>V$_+?W
M.:191 LHF SPQK"($S<<<;WMB[,_I9\XKP-__XK^LJ,0HL]4$TKY')X6/("6
MGO5IOUSGG2=/>O1U5$%BS^,O-'RT&#Z:X0O??)KNZH(>MUZ=('GAAHOO@BYX
M77=25G#EA@!MR<,05T8L&WHNZ2T4[/9PD6M1@"6S39=&MA#5Z#!!TH\I[42,
M=RH<MX6PV(YP6]9]YY(VN+'-1U ^EEEV]<@KT*\\>\*1U612)Y,ZF=2/'%!Q
M:YY8U"RMZNIDB01MQZ8CJ\A&E>DJYV+P((<SB*4:5;+$?]QL:@8M.BXWF":V
M70'/(QN,@-K-,;/R6$; G);%^6\GF?'0ARPH:M>F>^V)\#D3KZQB-2\D7^(
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M$,[B!MH13FPWR0-'[(21$3GQS1HCF%?9=5CN-:VR']5QLH1P&U._$UEIK!
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M88H+#B;(K$-.XB&16*JCSZR5!\[(,89FTO.?#?313_HU&2@Y_Z^43WBB0]=
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M/H9J8V190P&W=[!5RVY,UJ4LO.4^YX1XG1VAQS_SUVBEFL5>>GR.";]Q-^
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M7=47$1P<1;)'0+*ER$#5M>$F'4I1NOAU)W<%O4'0OE0@FC4>@%"J%*36H;V
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M;([X]S_RH8S"_,]5WQ\U5_N<\7I,E/=SG!AU 9B_]6M4<C'6KZJV;F]9&6?
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M"'*.F7DF-4B!+G-#K=(7JMVB'+!MUT=T+8R(:Y::ZU?9&MKGF1&HMV[]D8M
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MG*NHA$![@"7V" 2CPXJY<(TUO_KA.X(U.'4_"T9"/%[KSJ8TG(%V&0A#49"
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M(#K6B.C0T<<PX2V%=!@^=3P/&6-9=N&A"0=C.+J5'@RJ#B>.4M*:.4O! ;3
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M>&3Z\LQ9U$2+".K&,Y4DR/#DE!S$__5<>(ZM$]ZZ+6-!]>=B*A($K>O:3N:
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MI7]%5KX<R5"(&1J-N)[$0/?MO:^#G?#?SY3^[*"G=TQB?4GTB$>%HC-[!G2
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M,,> ?2A=V] RV."_>3&T76:5JA&7@R=XH3S9*\.!4\I!)(:2HBY?(406!R)
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MK^#_V7X/#^?_1B6]_,6BP_<V*M&:8^Y=0(KPC-#P-7F4R/G06^2YAHV<7B$
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MZY ("[PE I:(\!""/##F)SOUOM,];E#H-C-3JP0*2;.'H$':;#E2+YE?+7/
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M11?=:+50SE&.]>L_OWR1MD]O1+.X7;84Z3F?,]/2N^C/"R-S6VE977\\E<(
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M7)\4;8[I_B?B*9<O>UY17(TAZZ6,91/\\,S%_94MLTG#S+P@COYRAL2+(5D
M%CPI*S:/_+.\DV;#2?ZPP$D^ )SD=PN<9(&3++G_)]:UU\;Q'/&1/KM)F&+8
M3.\2"Q7/44G>)^X[*3L=(05@A$!@S%#B;3_Y!*!V13F)+S3S8$?\Q!)-8&&>
M4P=0,1D((\XYO%W*0@P^*^R(NXMM&<!G+75K"0$NL!X&GM,QZ\P.$-D1+AK+
MCJ@LU'1V1.U<<>5!JH\@?'&4H#-,CZ8R#/K4E/A4J@(5(B@^4YLX7P$Q/M&2
MI+^7>L<$WU9?K-%PK)1/Q@YY+ETS'FD4#TY1.R;9S40Q?()"*^;P<3X,J;&(
M):1O.P:BG!:<V5/MVK?! <ZFY84\]8Z(!U**K#ZRB!"OBR'@0U),$RLJ'\8S
M)OG</.%9:,O^M$,%K?C0(G9&(9YP9I61!>(OKW_ZZM5?$&M5*$PLP=_LBKYG
M<@I$MC7]!L97A&PCQE_!'IE[H=P9I]Z>7=;A4#ZFD;+Z:$P)3+S3)B6[EF^&
MEPTJ L.FB#13VDT38XQR(30W+$T@*3IK1W@7_[0 +\B+T.(7Q;HZJE BA6D.
M=4?#'8:]V=3AU._I>FR$I8Q\:4:\X1=R$Q3*HYM*^64FV(:S)B&2'VF;2&TH
M918X2Z/W6>3C(:VLDA/+3D4G.8ZPV H>F1<R@5/K5@1*1LMU):)^G)+OPT-[
M+(ADJ-/Y W3 ^+Y94^M"B[-QBP<RA!*I,EQ:3U%59F406HKA("1;YYK>8JZ!
ME$Q']G@'>0^BHT&0*XV"29[?I!'#3'8Q7V^#!Z=LW495EZ:,ZPW3X6FM?L6Y
MYKJ;/$Q^#<JIJNE:R!]QY$5."MJ;O+!<2>!+CKQ>TMY1%<'>I2O#O"+1ID1[
M4[Q/3AS'K"GCQ^/"3:#-F(SJLI@CGWJUD9A1$(P.&5XD]L4,X;SCW>2*ENHE
MI^*XF%Q/K&N^:BY3IGJ%<"0\GJ!@D%7E%ZI\[#C.QY(>%$4\UALM8>8/HDB5
M[4FNU\Q283.6 V[C_H[;6N%6@F&E[Z3"O(W]P&D@R#G0!V="D4;)R:A$<9-'
MXO>*Z6:- Y4%DEALVC2MIIPR)&+-@P!LE HHG#),^@\R&[\5$;T] :4N_#.L
M=]9JTC823RFA/)VJG%,?Z!.X8:#;05-:KJ,_3R8FD.0N,X\)V!0'L/K$5%8L
MAJ5?-)*NNFT'FJY#+:3#4*+8F/68X?15+'O4,M*,I=32(U)Y_O1Y,AAD)#%#
M7RES%<?+$::82I7&]>FV95&G7<UI9],NLI0_$H3('45T6JPQCMP\KM1=*C5-
M]4!3.US.N9"2/.VN<0"L38M%=,4-" >2.I-\]>J'[WQF2G[3LF0#EM?NB)IQ
MTN@8L?\X$4-1Z<C86@@_)BJRG6<F2(A*+VD8%Y'?U),:>$DVB7]%I04[#JWQ
M>J:Z,TBAL+P]!F48EX)T?H-$KHK>5\V8V72I;B;8F4G"SK\[YU&FEZ393:/5
MBI4O7- D?,ZQLAXD'?ZA$S0=L8.9S\53K7PP?4EUIF'R!3F@7*'3F.A!QQ]Z
MZ)JP&Q\P'$=3+7D^1$.32>G#=35SIW><6RS&!R)*56((LH$YEPRB5 ,HV9&U
MBF ]1=/",]T!+%#(@V\1%P0#:QL#/7EF9*HTKLEET'I"!W#AD>[D<D(^L:YQ
ML(_/R:F3S EC4Y18R_L0IP?-RP7!N'B(#:M4F8W,QS102$9*<IG0@O@K&'QB
MRA3V"+/"\PX>\E3I6GS&'?V9+P:W9DRF[3V7HR>L)3,[BK.9GW#F<$9YZBRW
M4V6JX"2B;20/%@ZY/):*JO4>G!YFXKDK_EYT)355UZR@R(J>P3=#B0M6<':U
M#O$)J #<%?L](D/V/-^=<#;O*2*35J70X:[?'KU2ZT0(E.)>A@8ZH/3/'L>G
M%D0VP0&NQ0%^%%A\8'H$(HJUVB'$)Q!<Y84#:B^ZA)VR"$65B,QU[O4@Y'+I
MUVSRTY#A.71JC,;;C; WPNZJG3H=E@2UQT6]9:1.F[,GB,$3JK=@Y$KHB3B^
M3!-A9*&GI%Y*39M!R: )T%IT%*<I_)X8(GZ6A\)LX,\?%^#/!P#^_'X!_BS
MG^=I9CQCJ_YEL(HH<9,AZR&9HH<V^+T6 F#]BZ8O1._1>.Q:3FL2&<*V[:9\
M;$FE\*55 A3/UZR@A^FJJX(+T9XK('GTJC1:^FLWK\1;M3E#2CH#)PT)Z2:
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MJEU]U[9A&33%46J= -M U=3D!HR42P7XB9F.0*AI"%\A7P-FQV=],SR;Y'
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MP8\I+QAO 61@:P!>G8'X,.">2V:=210T!JA_1@XP$237U;NGII(!E#(LI;J
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M5G#U[S<?[WZ_H%]4B4 KDB)(>HFRWR CG,4K<GAJ?.@&/<O;X!E?=-\U5<8
M1-T0HUVB4$7SP3E 0EX*,\5&$:QX: D\4F)>^$!@PC$2I#CAFGS'/9]CO*,*
MIH*B9U>D"1-%+A!$/ 3KC-O6O\$),.!II: )OT:BA_@/:KUN<8.R(X H7=$
MC>S=<0"&MCI=LD!6(Q)E-4,N@#$Y7JE/W79PVBQS_R[1CVQTD=VLOCYU=&+F
M6JBC!95H&WT?-1;Q#+ZJH30(D177Q3/$**GY,H.>^ZE7_G.?PSZ.M6;?N4FG
M0]M<'M/VH7DL.)>H@+]72] $"(!T5552-:'I8^41B94Y,-)_55P -DO::8]*
M55Q_5NL@!EW$&+-Y=#Y0+(2<$]H(-0/:/_]#>$1SO.LS1GAP26:NUZV6#1*Q
M07]'.PIAT6NAW/ )@JZ >M1=?W0ENN>)S@UDJ2:4MB:08^\+%ULE<+%W@(AE
MLE7V*+2D<43=_'!R>)O3MI&=2@^CP3_NN&?%X"P1=,ZW0&Q__OM\]<5GG_\V
M-XN2F+K(H(L!I4S /A2*@3!1-)0D+8(@7*I.I/D$7,5J@Q&J_$&6M4T0'V8>
MP*K(/JD><L47+C:FYQ*/9UKP^/7D8(FD.Q>^L%U-J\B/E8W4A4%B8A,*AQO3
MVXX,#11HF.K 63=-9%2@OU!*)F)T@_=P:P?[R[!(0CM7KS$6_>IE-+_6<(B.
MC.@7@1\7L,M4!5NS3I!@B4P.WJ]KPON57EW(25Q2YVJ1%S),2<W4)V,W74>+
M_&Y!BWP M,@7"UID08L\9Z?E67:*9&-=E/O:_?%/@&M\[?+[V<,0N[&*V(T7
M[XG=N #=^/Z;']PMFCLH1Y]G$<O1#P <O8 Q?*8NOQBMJ79]!5Z7/+FBQZ:C
MQ-V2/V9.VS8FG5>7D\X.L9NF#3] QC7/)E.N.=NN+4-X16$X1;S^$]*QV;QT
M[,6**C4[+SQND.R\K2E72@\J]N0I(<L;MI8F8$L+(KOBR6!L4NV+E(<(C4A+
MDIN5&I)BSXVE=-,*<PS&B<5KC$2#%DJ&2*)Y!)2$O6N[(Y)(9-H.?R31^ICG
M+!EL[J)Y4L$&'^ZB'O1#"N?)+@ )YFA=+NCG3^]*Y3)++@;C+'O.!%'M-?EM
MN28H+2)Q_^,=7"Q''_EB>T)X*/SHMBOVJD%]ZB<NF6U54I%;YHA^K-Y9XH=[
M\B)?U(U&#Q7/HL&+KB)R.]JF<B#$BF-RWBMUR34&\&)=$#K&X I45:%,1(Q3
M0 -\BZ!*;.>I'N?&\T.OFCQNP5! X2<\ELH4X& F5=A+ROB)=NW'L%D4<70U
MJ"G65;%AO) A^JI!897L#J[[/+JMY3A.AC2NM-4HR*1:T$<E%QOL,Y-[Y?WF
M5[>J-P\?+:V7Y!U$("F!B1QJJI<VR<WC0R=<HF/[!A#!%V%G-'W8G&+/= S>
M)0<STJ[J0 $$5?DDQ%;(O%)UO5,7K,GJ)DL," OLN,X9;:<1WN6K$Z!^.E*J
MP#W@RPLM4> 7PYD84^SZ)G)SNW/F_DA);S\$VK->B8:,3,'U<02@IA3",48$
MN4#M3ZM?U;\V ?"PM*L#TZ])$)@*?HLW9$(-(8@\=_*Z+\-CPG,\1?!&61AB
MOIZ2QU5U5,9<IL6%[5-LJR-E%JNR_Y+^$)Z6/"Z[]KCDY*:IE>>#5PW3,K%P
M5[\"5 \G?"?1VM&M(4M5+H]?0^YT<C7@66,.1!JZ%4*<XMVD4R1(/ 66;^I#
MC6T9;#K,GW%>)&.=B:/DFM!V\4<2=$^"[5AWMU1VW5TY<>B>(;RB\1[!4,92
MAED]\9LLGC<\TL7P?(E7N4&9)TZ6Z6LX']'\Q;1XLH\RL(J6"=329$ &'L'4
MAI:'*>M08QQC_:K:K]ORS+[ ]$:SBL**P.BC0_?2S]:5O\K+@9C)E',J!%03
M5@DQ,84[JCMK-O*AJ.]C.D"7/X1#SU:ASN!.OD-$%%QPF@_">5KT%.ZN+%8^
MO6XH1Q&\EP=^<"14S0AF?FJ<['!%2FA'.6" =8>(BAV$=JZ%-6NB5>&X8A(<
M4SF6K^E\&>7%KGY#J 1@5&QDL\<'UNKQ>0TC-N(/[E49;NM@ FS\<V-=3J1Z
M#2-=@-%U-%79Y%3-,OS434L,0#[O=+$Z.(UP44W,5SC%6@&S'%WV!UE+94*8
MFF;=ON]C8N226#?!V)8I6OZK.-^]^#-%(EYN^"25:=\Q\^5Y<0V?6-?4-9PB
M7!3#3PI.]"*O459=DN1 6GPC:/)>8073-?>+!_0TNT;UCB*H&<Z-"-4W-4VH
M9L;J@ZM>$NK6U)A8"Z3BZB]P!>'XE9"Q>4' ZXA!O#.6T"34Q2'WCLYNMN,M
MXG9YG?J@^9^>Y8PN.C2+6D:4^D.>X'V$:!2YIS!2LVZ,$M3IF5Z(7Y/E:5^G
MFN8Y[7!6E"'_^C0?,=+,%)/THU.2_#07W\-\F>Z4#-!,X8044PI^3.\ 'DP"
MJ-K#X??>^KPM,%AZ ZKD1Q*]RY)<EN1X22(>-%6//7M=@H%.;*P1L/LCD/O\
MEX+1?K^ T3X &.VW"QAM :,M^IV+W_3)V@GOZ3?1\B3;D&DWU75Z1T+$\L1F
M0>5CP?Y+LYJC-"..5/&Q^,UBHWX4:Z^>YR=3@B-1L$LL5BG%O>JQH"*7;-==
M52 %RP[/K%:(<[0LH8]C";WW!%YP7S4J!!BK8%OIXP&B=<"#"^ZS>1Y.PIP[
MH.1?%M='L;BH4'#6G#J:8?:314/PLFR*4R6LG9"4"'T:6]JL9GB%7P?Z"Q=]
M@[0IQXNLJID.PXYP4DY3,+;*!49=GF'>AM. ZA;0FUVE#&[[XF\)F%NJ]Y?E
M_W$L_YDA),UE&1V#0&#$_ K+^@@4E3<&+68>%8>6R7^*DR]EVDJ6DM(%);44
MGK\D7-YDJC'&N?6TCFF=_#PST9"<2MGBZCJN!; C22(;BK$VYA^P,ASS"[_O
M,;9;4:,+QS_X4\?HH;EQ73IL,0PCN<)EJWT46RU,SKR]9@G"]]A+=DR/545G
M-:*X+8@'8"BM<%&KHC>VA[0V<"@;L:S)CV)-UMM9JT$EOG/(D9ZZHRVSNW97
M.D(N)43IA$PF3T0[F-R:]2S+925\%"OA?:S B@'N=;BV:@KS.3YC.B/*??BD
M/W:%"DL9G:W3KP]KX3<4*ZRV%7/(O\?U:T4MS(]DPNX]>(K%.B J&:YC).S[
MLNJ>ZJK;W+54NT"'CI4E3#$!8:Z!NW8X.B,7Z@@@WE>;K@( 8E8K2-CHQ5W[
M(#13234,L,:GM0DB76D@-!.XN+;X!VS/F$2_C,U>5OM37>U4?X,BHC%R%+7.
M+;DRG%BA)4V1%0D#^17^)?UI60,?PQJ8ZP482$L)(&*98-$\6CH?G>3:?L]G
MSGLU BX)'S4)GY='3G9$;T=.!VB'BX2,=9KN?9Y#XFG!_O7@H 6J_P\4*]]1
MA5665+)5S);6;C:G3D0<F30BU:4D?=K!4E\((9Y?U[CJATB)7/9 "O^,\C5=
M&7($NKHW(<J< A!XY'64E?=A;.7DV;*5ET752Z')&6IK:K!1_5OA)YUXYH"7
MI]8F4_JD+/843.$B4!'P)2=I5^ 0S5QN2?25QV3E4A6Y5#(]T:X]LNR%8(D6
M?''?UGS)RZ+;.\;CY+Z]O+*CGNM?V@?BW&==><UHYEF2SIQ<<"Z=."95\;%Q
MOSU4QPR2N/=U2_2M'IG.6W*2S<&Z\-"(ZFT8PJ[=[2;BC3>K[_ @4(-J"V%%
MT3O6CM9(*Z^' R6VC-%892/^^C=53F']/%C=Q&K;!INLB\E0-HS:[J)ZMZ>;
MBIS.5+ER('LJ$JPI,PX_L:B[;%@>IO1E7NTKJ6)GUBI69M*83;X*J_U.R_59
MT>](C/+CW(0JO7L 3E-FX[D:5]1Q%\8:\UJ_[&U6X[]WJYH84$_U<<#2-B!F
MR[,!+1NZ8S1O\C<AR8KL<!*+FE;+NUG]GU-8\"U5YCD..B:E;4K[55I<D7F5
MBJDX/63K;68)9NLX@(7JVVD13Q$:&V$X+99IO9IL&B;E<E:M\7'UH";>*Z-%
MOMI7X>(L<53X0G6*\\LG(#NCHEJA/3 .9BOA[I+:^<O25\_R)'_&E]3+/KN^
MGTG;HJ#[B@G&NRI)#BCY/-.;]&]H\Q/3@QI2%X[*T?62Q639Y3OP\I7W<Q4S
MVYPN(Z?$A!&E,5-;2XK.L8L3^:9U9=D22Z+AF!8=L>FL<"HM9EX-W^VKJF9I
M$@IN_NW4<*X]?/>N7M=' <1F=-D@"Y</6?E8_XT_#L]HUSN+UFL>D?DR#V29
MMN=BAYM23D5++O,PX[II^D*)8-(1S:[QSQ<XK3@BRUKS(W[YPB*UD5W^6)/&
M6[BV*"*6*"WXJ&\?^>4]AZBJ=NK<#Z;17[>6F2(C8E(#R.LO39 UTDKWE/;9
MNU+:/T)H7XS?!HH18ZR\67T;-E@+XVU]>0+ _@X.H3WUY!P,O-Y0LL*(;BE<
M7JX4=GRL1!#$(R!0'R(JTF&^H*#$<',>^J&TX$BY:D+3QYMITOA$X2GE]B19
MCYHN]M#0;#!6;/%BS_5D81&#?ACT\L3UP_56R%?8F@'ME1"&[EL;( Z^J1!6
MZ&*QQK&F*DWV]O^?O6]M<MO(LOR>OX+1T1,A1T#54LGR8WJV(]22[?9$JZVP
M/.N83QL@F:Q""P38>%29_>LWSWWD P!95;)D%TO8#[-M%0EF)C)OWL>YYQ!W
M#.1T6]">DC7=VIPX[8<:7&Y9.L^7DF*D_55_74UXOR/QD)L%6PT^-ES  U[K
M.&Q.T%]R"L6+R<2)CI57AZ=N<HN,")?B">('!FY\2F1'(0LI!# E3Q",3<:J
MPPBR'WY?.*L&:M1PTTRYIZR+//4*/)T0[!B)-?5;Y8*E%9G9&^8NI%]9_/B0
MKTW**%&"_1Y64_BFN2-N4)$!$5S!WQI\$:@6F5#^%5,5U*E2PXV;3D_#S8V_
M7\Z-OQ^@\??SN?%W;OR=&W_G*_>3Q1NXX^P6\$XW)+QF<E()WM1U3,61N,N4
MXF$%Q,J6 R7Y&6UT+]X\N3)W>O%QB8=JC3-,^WZ\2JD!W^EE]J*F,A11.9J\
MBM)K/I*5,)>51>X,EH0Z)7IL(>+!1+G3O;;,1MY%>0"D101ECCI5?CUOQGNQ
M&875^JZ;,>HP!?=PC,+P:;E$H%K40C7-5?-V:+O'#'9#>+;,VV*V4?=C6T@Q
MYCVV103@B6 PPYH""/SG-WT?WO3[&P"*ZUGWE.M+^T#)0'<3>'N%HW]D"8+^
M=ETE].AW&DC@D6<*>()1J!"Q^Y^#&MY (R06,PM5C@&MPYW&<Z'ZM8SND9IY
MFV]M7-B9@:ZG/+47)9"'%Y>9D3H*.DA*N[X@U9FD?^02C"/J>:FF\:%:@Y25
M>WQ%2]U!7!Z%HJKJ2;,"N*,L I ;ZM<[CG+RP,-I3Y&<2U8)9#X'U8[CH3[6
MPB5QIJAN2S1DQ9(;Q3HBB&RM?2>*[[;Z9UTDH+*;]> %NH639%5M3D$"_4CM
M(0)<ZB!B]%'76%@)'5ZQ\:5;+W9#Q2OTFVUZ]FWY[60B\!=+\FBG3RP?-$#3
MB'MT0#SO;/$*/7*M#6!I+D4!)'"1-^O2MKH+"D!SF@+JB[0&(G:90,"B[#?)
MG+0<[VN9RJ2 ,4HCJ+AF"/7I*W:[*^N]M4$;A3='C,].,1;,'A!WYOD=AWZ7
M2,A2%'J"E@;^H$OHQ19%)"8&DOO&?"V[D23(P3N$[.^NB^\%]\+Y7C@SH:R.
M(R%;0;A4I;Y(?8[VHEC10:YPSFBO*.WT\/TKYL5#@?FR.7K7F/%=<^S^F);I
M2*NH,4YA,<0IZ&^O+5RT0X7[Y,P!I@ T:F*I:"V]P)*S$JM5W>",E?LL[F(9
MRYDZ:^RV"C;@L892$B2E6N](MC+(.JD(3#8P;QHG1R"[(;S5Z[1.@#VBMV0F
MNA(FM"NY9,XM"J1,1'T+,_+MQ*;VAL,2L\WIQA)80'3!#7CG6S>$W$LDMYU'
M497V%[W>(YM,4#D?Z98DKU3)<?7@'NJ/ 8IYH$9T 2PF W'$( . 61.LQZ,A
M9,-3IF4*L0N?85.71<T^,L#!9XMO^P8V&\\*&"-Q/:(QF  P5EG.?3#75(*M
MJE@[=GH(MVTH5] 2X9P)1P@39F+IT 1B%M-B>30*WH4S!$7+Z U127.K-3"9
MN&:\*H@X)@K2(TO"Q%O4$P^Z#;8F[I/.%XL19-'D[J*+&\7'30[0?$3 !%FD
M-H74\T/-K<5V1Z)1N&J\*B1[>KLR7]D#'5>'3=[<AG6J4^,VK)^M\0C)H)VN
M>'QRKE73IO'T#G''9R)LWNK!],R>J<<#_"RYI>0+H1SUV&.FZ$C%"G#>+F7"
M":L,3^LA G& /3N8C78.2ZIL3XGHN9?J1*?V,LK.Q$#3X?Z\10=+?4SK,B#,
MDZU]MO@)HI1Y:Y6D(3C'AO9>WG>7=0,!=FXANO;,**E>@T>VRE6JV.$D,:!Q
MH9PG<AC":6((:G*@SDQR?M*?4YJ7P[_#O4+#[UFL3L+3P>KS F7]H1_*CI@$
M4QS"DA&./@56[B!J6*RTGS,"^=)/\?%EOLOX^7U% 3.;$A2]%'YMR&2T,4]F
MW',^@"97 ;:=K$T4G21D26N[XI8JQ);ZS3$];=$:S%[(DTB';,"@A+TA6I&^
M9N8&IZ%I5.9+U#Y" F12]X.AZ8'3QW#Z)FFEDK>0$I_$E#XZK;7;HBM*9,'1
ML,<P\Y2Z(@Z@O-($%!'8N1@,;]$,N*4(FBW&6Q9C8,#10U5+WQVW2M*K&WG:
M6?J[_A=)-=!><.L%_9!SB<SXM]A5RFDEM]NZ(N?H;/%=4Y,SQMT,^OUPJ7C]
M:L2_^"$PLX;PE12(Y1VV:,=$!VCGG'?WEO8F5;,-*2N" [IO5,[AEN3Z=5,
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ML+<K/1QMU&@.TAX]')BA[TC7#4;?B>;G<R7(9Q& 1,YMR&3)ZQ\T9+>4<$<
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M@;07;5->-!FX?%X<4V']V,<;:G*_*\I<N+>%<_4V8(,ISFD!/?I^/'E=_E!
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M1UU4*1NDC;)@W[YZD2V^>?TBZO^^RR"BACIM3XA+&M)CI^K*TF8AP@-':B0
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M;O*R=/;>^0'7R3PY83=84NM>/,,9W8T6UNE 7.]^H-T(IV-U46,BNL@KY[0
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MTP_A)O4<VMCP".R43--A8#(G14@#A--.=/DKGVN8Q-GBM8O!<(%)__[@TY*
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MMR?)HG^1/1\O^J^Q7+_S?)YES\Z?/*CYG#^YX_OY@,;\_MY8\V#ND2'\J>Z
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MT-X%I+E(BXQ=W=BQR1Q1!MR=PG]4Y[W'.B;%-JS9(SXMGCDM'-,<-T?3E.#
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MU9O /<_G9<*5WK;WFXN35$%9XY?36:0FM!I<XGJN_ _<)2[C&(G\5MD5^K>
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M@UFX_KI!@<O]633WB[8\Z-H9Z6L1-N8>V&P8)Q.FPF0RO^H\F6_U"E#3Y8R
MPYJ#S4NI_=35=I@9<N>]"BFCN$!1]"@<:YA'U%O%YFP:T1U4 HM!$Z7^,1S-
MV.PERP[OH\A8T".U1ZF-6A3[63^EPF30P**N!?@A_.*_CN+89V.KDI+:QDL4
M$554P+,92-%5EMJ2UO*ZDL45PBRM R^-8%7P CI@5IZ#HU$GPUG9"K7S-\&G
M->"H)Y,)&>ZF%-C\^C%#J&WNO[6 (YC]A]?/=X[WGJ!(C7^ET3YA(B]D(FQQ
MO%9S.U'BZ?"+&J^8:216. *B?PYX@A<68LN0AN%:L%2X-W4:DX_JPFAAP625
M:6.2DK2G9@2#A.&Z:<9GL#B2@H0U3A.2R71@OJQPI> +[[7B"VL-8!BIVFOB
M8T%.YH>+2 ,H5(3H2=I:QRB9Q.$<"Y@MP1X<VK'%)=.R"/@_XE+#$G%==#D"
M;(CX;*12&0/6@$C%BB%.P2*VIC<<94 8XH&BB<+!VO7/7!:SV*T6]HQX*8)"
M$FU,8F289HEL%,ES;,E[-:<3SX_'8SHQ5A6\3G,@7L2!]E3X?><T%/Z_3]^>
M^!]BZ(?_ ,G3[/\I'\5  ZR!))HV;3W1G$M=W*DYVA_I%5A,(RYUQ]1>D!4S
M]G]3DXE*'#0E0[*GOUO;:#KN(K%& H$J!^8C3)30[-5[S6/.Y%%4I]6G4VMG
M$(-C8MH$!=YO8"6,Y40S8#3#>!$O[H1E,<.$DE:0E!J@1AW\PQ$,*(8% $A;
M9;M%B]!G(6] I0NXD$Q=&VBH$;588 8FFW6Y@Y1<0]DU(&0 24[3<5Y;V:JR
MD<9^]T+L"P/+8,2I[%(@SYQ@3#K>HQD=*@9(8!RN]NI',](*Y!:--&PB\LJX
M# )L8(( D< #_9:6]'3FG0++ _$"Q\ZIIJ.'8@">A &876E W_V2I!>Q GA(
M*R)L+K:H8_BHK-WP\>["\.G6W<63_N[B%NXN#ON[B_[NXH'=7>CLVI7,6N?:
M0AXQR;??<V]AAHARMX-'4.L>LCZL<TFW0SSX6[PD(XZTD@W2P#+S+4*LC4,U
MX1YJ\19-HG<1-FALBV.WMP\I5?S?I<J+*EJD >PRB1;:HF<']X7,D'*Q( =)
M,'?F%DG>D_N"KS[9-VGS-:?) 8=0'+B/LS C7R'Q7R8J(VUY(J&5W'_[42*Q
MC!STI+XME7O$4>4=AXK*FI6V#< NJ;<"F409$!0K]-+_(2/L:Q.F1"-"K<5X
M14S30ON=F;X$]%<>#1BE"7'#"LRL=GVP8:L#5EBQ=D!89O_S5H_F0F.U4,@V
M/AN%=MG))6%<)]O[@/T%#8A?,K*3AA^JA98T@@U'RB,@/UE;%+V3)(C''C/]
MKCA@1 _,&;15EIT7 5BL?HC+DE"''L7M1"<-('W1.RHA0:+ M>[V#A604>O@
M.ZMX<2=V9)G/&5*CFDC,C]Z?G"'(:Y<+ ?L9 PB22SLLH[CP.:>*K.NR* "%
M&S/6,-!I<XNSQE]^H19A5A@S^X6:P-)'G"_S_X"?:!QEN0\;LW'*< )X? J?
M,L'+.Q/N".(UNM.X,D!;F+8U19W[+RPZJ%T_1A006!S3HH?H3_3>Z@F:-A=Y
M3E8_ATS%+A ,28'J302QN6H_TPB"RB*?M9%E@XIG#K+NB;/]$G!VM_^E)M]T
MK?%6@4W>Q.0,I1K*BK@"F+J&'=HZ7ZP$*S5YUB%H"TIJ)YF\HBP-QY[>,MX@
M%[;-@#$UNY]4#@"@6$-V@*$DOZBB)FAT:-4\$AA@4I\V K/@?9-C9M[V^GCI
M%A(M)HGDZCMY^B94RC]P G\#-?@:S4X,A#U?J;(Y0KZU'6JE\97A9D]R$8S^
M<*T&A\_9ZS7 H>:^?S5$:3U]B12MB8L:J&IK4@!][ WG$OR&)3$VA0F_21>F
MW$U$P& )P%JG%5@K\!:1)9".ESN,D$A"Z<]R&J*/"RRR.6P4-&0KT()+1+2^
MP#.]L'8]JW4=>NQ".MAR8SJ'N0WNU&[-+D^AJ!ISX?ONZEG=G /$<8WY$%2K
M]Z*14-*&X6]E5@TMTB#)!1(,%_!#+2A):O*5<649.8MBXL<R?6=EJKBQC09=
MX_(X9+#=_UW.ZUV>'I%49-&8<*9%F*23R#SX./ JL=BR.J^AW.BC;L!Y_9*]
MY: ;#65OAYOCZ4"W&59;;H)GWS8LK8E9@+-1K#)!5PSG: &68N]SYV"N)#?I
MK)37<H%'2JGJ#Z6G<I:.#.;?"=E-I&3,(Y[$04U,/O?_;S@G%_?EN-3@<2>F
M&=:IN44UEQ>N='E'6AX>AHD;GQB& #M]4N:\04=6W:[,A$S\SF-E3MS@)B"\
M'(GZSM="VP-J;S0K28L6-;5MGW]!4H\^\UL6CDNV=E?@[U=5/-RM_T00\E%8
MU_&::KO&;IRNKJ>OV[MI?:S.ZY7NO;>.D=(6*6NI&L;P7[G8Y7O\?ON^@]#?
M?@VD.\TY7>C<)I>K3&5LQY9,2*U/3VVJF*M1_3-V1VS@^M'9;Z\_/]9I23H[
MQJ/_/:C[@BSW!3LR*Q)QH3YDD!^UEG+B:UN@?-C_D'O 'S4>J D)V$_N'>O$
MA4&U9/IF@4%XIU6Z1&L'->>^J?#?E_^1IH9&\ZXTU*S:]<WATVB1HA*@KM8!
MW1DO?('K'KQC>A0 R TXVMR*X"2O>]SF\T;SPS.L:3>Y[H"FJG6B@4,GA%K5
M#(1DOFY@$@*R:\HL7<R6N5Q=2-> &C%6'S>IJ#@1,8XJA;"U.0MYI>62]M8.
MS+.6OYXM6+";-"7+>U[%>PCC9+@.O22<1?H])"<*><&I=;>OE8/%RG8!_VZ8
MHJ-3&"_M "](J9 >^?!)ED:0](G[:+S/M<M]VS'II>W[T^H!5NK!+J"]B8(F
M>RD7?-@2=CZM2I7H >U-[ME[OC7*K5T%Z<^UJ*#U F'9."%.]X_>Y]M"O,Y7
M_*KW20E?XA!V$:VSDZH?.8[<U=5/4E\&0;I#M1':-(>3IEUK1P3UK=_OZ<A4
MZ3R>]5HX&[(_-YLA^@\R4$/TV:UEF)BM&$IB*J(;6<2I41KTW19B7J19/-XA
MFX&<>&4;)^5%7LLX*JJ,)W/)@Q25G)-/$:G)O+576M+UX$$<Q[M'N_U62-O6
M.O'OP330-.WM[A]%R;;6EM>(W !'/#M^\NR62+]C6D_CL!QKU+NWY0C9L:HH
M(H&^TSWP;@U=XY99KT/@!CVIZTG='I;Z8;>D._+J;)=)^SRCIW/_-,SFR/11
M<2^P.L9R'29U>UCJA]V2[@BL?X6%8N(^E<,(V5J]A.K$OG6:U.UAJ1]V2[HC
MH5X"KF2HBAE3>#9;A+$VI[:3I?JC_T!([5EJ.TGMCNAZKZ*8B7L^2R_($_QR
MF7GU\, <+Z^?>]K7S]U"_=Q17S_7U\^96\S--+>\@^O7YZ:F^"ZZBVZ;6-S^
M.\,/9>:U9$A5"8'(ON/+56XJ_]7)[_'I70-3,-)-1Z-DY"1;ZRR]7)>9Y>7P
M3Q2,:8"B#$EK/"Z*=)1@8R%9(E><F*AS)A:9T@W<<P;2H[=5C&$L)8)(44&,
M.5D6ZS,M9^1;^$,T$_]*0TMB%2T5$A?Y?TD%*9K^$#D=N:YP,W?1\_#/--.Y
M5_AWD:*VIB) P!1HE<<ND1<SA21MI'XD*:>*94BPHL7E69^'*!C02 85=I?7
M-ABR2W;]E^%HMII98K+HB'.RN:\27591E37HGK!SI0K=5!T#\.+JC7 NV_.2
MOF$&M^G@O &\()D?+A9IE!0Z^[_:XM8W&;LAHD48J["8!2A/T'EEDO468+6)
MUT,S>J;FZ7D8/X2K^*TG^F.9Y>B]#JB6](JSO7*:Y9@B$P/(1\VC[5_G: ?\
M2*(N(';(4BG4V'-97HIUB$'*N-")_F%B2D!L]GRK',B<([:\1"R,&+H4YQZ2
M(8ZY&I@+ ,,)2G1#SM<Z3V5%PBLE034R_0I:=:Y7P!6J?C0A%<M .$#O\?\J
MTZR<,RH;R9V091!.0,B5,5X-08XHA11QZ=1X=M4YWO5?E1GDC*SLE65> ("A
M7[")66OB[#Q<>F9Y^&1"='*I4XDT&YTQ:Y90"&I;./S=Y8P"2<0D!X^/_YF7
MBU_W_XX.)_0?/V/%Z"7.&4\O+/$>S[(7"AL@^M^HW^<*$_)'4"(LE7D*A;MJ
M?(6,6,-GJ+>+8!D@]YGE!PIS1S&*@*$HD<955VBLBHIP.E49EP_3\SLH@& E
M]R 2M;:>Z#_H8'ML#8ZE-MK8,]5.<5I?O15"X-?T.^K5BB*+AB4J)U$:\86D
M%RRX\(M*)'W_@B0#O0<[+V%/M)V+H*5R&C2?++GDOZJ#6*F5  (7PXG'2'3W
M8U,MP0/;XBZ@#W"=>9FI8%WI@,!9HP EHN5'[C40+V&("0!'5=%M^_?HE'H7
MJXWT'BPHJ6K$EUQ8"[*)Z!NY_*BTC<>06H8* _X4)7R,:($]VYA"Y5S<CP3&
MF1\.:55J50&L0NL&H[;2&4!N0?^@J>$TS\G8;X#,885XOZHD2ZW]P2B,8D"6
M&XK)&XO;'] ->-;&H?;>D)A>0%;3IFTHJ5G_,<)'B[O(P7P D$%K7&T4]HT5
M]%@DT!A !(UC;:WEZ\TULB&_CA21_I'>]C]HH?!: =R"Q&P&J6(8H:B)L,Q;
ME*2E<V5Q'0'GR_]XSUC+MD+W[.4IHP9JJ-]B%E7$7J[CC:;0:!_UP@B>)$2;
MU]HBA]>$K8#25HY+A;,_"0UVX"C*1N6<C *N0+1RK864L5)S-;8RRP6_8"FO
M$D7Z"7CZR"@75T.O.LK<@'[*D0<R:%D<M]+<B[B-E [4%9G P\PM2BWXPH!
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MXRS:T]C@<^A5.]4Z@7;:,SNM(3D:"_JXE]>;O.9;-3H=P[#%AJO+DE!#%ZU
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MX/CI,^XQ<7,"]YL$>I9 0:ZSY_:29AQO[,&4@OF0Q@'6(GU@GYW?*^AJ+A-
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MYZ&$S"8:W_5!#@Z?[&_))A\&>W>WRS^&@.L QVV;F#M"QM664'/_8L[T[>O
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M3;5*KEDA6?OTT&M !>X0VY"^;HQG>TS-?3XWP\DGG0U]>H.U"(>#H"Y!4R'
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ML'>TES9 8HS("U@GG63X?Y'#_5>H1?FB)KFM7VG3-V-U;_0N?C[W2>_UR,K
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M8Q!WL,<0PI(C%Y5D+K'X&42&0$"I@P!?H"-_X$<#Z3TF)UG8^L3(G;:[08.
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M KR*)N*<-B%<'PP6R<\0J86Z!$@!(O_2V1%I!D1W8.<F>^"Y3$/P<T75Q$*
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M!K:+"@V\"J10[UJBHI4,))JZ1H1(-$W;(*\6N[J-'S% ^!L&%VK^0>Y[!D)
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M4; J5K#VFJP+5*D3O\M$*UO,&QR@84SIJN@260LUZU='O?V-?M7/K[N9&=0
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MB6R0N,;,,L9*=&2[DE82J8Y=/EZR([Q ,8%D1U01[MBR4+G0U&YCL')@M:S
M:_UT1]35_!J=GS7N7MJC[\M7DW["(UL97BGM&#7ED>E26I6=_5:[W&S%-X,)
M93R6E6!-JZ:LIV5@?O=;?ZO?*F=?SA><RRW1SO#"X5#M3&]!RNBH]>73^/SP
M1,U![B.^5$-L"9+]I!NRB;1X8IU*4G)#:Q%V]C7]524_H.E!H9,?]36S-X')
MC_ #QS4+/ Z# >1K[=94CA33NEZE9V5V!1[A)UGI%GB$L$U7?[](_%WUO+G
M,<IA@4?(<D8_M$OS;ZTR'$>\3)-M@4<@U4EF"EHQ,^D)%'BDOZ9:*MF/9>Y/
MT@4>(1(K?_MV(8D_?A\9"W)V$7(?RVX[)%W@$;*<SF^U:YWUY*,?RR^A;*#
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M)5 >ZZ#L-4C,:E!>*R"4APW%KGV3U9]6[>JOR* \TP:=[=K.?JW,-_ER+>;
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MP<_*[BYG,DU_3E]Y%MEE!=;Q/Z1ZND'#X#+\_W9R._AONK2.^'?X'507&.K
MH4L1/_VCO.B:VX/=Y?Z*V>Z$9 "]A3A=D<"_["9"K]O9/]Z5CTX<VC_*W7!
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MU?]=26R \,1P?%]](M!V#S_(?P"?ZT&U,8!$Q99%%2R!R)+5"<+ZT*[E8*J
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M@@]_GE(<.".?QX3_'MC0+*X\0&FB"<JS;6G#K6)XNV( 9_9.?9T4?:K4Q^&
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MA5!*Z>/$9BH08+7T=?PR<-PJVRN!$KM^WP*R@64X.-B7KKB#X8JQ4;U-R8;
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M=:V4I^I>/,ZQ0\RE/L1Q-3AH5KR3LQ_$:2_]$&-TZ$*/L+"S7TAQAEE*\,Y
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M^$X?=X2>A>Z$8$P27H:@)KRV'-!9J.X#VX491P-#9WZ-:2GH*Q&-(Z\PG.E
M27.*#6LVU&J<AOGZVI9J:\RSH(]P+1N@V5"7>P;H6R8H$6UM8%A#0G#N10!9
M-;<</.+/.Z!^9E=WKPW53)2(HZ/;N\LO!YW3SGT0%!,/H,H=GZ ,Z"/>1,DQ
M2UHHDL-4@H4A).5\ME">8'BC @JL9&S(XT#C#,9D(LA(9(LPHP/7<0"8^T F
MU"-&PXAR)T"J3P+/*'[/J??]@GE3J44&AC$$_X[TN&GW,NNZUH&P482T>Z66
MJJ5)( V)F$<$O\@A?B .A0DR?6CN@=O3;6T7_)*A- .!V[S"L). F.A?Q#L^
M:GO)#+"U]2UL[8)A:XM;V-HM;.W'R &>FAD9$SR:U^LS]P^,HR:01E?O\"EX
MIZ8<7G"E ,%$CX!G&;^;H-<6%AJ8U(TYNM"O&YTKK9]3"PM,>L5O9(9D2.QJ
M%V8\ 0#6M,C S*@EBA0GF 0\MNRL5\)%=V^>&_KY<UL]ZVY2UFNY%PW81[5\
MME).M,4R@8$<2C]-Q,"]9FD6<0VGW)QJ6H[K3+"#%WB;U=/[:_7RJYK_219U
MFQ/V-&.@YNTWF];.+@$CYY.=H(RPM./R=8F,W,-QU?&I*D7M4BV>-GH/B38_
MJ\?C:8&PH![*[CWSZ^6_+6ZM<5C.Y=D2:DN52;G?#T?ZMU%Q^&N"\DG8FS^Q
M>0&9M;7(JX19U<7RSGYEKYHX3E(>5>UX[4>>^54U,(KZ&'4"FN#Q(LPU<PS]
M%]TP0(=;D(#O8':$9Y-8+BE$G^A<0K4@QT.F-'1Z?97!.51L05D%A_%U$6E?
MCY_KV. F$KS^AC@N9M$FV4H?U2-]ISNA!K  D>>0.I9"Z=] HAO/@&(Y@AS_
ME%.BNM/Q'#[J'JI1E7P^K3V=&;>G/P=Y64:KE#JSRB&&)I5SW0'JQX3O+<\.
MRF^:(<O\5OD95Y"0RV-0[.K']7FI46GW BBQ\UA9M^3: :K&%QX 2U\7D(F7
M[UF 7.^K3R3FLA*588*J\*M+IMUYYI:I'*RS^8P%-;8%931\F.BL=):2QE P
M Z8_&%P&7088H*;%T#@TLI6,\3O9M5DWKUQB/JGF?&TB-!'*<B$!A#D*#!AV
MWNA+Z;ME=;Y\^:.JZZH+X"AU"W/XJCO[^:FEPY)K+]L\,/.W8Q/5X<,*_ RH
M5-V14A#Q%W@#)0:-K##OA2W0\K[37XU!/G=P7\ZO^>I7&@^H06]4.NK@(YXG
M<=[14B]28,'Q<[DR2?Q5FC^;W\Z_#[_6K/CJGM7=)(=VF[S@A=UE/?U=Q@3Q
M=O/)VI@:L=,LB0D6)-@T4R'D8CS\Y!7-[.-7YO?QYR?0?(*/?S#L]%^-LG>R
M>2Y^/.'&;F21+GXI!PTN>Y-Z,7P?/[-R'U^)^/B9K8__H7U\5MV2F5+3&#%=
M;55WIE60)%30H"LJE;<E#JY9H+E3O^O<U)Y*%S]Z@8YD/! N[!S@"K.L9!^Z
M_E_8!Z8BJ*;:ZU04U36%T4MY&&E7*4QWUGT@A"X!DA(=-2IE_ ?/8 *\>1P,
M4D-=.@F-=\8:R"62R)^ZUKS_=M*L_^BE(A%A);Z91M+41BZ32*9:6J7"SGZM
MGLL6\]/*J#/IDZ7L4+.)@J2RD8)$^I37=G1-5^TA!'[BGW2-,_;(M:%V\*6"
MU+Z-^A<W]EVN+#40O6=IY'\F?L,+%E9%=/&+A11#P ![&;KJ8%%0]-F1PM23
MO/*-D4J+H3?GJGI0?/KUY<7K?A#1MAB*FR[YH',Z6ZE1'[-66MBL E_VL=;/
M>/F76[7\2QEN6 Q%OCS\,)T3B]0.WX$]EBJLL5H9B$-V\O7D^1ESB<#&BD7@
M2DGNLGU;O2B_'!P<O O[;H5$-UT,5L  S%9K<9A241DX/9P% ;(HZ5672GH,
MCP=\5\N$&J<(R?Q0;5L-*"5_,_C]DGN^_=UX%Y0B:""TBX5=?95;6\E7_\+>
M*^K,MM&=!>SDU%2N.JX5.\HHHTH!-UL$W""'V D'W?10#A$E/H:M7?[W0V*H
M+]"$@X.O1>9K/%]5FA.D* =5#H/;7Q7CO)O_>E%;.TA1;H$-6*4:,,9TE")1
M@^G*VY/<Y;B.8P 9X ..QNS"P_B<T[5J7]EXL\S&H0(%%PTW(MU&_:AVJ3>.
MS,.'I#9?>#4TT3.J8HM('8=/L:"%WTU2C+V^LP\A]EPN67))E724E+Q.+/77
MYDCRX6$OKC_W\NO5^5#M_#HL/*TO68LWM,*6W'(.QH*]B;\F=?4#H6<2>*PT
M.X\MZ^KM/[U?Q=>O!^5VTM7[LF+)S+FLJT_@WW)^)O[%UN/$1'UR/G31;,SL
M]69\B+GV9>0\?3TO_+XL;80NC$1:8E>],'86/3?IPRC-J.<P43$F0RDNBV\G
MWO5K\>KWK_9E[_KP(?FN4_-NN@VMY:Z3^+<X _^&ZB&:T7I,A$=S%(>8O)%B
M#!-M$E[:HR>^)M5L-,9)B__E(-9=%7_<S8_]>5X<M?@=!_5CAL$ B4R+VX@,
M-\X)4.)47HP:!X09"N4$L9)K6^^LAOY?[G/D3#VH#$X> R>:E\@*ZH?%I#<N
MD[:Q450/ >/B1(/EF0'+BUTG%&'L32SS#$\8D)#'H37[JLO"';>DXP%NEKA?
M/TB"GL ?_:GRS;K/'>9T_W[@L=03%,\5E2-\3J!#/<1!"*%A(@@V/7\1IF"V
M_:0A"5.V( -?UZ&V?"+S<.PP! DS&'Z)#X:8S<Q<3'7PAF*J17.5VQB]?'5>
MS^K%ITVLIEH/ST$PO):NFBJI8ZJO#K$ WP?7R_^=CT'04ZS!.'Y>!@NKPLX%
MB.2$ZBJLT-*[K,J*7UQ\P1:L8>S9>V. ]-MPVP;MI&$X%B6(Y.B=TM4-C-TI
ML6&\MX3P^GVBZ?0/@%G9[5(JSZ@3 ;*1'T-# FX(C($FS)$ !*FH) OT1V/T
MS>V>/%[?O0:MF_SK,@15:EU1G* K4BPT+!&HALCO4@FS6Z(G.[:F! [:4QH&
MQTMBX,&^BE;[;'PS*X"D#SO63=7LZ*JA^!+=D>$C4;+ $%U(OMG$M2T5 ;0!
MN$=W,I$F.G990JC$+/C#AM27-UOC^.#\Y&]4%I S[-@Z"FZ_4S%VI$8=TJJA
MD1K-%O%SE-.?U1I]5T_4YMGE2?[A_8[2J*UNE$:5NLD_'L[ROW\TS?SCSCZ#
M!),/.>@MW0[*V-2=7)F92^N9%0OG"U@L'&GL1> C@5BL*NR:KSV[TU-E4'6F
MWP*,=YB18MF.CXPF<'Y95]68G5Y/ -*Y QP\@+&XLT[%,\,-N7GZ?P7)!&<N
M2 /2F@^XLDBY JQ?+-]?O0^V6[Z^+MA/W>*HZ"M&_[VXAZGIX6FKC[6^\[MY
M^I^"7S@P89&++48I5_U,V/1FWRA*]2>X6-%!\T"7^0"6S;G>UUU>/O"9 V*J
M/IGH.*<>0B+P+S2S0UV5G9Y.$"9:509>VZ":Q&!]NFA1N4XF9$\K%X O39G$
M[OL(Y-*[3(380J#+/ET4_K)+2!RP[V&@+9K^AX\)!"H ^TM]\'U#;=#RZ-V0
MQ5/?@5WH/E3SW9^E4BA?(*U\X"\GB0Y1>29L846TAYX?)[[=@D1]<&QA\@/,
MWB3"^TO<:(2V?&161]$\C+$9*L"ZN#UZHX"I#IT0&0;U$J$A@ $'_XU^1[/5
M%\UZ@8$*8(*K3\1DKE^7VGJ[V$P1*8X08<A N$60&2,O<RT8H,'D9">FI\_O
M1ROY.V6PGP3-9)"X!'P+)]J9SE\+\.V\Q_4S_B(2DQ/(\6)Y^)$(3]G0J0]_
M^.-9KLY1^,>D<XH"G\1Z1LXAB^85M5/]VOA:[G3=QS J*;\M1Z'GIP..O-BS
MZ&M87O4AYZ2URO/ZSGXUI3SG@34?2Y@17] Y/4:&G[H>A#@TW4 49$;3O$OS
M\WC04Q*IA\2W"J^ZR=9X;$G8Z%YW:A5U^*O^Y4&*=@9FIH"YQN$!_F]]-9#.
MBXUQ321YFG+]H:NHY%BH4W MA*EL -1T7)A1P,4/PD\(XRA.2D2%#OW",V$V
M52"I0 $R%I>5;:9K&8;U(D#O([SOL?D/\%4^(8,^R=")S=(;S&\6<B.0EGP+
M8!$Z"J"X2",C7%N%?(GR;!E>G_C3&J)-AW';]#=5S.UJ]*18?1Z$0#M$$SL(
M#@W;NV-$GBZ)U7K.EZO4N[>I_LM$/\[?2@6E0R^;OW1/:2CYOU#=]@$?ODW_
MH.HQXE^/#$%R %4V4K6+5RLU92JV"FFD#"HK@$XVB#O!W!%P]8F!PZ6[(!N#
M]EO,;=%^%XSV6]JB_6[1?E<2R%AHG&O%(WZA_[U/[M37*5-]Z]5H"%+./DYZ
M2FO4.+[.'Y1Z@T.M]'ZCC_65#O*]:IZVR_G"Z3-1H>8:3E>AQTN<#QUM5#C9
M+V&2=:='- _*-(XPIT&-2Y]F;Z@I<T/H6SJZH6,^ZPYD7SP;U$IA-JC+4#MO
M>4MK=#%4'[_4OI4/7ZI+F4>^_!1CQ@YM4!BH.J-?5WWUYYR <8A^EN<(^[=+
M %#.P )OCYJ@0_E[-IB;W$:-6MQ$G#7_0L;_ O@+$*4%1\'Y>T'Z0-.=@:'2
MXZ$D2MY\[CXA'<!$^N&%V3WZ=G;?(SO[@I@@,NF3DQ+( @4HZB.$Z>/N92:;
M*OUNTUE?.V#P2/96Y,:CYA?3.?3AU"1_L*ECJ<$++/MOQ7YH?RKD2ME"L98M
ME,N?=[@E-<DP"]MBJ3\YQX,%Z97JC59<:.+;X_"Z;#<[HZN=A2]W11L[;L4-
M_3&.?N0/CNY_GM^5EK S,)\S$ZQU1BZ32<$W+..7@"ST0AC(9)NZY?\HG$U\
M PA=P_B#I,0)K/9_.Y6H5S+!NXQY9=Q!_"*J[2A'8T ]T1W$+C?F+3%'&V+-
MS3W<PN(/%UAS,0?Y3G9;6#C9^*(AY+ZDL=8:[C$S4&Z%?1+Z<$N_Y DTG6?0
M^NKI'14VO<'Q0:%]-;1_JSN3J78^#<+U5J7T5X)O>CQF5]EH.(1/EC^F\-=$
MX2N4Y%]Q\89X A-?B:X/:\9W]C]-F:GV]IN9U*P<=B 6G/^KY"D1Y_?B<A7Q
M1Q1[JI__^I=?U9LF%::[J,(B+RI6VA2#=%&:<[HF=(, "'#JDKXC,O-<HN0O
M+@:WQFFI;<PC47[T='K0Z12DOPQ%AW6(XTAKGDVBM1CZFI#RG_W,UL?UQ9W]
M^EY<WC_Y .(.ZMT>\@KXM00=7'&#DV8YXE@^;<[(I]#Q!#;O)7&O!HB';SZ<
M6XYSR#L+Z+<:.-Q=M@\X'WOETN/!LUDY?*TLQ3*(9>D[VR/0\H6]6BR_BL")
M8O&*05</PU-8_3^$4G Z_;+)4HXF[#JDLZN_[O9T32/T,_1J"OIKVS9R=<@[
M8^"G$ 0,-H*O$I1C>L9*34GK8CJ<_A/7,CGM_#]/X+?&C%;XI06NI=?!AJPC
M-J V?L@N5"9&%*=^KW;^_*R4?U9K2U:<,#\K6"<O!I!G":]%RL]BJ<UVT.O3
MMM!0L1<WDFHCI,)&W,,*9$,56ZJ7H9"/9A005U" TO ;Z**V<_WJY^6 7%]9
M/^<1 7/J7%R3PD8X+MV(3JM(*QNJ2-_.,E$26!=3  [37GT93%&:D2F:2'JG
MYI@M<2^FLC<@109#GB+\TBN?#DK5L[;W8"Q5929&'=G2H>PLF""OBL6F"@].
MC)),CU:F)>79GK0P8I_A:M>GI.O0AY'")TX([Z:]@NWUSWS]RQ>#51@I4MJ+
M RF>\_(GQ=DJ4R5C$QMT//HF[F99)G7.[WRYYZ+<.VDTKT\:OVT M%V1G3 N
M @N,?K'1:MII%>:C=?R:HED>M2[?2.S)CWH#M<?=UMKD6#6?SLR-O9L)E+R]
MU:1;78%X*BSG3H5TXG6T,;6<4A%9H]@::0??C,MA.:=5>TNI_EIVQ<XR:_;&
MM%O#U,YUM4VUH*L3)[%<KY*KU2/E>K78<KW_W]Z[-B6.M '#W_D5>:UGW]JM
M0A?"^=Y]K$($!P>%43S-%RJ0 -&08!)0^/5/7]V=\Q%($%WOJGMG1I-.]]77
M^;C1!P;KW_>KVZYT/=<N1Y\S4Z\_%:#6E#:==I7@F8EUX!CV>H))3:$MK^[
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MXG4B2)4106?/;"U&5M$W*]KU M/A2 5PY++E!!WP83PIP(=+X' MZ.[ $>5
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MQ^75LK%;J_^(#W/UZQB#;WS]>ZVNY$GE8G9N-:XTUL(28E.N%[*/>#PN63T
MK7=:8&/<BUNTP=E].E9L*=[V)MK$7]<WL_>+O#Z>?HNV -%68..(ME! P3A<
M/C-<.50O).!LHZ3!]7G&T5G I)^@1+H(3L6Y33/T:FH<2"##"<0-E:5 ##9?
MMO_&:1E3-!#1QDTX4:8C'V&\)77^65=BM&3#XJ9N-6P#+G,,DZ;)O%[;K&'_
M9<#]:QI9_$GF?*'2^=P;3%%6.1& Y()VU P5.\;%C %ZNF7=M<8W<VXX+K_8
M>)_CNO]4S:71COXB5VA*+A[B=9'64[Q]?DRKK0+DN96SQ7PUAN!RX3\9>1$L
MG&J[""=R0?Q/\?E7\<?/B]</E4TIPA_BJ]D"&]BT*V."GS E*/8Q,-0EL4X8
M4I&@,4:L7<!U"@8[\^4>G*-_,7H6>TKQV'$Z;=OT1&BV#B'&K$=5\)UF58FC
M=OK,'4U>')Y?/#^\+Z_D1YVU#=KV B))?=/1K"E"G.T\P;-<* 5,\"3DZW_K
M>+116(J%3=/Q/7J/O-M7;-?AN-<T+_5&;,[+6GFN/-3"+A6$JW%&;%99O%L,
MMC PI]CDS E@P>Y\I(SX>#&_N9;[7QO,GGXBH97;![V29V#.8H9)D::A:+IV
M.T5\%^N&ADCR3RZLNI,+[46'.WYHL![61FRCWKV[>_[$^8;L_O(-"X/U2ZU[
M<?.^; Q7DZ-3#-QCHN+;+^"CTPV_3!0LT8/X5>SX9"IRO#E9U)B1E7-/?M/
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M,):)M0''>3\I"D$+KFPN#A+-*04"#@&BC!R PG@28-_9Q2RUQ1XXN#&]J]Z
M&F[:+*9QWN"@K>W9BCZGT0>U@=@V'<('ADS]64V9%&KGM1KOTT/FC1XDBDOM
M"!_?7AK[QKUHDZYT=)K/LK5:ME(M!&*> 3)@7W.Z(8QUV+\#5ATU_,#VD5TM
M4'S-H$A$=/0E,7]I0C=_P.AW]]Q0\E.E?%4K><='8)!LA7I1$#E A N(>53+
MB-7E3TJ!08\,L#",2'.16NRFR>\PI<T+,Z"!3#$"#EN3--Q-&:$+/SI$;+EL
MW5;N;[A?PVM;YW%RFNB4K51OV4CL>D,:AR;([MA*%,B=5UXY.AV+2R&#H^%!
M:7?8Z/13?:AA*Z@"9#I-L=Z/>!$\*LI+0<-N&9&H3?A\C'% QCPA@]W(VD@5
MA\2K=ZWH0J::<"#-\OGOV]G?EIF6,%1M+F>[9:,I$BB-NJ(CX]Z'F-BX<WC0
MOO&O-$I,K.GS9=E:4CZFW?V]]>E9[_SFY_+ZE]5'CAP @R+2C1L+!$&:)FLZ
M<-EC!)0X/J7].' A^:#((GGOUUB+L%XJR4&W]$CM0C22X#"ZA2-SWK0\#A11
MSEY^7&J_]>?17=D/4;(Q\Q3B0./ T"47SRZ!F6K9&NM7IN8V;J>JLIA,P[FP
MAP4SP()]\P%L(?E\=;#NL>-UY;7YJWA;VS5O+N48;^;?_^_XF&F)@L3_C^EQ
M$^$?]#;<T@C>*A3_H<U3M/\Q'4[3F>-CFL7)B\OX1>BNU( R#KIOU)LDNN-(
M/I?[PR^V'UPQI"MSOS+%T!X5CL\=G;:.[? S(/</ T3]/Z:N<D-Q] ]SC0B0
M0/=: 0CFJ_:W_C9>@U]9B9I&EN:_?R-04Z#;WX+E\'4DH0DDF$OAP*XD__?O
MWT.%7YVB/Z?Z3#K]?U!+ P04    "  MB5U8,!6K-80I  !/.   $    &9O
M<FTQ,"UK7S P,2YJ<&?M>P=0E,NV[B H:9.1H 05D(SD#(.RR1*&S! E#CD*
M"L(@J.@0AHP2)><D64%$,@@(#&E(DN. 9$G#&V ;]KG[U#OOG?U.U;MUA^JJ
MO[I7^-;J[M5K_?US,GSR!4"J+*\D#\#"P@*88?X )Z, 60 !+BX^[B4"?#Q\
M0D*"WTAH24F(B4D8J*C):9FOW61ANL9T@XU;C)>-0YCS!A/_[_S"$E(R,C(W
M>>55Y*25Q8 R4J="L @)"4F(2.A)2>FEV)G8I?Z/?R<? &1X6$H79+"Q;@ N
MD&%ADV&=- $8 0"LBUAG/\ ?/ZP+V#@7+^'BX1,08@@J2 $7L+"Q+^!@7[R(
M@X,9]<6, W#(+I)?Y[M]B0)T#_>&*R7_XXA4/*8[I0V7-7N_,@N8NP7@$U!1
MT]!>8;G)RL;.(2@D+"(J)B[[NYR\@J*2LI:VCJZ>O@'8PM+*V@9B:^?N<=_3
MZ\%#[\ G3Y\%/7\!BXR*CHF->_DJ/BT](S,K.R<W[TU9>45E577-VX^-3<TM
MK6WM'7W]B('!H>$1Y-3TS.S<_,+BTO+&YM;VSN[>M_V#4[NP -A8WW]_:1<9
MQJX+.#C8.+BG=F%=\#HE(,.Y>)WO$OEM$.X]5XH;_(_Q*.]$I)8VX#,):'Z]
M;.[62T#%+#C%LG%JVIEE_YIA ?]7EOTP[*==2,!OV%B8R<,F P !NW9L:?X$
M_^EF1I/=#\'"9U3WOD0BQ@@RDJ]_R+U;Z(X3V4Z?F</X+K3$* 6L>FG3GL@$
MB3<7@7*J(N&137KB?:4_5G*B)V&B C7K[F.[>:AFZK9;_VK,1K BI6"9),LV
MRBC#:MR%TH*)=;#,L(FBD=G^!B=ZQR*<V;':2J!_,-JV0WDQ=^@)2T?W<U\(
MRH"IR9.K#5MI2V'>YM['8BEUIQCF*Y]$+$@+$@;\+3VNERC@,D1GTLH9ITWI
M4CPJM0[/S O8$?=_R.A%MY#%)I)'0T=:+8;CGBQZ;,_S8$]X-L()5KB+6*K8
ML[GJN:5JN-C#Q$SG"'![T$6WL4874J6B$[M#^]&_*2*J5;U0/T]5ZDF_8; <
MI18I2"D^S/!Y*FVLW.WE5LJ+JRIR?"Q*E((.M.KWQ2A78<)8D(RVG-EJ&-?#
MR!LV6?/8@A?;(5E<L)4:?5ZIABX)E]<7TZ)<<D+'+LPY?@I>X%_#3W9=D3&*
MAZE^#($!P.RIC[/:)5W\K>[+/.BDT^",!&E(S=6ZO(JW)",NKC;S$^)X^^:9
M5KC\;?I%PE2$IG5Z_#3G [!!(K,=_R=O@DO;+&FO5=H8=$*M[JR^^QC8/0E.
M<$E=9.X?!K,+R$-HRD%R ,I_LUVF(,WK"7 1)][A%G$63'[MKJFO4M#(/5=@
M:RL9@KNNQ>*_YLOQ5H$8[DX7E:;N<\5QE!:9#C0U<34VTQHLV7$FZ7SHZ>0X
M<:T;X!&CI!7VQ&)%C7USO=CKV,$&I!"_)&W2F1U?K_D9(BF;(7YA(R/(GCBD
M@$2]+RVEL5VPBW],E2X+Q%'2@&SP'*AC515W?/TB8XO9FF<]Q IN1%"GU]6!
M#&OB4+85#]:Z0D(T*DL7L1X1JR@9BUO=+G8P&Q_9*4\5LNF;9G#3,=UG)FV;
M9GN^ M+,KJ:I:W4GY%H_;#B'2P80Y#B3>+@@EKXJ=MC=W*TVM=+Z3><MI[1B
MPM:;D-@W[%NDL>')ZM@AFLWF(-+U&W( &X: 8I#*2/Z8V#CLV:>R=%H:5*OH
M+%K(GDZS5SORCM.4$F:-$ EUL92#BV'%Y/N/FA[CQEWUH%V'+94:>"%QJ*ON
MS*IP43P.V! F)/&N%JSBSZ=F+KBG(+!$8>\Z7#F<&B*.W::[76B*XDQ!$?'0
M=[Z9O[%)5*<&5*YP?HTT'.ZRP^;O2>$;GDO8R'$X$G*VN4_TL4LR\@Z>)BI9
MBM- C;SN!%#XFX5:AJ-C_9=PB!<X-E4P2I4+:ATZ(?78SWI;+&^"A8S(0FWK
MB^T,<B147L7O\KOLI=*EDEJ7LLM>/%[>\2JAPA+!ASZ5UN2WPU\S$/O::?<E
M#38K1R=)FV0+44PN(E7:*:T9Q1?QS*.2\NSO3*]KP>RE1(WD=FOV!+K*GH*&
M"080@FT[-)IB!M', ;>K$%I"]#?H53ILO,+TPS05NVFT=B.<4/B]B5H@Z) 6
M;<5*I^'5V83.R/D)G1=&OV$G?\N2N75C0U!^4W\N&ES&F3<#]QY4)T;RI'"G
M.[ORC:VU<K4."1H\\";DS*RF4.=*%:9@6K@1GTCN2?TF!_E.0 M<*\X=T[*]
ME5E-5C/:0+N=VSR?#LTW;K81U&BV:U"\W[TUN:1YZ\GJ .*%DS#3^N^3F[G=
M=O8I)(9C)A4=79)WOVU1"7^ %A)K'UQX:E+_2E;1L'%:XGCH6A[O%K7SQ(R_
M%)_Z!L24I_&3[ W"Q]'8+-5+L%YC*N8!U2.WCK#AB<?O=3^TWLAZWV]>;^\9
M\9*&F9RG/\S61ZX[0^]-7)FKF&Y5[)#Z (_NYP;(X:.<FT8A"T7(OO@MC2@M
M6$L')$VWTH"_/=&7TT:C! XJ\[%]%0#4S(YO?=?+_':([$6D*/G8M9BK1-5:
M6B'O;[ H:WQ3;FT2L5%\_![DMO62]J,3-KT:>Q7UGAZ8.)>^S48?\=#M)<P9
M%UE)$E30G40?OP\K%=YQF>1U-NJO+^DMR*Z,7YX&B6*]&F7V95L(<DK?O>_]
M_IEQ[;P4Z$*&65$RC73O.]&=[9S""E\-A7M>@A&"U.3[UKR)Q^Z&P6D?XJ3=
MRM8V)4-L0M_7@T,>^(V!P:-!48YE+T@7(GT7%P+'I&+DRM#E_+?NC\[X/.!.
MN#"^FW&''&U3I&ZWA)KE'VUE8M>UPLE%&?1_\V-WRDSF3 AV9_\4P/K!#O'[
M,.QU)*4%:Z&-)LC6+;XO9'I2@%Z.4M>Z08Y2 ^L_UZ(!Y3H^[X8=S 3&JA4;
M )$2R1<5G// XWGEY/GY[&;C_KBXTL_\>4"@_1SQMV$"0U6%'&U74W$7(5C;
MVGYN%I[;HXDV-UZY>A%EUD:-*9*SM<P[WY:AT+2(SW8L,#!1?(&SO+JL3YQ$
MC'>PU5>PW[Y%O_)4E-5E.O2IFS(8_NDB+("0.%VRO^&U>:]2O( ,H=Q-NT1D
M75+=,EC%)5AB!L_WP'U=AAJ2<S30=C6.>89V?4E#/=?04/$%<Z#[V@>Z[97^
M%1FJQ1S+FC 6KE71:Z1BUZ(>JRRP[O5?FUGWVGZ-#\GA7DM_JPLQ=-&SE+0(
M=[&SPQQ*[!! &HP-TW*%<VV=/2JWC)JB>,?(X,P:%]]RL-D83"M9F/6^?:9+
MW["D/MYC![A_V61^DU"Q*8X\0U%1PVB&>?NR- 1S,&:^O@!C^Z-Q),WGVV;3
M-(]UDD5)N)$X96%\IO/E?<"<<5J,HCS'V#93H=)\D<Q8;4B8-^S";+0VQ7BC
MH\,>N>AFN&4)+5H;/"[GXQ0U^K96C;] XC/.]H\C2F/,J-F>+';Z=QC?0.(7
M#1R$-NEXHXOB,^UP?QJ4V)=M(1XU5QGBM)>F$)82P,+-],K:9RB1T8[(+-=H
ML7E_UG-#_Z*%;Q>):&\XSL?E+3OS!]J;Y7T<,)>8AP/*'Q^XJ D?:N#:R+EH
M/!C5-U;VT>MKZEY+U@SMG.-T:)D)L9B7/+RBNU&4[MG[NNJ*A[1?NU/RS6A6
M7#P]['GF^XL",O1SEQ>JI(4&G:;ERTM\C(S*%3RL1H+,Y:6U)A?M<_K2-W"\
MGZ0@JZ@T1U;W?V/3V?/9;04#D!F"Q')N:.ZA-<%Y%<,[Y :7YJ-H.:3REOIC
ME-R:6NH@GP,30T.M^^Q'27A&S6(LE:@?7J,O(''.M%"?>M?>W!3V]16/B$1+
M@8YL)-].BU@/>+:[(M<&Z)R"/LQ CR"@"P<SZ,.B.?^<M^F=#^M$=@T&E:96
MEB3'YP=F?4/GZ3L, =:2GEKPP:=?NR8L"%TBY*="2E,MR@/NWE-_/7Z@QWI<
MEG,"Z#EN/=Y3V.U./P$ ]QCWQH$Y"+3E+92W:4?WV\:/JZ'.NP,*^GO.IKPE
MS#D:'US#@K8RW_3RS'T]GJ5HZW1U&25+R&L)PO_VQ6:C2/;0!G0"2%F!'Z[!
M44D*:&@1</VM*2C% XCRAG9T=ZQ_7&%.2.50?%&R26[:Q87O@+X,5B=:)F]_
MR%118ZN\2M!\VZSI&1/-]DSB$/<YN)V?X(8PX!A!N4<?T4.91P6H\CKBZ1Z]
MR+7IVS=13>(UM-VBG&&!54*U1 ]-=P>_&\-D#PYGW#@!N)X ?/L>X+_/R4S4
M0NMZ5[K+VW?45]YGW#\!5)\ WB^>>1.-\6;ZH;1OXZ%URF;9@+O^WA6:=X.6
MM:\Z?P==:*+Q-U"Z5K(>,G3Q5V2#WY$1WHI?9AREG!RVT9;DY!=ZJ7!!=(;P
MF@%!S*/9ZAW!V:]SDR,S<.&-6I_''MRO!. O#S>,4GZQ:Q0,/SH!&$$G[YMB
M3&PZ =CWH74]&;^&C#&',FNF*3&51CQVJ+3\#7B- []6)$<ZN;+7-P+/#2RC
MMB"5(@6O<)L<!<=A)(Q!)SV@#LO K7.;>W>NI'P*.BY6V3=8NJ*3,#PJZ,9?
M1DN_B9O;9=SU4.]/ /Y@OP\<V5H#HN*A'3TZ76S%'%<&,TBH,;X<\!"_5'??
M;\79E9.6E*(:2MKJW9U%X#$DU/5U/TF\?[;L+HK=GK4[#NTMQ/ H9:LW/[(U
MW1U<XBQ(53=XLR:B%#]4^)JD0)$B]ZJ KN0^<"$=M*!T I"Z$J^*/_*R[('3
M ;?H*)C+QT2T\5GXURE%:Z/M6=BC ZJL$P"$8.4%CMR>LE)XD0B;Z)3BJL]@
M?1+KT;:=Y!+)4;F=E_D;CG';.(5&D($<:?)]#G?)0,YGXT,,PX5M>Y2:7S@M
M(A*GRR27,!K]/-Y[8)#EZEL7<EON]T%[Y--[HC!X.8GG*UBL'FYB9E4^YWVO
M"-)UOE*R%EWN]K0K#]R^-7L"2 Y52#G5R$4ME,^JU7L"*%]'32C1.LZ$]OVN
M>ZWM*AVCDUAZ]ZDLAE,-.65W' 6$C@1<KW9QYU896/*O31#3"5QX?0S(H?BX
MMX(#J2)K0:NT]*UQR9@K CQ;O&$C6QEG6L[LRB\U(#58BD/Z!4D*6S/71KS0
MW*228\5F"I-R7=';#M:RR)9U:LO1H'MJ/B+6+K8C9??='1@;-;TLP%<0NNIG
M<,_\K%FR9M<W>#O>='\1T;9VD[_CMT)_>2 '%[5P_BV3T@2-4D7'-@.<ML/G
MN  &-9)+"0N=I],"%U?'T.OS6!4'L9;6\@_''D]&D[[BI7DTNH>UD\.]76A%
MIB+?\+2CK93VO0ROB$WBC!2G_9D';IW;\,8!%L^3 K67&HOKXBI8_G#A0T80
M<X"4Z$Q\0F,EM;#\SAH3WXMYXM3GW'LR8JTT,["H7[C!<%DP[$^>UZ7OLN-D
M/9NNL^654V(TD%F061VC)ANUDQ_K3OND0!WK*V[VA>"+G8(@N>M/*4$R%S$-
M?_"5()F1?&_7%<407IVX:[!(&$#FM0< 5.[&*[:;F>9/ =FFZU7!5$T=#QKO
M)*,5UU;[/T50V[]>5G#0TU-MZS(6#TN,C@CU)BM6[8]MC3H!6)L22[=B-I=?
M%^NNX][1/F;/E)F4J<!0Z,]QF\FFNX+ 5\DJQPF^)P!I+\:]U=Z?CT.%YB&@
MX_1;<R2K$*B 9-RA\"'ZT1IP?23]QU,QN)DF_5#>M(-Q^#/:^N&M'QH4?NJJ
M@/$I[(;41P-+4X\^;9JNCJ[O;V&B6+UUQ/;HYQIA+X#WOG6=\V63/;14&+ 6
MF 1$X4/9H!:R^Z_F6E7?8P(T)_QPUQ98YER_T#V#/H[?2=2<CMM]\A<"X3\?
MZ^PIS>$HVC\$S=:/5$UN+9QY@?'GH_<@6S,CDA^M@6X)VA)HA_Y0\8NR A ,
M6&YUE'H<2C)O$XEQYR2T)ZGU^% 0^OU):$4_G1(*4=F7/;S"^*F'!=WU7M(7
M-I-R8&V?]A4=[&[%;V34U,G\2N>N!\VZ<0L'?OW,/$DN6N<RWYM<!D/]B6<&
M:J%RFGN0GLW)P]!]T)S2<<M1O@ELYNZV@^5#3:AK/8=D+K!Z,L:^5^YCBT(,
MZ][5S?2.* RI;AVE$=>_3A+<":VTL(#F;>\5=A2> &Z= '8[#_KO7F';=_M%
M0EAT>9$$#5H[9<RY \ZAOB8R9T@)<BF%G\'*V<Q S_CIE,I1$_[O2)1^(,F9
M"3W:1\L?=HX.ZX[DW#L!P(/A>T&;E&LW0];/N,_)"KW!>O]%JNMPZYD\[7,3
MAM."GX9 ?V6"L57K_U>2I\_D1?&@5VK, _CX%S*"]@G*[0A-ZX#''H*F,J7F
M,&6P[/=74:3;1;):&SJH3'1>92^8WS:/MG#6C37)\YFUVG!#*^+*2M?ONQME
M<9!T&\XJ5U"BMR\;=N"[;X_S]%6%R@\<N%TK;P99\)G(V&(SC.H\D[+K>S ]
M9P-94!&R0I"/#/FY7KUPFRB1;R9B5&ADGR_Y+D3],.W5KB)?5ZW"_/@>KJEI
M(<"UDD'\;8V]NK@$L]*Z194YLR1GKH2\]]N(P)VB6:\<U0Q<VJI@K"J2<!=?
MOPK>)1E"H^+@BJ7R!15#X1&N0/?W8MC(MWFSM19I1B9O3<#7(V8TBX(1<)#A
M5(UOVL+P3*LX+'#7)S%U8(>B_7UUS^%V"A(9],?13?OF'9UO+&8G.'0QFK_%
M;#2#$P!F2UMQ^"E\$M-;.P&0JZ,<9<_3(F!%!<D^^C3Y6 :6CD-["DX F%BQ
M*U&\OY."V2:>V2,$.X?U35&'AAH_4JKOO/!5+].M%2!FS_B&K:!];4[W9[#6
M:L"_RQ!18;B9(81J8%SOEVZ]CPE:92> R3)5>XG7-<+]\$-K2(5TVZ.!=_5-
M"7^M1.^OE 3&UWM]BX3:VS%N'9^E),>%.="S[ ET_(,._M,%=K[AQ:;OCI1^
M.F@1/8@ GN6Z.>B?L!2&U^H7!J&'NZ>H;OWG.9:(\W.<M'9'0W;WEU(L?LQV
MAK"78;1OO!]TZ54:XO!ZKN[IM)O^];0;8Q*.?YAW;O4W1Q>[_G^P_U_ET--'
M@ ()ES:E#(4&(.!:Y$N;F.?Q0@3?UC'EC.Y'U/#%BL2HT4ZA@<4KVDBW"/X(
MP1S::"B)%&<<9:Z;;<V255A]Q>#NEG#MR%D"]_ -)FL[6A(&[AENIEM@DMQZ
MCLT>OT^FPIAL93*)P0&3&=2+J\)/X^8P)IUU[@C%!CWZ1]:KWUD%B>2V+$]S
MC/W>^79,UG-U*^,/KC,)GX6HNS )A\B"0@(F!7'NCCKG.I<@@S 5/U,J1]GW
M<.L(M1<$O:?.5X_!E3.ML+6P;[A^R_G>G1*I]MJE7]5+5IV&5@<H)N+*/\YY
M?PY8\AQA N/I>56*J4DF8ZY<2ML_XUC\ V'?.4_K*3OD2O ?>-// 2J=,UT]
M$_#:[M8Y7OBY5VZ>\3QT/C>)KHK\>IN;;ZA1*92/V75"5CN6EL:?%*WCV2!9
MG>0]+8_V>-EK'0OC4/YQN7#W\>TEH]C,Z95\B7$=1U1A1K J5L:+N::^HL^?
MVNIXL5J'!+$&9T'Q7YS0U\>6]C@='V:E=<AX(F>?ZFF8+XR']6]GCQW)5%>\
MR(Q%#B@@5>OCYBF8#=WK$KU=7&& M3T2,*=__;<7KM91[9<K$C<RAQ^SA&D%
MO',;H7<3[1E\-YS@8=?(R(L+ _CRA1%)UQ1?-5&USTR[TXS3YVC-\'))3XVA
M3UGJ4[Z.MNU;>&H!\GW*U<OVP]C$Z0_2#^U53\,4]/ ;9T<E7%D8?GM?+_,X
MA7%>$HAZ=0+@D-+[2<&&1O9C*NI)-)I@LX#D]C[H\2*0 UB6/AZT^^D$$./'
MFG<"<+2MWSIV/@% +V+J)6=,U#?$K/D&$YU34EXIW#F%70^?$O1(RF9QTXXI
MJE $#<7D!>M?_H2C!$,GC_OZ* ?=#?=D'!5 ZWQ+SC^NR#HM*>N/CRX3391F
M)[A7'DR*,6Y^]AYZZ<@0N)EAQO<9=)S"L JLO(GN.%+718_TUY]B/:2$_L3T
M4+=WD>W#-F,,XTCO&J:(A7;44PQ *\LG]]%5F" ; /^)J)CCE(X&(SK]4%QJ
M&.K0LZ\W[5V\.YB J0<',2'I*^BX[ >D.?U30NS/FK] KB+:*?P8^VQ:C/(^
MQP=$L@=TJQ<JOMG%,:\B)8_[/"*6H/'PPP%L_?GLT$TFDE7C(N\'DJ:#YJ.Z
MD($M3,V9'+S?NZ" 6<'46P4%!+R<Q-J>1M\'$/Q=C$BSX^D9[DEDCIFV)LGV
M<^G"HQS0;7?[;OCARI\8V?5Y[/8QY5B/'&:?G+,/ZEZDH=S7,/HK/6QSM]WU
MNN%H[UL+"DF,1]NFW6]*V#ZDQV BKCAP?[$^B>'<CHX/Z1?"M*F%'F&BP?OZ
MI-OSV:/H@YF.G;T\T<O41W704>#*G3L.HS\TM)YK2"11YF4K6;-_N/$'HIES
M1&H81/H\?U/WN;7+-%GPGI0%TUJ)0X*>#SGIC/4IQW/H.\$0H@231V<VF$J?
M663Y!?18+F"^*N7,7/C?U0G#5,)-SUOGS/R>I54LL1Y[."\8O(XQ4\#1?1KH
M7,7E'>>\H#PHJS:7QY86_O&/-XHX3$R7L8='V_EB%:_;$JSR:%!Q+J6HVY7*
M 61VPQ7=OC:U BQ?2Q(KS-WU%>Y3L/'1ITT,6.T-T ][<LPQ0(FE?LC1RGP<
M-AH[ ?40<S8M-,2F+-? TA9RY. &=Q7.L]R>T[^OM:*WQ)XUO?8B6KL_)#;H
M$AKG/='SM==6.]=@ZM]N"Y'L?ZLZMJ]+>_O^G6%-PW',,]2W1.JC:_%!1T>&
MZ'+H1WQ,9M)<OV*,HO3UKG*%6MU[Y\=Z\02 =S,5LRVH3@"%C%\#,'G,AO/!
MD(\<HTGA&/!-R7@]1< )X G%:4(4#!V$_Z(&7JR[QCBB[S3YHN&';,5'N#ED
M)P#&4VE>"-#.\GCC(2?1Z(;HK>^,D%^DO4.R'>PXS: [&CV/U C1I*JR:#_N
M$P 8.(6#.7RG)W>*=F'2=8;5]?\$Q_H_((WHJZ5FR>P8,U:G"TFY3TEG@SC
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M.FJP;)I.W9 9,99T'JC],O#[:Y#B[[=(VHN9JS/#Q?9:[_[9>/I(:XF/P0E
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M?)2G'DY1RWS(D-H0*%1'\Z'#;+\U"X@:D#?#))W$/NC]].F8O$\C><>GW5$
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MF!9CZNEJ$XZT^K61L9+R$\#"-"(;QLNQGN)4[5OS:)<N#-$C?CE9)-0S#Y[
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M5R,PNJD!2$/NY___WE<@#89_F"3!S_P/4$L#!!0    ( "V)75C2+EOZZ1D
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MJ3'&(H/>R6%M+)M\\X+(T%A,->GTOB-SB?->+0@\V[%VI)$!Z>SYQN9!NJN
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ME>3+.)-;MQ+'V2T66$%QUR\(T\KQRY>@U-1J"BS+K?+X^]<!.<3OXC;])#D
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M>WONR[/^R#*-Q*[QB =ICKEDG_Q"%GJ=GKWO0Y793FWHM789$^!]O /JA>X
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M9!W?>.+IVJ3!3N+^AC9?QB2J7G),EM)W+NNT/!+O;(RN9&4$%RE$\2&4;9$
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M HH6Q9FBWK2OX.F6YDQU:G35FN3VG?.AUE*C^9LN6"SX*!DH:(%]=-AD)X(
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MH(*U3-/1FU>PCWW,V0[CVPZ*.)N.;R_7\76H&/F^5R?K$;BI=U"XH#LW=&%
M"ROL2"OAI>X-])EL/[.",_M/X$]CVY>VC6=SKFNW,A!@4P$,9:BX_G5]O^T3
M<+@26+D!*[<^,<__%VV3DC$_N_>;@G3DUL38;#KSWL'$#&V2\]-&ULV98-$C
MD1KQ\\F-VE/O9SFT3R363TZI)7A'3>=S]X\8^(*\?DD9P8L5HE<U55^VOWKE
MFDLW6)KLXYEG/"&9J?F%Z#0T-B=#@/E/WU0IU*J/']&P[TV["<9UORMZF@6C
M#&B/,XY5X%6HZS%[0\,B!.!<1//P5[GPW]:ZJ-C=9#:O-4PM)^+&NH5-PX82
M"PIEP9ZY:HPW&N=J[&I;^E4L!3;'XBL:AD&U"B)@/U'\A/<LMI*=.7;BPA]D
MOX*X\GB%K.F;*^X27'\=?Y]:#SN;.,9V;_I.RR=$FJ'0RWV24B.#/T%TWB/C
MRO&U(37),3N,*?1W]8N0R6.T _.&6K\S,?=:Y%%,(0HGC:MPGZ86-EM;ODCS
MK^]9J=I1O:]%Y2@B+3UMY=LFXJS8S#^NN[3XU@IJ_O(NW.=<JVMQ'BR3,>29
MIF#6;1/+G/L^]?SM"B$_N_<].UNV9T%WVVF4G+G_IFZ;=4+.!2\)!*B4KE=?
M\S<[=VKOH<L,/Z2OJ[3]<DR=<BSZB[HV45NA0T G\+T@ZJOM0%F!G5J&RJC-
M\]F]A:XE D88(N$DZ[$-[9M5S!_3(DH.Y6,B.SMKY+KOOP138G?AL<' _Y1"
MV!48XYUVP3_T]<M>L3XS?'710=I@C%':W9U#P=-&3T-Z)?[B4$FG]BPCWON]
M3,$2'6'\EV>I+^*M&?6Y$55?)OR:[[A:WWKN'^Q--_RLC[>G>^39NPN&NIKD
M9&6.-A$6/'1C?. ^7N_LUF:6^&@G;.<G.0I-K#R32R4W.:;6=W67*#_D+*2]
ME$O=_(K"!4DTY-).&$>5H1=T07;D =^)CUWV1EO,]U:?3_*DJY^H3AVREEDV
MRNCX?E&#,P:- 3@*]@H''W6G_^GE_;<*9,6E+JN&B?.Y+*S!JG+*2NJ-#=;Z
MQ2J.IU>PF@,0 '7"142M$V2])_)!-^9<6O]R=V_,9KB1;0[=/-C$GBNL2>*1
M*:>$[M#V]O>%)+0_;-A($.-SP HF_=-NI#]5FB0E7W-T3Y7NT')E)^B@1K:3
MFL/]<A2G4OG[NA3YTV:?_ZY%6J1O,ZM95V+M)"1#(VL^'('OE.8F.B;B\UQL
MA659=V$8 AP-HS-B?5_F_T E_^245!N\J'SD.^+W]3"]FFV:G]#]NDGZ@II[
MUS3^0KPR*O=RW7N:PJP^%2Q6H5_Q,O'@YXM'9SUQ60KEAHS5R=4YIT \65\'
M8S'+&[/IC.9,7<'\:\TK*$L&FUBQKCR)CT!G &F)C1X"1.LQ,$^+=GF]\D<G
M&)N1F\M7 2TK00 *K7*M[XINYU_!@JR9.5@%^BO9T9;^H6NG1I_O/E?7=9;=
M@LU5]21M@EDWHO 8Z,PD<L2:WU:KZ=+&57+;U;E#81/G[]H%_T&(%X]S^&*_
MK]IPZ/J5'>5<H(L91S.)G2U+_FH0N^TQOV7OB?=L'-T_JAX#=: '\CB(*+2
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MSLS?$&R?I^FY;@UXJ$T'[TOT#]QDH?SZ%Y+/A+84:VGBY*KE&$(?4[[>T,Y
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M0]I+ND."JH6C^VPJAGN))D5Q#>W6R?!$K;4F5.."Y5Q)&%Z52WN]=@8ISBE
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MUM_>0:G(5/_U!NW;XE97%D==_9>E.EMNJ;F+ZZOX'A>F1%=GOHKZ(@@2@^4
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M>TO?S$,UL%3]**&*HU[.L73:_DWJ@^I4%R2*>Q:&GFF2> 9I-HX1CR(]L*H
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M!2>&^*P]OWE,98TX9.(X'"G^U@%;SD3BB,'96[5.$Z#8W5IP'=6(PSSI?#S
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M"P-V]]%"XM[7&<KYA!C48[6I'\;-Q&RCGO49WMQB".;C;R]8_5Y\U>^>?63
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M:&(<_+:CR6_:D[N/$- /:3OQKG7/SV'6.-K8GUW*?AYOV<086REH+LRHWNS
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M8-B7LC,N,$TMN>>[1U*C8P_JRFM23H5;\A%($5+ZWKK9?/7%I)6D0PBL VR
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M%?PN(YN[-H,X@<R8E<>M=&$Z/GAL*"%=T#%A"XQ-A92_VCK?WN*U?DK67CV
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M2P$"% ,4    "  MB5U8T<(4KF<9  #%O0  "               @ $
M97@Q-"YH=&U02P$"% ,4    "  MB5U85'JKRBT$  !3$P  "@
M    @ &-&0  97@R,RTR+FAT;5!+ 0(4 Q0    ( "V)75@YU$C**0@  $),
M   *              "  >(=  !E>#,Q+3$N:'1M4$L! A0#%     @ +8E=
M6'N3NT\A"   ,$X   H              ( !,R8  &5X,S$M,BYH=&U02P$"
M% ,4    "  MB5U8"CMB<60$   4(   "@              @ %\+@  97@S
M,BTQ+FAT;5!+ 0(4 Q0    ( "V)75CK3YE^V1P  'K3   )
M  "  0@S  !E>#0M,BYH=&U02P$"% ,4    "  MB5U8@!(I(&00  #[FP
M"               @ $(4   97@Y-RYH=&U02P$"% ,4    "  MB5U8=3KM
M\_4.  "7I   $0              @ &28   9F)L9RTR,#(S,3(S,2YX<V10
M2P$"% ,4    "  MB5U8O+%,4PD2  "/[0  %0              @ &V;P
M9F)L9RTR,#(S,3(S,5]C86PN>&UL4$L! A0#%     @ +8E=6$S/KA4-*
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M<FTQ,"UK+FAT;5!+ 0(4 Q0    ( "V)75@P%:LUA"D  $\X   0
M      "  =@1!0!F;W)M,3 M:U\P,#$N:G!G4$L! A0#%     @ +8E=6/WK
MZK[-%0  81@  !               ( !BCL% &9O<FTQ,"UK7S P,BYJ<&=0
M2P$"% ,4    "  MB5U8TBY;^ND9  #]&P  $               @ &%404
M9F]R;3$P+6M?,# S+FIP9U!+ 0(4 Q0    ( "V)75CK _S7S3H  %Q(   0
M              "  9QK!0!F;W)M,3 M:U\P,#0N:G!G4$L! A0#%     @
M+8E=6+&V#F( +P  :CP  !               ( !EZ8% &9O<FTQ,"UK7S P
M-2YJ<&=02P$"% ,4    "  MB5U8PRZ\L2T@   [+0  $
M@ '%U04 9F]R;3$P+6M?,# V+FIP9U!+ 0(4 Q0    ( "V)75@I0:$>52,
M $$O   0              "  2#V!0!F;W)M,3 M:U\P,#<N:G!G4$L%!@
0   4 !0 N@0  *,9!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:FBLG="http://fibrobiologics.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fblg-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-02-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_VotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_VotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_NetParentInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:NetParentInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_VotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NetParentInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:NetParentInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_VotingCommonStockMember37662156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NetParentInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:NetParentInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NetParentInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:NetParentInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_VotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_NetParentInvestmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:NetParentInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_VotingCommonStockMember37662203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FBLG:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-18_us-gaap_NonvotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-18</instant>
        </period>
    </context>
    <context id="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-18</instant>
        </period>
    </context>
    <context id="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-18</instant>
        </period>
    </context>
    <context id="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-18</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">FBLG:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">FBLG:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LaborataryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">FBLG:LaborataryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputMaturityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">FBLG:LiabilityInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">FBLG:LiabilityInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">FBLG:LiabilityInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">FBLG:LiabilityInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">FBLG:LiabilityInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-02-28_custom_TwoThousandTwentyTwoNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="From2023-02-282023-02-28_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_TwoThousandTwentyOneNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyOneNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_TwoThousandTwentyTwoNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="From2023-04-302023-04-30_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_TwoThousandTwentyTwoNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">FBLG:TwoThousandTwentyTwoNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_NonvotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-08-012022-08-31_us-gaap_NonvotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_SeriesBOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_SeriesB1PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesB1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesBOnePreferredStockMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FBLG:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-31_us-gaap_NonvotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="From2023-10-012023-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-10-312023-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-12_custom_SharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-12</instant>
        </period>
    </context>
    <context id="From2021-11-122021-11-12_custom_SharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-12</startDate>
            <endDate>2021-11-12</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ShortTermLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:ShortTermLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="AsOf2022-10-31_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="From2023-06-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-09-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OperatingLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FBLG:OperatingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShorttermLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FBLG:ShorttermLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_FibroGenesisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">FBLG:FibroGenesisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_FibroGenesisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">FBLG:FibroGenesisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FibroGenesisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">FBLG:FibroGenesisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-09-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2023-02-012023-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="From2023-08-012023-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember_custom_DirectorsAndOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">FBLG:DirectorsAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-24</instant>
        </period>
    </context>
    <context id="From2024-02-012024-02-29_custom_SharePurchaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001958777</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FBLG:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="ixv-16887">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="ixv-16888">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="ixv-16889">0001958777</dei:EntityCentralIndexKey>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0058"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0068"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:ParentCompanyPayable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0086"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0097"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:NetParentInvestment
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0115"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0134"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0135"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0154"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0173"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:FairValueAdjustmentOfLiabilityInstrument
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:DeemedDividend
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0308"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0310"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0312"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0314"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0328"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0330"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0332"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0334"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_custom_NetParentInvestmentMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_custom_NetParentInvestmentMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_NetParentInvestmentMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_NetParentInvestmentMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_VotingCommonStockMember37662156"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0396"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_VotingCommonStockMember37662156"
      id="xdx2ixbrl0400"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_VotingCommonStockMember37662156"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0416"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_custom_VotingCommonStockMember37662156"
      id="xdx2ixbrl0420"
      unitRef="Shares"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest
      contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest
      contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability
      contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_VotingCommonStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_NetParentInvestmentMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_VotingCommonStockMember37662203"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_VotingCommonStockMember37662203"
      id="xdx2ixbrl0506"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_NetParentInvestmentMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_VotingCommonStockMember37662203"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_VotingCommonStockMember37662203"
      id="xdx2ixbrl0526"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:IncreaseDecreaseInChangeInPayableToParent
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0588"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:RofnAgreementPaymentsToParent
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0592"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:AdditionToDerivativeLiabilityForDebtIssuanceDiscount
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:ObtainingOperatingLeaseRightofuseAssetAndLiability
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0633"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:DeemedDividend
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_LaboratoryEquipmentMember"
      id="xdx2ixbrl0736"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember"
      id="xdx2ixbrl0739"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0742"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0748"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0754"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0760"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0762"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0766"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0767"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0768"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0769"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0771"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0772"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0776"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0777"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0781"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0782"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0786"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0787"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0788"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0789"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0791"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0792"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0798"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0799"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount
      contextRef="From2022-01-012022-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0802"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0805"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0808"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock
      contextRef="From2023-01-012023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0811"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0813"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0816"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0819"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputMaturityMember"
      id="xdx2ixbrl0824">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputMaturityMember"
      id="xdx2ixbrl0830">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0859"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0862"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0865"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0960"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0966"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0995"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1008"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:DeferredTaxLiabilitiesUnamortizedDebtDiscount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1010"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1019"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1020"
      unitRef="USD"
      xsi:nil="true"/>
    <FBLG:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1076"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1157"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1165"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1167"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1181"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1189"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="ixv-18197">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="ixv-18198">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="ixv-65">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="ixv-18199">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="ixv-18200">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="ixv-18201">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="ixv-18202">001-41934</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="ixv-18203">FibroBiologics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="ixv-18204">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="ixv-18205">86-3329066</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="ixv-18206">455                                             E. Medical Center Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-12-31" id="ixv-18207">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="ixv-18208">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="ixv-18209">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="ixv-18210">77598</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="ixv-18211">77598</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="ixv-18212">(281)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="ixv-18213">651-5150</dei:LocalPhoneNumber>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="ixv-18214">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="ixv-18215">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="ixv-18216">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="ixv-18217">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="ixv-18218">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="ixv-18219">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="ixv-18220">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-01-01to2023-12-31" id="ixv-18221">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-01-01to2023-12-31" id="ixv-18222">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="ixv-18223">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="ixv-18224">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="ixv-18225"
      unitRef="USD">0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-02-20"
      decimals="INF"
      id="ixv-18226"
      unitRef="Shares">32634366</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="ixv-18227">WithumSmith+Brown, PC.</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="ixv-18228">East Brunswick, New Jersey</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="ixv-18229">100</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18230"
      unitRef="USD">9163000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18231"
      unitRef="USD">2266000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18232"
      unitRef="USD">36000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18233"
      unitRef="USD">29000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18234"
      unitRef="USD">300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18235"
      unitRef="USD">16000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18236"
      unitRef="USD">30000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18237"
      unitRef="USD">9215000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18238"
      unitRef="USD">2625000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18239"
      unitRef="USD">797000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18240"
      unitRef="USD">1809000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18241"
      unitRef="USD">2199000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18242"
      unitRef="USD">11821000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18243"
      unitRef="USD">4824000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18244"
      unitRef="USD">1444000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18245"
      unitRef="USD">758000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <FBLG:ParentCompanyPayable
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18246"
      unitRef="USD">141000</FBLG:ParentCompanyPayable>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18247"
      unitRef="USD">362000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18248"
      unitRef="USD">326000</us-gaap:OperatingLeaseLiabilityCurrent>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18249"
      unitRef="USD">7236000</FBLG:LiabilityInstrument>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18250"
      unitRef="USD">538000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18251"
      unitRef="USD">5451000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18252"
      unitRef="USD">9183000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18253"
      unitRef="USD">7073000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18254"
      unitRef="USD">1385000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18255"
      unitRef="USD">1747000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18256"
      unitRef="USD">10568000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18257"
      unitRef="USD">8820000</us-gaap:Liabilities>
    <FBLG:NetParentInvestment
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18258"
      unitRef="USD">1461000</FBLG:NetParentInvestment>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18259"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18260"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18261"
      unitRef="Shares">8750000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18262"
      unitRef="Shares">8750000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18263"
      unitRef="Shares">8750000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18264"
      unitRef="Shares">8750000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18265"
      unitRef="Shares">8750000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18266"
      unitRef="Shares">8750000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18267"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18268"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18269"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18270"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18271"
      unitRef="Shares">4171445</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18272"
      unitRef="Shares">4171445</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18273"
      unitRef="Shares">381658</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18274"
      unitRef="Shares">381658</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18275"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18276"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18277"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18278"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18279"
      unitRef="Shares">89781</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18280"
      unitRef="Shares">89781</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18281"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18282"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18283"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18284"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18285"
      unitRef="Shares">2500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18286"
      unitRef="Shares">2500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18287"
      unitRef="Shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18288"
      unitRef="Shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18289"
      unitRef="Shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18290"
      unitRef="Shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18291"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18292"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18293"
      unitRef="Shares">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18294"
      unitRef="Shares">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18295"
      unitRef="Shares">28230842</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18296"
      unitRef="Shares">28230842</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18297"
      unitRef="Shares">28230842</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18298"
      unitRef="Shares">28230842</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="-3"
      id="ixv-18299"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="-3"
      id="ixv-18300"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_VotingCommonStockMember"
      decimals="INF"
      id="ixv-18301"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_VotingCommonStockMember"
      decimals="INF"
      id="ixv-18302"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_VotingCommonStockMember"
      decimals="INF"
      id="ixv-18303"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_VotingCommonStockMember"
      decimals="INF"
      id="ixv-18304"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_custom_VotingCommonStockMember"
      decimals="INF"
      id="ixv-18305"
      unitRef="Shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_VotingCommonStockMember"
      decimals="INF"
      id="ixv-18306"
      unitRef="Shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31_custom_VotingCommonStockMember"
      decimals="INF"
      id="ixv-18307"
      unitRef="Shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_VotingCommonStockMember"
      decimals="INF"
      id="ixv-18308"
      unitRef="Shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18309"
      unitRef="USD">25609000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18310"
      unitRef="USD">2414000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18311"
      unitRef="USD">-24357000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18312"
      unitRef="USD">-7872000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18313"
      unitRef="USD">1253000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18314"
      unitRef="USD">-3996000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18315"
      unitRef="USD">11821000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18316"
      unitRef="USD">4824000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18317"
      unitRef="USD">2368000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18318"
      unitRef="USD">1147000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18319"
      unitRef="USD">6521000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18320"
      unitRef="USD">3320000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18321"
      unitRef="USD">8889000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18322"
      unitRef="USD">4467000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18323"
      unitRef="USD">-8889000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18324"
      unitRef="USD">-4467000</us-gaap:OperatingIncomeLoss>
    <FBLG:FairValueAdjustmentOfLiabilityInstrument
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18325"
      unitRef="USD">7236000</FBLG:FairValueAdjustmentOfLiabilityInstrument>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18326"
      unitRef="USD">-213000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18327"
      unitRef="USD">147000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18328"
      unitRef="USD">654000</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18329"
      unitRef="USD">-16485000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18330"
      unitRef="USD">-5121000</us-gaap:NetIncomeLoss>
    <FBLG:DeemedDividend
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18331"
      unitRef="USD">-2573000</FBLG:DeemedDividend>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18332"
      unitRef="USD">-19058000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18333"
      unitRef="USD">-5121000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18334"
      unitRef="USDPShares">-0.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18335"
      unitRef="USDPShares">-0.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18336"
      unitRef="USDPShares">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18337"
      unitRef="USDPShares">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18338"
      unitRef="Shares">28230842</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18339"
      unitRef="Shares">28230842</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18340"
      unitRef="Shares">28230842</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18341"
      unitRef="Shares">28230842</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_NetParentInvestmentMember"
      decimals="-3"
      id="ixv-18342"
      unitRef="USD">1461000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18343"
      unitRef="Shares">8750000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-18344"
      unitRef="USD">-2751000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="ixv-18345"
      unitRef="USD">-1290000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_NetParentInvestmentMember"
      decimals="-3"
      id="ixv-18346"
      unitRef="USD">1461000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18347"
      unitRef="Shares">8750000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-18348"
      unitRef="USD">-2751000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="ixv-18349"
      unitRef="USD">-1290000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-18350"
      unitRef="Shares">28179592</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-18351"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18352"
      unitRef="USD">-1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18353"
      unitRef="Shares">381658</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18354"
      unitRef="USD">2150000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18355"
      unitRef="USD">2150000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-18356"
      unitRef="Shares">51250</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18357"
      unitRef="USD">265000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18358"
      unitRef="USD">265000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-18359"
      unitRef="USD">-5121000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18360"
      unitRef="USD">-5121000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_NetParentInvestmentMember"
      decimals="-3"
      id="ixv-18361"
      unitRef="USD">1461000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18362"
      unitRef="Shares">8750000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18363"
      unitRef="Shares">381658</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-18364"
      unitRef="Shares">28230842</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-18365"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18366"
      unitRef="USD">2414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-18367"
      unitRef="USD">-7872000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18368"
      unitRef="USD">-3996000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_NetParentInvestmentMember"
      decimals="-3"
      id="ixv-18369"
      unitRef="USD">1461000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18370"
      unitRef="Shares">8750000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18371"
      unitRef="Shares">381658</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-18372"
      unitRef="Shares">28230842</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-18373"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18374"
      unitRef="USD">2414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-18375"
      unitRef="USD">-7872000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18376"
      unitRef="USD">-3996000</us-gaap:StockholdersEquity>
    <FBLG:SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18377"
      unitRef="Shares">2570394</FBLG:SaleOfSeriesBPreferredStockSharesNetOfDirectCostsShares>
    <FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18378"
      unitRef="USD">14945000</FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18379"
      unitRef="USD">14945000</FBLG:SaleOfSeriesBAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <FBLG:SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18380"
      unitRef="Shares">89781</FBLG:SaleOfSeriesB1PreferredStockSharesNetOfDirectCostsShares>
    <FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18381"
      unitRef="USD">1193000</FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18382"
      unitRef="USD">1193000</FBLG:SaleOfSeriesBOneAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <FBLG:IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18383"
      unitRef="Shares">1219393</FBLG:IssuanceOfSeriesBPreferredStockSharesForConversionOfNotesAndAccruedInterestShares>
    <FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18384"
      unitRef="USD">6404000</FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest>
    <FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18385"
      unitRef="USD">6404000</FBLG:IssuanceOfSeriesBAdjustmentsToAdditionalPaidInCapitalConversionOfNotesAndAccruedInterest>
    <FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability
      contextRef="From2023-01-012023-12-31_custom_NetParentInvestmentMember"
      decimals="-3"
      id="ixv-18386"
      unitRef="USD">-1461000</FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability>
    <FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18387"
      unitRef="USD">-1112000</FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability>
    <FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18388"
      unitRef="USD">-2573000</FBLG:DeemedDividendRelatedToRofnAgreementDerivativeLiability>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18389"
      unitRef="USD">1765000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18390"
      unitRef="USD">1765000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-18391"
      unitRef="USD">-16485000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18392"
      unitRef="USD">-16485000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18393"
      unitRef="Shares">8750000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18394"
      unitRef="Shares">4171445</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18395"
      unitRef="Shares">89781</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-18396"
      unitRef="Shares">28230842</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-18397"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18398"
      unitRef="USD">25609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-18399"
      unitRef="USD">-24357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18400"
      unitRef="USD">1253000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18401"
      unitRef="Shares">8750000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18402"
      unitRef="Shares">4171445</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18403"
      unitRef="Shares">89781</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="ixv-18404"
      unitRef="Shares">28230842</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="ixv-18405"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ixv-18406"
      unitRef="USD">25609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ixv-18407"
      unitRef="USD">-24357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18408"
      unitRef="USD">1253000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18409"
      unitRef="USD">-16485000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18410"
      unitRef="USD">-5121000</us-gaap:NetIncomeLoss>
    <FBLG:FairValueAdjustmentOfLiabilityInstrument
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18411"
      unitRef="USD">7236000</FBLG:FairValueAdjustmentOfLiabilityInstrument>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18412"
      unitRef="USD">1765000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18413"
      unitRef="USD">265000</us-gaap:ShareBasedCompensation>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18414"
      unitRef="USD">72000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18415"
      unitRef="USD">81000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18416"
      unitRef="USD">389000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18417"
      unitRef="USD">390000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18418"
      unitRef="USD">94000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18419"
      unitRef="USD">47000</us-gaap:Depreciation>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18420"
      unitRef="USD">7000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18421"
      unitRef="USD">-8000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18422"
      unitRef="USD">671000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18423"
      unitRef="USD">525000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18424"
      unitRef="USD">-14000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18425"
      unitRef="USD">6000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <FBLG:IncreaseDecreaseInChangeInPayableToParent
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18426"
      unitRef="USD">141000</FBLG:IncreaseDecreaseInChangeInPayableToParent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18427"
      unitRef="USD">-326000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18428"
      unitRef="USD">-220000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18429"
      unitRef="USD">-6401000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18430"
      unitRef="USD">-4066000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18431"
      unitRef="USD">495000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18432"
      unitRef="USD">-495000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18433"
      unitRef="USD">225000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <FBLG:RofnAgreementPaymentsToParent
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18434"
      unitRef="USD">2645000</FBLG:RofnAgreementPaymentsToParent>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18435"
      unitRef="USD">300000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18436"
      unitRef="USD">-300000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18437"
      unitRef="USD">4300000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18438"
      unitRef="USD">14945000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18439"
      unitRef="USD">2150000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <FBLG:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18440"
      unitRef="USD">1193000</FBLG:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18441"
      unitRef="USD">13793000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18442"
      unitRef="USD">5925000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18443"
      unitRef="USD">6897000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18444"
      unitRef="USD">1859000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18445"
      unitRef="USD">2266000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="ixv-18446"
      unitRef="USD">407000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18447"
      unitRef="USD">9163000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18448"
      unitRef="USD">2266000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18449"
      unitRef="USD">2000</us-gaap:InterestPaidNet>
    <FBLG:AdditionToDerivativeLiabilityForDebtIssuanceDiscount
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18450"
      unitRef="USD">538000</FBLG:AdditionToDerivativeLiabilityForDebtIssuanceDiscount>
    <FBLG:ObtainingOperatingLeaseRightofuseAssetAndLiability
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18451"
      unitRef="USD">2293000</FBLG:ObtainingOperatingLeaseRightofuseAssetAndLiability>
    <FBLG:IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18452"
      unitRef="USD">5866000</FBLG:IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest>
    <FBLG:ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18453"
      unitRef="USD">538000</FBLG:ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock>
    <FBLG:AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18454"
      unitRef="USD">349000</FBLG:AdditionsToAccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14706">&lt;p id="xdx_805_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z8yDXCzy2FT4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_828_z4uUjpBA0Hre"&gt;Organization, Description of Business, and Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Organization
and Business&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FibroBiologics,
Inc. (the &#x201c;Company&#x201d; or &#x201c;FibroBiologics&#x201d;) was originally formed as a limited liability company (&#x201c;LLC&#x201d;)
under the laws of the State of Texas on April 8, 2021 (&#x201c;Inception&#x201d;) and then converted to a Delaware corporation on December
14, 2021. FibroBiologics is an early stage, cell therapy company headquartered in Houston, Texas, developing innovative treatments for
chronic diseases using fibroblast cells. The Company&#x2019;s primary focus is the initiation and progression of preclinical studies and
clinical-stage U.S. Food and Drug Administration trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis,
Cancer, Wound Healing and other diseases. Prior to Inception, preclinical research and development related to these disease pathways
took place under the parent company, SpinalCyte, LLC (the &#x201c;Parent&#x201d; or &#x201c;FibroGenesis&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Direct
Listing&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 31, 2024, the Company completed a direct listing of its common stock on Nasdaq (the &#x201c;Direct Listing&#x201d;). Upon completion
of the Direct Listing, all outstanding shares of the Company&#x2019;s Non-voting Common Stock, Series B Preferred Stock, and Series B-1
Preferred Stock automatically converted into shares of Voting Common Stock on a one-for-one basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Going
Concern and Management&#x2019;s Plan&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has incurred operating losses since Inception and expects such losses to continue in the future as it builds infrastructure,
develops intellectual property and conducts research and development activities. The Company has primarily relied on a combination of
angel investors and private debt placements to funds its operations. As of December 31, 2023, the Company had an accumulated deficit
of $&lt;span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20231231_z98ot1puN5v5"&gt;24,357&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand
and cash and cash equivalents of $&lt;span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20231231_zbYmnjiej6kf"&gt;9,163
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand. A transition to profitability will
depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues
to support the Company&#x2019;s cost structure. The Company currently does not generate revenues and may never achieve profitability.
Unless and until such time that revenue and net income are generated, the Company will need to continue to raise additional capital.
As further described in Note 8, management has entered into a share purchase agreement as of November 12, 2021. With the completion of
the Company&#x2019;s Direct Listing, this agreement provides the Company with access to additional liquidity. In February 2024, the Company
utilized this facility to raise a total of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20230101__20231231_zXVMtP5hN2T7"&gt;1,924&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand. As a result, the Company believes it
has adequate capital to fund its current operating plan for at least the next 12 months from the date of issuance of these Financial
Statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Segments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief executive
officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources
and evaluating financial performance. The Company operates and manages its business as a single operating segment and therefore has one
reportable segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18455"
      unitRef="USD">-24357000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18456"
      unitRef="USD">9163000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18457"
      unitRef="USD">1924000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14772">&lt;p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zYB9wikvYkDl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82A_z4wlpIcxE08c"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zLg19Zjf7Xtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z8O3Z4jtpqqg"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding
annual financial reporting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period from January 1, 2021, to its formation on April 8, 2021, the Company operated as a line of business of FibroGenesis rather
than as a separate stand-alone entity. Consequently, prior to the Company&#x2019;s formation on April 8, 2021, the financial statements
were derived from the historical accounting records of the Parent. All general and administrative expenses and research and development
expenses directly associated with the business activity of the Company that were originally incurred by the Parent from January 1, 2021,
through the Company&#x2019;s formation on April 8, 2021, were allocated and included in the Company&#x2019;s financial statements. The
resulting net Parent investment was presented within stockholders&#x2019; equity/(deficit) and represented the Parent&#x2019;s interest
in the recorded net assets of the Company and has been eliminated through the ROFN Agreement as further described in Notes 7 and 11.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2023, the Company amended and restated its certificate of incorporation with the State of Delaware to immediately effect a 1-for-4
shares reverse stock split. All share and per share amounts have been adjusted on a retroactive basis to reflect the effect of the
reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zwt2zNhO5J4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zw1DrwJNNSH8"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements
and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date
of the Financial Statements; therefore, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zbzlq04VIvr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zIVIo5Wbo1Te"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The
Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit
of $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20231231_z1s2CkMyVJma" title="Federally insured limit"&gt;250,000&lt;/span&gt;. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial
condition, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--RisksAndUncertaintiesPolicyTextBlock_zCM0wh8e2bCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zKNfC1n28vKk"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the
Company believes could have a material adverse effect on the future financial position or results of operations: the timing of, and the
Company&#x2019;s ability to advance its current and future product candidates into and through clinical development; costs and timelines
associated with the manufacture of clinical supplies of the Company&#x2019;s product candidates; regulatory approval and market acceptance
of its product candidates; performance of third-party contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing
organizations (&#x201c;CMOs&#x201d;); competition from pharmaceutical companies with greater financial resources or expertise; protection
of the intellectual property, litigation or claims against the Company based on intellectual property, or other factors; the need to
obtain additional funding; and its ability to attract and retain employees necessary to support its growth. Disruption from CROs&#x2019;,
CMOs&#x2019; or suppliers&#x2019; operations would likely have a negative impact on the Company&#x2019;s business, financial position and
results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zOqnLLqHGWq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zKIHFte91RX1"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three
months or less at the time of purchase. There were &lt;span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_zdGKDMCreLA3" title="Cash equivalents"&gt;&lt;span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zTcjr9BCeQn" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zMVkNCl4TJTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zoHu2zwW1ubi"&gt;Property
and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is computed using the straight-line
method over the estimated useful lives of the respective assets, generally three to five years, and includes laboratory equipment that is
recorded at cost and depreciated using the straight-line method over the estimated useful lives of five years. Depreciation expense is
classified in either research and development expense or in general and administrative expense, depending upon the nature of the asset,
in the accompanying Statements of Operations. When property and equipment assets are retired or otherwise disposed of, the cost and related
accumulated depreciation are removed from the balance sheets and the resulting gain or loss is recorded in other income (loss) in the
period realized. Maintenance and repairs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets
might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable
market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that
would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used,
the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and
measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for
the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_znec43ArZIxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_865_zYvw03D16fRi"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company determines if an arrangement is a lease at inception. An arrangement is or contains a lease if it conveys the right to control
the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification is determined
at lease commencement. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement
date. The Company&#x2019;s leases do not provide an implicit interest rate and therefore the Company estimates its incremental borrowing
rate to discount lease payments. The incremental borrowing rate reflects the interest rate that the Company would have to pay to borrow
on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term. Operating lease
right-of-use (&#x201c;ROU&#x201d;) assets are based on the corresponding lease liability adjusted for any lease payments made at or before
commencement, initial direct costs, and lease incentives. Renewals or early terminations are not accounted for unless the Company is
reasonably certain to exercise these options. Operating lease expense is recognized and the ROU asset is amortized on a straight-line
basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Operating
leases are included in operating lease right-of-use asset, operating lease liability, short-term, and operating lease liability, long-term
on the Company&#x2019;s Balance Sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company has elected in accordance with ASC 842-20-25-2 an accounting policy to not record short-term leases, defined as those with terms
of 12 months or less, on the Balance Sheets. Rent expense recorded under leases, for financial statement purposes, is recognized on a
straight-line basis over the lease term based on the most recent contractual terms available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgvxc4Dp8Fl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_86E_z69gfL6mD6u2"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Accounting
Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, establishes a fair value hierarchy for instruments measured
at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions
(unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market
data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about
the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available
in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions
in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Level
1 - Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Level
2 - Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates
and yield curves.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Level
3 - Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#x2019;s
own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about
risk).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Categorization
within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zey6YkvhidG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;&lt;span id="xdx_863_zuS18C0BfOIb"&gt;Derivatives&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Derivative financial instruments,
including the Liability instrument, are recorded at fair value on the Balance Sheet. Liability classified derivatives are remeasured at their
fair value at each reporting date, with decreases or increases in the fair value recognized as other gain or loss, respectively, within
the Statement of Operations. Equity classified derivatives are not remeasured at each reporting date. If a liability classified derivative
becomes eligible for reclassification to an equity classified derivative, any gains or losses recognized up to the point of reclassification
are not reversed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZ1BEmZTWuR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zAmDAIw1ZIO5"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research
and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory
supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain
research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern
of costs incurred, and are reflected in the Financial Statements as prepaid or accrued research and development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zbOxJbLR5wDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zbLAotx4dYh8"&gt;Patent
Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company continues to incur costs to obtain market approval of patented technology, patent costs are expensed as incurred in general,
administrative and other expense in the Statements of Operations. Costs include fees to renew or extend the term of recognized intangible
assets, patent defense costs, and patent application costs. Management will continue to expense such costs until market approval is obtained
through regulatory approval by the appropriate governing body.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zHewRXz5l1E1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zFTimCOV9u3k"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company is a C corporation, and accounts for income taxes under the asset and liability
method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement
and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.
Valuation allowances are established when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the provisions of ASC 740-10, &lt;i&gt;Income Taxes&lt;/i&gt;, the Company evaluates uncertain tax positions by reviewing against applicable tax
law all positions taken by the Company with respect to tax years for which the statute of limitations is still open. ASC 740-10 provides
that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained
upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The Company recognizes
interest and penalties related to the liability for unrecognized tax benefits, if any, as a component of the income tax expense line
in the accompanying Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z2DJvtjEuD1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zbrppPtA8Sm9"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes compensation costs related to stock options granted to employees and nonemployees based on the estimated fair value
of the awards on the date of grant and recognizes expense on a straight-line basis over the requisite service period, which is generally
the vesting period of the award. Forfeitures are recognized as they occur. The fair value of stock options is estimated on the date of
grant using a Black-Scholes option pricing model which requires management to apply judgment and make estimates, including:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
    Value of Common Stock&lt;/i&gt;&#x2014;The estimated fair value of our common stock underlying our stock-based awards has been determined
    by our board of directors as of each option grant date with input from management, considering our most recently available
    third-party valuations of common stock and our board of directors&#x2019; assessment of additional objective and subjective factors
    that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant.
    These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public
    Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the
    Practice Aid). Now that a public trading market for our common stock has been established in connection with the completion of the
    Direct Listing, the fair value of common stock in future grants will be based on the closing price as reported on The Nasdaq Global Select Market on the
    date of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Term&lt;/i&gt;&#x2014;The expected term represents the period that a stock-based award is expected to be outstanding. The Company uses the
    simplified method to determine the expected term, which is based on the average of the time-to-vesting and the contractual life of
    the option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Volatility&lt;/i&gt;&#x2014; Due to the Company&#x2019;s limited operating history and lack of company-specific historical and implied volatility
    data, the expected volatility is estimated based on the average historical volatilities of common stock of comparable publicly traded
    entities over a period of time commensurate with the expected term of the stock option grants. The comparable companies are chosen
    based on their size, stage in the product development cycle, or area of specialty. The Company will continue to apply this process
    until sufficient historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-Free
    Interest Rate&lt;/i&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon
    U.S. Treasury notes with maturities approximately equal to the expected term of the awards.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Dividend&lt;/i&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock.
    Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--EmergingGrowthCompanyPolicyTextBlock_z4MVFVraF6ue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zvsvRe7B3p5k"&gt;Emerging
Growth Company&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
the completion of the Direct Listing, the Company is an emerging growth company (EGC), as defined in the Jumpstart Our Business Startups
Act of 2012 (JOBS Act). Under the JOBS Act, an EGC can delay adopting new or revised accounting standards issued subsequent to the enactment
of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition
period for complying with new or revised accounting standards that have different effective dates for public and private companies; however,
the Company may adopt new or revised accounting standards early if the standard allows for early adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, the Company will utilize other exemptions and reduced reporting requirements provided to EGCs by the JOBS Act. Subject to certain
conditions set forth in the JOBS Act, an EGC is not required to, among other things, (i) provide an auditor&#x2019;s attestation report
on the company&#x2019;s system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002,
(ii) provide all of the compensation disclosure that may be required of non-EGC public companies under the Dodd-Frank Wall Street Reform
and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding
mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the
financial statements (auditor discussion and analysis), or (iv) disclose certain executive compensation-related items, such as the correlation
between executive compensation and performance and comparisons of the chief executive officer&#x2019;s compensation to median employee
compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zF9lBFxyj566" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zy4HvretUkF8"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;There have been no accounting pronouncements issued but not yet adopted by the Company that are expected to have a material impact on
the Company&#x2019;s Financial Statements.&lt;/p&gt;

&lt;p id="xdx_85A_zFDTBd9KMsG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14781">&lt;p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zLg19Zjf7Xtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_z8O3Z4jtpqqg"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding
annual financial reporting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period from January 1, 2021, to its formation on April 8, 2021, the Company operated as a line of business of FibroGenesis rather
than as a separate stand-alone entity. Consequently, prior to the Company&#x2019;s formation on April 8, 2021, the financial statements
were derived from the historical accounting records of the Parent. All general and administrative expenses and research and development
expenses directly associated with the business activity of the Company that were originally incurred by the Parent from January 1, 2021,
through the Company&#x2019;s formation on April 8, 2021, were allocated and included in the Company&#x2019;s financial statements. The
resulting net Parent investment was presented within stockholders&#x2019; equity/(deficit) and represented the Parent&#x2019;s interest
in the recorded net assets of the Company and has been eliminated through the ROFN Agreement as further described in Notes 7 and 11.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2023, the Company amended and restated its certificate of incorporation with the State of Delaware to immediately effect a 1-for-4
shares reverse stock split. All share and per share amounts have been adjusted on a retroactive basis to reflect the effect of the
reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="ixv-14800">&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zwt2zNhO5J4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zw1DrwJNNSH8"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements
and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date
of the Financial Statements; therefore, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-12-31" id="ixv-14811">&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zbzlq04VIvr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zIVIo5Wbo1Te"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The
Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit
of $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20231231_z1s2CkMyVJma" title="Federally insured limit"&gt;250,000&lt;/span&gt;. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial
condition, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-18458"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <FBLG:RisksAndUncertaintiesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14824">&lt;p id="xdx_84A_ecustom--RisksAndUncertaintiesPolicyTextBlock_zCM0wh8e2bCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zKNfC1n28vKk"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the
Company believes could have a material adverse effect on the future financial position or results of operations: the timing of, and the
Company&#x2019;s ability to advance its current and future product candidates into and through clinical development; costs and timelines
associated with the manufacture of clinical supplies of the Company&#x2019;s product candidates; regulatory approval and market acceptance
of its product candidates; performance of third-party contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing
organizations (&#x201c;CMOs&#x201d;); competition from pharmaceutical companies with greater financial resources or expertise; protection
of the intellectual property, litigation or claims against the Company based on intellectual property, or other factors; the need to
obtain additional funding; and its ability to attract and retain employees necessary to support its growth. Disruption from CROs&#x2019;,
CMOs&#x2019; or suppliers&#x2019; operations would likely have a negative impact on the Company&#x2019;s business, financial position and
results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</FBLG:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14836">&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zOqnLLqHGWq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zKIHFte91RX1"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three
months or less at the time of purchase. There were &lt;span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_zdGKDMCreLA3" title="Cash equivalents"&gt;&lt;span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zTcjr9BCeQn" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="ixv-18459"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="ixv-18460"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14861">&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zMVkNCl4TJTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zoHu2zwW1ubi"&gt;Property
and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is computed using the straight-line
method over the estimated useful lives of the respective assets, generally three to five years, and includes laboratory equipment that is
recorded at cost and depreciated using the straight-line method over the estimated useful lives of five years. Depreciation expense is
classified in either research and development expense or in general and administrative expense, depending upon the nature of the asset,
in the accompanying Statements of Operations. When property and equipment assets are retired or otherwise disposed of, the cost and related
accumulated depreciation are removed from the balance sheets and the resulting gain or loss is recorded in other income (loss) in the
period realized. Maintenance and repairs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets
might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable
market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that
would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used,
the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and
measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for
the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14877">&lt;p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_znec43ArZIxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_865_zYvw03D16fRi"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company determines if an arrangement is a lease at inception. An arrangement is or contains a lease if it conveys the right to control
the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification is determined
at lease commencement. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement
date. The Company&#x2019;s leases do not provide an implicit interest rate and therefore the Company estimates its incremental borrowing
rate to discount lease payments. The incremental borrowing rate reflects the interest rate that the Company would have to pay to borrow
on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term. Operating lease
right-of-use (&#x201c;ROU&#x201d;) assets are based on the corresponding lease liability adjusted for any lease payments made at or before
commencement, initial direct costs, and lease incentives. Renewals or early terminations are not accounted for unless the Company is
reasonably certain to exercise these options. Operating lease expense is recognized and the ROU asset is amortized on a straight-line
basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Operating
leases are included in operating lease right-of-use asset, operating lease liability, short-term, and operating lease liability, long-term
on the Company&#x2019;s Balance Sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company has elected in accordance with ASC 842-20-25-2 an accounting policy to not record short-term leases, defined as those with terms
of 12 months or less, on the Balance Sheets. Rent expense recorded under leases, for financial statement purposes, is recognized on a
straight-line basis over the lease term based on the most recent contractual terms available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14896">&lt;p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgvxc4Dp8Fl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_86E_z69gfL6mD6u2"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Accounting
Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, establishes a fair value hierarchy for instruments measured
at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions
(unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market
data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about
the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available
in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions
in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Level
1 - Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Level
2 - Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates
and yield curves.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Level
3 - Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management&#x2019;s
own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about
risk).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Categorization
within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14937">&lt;p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zey6YkvhidG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;&lt;span id="xdx_863_zuS18C0BfOIb"&gt;Derivatives&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Derivative financial instruments,
including the Liability instrument, are recorded at fair value on the Balance Sheet. Liability classified derivatives are remeasured at their
fair value at each reporting date, with decreases or increases in the fair value recognized as other gain or loss, respectively, within
the Statement of Operations. Equity classified derivatives are not remeasured at each reporting date. If a liability classified derivative
becomes eligible for reclassification to an equity classified derivative, any gains or losses recognized up to the point of reclassification
are not reversed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-12-31" id="ixv-14945">&lt;p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZ1BEmZTWuR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zAmDAIw1ZIO5"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research
and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory
supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain
research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern
of costs incurred, and are reflected in the Financial Statements as prepaid or accrued research and development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-12-31" id="ixv-14957">&lt;p id="xdx_84F_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zbOxJbLR5wDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zbLAotx4dYh8"&gt;Patent
Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company continues to incur costs to obtain market approval of patented technology, patent costs are expensed as incurred in general,
administrative and other expense in the Statements of Operations. Costs include fees to renew or extend the term of recognized intangible
assets, patent defense costs, and patent application costs. Management will continue to expense such costs until market approval is obtained
through regulatory approval by the appropriate governing body.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14969">&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zHewRXz5l1E1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zFTimCOV9u3k"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company is a C corporation, and accounts for income taxes under the asset and liability
method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement
and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.
Valuation allowances are established when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the provisions of ASC 740-10, &lt;i&gt;Income Taxes&lt;/i&gt;, the Company evaluates uncertain tax positions by reviewing against applicable tax
law all positions taken by the Company with respect to tax years for which the statute of limitations is still open. ASC 740-10 provides
that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained
upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The Company recognizes
interest and penalties related to the liability for unrecognized tax benefits, if any, as a component of the income tax expense line
in the accompanying Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-14984">&lt;p id="xdx_84B_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z2DJvtjEuD1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zbrppPtA8Sm9"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes compensation costs related to stock options granted to employees and nonemployees based on the estimated fair value
of the awards on the date of grant and recognizes expense on a straight-line basis over the requisite service period, which is generally
the vesting period of the award. Forfeitures are recognized as they occur. The fair value of stock options is estimated on the date of
grant using a Black-Scholes option pricing model which requires management to apply judgment and make estimates, including:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
    Value of Common Stock&lt;/i&gt;&#x2014;The estimated fair value of our common stock underlying our stock-based awards has been determined
    by our board of directors as of each option grant date with input from management, considering our most recently available
    third-party valuations of common stock and our board of directors&#x2019; assessment of additional objective and subjective factors
    that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant.
    These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public
    Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the
    Practice Aid). Now that a public trading market for our common stock has been established in connection with the completion of the
    Direct Listing, the fair value of common stock in future grants will be based on the closing price as reported on The Nasdaq Global Select Market on the
    date of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Term&lt;/i&gt;&#x2014;The expected term represents the period that a stock-based award is expected to be outstanding. The Company uses the
    simplified method to determine the expected term, which is based on the average of the time-to-vesting and the contractual life of
    the option.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Volatility&lt;/i&gt;&#x2014; Due to the Company&#x2019;s limited operating history and lack of company-specific historical and implied volatility
    data, the expected volatility is estimated based on the average historical volatilities of common stock of comparable publicly traded
    entities over a period of time commensurate with the expected term of the stock option grants. The comparable companies are chosen
    based on their size, stage in the product development cycle, or area of specialty. The Company will continue to apply this process
    until sufficient historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-Free
    Interest Rate&lt;/i&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon
    U.S. Treasury notes with maturities approximately equal to the expected term of the awards.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Dividend&lt;/i&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock.
    Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <FBLG:EmergingGrowthCompanyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15052">&lt;p id="xdx_847_ecustom--EmergingGrowthCompanyPolicyTextBlock_z4MVFVraF6ue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zvsvRe7B3p5k"&gt;Emerging
Growth Company&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
the completion of the Direct Listing, the Company is an emerging growth company (EGC), as defined in the Jumpstart Our Business Startups
Act of 2012 (JOBS Act). Under the JOBS Act, an EGC can delay adopting new or revised accounting standards issued subsequent to the enactment
of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition
period for complying with new or revised accounting standards that have different effective dates for public and private companies; however,
the Company may adopt new or revised accounting standards early if the standard allows for early adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, the Company will utilize other exemptions and reduced reporting requirements provided to EGCs by the JOBS Act. Subject to certain
conditions set forth in the JOBS Act, an EGC is not required to, among other things, (i) provide an auditor&#x2019;s attestation report
on the company&#x2019;s system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002,
(ii) provide all of the compensation disclosure that may be required of non-EGC public companies under the Dodd-Frank Wall Street Reform
and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding
mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the
financial statements (auditor discussion and analysis), or (iv) disclose certain executive compensation-related items, such as the correlation
between executive compensation and performance and comparisons of the chief executive officer&#x2019;s compensation to median employee
compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</FBLG:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15067">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zF9lBFxyj566" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zy4HvretUkF8"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;There have been no accounting pronouncements issued but not yet adopted by the Company that are expected to have a material impact on
the Company&#x2019;s Financial Statements.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15077">&lt;p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_z2u7DmYYXDTd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_828_zBXZptKVMQFk"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z0dYk4poM839" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zVKpKEtpCaTa" style="display: none"&gt;Schedule
of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zu8kbZ2g6hlf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20221231_zQsA2Qcw3FAd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;(in thousands, except share and per share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zi9yPG10Rbrh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: justify"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(16,485&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(5,121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Adjustment to numerator for earnings per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeemedDividend_pn3n3_zejgX65pHSMk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Deemed dividend&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,573&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zMGm5Vglj8Q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Net loss attributable to common stockholders:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,058&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,121&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Weighted-average number of common shares outstanding, basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zdJApRGVbmnf" title="Weighted average number of shares outstanding, basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zlhNGNuwHShi" title="Weighted average number of shares outstanding, diluted"&gt;28,230,842&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231_zpuyPZbdiYSf" title="Weighted average number of shares outstanding, basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20221231_zqNTkQR0nUtg" title="Weighted average number of shares outstanding, diluted"&gt;28,230,842&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Net loss per common share attributable to common stockholders, basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zXJeHCOo15C7" title="Net loss per share, basic"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zT0ZKNo8sKmf" title="Net loss per share, diluted"&gt;(0.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zWoD99bcKbqf" title="Net loss per share, basic"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_zdCCF9wil7Mh" title="Net loss per share, diluted"&gt;(0.18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zLZZJHROg5lk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
further described in Note 7, the Company issued &lt;span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zyI04K1twSRf" title="Common stock, shares issued"&gt;28,230,842&lt;/span&gt; shares of non-voting common stock on August 18, 2022. The weighted average
number of shares outstanding for the years ended December 31, 2023 and 2022, is based upon the non-voting common stock shares issued
on August 18, 2022. Because the issuance of nonvoting common stock shares was treated as a stock split for accounting purposes, these
shares are treated as having been issued on January 1, 2022, and outstanding for the entire years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
further described in Note 11, the Company agreed to pay to FibroGenesis 15% of the gross proceeds from any equity investments in FibroBiologics
prior to an Initial Public Offering (&#x201c;IPO&#x201d;), Direct Listing or Sale of the Company to eliminate upon the occurrence of such
event the Series A Preferred Stock and its $&lt;span id="xdx_903_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn6n6_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5p5yDhUxLU" title="Preferred stock liquidation value"&gt;35&lt;/span&gt; million liquidation preference. This redemption of preferred stock created a derivative
liability that exceeded the net Parent Investment of $&lt;span id="xdx_908_eus-gaap--PreferredStockRedemptionAmount_iI_pn3n3_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MaximumMember_znyXxZJdeAgj" title="Preferred stock, redemption amount"&gt;1,461&lt;/span&gt; thousand by $&lt;span id="xdx_903_eus-gaap--PreferredStockRedemptionAmount_iI_pn3n3_c20220818__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zhorCztprQo8" title="Preferred stock, redemption amount"&gt;1,112&lt;/span&gt; thousand, and is reflected here as a reduction of the
amount available to common stockholders in the calculation of earnings per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had $&lt;span id="xdx_906_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20221231_zVOm3YkF9PAl" title="Convertible notes outstanding"&gt;5,600&lt;/span&gt; thousand of convertible notes outstanding as of December 31, 2022, which could have been converted into common stock
in the event that the Company sold and issued shares of capital stock in excess of $&lt;span id="xdx_900_ecustom--CapitalStockInExcess_iI_pn3n3_c20221231_z6mkqfnyFqk" title="Capital stock in excess"&gt;10,000&lt;/span&gt; thousand, and were all converted by December
31, 2023, into shares of Series B Preferred Stock as further described in Note 6. As of December 31, 2022, the estimated number of shares
of common stock that would have been issued upon conversion was &lt;span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220101__20221231_zo42ctilWFl6" title="Issued upon conversion of common stock"&gt;801,145&lt;/span&gt; shares. For the years ended December 31, 2023 and 2022, the Company
reported net losses and, accordingly, potential common shares were not included since such inclusion would have been anti-dilutive. As
a result, the Company&#x2019;s basic and diluted net losses per share are the same because it generated a net loss in all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15086">&lt;p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z0dYk4poM839" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zVKpKEtpCaTa" style="display: none"&gt;Schedule
of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zu8kbZ2g6hlf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20221231_zQsA2Qcw3FAd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;(in thousands, except share and per share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zi9yPG10Rbrh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: justify"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(16,485&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(5,121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Adjustment to numerator for earnings per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeemedDividend_pn3n3_zejgX65pHSMk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Deemed dividend&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,573&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zMGm5Vglj8Q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Net loss attributable to common stockholders:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,058&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,121&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Weighted-average number of common shares outstanding, basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zdJApRGVbmnf" title="Weighted average number of shares outstanding, basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zlhNGNuwHShi" title="Weighted average number of shares outstanding, diluted"&gt;28,230,842&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231_zpuyPZbdiYSf" title="Weighted average number of shares outstanding, basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20221231_zqNTkQR0nUtg" title="Weighted average number of shares outstanding, diluted"&gt;28,230,842&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Net loss per common share attributable to common stockholders, basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zXJeHCOo15C7" title="Net loss per share, basic"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zT0ZKNo8sKmf" title="Net loss per share, diluted"&gt;(0.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zWoD99bcKbqf" title="Net loss per share, basic"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_zdCCF9wil7Mh" title="Net loss per share, diluted"&gt;(0.18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18461"
      unitRef="USD">-16485000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18462"
      unitRef="USD">-5121000</us-gaap:NetIncomeLoss>
    <FBLG:DeemedDividend
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18463"
      unitRef="USD">-2573000</FBLG:DeemedDividend>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18464"
      unitRef="USD">-19058000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18465"
      unitRef="USD">-5121000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18466"
      unitRef="Shares">28230842</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18467"
      unitRef="Shares">28230842</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18468"
      unitRef="Shares">28230842</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18469"
      unitRef="Shares">28230842</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18470"
      unitRef="USDPShares">-0.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18471"
      unitRef="USDPShares">-0.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18472"
      unitRef="USDPShares">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18473"
      unitRef="USDPShares">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-08-18_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18474"
      unitRef="Shares">28230842</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember"
      decimals="-6"
      id="ixv-18475"
      unitRef="USD">35000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockRedemptionAmount
      contextRef="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember_srt_MaximumMember"
      decimals="-3"
      id="ixv-18476"
      unitRef="USD">1461000</us-gaap:PreferredStockRedemptionAmount>
    <us-gaap:PreferredStockRedemptionAmount
      contextRef="AsOf2022-08-18_us-gaap_SeriesAPreferredStockMember_srt_MinimumMember"
      decimals="-3"
      id="ixv-18477"
      unitRef="USD">1112000</us-gaap:PreferredStockRedemptionAmount>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18478"
      unitRef="USD">5600000</us-gaap:ConvertibleNotesPayable>
    <FBLG:CapitalStockInExcess
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18479"
      unitRef="USD">10000000</FBLG:CapitalStockInExcess>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18480"
      unitRef="Shares">801145</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15237">&lt;p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_ziBYyVzNIDYi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_820_zn1Stxouvjgl"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwkvNwMSVfij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zrZpqfg7xer2" style="display: none"&gt;Schedule
of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zJHTNJbuNowg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zfBe724ZDyel" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zVFYgHl8sNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;816&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0736"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zhVeI3z0qLvg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Computer equipment, software, and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzT4x_zdxjoNYWrnJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total property and equipment at cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzT4x_zVMRjGrd2pWh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzT4x_z9sJOuSJjzkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;797&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0748"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z2nWgZqRmgei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The useful life of Laboratory
equipment is &lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaborataryEquipmentMember_zSvB5AL4Iaj2"&gt;five
years&lt;/span&gt;, and the useful life of Computer equipment, software, and other is &lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zi2KZge2USk3"&gt;three
years&lt;/span&gt;, for deprecation. &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation expense was $&lt;span id="xdx_904_eus-gaap--Depreciation_pn3n3_c20230101__20231231_z2rUirPXyKCh" title="Depreciation expense"&gt;47
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;thousand and $&lt;span id="xdx_906_eus-gaap--Depreciation_dxL_c20220101__20221231_zu74kcDkYkyf" title="Depreciation expense::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0754"&gt;0&lt;/span&gt;&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the years ended December 31, 2023 and 2022,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15246">&lt;p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwkvNwMSVfij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zrZpqfg7xer2" style="display: none"&gt;Schedule
of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zJHTNJbuNowg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zfBe724ZDyel" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zVFYgHl8sNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;816&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0736"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zhVeI3z0qLvg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Computer equipment, software, and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzT4x_zdxjoNYWrnJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total property and equipment at cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzT4x_zVMRjGrd2pWh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzT4x_z9sJOuSJjzkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;797&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0748"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_LaboratoryEquipmentMember"
      decimals="-3"
      id="ixv-18481"
      unitRef="USD">816000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="ixv-18482"
      unitRef="USD">28000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18483"
      unitRef="USD">844000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18484"
      unitRef="USD">47000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18485"
      unitRef="USD">797000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_custom_LaborataryEquipmentMember"
      id="ixv-18486">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember"
      id="ixv-18487">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18488"
      unitRef="USD">47000</us-gaap:Depreciation>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15342">&lt;p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zg0tRzLLlj1g" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82F_zBdkAFbTAe48"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company measured its derivative liability related to the conversion option feature in the 2022 Notes, as described
in Note 6, at fair value. As of December 31, 2023, the 2022 Notes had been converted, which eliminated the derivative liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the Company measured its liability instrument to investors under the Share Purchase Agreement, as further
described in Note 8, at $&lt;span id="xdx_901_ecustom--LiabilityInstrument_iI_pn3n3_c20231231_z06TqnkKKje6" title="Liability instrument"&gt;7,236&lt;/span&gt;
thousand. This liability instrument is classified within Level 3 of the value hierarchy because the liability was based upon a
valuation model that used inputs and assumptions including potential outcomes, interest rates, probabilities, and timing. As of
December 31, 2022 and 2021, this liability instrument was assigned &lt;span id="xdx_908_ecustom--LiabilityInstrument_iI_pn3n3_dxL_c20221231_z5fMYDm37JCl" title="Liability instrument::XDX::-"&gt;&lt;span id="xdx_906_ecustom--LiabilityInstrument_iI_pn3n3_dxL_c20211231_zUHhhLd97fU2" title="Liability instrument::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0762"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
value by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zxcyuXtjdMae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize the Company&#x2019;s financial liabilities measured at fair value on a recurring basis based on the three-tier
fair value hierarchy:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zNKASbrI9hL4" style="display: none"&gt;Schedule
of Financial Liabilities Measured at Fair Value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLLuS0PczDq9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4QwOa4vrGDf" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqK5YCQi6hRc" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_zHDTFayCne1h" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurement as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3n3_maFLFVDzjkJ_zd28TiS69tu" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Derivative liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0769"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--LiabilityInstrument_iI_pn3n3_maFLFVDzjkJ_zSVJOIJHeuMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1.5pt"&gt;Liability instrument&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0771"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iTI_pn3n3_mtFLFVDzjkJ_zUTrzedZQ5v4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0777"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zv9FVDrwyWrh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbm3b64kBb53" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAs0SJ0b4x91" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zVaRRvyjdPe3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurement as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3n3_maFLFVDzjkJ_zE4RX3P8S3nb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: justify"&gt;Derivative liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0781"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LiabilityInstrument_iI_pn3n3_maFLFVDzjkJ_zEUrEX1sjtxi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Liability instrument&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0786"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0787"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0788"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0789"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iTI_pn3n3_mtFLFVDzjkJ_zrwptT3BQmp4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0791"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zip3wzSjs8xb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z6c68rgTTnp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the transfers in and out of Level 3 financial liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zTHKXPMPqPb5" style="display: none"&gt;Schedule
of Financial Liability Transfers&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BB_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zDan4JiNQ9Ji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Derivative Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B8_us-gaap--FinancialInstrumentAxis_custom--LiabilityInstrumentMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zaoNWEPM5a0c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Liability Instrument&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43B_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z92TrGkB33X8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Fair value at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0799"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_i01_zOqdkfh6hZhf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: justify; padding-bottom: 1.5pt"&gt;Addition to derivative liability for debt issuance discount&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0802"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43C_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z3GoE9sf6z76" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Fair value at December 31, 20222&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43D_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zTb4d5OK5Ltl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Fair value, beginning balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_i01_zGJdBDaCkNN2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(538&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_i02_zT8ZthOEVd78" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Increase in the fair value of the liability instrument&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_432_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zApiiV7yRhxd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Fair value at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_437_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zVTS1vt1qSaa" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Fair value, ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A2_zcA3Gu1mOI3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the liability instrument includes the contingent warrant and the contingent put option as a single unit of
account. The liability instrument value was determined using a Black-Scholes valuation model and management&#x2019;s assumption of a
50% likelihood as of December 31, 2023, of becoming a public company prior to the expiration of the Stock Purchase Agreement. Inputs
used in the Black-Scholes valuation model included an estimated number of warrants, an assumed common stock share price of $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_c20231231_zGZgzBBrQirl" title="Share price"&gt;15.00&lt;/span&gt;
per share, the &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputMaturityMember_zl0YAK8Sb2n" title="Maturity period::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0824"&gt;five-year&lt;/span&gt;&lt;/span&gt;
time to maturity, a &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJdWIEpXDIy" title="Dividend yield"&gt;0&lt;/span&gt;%
dividend yield, an annual risk-free interest rate of &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ziQDhX260m44" title="Dividend yield"&gt;3.84&lt;/span&gt;%
for the &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputMaturityMember_zoBmK2rRcmp3" title="Maturity period::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;five-year&lt;/span&gt;&lt;/span&gt;
time to maturity, and an assumed annualized volatility of &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zHWZLdXUg6fe" title="Dividend yield"&gt;96&lt;/span&gt;%
based on comparable companies with a five-year history of stock prices. As of December 31, 2023, the Company evaluated the put option component of the liability instrument and determined
that any value as it relates to the liability instrument would be de minimus given the Company&#x2019;s financial condition, intention
to seek other sources of financing as needed, and ability to do so given access to public markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
derivative liability was determined based upon a valuation model that used inputs and assumptions including potential outcomes, interest
rates, probabilities, and timing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash and cash equivalents, prepaid expenses, other current assets, accounts payable, accrued expenses, convertible
notes payable, and Parent company payable and receivable approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
than those transfers noted in the table above, there were no transfers in or out of Level 1, Level 2 or Level 3 assets and liabilities
for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18489"
      unitRef="USD">7236000</FBLG:LiabilityInstrument>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15364">&lt;p id="xdx_893_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zxcyuXtjdMae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize the Company&#x2019;s financial liabilities measured at fair value on a recurring basis based on the three-tier
fair value hierarchy:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zNKASbrI9hL4" style="display: none"&gt;Schedule
of Financial Liabilities Measured at Fair Value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLLuS0PczDq9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4QwOa4vrGDf" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqK5YCQi6hRc" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_zHDTFayCne1h" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurement as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3n3_maFLFVDzjkJ_zd28TiS69tu" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Derivative liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0769"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--LiabilityInstrument_iI_pn3n3_maFLFVDzjkJ_zSVJOIJHeuMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 1.5pt"&gt;Liability instrument&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0771"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iTI_pn3n3_mtFLFVDzjkJ_zUTrzedZQ5v4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0777"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zv9FVDrwyWrh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbm3b64kBb53" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAs0SJ0b4x91" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zVaRRvyjdPe3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurement as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeLiabilitiesCurrent_iI_pn3n3_maFLFVDzjkJ_zE4RX3P8S3nb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: justify"&gt;Derivative liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0781"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--LiabilityInstrument_iI_pn3n3_maFLFVDzjkJ_zEUrEX1sjtxi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Liability instrument&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0786"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0787"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0788"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0789"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iTI_pn3n3_mtFLFVDzjkJ_zrwptT3BQmp4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0791"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ixv-18490"
      unitRef="USD">7236000</FBLG:LiabilityInstrument>
    <FBLG:LiabilityInstrument
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18491"
      unitRef="USD">7236000</FBLG:LiabilityInstrument>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ixv-18492"
      unitRef="USD">7236000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18493"
      unitRef="USD">7236000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ixv-18494"
      unitRef="USD">538000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18495"
      unitRef="USD">538000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ixv-18496"
      unitRef="USD">538000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18497"
      unitRef="USD">538000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15615">&lt;p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z6c68rgTTnp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the transfers in and out of Level 3 financial liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zTHKXPMPqPb5" style="display: none"&gt;Schedule
of Financial Liability Transfers&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BB_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zDan4JiNQ9Ji" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Derivative Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B8_us-gaap--FinancialInstrumentAxis_custom--LiabilityInstrumentMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zaoNWEPM5a0c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Liability Instrument&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43B_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z92TrGkB33X8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Fair value at December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0799"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount_i01_zOqdkfh6hZhf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; text-align: justify; padding-bottom: 1.5pt"&gt;Addition to derivative liability for debt issuance discount&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0802"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43C_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z3GoE9sf6z76" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Fair value at December 31, 20222&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43D_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zTb4d5OK5Ltl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Fair value, beginning balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock_i01_zGJdBDaCkNN2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(538&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_i02_zT8ZthOEVd78" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Increase in the fair value of the liability instrument&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_432_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zApiiV7yRhxd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Fair value at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_437_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zVTS1vt1qSaa" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Fair value, ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,236&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <FBLG:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount
      contextRef="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ixv-18498"
      unitRef="USD">538000</FBLG:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationAdditionToDerivativeLiabilityForDebtIssuanceDiscount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ixv-18499"
      unitRef="USD">538000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ixv-18500"
      unitRef="USD">538000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <FBLG:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock
      contextRef="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ixv-18501"
      unitRef="USD">-538000</FBLG:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ixv-18502"
      unitRef="USD">7236000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ixv-18503"
      unitRef="USD">7236000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_custom_LiabilityInstrumentMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="ixv-18504"
      unitRef="USD">7236000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-18505"
      unitRef="USDPShares">15.00</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="ixv-18506"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="ixv-18507"
      unitRef="Pure">0.0384</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="ixv-18508"
      unitRef="Pure">0.96</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15745">&lt;p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zQzF13VFyLuj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82B_zFvXv0qrDcHj"&gt;Convertible Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company entered into multiple convertible promissory note agreements in December 2021 (collectively, the &#x201c;2021 Notes&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;At
the inception of the 2021 Notes, and at December 31, 2021 and 2022, the Company determined that an embedded derivative for the conversion
feature did not meet the criteria because it met the &#x201c;indexed to the entity&#x2019;s own stock&#x201d; exception per the guidance
in ASC 815-10-15-74(a) and therefore was not required to be bifurcated from the host instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company issued additional convertible promissory notes between January and April 2022 with a total principal amount of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20221231_zMPzXaM98Ebe" title="Long-term debt, gross"&gt;4,300&lt;/span&gt; thousand
and a one-year maturity (collectively, the &#x201c;2022 Notes&#x201d;). The 2022 Notes may be converted at the lesser of &lt;span id="xdx_902_eus-gaap--ConversionOfStockDescription_c20220101__20221231_z1EosKjra0Na"&gt;a) a 15% discount
to the offering price of the Company&#x2019;s common stock in the event of an initial public offering of the Company or b) the quotient
of $200,000 thousand divided by total equity interests prior to the dilution from the offering. The conversion option feature in the
2022 Notes was evaluated in accordance with ASC 815, and a derivative liability for the $538 thousand estimated fair value of the conversion
option was recorded at the time the notes were issued and as of December 31, 2022.&lt;/span&gt; An offsetting discount on the issuance of the notes
was recorded and is being amortized to interest expense over the expected life of the 2022 Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
interest expense, excluding amortization of the discount recorded on the 2022 Notes, on the 2021 and 2022 Notes for the years ended December
31, 2023 and 2022, was $&lt;span id="xdx_905_eus-gaap--InterestExpenseDebt_pn3n3_c20230101__20231231_zheOCS5KAJu5" title="Interest expense"&gt;65&lt;/span&gt; thousand and $&lt;span id="xdx_900_eus-gaap--InterestExpenseDebt_pn3n3_c20220101__20221231_z1pC6uGJWesb" title="Interest expense"&gt;265&lt;/span&gt; thousand, respectively. Accrued interest was outstanding and included within accounts payable
and accrued expenses at December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2023, the Company converted the principal and interest on $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230228__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_z3ytIkqOtnih" title="Face value"&gt;3,700&lt;/span&gt; thousand of principal value of the 2022 Notes into &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230228__20230228__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zWMOTQ4RQKHg" title="Converted principal shares"&gt;799,603&lt;/span&gt;
shares of Series &#x201c;B&#x201d; Preferred Stock. In April 2023, the Company also converted the principal and interest on $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230430__us-gaap--AwardDateAxis__custom--TwoThousandTwentyOneNotesMember_zIoGHQedMyZg" title="Face value"&gt;1,300&lt;/span&gt; thousand
of principal value of the 2021 Notes and $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230430__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zFzUss0XgUS9" title="Face value"&gt;300&lt;/span&gt; thousand of principal value on the 2022 Notes into &lt;span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230430__20230430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zTJC820zOXkc" title="Converted principal shares"&gt;353,713&lt;/span&gt; shares of Series &#x201c;B&#x201d;
Preferred Stock. In September 2023, the Company converted the principal and interest on $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230930__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zlv5MlBJA2D1" title="Face value"&gt;300&lt;/span&gt; thousand of principal value of the 2022
Notes into &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoNotesMember_zIlIicarrrhk" title="Converted principal shares"&gt;66,077&lt;/span&gt; shares of Series &#x201c;B&#x201d; Preferred Stock. No interest was outstanding and included within accounts payable
and accrued expenses at December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ConvertibleDebtTableTextBlock_zVO08cHnhuP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
convertible debt balances consisted of the following at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zX3mntGP8fJj" style="display: none"&gt;Schedule
of Convertible Debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_z25Oeg9YnNC2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_z1IL1owBFkX9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_zCuYZINdJ0Rl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Convertible notes principal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_ziuOa8C2CBp6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Convertible notes discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0862"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(149&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_ztByUfwJGlS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Convertible notes payable, net of discount&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,451&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zGjAiLLeI8dl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18509"
      unitRef="USD">4300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConversionOfStockDescription contextRef="From2022-01-012022-12-31" id="ixv-18510">a) a 15% discount
to the offering price of the Company&#x2019;s common stock in the event of an initial public offering of the Company or b) the quotient
of $200,000 thousand divided by total equity interests prior to the dilution from the offering. The conversion option feature in the
2022 Notes was evaluated in accordance with ASC 815, and a derivative liability for the $538 thousand estimated fair value of the conversion
option was recorded at the time the notes were issued and as of December 31, 2022.</us-gaap:ConversionOfStockDescription>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18511"
      unitRef="USD">65000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18512"
      unitRef="USD">265000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-02-28_custom_TwoThousandTwentyTwoNotesMember"
      decimals="-3"
      id="ixv-18513"
      unitRef="USD">3700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-02-282023-02-28_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember"
      decimals="INF"
      id="ixv-18514"
      unitRef="Shares">799603</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-04-30_custom_TwoThousandTwentyOneNotesMember"
      decimals="-3"
      id="ixv-18515"
      unitRef="USD">1300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-04-30_custom_TwoThousandTwentyTwoNotesMember"
      decimals="-3"
      id="ixv-18516"
      unitRef="USD">300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-04-302023-04-30_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember"
      decimals="INF"
      id="ixv-18517"
      unitRef="Shares">353713</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-09-30_custom_TwoThousandTwentyTwoNotesMember"
      decimals="-3"
      id="ixv-18518"
      unitRef="USD">300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-09-30_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyTwoNotesMember"
      decimals="INF"
      id="ixv-18519"
      unitRef="Shares">66077</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15796">&lt;p id="xdx_89A_eus-gaap--ConvertibleDebtTableTextBlock_zVO08cHnhuP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
convertible debt balances consisted of the following at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zX3mntGP8fJj" style="display: none"&gt;Schedule
of Convertible Debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_z25Oeg9YnNC2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_z1IL1owBFkX9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_zCuYZINdJ0Rl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Convertible notes principal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_ziuOa8C2CBp6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Convertible notes discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0862"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(149&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_ztByUfwJGlS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Convertible notes payable, net of discount&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,451&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18520"
      unitRef="USD">5600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18521"
      unitRef="USD">149000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18522"
      unitRef="USD">5451000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15861">&lt;p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z5LOF9CdNifl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_824_zJQs3LQTfNEd"&gt;Stockholders&#x2019; Equity/(Deficit) and Net Parent Investment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Authorized
Capital - &lt;/b&gt;As of December 31, 2023 and 2022, the Company authorized &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zNxjJLRwUema" title="Preferred stock, shares authorized"&gt;20,000,000&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_zitD7LmHlsP5" title="Preferred stock, shares authorized"&gt;12,500,000&lt;/span&gt; preferred stock shares, respectively.
As of December 31, 2022, the Company had issued &lt;span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zvexj6QAIVN6" title="Preferred stock, shares issued"&gt;8,750,000&lt;/span&gt; Series &#x201c;A&#x201d; Preferred Stock shares to FibroGenesis, which were tendered
pursuant to the formation of the Company in exchange for the contribution of certain in-process research and development and patent assets
through Patent Assignment and Intellectual Property Cross-License Agreements. The Series &#x201c;A&#x201d; Preferred Stock shares had the
right to vote and ranked prior to non-voting common stock and common stock with respect to payment of dividends and distributions and
upon liquidation, dissolution, winding-up or otherwise. In addition, the Series &#x201c;A&#x201d; Preferred Stock had a liquidation preference
equal to $&lt;span id="xdx_90A_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGmZYyyCqEac" title="Preferred stock liquidation value"&gt;35,000&lt;/span&gt; thousand to be allocated among the holders of the Series &#x201c;A&#x201d; Preferred Stock shares in the event of a liquidation,
dissolution, or winding-up of the Company, which was subsequently eliminated as part of the ROFN Agreement as further described below,
and each share of Series &#x201c;A&#x201d; Preferred Stock could have been converted into one share of common stock at any time at the
election of the holder of such shares of Series &#x201c;A&#x201d; Preferred Stock. Unless otherwise elected by the holder(s), a merger
or consolidation in which the Company is not the majority surviving entity or the sale of all or substantially all of the assets of the
corporation would have been a deemed liquidation event. The Company had also authorized &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_z6bMcFqJxuO5" title="Common stock, shares authorized"&gt;62,500,000&lt;/span&gt; shares of non-voting common stock,
and issued during the year ended December 31, 2022, a total of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_z7sIcyE2Pqf6" title="Common stock, shares issued"&gt;28,230,842&lt;/span&gt; shares. In August 2022, the Company issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zHvRzkOXrY98" title="Number of shares issued"&gt;28,179,592&lt;/span&gt; shares
of non-voting common stock to its Parent, which in turn distributed the shares to its members. This issuance of non-voting common stock
was accounted for as stock split and no proceeds were received by the Company. The Company also issued to its board of directors, a consultant,
and an employee an additional &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_pid_c20220101__20221231_zESTNHBcIcVa" title="Employee benefit plan"&gt;51,250&lt;/span&gt; total shares in 2022 and recorded $&lt;span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_pn3n3_c20220101__20221231_z3U0aVm2nR68" title="Share based compensation"&gt;168&lt;/span&gt; thousand of expense for the issuance of these shares, which
was based upon a third-party valuation of the shares at the time of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2022, the Company amended its Certificate of Incorporation to authorize &lt;span id="xdx_90C_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zMiPAcOdm0a2" title="Preferred stock, shares authorized"&gt;2,500,000&lt;/span&gt;
shares of Series &#x201c;B&#x201d; Preferred Stock and issued &lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfRvAiLvbaJf" title="Preferred stock, shares issued"&gt;381,658&lt;/span&gt;
shares in exchange for $&lt;span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7IVPaNKa1Xe" title="Preferred stock, shares issued"&gt;2,150&lt;/span&gt;
thousand. The Series &#x201c;B&#x201d; Preferred Stock has a liquidation preference after Series &#x201c;A&#x201d; Preferred Stock and
prior to Common Stock and Non-Voting Common Stock. The Series &#x201c;B&#x201d; Preferred Stock has a liquidation preference of $&lt;span id="xdx_905_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0ZgEiQz3yY2" title="Preferred stock, liquidation preference per share"&gt;6.76&lt;/span&gt;
per share, subject to adjustment, has voting rights, and will automatically convert into Common Stock upon closing of an IPO
transaction, as defined in the Company&#x2019;s Amended and Restated Certificate of Incorporation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, to reflect the ROFN Agreement with its Parent, as further discussed in Note 11, the Company amended its Certificate of
Incorporation to a) eliminate upon IPO, Direct Listing, or Sale of the Company the Series &#x201c;A&#x201d; Preferred Stock $&lt;span id="xdx_905_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20230131_z3OWPL4A6bh9" title="Liquidation preference"&gt;35,000&lt;/span&gt; thousand
liquidation preference, b) make the Series &#x201c;B&#x201d; Preferred Stock liquidation preference equal to Series &#x201c;A&#x201d; Preferred
Stock, and c) to provide that upon IPO, Direct Listing, or Sale of the Company Series &#x201c;A&#x201d; Preferred Stock will be canceled
for no consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2023, the Company amended its Certificate of Incorporation to authorize &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230430_zH4UoocHHqaa" title="Common stock, shares authorized"&gt;10,000,000&lt;/span&gt;
shares of Common Stock, increase the number of authorized Series &#x201c;B&#x201d; Preferred Stock shares up to &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zTixlp10BV51" title="Common stock, shares authorized"&gt;5,000,000&lt;/span&gt;
shares, and to authorize &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230430__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_znXCQLUyK8o5" title="Common stock shares authorized"&gt;5,000,000&lt;/span&gt;
shares of Series &#x201c;B-1&#x201d; Preferred Stock with liquidation preference equal to the Series &#x201c;A&#x201d; and
&#x201c;B&#x201d; Preferred Stock. The Series &#x201c;B-1&#x201d; Preferred Stock has a liquidation preference of $&lt;span id="xdx_906_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20230430__us-gaap--StatementClassOfStockAxis__custom--SeriesB1PreferredStockMember_z0Bycmxl5uG" title="Preferred stock, liquidation preference per share"&gt;20.00&lt;/span&gt; per share,
subject to adjustment, has voting rights, and will automatically convert into Common Stock upon closing of an IPO transaction, as
defined in the Company&#x2019;s Amended and Restated Certificate of Incorporation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company raised $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9TcR8k4MWh5" title="Stock issued during period, value, new issues"&gt;4,620&lt;/span&gt; thousand, net of fees, through a Regulation CF offering with &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zq9dCVQGC9Wh" title="Stock issued during period, shares, new issues"&gt;890,310&lt;/span&gt; shares
of Series &#x201c;B&#x201d; Preferred Stock issued, raised $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zQzmMRrT05ac" title="Stock issued during period, value, new issues"&gt;10,325&lt;/span&gt; thousand in a private placement with &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsO7B3kYHwuf" title="Stock issued during period, shares, new issues"&gt;1,680,084&lt;/span&gt; shares of Series &#x201c;B&#x201d;
Preferred Stock issued, and raised $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwgWnsGoe8D5" title="Stock issued during period, value, new issues"&gt;1,193&lt;/span&gt; thousand in a private placement with &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNbS7M5wBBBh" title="Stock issued during period, shares, new issues"&gt;89,781&lt;/span&gt; shares of &#x201c;B-1&#x201d; Preferred Stock and
&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1RpZw0vSZAh" title="Stock issued during period, shares, new issues"&gt;10,321&lt;/span&gt; warrants issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In October 2023, the Company
amended and restated its certificate of incorporation with the State of Delaware to increase to &lt;span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231031_zpSY6lLf1KM8" title="Preferred stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares its authorized shares
of voting common stock, par value $&lt;span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231031_z9E8NiAEnDg6" title="Common stock, par or stated value per share"&gt;0.00001&lt;/span&gt; per share, reduce to &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zNKOLyacYD2k" title="Common stock, shares authorized"&gt;30,000,000&lt;/span&gt; shares its authorized shares of non-voting common stock, par
value $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zrqhY3xKB5bk" title="Common stock, par value"&gt;0.00001&lt;/span&gt; per share, and authorize &lt;span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z8HzskKL2ZN4" title="Preferred stock, shares authorized"&gt;2,500&lt;/span&gt; shares of Series C Preferred Stock, par value $&lt;span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zx3OZYbNhPDg" title="Preferred stock, par value"&gt;0.00001&lt;/span&gt; per share. The Series C Preferred
Stock ranks senior to common stock and non-voting common stock and junior to the Series A Preferred Stock, Series B Preferred Stock and
Series B-1 Preferred Stock upon liquidation, dissolution, winding-up or otherwise. The Series C Preferred Stock shall have no voting
rights prior to an IPO, and &lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zwV0eJaB6pGj" title="Sale of stock, price per share"&gt;13,000&lt;/span&gt; votes per share upon closing of an IPO. &lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleTypeOfEquitySecurity_c20231001__20231031_zqik6QoV0D0i" title="Debt instrument convertible descreption"&gt;The Series C Preferred Stock is not entitled to dividends,
has a liquidation preference of $&lt;span id="xdx_90B_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ztAzwKsxJ93k" title="Preferred stock, liquidation preference per share"&gt;18.00&lt;/span&gt; per share, subject to adjustment, may be converted 1:1 at any time at the option of the holder
into common stock, and upon closing of an IPO will if transferred automatically convert 1:1 into common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Also
in October 2023, the Company filed an amended and restated certificate of incorporation with the State of Delaware to immediately effect
a &lt;span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_pid_c20231031__20231031_zAzQtfGjPTx2" title="Reverse stock split"&gt;1-for-4 reverse stock split&lt;/span&gt;. All share and per share amounts in these Financial Statements have been adjusted on a retroactive basis
to reflect the effect of the reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-18523"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-18524"
      unitRef="Shares">12500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="ixv-18525"
      unitRef="Shares">8750000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      id="ixv-18526"
      unitRef="USD">35000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18527"
      unitRef="Shares">62500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18528"
      unitRef="Shares">28230842</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-08-012022-08-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18529"
      unitRef="Shares">28179592</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18530"
      unitRef="Shares">51250</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18531"
      unitRef="USD">168000</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18532"
      unitRef="Shares">2500000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18533"
      unitRef="Shares">381658</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="ixv-18534"
      unitRef="USD">2150000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18535"
      unitRef="USDPShares">6.76</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2023-01-31"
      decimals="-3"
      id="ixv-18536"
      unitRef="USD">35000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-04-30"
      decimals="INF"
      id="ixv-18537"
      unitRef="Shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-04-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18538"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-04-30_custom_SeriesBOnePreferredStockMember"
      decimals="INF"
      id="ixv-18539"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2023-04-30_custom_SeriesB1PreferredStockMember"
      decimals="INF"
      id="ixv-18540"
      unitRef="USDPShares">20.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="ixv-18541"
      unitRef="USD">4620000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="ixv-18542"
      unitRef="Shares">890310</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PrivatePlacementMember"
      decimals="-3"
      id="ixv-18543"
      unitRef="USD">10325000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="ixv-18544"
      unitRef="Shares">1680084</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_SeriesBOnePreferredStockMember_us-gaap_PrivatePlacementMember"
      decimals="-3"
      id="ixv-18545"
      unitRef="USD">1193000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_custom_SeriesBOnePreferredStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="ixv-18546"
      unitRef="Shares">89781</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="ixv-18547"
      unitRef="Shares">10321</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-10-31"
      decimals="INF"
      id="ixv-18548"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-10-31"
      decimals="INF"
      id="ixv-18549"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-10-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18550"
      unitRef="Shares">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-10-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="ixv-18551"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-10-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18552"
      unitRef="Shares">2500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-10-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18553"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-10-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18554"
      unitRef="USDPShares">13000</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DebtInstrumentConvertibleTypeOfEquitySecurity contextRef="From2023-10-012023-10-31" id="ixv-15936">The Series C Preferred Stock is not entitled to dividends,
has a liquidation preference of $18.00 per share, subject to adjustment, may be converted 1:1 at any time at the option of the holder
into common stock, and upon closing of an IPO will if transferred automatically convert 1:1 into common stock.</us-gaap:DebtInstrumentConvertibleTypeOfEquitySecurity>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2023-10-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="ixv-18555"
      unitRef="USDPShares">18.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-10-312023-10-31" id="ixv-18556">1-for-4 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <FBLG:ShareSubscriptionAgreementTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15945">&lt;p id="xdx_80C_ecustom--ShareSubscriptionAgreementTextBlock_zUaGaCJNG1g" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_827_zxWgJ1ZWCn1j"&gt;Share Subscription Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 12, 2021, the Company entered into a Share Purchase Agreement with certain investors for the sale of up to $&lt;span id="xdx_909_eus-gaap--CapitalUnitsTotalCostToInvestors_iI_pn3n3_c20211112__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z65PP2rkf3z3" title="Investors sales"&gt;100,000&lt;/span&gt; thousand
of common stock (the &#x201c;Aggregate Limit&#x201d;). This agreement is contingent upon the Company achieving a public listing of its
common stock. Major terms of the agreement include a commitment fee of &lt;span id="xdx_90D_ecustom--CommitmentFeePercentage_iI_pid_dp_uPure_c20211112__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zBr2fg71fX44" title="Commitment fee percentage"&gt;2&lt;/span&gt;% of the Aggregate Limit, which is due no later than one year
after public listing even if no drawdowns are taken, and five-year warrants issued to the investors at the time of public listing to
purchase common stock shares equal to 4% of the total equity interests of the Company at the lesser of a) the price per share at the
time of the public listing or b) the quotient of $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20211112__20211112__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zac7KAK5cftj" title="Shares issues  initial public offering"&gt;700,000&lt;/span&gt; thousand divided by the total number of equity interests (fully diluted common
shares). &lt;span id="xdx_90D_ecustom--DescriptionOfShareSubscriptionAgreement_c20230101__20231231_zVis86ayY9Hg" title="Description of share subscription agreement"&gt;The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement
following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the
Company&#x2019;s common stock shares over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average
price per share over that same period. A 1% fee must be paid to the investors if the Company is sold in a private sale transaction rather
than completing a public listing of its shares.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</FBLG:ShareSubscriptionAgreementTextBlock>
    <us-gaap:CapitalUnitsTotalCostToInvestors
      contextRef="AsOf2021-11-12_custom_SharePurchaseAgreementMember"
      decimals="-3"
      id="ixv-18557"
      unitRef="USD">100000000</us-gaap:CapitalUnitsTotalCostToInvestors>
    <FBLG:CommitmentFeePercentage
      contextRef="AsOf2021-11-12_custom_SharePurchaseAgreementMember"
      decimals="INF"
      id="ixv-18558"
      unitRef="Pure">0.02</FBLG:CommitmentFeePercentage>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-11-122021-11-12_custom_SharePurchaseAgreementMember"
      decimals="-3"
      id="ixv-18559"
      unitRef="USD">700000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <FBLG:DescriptionOfShareSubscriptionAgreement contextRef="From2023-01-01to2023-12-31" id="ixv-18560">The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement
following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the
Company&#x2019;s common stock shares over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average
price per share over that same period. A 1% fee must be paid to the investors if the Company is sold in a private sale transaction rather
than completing a public listing of its shares.</FBLG:DescriptionOfShareSubscriptionAgreement>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15975">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zAFP1B4hpDd4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_824_zOCIb512Ivea"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMyajH8Q5Dw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&#x2019;s effective income
tax rate is as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B9_zGyMnfEQJVhe"&gt;Schedule
of Effective Income Tax Rate&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20230101__20231231_zQjyP5rCczO" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20220101__20221231_zlEW1BEVXLT4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maIT1_zhpFB2bOyrZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maIT1_z1MMpSlI4bla" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Permanent items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets_iN_pid_dpi_maIT1_zu54jBvn6Dx6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;True-up prior-year net operating loss deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_maIT1_ziVacqX65X78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Non-deductible stock compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maIT1_z9OXNpePOoX8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Other changes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0966"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maIT1_zh5Ip47Jbugl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtIT1_zGACPGAZr545" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zdBQlNy50d7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zZVySOlNpsJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the Company&#x2019;s net deferred tax assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zgVOZU6KCUYa"&gt;Schedule
of Net Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20231231_zoKa37FeocX" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20221231_zFmEtHCPGy01" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands of dollars)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zof6IgjI7NRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzVPk_zzEu0bznNSig" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,005&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzVPk_zzj6ANgkgWDc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability_iI_pn3n3_maDTAGzVPk_zWUnvKIYM492" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzVPk_zw5gAXVTkeij" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzVPk_zOff63TXUi01" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Stock compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsDerivativeInstruments_iI_pn3n3_maDTAGzVPk_zJEuhrbFNNH1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzVPk_maDTANzrSY_zGxD84s8cJi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,326&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_pn3n3_zTyyXVBVfxv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_iNI_pn3n3_di_maDITLzuqP_zVFjhlXtF8P7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Lease right-of-use asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(380&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(462&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_maDITLzuqP_zGQ8CV25vpLl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesUnamortizedDebtDiscount_iNI_pn3n3_di_maDITLzuqP_zioBQTZ1W2Bj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1010"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzuqP_msDTANzrSY_zTgYuoWn5gI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(493&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzrSY_zjv9ACfJB2l3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,935&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,266&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzrSY_zaO9ru3yPtf4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1020"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zFmecsOB2FJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was initially formed as an LLC and was converted to a Delaware corporation in December 2021. As a result of generating net operating
losses during the years ended December 31, 2023 and 2022, the Company had &lt;span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_do_c20230101__20231231_zqpqr8sTM2Ih" title="Income tax expenses"&gt;&lt;span id="xdx_90D_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_do_c20220101__20221231_zpvOMOSR3Lf" title="Income tax expenses"&gt;no&lt;/span&gt;&lt;/span&gt; income tax expense for years ended December 31, 2023 and
2022. As of December 31, 2023, the Company had U.S. federal net operating loss (&#x201c;NOL&#x201d;) carryforwards of $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20231231_zzg8Ahi5mNS6" title="Operating loss carryforwards"&gt;9,547&lt;/span&gt; thousand.
The federal NOL carries forward indefinitely and may become subject to an annual limitation in the event of certain cumulative changes
in the ownership interest. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income
or tax liabilities. Subsequent ownership changes may further affect the limitation in future years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental
to research and experimentation (&#x201c;R&amp;amp;E&#x201d;) activities under IRC Section 174. While taxpayers historically had the option
of deducting these expenses under Internal Revenue Code (&#x201c;IRC&#x201d;) Section 174, the December 2017 Tax Cuts and Jobs Act mandates
capitalization and amortization of R&amp;amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection
with R&amp;amp;E activities in the United States must be amortized over a 5-year period if incurred, and R&amp;amp;E expenses incurred outside
the United States must be amortized over a 15-year period. R&amp;amp;E activities are broader in scope than qualified research activities
considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an
analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization
and amortization of its R&amp;amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect
R&amp;amp;E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company has included the impact
of this provision, which results in a deferred tax asset of approximately $&lt;span id="xdx_90D_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_c20231231_z52aJ2Mc9QVf" title="Deferred tax assets"&gt;680&lt;/span&gt; thousand as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has evaluated the positive and negative evidence bearing upon the realizability of the Company&#x2019;s net deferred tax assets and has
determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result,
the Company has recorded a full valuation allowance at December 31, 2023 and 2022. The Company will continue to assess the realizability
of its deferred tax assets going forward and will adjust the valuation allowance as needed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and 2022, the Company had &lt;span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20231231_z59Ay7r2cY06" title="Uncertain tax positions"&gt;&lt;span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_do_c20221231_zLijGq7bmyH9" title="Uncertain tax positions"&gt;no&lt;/span&gt;&lt;/span&gt; uncertain tax positions. The Company recognizes both interest and penalties associated
with unrecognized tax benefits as a component of income tax expense. The Company has not recorded any interest or penalties for unrecognized
tax benefits since its inception, and no taxes are due.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-15984">&lt;p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMyajH8Q5Dw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company&#x2019;s effective income
tax rate is as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B9_zGyMnfEQJVhe"&gt;Schedule
of Effective Income Tax Rate&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20230101__20231231_zQjyP5rCczO" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20220101__20221231_zlEW1BEVXLT4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maIT1_zhpFB2bOyrZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maIT1_z1MMpSlI4bla" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Permanent items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets_iN_pid_dpi_maIT1_zu54jBvn6Dx6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;True-up prior-year net operating loss deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_maIT1_ziVacqX65X78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Non-deductible stock compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maIT1_z9OXNpePOoX8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Other changes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0966"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maIT1_zh5Ip47Jbugl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtIT1_zGACPGAZr545" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18561"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18562"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <FBLG:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18563"
      unitRef="Pure">0.092</FBLG:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <FBLG:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18564"
      unitRef="Pure">0.008</FBLG:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <FBLG:EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18565"
      unitRef="Pure">0.061</FBLG:EffectiveIncomeTaxRateReconciliationPriorYearNetOperatingLossDeferredTaxAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18566"
      unitRef="Pure">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18567"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18568"
      unitRef="Pure">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18569"
      unitRef="Pure">0.102</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18570"
      unitRef="Pure">0.244</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18571"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18572"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16089">&lt;p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zZVySOlNpsJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the Company&#x2019;s net deferred tax assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zgVOZU6KCUYa"&gt;Schedule
of Net Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20231231_zoKa37FeocX" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20221231_zFmEtHCPGy01" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands of dollars)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zof6IgjI7NRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzVPk_zzEu0bznNSig" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,005&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzVPk_zzj6ANgkgWDc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability_iI_pn3n3_maDTAGzVPk_zWUnvKIYM492" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzVPk_zw5gAXVTkeij" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzVPk_zOff63TXUi01" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Stock compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsDerivativeInstruments_iI_pn3n3_maDTAGzVPk_zJEuhrbFNNH1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzVPk_maDTANzrSY_zGxD84s8cJi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,326&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_pn3n3_zTyyXVBVfxv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_iNI_pn3n3_di_maDITLzuqP_zVFjhlXtF8P7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Lease right-of-use asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(380&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(462&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_maDITLzuqP_zGQ8CV25vpLl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeferredTaxLiabilitiesUnamortizedDebtDiscount_iNI_pn3n3_di_maDITLzuqP_zioBQTZ1W2Bj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1010"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzuqP_msDTANzrSY_zTgYuoWn5gI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(493&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzrSY_zjv9ACfJB2l3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,935&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,266&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzrSY_zaO9ru3yPtf4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1020"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18573"
      unitRef="USD">2005000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18574"
      unitRef="USD">896000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18575"
      unitRef="USD">675000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18576"
      unitRef="USD">299000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <FBLG:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18577"
      unitRef="USD">367000</FBLG:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability>
    <FBLG:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18578"
      unitRef="USD">435000</FBLG:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18579"
      unitRef="USD">156000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18580"
      unitRef="USD">81000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18581"
      unitRef="USD">123000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18582"
      unitRef="USD">17000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18583"
      unitRef="USD">31000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18584"
      unitRef="USD">3326000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18585"
      unitRef="USD">1759000</us-gaap:DeferredTaxAssetsGross>
    <FBLG:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18586"
      unitRef="USD">380000</FBLG:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <FBLG:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18587"
      unitRef="USD">462000</FBLG:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18588"
      unitRef="USD">11000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <FBLG:DeferredTaxLiabilitiesUnamortizedDebtDiscount
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18589"
      unitRef="USD">31000</FBLG:DeferredTaxLiabilitiesUnamortizedDebtDiscount>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18590"
      unitRef="USD">391000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18591"
      unitRef="USD">493000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18592"
      unitRef="USD">2935000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18593"
      unitRef="USD">1266000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18594"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18595"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18596"
      unitRef="USD">9547000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18597"
      unitRef="USD">680000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18598"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="ixv-18599"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16306">&lt;p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zCLqrIYI2o52" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_822_zPKT8WWMx8l8"&gt;Leases, Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2021, the Company had entered into two short-term lease agreements for lab and office space. The Company opted on March
30, 2022, to extend the lease term for one of its leases for lab and office space, with a commencement date for the lease extension on
May 1, 2022. The extended lease term was &lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20211231_zNWSb3bjMqCe" title="Extended lease term"&gt;126 months&lt;/span&gt; and was accounted for as an operating lease under the ASC 842 guidance for lease
accounting. A right-of-use lease asset and tenant improvement allowance receivable with a combined total of $&lt;span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--ShortTermLeaseAgreementMember_zFyVFAjEw8el" title="Operating lease right-of-use asset"&gt;2,799&lt;/span&gt; thousand and a lease
liability of $&lt;span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--ShortTermLeaseAgreementMember_zbD1czDHoJbk" title="Lease liability"&gt;2,799&lt;/span&gt; thousand were recorded at the time of the extension. This lease was terminated as of July 31, 2022, and the remaining
balances of the right-of-use asset, tenant improvement allowance receivable, and lease liability were written off.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expanded the scope and extended for six months the term for the remaining lease for temporary lab and office space on July 1,
2022, then further expanded the scope on August 1, 2022, and October 7, 2022, which increased the monthly license fee to $&lt;span id="xdx_905_ecustom--LicenseFee_iI_pn3n3_c20231231_zfIdHlCa3wXf" title="License fee"&gt;15&lt;/span&gt; thousand
per month. In January 2023, the Company extended this lease for an additional six months and it expired at the end of June 2023. This
lease for temporary lab and office space was accounted for as a short-term lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2022, the Company entered into a lease agreement for office space with a term of &lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20221031_zfUEngX8MJ6a" title="Extended lease term"&gt;62 months&lt;/span&gt;, which expires on November 30, 2027.
This lease will be accounted for as an operating lease under the ASC 842 guidance for lease accounting. A right-of-use lease asset and
lease liability of $&lt;span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221031__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zBbz7GvV0kX8" title="Operating lease right-of-use asset"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20221031__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zLyqbpYaBJP7" title="Operating lease liability"&gt;2,293&lt;/span&gt;&lt;/span&gt; thousand each were recorded at inception of the lease term using a discount rate of &lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_c20221031__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zZ6utFKyho7b" title="Operating lease discount rate"&gt;7.5&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2023, the Company entered into a new lease for temporary lab and office space for its research operations. This lease has a term
of &lt;span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20230630_zocVOGhQTBr3" title="Extended lease term"&gt;12 months&lt;/span&gt; and monthly rent of $&lt;span id="xdx_90B_eus-gaap--PaymentsForRent_pn3n3_c20230601__20230630_zirCUd32eMfc" title="Monthly rent"&gt;6&lt;/span&gt; thousand and will be accounted for as a short-term lease. This lease commenced in August 2023. In
September 2023, the Company entered into an amendment of this lease to additional space, and the monthly rent increased to $&lt;span id="xdx_909_eus-gaap--PaymentsForRent_pn3n3_c20230901__20230930_zocx9o0Xrx54" title="Monthly rent"&gt;7&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rent
expense for the years ended December 31, 2023 and 2022, was $&lt;span id="xdx_90A_eus-gaap--PaymentsForRent_pn3n3_c20230101__20231231_z2tbG4unDuSg" title="Rent expense"&gt;685&lt;/span&gt; thousand and $&lt;span id="xdx_900_eus-gaap--PaymentsForRent_pn3n3_c20220101__20221231_z8IdFn2081Yd" title="Rent expense"&gt;392&lt;/span&gt; thousand, respectively. As of December 31, 2023, noncancelable
lease payments under operating leases were $&lt;span id="xdx_905_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--OperatingLeasesMember_zxwa3Iw5OoB2" title="Noncancelable lease payments"&gt;2,017&lt;/span&gt; thousand and noncancelable lease payments under short-term leases were $&lt;span id="xdx_902_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ShorttermLeasesMember_zXEYXhLgz22i" title="Noncancelable lease payments"&gt;45&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zCRnIEfM2V4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maturities
of operating lease liabilities as of December 31, 2023, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zf9BJJ1cuxO5"&gt;Schedule
of Operating Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20231231_zf2juYoMbqC8" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;(in thousands of dollars)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzBez_zhOzemaUykAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzBez_z9nlfMXuyQzk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzBez_zqXVngmSJso3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzBez_zD9NssKUpFKf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzBez_ze69Bh99KOJi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1076"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzBez_zovClIaNjQ5f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zcY2uAGnGOwa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(270&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z4Z5KHIIc0wg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zMB0sVExmf1l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: Current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(362&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zqnsXs4umSc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total non-current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,385&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zw00hGigI3wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2021-12-31" id="ixv-18600">P126M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31_custom_ShortTermLeaseAgreementMember"
      decimals="-3"
      id="ixv-18601"
      unitRef="USD">2799000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-12-31_custom_ShortTermLeaseAgreementMember"
      decimals="-3"
      id="ixv-18602"
      unitRef="USD">2799000</us-gaap:OperatingLeaseLiability>
    <FBLG:LicenseFee
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18603"
      unitRef="USD">15000</FBLG:LicenseFee>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2022-10-31" id="ixv-18604">P62M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-10-31_custom_LeaseAgreementMember"
      decimals="-3"
      id="ixv-18605"
      unitRef="USD">2293000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-10-31_custom_LeaseAgreementMember"
      decimals="-3"
      id="ixv-18606"
      unitRef="USD">2293000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2022-10-31_custom_LeaseAgreementMember"
      decimals="INF"
      id="ixv-18607"
      unitRef="Pure">0.075</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2023-06-30" id="ixv-18608">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForRent
      contextRef="From2023-06-012023-06-30"
      decimals="-3"
      id="ixv-18609"
      unitRef="USD">6000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2023-09-012023-09-30"
      decimals="-3"
      id="ixv-18610"
      unitRef="USD">7000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18611"
      unitRef="USD">685000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18612"
      unitRef="USD">392000</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="AsOf2023-12-31_custom_OperatingLeasesMember"
      decimals="-3"
      id="ixv-18613"
      unitRef="USD">2017000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="AsOf2023-12-31_custom_ShorttermLeasesMember"
      decimals="-3"
      id="ixv-18614"
      unitRef="USD">45000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16350">&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zCRnIEfM2V4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maturities
of operating lease liabilities as of December 31, 2023, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zf9BJJ1cuxO5"&gt;Schedule
of Operating Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20231231_zf2juYoMbqC8" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;(in thousands of dollars)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzBez_zhOzemaUykAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzBez_z9nlfMXuyQzk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;487&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzBez_zqXVngmSJso3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzBez_zD9NssKUpFKf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzBez_ze69Bh99KOJi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1076"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzBez_zovClIaNjQ5f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zcY2uAGnGOwa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(270&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z4Z5KHIIc0wg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zMB0sVExmf1l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: Current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(362&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zqnsXs4umSc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total non-current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,385&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18615"
      unitRef="USD">477000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18616"
      unitRef="USD">487000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18617"
      unitRef="USD">544000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18618"
      unitRef="USD">509000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18619"
      unitRef="USD">2017000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18620"
      unitRef="USD">270000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18621"
      unitRef="USD">1747000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18622"
      unitRef="USD">362000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18623"
      unitRef="USD">1385000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16446">&lt;p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5nBpXuPHj97" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82B_zD6hWj5F1Wz"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="background-color: white"&gt;The
Company repaid in April 2022 the remaining Parent company payable of $&lt;span id="xdx_90A_eus-gaap--RepaymentsOfRelatedPartyDebt_pn3n3_c20220401__20220430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_z0CHr6Zmlb8f"&gt;225
&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: white"&gt;thousand&lt;span style="background-color: white"&gt;, which was outstanding at December
31, &lt;span style="background-color: white"&gt;2021&lt;/span&gt;&lt;/span&gt;. In July 2022, the Company loaned $&lt;span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20220731_zNIArsqJy5U8"&gt;300
&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: white"&gt;thousand to the Parent on a one-year note bearing no interest. In October 2022, the
Company loaned $&lt;span id="xdx_904_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20221031_znXza2ik8YKf"&gt;60&lt;/span&gt;&lt;/span&gt; &lt;span style="background-color: white"&gt;thousand
to the Parent on a one-year note bearing no interest and this note was repaid before December 31, 2022. In April 2023, FibroGenesis repaid
in full the $&lt;span id="xdx_90A_eus-gaap--AccountsReceivableNetCurrent_iI_pn3n3_c20230430_zifVC6LjHs1l"&gt;300&lt;/span&gt;&lt;/span&gt; &lt;span style="background-color: white"&gt;thousand
Parent company receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
described in Note 7, the Company acquired from FibroGenesis certain in-process research and development and patent assets through Patent
Assignment and Intellectual Property Cross-License Agreements. The Patent Assignment Agreement transferred the right, title and interest
in and to certain patents from FibroGenesis to the Company for further development. The Intellectual Property Cross-License Agreement
grants to the Company exclusive rights to patents owned by FibroGenesis in a limited field of use, which includes the diagnosis, treatment,
prevention and palliation of a) spinal diseases, disorders, or conditions, b) cancer, c) orthopedics diseases, disorders or conditions,
and d) multiple sclerosis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, the Company entered into an Agreement Regarding Right of First Negotiation (&#x201c;ROFN Agreement&#x201d;) with its Parent,
FibroGenesis. In exchange for FibroGenesis&#x2019; consent to amend the Certificate of Incorporation to a) eliminate upon IPO, Direct
Listing, or Sale of the Company the Series A Preferred Stock $&lt;span id="xdx_907_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zeVVni01342l" title="Liquidation preference"&gt;35,000&lt;/span&gt; thousand liquidation preference, b) make the Series B Preferred
Stock liquidation preference equal to Series &#x201c;A&#x201d; Preferred Stock, and c) to provide that upon IPO, Direct Listing, or Sale
of the Company Series A Preferred Stock will be canceled for no consideration, FibroBiologics agreed to pay to FibroGenesis &lt;span id="xdx_900_ecustom--PercentageOfGrossProceedsFromEquityInvestments_pid_dp_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_zR3a02I16Y08" title="Percentage of gross proceeds from equity investments"&gt;15&lt;/span&gt;% of the
gross proceeds from any equity investments in FibroBiologics prior to an IPO, Direct Listing or Sale of the Company. In addition, FibroBiologics
will receive a five-year right of first negotiation if FibroGenesis decides to license externally any of its technology. In January 2023,
the Company amended its Certificate of Incorporation to reflect these changes, recorded a derivative liability of $&lt;span id="xdx_903_eus-gaap--DerivativeLiabilities_iI_c20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zaVBJu9Tipnd" title="Related party transaction, expenses"&gt;2,573&lt;/span&gt; thousand for
the expected future payments to FibroGenesis, and paid $&lt;span id="xdx_90F_ecustom--PaymentsForEquityInvestments_pn3n3_c20230101__20230131_zZzryng7GmD7" title="Payments for equity investments"&gt;323&lt;/span&gt; thousand to FibroGenesis for &lt;span id="xdx_902_ecustom--PercentageOfGrossProceedsFromEquityInvestments_dp_c20230101__20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_ziQNRmxG1tfh" title="Percentage of gross proceeds from equity investments"&gt;15&lt;/span&gt;% of the gross proceeds from equity issued
by the Company in December 2022. Based on its relationship to Series A Preferred Stock as described above, the derivative liability was
recorded first against the net Parent Investment and then to Additional paid-in capital after the net Parent Investment was eliminated.
During the year ended December 31, 2023, the Company raised gross proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_pn3n3_c20230101__20231231_zUFfRpabf6k7" title="Proceeds from (repayments of) related party debt"&gt;16,418&lt;/span&gt; thousand from equity issuances and paid $&lt;span id="xdx_909_ecustom--PaymentsForEquityInvestments_pn3n3_c20230101__20231231_zdKijQ4HKGq" title="Payments for equity investments"&gt;2,322&lt;/span&gt;
thousand of these proceeds to FibroGenesis. Amounts paid in excess of the derivative liability are recorded as other loss in the Statements
of Operations. There was &lt;span id="xdx_907_eus-gaap--DerivativeLiabilities_iI_pn3n3_do_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_zDGjWxvMnXt2" title="Derivative liability"&gt;no&lt;/span&gt; derivative liability and a payable of $&lt;span id="xdx_902_ecustom--DerivativeLiabilitiesPayableToRelatedParties_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FibroGenesisMember_zRiEp6s6poW9" title="Derivative liabilities payable to related parties"&gt;141&lt;/span&gt; thousand to FibroGenesis as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-04-012022-04-30_custom_FibroGenesisMember"
      decimals="-3"
      id="ixv-18624"
      unitRef="USD">225000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2022-07-31"
      decimals="-3"
      id="ixv-18625"
      unitRef="USD">300000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2022-10-31"
      decimals="-3"
      id="ixv-18626"
      unitRef="USD">60000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-04-30"
      decimals="-3"
      id="ixv-18627"
      unitRef="USD">300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="AsOf2023-01-31_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      id="ixv-18628"
      unitRef="USD">35000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <FBLG:PercentageOfGrossProceedsFromEquityInvestments
      contextRef="From2023-01-012023-01-31_custom_FibroGenesisMember"
      decimals="INF"
      id="ixv-18629"
      unitRef="Pure">0.15</FBLG:PercentageOfGrossProceedsFromEquityInvestments>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-01-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="ixv-18630"
      unitRef="USD">2573</us-gaap:DerivativeLiabilities>
    <FBLG:PaymentsForEquityInvestments
      contextRef="From2023-01-012023-01-31"
      decimals="-3"
      id="ixv-18631"
      unitRef="USD">323000</FBLG:PaymentsForEquityInvestments>
    <FBLG:PercentageOfGrossProceedsFromEquityInvestments
      contextRef="From2023-01-012023-01-31_custom_FibroGenesisMember"
      decimals="INF"
      id="ixv-18632"
      unitRef="Pure">0.15</FBLG:PercentageOfGrossProceedsFromEquityInvestments>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18633"
      unitRef="USD">16418000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <FBLG:PaymentsForEquityInvestments
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18634"
      unitRef="USD">2322000</FBLG:PaymentsForEquityInvestments>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-12-31_custom_FibroGenesisMember"
      decimals="-3"
      id="ixv-18635"
      unitRef="USD">0</us-gaap:DerivativeLiabilities>
    <FBLG:DerivativeLiabilitiesPayableToRelatedParties
      contextRef="AsOf2023-12-31_custom_FibroGenesisMember"
      decimals="-3"
      id="ixv-18636"
      unitRef="USD">141000</FBLG:DerivativeLiabilitiesPayableToRelatedParties>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16486">&lt;p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zb9c2CAOUUj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_823_zk9OGRxvCbyg"&gt;Share-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company adopted on August 10, 2022, and the stockholders approved on August 18, 2022, the 2022 Stock Plan (the &#x201c;Plan&#x201d;). The
Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards,
restricted stock unit awards, and other stock awards. The Plan, through the grant of stock awards, is intended to help the Company secure
and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of
the Company and provide a means by which the eligible recipients may benefit from increases in value of the common stock. In September
2022, the Company issued a total of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220901__20220930_zka9horPxiG9" title="Number of options granted"&gt;101,250&lt;/span&gt; options with a strike price of $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_c20220930_zc3qfwciguw7" title="Strike price per share"&gt;3.28&lt;/span&gt; per share to employees, directors, and scientific advisory
board members under this Plan. In February 2023, the Company issued an additional total of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230201__20230228_zSLJPrlLJs1h" title="Number of options granted"&gt;3,689,750&lt;/span&gt; options with a strike price of $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230228_znbPofZfhsg3" title="Strike price per share"&gt;2.28&lt;/span&gt;
per share to employees and directors under this Plan. In August 2023, a total of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831_zfSBCI55HU08" title="Number of options granted"&gt;2,500&lt;/span&gt; options with a strike price of $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230831_z9VpmBUofC6f" title="Strike price per share"&gt;3.28&lt;/span&gt; per share
were forfeited. Generally, awards granted by the Company vest over four years and have an exercise price equal to the estimated fair
value of the common stock as determined by the board of directors with consideration given to contemporaneous valuations of the Company&#x2019;s
common stock prepared by an independent third-party valuation firm.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of December 31, 2023 and 2022, respectively, there were &lt;span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231_zOFJaGZrd4W1" title="Shares available for future issuance"&gt;8,711,500&lt;/span&gt; shares and &lt;span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231_zVS6Et3ol1f9" title="Shares available for future issuance"&gt;12,398,750&lt;/span&gt; shares available for future issuance under the
Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zh0yQPadnZPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock-based
compensation expense is recognized in the Statements of Operations as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_8B3_zUX2A2LrRE1b"&gt;Schedule
of Stock Based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20230101__20231231_z9eSO3sapg91" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20220101__20221231_z702WuTnT3z4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands of dollars)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zhcrZZFUICT" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;262&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;115&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTRmoKvIK3Ik" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,503&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zXxazF0T9EQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,765&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;265&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zb2tNHog1mEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock-based
compensation expense for the year ended December 31, 2022, includes $&lt;span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20220101__20221231_zM0EQhjuM81" title="Stock-based compensation expense"&gt;168&lt;/span&gt; thousand of expense for non-voting common stock issued to the
Board of Directors and consultants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zHxjvMNJjb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Unrecognized
stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized
as of December 31, 2023, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zWdVvGnHmbtl"&gt;Schedule
of Unvested Awards and Weighted Average Period&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Unrecognized stock-based compensation expense (in thousands)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20231231_zYSDmsjuEUQ" style="width: 16%; text-align: right" title="Unrecognized stock-based compensation expense"&gt;5,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected weighted-average period compensation costs to be recognized (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231_zcpL9ld1uW9b" title="Expected weighted average period compensation cost"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zjJfVT3RGgU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwqf5TqVMjnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;A
summary of the Company&#x2019;s stock option activity is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_8B2_zqqTOyjFUZgg"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average Exercise Price per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average Remaining Contractual Life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbP6kgzJ6Gcb" style="width: 11%; text-align: right" title="Stock options, outstanding, beginning balance"&gt;101,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBz6REdlYfF4" style="width: 11%; text-align: right" title="Weighted-average exercise price, outstanding, beginning balance"&gt;3.28&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z72N8IwOlim2" style="width: 11%; text-align: right" title="Weighted average remaining contractual life (years), outstanding"&gt;9.4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOpPuF3DMiGe" style="width: 11%; text-align: right" title="Stock options, outstanding, beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1157"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Ci2rNYjzti" style="text-align: right" title="Number of options, granted"&gt;3,689,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXvfUXGGWWLl" style="text-align: right" title="Weighted-average exercise price, granted"&gt;2.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqdx6fStLRpb" style="text-align: right" title="Weighted average remaining contractual life (years), granted"&gt;10.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7Xzq41y6Pl8" style="text-align: right" title="Exercise of stock options, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1165"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4xd9My6xiWb" style="text-align: right" title="Weighted-average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z70lZiLhfzve" style="text-align: right" title="Number of options,  forfeited/cancelled"&gt;2,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRldCJLlibJk" style="text-align: right" title="Weighted-average exercise price, forfeited/ cancelled"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTgq4surmE2j" style="text-align: right" title="Weighted average remaining contractual life (years), forfeited/canceled"&gt;8.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSnTPuaaFv1d" style="text-align: right" title="Stock options, outstanding, ending balance"&gt;3,788,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHeGMDESVcwa" style="text-align: right" title="Weighted-average exercise price, outstanding, ending balance"&gt;2.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmicfoetnQE4" style="text-align: right" title="Weighted average remaining contractual life (years), outstanding"&gt;9.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlri9qo5oMm5" style="text-align: right" title="Stock options, outstanding, beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1181"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Exercisable as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNP45NBCRnB7" style="text-align: right" title="Number of options, exercisable"&gt;68,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKqLUqZV62Z8" style="text-align: right" title="Weighted-average exercise price, exercisable"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPzPEQo5P3Kg" style="text-align: right" title="Weighted average remaining contractual term, exercisable"&gt;8.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3Z6Wgu1Fs5g" style="text-align: right" title="Stock options, outstanding, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1189"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z6JLObo2IKgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zW2ZWmdL32ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes
option pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_8B3_zs1LT43eQ5wi"&gt;Schedule
of Fair Value of Option Granted Black Scholes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20230101__20231231_z0Jq0AAdL8Z7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20220101__20221231_zv9X23ehdzDk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Assumptions:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_zLGdqDw2rX28" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3.9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_zOB81iNekj4e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zcOM7z7aJ6E3" title="Expected term"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zPTTjRTBR7w5" title="Expected term"&gt;5.4&lt;/span&gt; to &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zJUCTi2LkEL5" title="Expected term"&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_zX4zcYzKkln9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected dividend&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_ztuJbgiEKRe8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
weighted-average grant date fair value of the options granted during the years ended December 31, 2023 and 2022 was $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zPaivk3O5Cyd" title="Weighted-average grant date fair value"&gt;1.80&lt;/span&gt; per share and
$&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zE92Vuyjax82" title="Weighted-average grant date fair value"&gt;2.64&lt;/span&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-09-012022-09-30"
      decimals="INF"
      id="ixv-18637"
      unitRef="Shares">101250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharePrice
      contextRef="AsOf2022-09-30"
      decimals="INF"
      id="ixv-18638"
      unitRef="USDPShares">3.28</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-02-012023-02-28"
      decimals="INF"
      id="ixv-18639"
      unitRef="Shares">3689750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharePrice
      contextRef="AsOf2023-02-28"
      decimals="INF"
      id="ixv-18640"
      unitRef="USDPShares">2.28</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-08-012023-08-31"
      decimals="INF"
      id="ixv-18641"
      unitRef="Shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharePrice
      contextRef="AsOf2023-08-31"
      decimals="INF"
      id="ixv-18642"
      unitRef="USDPShares">3.28</us-gaap:SharePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="ixv-18643"
      unitRef="Shares">8711500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="ixv-18644"
      unitRef="Shares">12398750</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16522">&lt;p id="xdx_89B_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zh0yQPadnZPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock-based
compensation expense is recognized in the Statements of Operations as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_8B3_zUX2A2LrRE1b"&gt;Schedule
of Stock Based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20230101__20231231_z9eSO3sapg91" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20220101__20221231_z702WuTnT3z4" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;(in thousands of dollars)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zhcrZZFUICT" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;262&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;115&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTRmoKvIK3Ik" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,503&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zXxazF0T9EQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,765&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;265&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ixv-18645"
      unitRef="USD">262000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ixv-18646"
      unitRef="USD">115000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="ixv-18647"
      unitRef="USD">1503000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="ixv-18648"
      unitRef="USD">150000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="ixv-18649"
      unitRef="USD">1765000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18650"
      unitRef="USD">265000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="ixv-18651"
      unitRef="USD">168000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16591">&lt;p id="xdx_89A_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zHxjvMNJjb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Unrecognized
stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized
as of December 31, 2023, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zWdVvGnHmbtl"&gt;Schedule
of Unvested Awards and Weighted Average Period&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Unrecognized stock-based compensation expense (in thousands)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20231231_zYSDmsjuEUQ" style="width: 16%; text-align: right" title="Unrecognized stock-based compensation expense"&gt;5,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected weighted-average period compensation costs to be recognized (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231_zcpL9ld1uW9b" title="Expected weighted average period compensation cost"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="ixv-18652"
      unitRef="USD">5039000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2023-01-01to2023-12-31" id="ixv-18653">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16619">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwqf5TqVMjnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;A
summary of the Company&#x2019;s stock option activity is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_8B2_zqqTOyjFUZgg"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average Exercise Price per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average Remaining Contractual Life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbP6kgzJ6Gcb" style="width: 11%; text-align: right" title="Stock options, outstanding, beginning balance"&gt;101,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBz6REdlYfF4" style="width: 11%; text-align: right" title="Weighted-average exercise price, outstanding, beginning balance"&gt;3.28&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z72N8IwOlim2" style="width: 11%; text-align: right" title="Weighted average remaining contractual life (years), outstanding"&gt;9.4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOpPuF3DMiGe" style="width: 11%; text-align: right" title="Stock options, outstanding, beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1157"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Ci2rNYjzti" style="text-align: right" title="Number of options, granted"&gt;3,689,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXvfUXGGWWLl" style="text-align: right" title="Weighted-average exercise price, granted"&gt;2.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqdx6fStLRpb" style="text-align: right" title="Weighted average remaining contractual life (years), granted"&gt;10.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7Xzq41y6Pl8" style="text-align: right" title="Exercise of stock options, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1165"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4xd9My6xiWb" style="text-align: right" title="Weighted-average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Forfeited/canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z70lZiLhfzve" style="text-align: right" title="Number of options,  forfeited/cancelled"&gt;2,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRldCJLlibJk" style="text-align: right" title="Weighted-average exercise price, forfeited/ cancelled"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTgq4surmE2j" style="text-align: right" title="Weighted average remaining contractual life (years), forfeited/canceled"&gt;8.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSnTPuaaFv1d" style="text-align: right" title="Stock options, outstanding, ending balance"&gt;3,788,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHeGMDESVcwa" style="text-align: right" title="Weighted-average exercise price, outstanding, ending balance"&gt;2.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmicfoetnQE4" style="text-align: right" title="Weighted average remaining contractual life (years), outstanding"&gt;9.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlri9qo5oMm5" style="text-align: right" title="Stock options, outstanding, beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1181"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Exercisable as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNP45NBCRnB7" style="text-align: right" title="Number of options, exercisable"&gt;68,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKqLUqZV62Z8" style="text-align: right" title="Weighted-average exercise price, exercisable"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPzPEQo5P3Kg" style="text-align: right" title="Weighted average remaining contractual term, exercisable"&gt;8.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3Z6Wgu1Fs5g" style="text-align: right" title="Stock options, outstanding, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1189"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ixv-18654"
      unitRef="Shares">101250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ixv-18655"
      unitRef="USDPShares">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      id="ixv-18656">P9Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ixv-18657"
      unitRef="Shares">3689750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ixv-18658"
      unitRef="USDPShares">2.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <FBLG:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="ixv-18659">P10Y</FBLG:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ixv-18660"
      unitRef="Shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ixv-18661"
      unitRef="USDPShares">3.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <FBLG:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="ixv-18662">P8Y8M12D</FBLG:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ixv-18663"
      unitRef="Shares">3788500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ixv-18664"
      unitRef="USDPShares">2.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="ixv-18665">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ixv-18666"
      unitRef="Shares">68519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ixv-18667"
      unitRef="USDPShares">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="ixv-18668">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16757">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zW2ZWmdL32ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes
option pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_8B3_zs1LT43eQ5wi"&gt;Schedule
of Fair Value of Option Granted Black Scholes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20230101__20231231_z0Jq0AAdL8Z7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20220101__20221231_zv9X23ehdzDk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Assumptions:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_zLGdqDw2rX28" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3.9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_zOB81iNekj4e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zcOM7z7aJ6E3" title="Expected term"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zPTTjRTBR7w5" title="Expected term"&gt;5.4&lt;/span&gt; to &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zJUCTi2LkEL5" title="Expected term"&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_zX4zcYzKkln9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected dividend&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18669"
      unitRef="Pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18670"
      unitRef="Pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18671"
      unitRef="Pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18672"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-01to2023-12-31" id="ixv-18673">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_srt_MinimumMember"
      id="ixv-18674">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_srt_MaximumMember"
      id="ixv-18675">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18676"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18677"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="ixv-18678"
      unitRef="USDPShares">1.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="ixv-18679"
      unitRef="USDPShares">2.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="ixv-16848">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zUFhYfNdmdWj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_826_zZiyznBGbnRh"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company&#x2019;s registration statement filed with the Securities and Exchange Commission (SEC) was declared effective on January 24,
2024, and trading of the Company&#x2019;s stock commenced on Nasdaq on January 31, 2024 (Direct Listing). &lt;span style="background-color: white"&gt;In
January 2024, in conjunction with &lt;span style="background-color: white"&gt;its&lt;/span&gt; Direct Listing, &lt;span style="background-color: white"&gt;the Company&lt;/span&gt; issued &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20240131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhNiqXno1mM2" title="Sale of stock number of shares issued in transaction"&gt;2,500&lt;/span&gt; shares of Series C Preferred Stock with super voting rights to
our CEO. &lt;/span&gt; Upon the effectiveness of &lt;span style="background-color: white"&gt;its&lt;/span&gt; registration with the SEC, the Company obtained a public company directors and
officers insurance policy at a cost of $&lt;span id="xdx_901_ecustom--InsurancePolicyCost_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zK7qwlwueBT9" title="Insurance policy cost"&gt;756&lt;/span&gt;
thousand, which will be expensed over the one-year life of the policy. Upon approval from Nasdaq and prior to &lt;span style="background-color: white"&gt;the Direct Listing&lt;/span&gt;, the
$&lt;span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z4oTAv7qYPv2" title="Application fee"&gt;270&lt;/span&gt;
thousand remainder of the listing application fee was due and paid to Nasdaq. Also upon completion of the Direct Listing, the
Company &lt;span style="background-color: white"&gt;paid &lt;/span&gt; $&lt;span id="xdx_90D_eus-gaap--RepaymentsOfRelatedPartyDebt_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z4WjQU7PiGL9" title="Payable to its services as advisor"&gt;200&lt;/span&gt;
thousand to Maxim for its services as advisor on the Direct Listing, and recorded a $&lt;span id="xdx_902_ecustom--CommitmentFee_pn3n3_c20240124__20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zL6dCV1oSyn8" title="Commitment fee"&gt;2,000&lt;/span&gt;
thousand payable for the commitment fee and issued &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zTm9og39D99d" title="Number of warrants"&gt;1,299,783&lt;/span&gt;
warrants to purchase common stock shares at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zUjCo1ho6M95" title="Exercise price"&gt;21.54&lt;/span&gt;
and an expiration of &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20240124__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zJFS7VRaQbNk" title="Warrant term"&gt;five
years&lt;/span&gt; from the Direct Listing, which were both due to the investors in the Share Purchase Agreement as described in Note
8.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In February 2024, the
Company sold a total of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240201__20240229__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAhBPDRKvNQ7" title="Shares sold"&gt;142,298&lt;/span&gt;
shares for $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pdn3_c20240201__20240229__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBkHJsZtjcU6" title="Shares sold, value"&gt;1,921&lt;/span&gt;
thousand through the Share Purchase Agreement described in Note 8.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-012024-01-31_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="ixv-18680"
      unitRef="Shares">2500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <FBLG:InsurancePolicyCost
      contextRef="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember_custom_DirectorsAndOfficersMember"
      decimals="-3"
      id="ixv-18681"
      unitRef="USD">756000</FBLG:InsurancePolicyCost>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember"
      decimals="-3"
      id="ixv-18682"
      unitRef="USD">270000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember"
      decimals="-3"
      id="ixv-18683"
      unitRef="USD">200000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <FBLG:CommitmentFee
      contextRef="From2024-01-242024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember"
      decimals="-3"
      id="ixv-18684"
      unitRef="USD">2000000</FBLG:CommitmentFee>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember"
      decimals="INF"
      id="ixv-18685"
      unitRef="Shares">1299783</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember"
      decimals="INF"
      id="ixv-18686"
      unitRef="USDPShares">21.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-01-24_us-gaap_SubsequentEventMember_custom_SharePurchaseAgreementMember"
      id="ixv-18687">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-012024-02-29_custom_SharePurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="ixv-18688"
      unitRef="Shares">142298</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-02-012024-02-29_custom_SharePurchaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="ixv-18689"
      unitRef="USD">1921000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
